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The development of technologies that allow targeting of specific cells has progressed 
substantially in recent years for several types of vectors, particularly viral vectors, 
which have been used in 70% of gene therapy clinical trials. Particular viruses have been 
selected as gene delivery vehicles because of their capacities to carry foreign genes and 
their ability to efficiently deliver these genes associated with efficient gene expression. 
This book is designed to present the most recent advances in viral gene therapy
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Preface 
The general meaning of gene therapy is to correct defective genes that are responsible
for disease development. The most common form of gene therapy involves the 
insertion, alteration or removal of genes within an individual's cells and biological
tissues. Many of gene transfer vectors are modified viruses. The ability for the delivery
of therapeutic genes made them desirable for engineering virus vector systems. 
Recently, the viral vectors in laboratory and clinical use have been based on RNA and
DNA viruses processing very different genomic structures and host ranges. Various 
viral vectors have been developed and optimized, such as retrovirus, adenovirus, 
lentivirus and adeno-associated virus. This book provides broad coverage of the field 
of viral gene therapy.
In the first section of this book, ‘Retroviral Vector’, chapter one discusses the efficiency
of retroviral DNA integration, the preferences of integration for certain regions, and 
advances on integration site selection and gene therapy. Chapter two reviews and 
discusses the current cell lines and bioreaction platforms used for production of 
retroviral and lentiviral vectors, focusing on the current bottlenecks and future
directions with a particular emphasis in the metabolic constrains.  Modification of the
surface of these vectors is a key element for their successful research and clinical use.
Chapter three discusses the methods to modify surfaces of retroviral vectors, and the
applications for surface modification of retroviral vectors, such as targeting and 
immune modulation. Chapter four reviews the role of the nuclear glucocorticoid
receptor in controlling retroviral infection and function, and highlights its potential
importance in retroviral-based gene therapy applications. 
Adenoviral vectors serve as an excellent gene delivery system for a variety of cell
types or organs for gene therapy and immunization applications. In the second section 
‘Adenoviral Vector’, chapter five introduces the history of adenovirus research, the
advantage and disadvantage of adenoviral vector, the adenoviral vector induced 
innate immune response, the evolution of adenoviral vector system, the application of 
adenoviral vector in gene therapy, and adenoviral vaccine. Chapter six reviews the 
background of virotherapy and the approaches of conditionally replicating 
adenoviruses (CRAds) on cancer treatment. The author also points out the exiting 
problems and obstacles in this field. In chapter seven, Adams et al. discuss how 
adenoviral vectors interact with human immune cells, particularly how adenoviral 
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vectors interact with professional antigen presenting cells, namely dendritic cells. 
Chapter eight reviews the properties of the immune response induced by adenoviral 
vaccines and the mechanisms which control the quality of T cell response generated 
during such vaccination. Holst et al. compare the adenovirus vectors with other 
vaccination tools in the immunological arsenal, and discuss potential future clinical 
application of adenovirus vectored vaccines. 
The third section of this book is ‘Adeno-associated-virus Vector’. Chapter nine by Sun 
et al. introduces the adeno-associated virus (AAV) mediated β-thalassemia gene 
therapy. Human hematopoietic stem cells (HSCs) were obtained from β-thalassemia 
patients, transfected with the recombinant AAV containing β-globin gene. The 
transfected cells were then transplanted into Nude/SCID mice, and the long term 
expression of β-globin in vivo was examined. In the tenth chapter, Korecka et al. 
compare AAV serotypes for gene delivery to dopaminergic neurons in the substantia 
nigra (SN). They found that AAV5 and 7-syn-GFP resulted in the highest percentage of 
nigral dopaminergic neurons transduction, where AAV7 showed the highest efficiency 
in transducing the nigrostriatal projection pathway. Accordingly, they conclude that 
AAV7-syn-GFP is the most suitable SN gene delivery vehicle in mice. In the eleventh 
chapter, Okada et al. developed a new method of producing AAV vectors. They 
applied these AAV vectors in muscle transduction for the treatment of Duchenne 
muscular dystrophy (DMD). In chapter twelve, Sunico et al. introduce their study on 
the function of 2 dysregulated proteins in pathological events occurring at the 
peripheral (nerve) and central (motoneuron) levels after the severe crushing of a motor 
nerve in adult rats, using AAV and lentiviral vector. 
In the section on ‘Lentiviral Vector’, the generation of high-titre lentiviral vectors 
capable of efficiently expressing transgenes over long periods of time is governed by a 
number of vector design rules. Chapter thirteen highlights the guiding design 
principles and the technical of the successful lentiviral gene vector design. Chapter 
fourteen reviews current status of lentiviral vector development, especially the 
progress in the lentiviral vector systems allowing the controlling of gene expression. It 
also discusses the ability of future application of the gene regulatable lentiviral vectors 
to therapeutic approach for the treatment of HIV-1 infection and acquired 
immunodeficiency syndrome (AIDS). Chapter fifteen discusses the development of 
lentiviral vectors, their evaluation for ex vivo and in vivo gene delivery to dendritic 
cells, and the efforts made to improve the biosafety of the lentiviral vector system.  
In the last section on ‘Other Types of Viral Vector’, chapter sixteen introduces the 
development of HIV vector pseudotyped with HIV envelope, and applications of these 
vectors for AIDS or adult T-cell leukemia. Chapter seventeen introduces the 
development of novel vector system for highly efficient retrograde gene transfer by 
pseudotyping the HIV-1 vector with fusion glycoprotein B type (FuG-B). Herpes 
simplex virus type 1 (HSV-1) is a human pathogen associated with keratitis and cold 
sores. Chapter eighteen reviews the biology of HSV-1, and clinical trails and 
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challenges of oncolytic Herpesvirus. In chapter nineteen, Kaneda et al. develop a 
hemagglutinating virus of Japan envelope (HVJ-E) vector using inactivated Sendai 
virus, as a pseudovirion for gene and drug delivery. They evaluate the anti-tumor 
effects of HVJ-E itself on mouse and human melanoma in animal models, and also the 
enhancement of anti-tumor effects of HVJ-E containing IL-12 gene. The last chapter 
reviews the pharmacokinetic study of viral vectors for gene therapy, including 
pharmacokinetic characteristics of viral vectors, analysis methods used for 
pharmacokinetic evaluations of viral vectors, and challenges and prospects. 
We hope that the reviews and research described here will provide a wide-ranging 
forum in the viral gene therapy field. It is clear from these chapters that much more 
progress is required for the improvement of viral gene therapy. It is believed that the 
next few decades will see the application of viral gene therapy in the treatment of 
diseases. 
Ke Xu 
Tianjin Lung Cancer Institute 
Tianjin Medical University General Hospital 
Tianjin, China 
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Stem Cell Biology and Regenerative Medicine, Thomas Jefferson University, Philadelphia 
 2Department of Stem Cell Biology and Regenerative Medicine, Thomas Jefferson 
University, Philadelphia,  
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1. Introduction 
Retroviral vectors have gained an increasing value in gene therapy because they stably deliver 
therapeutic genes to the host cell genome. These therapeutic genes are supposed to rectify 
consequences of inherited and acquired mutated genes in the host cell genome, or alter host 
cell function to cure diseases. In the following section we will discuss the biology and life cycle 
of retroviruses which starts with viral entry into the host cell, reverse transcription of viral 
RNA, nuclear import of the provirus, and finally integration of viral DNA into the cell host 
genome (Flint, Racaniello et al. 2004). Integration involves viral and host cellular proteins. 
Their role is discussed in the third and fourth sections of this chapter. Recently, the process of 
integration site selection (which is where the viral DNA integrates with the host cell DNA) has 
been quite understood throughout many in vitro and in vivo studies. The human genome 
project has enabled us to identify integration site preferences for retroviral vectors in human 
trials. The results of these human trials are reviewed in the fifth section of the chapter. Finally, 
the last section of the chapter will demonstrate the latest gene therapy trials attempts to control 
integration sites by manipulation of retrovirus genes and proteins. 
1.1 Retrovirus structure and life cycle 
Viruses are obligate parasites which depend on living cells to multiply. Their ability to 
deliver stable RNA and DNA into cells has determined their use in gene therapy. In 1983 
Mann et al. developed one of the first retroviral gene therapy vectors for delivery in vitro 
(Mann, Mulligan et al. 1983). This development was followed by many successfully gene 
therapy trials of retroviruses (Anderson, Blaese et al. 1990; Levine and Friedmann 1991; 
Blaese, Culver et al. 1993). Now, retrovirual vectors are implemented in nearly 22.2% of 
clinical trials (http://www.wiley.com//legacy/wileychi/genmed/clinical/[June 2010]).  
Retroviruses belong to the Retroviriade family. The retroviral particle consists of 2 copies of 
positive-single strand (+ss) RNA and viral proteins (reverse trascriptase, integrase, and 
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protease) which are all contained by nucleocapsid. The nucleocapsid complex is surrounded 
by a protein shell called capsid to form the viral core. A layer of matrix protein, which is 
formed outside the capsid, interacts with the envelope (env) which consists of lipid 
envelope derived from the host cell and viral envelope glycoproteins. Viral glycoproteins 
are made of two units: a transmembrane portion, which attaches the protein into the lipid 
bilayer, and a surface portion, which binds to the cellular receptor. 
The life cycle of the retrovirus consist of several steps. It begins with the binding of the viral 
envelope to cellular receptors, which enables fusion of the viral envelope with the cellular 
membrane. Consequently, the viral particle is uncoated, liberating the viral core into the cell 
cytoplasm. The viral DNA is reverse transcribed to DNA. Then, the viral DNA is 
transported to the nucleus where it is integrated into the host cell’s genome. From there, 
viral DNA is transcribed to RNA, some of which is translated to proteins. The viral RNA is 
packed in a viral particle along with viral proteins. Then, virion is produced when viral 
particles bud from the hosting cells (Escors and Breckpot).  
1.2 Integration 
The retroviral enzyme integrase (IN) plays a vital role in integration. It exists as a tetramer 
(dimer-of-dimers) inside the virion or the preintegration complex. IN facilitate viral DNA 
integration in vitro, even in the absence of other viral or cellular proteins (Coffin, Hughes et 
al. 1997; Flint, Racaniello et al. 2004). Integration is classified into two distinct steps. The first 
step called processing, where the IN removes two nucleotides from the 3’ ends of the viral 
DNA, the synthesis of which was produced by the viral enzyme reverse transcriptase 
(Coffin, Hughes et al. 1997; Flint, Racaniello et al. 2004). Then, when the viral preintegration 
complex is in the vicinity of targeted host DNA, IN catalyzes a coupled cleavage-joining 
reaction, where the 3’ ends of viral DNA are joined to host cell DNA, in the joining step 
(Coffin, Hughes et al. 1997; Flint, Racaniello et al. 2004). The intermediate product of the 
integration process is flanked by short single-stranded gaps in host cell DNA. After the 
integration reaction, postintegration repair takes place, in which the 5' ends of viral DNA are 
trimmed, the gaps filled, and ligated to host cell DNA. Lastly, the appropriate chromatin 
structure is reconstituted at the integration site. Postintegration repair does not require viral 
proteins, but instead depends on host cell DNA repair proteins (Daniel, Katz et al. 1999; Lau, 
Swinbank et al. 2005).  
In vitro experiments show that incubating IN with oligonucleotides as DNA substrate, and 
target DNA were sufficient to achieve integration of one end of the DNA substrate (Flint, 
Racaniello et al. 2004). However, in vivo, stable integration requires cellular proteins to be 
accomplished. These cellular proteins have invoked interest of their potential as cofactors of 
integration. Using a yeast two-hybrid screen, human immunodeficiency virus (HIV)-1 IN-
binding protein termed integrase interactor 1 (INI1) was identified (Kalpana, Marmon et al. 
1994). At the beginning, INI1 protein was found to boost integration efficiency when it was 
added to the integration reaction in vitro (Kalpana, Marmon et al. 1994). Also, small 
interfering RNA (siRNA) targeting INI1, demonstrated that knocking down INI1 was 
sufficient to significantly reduce HIV-1 replication (Ariumi, Serhan et al. 2006). However, 
another study showed that lacking INI1 protein did not affect integration reaction (Boese, 
Sommer et al. 2004). Now it is accepted that INI1 does not affect integration but it appears to 
be involved in other process of the retroviral life cycle (Ariumi, Serhan et al. 2006; 
Mahmoudi, Parra et al. 2006; Treand, du Chene et al. 2006). Another cellular non-histone 
chromatin protein called high-mobility group protein-1 (HMG-1) was found to enhance 
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integration in vitro (Aiyar, Hindmarsh et al. 1996). This enhancement was thought to be 
attributed to its DNA-bending ability (Aiyar, Hindmarsh et al. 1996; Flint, Racaniello et al. 
2004). HMG-I(Y), another related protein in the HMG family, was found in HIV-1 
preintegration complexes (Farnet and Bushman 1997). As with HMG-1, HMG-I(Y) and 
HMG-2 boost integration in in vitro (Aiyar, Hindmarsh et al. 1996; Farnet and Bushman 
1997; Hindmarsh, Ridky et al. 1999). Unfortunately, studies using HMG-I(Y) deficient cells 
did not elucidate the role of this protein in the integration reaction (Beitzel and Bushman 
2003). Thus the role of HMG proteins in integration remains unclear. Autointegration is the 
integration of the viral DNA into itself which will eventually abort the retroviral life cycle. 
An 89 amino acid protein, which was identified in murine leukemia virus (MLV) 
preintegration complexes, forbids autointegration of viral DNA, and was hence called the 
barrier-to-autointegration factor (BAF) (Lee and Craigie 1998). Also BAF was detected in 
HIV-1 preintegration complex to block autointegration (Lin and Engelman 2003). Finally, in 
2003, a yeast two-hybrid system resulted in the isolation of a new HIV-1 IN-binding protein, 
a previously identified cellular protein termed LEDGF/p75 (lens epithelium-derived growth 
factor) (Cherepanov, Devroe et al. 2004). In knockout mice experiments, LEDGF/p75 was 
found not to be a lens growth factor, actually, the knockout mice of the mouse LEDGF/p75 
homolog, PSIP1 (PC4 and SFRS1-interacting protein-1), had skeletal abnormalities, 
indicating that this protein is involved in bone development (Sutherland, Newton et al. 
2006). Furthermore, many studies demonstrate that LEDGF/p75 targeting with siRNA or 
LEDGF/p75 null cells, from the LEDGF/p75 null transgenic animals, showed that 
integration of HIV-1-based vectors is reduced 89–96% in the absence of LEDGF/p75 (Llano, 
Saenz et al. 2006; Shun, Raghavendra et al. 2007). Therefore, LEDGF/p75 appears to be 
essential for efficient integration of HIV-1. Meanwhile, numerous studies displayed that 
LEDGF/p75 does not bind to MLV IN nor is it essential for MLV integration (Llano, 
Vanegas et al. 2004; Busschots, Vercammen et al. 2005; Shun, Raghavendra et al. 2007). In 
addition to the LEDGF/p75 role in enhancing integration in in vitro, it has the ability to 
target HIV-1 and HIV-1-based vector integration sites (Ciuffi, Llano et al. 2005; Llano, 
Vanegas et al. 2006; Shun, Raghavendra et al. 2007). 
In summary, retroviral DNA integration is catalyzed by the viral protein integrase, but host 
cell proteins play a significant role in enhancing the efficiency of the reaction, and 
preventing autointegration. 
2. Integration site preferences of retroviruses and retroviral vectors 
While Integration of viral DNA can take place anywhere in the host cell genome and there is 
no strict host sequence for site selection, many studies showed that site selection is not a 
haphazard process (Schroder, Shinn et al. 2002; Wu, Li et al. 2003; Mitchell, Beitzel et al. 
2004). In vitro studies demonstrated that some DNA-binding proteins can prevent contact of 
IN to target DNA and subsequently block the integration reaction at their binding sites 
(Pryciak and Varmus 1992; Bushman 1994). On the contrary, bending or distortion of DNA 
seems to enhance integration (Pryciak, Muller et al. 1992; Pryciak and Varmus 1992; Katz 
and Skalka 1994; Pruss, Bushman et al. 1994; Pruss, Reeves et al. 1994). Furthermore, studies 
showed that DNA wrapping around nucleosomes promotes distortion of DNA and thus 
promotes integration in the nucleosomes-bound DNA (Pryciak, Sil et al. 1992; Pryciak and 
Varmus 1992; Pruss, Bushman et al. 1994). All of the previous studies show that there are 
certain integration site preferences in DNA substrate in in vitro models. However, it should 
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be considered that host DNA exists in a higher order chromatin structure, as the results of 
these in vitro studies may not translate to what really happens in the infected cell. To mimic 
the in vivo model, Taganov et al. used a 13-nucleosome extended array which includes 
binding sites for specific transcription factors and can be compacted into a higher-ordered 
structure using the histone H1 (Taganov, Cuesta et al. 2004).  They noticed that chromatin 
structure impacts the integration site selection of HIV-1 and avian sarcoma virus (ASV) IN 
proteins differentially. In particular, HIV-1 IN-mediated integration was reduced after 
compaction of the target DNA/chromatin structure, whereas ASV IN-mediated integration 
was more efficient after compaction (Taganov, Cuesta et al. 2004). These results reveal that a 
higher order chromatin structure is involved in integration site selection and variant 
retroviruses may exhibit differential selectivity of their integration. According to the 
International Human Genome Sequencing Consortium (IHGSC), in 2004, 25,000 genes had 
been identified in the human genome. In 1990, two studies indicated that retroviruses have a 
preference to integrate in the vicinity of transcriptionally active regions (Mooslehner, Karls 
et al. 1990; Scherdin, Rhodes et al. 1990). These studies were challenged by the relatively low 
number of identified transcription sites (Bushman, Lewinski et al. 2005). Also, due to 
incomplete human genome sequencing, the percentage of the genome containing these 
“favored” integration sites was not clear. Thus, after the IHGSC announcement, researchers 
were able to define accurate statistical analysis of integration sites. Large-scale studies on 
HIV-1 integration in human T cell lines revealed that roughly 70% of integration events 
occurred in genes (Schroder, Shinn et al. 2002; Bushman, Lewinski et al. 2005). Furthermore, 
the 11q13 chromosomal region was found to be a “hotspot” of integration. Also, Schroder et 
al. showed similar results when using pseudotyped HIV-1-based vectors (Schroder, Shinn et 
al. 2002). Many studies have revealed that many retroviruses and retroviral vectors like 
simian immunodeficiency virus, an SIV-based vector, HIV-2, and feline immunodeficiency 
virus (FIV) integration preferences resemble HIV-1 integration preferences (Hematti, Hong 
et al. 2004; Crise, Li et al. 2005; Kang, Moressi et al. 2006; MacNeil, Sankale et al. 2006). On 
the contrary, MLV and MLV-based vectors demonstrated diverse integration preferences 
compared with HIV-1 (Wu, Li et al. 2003; Mitchell, Beitzel et al. 2004; Lewinski, Yamashita et 
al. 2006). 20% of MLV integration occasions occur in the vicinity of the 5’ ends of 
transcription (Wu, Li et al. 2003), approximately 17% of MLV integration events take place 
in the vicinity of CpG islands (Mitchell, Beitzel et al. 2004), 11% of the integration sites were 
detected in the vicinity of DNase I-hypersensitive sites (Lewinski, Yamashita et al. 2006), 
and the remaining integration sites are scattered in a random manner (Wu, Li et al. 2003).  
Avian retroviruses and vectors show only a weak preference for integration around genes 
(about 40%) and no MLV-like preference for 5’ ends of transcription units (Mitchell, Beitzel 
et al. 2004; Narezkina, Taganov et al. 2004). Interestingly, high levels of transcription may 
even inhibit ASV integration in genes (Weidhaas, Angelichio et al. 2000; Maxfield, Fraize et 
al. 2005). These preferences are consistent with the above-described data from the in vitro 
system, which used nucleosomal arrays (Taganov, Cuesta et al. 2004). Interestingly, the 
human T-leukemia virus type 1 (HTLV-1) and mouse mammary tumor virus (MMTV), like 
avian retroviruses, do not specifically target genes and transcription start sites (Derse, Crise 
et al. 2007; Faschinger, Rouault et al. 2008).  
Lastly, it appears that there is a symmetric base preferences surrounding integration sites for 
integration of HIV-1, SIV, MLV, and avian sarcoma-leukosis viruses (Crise, Li et al. 2005; 
Holman and Coffin 2005). These weak consensus sequences are virus specific and possibly 
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reflect the influence of IN on integration site selection (Holman and Coffin 2005). This 
proposal is supported by the symmetry of the target site sequence, because IN likely 
functions as a tetramer (Coffin et al., 1997; Flint et al., 2004; Wu et al., 2005; and see above).  
In summary, the integration preferences described in this section are distinct for different 
group of retroviruses. The first group including HIV-1, HIV-2, SIV, and FIV, show a 
preferential integration into genes (Daniel and Smith 2008). While the second group, 
consisting of MLV and FV, integrate in 5' ends of transcription units and CpG islands. The 
last group consists of AVLS, HTLV-1, and MMTV (Daniel and Smith 2008). This group 
shows weak or even no preferences for gene or transcription start sites. Also, it appears that 
DNA sequence has a role in integration site selection. However, other factors (cellular 
cofactors and cellular structures) are likely to be the principal controllers of integration site 
selection.   
3. Mechanism of integration site selection 
As mentioned before, IN has a low specificity for binding to host cell DNA. So, it seems that 
host cell proteins participate in the integration process. Using the yeast two-hybrid system, 
Debyser and coworkers have identified a new HIV-1 IN-binding protein, termed 
LEDGF/p75 (Cherepanov, Maertens et al. 2003). LEDGF/p75 is required for efficient 
integration of HIV-1 DNA.  Also, LEDGF/p75 is a transcription factor and has a C-terminal 
IN-binding domain and N-terminal chromatin-binding domain (Cherepanov, Maertens et 
al. 2003; Cherepanov, Devroe et al. 2004; Vanegas, Llano et al. 2005; Llano, Vanegas et al. 
2006; Turlure, Maertens et al. 2006). Chromatin binding is mediated by PWWP and AT-hook 
motifs in the N-termianl domain of LEDGF/p75 (Llano, Vanegas et al. 2006; Turlure, 
Maertens et al. 2006). In addition, LEDGF/p75 was detected in association with 
preintegration complexes of HIV-1 and FIV in cultured cells (Llano, Vanegas et al. 2006). 
Moreover, LEDGF/p75 halts proteasomal degradation of ectopically expressed HIV-1 IN, 
therefore it might assist to the stability of preintegration complexes during infection 
(Maertens, Cherepanov et al. 2003; Llano, Vanegas et al. 2006). Also, LEDGF/p75 null cells 
showed that the residual integration sites in these cells no longer take place in active genes 
(Shun, Raghavendra et al. 2007). However, integration occurred preferentially near 
promoters and CpG islands (Shun, Raghavendra et al. 2007). The symmetric base 
preferences surrounding the integration site remained preserved (Holman and Coffin 2005). 
As a result, in the absence of LEDGF/p75, HIV-1 integration site preferences resemble those 
of MLV (Shun, Raghavendra et al. 2007). All these results strongly support the hypothesis 
that LEDGF/p75 targets HIV-1 (and other lentiviral) integration into active genes by 
tethering the IN protein to chromatin.  
Although LEDGF/p75 appears to be a major HIV-1 IN-binding cellular protein, other 
factors are likely involved in integration site selection by HIV-1 and HIV-1-based vectors. 
Analysis of robust number of integration sites demonstrated that preferred integration sites 
are found in the vicinity of certain computer-predicted epigenetic marks, such as histone H3 
K4 methylation, H4 acetylation, or H3 aceytlation  (Kalpana, Marmon et al. 1994). These 
results may suggest that the chromatin structure, including the histone code, may also affect 
integration site selection. However the decisive evidence that these marks play a role in 
integration site selection has yet to be revealed. Moreover, other factors which affect 
integration site selection have been identified. Knockdown of the T-cell lineage-specific 
chromatin organizer, SATB1 (special AT-rich sequence-binding protein-1), reduces HIV-1 
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integration in the vicinity of SATB1-binding sites (Kumar, Mehta et al. 2007). Consequently, 
SATB1 seems to be implicated in integration site selection by an unknown mechanism. 
Lastly, it has been shown that the cellular protein Ku80, which is present in the 
preintegration complex, directs integration to chromatin domains prone to silencing (Li, 
Olvera et al. 2001; Masson, Bury-Mone et al. 2007). In contrast to HIV-1, integration of MLV-
based and ASV-based vectors does not seem to be determined by LEDGF/p75 (Mitchell, 
Beitzel et al. 2004; Narezkina, Taganov et al. 2004). It is still unknown what controls ASV 
integration site selection. While in the case of MLV, a study using HIV chimeras with MLV 
genes demonstrated that MLV IN appears to be the major director for integration site 
selection (Lewinski, Yamashita et al. 2006). Furthermore, Gag-derived proteins play an 
auxiliary role in the integration selection process, as an HIV-1 chimera with MLV Gag 
demonstrated other site preferences different from both HIV and MLV (Lewinski, 
Yamashita et al. 2006). All the previous data support a different mechanism of integration 
site selection for MLV versus HIV.  
In conclusion, current data has promoted our understating of the retroviral site selection 
process and demonstrates a major role of host cell proteins in the process. Yet, the process is 
not entirely understood, and there will likely be new determinate members involved in the 
retroviral integration site selection process revealed in the near future.  
4. Integration site selection and gene therapy 
MLV and HIV-1 vectors are the two most widely used vectors in gene therapy. It was 
hypothesized that even if a retroviral vector integrates in the "wrong spot", it may not 
necessarily lead to the development of a tumor (Hahn and Weinberg 2002; Baum, Kustikova 
et al. 2006). However, this hypothesis was challenged when serious adverse effects emerged 
in gene therapy trials involving children to treat X-linked severe combined 
immunodeficiency (SCID-X1) (Hacein-Bey-Abina, Von Kalle et al. 2003; Alexander, Ali et al. 
2007; Bushman 2007; Deichmann, Hacein-Bey-Abina et al. 2007; Faschinger, Rouault et al. 
2008). In one these trials, which used an MLV-based vector, 4 out of 11 patients developed T 
cell leukemia. Moreover, in another SCID-X1 gene therapy trial, it has been reported that a 
patient, of 10 patients enrolled, developed leukemia (Alexander, Ali et al. 2007; 
Schwarzwaelder, Howe et al. 2007; Thrasher and Gaspar 2008). Using sequencing analysis, T 
cells from two of the patients in the first trial who developed leukemia, showed an insertion 
of the vector near (and subsequent activation of) Lin-1, IsI-1, Mec-3 (LIM) domain only-2 
(LMO2) protooncogene by the long terminal repeat (LTR) enhancer of the vector  (Hacein-
Bey-Abina, Von Kalle et al. 2003). Also, in the second trial, the vector insertion was in the 
vicinity of the LMO2 protooncogene (Thrasher and Gaspar 2008).  These striking data 
demonstrate that vector integration at a dangerous spot of the human genome could lead to 
cancer development. It is also true that there could be other unknown factors that 
contributed to the leukemia development. Proposed factors that may have been involved 
are expression of the transgenes and chromosomal rearrangement (Hacein-Bey-Abina, Von 
Kalle et al. 2003; Pike-Overzet, de Ridder et al. 2006; Thrasher, Gaspar et al. 2006; Woods, 
Bottero et al. 2006). A follow-up analysis of the patients of these gene therapy trials 
exhibited a nonrandom distribution of integration sites in vivo (Deichmann, Hacein-Bey-
Abina et al. 2007; Schwarzwaelder, Howe et al. 2007). Integration of vectors occurred 
preferentially near the 5' ends of genes and associated CpG islands, which is consistent with 
the data obtained with MLV in in vitro studies (Bushman 2007; Deichmann, Hacein-Bey-
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Abina et al. 2007; Schwarzwaelder, Howe et al. 2007). Comparison of integration sites, in 
transduced-cells before and after infusion into patients, showed that vector integration 
manipulates cell growth, survival and proliferation in vivo (Deichmann, Hacein-Bey-Abina 
et al. 2007; Schwarzwaelder, Howe et al. 2007). Similarly, clonal evolution was noticed in a 
gene therapy trial using ADA-SCID. However, in this trial, no adverse effects were related 
with vector integration site (Aiuti, Cassani et al. 2007). In similar trials, vector insertion 
caused a deregulation of gene expression without any development of cancer (Ott, Schmidt 
et al. 2006; Recchia, Bonini et al. 2006). Likewise, animal gene therapy model results were 
similar to results obtained in human gene therapy trials (Li, Dullmann et al. 2002; Hematti, 
Hong et al. 2004; Modlich, Kustikova et al. 2005; Baum, Kustikova et al. 2006; Montini, 
Cesana et al. 2006). Moreover, Kaiser described in his article the first successful gene therapy 
for Beta-thalassemia disease using an HIV vector to correct β-globin coding gene (Kaiser 
2009). The infused cells with corrected genes were highly proliferating due to 
overexpression of mutated HMGA2. The follow-up of the patient did not show any serious 
adverse effects, still the elevation  of HMGA2 seems to be a caveat.  
In conclusion, integration of a retroviral vector into the human genome contributed to the 
development of leukemia both in animal models and human patients.  Nevertheless, these 
insertions may not be directly involved in cancer development, few patients of gene therapy 
trials developed malignancies (Hacein-Bey-Abina, Von Kalle et al. 2003; Dave, Jenkins et al. 
2004). These cases emphasize the need for further improvements of retroviral vector designs 
to obtain vectors with low preferences for “wrong spots” to increase the safety margin in 
gene therapy applications.  
5. Retargeting integration 
The hypothetical need for integration targeting was realized even prior to the adverse 
events described above. Thus, attempts to target integration were made in the last decade of 
the 20th century. These attempts involved attaching a specific DNA binding domain 
(binding to a known DNA sequence) to the retroviral integrase protein.  It had been shown 
that these fusion proteins target integration in vitro (“testube”), however, when these 
proteins were introduced into a vector particle, they either failed to perform integration or 
did not target it efficiently to predicted sites ((Goulaouic and Chow 1996)). Following the 
discovery of LEDGF/p75, it has been hypothesized that it is possible to retarget integration 
using a modified LEDGF/p75 protein. Thus, the Daniel laboratory created a fusion protein, 
in which the LEDGF/p75 chromatin binding domain was replaced by the chromatin 
binding domain of the heterochromatin protein 1a (HP-1a, (Silvers, Smith et al.)). HP-1a 
binds to the trimethylated lysine 9 of the histone H3, which is a hallmark of 
heterochromatin. It should be noted that cellular chromatin consists of euchromatin, 
containing most genes, and heterochromatin, which contains mainly repetitive sequences 
and relatively few genes. Thus, integration into heterochromatin should be “safer” than 
integration into euchromatin and genes.  This fusion protein, when transfected into cells 
prior to infection with a HIV-1 vector, indeed reduced integration events occurring in genes. 
Other labs, following a similar strategy, demonstrated that further reduction in genes can be 
achieved by knocking down the endogenous LEDGF/p75 (Ferris, Wu et al. 2010; Gijsbers, 
Ronen et al. 2010). It should be noted that the knockdown did not result in reduced 
integration efficiency, because the novel fusion proteins efficiently replaced LEDGF/p75 
function. These results thus pave the way to retargeting integration, and reducing the safety 
  
Viral Gene Therapy 
 
8 
integration in the vicinity of SATB1-binding sites (Kumar, Mehta et al. 2007). Consequently, 
SATB1 seems to be implicated in integration site selection by an unknown mechanism. 
Lastly, it has been shown that the cellular protein Ku80, which is present in the 
preintegration complex, directs integration to chromatin domains prone to silencing (Li, 
Olvera et al. 2001; Masson, Bury-Mone et al. 2007). In contrast to HIV-1, integration of MLV-
based and ASV-based vectors does not seem to be determined by LEDGF/p75 (Mitchell, 
Beitzel et al. 2004; Narezkina, Taganov et al. 2004). It is still unknown what controls ASV 
integration site selection. While in the case of MLV, a study using HIV chimeras with MLV 
genes demonstrated that MLV IN appears to be the major director for integration site 
selection (Lewinski, Yamashita et al. 2006). Furthermore, Gag-derived proteins play an 
auxiliary role in the integration selection process, as an HIV-1 chimera with MLV Gag 
demonstrated other site preferences different from both HIV and MLV (Lewinski, 
Yamashita et al. 2006). All the previous data support a different mechanism of integration 
site selection for MLV versus HIV.  
In conclusion, current data has promoted our understating of the retroviral site selection 
process and demonstrates a major role of host cell proteins in the process. Yet, the process is 
not entirely understood, and there will likely be new determinate members involved in the 
retroviral integration site selection process revealed in the near future.  
4. Integration site selection and gene therapy 
MLV and HIV-1 vectors are the two most widely used vectors in gene therapy. It was 
hypothesized that even if a retroviral vector integrates in the "wrong spot", it may not 
necessarily lead to the development of a tumor (Hahn and Weinberg 2002; Baum, Kustikova 
et al. 2006). However, this hypothesis was challenged when serious adverse effects emerged 
in gene therapy trials involving children to treat X-linked severe combined 
immunodeficiency (SCID-X1) (Hacein-Bey-Abina, Von Kalle et al. 2003; Alexander, Ali et al. 
2007; Bushman 2007; Deichmann, Hacein-Bey-Abina et al. 2007; Faschinger, Rouault et al. 
2008). In one these trials, which used an MLV-based vector, 4 out of 11 patients developed T 
cell leukemia. Moreover, in another SCID-X1 gene therapy trial, it has been reported that a 
patient, of 10 patients enrolled, developed leukemia (Alexander, Ali et al. 2007; 
Schwarzwaelder, Howe et al. 2007; Thrasher and Gaspar 2008). Using sequencing analysis, T 
cells from two of the patients in the first trial who developed leukemia, showed an insertion 
of the vector near (and subsequent activation of) Lin-1, IsI-1, Mec-3 (LIM) domain only-2 
(LMO2) protooncogene by the long terminal repeat (LTR) enhancer of the vector  (Hacein-
Bey-Abina, Von Kalle et al. 2003). Also, in the second trial, the vector insertion was in the 
vicinity of the LMO2 protooncogene (Thrasher and Gaspar 2008).  These striking data 
demonstrate that vector integration at a dangerous spot of the human genome could lead to 
cancer development. It is also true that there could be other unknown factors that 
contributed to the leukemia development. Proposed factors that may have been involved 
are expression of the transgenes and chromosomal rearrangement (Hacein-Bey-Abina, Von 
Kalle et al. 2003; Pike-Overzet, de Ridder et al. 2006; Thrasher, Gaspar et al. 2006; Woods, 
Bottero et al. 2006). A follow-up analysis of the patients of these gene therapy trials 
exhibited a nonrandom distribution of integration sites in vivo (Deichmann, Hacein-Bey-
Abina et al. 2007; Schwarzwaelder, Howe et al. 2007). Integration of vectors occurred 
preferentially near the 5' ends of genes and associated CpG islands, which is consistent with 
the data obtained with MLV in in vitro studies (Bushman 2007; Deichmann, Hacein-Bey-
 
Integration Targeting and Safety in Gene Therapy 
 
9 
Abina et al. 2007; Schwarzwaelder, Howe et al. 2007). Comparison of integration sites, in 
transduced-cells before and after infusion into patients, showed that vector integration 
manipulates cell growth, survival and proliferation in vivo (Deichmann, Hacein-Bey-Abina 
et al. 2007; Schwarzwaelder, Howe et al. 2007). Similarly, clonal evolution was noticed in a 
gene therapy trial using ADA-SCID. However, in this trial, no adverse effects were related 
with vector integration site (Aiuti, Cassani et al. 2007). In similar trials, vector insertion 
caused a deregulation of gene expression without any development of cancer (Ott, Schmidt 
et al. 2006; Recchia, Bonini et al. 2006). Likewise, animal gene therapy model results were 
similar to results obtained in human gene therapy trials (Li, Dullmann et al. 2002; Hematti, 
Hong et al. 2004; Modlich, Kustikova et al. 2005; Baum, Kustikova et al. 2006; Montini, 
Cesana et al. 2006). Moreover, Kaiser described in his article the first successful gene therapy 
for Beta-thalassemia disease using an HIV vector to correct β-globin coding gene (Kaiser 
2009). The infused cells with corrected genes were highly proliferating due to 
overexpression of mutated HMGA2. The follow-up of the patient did not show any serious 
adverse effects, still the elevation  of HMGA2 seems to be a caveat.  
In conclusion, integration of a retroviral vector into the human genome contributed to the 
development of leukemia both in animal models and human patients.  Nevertheless, these 
insertions may not be directly involved in cancer development, few patients of gene therapy 
trials developed malignancies (Hacein-Bey-Abina, Von Kalle et al. 2003; Dave, Jenkins et al. 
2004). These cases emphasize the need for further improvements of retroviral vector designs 
to obtain vectors with low preferences for “wrong spots” to increase the safety margin in 
gene therapy applications.  
5. Retargeting integration 
The hypothetical need for integration targeting was realized even prior to the adverse 
events described above. Thus, attempts to target integration were made in the last decade of 
the 20th century. These attempts involved attaching a specific DNA binding domain 
(binding to a known DNA sequence) to the retroviral integrase protein.  It had been shown 
that these fusion proteins target integration in vitro (“testube”), however, when these 
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integration efficiency, because the novel fusion proteins efficiently replaced LEDGF/p75 
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risk in gene therapy trials. However, caveats remain. One disadvantage of these methods is 
that targeting requires two vectors, one to deliver the fusion LEDGF/p75-based protein, and 
one to deliver the therapeutic genes. In addition, a significant percentage of integrations still 
occurred in genes. One possible approach to address the first weakness is to introduce the 
targeting protein directly into a vector particle. It is possible that the second disadvantage 
can be removed by using chromatin binding domains that show more specificity for 
heterochromatin than that of HP-1a. These approaches are currently being explored. We 
hope they ultimately result in self-targeting HIV-1 vectors that can carry negligible risk of 
adverse events in gene therapy trials.  
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1. Introduction 
Gamma-retroviral vectors, commonly designated retroviral vectors, were the first viral 
vector employed in Gene Therapy clinical trials in 1990 and are still one of the most used. 
More recently, the interest in lentiviral vectors, derived from complex retroviruses such as 
the human immunodeficiency virus (HIV), has been growing due to their ability to 
transduce non-dividing cells (Lewis et al. 1992; Naldini et al. 1996), an attribute that 
distinguishes them from other viral vectors, including their simple counterparts, gamma-
retroviral vectors. Retroviral and lentiviral vectors most attractive features as gene transfer 
tools include the capacity for large genetic payload (up to 9 kb), minimal patient immune 
response, high transducing efficiency in vivo and in vitro, and the ability to permanently 
modify the genetic content of the target cell, sustaining a long-term expression of the 
delivered gene (Coroadinha et al. 2010; Schweizer and Merten 2010). 
According to the most recent updates, retroviral and lentiviral vectors represent 23% of all 
the vector types and 33% of the viral vectors used in Gene Therapy clinical trials. Moreover, 
retroviral vectors are currently the blockbuster vectors for the treatment of monogenic and 
infectious diseases and gene marking clinical trials (Edelstein 2010).  
Retroviruses are double stranded RNA enveloped viruses mainly characterized by the 
ability to “reverse-transcribe” their genome from RNA to DNA. Virions measure 100-120 
nm in diameter and contain a dimeric genome of identical positive RNA strands complexed 
with the nucleocapsid (NC) proteins. The genome is enclosed in a proteic capsid (CA) that 
also contains enzymatic proteins, namely the reverse transcriptase (RT), the integrase (IN) 
and proteases (PR), required for viral infection. The matrix proteins (MA) form a layer 
outside the capsid core that interacts with the envelope, a lipid bilayer derived from the host 
cellular membrane, which surrounds the viral core particle (Coffin et al. 1997). Anchored on 
this bilayer, are the viral envelope glycoproteins (Env) responsible for recognizing specific 
receptors on the host cell and initiating the infection process. Envelope proteins are formed 
by two subunits, the transmembrane (TM) that anchors the protein into the lipid membrane 
and the surface (SU) which binds to the cellular receptors (Fig. 1).  
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Fig. 1. Schematic representation of a retrovirus particle structure. 
Based on the genome structure, retroviruses are classified into simple (e.g. MLV, murine 
leukemia virus) or complex retroviruses (e.g. HIV) (Coffin et al. 1997). Both encode four 
genes: gag (group specific antigen), pro (protease), pol (polymerase) and env (envelope) 
(Fig. 2). The gag sequence encodes the three main structural proteins: MA, CA, NC. The 
pro sequence, encodes proteases (PR) responsible for cleaving Gag and Gag-Pol during 
particles assembly, budding and maturation. The pol sequence encodes the enzymes RT 
and IN, the former catalyzing the reverse transcription of the viral genome from RNA to 
DNA during the infection process and the latter responsible for integrating the proviral 
DNA into the host cell genome. The env sequence encodes for both SU and TM subunits of 
the envelope glycoprotein. Additionally, retroviral genome presents non-coding cis-acting 
sequences such as, two LTRs (long terminal repeats), which contain elements required to 
drive gene expression, reverse transcription and integration into the host cell 
chromosome, a sequence named packaging signal (ψ) required for specific packaging of 
the viral RNA into newly forming virions, and a polypurine tract (PPT) that functions as 
the site for initiating the positive strand DNA synthesis during reverse transcription 
(Coffin et al. 1997). 
Additionally to gag, pro, pol and env, complex retroviruses, such as lentiviruses, have 
accessory genes including vif, vpr, vpu, nef, tat and rev that regulate viral gene expression, 
assembly of infectious particles and modulate viral replication in infected cells (Fig 2B).  
Production of Retroviral and Lentiviral Gene  





Fig. 2. Retroviral genomes. Schematic representation of (A) MLV and (B) HIV-1 wild-type 
genomes representing simple and complex retrovirus, respectively. 
2. Cell line platforms for the production 
The establishment of retroviral and lentiviral producer cells, named packaging cell lines, has 
been based on the physical separation of the viral genome into different transcriptional units 




Fig. 3. Transcriptional units used for retroviral and lentiviral vector generation.  
(A) Three construct system used for (simple) retroviral vector and (B) four construct system 
used for third generation lentiviral vector production. Only the most relevant parts of the 
constructs are show; for further details see (Blesch 2004; Sinn et al. 2005).  
GOI: gene of interest; Prom_GOI: heterologous promoter and gene of interest. 
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assembly of infectious particles and modulate viral replication in infected cells (Fig 2B).  
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Fig. 2. Retroviral genomes. Schematic representation of (A) MLV and (B) HIV-1 wild-type 
genomes representing simple and complex retrovirus, respectively. 
2. Cell line platforms for the production 
The establishment of retroviral and lentiviral producer cells, named packaging cell lines, has 
been based on the physical separation of the viral genome into different transcriptional units 




Fig. 3. Transcriptional units used for retroviral and lentiviral vector generation.  
(A) Three construct system used for (simple) retroviral vector and (B) four construct system 
used for third generation lentiviral vector production. Only the most relevant parts of the 
constructs are show; for further details see (Blesch 2004; Sinn et al. 2005).  
GOI: gene of interest; Prom_GOI: heterologous promoter and gene of interest. 
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these constructs are additionally engineered with heterologous sequences including: 
promoters (Dull et al. 1998) to support their independent expression or for improved safety, 
enhancers (Gruh et al. 2008) and stabilizing elements (Zufferey et al. 1999) to increase the 
overall levels of transcripts both in producer and target cells, hence increasing viral titers 
and transgene expression.  
2.1 Retroviral vectors 
For both retroviral and lentiviral vector production, different packaging systems, named 
generations, have been developed. Each new generation aimed at minimizing and reduce 
the risk of RCPs formation face to the previous one (Fig 3).  
In the case of vectors based on MLV or other simple retrovirus, the non-cytotoxicity of the 
viral genes has allowed the establishment of cell lines stably and constitutively expressing 
viral vectors. Table 1 lists some of the available retroviral vector packaging cell lines. 
The first packaging cells reported as so for simple retroviral vector production were 
established by providing the packaging functions (gag-pro-pol) with a retroviral genome 
where the packaging signal was deleted, thus preventing their incorporation into the viral 
particles (Cone and Mulligan 1984). However, a single event of homologous 
recombination was sufficient to restore replicative competence. This led to a second 
generation of retroviral packaging cells (Miller and Buttimore 1986), in which further 
modifications were introduced including the replacement of the 3’LTR and the second 
strand initiation site with the polyadenylation site of SV40. The third generation (Danos 
and Mulligan 1988) (Fig. 3A) further separates the construct that expresses gag-pro-pol 
from env, in a total of three independent transcriptional units. Although three 
homologous recombination events would be needed to restore replicative competence, 
which is very improbable, replicative competent viruses can still occur in third generation 
cell lines (Chong et al. 1998; Chong and Vile 1996). Therefore, additional improvements 
were made by means of decreasing the homology in the vector construct, using different 
LTR species to those used in the packaging functions (Cosset et al. 1995) or using 
heterologous promoters such CMV’s (Rigg et al. 1996; Soneoka et al. 1995). The most 
recently developed retroviral vector packaging cell lines are based on this third 
generation optimized system. Gag-pro-pol genes are expressed from a single construct 
driven by a heterologous promoter. Vector construct contains a cassette for transgene 
expression typically driven by the 5’LTR promoter; it additionally contains the packaging 
signal (ψ) and the initial gag sequence known to provide enhanced packaging (Bender et 
al. 1987). The envelope expression is supplied by a third independent construct usually 
driven by a heterologous promoter. The separation of the envelope in an independent 
transcriptional unit offers great flexibility for envelope exchange – pseudotyping – and for 
the use of genetically or chemically engineered envelope proteins, thus allowing 
changing, restricting or broadening vector tropism (McTaggart and Al-Rubeai 2002; Yu 
and Schaffer 2005). For simple retroviruses several envelope glycoproteins have been used 
including MLV’s amphotropic 4070A and 10A1 (Miller and Chen 1996), GaLV’s (gibbon 
leukemia virus) (Miller et al. 1991), RD114 from cat endogenous virus (Takeuchi et al. 
1994), HIV’s gp120 (Schnierle et al. 1997) and the G protein from vesicular stomatitis virus 
(VSV-G) (Burns et al. 1993). Since the proteins encoded by these sequences are usually 
non-toxic, except for the last one, they can be constitutively expressed such that simple 
retroviral vector packaging cell lines are typically stable and continuously producing 
systems. 
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are expressed in terms of reverse transcriptase activity, which the correlation with infectious 
titers depends on the cell system.)   
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these constructs are additionally engineered with heterologous sequences including: 
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enhancers (Gruh et al. 2008) and stabilizing elements (Zufferey et al. 1999) to increase the 
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and transgene expression.  
2.1 Retroviral vectors 
For both retroviral and lentiviral vector production, different packaging systems, named 
generations, have been developed. Each new generation aimed at minimizing and reduce 
the risk of RCPs formation face to the previous one (Fig 3).  
In the case of vectors based on MLV or other simple retrovirus, the non-cytotoxicity of the 
viral genes has allowed the establishment of cell lines stably and constitutively expressing 
viral vectors. Table 1 lists some of the available retroviral vector packaging cell lines. 
The first packaging cells reported as so for simple retroviral vector production were 
established by providing the packaging functions (gag-pro-pol) with a retroviral genome 
where the packaging signal was deleted, thus preventing their incorporation into the viral 
particles (Cone and Mulligan 1984). However, a single event of homologous 
recombination was sufficient to restore replicative competence. This led to a second 
generation of retroviral packaging cells (Miller and Buttimore 1986), in which further 
modifications were introduced including the replacement of the 3’LTR and the second 
strand initiation site with the polyadenylation site of SV40. The third generation (Danos 
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driven by a heterologous promoter. Vector construct contains a cassette for transgene 
expression typically driven by the 5’LTR promoter; it additionally contains the packaging 
signal (ψ) and the initial gag sequence known to provide enhanced packaging (Bender et 
al. 1987). The envelope expression is supplied by a third independent construct usually 
driven by a heterologous promoter. The separation of the envelope in an independent 
transcriptional unit offers great flexibility for envelope exchange – pseudotyping – and for 
the use of genetically or chemically engineered envelope proteins, thus allowing 
changing, restricting or broadening vector tropism (McTaggart and Al-Rubeai 2002; Yu 
and Schaffer 2005). For simple retroviruses several envelope glycoproteins have been used 
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leukemia virus) (Miller et al. 1991), RD114 from cat endogenous virus (Takeuchi et al. 
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(VSV-G) (Burns et al. 1993). Since the proteins encoded by these sequences are usually 
non-toxic, except for the last one, they can be constitutively expressed such that simple 
retroviral vector packaging cell lines are typically stable and continuously producing 
systems. 
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Retroviral vectors have been based on several viruses including avian, simian, feline and 
murine retroviruses, being the latter (MLV) the most used. As so, the majority of the 
retroviral vector packaging cell lines established were murine derived, being NIH/3T3 
the most widely employed. However, it was rapidly found that the presence of 
galactosyl(α1-3)galactose carbohydrate moieties produced by murine cells in retroviral 
envelope lead to its rapid detection and inactivation by the human complement system 
(Takeuchi et al. 1994; Takeuchi et al. 1997; Takeuchi et al. 1996). Nowadays, murine cells 
are being replaced by human cell lines, to reduce the possibility of endogenous retroviral 
sequences packaging and also to improve vector half-life in vivo (Cosset et al. 1995).  
Establishing a producer cell line involves at least three transfection and clonal selection 
steps, taking a time-frame of around one year which constitutes a major drawback in stable 
cell line development (see section 3.1). Yet, this process is undertaken for each new 
therapeutic gene and/or different envelope protein required (for changing vector tropism). 
On the other hand, high-titer packaging cells development has been based on an efficient 
method to facilitate the selection of a high producer cell clone in which a selectable marker 
gene is inserted in the vector construct downstream of the viral genes, so they are translated 
from the same transcript after ribosomal reinitiation (Cosset et al. 1995). This strategy, 
however, although very efficient for screening stable integration and/or high level long-
term viral genome expression, raises considerable problems in therapeutic settings 
including immune response against the selection (foreign) gene product(s) (Liberatore et al. 
1999). Therefore, a new generation of retrovirus packaging cell lines based on cassette 
exchange systems that allow for flexible switch of the transgene and/or envelope, as well as 
selectable marker(s) excision, were developed (Coroadinha et al. 2006b; Loew et al. 2004; 
Persons et al. 1998; Schucht et al. 2006; Wildner et al. 1998). 
Schucht et al (2006) and Coroadinha et al (2006) established modular cell lines, based on targeted 

















Fig. 4. Schematic representation of the modular cell lines based on the recombinase 
mediated cassette exchange (RMCE) technology. (A) Integrated retroviral transgene cassette 
harboring a marker gene and (B) targeting therapeutic transgene plasmid allowing a fast 
exchange and establishment of a new retroviral producer cell. 
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Two cell lines were created; Flp293A and 293 FLEX, both derived from 293 cells. The former 
pseudotyped with amphotropic and the latter with GaLV envelopes. Recently, a PG13-based 
murine producer cell line was also established using this strategy (Loew et al. 2009). A 
favorable chromosomal site for stable and high retroviral vector production is first identified 
and tagged. Due to the presence of two heterologous non-compatible FRT sites flanking the 
tagged retroviral genome, the subsequent re-use of this defined chromosomal site by means 
of RMCE is than performed to express a therapeutic gene. In order to select cell clones that 
underwent correct targeted integration reaction, the targeting viral vector contains a start 
codon that complements a transcriptionally inactive ATG-deficient selection marker after 
recombination.  
The modular producer cell lines present several advantages: they are safer since integration 
of the vector within the packaging cell line was identified, the duration of the entire 
development process is much reduced as there is no need for screening and, in addition, 
production conditions are favorable due to the possibility of pre-adaptation of the master 
cell line to culture conditions and media. Thus, therapeutic virus production from bench to 
bedside becomes safer, faster, and cheaper (Coroadinha et al. 2010). 
2.2 Lentiviral vectors 
Similarly to retroviral vectors, the design of lentiviral vector packaging systems has evolved 
to minimize the risk of RCPs generation towards maximum safety. Currently, three 
generations of lentiviral vectors are considered. The first-generation (Naldini et al. 1996) 
closely resembles the three plasmid packaging system of simple retroviruses, except for the 
fact that the gag-pol expression is driven by a heterologous promoter instead of the viral 
LTR; additionally, the gp120 HIV-1’s envelope was replaced by VSV-G’s. However, this 
system contained all the necessary sequences for the generation of RCPs with three 
homologous recombination events which, although improbable, could not be accepted for a 
human and potentially lethal pathogen. 
In the second generation (Zufferey et al. 1997), the three plasmid system was maintained 
but all the accessory genes were deleted including vif, vpr, vpu, and nef. The third 
generation (Fig. 3B) allowed for a tat independent lentiviral vector expression by 
engineering a chimeric 5’LTR with a heterologous viral promoter/enhancer, such as 
CMV’s (cytomegalovirus) or RSV’s (Rous sarcoma virus) (Dull et al. 1998); rev 
complementation was separately provided in trans, thus this system has a total of four 
constructs. A schematic representation of the third generation system is shown in Fig. 3B. 
Gag-pro-pol genes are expressed from a CMV promoter and none of the accessory or 
regulatory proteins is present in this construct. Only rev accessory gene is maintained but 
is provided by a nonoverlapping plasmid. Vector cassette for transgene expression is 
driven by a heterologous promoter, as virus LTRs were partially deleted. Similarly to 
simple retroviruses, the transgene vector construct additionally contains the packaging 
signal (ψ) and the initial sequence from gag. The envelope cassette encodes typically, but 
not necessarily, for VSV-G envelope glycoprotein. 
The development of a fourth generation of lentiviral vectors, rev independent, has also been 
claimed by means of replacing RRE (rev responsive element) with heterologous viral 
sequences or by codon-optimization (Bray et al. 1994; Delenda 2004; Kotsopoulou et al. 2000; 
Pandya et al. 2001; Roberts and Boris-Lawrie 2000). However, its use is not widespread 
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Two cell lines were created; Flp293A and 293 FLEX, both derived from 293 cells. The former 
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murine producer cell line was also established using this strategy (Loew et al. 2009). A 
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since, contrary to the other generations of lentiviral vectors, these packaging systems have 
not been made available for the research community; also the reported titers are typically 
one to two logs bellow the maximum titers obtained with the second or third generation 
systems.  
In addition to HIV-derived, other lentiviral vectors have been developed and reported to 
retain identical features to those of HIV’s based, including the ability to transduce non-
dividing cells, high titers production, and the possibility to be pseudotyped with different 
envelope glycoproteins. These include lentiviral vectors based on SIV (simian 
immunodeficiency virus) (Pandya et al. 2001; Schnell et al. 2000), BIV (bovine 
immunodeficiency virus) (Matukonis et al. 2002; Molina et al. 2004), FIV (feline 
immunodeficiency virus) (Poeschla et al. 1998; Saenz and Poeschla 2004) and EAIV 
(equine infectious anaemia virus) (Balaggan et al. 2006; Mitrophanous et al. 1999; Stewart 
et al. 2009). Most of non-HIV derived lentiviral vectors have been reported to be tat and 
sometimes rev independent, thus falling in the 3rd or 4th generation of packaging systems. 
For clinical trials purposes, both second and third generation lentiviral vector systems 
were reported although only HIV-1 and EAIV derived vectors have been used (Schweizer 
and Merten 2010). 
Contrarily to simple retroviral vectors, the cytotoxicity of some of the lentiviral proteins 
has hampered the establishment of stable cell lines constitutively expressing vector 
components. Therefore, the majority of the reported packaging cells for lentivirus 
manufacturing have been based on inducible systems that control the expression of the 
toxic proteins (for further details see section 3.1). Nevertheless, it is worth notice that 
transient production is still the main mean for lentiviral vector generation for both 
research and clinical purposes. Table 2 summarizes some of the available (stable) 
lentiviral vector packaging cell lines. 
Except for the systems reported by and Ni et al. (2005), all the packaging cell lines for 
lentiviral vector production have been based on human 293 cells transformed with 
oncogenes such as the SV40 (simian vacuolating virus 40) large T antigen – 293T – or the 
Nuclear Antigen of Epstein-Barr Virus – 293EBNA.  
For clinical application human 293 and 293T cells have been the exclusive cell substrates 
(Schweizer and Merten 2010). However, safety concerns arise from the fact that 90% of non-
coding mobile sequences of the human genome are endogenous retrovirus and although 
most of them are defective, because of mutations accumulation, some are still active 
(Zwolinska 2006). Therefore, using human cell lines for the production of human 
retroviruses increases the chances of replicative-competent particles generation by 
homologous recombination (Pauwels et al. 2009). Also, the possibility of contamination with 
other human pathogens during the production process, poses additional hindrances to the 
use of human cells for biopharmaceuticals production, viral or not. In this context, the use of 
non-human cells would be strongly recommended, although the different glycosylation 
patterns of the envelope proteins could be an obstacle. For research purposes other human 
or monkey derived cells were tested (other 293 derived clones, HeLa, HT1080, TE671, COS-
1, COS-7, CV-1), although most of them showed reduced vector production titers. Yet, COS-
1 cells have shown to be capable of producing 3-4 times improved vector quality (expressed 
in infectious vector titer per ng of CA protein, p24), comparing with 293T cells (Smith and 
Shioda 2009).  
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Table 2. Packaging cell lines for lentiviral vector manufacture (1 – No lentiviral packaging 
cell line was developed based on the first generation lentiviral vector system.  
Tet-on/ Tet-off – tetracycline inducible system; tet-on becomes active upon tetracycline  
(or an analogous molecule such as doxycycline) is added and tet-off is activated by 
tetracycline removal.  NR: not reported) 
3. Bioreaction platforms and production media 
3.1 Stable vs. transient expression  
Production platforms for lentiviral and retroviral vectors have been restrained to 
mammalian cells, typically murine or human derived, which are transfected with gag-pol the 
packaging functions, vector (transgene) and envelope constructions. This can be based on a 
short-term transfer of the viral constructs, known as transient production, into exponentially 
growing cells followed by 24-72 hours vector production and harvesting, or by their stable 
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1 cells have shown to be capable of producing 3-4 times improved vector quality (expressed 
in infectious vector titer per ng of CA protein, p24), comparing with 293T cells (Smith and 
Shioda 2009).  
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Table 2. Packaging cell lines for lentiviral vector manufacture (1 – No lentiviral packaging 
cell line was developed based on the first generation lentiviral vector system.  
Tet-on/ Tet-off – tetracycline inducible system; tet-on becomes active upon tetracycline  
(or an analogous molecule such as doxycycline) is added and tet-off is activated by 
tetracycline removal.  NR: not reported) 
3. Bioreaction platforms and production media 
3.1 Stable vs. transient expression  
Production platforms for lentiviral and retroviral vectors have been restrained to 
mammalian cells, typically murine or human derived, which are transfected with gag-pol the 
packaging functions, vector (transgene) and envelope constructions. This can be based on a 
short-term transfer of the viral constructs, known as transient production, into exponentially 
growing cells followed by 24-72 hours vector production and harvesting, or by their stable 
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integration and constitutive expression into the host cell genome, for continuous production 
(Fig. 5).  
Transient production, makes use of transfection methods to introduce the viral 
constructions, commonly cationic agents that complex with the negatively charged DNA, 
thus allowing it to be up-taken by the cell via endocytosis (Al-Dosari and Gao 2009). From 
those, polyethylenimine (PEI) (Boussif et al. 1995) is probably the less expensive, one of the 
most efficient and the most widely used in the current protocols (Schweizer and Merten 
2010; Segura et al. 2010; Toledo et al. 2009). Others methods such as calcium phosphate 
precipitation (Jordan and Wurm 2004; Mitta et al. 2005) and cationic lipids complexation 
including LipofectAMINE® and FuGENE®, have also been used, although at small-scale 
production or for research purposes only since, these are either difficult to scale-up or very 
expensive. Alternatively, viral infection has also been developed and validated namely for 
lentiviral vector production, using baculoviruses as transfection agents (Lesch et al. 2008). 
However, the additional downstream work to separate lentiviral vector and baculoviruses 
to achieve clinical-grade viral preparations standards, as well as the final titers reported 
(Lesch et al. 2011) reduced the competitiveness of lentiviral vector production using 
baculoviruses over plasmid DNA transfection methods.  
 
 
Fig. 5. Stable vs. transient viral vector production. (A) Stable and continuous production 
from cell lines constitutively expressing viral vector transgene, gag-pro-pol and env; vector 
titers are nearly dependent on cell density until the end of the exponential phase of cell 
growth. (B) Transient production after plasmid transfection of viral vector transgene, gag-
pro-pol and env; high titers are obtained usually between 24 to 72 hours post-transfection, 
after which a pronounced decrease occurs, typically due to cell death. 
Stable production relies on cell substrates in which the viral constructs where separately 
integrated into the cell genome, thus allowing their constitutive expression. Typically, the 
packaging functions are first inserted and after clonal selection of a high-level gag-pol 
expression, the envelope construction is then inserted and a second round of clonal selection 
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
25 
is performed. At this point, a packaging cell line is established, in principal supporting the 
packaging of any viral vector (retroviral or lentiviral, depending on the gag-pro-pol 
functions). Finally, the transgene is introduced. If non-SIN vectors are used, this can be 
achieved directly by viral infection; otherwise, chemical transfection methods as those 
described above followed by stable integration and selection are required and equally 
suitable. Cosset and co-workers (1995) reported a very efficient method in which viral vector 
construct containing a (selectable) marker gene is firstly inserted in nude cells, facilitating 
the screening for stable integration and high-level long term expression (Cosset et al. 1995). 
This scheme was demonstrated to allow for the establishment of high-titer human derived 
retroviral vector packaging cell lines. Additionally, it permits high-titer retroviral vector 
production from single copy integration allowing for modular cell lines development, 
flexible platforms for transgene and/or envelope exchange (Coroadinha et al. 2006b; 
Schucht et al. 2006) (Fig. 4). Moreover, it allows optimization of the stoichiometry of the 
packaging constructs, maximizing viral titers and vector preparation quality, expressed by 
the ratio of infectious particles to total particles, which has a drastic impact on vector 
transduction efficiency a crucial parameter for clinical purposes (Carrondo et al. 2008).  
Stable retroviral vector cell line development is a tedious and time consuming process 
which can take up to one year for a fully developed and characterized cell platform. 
However, it is compensated by obtaining continuously producing and highly consistent cell 
systems, prone to single-effort bioprocess and product characterization, a critical 
consideration for market approval. 
Transient production is undoubtedly faster, when compared to the time frame necessary to 
develop a stable packaging cell line, presenting very competitive titers (up to 107 infectious 
vector per mL). Yet, for clinical purposes, continuous production by stable cell lines is highly 
desirable, since transient systems are difficult to scale-up, time and cost-ineffective at large 
scales and, more importantly, are unable to provide a fully characterized production 
platform with low batch-to-batch variability of the viral preparations. Therefore, transient 
production is unlikely to be of value after the transition from clinical to market. Retroviral 
vector manufacture, including those used in clinical trials, has been making use of stable 
and continuous cell lines for more than ten years (Cornetta et al. 2005; Eckert et al. 2000; 
Przybylowski et al. 2006; Wikstrom et al. 2004). However, the establishment of stable 
lentiviral vectors packaging cell lines has remained a challenge due to the inherent 
cytotoxicity of the lentiviral protease which has prohibited its constitutive expression 
(Schweizer and Merten 2010). It is well established that numerous HIV-1-encoded proteins 
are capable of causing cell death, including tat, nef, env, vpr and the protease (PR) (Gougeon 
2003); from those, only the protease is still required in the current packaging systems. HIV 
protease mediates its toxicity in vitro and in vivo, by cleaving and activating procaspase 8, 
leading to mitochondrial release of cytochrome c, activation of the downstream caspases 9 
and 3 and lastly, nuclear fragmentation (Nie et al. 2007; Nie et al. 2002). Ikeda and co-
workers have reported the development of a 293T derived cell line, STAR, stable and 
continuously producing LV using an HIV-1 codon optimized gag-pol (Ikeda et al. 2003). 
However, significant titers could only be obtained by MLV-based vector transduction of the 
optimized gag-pol. This procedure raises biosafety issues, since it increases the chances of 
generating replicative-competent particles by homologous recombination and, posing 
further concerns of co-packaging (Pauwels et al. 2009).  
At a laboratory scale, transient production by plasmid transfection has been the first choice 
to cope with the cytotoxic proteins. For larger-scale production purposes, conditional 
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is performed. At this point, a packaging cell line is established, in principal supporting the 
packaging of any viral vector (retroviral or lentiviral, depending on the gag-pro-pol 
functions). Finally, the transgene is introduced. If non-SIN vectors are used, this can be 
achieved directly by viral infection; otherwise, chemical transfection methods as those 
described above followed by stable integration and selection are required and equally 
suitable. Cosset and co-workers (1995) reported a very efficient method in which viral vector 
construct containing a (selectable) marker gene is firstly inserted in nude cells, facilitating 
the screening for stable integration and high-level long term expression (Cosset et al. 1995). 
This scheme was demonstrated to allow for the establishment of high-titer human derived 
retroviral vector packaging cell lines. Additionally, it permits high-titer retroviral vector 
production from single copy integration allowing for modular cell lines development, 
flexible platforms for transgene and/or envelope exchange (Coroadinha et al. 2006b; 
Schucht et al. 2006) (Fig. 4). Moreover, it allows optimization of the stoichiometry of the 
packaging constructs, maximizing viral titers and vector preparation quality, expressed by 
the ratio of infectious particles to total particles, which has a drastic impact on vector 
transduction efficiency a crucial parameter for clinical purposes (Carrondo et al. 2008).  
Stable retroviral vector cell line development is a tedious and time consuming process 
which can take up to one year for a fully developed and characterized cell platform. 
However, it is compensated by obtaining continuously producing and highly consistent cell 
systems, prone to single-effort bioprocess and product characterization, a critical 
consideration for market approval. 
Transient production is undoubtedly faster, when compared to the time frame necessary to 
develop a stable packaging cell line, presenting very competitive titers (up to 107 infectious 
vector per mL). Yet, for clinical purposes, continuous production by stable cell lines is highly 
desirable, since transient systems are difficult to scale-up, time and cost-ineffective at large 
scales and, more importantly, are unable to provide a fully characterized production 
platform with low batch-to-batch variability of the viral preparations. Therefore, transient 
production is unlikely to be of value after the transition from clinical to market. Retroviral 
vector manufacture, including those used in clinical trials, has been making use of stable 
and continuous cell lines for more than ten years (Cornetta et al. 2005; Eckert et al. 2000; 
Przybylowski et al. 2006; Wikstrom et al. 2004). However, the establishment of stable 
lentiviral vectors packaging cell lines has remained a challenge due to the inherent 
cytotoxicity of the lentiviral protease which has prohibited its constitutive expression 
(Schweizer and Merten 2010). It is well established that numerous HIV-1-encoded proteins 
are capable of causing cell death, including tat, nef, env, vpr and the protease (PR) (Gougeon 
2003); from those, only the protease is still required in the current packaging systems. HIV 
protease mediates its toxicity in vitro and in vivo, by cleaving and activating procaspase 8, 
leading to mitochondrial release of cytochrome c, activation of the downstream caspases 9 
and 3 and lastly, nuclear fragmentation (Nie et al. 2007; Nie et al. 2002). Ikeda and co-
workers have reported the development of a 293T derived cell line, STAR, stable and 
continuously producing LV using an HIV-1 codon optimized gag-pol (Ikeda et al. 2003). 
However, significant titers could only be obtained by MLV-based vector transduction of the 
optimized gag-pol. This procedure raises biosafety issues, since it increases the chances of 
generating replicative-competent particles by homologous recombination and, posing 
further concerns of co-packaging (Pauwels et al. 2009).  
At a laboratory scale, transient production by plasmid transfection has been the first choice 
to cope with the cytotoxic proteins. For larger-scale production purposes, conditional 
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packaging systems have been developed in which the expression of those is under the 
control of inducible promoters (Broussau et al. 2008; Farson et al. 2001; Kuate et al. 2002; 
Pacchia et al. 2001; Stewart et al. 2009). However transient transfection systems are, as 
discussed above, difficult to scale-up and do not fulfill adequate batch-to-batch variability 
standards; and, although the clinical trials currently using lentiviral vectors have been 
provided exclusively with transiently produced batches (Schweizer and Merten 2010), it is 
unlikely that a transient based systems will be approved when going from clinical to 
market. Conditional systems, on the other hand, require the addition/removal of the 
induction agents cumbering the production and requiring further down-stream stringency 
in processing of the viral preparations. 
3.2 Stirred bioreaction vs. adherent cultures 
It is widely accepted that stirred bioreaction systems using suspension cultures offer more 
advantages from the bioprocess view-point when compared to those under static/adherent 
conditions. The most evident advantage is the higher volumetric productivity, since 
suspension cultures in stirred systems present increased ratios of cell number per volume of 
culture medium. Because of this, they are easier to scale-up with less space requirements; 
the agitation allows for homogeneous cells suspension preventing the formation of chemical 
(nutrient, waste products), physical (pH, oxygen, carbon dioxide) and thermal gradients, 
thus maximizing the productivity potential of the culture (Sadettin and Hu 2006).  
The first suspension system reported for high-titer retroviral vector production was based 
on a T-lymphoblastoid cell line using a third generation packaging construct, producing 
MLV derived retroviral vectors pseudotyped with amphotropic envelope: CEMFLYA cells 
(Pizzato et al. 2001). These cells were able to produce in the range of 107 infectious units per 
mL and, the potential for scaled up vector production was demonstrated by continuous 
culture during 14 days in a 250 mL spinner flask. After CEMFLYA, other high-titer 
suspension cells were reported, namely suspension-adapted 293GPG cells producing MLV 
retrovirus vector pseudotyped with the vesicular stomatitis virus G (VSVG) envelope 
protein and expressing a TK-GFP fusion protein in a 3L acoustic filter-based perfusion 
bioreactor (Ghani et al. 2006). Another major landmark was achieved when the same group 
published for the first time retroviral vector production in suspension and under serum-free 
conditions (Ghani et al. 2007) (see section 3.4.1). Following retrovirus, lentiviral vector 
manufacture using suspension cultures has also been recently reported both for 
transfection-based transient production (Ansorge et al. 2009), as well as, for stable 
production using (inducible) packaging cell lines (Broussau et al. 2008). 
Despite the advances in the development of suspension cultures for stirred tank bioreactors 
and its clear advantage from the bioprocess view-point, retroviral and lentiviral vector 
manufacture for clinical batches has mainly been based on adherent static and preferably 
disposable systems, including large T-flasks, cell factories and roller bottles (Fig. 6) (Eckert 
et al. 2000; Merten et al. 2011; Przybylowski et al. 2006; Wikstrom et al. 2004). A good 
example is retroviral vector production at the National Gene Vector Laboratory, Indiana 
University, (Indianapolis, IN), a US National Institutes of Health initiative that has as main 
mission provide clinical grade vectors for gene therapy trials (Cornetta et al. 2005). Also for 
clinical-grade lentiviral vector production, the bioreaction system of choice has been Cell 
Factory or equivalent multitray systems (Merten et al. 2011; Schweizer and Merten 2010).  
These systems allow for 10 to 40 L vector production under GMP conditions, meeting the 
needs for initial trials, where usually a reduced number of patients are involved. In the 
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future, if lentiviral and retroviral vector Gene Therapy products reach the market, it is still 
not clear if such systems will continue to be used. In fact, several restrictions arise from the 
use of disposable systems and bioreactors including the increase in the costs of solid waste 
disposal and consumables, in addition to low scalability and the single-use philosophy itself 
(Eibl et al. 2010). However, the low infectivity stability of retro and lentiviral vectors has 
hampered the perspective of the “thousand-liter” production systems’ for further storage. 
Nevertheless, significant efforts are being made to overcome this drawback including, at the 
bioprocess level, by developing storage formulations (Carmo et al. 2009a; Cruz et al. 2006) 
and at the viral vector design level, by developing mutant vectors with increased infectivity 
stability (Vu et al. 2008). 
 
 
Fig. 6. Culture systems used for retroviral and lentiviral vector manufacture. Stirred tank 
bioreactor (A) vs. adherent disposable systems, T-flasks (B), roller bottles (C) and (D) cell 
factories. 
3.3 Bioreaction physicochemical parameters 
The cell culture parameters used in the bioreaction may have a profound effect on the virus 
titer by affecting the cellular productivities, vector stability or both. Several studies have 
been performed analyzing the impact of physicochemical parameters such as pH, 
temperature, osmolarity, O2 and CO2 concentrations. The optimal cell culture parameters 
have been shown to be producer cell line and viral vector dependent. 
The optimal pH range for retroviral vector production was found to be between 6.8 and 7.2 
for FLY RD18 and Te FLY A7; outside this range the cell specific productivities were 
considerable lower (McTaggart and Al-Rubeai 2000; Merten 2004), while the retroviral 
vector was observed to be stable between pH of 5.5 and 8.0 in ecotropic pseudotyped 
vectors (Ye et al. 2003). Both retroviral vectors (MLV derived) and lentiviral vectors (HIV-1 
derived), VSV-G pseudotyped, were stable at pH 7. The half-lives of both viral vectors at pH 
6.0 and pH 8.0 markedly decrease to less than 10 minutes (Higashikawa and Chang 2001). 
The viral half-life is also dependent on the temperature: at lower temperatures the vector 
decay kinetics are lower (Le Doux et al. 1999). Therefore one strategy explored in the 
production of retroviral vectors has been the reduction of the culture temperatures (28-
32ºC). Some authors reported increases in vector production at lower temperature (Kaptein 
et al. 1997; Kotani et al. 1994; Le Doux et al. 1999; Lee et al. 1996). The reduction of the 
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future, if lentiviral and retroviral vector Gene Therapy products reach the market, it is still 
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titer by affecting the cellular productivities, vector stability or both. Several studies have 
been performed analyzing the impact of physicochemical parameters such as pH, 
temperature, osmolarity, O2 and CO2 concentrations. The optimal cell culture parameters 
have been shown to be producer cell line and viral vector dependent. 
The optimal pH range for retroviral vector production was found to be between 6.8 and 7.2 
for FLY RD18 and Te FLY A7; outside this range the cell specific productivities were 
considerable lower (McTaggart and Al-Rubeai 2000; Merten 2004), while the retroviral 
vector was observed to be stable between pH of 5.5 and 8.0 in ecotropic pseudotyped 
vectors (Ye et al. 2003). Both retroviral vectors (MLV derived) and lentiviral vectors (HIV-1 
derived), VSV-G pseudotyped, were stable at pH 7. The half-lives of both viral vectors at pH 
6.0 and pH 8.0 markedly decrease to less than 10 minutes (Higashikawa and Chang 2001). 
The viral half-life is also dependent on the temperature: at lower temperatures the vector 
decay kinetics are lower (Le Doux et al. 1999). Therefore one strategy explored in the 
production of retroviral vectors has been the reduction of the culture temperatures (28-
32ºC). Some authors reported increases in vector production at lower temperature (Kaptein 
et al. 1997; Kotani et al. 1994; Le Doux et al. 1999; Lee et al. 1996). The reduction of the 
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culture temperature from 37ºC to 32ºC extends vector stability allowing for the 
accumulation of more infectious virus and thus, increasing the volumetric titers. However, 
the increments are not always very significant as the temperature affects also the cell specific 
yields negatively. The improvement in the viral volumetric titer will be only observed if, the 
increase in the viral half-life is higher than the decrease in the cell specific production rate 
(Le Doux et al. 1999). Additionally, the viral vector inherent stability was also demonstrated 
to be lower when the viral vector was produced at 32ºC instead of 37ºC (Beer et al. 2003; 
Cruz et al. 2005). It was shown that the culture temperature affected the lipid viral 
membrane composition namely, the cholesterol content. The increase in cholesterol content 
was demonstrated to be inversely proportional to retroviral stability (Beer et al. 2003; 
Coroadinha et al. 2006c). Since enveloped virus, such as retrovirus and lentivirus, bud out of 
the host cells, they take part of the host cell lipidic membrane. Thus, the origin of the 
producer cell will have a pronounced effect on the viral particle stability and explain the 
discrepant results obtained for virus produced in different cells and at different 
temperatures. For PA317 cells, decreasing the production temperature from 37ºC to 32ºC 
resulted in an increase of 5-15 fold in the vector titers (Kaptein et al. 1997) while for PG13 
lower titers were obtained (Reeves et al. 2000). The viral vector envelope glycoproteins also 
affect the viral particle inherent stability increasing the complexity and diversity of factors 
involved in the viral stability. Comparing lentiviral and retroviral vectors it was generally 
observed that HIV-1 derived vectors are more stable at 37ºC and at higher temperatures 
than MLV derived vectors (Higashikawa and Chang 2001). 
Augmenting the media osmolarity was also shown to be a valid strategy to increase retroviral 
vector titers in Te FLY A7 (Coroadinha et al. 2006c). This increment was correlated with higher 
cell specific productivities and higher inherent viral stability. The high osmotic pressure 
altered the cellular and viral envelope lipid membrane composition. High osmotic media were 
tested showing to induce a decrease in the cholesterol to phospholipids ratio in the viral 
membrane and thus conferring higher stability to the viral vectors produced (Coroadinha et al. 
2006c). These results, together with the studies of production at lower culture temperatures, 
strengthen the importance of lipid metabolism in the production of enveloped virus.   
CO2 gas concentration in the cultures did not affect virus production in packaging cell lines 
(Kotani et al. 1994; McTaggart and Al-Rubeai 2000). The dissolved oxygen levels used are 
between 20-80% and within this range do not affect viral production unless they became 
limiting to cell growth (Merten 2004). 
3.4 Media composition and cell metabolic bottlenecks 
Retroviral and lentiviral vector titers obtained in the production prior to purification are in 
the range of 106 to 107 infectious particles per mL of culture medium. Considering the 
average amount needed to treat a patient in a clinical trial, in the order of 1010  infectious 
vectors (Aiuti et al. 2009; Cavazzana-Calvo et al. 2000; Ott et al. 2006), around 10-100 L of 
culture volume can be previewed for each patient. Also, viral preparations are typically 
characterized by low ratios of infectious particles to total particles (around 1:100) which 
further reduce the therapeutic efficiency of the infectious ones (Carrondo et al. 2008). 
Additionally, these vectors are extremely sensitive losing their infectivity relatively fast, the 
reported half-lives are between 8-12 hours in cell culture supernatant at 37ºC (Carmo et al. 
2009b; Carmo et al. 2008; Higashikawa and Chang 2001; Merten 2004; Rodrigues et al. 2009). 
Thus, the productivity performance of retroviral and lentiviral vector producing systems is 
below the therapeutic needs. 
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The problems of low titers, short half-life and low ratios of infectious particles to total particles 
have been subject of intensive bioprocess research. However, the infection with wild type 
retroviruses, in particular HIV-1, is typically chronically and characterized by persistent but 
low titers of the infectious agents in the blood stream, with high amounts of non-infectious 
particles contaminants and with equivalently low half-lives (Perelson et al. 1996; Rusert et al. 
2004). Therefore, retrovirus and lentiviral manufacture starts in disadvantage – when 
compared to other viral vectors – in what concerns to such parameters. Several strategies have 
been attempted to circumvent these “natural” drawbacks in packaging cell lines, including 
engineering mutant vectors with improved resistance features and understanding and 
optimizing the metabolic pathways leading to improved productivities. Studying the 
metabolic features driving to high titer performances has been one important work lines of 
research. Therefore, this section will mainly focus on the metabolic bottlenecks of viral vector 
production. 
3.4.1 Serum supplemented vs. serum-free media 
The supplementation of mammalian cell culture media with animal sera has been common 
practice in biomedical and biotechnological research, since it provides critical nutrients and 
factors that support cell growth and proliferation. However, the ill-defined composition and 
high batch-to-batch variability of serum together with its potential source of contaminations, 
hinders safety and standardization of cell cultures, making it a highly undesirable 
supplement in the production of biopharmaceuticals (Falkner et al. 2006). Also, in the case of 
retroviral and lentiviral vectors, serum needs to be removed from the medium and/or viral 
preparations to prevent immunological responses in the patients. 
Retroviral and lentiviral vector manufacture has been reported to rely on considerable 
amounts (5-10% (v/v)) of animal sera in the culture medium; although some authors 
reported improved titers in short-term serum-free productions (Gerin et al. 1999a; 
McTaggart and Al-Rubeai 2000), the issue of serum dependence for retroviral and lentiviral 
vector production will be next discussed in the perspective of long-term cultures. The 
majority of the latest generation of packaging cell lines, specially the HEK293 (human 
embryonic kidney) derived ones, seem to require high concentrations of serum in the 
culture medium to support elevated viral productivities for long term culture (Chan et al. 
2001; Gerin et al. 1999a; Gerin et al. 1999b; Pizzato et al. 2001; Rodrigues et al. 2009).  
The need of serum for retroviral and lentiviral vector production has been mainly associated 
with the lipidic needs of packaging cell lines. Unless other supplements are added, serum is 
the only lipid source of the culture medium and, although cells should be able to sense lipid 
absence in the culture medium and activate biosynthetic pathways to stand up to lipid 
deprivation, the activation of lipid de novo synthesis may take hours or days, depending on 
the cell type (Alberts et al. 1974; Spector et al. 1980). In some cases, cells can no longer 
synthesize certain lipids (Seth et al. 2005). Membrane lipids are active players in the complex 
process of retroviral assembling, and pseudotyping that takes place at the host cell 
membrane, in which interactions of membrane lipid rafts select both envelope and core 
proteins, recruiting later the other viral components by cooperative interaction. The 
production of infectious particles is known to rely on the efficiency of this process, which is 
dependent upon a delicate equilibrium of lipid type and amounts, easily disturbed by lipid 
deprivation (Briggs et al. 2003). Therefore, changes in serum concentration that disturb cell 
membrane lipid composition will ultimately affect viral particle membrane properties 
(Rawat et al. 2003) possibly resulting in a higher production of non-infectious particles. In 
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culture temperature from 37ºC to 32ºC extends vector stability allowing for the 
accumulation of more infectious virus and thus, increasing the volumetric titers. However, 
the increments are not always very significant as the temperature affects also the cell specific 
yields negatively. The improvement in the viral volumetric titer will be only observed if, the 
increase in the viral half-life is higher than the decrease in the cell specific production rate 
(Le Doux et al. 1999). Additionally, the viral vector inherent stability was also demonstrated 
to be lower when the viral vector was produced at 32ºC instead of 37ºC (Beer et al. 2003; 
Cruz et al. 2005). It was shown that the culture temperature affected the lipid viral 
membrane composition namely, the cholesterol content. The increase in cholesterol content 
was demonstrated to be inversely proportional to retroviral stability (Beer et al. 2003; 
Coroadinha et al. 2006c). Since enveloped virus, such as retrovirus and lentivirus, bud out of 
the host cells, they take part of the host cell lipidic membrane. Thus, the origin of the 
producer cell will have a pronounced effect on the viral particle stability and explain the 
discrepant results obtained for virus produced in different cells and at different 
temperatures. For PA317 cells, decreasing the production temperature from 37ºC to 32ºC 
resulted in an increase of 5-15 fold in the vector titers (Kaptein et al. 1997) while for PG13 
lower titers were obtained (Reeves et al. 2000). The viral vector envelope glycoproteins also 
affect the viral particle inherent stability increasing the complexity and diversity of factors 
involved in the viral stability. Comparing lentiviral and retroviral vectors it was generally 
observed that HIV-1 derived vectors are more stable at 37ºC and at higher temperatures 
than MLV derived vectors (Higashikawa and Chang 2001). 
Augmenting the media osmolarity was also shown to be a valid strategy to increase retroviral 
vector titers in Te FLY A7 (Coroadinha et al. 2006c). This increment was correlated with higher 
cell specific productivities and higher inherent viral stability. The high osmotic pressure 
altered the cellular and viral envelope lipid membrane composition. High osmotic media were 
tested showing to induce a decrease in the cholesterol to phospholipids ratio in the viral 
membrane and thus conferring higher stability to the viral vectors produced (Coroadinha et al. 
2006c). These results, together with the studies of production at lower culture temperatures, 
strengthen the importance of lipid metabolism in the production of enveloped virus.   
CO2 gas concentration in the cultures did not affect virus production in packaging cell lines 
(Kotani et al. 1994; McTaggart and Al-Rubeai 2000). The dissolved oxygen levels used are 
between 20-80% and within this range do not affect viral production unless they became 
limiting to cell growth (Merten 2004). 
3.4 Media composition and cell metabolic bottlenecks 
Retroviral and lentiviral vector titers obtained in the production prior to purification are in 
the range of 106 to 107 infectious particles per mL of culture medium. Considering the 
average amount needed to treat a patient in a clinical trial, in the order of 1010  infectious 
vectors (Aiuti et al. 2009; Cavazzana-Calvo et al. 2000; Ott et al. 2006), around 10-100 L of 
culture volume can be previewed for each patient. Also, viral preparations are typically 
characterized by low ratios of infectious particles to total particles (around 1:100) which 
further reduce the therapeutic efficiency of the infectious ones (Carrondo et al. 2008). 
Additionally, these vectors are extremely sensitive losing their infectivity relatively fast, the 
reported half-lives are between 8-12 hours in cell culture supernatant at 37ºC (Carmo et al. 
2009b; Carmo et al. 2008; Higashikawa and Chang 2001; Merten 2004; Rodrigues et al. 2009). 
Thus, the productivity performance of retroviral and lentiviral vector producing systems is 
below the therapeutic needs. 
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fact, it has been not only demonstrated that lipids are one of the main serum components 
correlated with high retroviral infectious vector titers but also, that the reduction of serum in 
the culture medium affects infectious titers only, i.e. the total number of particles produced 
remained unaltered (Rodrigues et al. 2009). Indeed, high-titer production of retroviral and 
lentiviral vectors under serum-free conditions has only been achieved in the presence of 
lipid supplements, lipid carriers and lipoproteins addition (Broussau et al. 2008; Ghani et al. 
2007). 
The work done so far, addressing the issue of serum supplementation and infectious vector 
production, has mainly been focused on retroviral vectors, less attention has been paid to 
serum/lipid requirements in lentiviral vector production. Of notice is the work developed 
by B. Mitta et al (2005) in which optimal lentiviral production parameters were established, 
resulting in up to 132-fold improved productivities, and quality. The later is defined as the 
viral infectious titer (reflecting the number of transduction-competent lentiviral particles) 
relative to the number of total physical lentiviral particles produced (analysed by the levels 
of p24). A reduced-serum formulation was used and supplemented.  Among others, lipid 
supplementation, included cholesterol, lecithin and chemically defined lipid concentrates. 
The lipid supplements were identified as the main responsibles for the improved viral 
productivities obtained. 
In the case of lentiviral vectors, the short-term production periods associated with either the 
transient or conditional productions have not elucidated the extent of serum dependence in 
the production of high-infectious vector titers. Yet, the large majority of the current 
protocols for the production of lentiviral vectors still make use of 5 to 10% (v/v) of serum in 
the culture medium and up to now, only two publications have reported the production of 
lentiviral vectors under serum-free conditions (Ansorge et al. 2009; Broussau et al. 2008), 
both of them requiring lipid supplementation.  
More recently, studies on the effects of adapting retroviral vector packaging cell lines to 
serum deprivation conditions and how it impacts infectious vector production have been 
performed. These studies identified differences in cell lipid metabolism as a requirement 
needed by the packaging cells to be able to adapt to serum deprivation: cells capable of 
activating de novo lipid biosynthesis under serum withdrawal, particularly cholesterol, are 
able to be adapted to serum deprivation without significant loss of infectious vector titer 
production. On the other hand, cells facing serum removal from the culture medium that are 
unable to activate lipid biosynthesis – HEK293 – lose infectious titer productivity after a few 
passages (Rodrigues et al., 2011). In this context, it should be noticed that long term serum-
free production of retro and lentiviral vectors reported so far has been based not only in 
lipid supplemented media but also on oncogene transformed 293 cells, namely 293T, 
transformed with SV40 large T antigen (T-Ag) and 293 EBNA, transformed with Nuclear 
Antigen of Epstein-Barr Virus. These cells exhibit very different physiological features when 
compared to their non-transformed counterparts, 293, potentially facilitating serum-
independence for vector production.  For instance, SV40 transformed cells were shown to 
require minimal serum amounts or no serum at all, in the culture medium in order to 
proliferate. T-Ag expression is known to allow to overcome growth arrest mediated by 
contact inhibition and provide to the transformed cells an anchorage independent 
phenotype (Ahuja et al. 2005). Additionally, T-Ag expression drives even quiescent cells to 
the S-Phase (Ahuja et al. 2005), potentially providing raw material for viral replication. 
Besides those changes mentioned above, not much is known about the long-term 
physiological modifications induced by T-Ag and EBNA transformation. However, it is 
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possible that some of those changes target lipid biosynthetic pathways, given that oncogenic 
neoplastic transformation is typically characterized by an increase in lipid biosynthesis and 
turnover (Barger and Plas 2010; Swinnen et al. 2006). In conclusion, the major metabolic 
hinge between serum and high titers has been demonstrated to be the lipids and cellular 
lipid metabolism.  
3.4.2 Sugar carbon source 
Glucose has been the traditional sugar source employed in animal cell culture media and 
thus, the most used in the production of retroviral and lentiviral vectors. Together with 
glutamine, glucose is the major energy and carbon source in the culture medium. It is also 
the universal carbohydrate in animal cell culture, since glucose cellular transporters are 
present in the majority of the mammalian cell types. However, glucose is rapidly consumed 
and inefficiently metabolized to lactate which, per se, is toxic to the cell. Concentrations of 
lactate above 5 mM can inhibit cell growth of Te Fly Ga18 cells and retroviral production 
(Merten et al. 2001).  
The use of alternative sugar sources to glucose is a possible strategy to decrease lactate 
production. Indeed, the use of fructose and galactose was shown to improve the retroviral 
production in Te FLY A7, Te FLY Ga18, PG13 and Tel CeB cell lines (Coroadinha et al. 
2006a; Merten 2004). The lactate production decreased 2 to 6 fold in galactose and fructose 
media and the vector titers increased up to 8 fold. Both galactose and fructose consumption 
rates were lower than glucose in Te Fly A7, possible due to lower specificity of the sugar 
transporters expressed in these cells. The best results in terms of vector titers were obtained 
at high concentrations of fructose (15-25 g/L) (Coroadinha et al., 2006, Merten, 2004). 
Additionally to the metabolic shift induced by an alternative carbon source, an effect of high 
osmotic pressure can also be of relevance in the improvement of viral titers (see section 3.3). 
The increment of infectious titers observed at high sugar concentrations in Te Fly A7 was 
confirmed to be the result of higher cell specific productivities, higher vector stability and 
lower production of defective non-infective particles (Coroadinha et al., 2006a and 2006b) 









molar ratio in viral particles 
Glucose 25 mM 335 0.18 ± 0.01 8 ± 0.7 0.53±0.03 
Glucose 25 mM 
+ sorbitol 450 0.80± 0.09 14± 1 0.33±0.01 
Fructose 140 
mM 450 1.0± 0.1 14±2 0.30±0.01 
Table 3. Effect of alternative sugar sources and media osmolality in retroviral vector 
production. Te Fly A7 producer cells were used in this study. Sorbitol is a non-ionic osmotic 
agent, non-metabolized by the cells. 
Further metabolic studies were performed using 13C-NMR spectroscopy indicating changes 
in the lipid metabolism, namely higher synthesis of phospholipids (Coroadinha et al., 2006 
and Amaral et al., 2008). These results show that packaging cell line metabolism deeply 
influences the productivity performances, in particular lipid biosynthesis, thus suggesting it 
to be an important target for further improve retroviral and possibly lentiviral vector titers. 
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fact, it has been not only demonstrated that lipids are one of the main serum components 
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proliferate. T-Ag expression is known to allow to overcome growth arrest mediated by 
contact inhibition and provide to the transformed cells an anchorage independent 
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possible that some of those changes target lipid biosynthetic pathways, given that oncogenic 
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hinge between serum and high titers has been demonstrated to be the lipids and cellular 
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Glucose has been the traditional sugar source employed in animal cell culture media and 
thus, the most used in the production of retroviral and lentiviral vectors. Together with 
glutamine, glucose is the major energy and carbon source in the culture medium. It is also 
the universal carbohydrate in animal cell culture, since glucose cellular transporters are 
present in the majority of the mammalian cell types. However, glucose is rapidly consumed 
and inefficiently metabolized to lactate which, per se, is toxic to the cell. Concentrations of 
lactate above 5 mM can inhibit cell growth of Te Fly Ga18 cells and retroviral production 
(Merten et al. 2001).  
The use of alternative sugar sources to glucose is a possible strategy to decrease lactate 
production. Indeed, the use of fructose and galactose was shown to improve the retroviral 
production in Te FLY A7, Te FLY Ga18, PG13 and Tel CeB cell lines (Coroadinha et al. 
2006a; Merten 2004). The lactate production decreased 2 to 6 fold in galactose and fructose 
media and the vector titers increased up to 8 fold. Both galactose and fructose consumption 
rates were lower than glucose in Te Fly A7, possible due to lower specificity of the sugar 
transporters expressed in these cells. The best results in terms of vector titers were obtained 
at high concentrations of fructose (15-25 g/L) (Coroadinha et al., 2006, Merten, 2004). 
Additionally to the metabolic shift induced by an alternative carbon source, an effect of high 
osmotic pressure can also be of relevance in the improvement of viral titers (see section 3.3). 
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confirmed to be the result of higher cell specific productivities, higher vector stability and 
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No studies with alternative sugar sources have been reported with lentiviral vectors. 
Nevertheless, the above studies were performed with, Te671 and NIH 3T3 cells and most 
lentiviral vectors are produced in 293 derived cells. 
4. Conclusions and outlook 
Murine leukemia virus (MLV) derived vectors were the first viral vectors used in clinical 
trials and remain among the preferentially used vehicles for gene therapy applications due 
to their advantages relatively to other vectors. Lentiviral vectors have been developed more 
recently. From the therapeutic perspective they present the additional advantage of 
transducing non-dividing cells. From the manufacturing perspective lentiviral vectors 
present however, an additional difficulty as they contain cytotoxic proteins, requiring either 
the use of transient transfection or inducible systems. Both lentiviral and retroviral vectors 
are derived from virus belonging to the retroviridae family sharing many characteristics in 
terms of genome, biochemistry, structure and viral cycle. Thus many of the metabolic 
constraints in their production are common and reviewed herein.  
The success of the application of retroviral vectors in phase I and II clinical trials is now 
moving the prospects to phase III trials. This will create momentum to increase the efforts in 
research related with retroviral vectors development and production due to the large 
amounts of vectors needed, and the stringent demands by the regulatory agencies. 
Lentiviral vectors in particular possess many of the characteristics of MLV retroviral vectors, 
and as mentioned present the additional advantages of being able to transduce quiescent 
cells. The diversity of human gene therapy as well as the possibility of patients being treated 
more than once with viral vectors, which are recognized by the adaptive immune system, 
leaves space to both alternative vector technologies. MLV present a large safety record in 
clinical application that cannot be discarded. Since MLV retroviral vectors are not derived 
from human viruses they also show reduced vector genome mobilization and recombination 
in the host-cell and pre-existing immune response against the retroviral vector particle. 
Additionally, they are simple to develop in terms of plasmid cloning, transfection and cell 
culture; and from the clinical perspective they can be easily produced at large scale from 
stable packaging cell lines with satisfactory yields. From the manufacturing point of view, 
HIV-1 derived vector still requires further optimization, particularly in what concerns cell 
line development. There is still less clinical experience with this vector and the results on the 
ongoing clinical trials will be certainly important for their improvement. 
Thus the recent manufacturing strategies together with future innovations will certainly be 
important to increase productivity, stability, quality and safety of retroviral and lentiviral 
vectors for clinical applications. 
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Nevertheless, the above studies were performed with, Te671 and NIH 3T3 cells and most 
lentiviral vectors are produced in 293 derived cells. 
4. Conclusions and outlook 
Murine leukemia virus (MLV) derived vectors were the first viral vectors used in clinical 
trials and remain among the preferentially used vehicles for gene therapy applications due 
to their advantages relatively to other vectors. Lentiviral vectors have been developed more 
recently. From the therapeutic perspective they present the additional advantage of 
transducing non-dividing cells. From the manufacturing perspective lentiviral vectors 
present however, an additional difficulty as they contain cytotoxic proteins, requiring either 
the use of transient transfection or inducible systems. Both lentiviral and retroviral vectors 
are derived from virus belonging to the retroviridae family sharing many characteristics in 
terms of genome, biochemistry, structure and viral cycle. Thus many of the metabolic 
constraints in their production are common and reviewed herein.  
The success of the application of retroviral vectors in phase I and II clinical trials is now 
moving the prospects to phase III trials. This will create momentum to increase the efforts in 
research related with retroviral vectors development and production due to the large 
amounts of vectors needed, and the stringent demands by the regulatory agencies. 
Lentiviral vectors in particular possess many of the characteristics of MLV retroviral vectors, 
and as mentioned present the additional advantages of being able to transduce quiescent 
cells. The diversity of human gene therapy as well as the possibility of patients being treated 
more than once with viral vectors, which are recognized by the adaptive immune system, 
leaves space to both alternative vector technologies. MLV present a large safety record in 
clinical application that cannot be discarded. Since MLV retroviral vectors are not derived 
from human viruses they also show reduced vector genome mobilization and recombination 
in the host-cell and pre-existing immune response against the retroviral vector particle. 
Additionally, they are simple to develop in terms of plasmid cloning, transfection and cell 
culture; and from the clinical perspective they can be easily produced at large scale from 
stable packaging cell lines with satisfactory yields. From the manufacturing point of view, 
HIV-1 derived vector still requires further optimization, particularly in what concerns cell 
line development. There is still less clinical experience with this vector and the results on the 
ongoing clinical trials will be certainly important for their improvement. 
Thus the recent manufacturing strategies together with future innovations will certainly be 
important to increase productivity, stability, quality and safety of retroviral and lentiviral 
vectors for clinical applications. 
5. Acknowledgements  
The authors acknowledge the financial support received from the European Commission 
(CLINIGENE -LSHB-CT2006-018933) and the Fundação para a Ciência e a Tecnologia-
Portugal (PTDC/EBB-BIO/100491/2008). Ana F. Rodrigues acknowledges FCT for her PhD 
grant (SFRH/BD/48393/2008). 
6. References 
Ahuja D, Saenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular 
pathways to elicit cellular transformation. Oncogene 24(52):7729-45. 
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
33 
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, 
Andolfi G, Mirolo M, Brigida I and others. 2009. Gene therapy for 
immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 
360(5):447-58. 
Al-Dosari MS, Gao X. 2009. Nonviral gene delivery: principle, limitations, and recent 
progress. Aaps J 11(4):671-81. 
Alberts AW, Ferguson K, Hennessy S, Vagelos PR. 1974. Regulation of lipid synthesis in 
cultured animal cells. J Biol Chem 249(16):5241-9. 
Ansorge S, Lanthier S, Transfiguracion J, Durocher Y, Henry O, Kamen A. 2009. 
Development of a scalable process for high-yield lentiviral vector production by 
transient transfection of HEK293 suspension cultures. J Gene Med 11(10):868-76. 
Balaggan KS, Binley K, Esapa M, Iqball S, Askham Z, Kan O, Tschernutter M, Bainbridge 
JW, Naylor S, Ali RR. 2006. Stable and efficient intraocular gene transfer using 
pseudotyped EIAV lentiviral vectors. J Gene Med 8(3):275-85. 
Barger JF, Plas DR. 2010. Balancing biosynthesis and bioenergetics: metabolic programs in 
oncogenesis. Endocr Relat Cancer 17(4):R287-304. 
Beer C, Meyer A, Muller K, Wirth M. 2003. The temperature stability of mouse retroviruses 
depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. 
Virology 308(1):137-46. 
Bender MA, Palmer TD, Gelinas RE, Miller AD. 1987. Evidence that the packaging signal of 
Moloney murine leukemia virus extends into the gag region. J Virol 61(5):1639-46. 
Blesch A. 2004. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene 
transfer. Methods 33(2):164-72. 
Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. 1995. A 
versatile vector for gene and oligonucleotide transfer into cells in culture and in 
vivo: polyethylenimine. Proc Natl Acad Sci U S A 92(16):7297-301. 
Bray M, Prasad S, Dubay JW, Hunter E, Jeang KT, Rekosh D, Hammarskjold ML. 1994. A 
small element from the Mason-Pfizer monkey virus genome makes human 
immunodeficiency virus type 1 expression and replication Rev-independent. Proc 
Natl Acad Sci U S A 91(4):1256-60. 
Briggs JA, Wilk T, Fuller SD. 2003. Do lipid rafts mediate virus assembly and pseudotyping? 
J Gen Virol 84(Pt 4):757-68. 
Broussau S, Jabbour N, Lachapelle G, Durocher Y, Tom R, Transfiguracion J, Gilbert R, 
Massie B. 2008. Inducible packaging cells for large-scale production of lentiviral 
vectors in serum-free suspension culture. Mol Ther 16(3):500-7. 
Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. 1993. Vesicular stomatitis virus G 
glycoprotein pseudotyped retroviral vectors: concentration to very high titer and 
efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad 
Sci U S A 90(17):8033-7. 
Carmo M, Alves A, Rodrigues AF, Coroadinha AS, Carrondo MJ, Alves PM, Cruz PE. 2009a. 
Stabilization of gammaretroviral and lentiviral vectors: from production to gene 
transfer. J Gene Med 11(8):670-8. 
Carmo M, Dias JD, Panet A, Coroadinha AS, Carrondo MJ, Alves PM, Cruz PE. 2009b. 
Thermosensitivity of the reverse transcription process as an inactivation 
mechanism of lentiviral vectors. Hum Gene Ther 20(10):1168-76. 
 
Viral Gene Therapy 
 
34
Carmo M, Panet A, Carrondo MJ, Alves PM, Cruz PE. 2008. From retroviral vector 
production to gene transfer: spontaneous inactivation is caused by loss of reverse 
transcription capacity. J Gene Med 10(4):383-91. 
Carrondo MJT, Merten OW, Haury M, Alves PM, Coroadinha AS. 2008. Impact of retroviral 
vector components stoichiometry on packaging cell lines: Effects on productivity 
and vector quality. Human Gene Therapy 19(2):199-210. 
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, 
Hue C, Certain S, Casanova JL and others. 2000. Gene therapy of human severe 
combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669-72. 
Chan LM, Coutelle C, Themis M. 2001. A novel human suspension culture packaging cell 
line for production of high-titre retroviral vectors. Gene Ther 8(9):697-703. 
Chong H, Starkey W, Vile RG. 1998. A replication-competent retrovirus arising from a split-
function packaging cell line was generated by recombination events between the 
vector, one of the packaging constructs, and endogenous retroviral sequences. J 
Virol 72(4):2663-70. 
Chong H, Vile RG. 1996. Replication-competent retrovirus produced by a 'split-function' 
third generation amphotropic packaging cell line. Gene Ther 3(7):624-9. 
Cockrell AS, Ma H, Fu K, McCown TJ, Kafri T. 2006. A trans-lentiviral packaging cell line for 
high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 14(2):276-84. 
Coffin JM, Hughes SH, Varmus H. 1997. Retroviruses: Cold Spring Harbor. 
Cone RD, Mulligan RC. 1984. High-efficiency gene transfer into mammalian cells: 
generation of helper-free recombinant retrovirus with broad mammalian host 
range. Proc Natl Acad Sci U S A 81(20):6349-53. 
Cornetta K, Matheson L, Ballas C. 2005. Retroviral vector production in the National Gene 
Vector Laboratory at Indiana University. Gene Ther 12 Suppl 1:S28-35. 
Coroadinha AS, Gama-Norton L, Amaral AI, Hauser H, Alves PM, Cruz PE. 2010. 
Production of retroviral vectors: review. Curr Gene Ther 10(6):456-73. 
Coroadinha AS, Ribeiro J, Roldao A, Cruz PE, Alves PM, Merten OW, Carrondo MJ. 2006a. 
Effect of medium sugar source on the production of retroviral vectors for gene 
therapy. Biotechnol Bioeng 94(1):24-36. 
Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. 2006b. The 
use of recombinase mediated cassette exchange in retroviral vector producer cell 
lines: predictability and efficiency by transgene exchange. J Biotechnol 124(2):457-
68. 
Coroadinha AS, Silva AC, Pires E, Coelho A, Alves PM, Carrondo MJ. 2006c. Effect of 
osmotic pressure on the production of retroviral vectors: Enhancement in vector 
stability. Biotechnol Bioeng 94(2):322-9. 
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. 1995. High-titer packaging  
cells producing recombinant retroviruses resistant to human serum. J Virol 
69(12):7430-6. 
Cruz PE, Carmo M, Coroadinha AS, Bengala A, Gonçalves D, Teixeira M, Merten O-W, 
Genny-Fiamma C, Carrondo MJT. Retroviral Vector Stability: Inactivation Kinetics 
and Membrane Properties. In: Gòdia F, Fussenegger M, editors. Animal Cell 
Technology meets Genomics; 2005. Springer. p 303-308. 
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
35 
Cruz PE, Silva AC, Roldao A, Carmo M, Carrondo MJ, Alves PM. 2006. Screening of novel 
excipients for improving the stability of retroviral and adenoviral vectors. 
Biotechnol Prog 22(2):568-76. 
Danos O, Mulligan RC. 1988. Safe and efficient generation of recombinant retroviruses with 
amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 85(17):6460-4. 
Davis JL, Witt RM, Gross PR, Hokanson CA, Jungles S, Cohen LK, Danos O, Spratt SK. 1997. 
Retroviral particles produced from a stable human-derived packaging cell line 
transduce target cells with very high efficiencies. Hum Gene Ther 8(12):1459-67. 
Delenda C. 2004. Lentiviral vectors: optimization of packaging, transduction and gene 
expression. J Gene Med 6 Suppl 1:S125-38. 
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-
generation lentivirus vector with a conditional packaging system. J Virol 
72(11):8463-71. 
Eckert HG, Kuhlcke K, Schilz AJ, Lindemann C, Basara N, Fauser AA, Baum C. 2000. 
Clinical scale production of an improved retroviral vector expressing the human 
multidrug resistance 1 gene (MDR1). Bone Marrow Transplant 25 Suppl 2:S114-7. 
Edelstein M. 2010. Gene Therapy Clinical Trials Worldwide –  
 http://www.wiley.com//legacy/wileychi/genmed/clinical/. Wiley InterScience. 
Eibl R, Kaiser S, Lombriser R, Eibl D. 2010. Disposable bioreactors: the current state-of-the-
art and recommended applications in biotechnology. Appl Microbiol Biotechnol 
86(1):41-9. 
Falkner E, Appl H, Eder C, Losert UM, Schoffl H, Pfaller W. 2006. Serum free cell culture: 
the free access online database. Toxicol In Vitro 20(3):395-400. 
Farson D, McGuinness R, Dull T, Limoli K, Lazar R, Jalali S, Reddy S, Pennathur-Das R, 
Broad D, Finer M. 1999. Large-scale manufacturing of safe and efficient retrovirus 
packaging lines for use in immunotherapy protocols. J Gene Med 1(3):195-209. 
Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio 
A, Naldini L. 2001. A new-generation stable inducible packaging cell line for 
lentiviral vectors. Hum Gene Ther 12(8):981-97. 
Gerin PA, Gilligan MG, Searle PF, Al-Rubeai M. 1999a. Improved titers of retroviral vectors 
from the human FLYRD18 packaging cell line in serum- and protein-free medium. 
Hum Gene Ther 10(12):1965-74. 
Gerin PA, Searle PF, Al-Rubeai M. 1999b. Production of retroviral vectors for gene therapy 
with the human packaging cell line FLYRD18. Biotechnol Prog 15(5):941-8. 
Ghani K, Cottin S, Kamen A, Caruso M. 2007. Generation of a high-titer packaging cell line 
for the production of retroviral vectors in suspension and serum-free media. Gene 
Ther 14(24):1705-11. 
Ghani K, Garnier A, Coelho H, Transfiguracion J, Trudel P, Kamen A. 2006. Retroviral 
vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-
based perfusion bioreactor. Biotechnol Bioeng 95(4):653-60. 
Gougeon ML. 2003. Apoptosis as an HIV strategy to escape immune attack. Nat Rev 
Immunol 3(5):392-404. 
Gruh I, Wunderlich S, Winkler M, Schwanke K, Heinke J, Blomer U, Ruhparwar A, Rohde B, 
Li RK, Haverich A and others. 2008. Human CMV immediate-early enhancer: a 
useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene 
Med 10(1):21-32. 
 
Viral Gene Therapy 
 
34
Carmo M, Panet A, Carrondo MJ, Alves PM, Cruz PE. 2008. From retroviral vector 
production to gene transfer: spontaneous inactivation is caused by loss of reverse 
transcription capacity. J Gene Med 10(4):383-91. 
Carrondo MJT, Merten OW, Haury M, Alves PM, Coroadinha AS. 2008. Impact of retroviral 
vector components stoichiometry on packaging cell lines: Effects on productivity 
and vector quality. Human Gene Therapy 19(2):199-210. 
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, 
Hue C, Certain S, Casanova JL and others. 2000. Gene therapy of human severe 
combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669-72. 
Chan LM, Coutelle C, Themis M. 2001. A novel human suspension culture packaging cell 
line for production of high-titre retroviral vectors. Gene Ther 8(9):697-703. 
Chong H, Starkey W, Vile RG. 1998. A replication-competent retrovirus arising from a split-
function packaging cell line was generated by recombination events between the 
vector, one of the packaging constructs, and endogenous retroviral sequences. J 
Virol 72(4):2663-70. 
Chong H, Vile RG. 1996. Replication-competent retrovirus produced by a 'split-function' 
third generation amphotropic packaging cell line. Gene Ther 3(7):624-9. 
Cockrell AS, Ma H, Fu K, McCown TJ, Kafri T. 2006. A trans-lentiviral packaging cell line for 
high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 14(2):276-84. 
Coffin JM, Hughes SH, Varmus H. 1997. Retroviruses: Cold Spring Harbor. 
Cone RD, Mulligan RC. 1984. High-efficiency gene transfer into mammalian cells: 
generation of helper-free recombinant retrovirus with broad mammalian host 
range. Proc Natl Acad Sci U S A 81(20):6349-53. 
Cornetta K, Matheson L, Ballas C. 2005. Retroviral vector production in the National Gene 
Vector Laboratory at Indiana University. Gene Ther 12 Suppl 1:S28-35. 
Coroadinha AS, Gama-Norton L, Amaral AI, Hauser H, Alves PM, Cruz PE. 2010. 
Production of retroviral vectors: review. Curr Gene Ther 10(6):456-73. 
Coroadinha AS, Ribeiro J, Roldao A, Cruz PE, Alves PM, Merten OW, Carrondo MJ. 2006a. 
Effect of medium sugar source on the production of retroviral vectors for gene 
therapy. Biotechnol Bioeng 94(1):24-36. 
Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. 2006b. The 
use of recombinase mediated cassette exchange in retroviral vector producer cell 
lines: predictability and efficiency by transgene exchange. J Biotechnol 124(2):457-
68. 
Coroadinha AS, Silva AC, Pires E, Coelho A, Alves PM, Carrondo MJ. 2006c. Effect of 
osmotic pressure on the production of retroviral vectors: Enhancement in vector 
stability. Biotechnol Bioeng 94(2):322-9. 
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. 1995. High-titer packaging  
cells producing recombinant retroviruses resistant to human serum. J Virol 
69(12):7430-6. 
Cruz PE, Carmo M, Coroadinha AS, Bengala A, Gonçalves D, Teixeira M, Merten O-W, 
Genny-Fiamma C, Carrondo MJT. Retroviral Vector Stability: Inactivation Kinetics 
and Membrane Properties. In: Gòdia F, Fussenegger M, editors. Animal Cell 
Technology meets Genomics; 2005. Springer. p 303-308. 
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
35 
Cruz PE, Silva AC, Roldao A, Carmo M, Carrondo MJ, Alves PM. 2006. Screening of novel 
excipients for improving the stability of retroviral and adenoviral vectors. 
Biotechnol Prog 22(2):568-76. 
Danos O, Mulligan RC. 1988. Safe and efficient generation of recombinant retroviruses with 
amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 85(17):6460-4. 
Davis JL, Witt RM, Gross PR, Hokanson CA, Jungles S, Cohen LK, Danos O, Spratt SK. 1997. 
Retroviral particles produced from a stable human-derived packaging cell line 
transduce target cells with very high efficiencies. Hum Gene Ther 8(12):1459-67. 
Delenda C. 2004. Lentiviral vectors: optimization of packaging, transduction and gene 
expression. J Gene Med 6 Suppl 1:S125-38. 
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-
generation lentivirus vector with a conditional packaging system. J Virol 
72(11):8463-71. 
Eckert HG, Kuhlcke K, Schilz AJ, Lindemann C, Basara N, Fauser AA, Baum C. 2000. 
Clinical scale production of an improved retroviral vector expressing the human 
multidrug resistance 1 gene (MDR1). Bone Marrow Transplant 25 Suppl 2:S114-7. 
Edelstein M. 2010. Gene Therapy Clinical Trials Worldwide –  
 http://www.wiley.com//legacy/wileychi/genmed/clinical/. Wiley InterScience. 
Eibl R, Kaiser S, Lombriser R, Eibl D. 2010. Disposable bioreactors: the current state-of-the-
art and recommended applications in biotechnology. Appl Microbiol Biotechnol 
86(1):41-9. 
Falkner E, Appl H, Eder C, Losert UM, Schoffl H, Pfaller W. 2006. Serum free cell culture: 
the free access online database. Toxicol In Vitro 20(3):395-400. 
Farson D, McGuinness R, Dull T, Limoli K, Lazar R, Jalali S, Reddy S, Pennathur-Das R, 
Broad D, Finer M. 1999. Large-scale manufacturing of safe and efficient retrovirus 
packaging lines for use in immunotherapy protocols. J Gene Med 1(3):195-209. 
Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio 
A, Naldini L. 2001. A new-generation stable inducible packaging cell line for 
lentiviral vectors. Hum Gene Ther 12(8):981-97. 
Gerin PA, Gilligan MG, Searle PF, Al-Rubeai M. 1999a. Improved titers of retroviral vectors 
from the human FLYRD18 packaging cell line in serum- and protein-free medium. 
Hum Gene Ther 10(12):1965-74. 
Gerin PA, Searle PF, Al-Rubeai M. 1999b. Production of retroviral vectors for gene therapy 
with the human packaging cell line FLYRD18. Biotechnol Prog 15(5):941-8. 
Ghani K, Cottin S, Kamen A, Caruso M. 2007. Generation of a high-titer packaging cell line 
for the production of retroviral vectors in suspension and serum-free media. Gene 
Ther 14(24):1705-11. 
Ghani K, Garnier A, Coelho H, Transfiguracion J, Trudel P, Kamen A. 2006. Retroviral 
vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-
based perfusion bioreactor. Biotechnol Bioeng 95(4):653-60. 
Gougeon ML. 2003. Apoptosis as an HIV strategy to escape immune attack. Nat Rev 
Immunol 3(5):392-404. 
Gruh I, Wunderlich S, Winkler M, Schwanke K, Heinke J, Blomer U, Ruhparwar A, Rohde B, 
Li RK, Haverich A and others. 2008. Human CMV immediate-early enhancer: a 
useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene 
Med 10(1):21-32. 
 
Viral Gene Therapy 
 
36
Higashikawa F, Chang L. 2001. Kinetic analyses of stability of simple and complex retroviral 
vectors. Virology 280(1):124-31. 
Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M. 2003. Continuous 
high-titer HIV-1 vector production. Nat Biotechnol 21(5):569-72. 
Jordan M, Wurm F. 2004. Transfection of adherent and suspended cells by calcium 
phosphate. Methods 33(2):136-43. 
Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. 1999. A packaging cell line for 
lentivirus vectors. J Virol 73(1):576-84. 
Kaptein LC, Greijer AE, Valerio D, van Beusechem VW. 1997. Optimized conditions for the 
production of recombinant amphotropic retroviral vector preparations. Gene Ther 
4(2):172-6. 
Kotani H, Newton PB, 3rd, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson 
WF, McGarrity GJ. 1994. Improved methods of retroviral vector transduction and 
production for gene therapy. Hum Gene Ther 5(1):19-28. 
Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. 2000. A Rev-
independent human immunodeficiency virus type 1 (HIV-1)-based vector that 
exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74(10):4839-52. 
Kuate S, Wagner R, Uberla K. 2002. Development and characterization of a minimal 
inducible packaging cell line for simian immunodeficiency virus-based lentiviral 
vectors. J Gene Med 4(4):347-55. 
Le Doux JM, Davis HE, Morgan JR, Yarmush ML. 1999. Kinetics of retrovirus production 
and decay. Biotechnol Bioeng 63(6):654-62. 
Lee SG, Kim S, Robbins PD, Kim BG. 1996. Optimization of environmental factors for the 
production and handling of recombinant retrovirus. Appl Microbiol Biotechnol 
45(4):477-483. 
Lesch HP, Laitinen A, Peixoto C, Vicente T, Makkonen KE, Laitinen L, Pikkarainen JT, 
Samaranayake H, Alves PM, Carrondo MJ and others. 2011. Production and 
purification of lentiviral vectors generated in 293T suspension cells with 
baculoviral vectors. Gene Ther. 
Lesch HP, Turpeinen S, Niskanen EA, Mahonen AJ, Airenne KJ, Yla-Herttuala S. 2008. 
Generation of lentivirus vectors using recombinant baculoviruses. Gene Ther 
15(18):1280-6. 
Lewis P, Hensel M, Emerman M. 1992. Human immunodeficiency virus infection of cells 
arrested in the cell cycle. Embo J 11(8):3053-8. 
Liberatore C, Capanni M, Albi N, Volpi I, Urbani E, Ruggeri L, Mencarelli A, Grignani F, 
Velardi A. 1999. Natural killer cell-mediated lysis of autologous cells modified by 
gene therapy. J Exp Med 189(12):1855-62. 
Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H, Stein S, Grez M, 
Thornhill S, Thrasher A and others. 2009. A new PG13-based packaging cell line for 
stable production of clinical-grade self-inactivating gamma-retroviral vectors using 
targeted integration. Gene Ther 17(2):272-80. 
Loew R, Selevsek N, Fehse B, von Laer D, Baum C, Fauser A, Kuehlcke K. 2004. Simplified 
generation of high-titer retrovirus producer cells for clinically relevant retroviral 
vectors by reversible inclusion of a lox-P-flanked marker gene. Mol Ther 9(5): 
738-46. 
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
37 
Markowitz D, Goff S, Bank A. 1988. Construction of a safe and efficient retrovirus packaging 
cell line. Adv Exp Med Biol 241:35-40. 
Matukonis M, Li M, Molina RP, Paszkiet B, Kaleko M, Luo T. 2002. Development of second- 
and third-generation bovine immunodeficiency virus-based gene transfer systems. 
Hum Gene Ther 13(11):1293-303. 
McTaggart S, Al-Rubeai M. 2000. Effects of culture parameters on the production of 
retroviral vectors by a human packaging cell line. Biotechnol Prog 16(5):859-65. 
McTaggart S, Al-Rubeai M. 2002. Retroviral vectors for human gene delivery. Biotechnol 
Adv 20(1):1-31. 
Merten O, Landric L, Danos O. 2001. Influence of the metabolic status of packaging cells on 
retroviral vector production. Recombinant Protein Production with Prokaryotic and 
Eukaryotic Cells. Dordrecht: Kluwer Academic Publishers. 
Merten OW. 2004. State-of-the-art of the production of retroviral vectors. J Gene Med 6 
Suppl 1:S105-24. 
Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C, Audit M, Zanta-Boussif 
MA, Chautard H, Radrizzani M and others. 2011. Large scale manufacture and 
characterisation of a lentiviral vector produced for clinical ex vivo gene therapy 
application. Hum Gene Ther. 
Miller AD, Buttimore C. 1986. Redesign of retrovirus packaging cell lines to avoid 
recombination leading to helper virus production. Mol Cell Biol 6(8):2895-902. 
Miller AD, Chen F. 1996. Retrovirus packaging cells based on 10A1 murine leukemia virus 
for production of vectors that use multiple receptors for cell entry. J Virol 
70(8):5564-71. 
Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. 1991. Construction and 
properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 
65(5):2220-4. 
Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, 
Mazarakis N. 1999. Stable gene transfer to the nervous system using a non-primate 
lentiviral vector. Gene Ther 6(11):1808-18. 
Mitta B, Rimann M, Fussenegger M. 2005. Detailed design and comparative analysis of 
protocols for optimized production of high-performance HIV-1-derived lentiviral 
particles. Metab Eng 7(5-6):426-36. 
Molina RP, Ye HQ, Brady J, Zhang J, Zimmerman H, Kaleko M, Luo T. 2004. A synthetic 
Rev-independent bovine immunodeficiency virus-based packaging construct. Hum 
Gene Ther 15(9):865-77. 
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In 
vivo gene delivery and stable transduction of nondividing cells by a lentiviral 
vector. Science 272(5259):263-7. 
Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, 
Dropulic B. 2005. Generation of a packaging cell line for prolonged large-scale 
production of high-titer HIV-1-based lentiviral vector. J Gene Med 7(6):818-34. 
Nie Z, Bren GD, Vlahakis SR, Schimnich AA, Brenchley JM, Trushin SA, Warren S, 
Schnepple DJ, Kovacs CM, Loutfy MR and others. 2007. Human immunodeficiency 
virus type 1 protease cleaves procaspase 8 in vivo. J Virol 81(13):6947-56. 
Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, Krammer PH, Sekaly RP, Badley 
AD. 2002. HIV-1 protease processes procaspase 8 to cause mitochondrial release of 
 
Viral Gene Therapy 
 
36
Higashikawa F, Chang L. 2001. Kinetic analyses of stability of simple and complex retroviral 
vectors. Virology 280(1):124-31. 
Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M. 2003. Continuous 
high-titer HIV-1 vector production. Nat Biotechnol 21(5):569-72. 
Jordan M, Wurm F. 2004. Transfection of adherent and suspended cells by calcium 
phosphate. Methods 33(2):136-43. 
Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. 1999. A packaging cell line for 
lentivirus vectors. J Virol 73(1):576-84. 
Kaptein LC, Greijer AE, Valerio D, van Beusechem VW. 1997. Optimized conditions for the 
production of recombinant amphotropic retroviral vector preparations. Gene Ther 
4(2):172-6. 
Kotani H, Newton PB, 3rd, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson 
WF, McGarrity GJ. 1994. Improved methods of retroviral vector transduction and 
production for gene therapy. Hum Gene Ther 5(1):19-28. 
Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. 2000. A Rev-
independent human immunodeficiency virus type 1 (HIV-1)-based vector that 
exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74(10):4839-52. 
Kuate S, Wagner R, Uberla K. 2002. Development and characterization of a minimal 
inducible packaging cell line for simian immunodeficiency virus-based lentiviral 
vectors. J Gene Med 4(4):347-55. 
Le Doux JM, Davis HE, Morgan JR, Yarmush ML. 1999. Kinetics of retrovirus production 
and decay. Biotechnol Bioeng 63(6):654-62. 
Lee SG, Kim S, Robbins PD, Kim BG. 1996. Optimization of environmental factors for the 
production and handling of recombinant retrovirus. Appl Microbiol Biotechnol 
45(4):477-483. 
Lesch HP, Laitinen A, Peixoto C, Vicente T, Makkonen KE, Laitinen L, Pikkarainen JT, 
Samaranayake H, Alves PM, Carrondo MJ and others. 2011. Production and 
purification of lentiviral vectors generated in 293T suspension cells with 
baculoviral vectors. Gene Ther. 
Lesch HP, Turpeinen S, Niskanen EA, Mahonen AJ, Airenne KJ, Yla-Herttuala S. 2008. 
Generation of lentivirus vectors using recombinant baculoviruses. Gene Ther 
15(18):1280-6. 
Lewis P, Hensel M, Emerman M. 1992. Human immunodeficiency virus infection of cells 
arrested in the cell cycle. Embo J 11(8):3053-8. 
Liberatore C, Capanni M, Albi N, Volpi I, Urbani E, Ruggeri L, Mencarelli A, Grignani F, 
Velardi A. 1999. Natural killer cell-mediated lysis of autologous cells modified by 
gene therapy. J Exp Med 189(12):1855-62. 
Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H, Stein S, Grez M, 
Thornhill S, Thrasher A and others. 2009. A new PG13-based packaging cell line for 
stable production of clinical-grade self-inactivating gamma-retroviral vectors using 
targeted integration. Gene Ther 17(2):272-80. 
Loew R, Selevsek N, Fehse B, von Laer D, Baum C, Fauser A, Kuehlcke K. 2004. Simplified 
generation of high-titer retrovirus producer cells for clinically relevant retroviral 
vectors by reversible inclusion of a lox-P-flanked marker gene. Mol Ther 9(5): 
738-46. 
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
37 
Markowitz D, Goff S, Bank A. 1988. Construction of a safe and efficient retrovirus packaging 
cell line. Adv Exp Med Biol 241:35-40. 
Matukonis M, Li M, Molina RP, Paszkiet B, Kaleko M, Luo T. 2002. Development of second- 
and third-generation bovine immunodeficiency virus-based gene transfer systems. 
Hum Gene Ther 13(11):1293-303. 
McTaggart S, Al-Rubeai M. 2000. Effects of culture parameters on the production of 
retroviral vectors by a human packaging cell line. Biotechnol Prog 16(5):859-65. 
McTaggart S, Al-Rubeai M. 2002. Retroviral vectors for human gene delivery. Biotechnol 
Adv 20(1):1-31. 
Merten O, Landric L, Danos O. 2001. Influence of the metabolic status of packaging cells on 
retroviral vector production. Recombinant Protein Production with Prokaryotic and 
Eukaryotic Cells. Dordrecht: Kluwer Academic Publishers. 
Merten OW. 2004. State-of-the-art of the production of retroviral vectors. J Gene Med 6 
Suppl 1:S105-24. 
Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C, Audit M, Zanta-Boussif 
MA, Chautard H, Radrizzani M and others. 2011. Large scale manufacture and 
characterisation of a lentiviral vector produced for clinical ex vivo gene therapy 
application. Hum Gene Ther. 
Miller AD, Buttimore C. 1986. Redesign of retrovirus packaging cell lines to avoid 
recombination leading to helper virus production. Mol Cell Biol 6(8):2895-902. 
Miller AD, Chen F. 1996. Retrovirus packaging cells based on 10A1 murine leukemia virus 
for production of vectors that use multiple receptors for cell entry. J Virol 
70(8):5564-71. 
Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. 1991. Construction and 
properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 
65(5):2220-4. 
Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, 
Mazarakis N. 1999. Stable gene transfer to the nervous system using a non-primate 
lentiviral vector. Gene Ther 6(11):1808-18. 
Mitta B, Rimann M, Fussenegger M. 2005. Detailed design and comparative analysis of 
protocols for optimized production of high-performance HIV-1-derived lentiviral 
particles. Metab Eng 7(5-6):426-36. 
Molina RP, Ye HQ, Brady J, Zhang J, Zimmerman H, Kaleko M, Luo T. 2004. A synthetic 
Rev-independent bovine immunodeficiency virus-based packaging construct. Hum 
Gene Ther 15(9):865-77. 
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In 
vivo gene delivery and stable transduction of nondividing cells by a lentiviral 
vector. Science 272(5259):263-7. 
Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, 
Dropulic B. 2005. Generation of a packaging cell line for prolonged large-scale 
production of high-titer HIV-1-based lentiviral vector. J Gene Med 7(6):818-34. 
Nie Z, Bren GD, Vlahakis SR, Schimnich AA, Brenchley JM, Trushin SA, Warren S, 
Schnepple DJ, Kovacs CM, Loutfy MR and others. 2007. Human immunodeficiency 
virus type 1 protease cleaves procaspase 8 in vivo. J Virol 81(13):6947-56. 
Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, Krammer PH, Sekaly RP, Badley 
AD. 2002. HIV-1 protease processes procaspase 8 to cause mitochondrial release of 
 
Viral Gene Therapy 
 
38
cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 
9(11):1172-84. 
Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, 
Schilz A, Kunkel H and others. 2006. Correction of X-linked chronic granulomatous 
disease by gene therapy, augmented by insertional activation of MDS1-EVI1, 
PRDM16 or SETBP1. Nat Med 12(4):401-9. 
Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. 2001. An inducible packaging cell 
system for safe, efficient lentiviral vector production in the absence of HIV-1 
accessory proteins. Virology 282(1):77-86. 
Pandya S, Boris-Lawrie K, Leung NJ, Akkina R, Planelles V. 2001. Development of an Rev-
independent, minimal simian immunodeficiency virus-derived vector system. 
Hum Gene Ther 12(7):847-57. 
Pauwels K, Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser Z, 
Herman P. 2009. State-of-the-art lentiviral vectors for research use: risk assessment 
and biosafety recommendations. Curr Gene Ther 9(6):459-74. 
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in 
vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 
271(5255):1582-6. 
Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF. 1998. An improved method 
for generating retroviral producer clones for vectors lacking a selectable marker 
gene. Blood Cells Mol Dis 24(2):167-82. 
Pizzato M, Merten OW, Blair ED, Takeuchi Y. 2001. Development of a suspension packaging 
cell line for production of high titre, serum-resistant murine leukemia virus vectors. 
Gene Ther 8(10):737-45. 
Poeschla EM, Wong-Staal F, Looney DJ. 1998. Efficient transduction of nondividing human 
cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4(3):354-7. 
Przybylowski M, Hakakha A, Stefanski J, Hodges J, Sadelain M, Riviere I. 2006. Production 
scale-up and validation of packaging cell clearance of clinical-grade retroviral 
vector stocks produced in cell factories. Gene Ther 13(1):95-100. 
Rawat SS, Viard M, Gallo SA, Rein A, Blumenthal R, Puri A. 2003. Modulation of entry of 
enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol 
20(3):243-54. 
Reeves L, Smucker P, Cornetta K. 2000. Packaging cell line characteristics and optimizing 
retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene 
Ther 11(15):2093-103. 
Rigg RJ, Chen J, Dando JS, Forestell SP, Plavec I, Bohnlein E. 1996. A novel human 
amphotropic packaging cell line: high titer, complement resistance, and improved 
safety. Virology 218(1):290-5. 
Roberts TM, Boris-Lawrie K. 2000. The 5' RNA terminus of spleen necrosis virus stimulates 
translation of nonviral mRNA. J Virol 74(17):8111-8. 
Rodrigues AF, Carmo M, Alves PM, Coroadinha AS. 2009. Retroviral vector production 
under serum deprivation: The role of lipids. Biotechnol Bioeng 104(6):1171-81. 
Rodrigues AF, Amaral AI, Veríssimo V, Alves PA, Coroadinha AS 2011. Adaptation to 
serum deprivation: implications in lipid biosynthesis and vector production 
(submitted)  
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
39 
Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Gunthard HF, 
Trkola A. 2004. Quantification of infectious HIV-1 plasma viral load using a 
boosted in vitro infection protocol. Virology 326(1):113-29. 
Sadettin SO, Hu W. 2006. Cell culture technology for pharmaceutical and cell-based 
therapies. Sadettin SO, Hu W, editors. Boca Raton, FL, USA: CRC Press Taylor & 
Francis Group  
Saenz DT, Poeschla EM. 2004. FIV: from lentivirus to lentivector. J Gene Med 6 Suppl 1:S95-
104. 
Schnell T, Foley P, Wirth M, Munch J, Uberla K. 2000. Development of a self-inactivating, 
minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene 
Ther 11(3):439-47. 
Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, Kurth R, 
Groner B, Cichutek K. 1997. Pseudotyping of murine leukemia virus with the 
envelope glycoproteins of HIV generates a retroviral vector with specificity of 
infection for CD4-expressing cells. Proc Natl Acad Sci U S A 94(16):8640-5. 
Schucht R, Coroadinha AS, Zanta-Boussif MA, Verhoeyen E, Carrondo MJ, Hauser H, Wirth 
D. 2006. A new generation of retroviral producer cells: predictable and stable virus 
production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther 
14(2):285-92. 
Schweizer M, Merten OW. 2010. Large-scale production means for the manufacturing of 
lentiviral vectors. Curr Gene Ther 10(6):474-86. 
Segura MM, Garnier A, Durocher Y, Ansorge S, Kamen A. 2010. New protocol for lentiviral 
vector mass production. Methods Mol Biol 614:39-52. 
Seth G, Philp RJ, Denoya CD, McGrath K, Stutzman-Engwall KJ, Yap M, Hu WS. 2005. 
Large-scale gene expression analysis of cholesterol dependence in NS0 cells. 
Biotechnol Bioeng 90(5):552-67. 
Sheridan PL, Bodner M, Lynn A, Phuong TK, DePolo NJ, de la Vega DJ, Jr., O'Dea J, Nguyen 
K, McCormack JE, Driver DA and others. 2000. Generation of retroviral packaging 
and producer cell lines for large-scale vector production and clinical application: 
improved safety and high titer. Mol Ther 2(3):262-75. 
Sinn PL, Sauter SL, McCray PB, Jr. 2005. Gene therapy progress and prospects: development 
of improved lentiviral and retroviral vectors--design, biosafety, and production. 
Gene Ther 12(14):1089-98. 
Smith SL, Shioda T. 2009. Advantages of COS-1 monkey kidney epithelial cells as packaging 
host for small-volume production of high-quality recombinant lentiviruses. J Virol 
Methods 157(1):47-54. 
Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman 
AJ. 1995. A transient three-plasmid expression system for the production of high 
titer retroviral vectors. Nucleic Acids Res 23(4):628-33. 
Spector AA, Mathur SN, Kaduce TL, Hyman BT. 1980. Lipid nutrition and metabolism of 
cultured mammalian cells. Prog Lipid Res 19(3-4):155-86. 
Stewart HJ, Leroux-Carlucci MA, Sion CJ, Mitrophanous KA, Radcliffe PA. 2009. 
Development of inducible EIAV-based lentiviral vector packaging and producer 
cell lines. Gene Ther 16(6):805-14. 
 
Viral Gene Therapy 
 
38
cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 
9(11):1172-84. 
Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, 
Schilz A, Kunkel H and others. 2006. Correction of X-linked chronic granulomatous 
disease by gene therapy, augmented by insertional activation of MDS1-EVI1, 
PRDM16 or SETBP1. Nat Med 12(4):401-9. 
Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. 2001. An inducible packaging cell 
system for safe, efficient lentiviral vector production in the absence of HIV-1 
accessory proteins. Virology 282(1):77-86. 
Pandya S, Boris-Lawrie K, Leung NJ, Akkina R, Planelles V. 2001. Development of an Rev-
independent, minimal simian immunodeficiency virus-derived vector system. 
Hum Gene Ther 12(7):847-57. 
Pauwels K, Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser Z, 
Herman P. 2009. State-of-the-art lentiviral vectors for research use: risk assessment 
and biosafety recommendations. Curr Gene Ther 9(6):459-74. 
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in 
vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 
271(5255):1582-6. 
Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF. 1998. An improved method 
for generating retroviral producer clones for vectors lacking a selectable marker 
gene. Blood Cells Mol Dis 24(2):167-82. 
Pizzato M, Merten OW, Blair ED, Takeuchi Y. 2001. Development of a suspension packaging 
cell line for production of high titre, serum-resistant murine leukemia virus vectors. 
Gene Ther 8(10):737-45. 
Poeschla EM, Wong-Staal F, Looney DJ. 1998. Efficient transduction of nondividing human 
cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4(3):354-7. 
Przybylowski M, Hakakha A, Stefanski J, Hodges J, Sadelain M, Riviere I. 2006. Production 
scale-up and validation of packaging cell clearance of clinical-grade retroviral 
vector stocks produced in cell factories. Gene Ther 13(1):95-100. 
Rawat SS, Viard M, Gallo SA, Rein A, Blumenthal R, Puri A. 2003. Modulation of entry of 
enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol 
20(3):243-54. 
Reeves L, Smucker P, Cornetta K. 2000. Packaging cell line characteristics and optimizing 
retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene 
Ther 11(15):2093-103. 
Rigg RJ, Chen J, Dando JS, Forestell SP, Plavec I, Bohnlein E. 1996. A novel human 
amphotropic packaging cell line: high titer, complement resistance, and improved 
safety. Virology 218(1):290-5. 
Roberts TM, Boris-Lawrie K. 2000. The 5' RNA terminus of spleen necrosis virus stimulates 
translation of nonviral mRNA. J Virol 74(17):8111-8. 
Rodrigues AF, Carmo M, Alves PM, Coroadinha AS. 2009. Retroviral vector production 
under serum deprivation: The role of lipids. Biotechnol Bioeng 104(6):1171-81. 
Rodrigues AF, Amaral AI, Veríssimo V, Alves PA, Coroadinha AS 2011. Adaptation to 
serum deprivation: implications in lipid biosynthesis and vector production 
(submitted)  
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
39 
Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Gunthard HF, 
Trkola A. 2004. Quantification of infectious HIV-1 plasma viral load using a 
boosted in vitro infection protocol. Virology 326(1):113-29. 
Sadettin SO, Hu W. 2006. Cell culture technology for pharmaceutical and cell-based 
therapies. Sadettin SO, Hu W, editors. Boca Raton, FL, USA: CRC Press Taylor & 
Francis Group  
Saenz DT, Poeschla EM. 2004. FIV: from lentivirus to lentivector. J Gene Med 6 Suppl 1:S95-
104. 
Schnell T, Foley P, Wirth M, Munch J, Uberla K. 2000. Development of a self-inactivating, 
minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene 
Ther 11(3):439-47. 
Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, Kurth R, 
Groner B, Cichutek K. 1997. Pseudotyping of murine leukemia virus with the 
envelope glycoproteins of HIV generates a retroviral vector with specificity of 
infection for CD4-expressing cells. Proc Natl Acad Sci U S A 94(16):8640-5. 
Schucht R, Coroadinha AS, Zanta-Boussif MA, Verhoeyen E, Carrondo MJ, Hauser H, Wirth 
D. 2006. A new generation of retroviral producer cells: predictable and stable virus 
production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther 
14(2):285-92. 
Schweizer M, Merten OW. 2010. Large-scale production means for the manufacturing of 
lentiviral vectors. Curr Gene Ther 10(6):474-86. 
Segura MM, Garnier A, Durocher Y, Ansorge S, Kamen A. 2010. New protocol for lentiviral 
vector mass production. Methods Mol Biol 614:39-52. 
Seth G, Philp RJ, Denoya CD, McGrath K, Stutzman-Engwall KJ, Yap M, Hu WS. 2005. 
Large-scale gene expression analysis of cholesterol dependence in NS0 cells. 
Biotechnol Bioeng 90(5):552-67. 
Sheridan PL, Bodner M, Lynn A, Phuong TK, DePolo NJ, de la Vega DJ, Jr., O'Dea J, Nguyen 
K, McCormack JE, Driver DA and others. 2000. Generation of retroviral packaging 
and producer cell lines for large-scale vector production and clinical application: 
improved safety and high titer. Mol Ther 2(3):262-75. 
Sinn PL, Sauter SL, McCray PB, Jr. 2005. Gene therapy progress and prospects: development 
of improved lentiviral and retroviral vectors--design, biosafety, and production. 
Gene Ther 12(14):1089-98. 
Smith SL, Shioda T. 2009. Advantages of COS-1 monkey kidney epithelial cells as packaging 
host for small-volume production of high-quality recombinant lentiviruses. J Virol 
Methods 157(1):47-54. 
Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman 
AJ. 1995. A transient three-plasmid expression system for the production of high 
titer retroviral vectors. Nucleic Acids Res 23(4):628-33. 
Spector AA, Mathur SN, Kaduce TL, Hyman BT. 1980. Lipid nutrition and metabolism of 
cultured mammalian cells. Prog Lipid Res 19(3-4):155-86. 
Stewart HJ, Leroux-Carlucci MA, Sion CJ, Mitrophanous KA, Radcliffe PA. 2009. 
Development of inducible EIAV-based lentiviral vector packaging and producer 
cell lines. Gene Ther 16(6):805-14. 
 
Viral Gene Therapy 
 
40
Swift S, Lorens J, Achacoso P, Nolan GP. 2001. Rapid production of retroviruses for efficient 
gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc 
Immunol Chapter 10:Unit 10 17C. 
Swinnen JV, Brusselmans K, Verhoeven G. 2006. Increased lipogenesis in cancer cells: new 
players, novel targets. Curr Opin Clin Nutr Metab Care 9(4):358-65. 
Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK. 1994. Type C 
retrovirus inactivation by human complement is determined by both the viral 
genome and the producer cell. J Virol 68(12):8001-7. 
Takeuchi Y, Liong SH, Bieniasz PD, Jager U, Porter CD, Friedman T, McClure MO, Weiss 
RA. 1997. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by 
galactosyl(alpha1-3)galactosylation. J Virol 71(8):6174-8. 
Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins 
MK. 1996. Sensitization of cells and retroviruses to human serum by (alpha 1-3) 
galactosyltransferase. Nature 379(6560):85-8. 
Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, Greene M, De Ravin SS, 
Moayeri M, Malech HL, Sorrentino BP and others. 2009. Efficient construction of 
producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by 
concatemeric array transfection. Blood 113(21):5104-10. 
Toledo JR, Prieto Y, Oramas N, Sanchez O. 2009. Polyethylenimine-based transfection 
method as a simple and effective way to produce recombinant lentiviral vectors. 
Appl Biochem Biotechnol 157(3):538-44. 
Vu HN, Ramsey JD, Pack DW. 2008. Engineering of a stable retroviral gene delivery vector 
by directed evolution. Mol Ther 16(2):308-14. 
Wikstrom K, Blomberg P, Islam KB. 2004. Clinical grade vector production: analysis of yield, 
stability, and storage of gmp-produced retroviral vectors for gene therapy. 
Biotechnol Prog 20(4):1198-203. 
Wildner O, Candotti F, Krecko EG, Xanthopoulos KG, Ramsey WJ, Blaese RM. 1998. 
Generation of a conditionally neo(r)-containing retroviral producer cell line: effects 
of neo(r) on retroviral titer and transgene expression. Gene Ther 5(5):684-91. 
Xu K, Ma H, McCown TJ, Verma IM, Kafri T. 2001. Generation of a stable cell line producing 
high-titer self-inactivating lentiviral vectors. Mol Ther 3(1):97-104. 
Ye K, Dhiman HK, Suhan J, Schultz JS. 2003. Effect of pH on infectivity and morphology of 
ecotropic moloney murine leukemia virus. Biotechnol Prog 19(2):538-543. 
Yu JH, Schaffer DV. 2005. Advanced targeting strategies for murine retroviral and adeno-
associated viral vectors. Adv Biochem Eng Biotechnol 99:147-67. 
Zufferey R, Donello JE, Trono D, Hope TJ. 1999. Woodchuck hepatitis virus 
posttranscriptional regulatory element enhances expression of transgenes delivered 
by retroviral vectors. J Virol 73(4):2886-92. 
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. 1997. Multiply attenuated lentiviral 
vector achieves efficient gene delivery in vivo. Nat Biotechnol 15(9):871-5. 
Zwolinska K. 2006. Retroviruses-derived sequences in the human genome. Human 
endogenous retroviruses (HERVs). Postepy Hig Med Dosw (Online) 60:637-52. 
3
Surface Modification of
Retroviral Vectors for Gene Therapy 
Christoph Metzner and John A. Dangerfield 
University of Veterinary Medicine Vienna 
Austria 
1. Introduction 
If biomedicine is considered to be the use of biological or botanical agents in medicine then 
it is certainly the oldest kind of therapy. Since drugs, however, it is no longer the most 
prolifically used, at least in the developed world. Will this change, and if so will it be in the 
near or more distant future? It has been discussed amongst experts in the industry for some 
time that, despite ever-increasing funding and new high-tech methods of discovery and 
screening, amounts of new drugs and drug leads are declining. In part, this has opened the 
way for biologics. The frontrunner is of course antibody technologies, mainly monoclonals, 
the use of which has exploded over the last 5 years to the point where most of the major 
pharma players are involved or are getting involved in what has now become a multi-billion 
dollar industry. Antibodies have reached the point of being a well trusted and accepted 
form of medical product across the industry and communities from bench to bedside.  
Many believe the next similar success story will be for cell therapy, probably some 
differentiated form of stem cells. Although it has been happening for 20 years, it is only in 
the past 5 years that the amount of patients being treated with cells, as a therapy, has 
increased into the thousands per year. The vast majority of these are autologous cell 
treatments, undertaken by hospitals and private clinics on a patient to patient basis using 
the patients’ own cells to treat a wide variety of diseases and conditions. These are not 
officially approved medical products. However, there are several non-pharmaceutical giant 
companies now in clinical trials, notable amongst these are Geron in the USA, Mesoblast in 
Australia and ReNeuron in the UK, although there are some interesting endeavors in 
Southeast Asia too, e.g. Medipost in Korea. All of these are undergoing various stages and 
sizes of clinical trials for diverse indications, some of which are showing already very 
encouraging results. It is predicted that within the next few years one or more of these 
potential products will reach the market as an approved medical product. Having said this, 
other than showing ongoing safety and efficacy in the trials, some hurdles do remain in the 
industry as whole, such as up-scaling for mass production of the cells which is considered 
necessary for generating an off-the-shelf product.  
If this trend continues, it is only reasonable to assume that gene therapy will follow, most 
probably some years after cell therapy has been more widely accepted, but possibly in 
parallel to some extent, as there are also a number of human gene therapy trials already in 
progress. So, how significant will retroviral (RV) and lentiviral (LV) vectors be in this future 
gene therapy industry? One approach to answer this is to look at how popular they have 
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1. Introduction 
If biomedicine is considered to be the use of biological or botanical agents in medicine then 
it is certainly the oldest kind of therapy. Since drugs, however, it is no longer the most 
prolifically used, at least in the developed world. Will this change, and if so will it be in the 
near or more distant future? It has been discussed amongst experts in the industry for some 
time that, despite ever-increasing funding and new high-tech methods of discovery and 
screening, amounts of new drugs and drug leads are declining. In part, this has opened the 
way for biologics. The frontrunner is of course antibody technologies, mainly monoclonals, 
the use of which has exploded over the last 5 years to the point where most of the major 
pharma players are involved or are getting involved in what has now become a multi-billion 
dollar industry. Antibodies have reached the point of being a well trusted and accepted 
form of medical product across the industry and communities from bench to bedside.  
Many believe the next similar success story will be for cell therapy, probably some 
differentiated form of stem cells. Although it has been happening for 20 years, it is only in 
the past 5 years that the amount of patients being treated with cells, as a therapy, has 
increased into the thousands per year. The vast majority of these are autologous cell 
treatments, undertaken by hospitals and private clinics on a patient to patient basis using 
the patients’ own cells to treat a wide variety of diseases and conditions. These are not 
officially approved medical products. However, there are several non-pharmaceutical giant 
companies now in clinical trials, notable amongst these are Geron in the USA, Mesoblast in 
Australia and ReNeuron in the UK, although there are some interesting endeavors in 
Southeast Asia too, e.g. Medipost in Korea. All of these are undergoing various stages and 
sizes of clinical trials for diverse indications, some of which are showing already very 
encouraging results. It is predicted that within the next few years one or more of these 
potential products will reach the market as an approved medical product. Having said this, 
other than showing ongoing safety and efficacy in the trials, some hurdles do remain in the 
industry as whole, such as up-scaling for mass production of the cells which is considered 
necessary for generating an off-the-shelf product.  
If this trend continues, it is only reasonable to assume that gene therapy will follow, most 
probably some years after cell therapy has been more widely accepted, but possibly in 
parallel to some extent, as there are also a number of human gene therapy trials already in 
progress. So, how significant will retroviral (RV) and lentiviral (LV) vectors be in this future 
gene therapy industry? One approach to answer this is to look at how popular they have 
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been up to now, both in terms of previous and ongoing trials as well as the interest that the 
research community has in them compared to other forms of gene therapy tools.  
In order to asses this one must firstly consider all forms of gene delivery tools, as this is a 
pre-requisite for gene therapy. In general, gene delivery can be achieved either by viral or 
non-viral means. Mostly, when non-viral gene delivery is discussed, it involves the use of 
plasmid DNA, although there is much interest in other forms of nucleic acids such as 
bacterial artificial chromosomes (BACs) (for recent review on BACs see Tunster et al. 
2011). Nucleic acids can be transduced into the patients’ cells by physical or chemical 
mechanisms. Physical methods include obvious ways like direct injection, or 
aerosolisation/inhalation but also more ingenious techniques like the gene gun or using 
sound waves, such as ultrasound (Passineau et al. 2011) or by electroshock, which can 
intriguingly even work in vivo (De Vry et al. 2010; Kaneda 2010). Such non-viral means 
have classically been considered to be safer because viral vectors may cause insertional 
mutagenesis, revert to wild-type via recombinations during preparation or in vivo with 
other viruses (infections or endogenous viruses). But, at the same time, non-viral means 
are also considered to be far less effective, as once the nucleic acid is inside the cell it is 
only by chance that it will enter the nucleus and be expressed. Both of these views are 
changing somewhat though. From a safety perspective, as techniques for producing and 
detecting virus vectors are advancing and people’s understandings of viral vector safety is 
improving, and, from an efficiency perspective, as chemical and nanomaterial 
technologies improve.  
It boils down to a risk/benefit calculation and viral based methods are still generally 
considered to be far more efficient tools, and as such, outweighing the risks. Mammalian 
cells could be transformed with virus-based methods as early as the 1960’s, yet virus related 
vectorology, with respect to gene delivery, only started to strongly emerge in the early 
1980’s (Figure 1), showing that this is somewhat a matter of definition. In any case, 
adenoviruses (AdV) have always been and still are the most popularly researched and used 
vectors. One would expect that over the years, the number of different types of viruses and 
new viruses being researched as vectors would increase, and this is indeed the case (Fig. 1, 
see “others” from 1 in 1985 to over 400 in 2010). However, one trend that was not as 
expected is that the amount of studies on herpes simplex (HSV) as a vector has not 
increased. In other words, in 1980 the first talk of using viruses in connection with gene 
delivery was concerning HSV (Anderson et al. 1980), by 1985 a few publications related to 
RV, but the most were still HSV related, and surprisingly this number has almost not 
changed up to 2010 where still only approximately 20 publications related to using HSV as a 
vector for gene therapy or delivery. Is it fair to conclude from this that they may simply be 
unsuitable for the job? Further investigation would be required to make such a claim but it 
may be reasonable to suggest that if more successful steps had been made, then increasing 
popularity would be inevitable. Most surprising, however, is that over the last 10 years, 
publications of research and use of viruses as vectors seems to have reached a plateau, and 
in the last four years, have begun to decrease (see Figure 1, All). This may be a sign that that 
some technologies are being absorbed by industrial processes, e.g. patent before publication, 
trade secrets. Such translational activities, although more practical, are less academically 
novel and may reduce the number of research papers.  
Most relevant perhaps for this chapter on surface modifications of enveloped viruses and 
their application, is the changing relationship of interest between RV and LV vectors in the 
research community over the last ten years (Figure 1, compare RV and LV).  
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the last 25 years. A study was undertaken using the scientific reference collating 
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For example, both “retrovirus” and “retroviral” were searched together with either “gene 
delivery” or “gene therapy” and “vector” and each were cross-referenced with each other, 
which allowed not only to be sure that the topic in question was relating to gene 
delivery/therapy with viral vectors, and that nothing was missed, but it also gave an idea of 
publications which were using both types of system, i.e. that these were not counted twice. 
The same was done for lentivirus, adenovirus and adeno-associated virus vectors.  
Key: All = total number of all viral vectors for gene delivery and includes the following:  
RV = retroviral vectors; LV = lentiviral vectors; AdV = adenovirus vectors; AAV = adeno-
associated virus vectors; BV = baculoviral vectors; Others = vectors based on the following 
viruses: alphaviruses (e.g. Sindbis, Semliki Forest, Ross River, Venezuelan equine 
encephalitis), vaccinia viruses, poxviruses, infectious bursal disease, herpes simplex, 
Sendai/hemagglutinating virus of Japan, measles, transmissible gastroenteritis virus, 
human and avian influenza, oncolytic vesicular stomatitis, papilloma viruses, lymphocytic 
choriomeningitis, rabies, hepatitis B/C, combinations of viruses (e.g. RV-LV, AdV-RV) as 
well as replicons, amplicons, retroelements and virally related transposons.  
Although the actual numbers are not huge, there is clearly a significant shift in the focus of 
interest from RV vectors to LV vectors. When RV vectors are discussed, this means mainly 
the two forms of murine leukemia virus (MLV), the Friend and Moloney strains, although, 
studies also include vector work with mouse mammary tumour virus (MMTV) and Rous 
sarcoma virus (RSV) (Gunzburg 2003). When LV vectors are discussed, this means mainly 
human immunodeficiency virus type-1 (HIV-1), although again, studies also include vector 
work with simian and feline immunodeficiency viruses (SIV and FIV). There may be many 






























Viral Gene Therapy 42 
been up to now, both in terms of previous and ongoing trials as well as the interest that the 
research community has in them compared to other forms of gene therapy tools.  
In order to asses this one must firstly consider all forms of gene delivery tools, as this is a 
pre-requisite for gene therapy. In general, gene delivery can be achieved either by viral or 
non-viral means. Mostly, when non-viral gene delivery is discussed, it involves the use of 
plasmid DNA, although there is much interest in other forms of nucleic acids such as 
bacterial artificial chromosomes (BACs) (for recent review on BACs see Tunster et al. 
2011). Nucleic acids can be transduced into the patients’ cells by physical or chemical 
mechanisms. Physical methods include obvious ways like direct injection, or 
aerosolisation/inhalation but also more ingenious techniques like the gene gun or using 
sound waves, such as ultrasound (Passineau et al. 2011) or by electroshock, which can 
intriguingly even work in vivo (De Vry et al. 2010; Kaneda 2010). Such non-viral means 
have classically been considered to be safer because viral vectors may cause insertional 
mutagenesis, revert to wild-type via recombinations during preparation or in vivo with 
other viruses (infections or endogenous viruses). But, at the same time, non-viral means 
are also considered to be far less effective, as once the nucleic acid is inside the cell it is 
only by chance that it will enter the nucleus and be expressed. Both of these views are 
changing somewhat though. From a safety perspective, as techniques for producing and 
detecting virus vectors are advancing and people’s understandings of viral vector safety is 
improving, and, from an efficiency perspective, as chemical and nanomaterial 
technologies improve.  
It boils down to a risk/benefit calculation and viral based methods are still generally 
considered to be far more efficient tools, and as such, outweighing the risks. Mammalian 
cells could be transformed with virus-based methods as early as the 1960’s, yet virus related 
vectorology, with respect to gene delivery, only started to strongly emerge in the early 
1980’s (Figure 1), showing that this is somewhat a matter of definition. In any case, 
adenoviruses (AdV) have always been and still are the most popularly researched and used 
vectors. One would expect that over the years, the number of different types of viruses and 
new viruses being researched as vectors would increase, and this is indeed the case (Fig. 1, 
see “others” from 1 in 1985 to over 400 in 2010). However, one trend that was not as 
expected is that the amount of studies on herpes simplex (HSV) as a vector has not 
increased. In other words, in 1980 the first talk of using viruses in connection with gene 
delivery was concerning HSV (Anderson et al. 1980), by 1985 a few publications related to 
RV, but the most were still HSV related, and surprisingly this number has almost not 
changed up to 2010 where still only approximately 20 publications related to using HSV as a 
vector for gene therapy or delivery. Is it fair to conclude from this that they may simply be 
unsuitable for the job? Further investigation would be required to make such a claim but it 
may be reasonable to suggest that if more successful steps had been made, then increasing 
popularity would be inevitable. Most surprising, however, is that over the last 10 years, 
publications of research and use of viruses as vectors seems to have reached a plateau, and 
in the last four years, have begun to decrease (see Figure 1, All). This may be a sign that that 
some technologies are being absorbed by industrial processes, e.g. patent before publication, 
trade secrets. Such translational activities, although more practical, are less academically 
novel and may reduce the number of research papers.  
Most relevant perhaps for this chapter on surface modifications of enveloped viruses and 
their application, is the changing relationship of interest between RV and LV vectors in the 
research community over the last ten years (Figure 1, compare RV and LV).  
Surface Modification of Retroviral Vectors for Gene Therapy 43 
 
Fig. 1. The trend of scientific publications in the area of viral vectors for gene delivery over 
the last 25 years. A study was undertaken using the scientific reference collating 
programme, Endnote. The method used was to search and cross-reference various terms. 
For example, both “retrovirus” and “retroviral” were searched together with either “gene 
delivery” or “gene therapy” and “vector” and each were cross-referenced with each other, 
which allowed not only to be sure that the topic in question was relating to gene 
delivery/therapy with viral vectors, and that nothing was missed, but it also gave an idea of 
publications which were using both types of system, i.e. that these were not counted twice. 
The same was done for lentivirus, adenovirus and adeno-associated virus vectors.  
Key: All = total number of all viral vectors for gene delivery and includes the following:  
RV = retroviral vectors; LV = lentiviral vectors; AdV = adenovirus vectors; AAV = adeno-
associated virus vectors; BV = baculoviral vectors; Others = vectors based on the following 
viruses: alphaviruses (e.g. Sindbis, Semliki Forest, Ross River, Venezuelan equine 
encephalitis), vaccinia viruses, poxviruses, infectious bursal disease, herpes simplex, 
Sendai/hemagglutinating virus of Japan, measles, transmissible gastroenteritis virus, 
human and avian influenza, oncolytic vesicular stomatitis, papilloma viruses, lymphocytic 
choriomeningitis, rabies, hepatitis B/C, combinations of viruses (e.g. RV-LV, AdV-RV) as 
well as replicons, amplicons, retroelements and virally related transposons.  
Although the actual numbers are not huge, there is clearly a significant shift in the focus of 
interest from RV vectors to LV vectors. When RV vectors are discussed, this means mainly 
the two forms of murine leukemia virus (MLV), the Friend and Moloney strains, although, 
studies also include vector work with mouse mammary tumour virus (MMTV) and Rous 
sarcoma virus (RSV) (Gunzburg 2003). When LV vectors are discussed, this means mainly 
human immunodeficiency virus type-1 (HIV-1), although again, studies also include vector 
work with simian and feline immunodeficiency viruses (SIV and FIV). There may be many 






























Viral Gene Therapy 44 
in contrast to RV vectors, offer the ability to transduce non-dividing cells (Sakoda et al. 
2007). This is generally seen as an advantage, however, it may not be desirable in all gene 
delivery cases, as it may be useful to target only dividing cells (e.g. in cancer therapy). 
Another reason is likely to be the sheer amount of interest in HIV as its affliction on humans 
continues to globally expand, i.e. relatively large amounts of finance available and research 
undertaken to understand the virus for human medicine not only leads to drug targets but 
also to ingenious ways of using the virus as a vector for gene delivery or therapy, e.g. self-
inactivating vectors to increase safety (Liehl et al. 2007).  
Other than RV, LV, AdV and AAV, there are many types of viruses being developed as gene 
delivery vectors, all with limited impact, but it seems in more recent years that the numbers of 
these studies are no longer increasing (see Figure 1, Others). One explanation may be that this 
correlates with the amount of new viruses being discovered. Either man has discovered most 
viral entities already or a future technological breakthrough will allow discovery of viral or 
viral related entities of a new dimension. It may also be surprising to some to see how many 
“nasty” viruses are being used to make vectors. For example, HSV BACs were developed 
around 2000 mainly for studying viral genetics, but more recently they are being explored for 
gene therapy (Warden et al. 2011). Other ongoing examples include measles, influenza and 
papilloma viruses, the latter of which cause cancer. When considering this, however, one just 
has to remember what has happened with HIV over the last 15 years. First suggestions of 
using HIV vectors for human medicine were met with serious concern in the general media, 
and even scientists were skeptical, but now they are well accepted and even approved for use 
in human clinical trials (Sheridan 2011, also see below).  
Some publications relate to expression of viral genes within other more common types of 
vector system, e.g. the thymidine kinase gene of the HSV (HSV-TK) expressed using a RV or 
AdV vector, so it is somewhat a matter of definition as to whether they are included as virus 
based gene delivery systems. For this study, such cases were not included. In some cases 
there were also hits for viral components such as the envelope proteins of vesicular 
stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV) and amphotropic MLV 
(see also Table 2), but this is relating to pseudotyping, and, although there are a few genuine 
cases of scientists developing true gene delivery vectors from these viruses, the 
pseudotyping cases were not counted in this study. Pseudotyping as a method for viral 
surface modification is discussed later in this chapter. 
Finally, how has all the viral vector research culminated into gene therapy trials in the 
clinic? The majority of trials that have been undertaken and are currently ongoing (around 
14 human trials) are using AdV and AAV (for a recent review see Sheridan 2011). More 
relating to the topic of this chapter, however, are past and ongoing successes for enveloped 
viral vector gene therapies, i.e. RV and LV vectors. Most worthy of mention are the studies, 
human trials and treatments made by Alain Fischer, Marina Cavazzana-Calvo and Salima 
Hacein-Bey-Abina. Children who were suffering from severe combined immunodeficiency 
(SCID-X1) had their T-cells treated ex vivo with a RV vector (Moloney MLV based) to replace 
a defective part of the gene for the interleukin-2 receptor (Cavazzana-Calvo et al. 2000; 
Hacein-Bey-Abina et al. 2008). Although four of the twenty patients treated developed 
leukemia (caused by insertional mutagenesis and activation of a proto-oncogene), they were 
able to be treated for this secondary issue, and seventeen from twenty have had their 
immunodeficiency corrected over the follow-up period of almost 10 years now (Cavazzana-
Calvo et al. 2010). This is a great success in which the benefit clearly outweighed the risk, as 
without alternative treatment (the only one being a bone marrow transplant with only 25% 
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chance of success), the outcome would have been fatal within a few years at best. Other 
ongoing studies in the area of primary immunodeficiency are being undertaken by San 
Raffaele in Italy, also using a Moloney MLV vector (Aiuti et al. 2002), although it is unclear 
if more human trials are planned at present. Two USA companies have ongoing RV vector 
treatments in trials, namely Neurologix for Parkinson’s disease (Kaplitt et al. 2007; Lewitt et 
al. 2011) and Tocagen for a form of brain cancer, glioblastoma multiforme. The Tocagen trial 
is of particular interest as it is the first study in humans using a replication competent RV. 
All RV and LV vectors previously used in trials (even the vast majority used in research) are 
non-replicating or self-inactivating, which means after one round of infection/gene delivery 
that the virus is “dead” and cannot replicate further. It has been classically developed this 
way for safety reasons, unfortunately, as it turns out, the in vivo infection efficiency of such 
vectors may never be good enough for many applications. The MLV based replication 
competent vector developed by Tocagen and its research associates (Anliker et al. 2010) has 
the therapeutic gene, cytosine deaminase (CD), inserted into the viral genome in a stable 
position where the virus cannot easily reject it, even after multiple rounds of infection (Logg 
et al. 2001; Paar et al. 2007). As the RV vector is limited to replicating in dividing cells, and 
only very few cells in the brain are dividing at a speed comparable to the tumour, it is the 
ideal setting. Also, the prodrug used for the treatment, 5-FC, can only pass the blood-brain 
barrier in its non-activated form, i.e. once activated to 5-FU by the CD gene product at the 
cancer location, it cannot pass back into the rest of the body, where there are faster dividing 
cells which could be affected. Once the infected tumour is destroyed, so in turn are the 
replicating viruses in this so called suicide-gene therapy system. This trial is being followed 
by many and with great interest. 
Concerning clinical trials with LV, three companies are worth mentioning. Bluebird Bio 
(formerly Genetix Pharmaceuticals) in the USA, recently completed 2 trials with three 
patients in total who underwent ex vivo treatment of their own hematopoietic stem cells with 
a LV vector delivering corrective genes for either cerebral adrenoleukodystrophy (Cartier et 
al. 2009) or beta-thalassaemia (Cavazzana-Calvo et al. 2010). Although both showed positive 
results, no public announcement on further trials has been announced as yet. Lentigen, also 
in USA, are currently undertaking a pilot study through the University of Pennsylvania for 
several kinds of leukemia and lymphoma, whereby, once again, the patients T-cells will be 
modified ex vivo, but in this case the modification should turn-on the T-cells enabling them 
to attack and trigger the destruction of the cancerous B cells once re-implanted 
(ClinicalTrials.gov Identifier No. NCT00891215). Oxford BioMedica are currently 
undertaking Phase I/II trial for Parkinson’s disease by injecting their LV vector technology 
via stereotactic injection directly into the striatum of patients’ brains. Three genes which are 
necessary for dopamine production should be delivered/expressed and the results are 
predicted to be published soon (EudraCT No. 2007-001109). 
2. Methods to modify surfaces of RV/LV vectors 
2.1 Introduction - proteins of retroviral surfaces 
When retroviral or lentiviral (RV/LV) particles exit infected cells, they are surrounded by a 
lipid membrane, termed the envelope, derived from the infected cells. The envelope 
contains both virus-derived and cellular proteins (VP and CP, respectively), which may 
perform distinct functions for the virus. Since proteins displayed on the envelope are the 
first to make contact with neighboring molecules, they are often involved in virus-cell and 
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to attack and trigger the destruction of the cancerous B cells once re-implanted 
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necessary for dopamine production should be delivered/expressed and the results are 
predicted to be published soon (EudraCT No. 2007-001109). 
2. Methods to modify surfaces of RV/LV vectors 
2.1 Introduction - proteins of retroviral surfaces 
When retroviral or lentiviral (RV/LV) particles exit infected cells, they are surrounded by a 
lipid membrane, termed the envelope, derived from the infected cells. The envelope 
contains both virus-derived and cellular proteins (VP and CP, respectively), which may 
perform distinct functions for the virus. Since proteins displayed on the envelope are the 
first to make contact with neighboring molecules, they are often involved in virus-cell and 
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virus-medium interactions. In order to complete their life cycle, viruses are depending on 
this communication with their surroundings, specifically the soluble factors (i.e. antibodies 
or proteins of the complement system) contained in the liquid environment and elements 
displayed on the surface of potential host cells (i.e. the receptors found on the cell surface 
required for binding and entry of the virus).  
This is maybe best demonstrated by the VPs found in the lipid membrane of the RV/LV 
particle, termed envelope or Env proteins. The function of these proteins is to initiate cell 
entry (for more details see chapter 3.5.). The RV/LV envelope proteins may be replaced by 
surface glycoproteins of different virus species in a process termed pseudotyping (Bischof 
and Cornetta 2010; Cronin et al. 2005). The resulting viral pseudotypes can be of interest for 
gene therapy applications (see section 2.2. for details). Apart from the virus encoded Env 
proteins, CP are also incorporated into the viral envelopes. Theoretically, this may happen 
as a consequence of three processes: (i) interaction of host proteins with viral proteins (type 
1 incorporation), (ii) incorporation due to directed colocalisation (type 2 incorporation) and 
(iii) random incorporation (type 3 incorporation). The incorporation of the cytoplasmic 
protein cyclophilin A to HIV-1 particles is an example of a type 1 incorporation. The protein 
associates with the viral Gag proteins and is subsequently incorporated with a similar 
efficiency (Hammarstedt and Garoff 2004). A similar situation was shown for the tumor 
susceptibility gene 101 (Tsg-101) product, which presumably has a role in RV/LV particle 
release (Garrus et al. 2001; Pornillos et al. 2003). Additionally, in 1995 the incorporation of 
complement regulatory factors such as CD55 (decay accelerating factor) and CD59 
(protectin) into viral envelopes was described (Breun et al. 1999; Saifuddin et al. 1994; 
Saifuddin et al. 1995; Saifuddin et al. 1997). The levels of these proteins are high enough to 
ensure protection from the human complement system, a part of the innate immune system 
(Breun et al. 1999; Saifuddin et al. 1997). Both the glycosylphosphatidylinositol-anchored 
CD55 and CD59 molecules are enriched in membrane microdomains, often termed lipid 
rafts. Interestingly, it has been demonstrated that a range of viral species including 
retroviruses and lentiviruses may use lipid rafts as sites of viral assembly (Metzner et al. 
2008a). Thus co-localisation of these molecules at the site of viral budding would lead to 
their incorporation into viral envelopes. Thus, this may constitute a type 2 incorporation. 
The co-localisation of molecules at membrane microdomains may also form the framework 
for pseudotyping events (Briggs et al. 2003; Metzner et al. 2008a; Pickl et al. 2001) (see 
section 2.2.). Discriminating between type 2 and type 3 incorporation events may be 
difficult, since directed co-localisation is not easy to demonstrate and the concept of 
membrane microdomains is controversial (Shaw 2006). However, there is reason to believe 
that most incorporation events happen passively (Hammarstedt and Garoff 2004), i.e. 
concentration of proteins is not increased compared to normal membrane composition. To 
maintain a proteome not altogether dissimilar from the cellular membrane may generally be 
beneficial for the virus, since this would contribute to immune-camouflage, i.e. “hiding” the 
virus from the host’s immune system.  
A special case is the exclusion of host proteins from the viral particles. Several cases have 
been described including proteins such as CD45 (Esser et al. 2001), CD4 and the HIV co-
receptors CXCR4 and CCR5 (Lallos et al. 1999). Excluding receptors and co-receptors from 
budding viral particles can be beneficial for the virus, since premature receptor engagement 
and induction of fusion can be avoided. The mechanisms responsible for exclusion of 
proteins from viral envelopes may be that the formation of a network of viral Gag proteins 
inhibits access of proteins with large cytoplasmic domains (such as CD45) or multiple 
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transmembrane passes (such as the HIV co-receptors). Alternatively, involvement of 
excluded proteins in larger complexes may prevent them from being incorporated (such as 
CD4-p56lck). Recently, proteomics approaches have been used to identify host proteins 
found in viral envelopes to get an overview of incorporation (see Table 1) and to date, a long 
list of proteins have been identified in viral particle envelopes (Chertova et al. 2006; Segura 
et al. 2008b) including a range of molecules involved in cellular adhesion. Viruses may profit 
from these molecules, as they can provide additional or indeed, initial anchoring before 
specific interactions between Env and the cognate cell-membrane viral receptors.  
 
Protein Virus Function Comment Reference 
Tsg-101 HIV-1 MVB sorting;  HIV budding 
Interaction 
with Gag 
Hammarstedt and Garoff, 
2004; Pornillos et al.; 2002 
CD55 HIV-1, MLV 
Complement 
regulation GPI-anchored 
Saifuddin et al., 1995;  
Plewa et al., 2005 
CD59 HIV-1, MLV 
Complement 
regulation GPI-anchored 
Saifuddin et al., 1995;  
Plewa et al., 2005 




MLV Adhesion Random? 
Chertova et al., 2006;  
Segura et al., 2008 
CD44 HIV-1 Adhesion Random? Chertova et al., 2006 
CD54 
(ICAM 1) HIV-1 Adhesion Random? Chertova et al., 2006 
CD48 HIV-1 Signaling Random? Chertova et al., 2006 
CD45 HIV-1 Signaling Excluded Esser et al., 2001 
CD4 HIV-1 HIV receptor Excluded Lallos et al., 1999 
CXCR4 HIV-1 HIV co-receptor Excluded Lallos et al., 1999 
CCR5 HIV-1 HIV co-receptor Excluded Lallos et al., 1999 
Table 1. Examples for cellular proteins incorporated to RV/LV envelopes. Tsg tumor 
suppressor gene 101; MVB multivesicular bodies; ICAM intercellular adhesion molecule. 
Surface modification of RV/LV particles can be broadly separated into five categories (see 
Figure 2): (i) pseudotyping, (ii) generation of fusion proteins, (iii) post translational 
modification of proteins with lipophilic residues, most notably glycosylphosphatidylinositol 
(GPI) anchors, (iv) utilization of adaptor molecules, or (v) direct chemical modifications. 
These types of modification will be discussed in sections 2.2. to 2.6., while the purpose of 
such modifications and possible applications will be discussed in section 3. Special attention 
will be given to the “non-classical” methods for modification of viral surfaces discussed in 
section 2.4. to 2.6. 
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Fig. 2. Overview of strategies for modification of RV/LV vector surfaces. 
2.2 Pseudotyping 
The phenomenon that surface (glyco-)proteins of one virus species can be displayed on the 
surface of another retrovirus, or indeed other viral species has been termed “pseudotyping”. 
It was first described more that 55 years ago, after the observation that cells infected with 
two different viruses, can give rise to phenotypically mixed particles (Granoff and Hirst 
1954; Zavada 1982). Interestingly, surface glycoproteins from different families of viruses 
can be exchanged or mixed in such a manner (see Table 2), indicating some degree of 
similarity between these molecules or the mechanisms by which they are incorporated into 
the virions. Because of this compatibility, a limited set of modifications can be introduced to 
retroviral particles by displaying surface molecules of other viral species. Since the primary 
function of viral surface glycoproteins is to mediate binding and entry to host cells, the 
replacement of retroviral Env molecules in most cases changes the infectious range (the 
tropism) of the vector, because different receptors are engaged. This phenomenon can be 
exploited for gene therapy approaches, as it allows for example, the broadening or re-
direction of the virus’ host range (see Table 2). For example, HIV-1 based LV vectors, 
naturally having a very limited, highly specific tropism, infecting only CD4-expressing cells, 
can be redirected from these cells by replacing the Env proteins of HIV-1 with those of the 
vesicular stomatitis virus (VSV), thus generating a vector with a more diverse tropism 
(Bischof and Cornetta 2010). VSV-G, the surface glycoprotein of VSV, is probably the most 
often used molecule for pseudotyping applications. In addition to changing tropism, VSV-G 
also enhances virion stability (Burns et al. 1993) but is toxic to cells if expressed 
constitutively making it challenging to generate stable packaging cell lines. To overcome 
this, tetracycline-inducible promoters are frequently used to generate stable virus-producing 
cell lines (Ory et al. 1996). Additionally VSV-G pseudotypes are highly susceptible to 
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treatment e.g. by polyethylene glycol (PEG) modification or PEGylation (Croyle et al. 2004). 
Other examples for pseudotyping are described in table 2. It is not in all cases that 
pseudotyping is used to transfer new cell binding properties to the RV/LV vector. Recent 
approaches employ pseudotyping to transfer fusion properties of surface glycoproteins 
from Sindbis (Morizono et al. 2009a; H. Yang et al. 2008a), Influenza (Lin et al. 2001; H. Yang 
et al. 2008a) or measles virus (Anliker et al. 2010; Frecha et al. 2011). In these molecules, 
fusion activity is not strictly dependent on receptor binding. In such cases the original 
binding activity may be abrogated and replaced with a binding function of choice. This 
constitutes a “mixed” modification, since both, pseudotyping and generation of chimeric 
proteins are employed to generate vector particles (see also sections 2.3 and 3.5.).   
 
Viral Surface 
Protein Virus Family 
Vector 
Background Targeting Preference References 
MLV amphotropic Retroviridae HIV-1, SIV broad, fibroblasts Strang et al., 2004 
GALV Retroviridae HIV-1 hematopoietic,  cancer 
Diaz et al., 2000; 
Sandrin  
et al., 2002 
RD114 Retroviridae HIV-1, SIV hematopoietic 
Sandrin et al., 
2002; Zhang et 
al., 2004 
LCMV Arenaviridae HIV-1, EIAV, SIV 
CNS, glioma,  
pancreas 
Miletic et al., 
2004; Kobinger et 
al., 2004 
Sindbis Togaviridae HIV-1 broad Morizono  et al. 2009 
Ross River Togaviridae HIV-1, FIV Liver (non-hepatocyte) Kang et al. 2002 
VSG-G Rhabdoviridae 
HIV-1, HIV-
2, SIV, FIV, 
EIAV 
CNS, Liver, retina 
Watson et al. 
2002; Park et al. 
2003; Auricchio 
et al. 2001 
Ebola Filoviridae HIV-1, FIV Lung, muscle 
Kobinger et al. 
2004; MacKenzie 
et al. 2002 
Rabies Rhabdoviridae HIV-1, EIAV CNS Stein et al. 2005 
Influenza A Orthomyxoviridae HIV-1, EIAV, SIV Lung McKay et al. 2006 
Measles Paramyxoviridae HIV-1 broad  (Edmonston strain) 
Anliker et al. 
2010 
Sendai Paramyxoviridae HIV-1, SIV Liver, Lung 
Kowolik et al. 
2002; Sinn et al. 
2005 
Hepatitis C Flaviviridae HIV-1 Liver Hsu et al. 2003 
Table 2. Examples for the use of pseudotyping events for gene therapy approaches. MLV 
murine leukemia virus; SIV simian immunodeficiency virus; GALV gibbon ape leukemia 
virus; LCMV lymphocytic choriomeningitis virus; EIAV equine infectious anemia virus; 
FIV feline immunodefiency virus; VSV-G vesicular stomatitis virus glycoprotein. 
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fusion activity is not strictly dependent on receptor binding. In such cases the original 
binding activity may be abrogated and replaced with a binding function of choice. This 
constitutes a “mixed” modification, since both, pseudotyping and generation of chimeric 
proteins are employed to generate vector particles (see also sections 2.3 and 3.5.).   
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Table 2. Examples for the use of pseudotyping events for gene therapy approaches. MLV 
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virus; LCMV lymphocytic choriomeningitis virus; EIAV equine infectious anemia virus; 
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The mechanisms behind pseudotyping are believed to be related to the presence of 
membrane subdomains in cellular membranes which function as sites for viral assembly 
and/or budding of a range of different viral species (Briggs et al. 2003; Metzner et al. 2008a; 
Pickl et al. 2001). Since viruses from quite different taxonomical origins are assembled at 
such sites, incorporation of proteins from different virus backgrounds can occur. 
Consequently, pseudotyping can be viewed as a form of type 2 incorporation. Another pre-
requisite for pseudotyping, is that wild-type RV/LV Env proteins are not required for 
functional assembly of virions, inferring that the absence of the native glycoproteins does 
not interfere with particle production. Alternatively, direct or indirect (via a cellular 
intermediate) protein interaction may be responsible for pseudotyping. Recently, an indirect 
interaction model has been proposed using a scanning electron microscopy approach 
(Jorgenson et al. 2009) thus supporting involvement of type 1 incorporation events. To date, 
a large number of combinations have been tried and have been assessed in terms of their 
targeting potential in gene therapy approaches (see Table 2). Recent reviews provide a more 
extensive overview of pseudotyping of RV/LV vectors (Bischof and Cornetta 2010; Cronin 
et al. 2005). 
2.3 Fusion proteins 
Hybrid proteins consisting of amino acid sequence elements derived from more than one 
original polypeptide are termed fusion or chimeric proteins. To avoid confusion with 
proteins such as viral surface glycoproteins exhibiting membrane fusion activity, the latter 
term will be used. The technique of fusing protein parts by manipulation on the DNA level 
has been widely used to study the spatial distribution or kinetics of expression by utilizing 
fluorescent marker proteins such as green fluorescent protein (GFP). Fusing retroviral 
envelope proteins with molecules of interest allows for a more widespread modification of 
viral surfaces, since it is not limited by the availability of naturally occurring viral 
glycoproteins. In the case of chimeric proteins, the residual RV/LV Env molecule part is 
used as a sorting signal, directing the chimeric molecule to sites of budding. The advantage 
of this method is that theoretically no limit is placed on the type of amino acid sequence 
introduced and that incorporation to the viral particle is in most cases efficient (Ryu, 2008). 
The fused parts may be complete ligands (Kasahara et al. 1994), peptides (Gollan and Green 
2002; Morizono et al. 2009a) or single-chain antibodies (Anliker et al. 2010; Somia et al. 1995). 
However, limits have been shown to apply to this technique, as structural or functional 
elements are typically disturbed by their introduction, leading to loss of infectivity, since 
cellular uptake is inhibited at the level of envelope-cell membrane fusion (Galanis et al. 
2001; Ryu et al. 2008; Zhao et al. 1999). When a chimeric Env molecule, containing a CD33 
specific single-chain antibody, was generated to target CD33 positive cells, the collected data 
indicated, that the chimeric protein could not initiate fusion of the virus and cell membranes 
during infection (Zhao et al. 1999). The most widely accepted  explanation for this is that the 
chimeric proteins are unable to undergo a mandatory conformational change which 
activates the fusion activity (see also section 3.5.). Thus, the use of such modifications for 
targeting applications, i.e. the induction of cellular uptake upon engagement of the chimeric 
protein with a cognate receptor, is limited. Inclusion of wild-type RV Env proteins to 
targeted vectors can help to increase infectivity (Tai et al. 2003). This, however, may come at 
a cost for specificity of targeting. Studies conducted on chimeric Moloney murine leukemia 
virus (MoMLV) Env proteins suggest, that addition of as little as two point mutations might 
rescue targeted infection (Zavorotinskaya and Albritton 2001). More recent data suggests 
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that such mutations may need to be determined depending on the characteristics of the 
insert as well as the insertion site (Ryu, 2008).  
However, for purposes other than targeting, such as labeling of viral particles or tagging for 
enrichment purposes, this technique still holds appeal.  A GFP-Env chimeric protein, 
containing the sequence of enhanced GFP fused to the N-terminus of the amphotropic 
4070A Env of MLV has been generated and in this case viral particles retained their natural 
infection range (Spitzer et al. 2003). The construct was used to stain viral receptor-carrying 
cells and may be used for monitoring the dynamics of virus-cell interactions (Spitzer et al., 
2003). An interesting aspect is, that the “virion-targeting functions” of chimeric proteins 
may not necessarily have to be provided by RV/LV Env proteins, but could also be 
provided by the use of cellular proteins present or enriched in viral membranes such as Tsg-
101 (see Table 2).  Alternatively, virion-targeting function may be provided by GPI-
anchoring (see section 2.4.) or indeed, by making use of mixed modifications using fusion 
proteins of non-RV/LV glycoproteins, such as Sindbis virus (Morizono et al. 2009b; Pariente 
et al. 2007) influenza (Lin et al. 2001; L. Yang et al. 2006b) or measles virus (Anliker et al. 
2010; Frecha et al. 2008) with engineered novel binding properties. In these cases the wild-
type binding specificity was destroyed and replaced with molecules conferring specific 
targeting to molecules such as integrin (Morizono et al. 2009a) or the B lymphocyte marker 
CD20 (Anliker et al. 2010). In these cases, membrane fusion activity is inhibited to a lesser 
degree by the change in binding properties. For Sindbis and influenza, virus fusion is 
triggered by a decrease in pH. First in vivo experiments indicated that such vectors can be 
used for targeting applications (Anliker et al. 2010; L. Yang et al. 2006b) (see also section 3.5.) 
2.4 Glycosylphosphatidylinositol (GPI) modification 
GPI anchoring is a type of post-translational modification occurring in eukaryotic cells and 
probably constitutes the most complex and metabolically challenging way of attaching 
proteins to lipid membranes. Proteins targeted for GPI anchoring contain a GPI signaling 
sequence (GSS) at the C-terminal end. The GSS is recognized in the endoplasmatic reticulum 
by the transamidase enzyme complex where it is cleaved at the omega site, the point at 
which the preformed GPI anchor is attached. The biochemical pathway for synthesis of the 
GPI anchors is complex and chemical structures of GPI anchors vary to a great degree 
(Ikezawa 2002) however a common backbone structure is observed: Linkage of the GPI 
anchor to the C-terminal end of the protein is achieved by an amide bond to 
phosphoethanolamine. The following central three mannose residues are linked via a non-
acetylated glucosamine to the phosphoinositol part, which in turn is associated to the lipid 
residues, usually acyl or aryl fatty acid chains or sphingolipids e.g. ceramide (Ikezawa 2002). 
GPI anchored proteins have a variety of different functions. In addition to the mentioned 
complement regulatory activity of CD55 and CD59, GPI-linked proteins serve as hydrolytic 
enzymes like acetylcholinesterase and placental alkaline phosphatase (Ikezawa, 2002) or are 
involved in signal transduction like Thy1 (Haeryfar and Hoskin 2004). They share several 
unique properties: GPI-linked (or “glypiated”) proteins are targeted to the outer surface of 
the cell membrane (Ferguson 1999; Nosjean et al. 1997) and are frequently associated with 
dynamic membrane microdomains also known as lipid rafts (Legler et al. 2005). As 
mentioned previously, they have been suggested as the site of viral assembly for certain 
enveloped viruses e.g. HIV-1 (Briggs et al. 2003; D. H. Nguyen and Hildreth 2000). GPI 
proteins can also be found in serum and other body fluids both with intact or absent GPI 
anchors (Landi et al. 2003). Processes that release GPI-linked proteins into the medium with 
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The mechanisms behind pseudotyping are believed to be related to the presence of 
membrane subdomains in cellular membranes which function as sites for viral assembly 
and/or budding of a range of different viral species (Briggs et al. 2003; Metzner et al. 2008a; 
Pickl et al. 2001). Since viruses from quite different taxonomical origins are assembled at 
such sites, incorporation of proteins from different virus backgrounds can occur. 
Consequently, pseudotyping can be viewed as a form of type 2 incorporation. Another pre-
requisite for pseudotyping, is that wild-type RV/LV Env proteins are not required for 
functional assembly of virions, inferring that the absence of the native glycoproteins does 
not interfere with particle production. Alternatively, direct or indirect (via a cellular 
intermediate) protein interaction may be responsible for pseudotyping. Recently, an indirect 
interaction model has been proposed using a scanning electron microscopy approach 
(Jorgenson et al. 2009) thus supporting involvement of type 1 incorporation events. To date, 
a large number of combinations have been tried and have been assessed in terms of their 
targeting potential in gene therapy approaches (see Table 2). Recent reviews provide a more 
extensive overview of pseudotyping of RV/LV vectors (Bischof and Cornetta 2010; Cronin 
et al. 2005). 
2.3 Fusion proteins 
Hybrid proteins consisting of amino acid sequence elements derived from more than one 
original polypeptide are termed fusion or chimeric proteins. To avoid confusion with 
proteins such as viral surface glycoproteins exhibiting membrane fusion activity, the latter 
term will be used. The technique of fusing protein parts by manipulation on the DNA level 
has been widely used to study the spatial distribution or kinetics of expression by utilizing 
fluorescent marker proteins such as green fluorescent protein (GFP). Fusing retroviral 
envelope proteins with molecules of interest allows for a more widespread modification of 
viral surfaces, since it is not limited by the availability of naturally occurring viral 
glycoproteins. In the case of chimeric proteins, the residual RV/LV Env molecule part is 
used as a sorting signal, directing the chimeric molecule to sites of budding. The advantage 
of this method is that theoretically no limit is placed on the type of amino acid sequence 
introduced and that incorporation to the viral particle is in most cases efficient (Ryu, 2008). 
The fused parts may be complete ligands (Kasahara et al. 1994), peptides (Gollan and Green 
2002; Morizono et al. 2009a) or single-chain antibodies (Anliker et al. 2010; Somia et al. 1995). 
However, limits have been shown to apply to this technique, as structural or functional 
elements are typically disturbed by their introduction, leading to loss of infectivity, since 
cellular uptake is inhibited at the level of envelope-cell membrane fusion (Galanis et al. 
2001; Ryu et al. 2008; Zhao et al. 1999). When a chimeric Env molecule, containing a CD33 
specific single-chain antibody, was generated to target CD33 positive cells, the collected data 
indicated, that the chimeric protein could not initiate fusion of the virus and cell membranes 
during infection (Zhao et al. 1999). The most widely accepted  explanation for this is that the 
chimeric proteins are unable to undergo a mandatory conformational change which 
activates the fusion activity (see also section 3.5.). Thus, the use of such modifications for 
targeting applications, i.e. the induction of cellular uptake upon engagement of the chimeric 
protein with a cognate receptor, is limited. Inclusion of wild-type RV Env proteins to 
targeted vectors can help to increase infectivity (Tai et al. 2003). This, however, may come at 
a cost for specificity of targeting. Studies conducted on chimeric Moloney murine leukemia 
virus (MoMLV) Env proteins suggest, that addition of as little as two point mutations might 
rescue targeted infection (Zavorotinskaya and Albritton 2001). More recent data suggests 
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that such mutations may need to be determined depending on the characteristics of the 
insert as well as the insertion site (Ryu, 2008).  
However, for purposes other than targeting, such as labeling of viral particles or tagging for 
enrichment purposes, this technique still holds appeal.  A GFP-Env chimeric protein, 
containing the sequence of enhanced GFP fused to the N-terminus of the amphotropic 
4070A Env of MLV has been generated and in this case viral particles retained their natural 
infection range (Spitzer et al. 2003). The construct was used to stain viral receptor-carrying 
cells and may be used for monitoring the dynamics of virus-cell interactions (Spitzer et al., 
2003). An interesting aspect is, that the “virion-targeting functions” of chimeric proteins 
may not necessarily have to be provided by RV/LV Env proteins, but could also be 
provided by the use of cellular proteins present or enriched in viral membranes such as Tsg-
101 (see Table 2).  Alternatively, virion-targeting function may be provided by GPI-
anchoring (see section 2.4.) or indeed, by making use of mixed modifications using fusion 
proteins of non-RV/LV glycoproteins, such as Sindbis virus (Morizono et al. 2009b; Pariente 
et al. 2007) influenza (Lin et al. 2001; L. Yang et al. 2006b) or measles virus (Anliker et al. 
2010; Frecha et al. 2008) with engineered novel binding properties. In these cases the wild-
type binding specificity was destroyed and replaced with molecules conferring specific 
targeting to molecules such as integrin (Morizono et al. 2009a) or the B lymphocyte marker 
CD20 (Anliker et al. 2010). In these cases, membrane fusion activity is inhibited to a lesser 
degree by the change in binding properties. For Sindbis and influenza, virus fusion is 
triggered by a decrease in pH. First in vivo experiments indicated that such vectors can be 
used for targeting applications (Anliker et al. 2010; L. Yang et al. 2006b) (see also section 3.5.) 
2.4 Glycosylphosphatidylinositol (GPI) modification 
GPI anchoring is a type of post-translational modification occurring in eukaryotic cells and 
probably constitutes the most complex and metabolically challenging way of attaching 
proteins to lipid membranes. Proteins targeted for GPI anchoring contain a GPI signaling 
sequence (GSS) at the C-terminal end. The GSS is recognized in the endoplasmatic reticulum 
by the transamidase enzyme complex where it is cleaved at the omega site, the point at 
which the preformed GPI anchor is attached. The biochemical pathway for synthesis of the 
GPI anchors is complex and chemical structures of GPI anchors vary to a great degree 
(Ikezawa 2002) however a common backbone structure is observed: Linkage of the GPI 
anchor to the C-terminal end of the protein is achieved by an amide bond to 
phosphoethanolamine. The following central three mannose residues are linked via a non-
acetylated glucosamine to the phosphoinositol part, which in turn is associated to the lipid 
residues, usually acyl or aryl fatty acid chains or sphingolipids e.g. ceramide (Ikezawa 2002). 
GPI anchored proteins have a variety of different functions. In addition to the mentioned 
complement regulatory activity of CD55 and CD59, GPI-linked proteins serve as hydrolytic 
enzymes like acetylcholinesterase and placental alkaline phosphatase (Ikezawa, 2002) or are 
involved in signal transduction like Thy1 (Haeryfar and Hoskin 2004). They share several 
unique properties: GPI-linked (or “glypiated”) proteins are targeted to the outer surface of 
the cell membrane (Ferguson 1999; Nosjean et al. 1997) and are frequently associated with 
dynamic membrane microdomains also known as lipid rafts (Legler et al. 2005). As 
mentioned previously, they have been suggested as the site of viral assembly for certain 
enveloped viruses e.g. HIV-1 (Briggs et al. 2003; D. H. Nguyen and Hildreth 2000). GPI 
proteins can also be found in serum and other body fluids both with intact or absent GPI 
anchors (Landi et al. 2003). Processes that release GPI-linked proteins into the medium with 
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intact GPI anchors are reversible and it has been shown in a variety of in vitro and in vivo 
systems that GPI-linked proteins can be re-inserted into cell membranes (Dunn et al. 1996; 
Kooyman et al. 1995; Rifkin and Landsberger 1990; Rooney et al. 1993; Rooney et al. 1996; 
Vakeva et al. 1994). Transfer has been demonstrated for CD59 from erythrocytes to 
endothelial cells (Kooyman et al. 1995) as well as for trypanosomal variant surface 
glycoprotein (VSG) to erythrocytes of infected patients (Rifkin and Landsberger 1990). 
Therefore GPI-anchored proteins can be considered to be “hypermobile”. This 
hypermobility allows for the re-integration of purified GPI-anchored proteins to lipid 
membranes of cells (Legler et al. 2005; Medof et al. 1996) and viruses (Metzner et al. 2008b). 
This process has been termed cellular or viral painting, respectively. 
Technically, introducing a GPI anchor to a protein is achieved in the same way fusion 
proteins are made: Following genetic engineering, the recombinant protein is translated and 
the amino acid sequence describing the GSS is included to the nascent polypeptide, thus 
artificially GPI-anchored proteins are produced. A range of recombinant GPI-anchored 
proteins have been produced including glypiated GFP and CD4 (for a review see Metzner et 
al. 2008a). GPI-anchored proteins can be employed for the modification of RV/LV vectors 
by two distinct pathways: (i) after transfection of virus producing cells, facilitated by the co-
localisation of glypiated proteins at the site of viral budding and (ii) by viral painting, re-
introducing purified GPI-anchored proteins to mature viral particles as a result of the GPI-
anchored protein hypermobility.  
Co-transfection of plasmid vectors carrying genes for the production of retroviral vectors with 
constructs expressing the GPI-anchored proteins or super-transfection of pre-existing virus 
producing cell lines, leads to the formation of viral particles displaying GPI-anchored 
molecules on their envelopes. These particles acquire novel properties as a consequence of the 
incorporation of the GPI-anchored protein e.g. super-transfection of the murine retroviral 
producer cell line PALSG/S with the human GPI-anchored protein CD59, yields viral particles 
that are resistant to the activity of complement in human serum (Breun et al. 1999). These 
results suggested for the first time that incorporation of recombinantly expressed GPI-
anchored proteins into the envelopes of viral vectors is possible and that these modifications 
can be useful for gene therapy approaches. In two more recent studies, co-transfection 
approaches successfully produced virus-like particles (VLPs) containing glypiated proteins 
from mammalian (Kueng et al. 2007) or insect cells (Skountzou et al. 2007). In both cases, 
recombinant GPI-anchored different cytokine species were generated i.e. interleukin-2 (IL-2) 
and granuolocyte-macrophage colony stimulating factor (GM-CSF). In the first study, it was 
demonstrated that the GPI-anchored cytokines are functional and elicit cellular responses such 
as differentiation and proliferation with similar efficiency as their soluble counterparts when 
co-cultured with the appropriate target cells (Kueng et al. 2007); and in the second it was 
described that GPI-anchored cytokines engineered onto VLPs based on simian 
immunodeficiency virus (SIV) can enhance immunogenicity of the VLPs. In both cases a 
modulation of the immune responses was achieved by displaying GPI-anchored cytokine 
(Kueng et al. 2007; Skountzou et al. 2007). The major advantage of this approach is that stable 
transfection of RV/LV producer cell lines co- or super-transfected with GPI-anchored proteins 
can provide a reproducible long-term source of modified viral particles. In addition, no post-
exit steps that may reduce infectivity of the vectors are required.   
The second method to modify RV/LV vectors is by using GPI-anchored proteins that have 
been extracted and purified from cells and can be re-inserted after incubation with 
enveloped viruses. This was first described for the GPI-linked model protein CD59his which 
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associates to viral vectors based on MLV and HIV-1 (Metzner et al. 2008b). The association is 
specific and painted virus particles remain infectious after insertion of the GPI-linked 
protein, albeit at reduced efficiencies caused by the duration of the painting process, rather 
than the actual introduction of GPI-anchored molecules into the viral outer shell (Metzner et 
al. 2008b). Estimates of the number of GPI-anchored proteins painted onto retroviral 
particles were in the range of the numbers observed for Env molecules per virion and are 
thus similar to that achieved after incorporation of hybrid proteins produced in co-
transfection experiments (Skountzou et al. 2007). The main advantage of this approach is 
flexibility. Different GPI-anchored proteins can be attached to a range of enveloped viral 
particles without repeated genetic manipulations of the virus-producing cells. This also 
means a considerable gain of time, compared to transfection-based methods. Additionally, 
the amounts of protein deposited at the viral surface are controllable and only a limited 
amount of information about the genetic requirements of the virus is necessary for 
modification. Viral painting may be the method of choice for modification of enveloped 
viral particles in all situations where a degree of flexibility is favourable, e.g. in response to 
genetic heterogeneity in gene therapy approaches or in response to high antigen variability 
for vaccination. Also when genetic modification of virus producing cell lines is difficult, e.g. 
when applying toxic proteins or when genetically or biochemically poorly defined virus 
species are the targets of modification. Viral painting is an example of post-exit surface 
modification, since fully formed viral particles are the target for modification. While 
increasing the flexibility of such approaches, the time invested in modification after exit 
from cells most likely will result in loss of titer (Metzner et al. 2008b) depending on the 
duration of the modification steps. Thus, keeping post-exit incubation times as short as 
possible is vital. 
2.5 Using adaptors structures  
Another strategy to modify viral particles is to introduce adaptor molecule onto the particles 
which in turn can mediate association of other molecules. These adaptors can either be 
soluble, non-covalently attached molecules or membrane bound factors. Soluble adaptors 
have been used to enable targeting strategies in gene therapy. In these cases bispecific 
molecules or assemblies were used, contacting specifically a molecule present on the virus 
and another on the cells about to become infected. These bispecific adaptors or bridge 
complexes can take different forms.  For example, two different antibodies, modified with 
biotin, can be linked via avidin or streptavidin (Roux et al. 1989) thus providing specificity 
for viral surface proteins and the target molecule on the cell. Such a system has been 
proposed as early as 1989, showing directed infection of MHC class I and II expressing cells 
with murine retroviruses (Roux et al. 1989). This system is highly flexible and versatile, since 
a wide range of antibodies which can be biotinylated are available. Pre-treatment of the viral 
vector with the anti-viral antibody would effectively neutralize the viral particle, thus 
increasing the safety of the application. Alternatively, a receptor/ligand chimeric protein, in 
which the binding partner for the viral attachment protein is coupled to a ligand, binding to 
the target molecule on the cell surface may be used. Vectors pseudotyped with Avian 
sarcoma and leukosis virus (ASLV) have been used for implementing such strategies. The 
chimeric bridge protein consisted of the extracellular domains of the cellular receptor for 
ASLV, fused to ligands such as epidermal growth factor (EGF), vascular endothelial growth 
factor (VEGF) or heregulin, thus targeting cells expressing the respective receptors 
(Snitkovsky et al. 2000; Snitkovsky et al. 2001; Snitkovsky and Young 2002). Since these 
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intact GPI anchors are reversible and it has been shown in a variety of in vitro and in vivo 
systems that GPI-linked proteins can be re-inserted into cell membranes (Dunn et al. 1996; 
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Vakeva et al. 1994). Transfer has been demonstrated for CD59 from erythrocytes to 
endothelial cells (Kooyman et al. 1995) as well as for trypanosomal variant surface 
glycoprotein (VSG) to erythrocytes of infected patients (Rifkin and Landsberger 1990). 
Therefore GPI-anchored proteins can be considered to be “hypermobile”. This 
hypermobility allows for the re-integration of purified GPI-anchored proteins to lipid 
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This process has been termed cellular or viral painting, respectively. 
Technically, introducing a GPI anchor to a protein is achieved in the same way fusion 
proteins are made: Following genetic engineering, the recombinant protein is translated and 
the amino acid sequence describing the GSS is included to the nascent polypeptide, thus 
artificially GPI-anchored proteins are produced. A range of recombinant GPI-anchored 
proteins have been produced including glypiated GFP and CD4 (for a review see Metzner et 
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by two distinct pathways: (i) after transfection of virus producing cells, facilitated by the co-
localisation of glypiated proteins at the site of viral budding and (ii) by viral painting, re-
introducing purified GPI-anchored proteins to mature viral particles as a result of the GPI-
anchored protein hypermobility.  
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constructs expressing the GPI-anchored proteins or super-transfection of pre-existing virus 
producing cell lines, leads to the formation of viral particles displaying GPI-anchored 
molecules on their envelopes. These particles acquire novel properties as a consequence of the 
incorporation of the GPI-anchored protein e.g. super-transfection of the murine retroviral 
producer cell line PALSG/S with the human GPI-anchored protein CD59, yields viral particles 
that are resistant to the activity of complement in human serum (Breun et al. 1999). These 
results suggested for the first time that incorporation of recombinantly expressed GPI-
anchored proteins into the envelopes of viral vectors is possible and that these modifications 
can be useful for gene therapy approaches. In two more recent studies, co-transfection 
approaches successfully produced virus-like particles (VLPs) containing glypiated proteins 
from mammalian (Kueng et al. 2007) or insect cells (Skountzou et al. 2007). In both cases, 
recombinant GPI-anchored different cytokine species were generated i.e. interleukin-2 (IL-2) 
and granuolocyte-macrophage colony stimulating factor (GM-CSF). In the first study, it was 
demonstrated that the GPI-anchored cytokines are functional and elicit cellular responses such 
as differentiation and proliferation with similar efficiency as their soluble counterparts when 
co-cultured with the appropriate target cells (Kueng et al. 2007); and in the second it was 
described that GPI-anchored cytokines engineered onto VLPs based on simian 
immunodeficiency virus (SIV) can enhance immunogenicity of the VLPs. In both cases a 
modulation of the immune responses was achieved by displaying GPI-anchored cytokine 
(Kueng et al. 2007; Skountzou et al. 2007). The major advantage of this approach is that stable 
transfection of RV/LV producer cell lines co- or super-transfected with GPI-anchored proteins 
can provide a reproducible long-term source of modified viral particles. In addition, no post-
exit steps that may reduce infectivity of the vectors are required.   
The second method to modify RV/LV vectors is by using GPI-anchored proteins that have 
been extracted and purified from cells and can be re-inserted after incubation with 
enveloped viruses. This was first described for the GPI-linked model protein CD59his which 
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associates to viral vectors based on MLV and HIV-1 (Metzner et al. 2008b). The association is 
specific and painted virus particles remain infectious after insertion of the GPI-linked 
protein, albeit at reduced efficiencies caused by the duration of the painting process, rather 
than the actual introduction of GPI-anchored molecules into the viral outer shell (Metzner et 
al. 2008b). Estimates of the number of GPI-anchored proteins painted onto retroviral 
particles were in the range of the numbers observed for Env molecules per virion and are 
thus similar to that achieved after incorporation of hybrid proteins produced in co-
transfection experiments (Skountzou et al. 2007). The main advantage of this approach is 
flexibility. Different GPI-anchored proteins can be attached to a range of enveloped viral 
particles without repeated genetic manipulations of the virus-producing cells. This also 
means a considerable gain of time, compared to transfection-based methods. Additionally, 
the amounts of protein deposited at the viral surface are controllable and only a limited 
amount of information about the genetic requirements of the virus is necessary for 
modification. Viral painting may be the method of choice for modification of enveloped 
viral particles in all situations where a degree of flexibility is favourable, e.g. in response to 
genetic heterogeneity in gene therapy approaches or in response to high antigen variability 
for vaccination. Also when genetic modification of virus producing cell lines is difficult, e.g. 
when applying toxic proteins or when genetically or biochemically poorly defined virus 
species are the targets of modification. Viral painting is an example of post-exit surface 
modification, since fully formed viral particles are the target for modification. While 
increasing the flexibility of such approaches, the time invested in modification after exit 
from cells most likely will result in loss of titer (Metzner et al. 2008b) depending on the 
duration of the modification steps. Thus, keeping post-exit incubation times as short as 
possible is vital. 
2.5 Using adaptors structures  
Another strategy to modify viral particles is to introduce adaptor molecule onto the particles 
which in turn can mediate association of other molecules. These adaptors can either be 
soluble, non-covalently attached molecules or membrane bound factors. Soluble adaptors 
have been used to enable targeting strategies in gene therapy. In these cases bispecific 
molecules or assemblies were used, contacting specifically a molecule present on the virus 
and another on the cells about to become infected. These bispecific adaptors or bridge 
complexes can take different forms.  For example, two different antibodies, modified with 
biotin, can be linked via avidin or streptavidin (Roux et al. 1989) thus providing specificity 
for viral surface proteins and the target molecule on the cell. Such a system has been 
proposed as early as 1989, showing directed infection of MHC class I and II expressing cells 
with murine retroviruses (Roux et al. 1989). This system is highly flexible and versatile, since 
a wide range of antibodies which can be biotinylated are available. Pre-treatment of the viral 
vector with the anti-viral antibody would effectively neutralize the viral particle, thus 
increasing the safety of the application. Alternatively, a receptor/ligand chimeric protein, in 
which the binding partner for the viral attachment protein is coupled to a ligand, binding to 
the target molecule on the cell surface may be used. Vectors pseudotyped with Avian 
sarcoma and leukosis virus (ASLV) have been used for implementing such strategies. The 
chimeric bridge protein consisted of the extracellular domains of the cellular receptor for 
ASLV, fused to ligands such as epidermal growth factor (EGF), vascular endothelial growth 
factor (VEGF) or heregulin, thus targeting cells expressing the respective receptors 
(Snitkovsky et al. 2000; Snitkovsky et al. 2001; Snitkovsky and Young 2002). Since these 
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receptors are commonly overexpressed on tumor cells, the approach is already of some 
medical relevance. Instead of the ligands, also single-chain antibodies may be used. An 
approach which has been used for targeting cells expressing a tumor-specific form of the 
EGF receptor (Snitkovsky et al. 2000).  
When using membrane associated adaptors, in most cases, avidin or streptavidin 
engineered to contain a trans-membrane domain are utilised, due to their extraordinarily 
strong affinity to biotin and the comparative ease with which biotin can be attached to a 
wide range of compounds from DNA to antibodies. Avidin and streptavidin molecules are 
available in a wide range of modifications, tailor-made for different applications (Laitinen et 
al. 2007). Again, mixed modifications may be used, by generating fusion proteins of 
avidin/streptavidin with viral surface proteins (M.U. Kaikkonen et al. 2008; M. U. 
Kaikkonen et al. 2009) or even GPI-anchors (Pinaud et al. 2009). The main advantage of this 
system is its flexibility, since factors attached to avidin or streptavidin can be exchanged. 
However, similar to viral painting, post-exit modification steps may be necessary, which 
could potentially reduce infectivity of RV/LV vectors. Such a system has been implemented 
by fusing avidin and streptavidin with the transmembrane domain of VSV-G (M. U. 
Kaikkonen et al. 2009). The binding of biotin to such vectors was demonstrated and they 
could be used for dual imaging and for targeting application (see sections 3.2. and 3.5.). 
Other approaches lead to the biotinylation of the lentiviral vector. This can be achieved by 
direct chemical modification (G. Yang et al. 2006a) (see also section 2.6.) or after addition of a 
biotin-adaptor peptide (BAP), a site for specific enzymatic biotin ligation (G. D. Chen et al. 
2010a; Nesbeth et al. 2006) (see also section 2.6.). The bacterial enzyme, biotin ligase, has to 
be provided as a form of metabolic engineering to allow the modification of the BAP-
containing protein. Both a cellular protein, low-affinity nerve growth factor (Nesbeth et al. 
2006) and a viral protein, Sindbis virus glycoprotein (Morizono et al. 2009b), have been 
modified in such a way to generate novel LV vectors. The latter in fact constitutes 
pseudotyping of an LV vector with a chimeric envelope molecule, containing an adaptor 
element, added by enzyme-mediated covalent chemical modification, thus mixing four 
different strategies to modify viral RV/LV vectors. Alternatively, membrane proteins 
binding antibodies may be used to modify viral surfaces. Insertion of immunoglobulin G-
binding domains (the ZZ domain of staphylococcal protein A) into the Env protein of MLV 
vectors allowed for the binding of specific antibodies directed against the EGF receptor 
HER2. However, infectivity was significantly reduced, as can be expected (Tai et al., 2003). A 
similar approach utilizes a fusion of the same antibody binding domain with Sindbis 
envelope glycoproteins (L. Yang et al. 2006b). The main disadvantage of adaptor systems is 
that an additional, separate element is necessary for the system to work, thus introducing a 
new level of complexity. Additionally, adaptors may dissociate from one or the other 
binding partner, especially if antibody binding domains are used. Competition from serum 
antibodies in vivo may significantly enhance dissociation (Morizono et al. 2009b). Pre-
treatment of viral vectors with the adaptor at least allows administering the virus/adaptor 
complex as a single entity (Boerger et al. 1999). However, adaptor association in most cases 
requires post-exit procedures, which can again contribute to loss of infectivity. 
2.6 Direct chemical modification
Another option would be the direct chemical linkage of substrates to viral surfaces. While 
successful modification of polymers and polypeptides to adenovirues and adeno-associated 
viruses has been achieved (Croyle et al. 2000; Croyle et al. 2002) it has been difficult to carry 
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out such modifications on RV/LV particles and attempts have been rare. A successful example 
is the attachment of monomethoxy-poly(ethylene)glycol (PEG) to VSV-G pseudotyped LV 
vectors (Croyle et al. 2004). In this case an activated form of PEG is covalently attached to 
lysine residues on proteins displayed on the virus. PEGylation reduces the susceptibility of 
these vectors for the human and murine complement system, while maintaining transduction 
efficiencies (Croyle et al. 2004), thus manipulating the host immune system (see also section 
3.4.). In another, early attempt, MoMLV was modified by chemical addition of carbohydrate 
(galactose) moieties in order to change viral tropism (Neda et al. 1991). Introduction of these 
residues was supposed to specifically infect hepatocytes expressing asialoglycoprotein 
receptors recognizing the carbohydrate moieties on the viral vectors. However, the 
modification resulted in severely reduced infectivity of RV/LV particles. Direct chemical 
biotinylation of retroviral vectors has also been demonstrated, using sulfo-N-
hydroxysuccinimide-biotin MoMLV derived vectors (G. Yang et al. 2006). For this approach 
neutravidin was covalently linked to poly-lysine. The resulting compound was then associated 
to the biotinylated vector. The aim of the study was to allow transduction of human cells with 
ecotropic MLV vectors, which normally cannot infect human cells. In this case, progeny of 
modified viruses would lack the modification, hence infection of neighboring cells, even if 
replication competent vectors were generated, would not be possible. This could contribute to 
safety of gene therapy approaches. Another strategy to biotinylate viral surfaces includes the 
potential for chemical display of biotin using a metabolic engineering approach as  was 
described in section 2.5, i.e. that the introduction of biotin-adaptor peptides to viral surface 
glycoproteins allows for the specific biotinylation of these proteins by a secreted biotin ligase, 
conferring the possibility for avidin, streptavidin or neutravidin linkage. These adaptors can in 
turn be used for attachment of secondary biotinylated compounds (Morizono et al. 2009b). 
Alternatively, desthiobiotin can be metabolically introduced to RV/LV vectors (R. Chen et al. 
2010b). In this case, the binding to avidin and its derivates will be easier to reverse, owing to 
lower affinity. More recently, developments in bioorthogonal chemistry could bring new 
impetus to the field. Bioorthogonal chemistry describes the possibility to allow controlled, 
specific chemical reactions amidst the background of a biological system i.e. in cell culture. 
Specifically, cell surfaces can be modified by oxidation of sialic acids present on glycosylated 
surface proteins by periodate, generating reactive aldehyde groups, which in turn can be 
modified by conjugation of aminooxy-functionalised compounds (Zeng et al. 2009). When this 
technique was applied to cells producing VSV-G pseudotyped MoMLV, resulting viral 
particles carried the modification (S. Wong and Kwon 2011). They used this to introduce 
aminooxy-biotin and could subsequently associate magnetic particles to the virus, facilitating 
purification and concentration of virus preparations (Wong and Kwon 2011; see also section 
3.3.). This approach may also be applied to viral particles post-exit. Direct chemical 
modification of herpesvirus particles with radioactive labels has also been demonstrated and 
was used for biodistribution studies (Schellingerhout and Bogdanov 2002). Biological 
chemistry, by developing bioorthogonal methods, appears to have great potential for novel 
types of modification. 
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out such modifications on RV/LV particles and attempts have been rare. A successful example 
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can facilitate this in a number of ways, such as helping to produce more efficient vector stocks 
by enabling purification and concentration of viral vector stocks (thereby helping to increase 
transduction efficiencies) (see section 3.3.), by ensuring optimal interactions with the host 
organism, especially the host’s immune system (see 3.4.), or by limiting viral entry to a subset 
of host cells (see 3.5.). In its simplest form, physical vector surface modification leads to a more 
efficient way of detecting the viral particles, due to the association of labeling molecules, thus 
allowing for a controlled administration and delivery regime (see 3.2.). All of these aspects will 
also help to increase safety of gene therapy approaches, by eliminating potentially toxic or 
immunogenic contaminants and reducing adverse and off-target effects. Suitability of 
modification types for each application will be discussed in the following sections. Another 
important aspect of course is that multifunctional modifications can – and should - be applied 
to allow implementation of different applications such as easy detection by labeling and 
purification/concentration in one modification step. 
 
 
Fig. 3. Overview of applications for surface modifications of RV/LV vectors in gene therapy.  
3.2 Imaging/biodistribution  
Efficiency of gene therapy will be depending on administration regime and the subsequent 
distribution of vectors in the patient. Therefore, these events need to be controlled, already at 
the pre-clinical stages to assess vector performance i.e. in animal experiments. In vivo 
transgene expression analysis, as was used for the detection of specific targeting of LV vectors 
(Pariente et al. 2007) is not ideal, since the information yielded by measurement of 
transduction efficiency or, more generally, transgene expression is different from data 
describing physical particle distribution. Vector particles may be trapped or degraded long 
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before transduction, subsequently not contributing to transgene expression. Thus detection of 
the physical vector particles is required (in addition to and in parallel to transgene expression 
analysis) and may need to be facilitated by labeling of the RV/LV vector particle. Generally, 
labeling approaches should have only minimal to no influence on the performance of the 
RV/LV vector and on the host or target organism (low toxicity and low immunogenicity). 
Another requirement is the stability of label attachment. Loss of label from viral particles 
would not only lead to decrease of signal, but also to an increase of background noise. Finally, 
detection of the label should be easy and easily achievable in vivo. Small, chemically inert 
substances, giving a strong and localized signal, enabling non-invasive detection methods will 
be the ideal tags. For practical reasons, a “one size fits all” approach to labeling may be 
preferred. Flexible and versatile procedures which can be applied to a broad range of RV/LV 
vectors are called for. All mentioned aspects will obviously influence choice of technique for 
labeling and subsequently, location and type of label.  
RV/LV particles can be labeled at the level of the capsid, i.e. using chimeric proteins of 
capsid proteins and fluorescent proteins (Lampe et al. 2007; Lehmann et al. 2005). While loss 
of label will be less of a concern in such circumstances, changing the geometry of the capsid 
might very well have an influence on capsid and/or viral assembly. Modification can also 
be carried out at the level of viral surfaces, where they are much more susceptible to 
dissociation or degradation. So far viral particles are mainly labeled by incorporation of 
chimeric proteins of viral structural proteins and (fluorescent) marker proteins (Lampe et al. 
2007; Lehmann et al. 2005), owing to a high degree of stability of association caused by the 
covalent association. However, fluorescent proteins are comparatively big, increasing the 
chance for steric hindrance and thus influence on vector performance. Detection of 
fluorescence signal may allow for a limited depth of penetration only. Standard 
immunohistochemistry methods use non-protein fluorophore-labelled secondary antibody, 
and while acceptable for in vitro purposes, it cannot provide the stability of a covalent bond 
and therefore may not be suitable for in vivo applications. For the same reason, most 
adaptor-based systems will also not be suitable for labeling, with the possible exception of 
systems using membrane-bound avidin/biotin (M. U. Kaikkonen et al. 2009), due to the 
extraordinarily strong association, which is comparable to covalent interactions. The use of 
GPI-anchored marker proteins provides an alternative, as the modification pathway does 
not interfere with viral structural components, i.e. the envelope surface protein required for 
target cell binding and infection. Infection efficiency is not disturbed by painting (Metzner et 
al. 2008b). The use of viral painting technology can provide the additional advantage of 
flexibility. Incorporation of label is mostly independent of viral producer cell lines and can 
be performed relatively quickly (Metzner et al. 2008b; Metzner et al. 2008a). However, still 
comparatively large polypeptide molecules are attached to the viruses and the degree of 
stability of interaction still needs to be determined. Direct chemical attachment seems to 
have good prospects in this area, since small molecules can be attached to virus particles 
covalently, in a relatively small amount of time (R. Chen et al. 2010b; S. Wong and Kwon 
2011). However, such methods still need to be assessed in terms of their in vivo applications.  
So far fluorescent molecules were considered as primary detection labels. While 
fluorescence detection, together with luminescence has been used for pre clinical in vivo 
detection approaches, it will not be suitable for application in human patients due to low 
penetration depth (Shah et al. 2004). Alternatively, detection based on magnetic resonance 
imaging (MRI) and two radiological methods, positron emission tomography (PET) and 
single photon emission computer tomography (SPECT), may be used (for a review on 
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before transduction, subsequently not contributing to transgene expression. Thus detection of 
the physical vector particles is required (in addition to and in parallel to transgene expression 
analysis) and may need to be facilitated by labeling of the RV/LV vector particle. Generally, 
labeling approaches should have only minimal to no influence on the performance of the 
RV/LV vector and on the host or target organism (low toxicity and low immunogenicity). 
Another requirement is the stability of label attachment. Loss of label from viral particles 
would not only lead to decrease of signal, but also to an increase of background noise. Finally, 
detection of the label should be easy and easily achievable in vivo. Small, chemically inert 
substances, giving a strong and localized signal, enabling non-invasive detection methods will 
be the ideal tags. For practical reasons, a “one size fits all” approach to labeling may be 
preferred. Flexible and versatile procedures which can be applied to a broad range of RV/LV 
vectors are called for. All mentioned aspects will obviously influence choice of technique for 
labeling and subsequently, location and type of label.  
RV/LV particles can be labeled at the level of the capsid, i.e. using chimeric proteins of 
capsid proteins and fluorescent proteins (Lampe et al. 2007; Lehmann et al. 2005). While loss 
of label will be less of a concern in such circumstances, changing the geometry of the capsid 
might very well have an influence on capsid and/or viral assembly. Modification can also 
be carried out at the level of viral surfaces, where they are much more susceptible to 
dissociation or degradation. So far viral particles are mainly labeled by incorporation of 
chimeric proteins of viral structural proteins and (fluorescent) marker proteins (Lampe et al. 
2007; Lehmann et al. 2005), owing to a high degree of stability of association caused by the 
covalent association. However, fluorescent proteins are comparatively big, increasing the 
chance for steric hindrance and thus influence on vector performance. Detection of 
fluorescence signal may allow for a limited depth of penetration only. Standard 
immunohistochemistry methods use non-protein fluorophore-labelled secondary antibody, 
and while acceptable for in vitro purposes, it cannot provide the stability of a covalent bond 
and therefore may not be suitable for in vivo applications. For the same reason, most 
adaptor-based systems will also not be suitable for labeling, with the possible exception of 
systems using membrane-bound avidin/biotin (M. U. Kaikkonen et al. 2009), due to the 
extraordinarily strong association, which is comparable to covalent interactions. The use of 
GPI-anchored marker proteins provides an alternative, as the modification pathway does 
not interfere with viral structural components, i.e. the envelope surface protein required for 
target cell binding and infection. Infection efficiency is not disturbed by painting (Metzner et 
al. 2008b). The use of viral painting technology can provide the additional advantage of 
flexibility. Incorporation of label is mostly independent of viral producer cell lines and can 
be performed relatively quickly (Metzner et al. 2008b; Metzner et al. 2008a). However, still 
comparatively large polypeptide molecules are attached to the viruses and the degree of 
stability of interaction still needs to be determined. Direct chemical attachment seems to 
have good prospects in this area, since small molecules can be attached to virus particles 
covalently, in a relatively small amount of time (R. Chen et al. 2010b; S. Wong and Kwon 
2011). However, such methods still need to be assessed in terms of their in vivo applications.  
So far fluorescent molecules were considered as primary detection labels. While 
fluorescence detection, together with luminescence has been used for pre clinical in vivo 
detection approaches, it will not be suitable for application in human patients due to low 
penetration depth (Shah et al. 2004). Alternatively, detection based on magnetic resonance 
imaging (MRI) and two radiological methods, positron emission tomography (PET) and 
single photon emission computer tomography (SPECT), may be used (for a review on 
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molecular imaging techniques in gene therapy see Shah et al. 2004; Raty et al. 2007). While 
MRI has been recently utilized for in vivo transgene expression, using ferritin as the reporter 
gene (Hasegawa et al. 2010; M. U. Kaikkonen et al. 2009), SPECT shows promising qualities, 
combining high sensitivity with comparatively low cost equipment and reagents, in 
analyzing physical particle distribution. Such an approach has been utilized to study 
biodistribution of herpes- (Schellingerhout and Bogdanov 2002) and baculovirus (Raty et al. 
2007) in vivo. In these cases the radiolabels were attached to the virus either by direct 
chemical modification (Schellingerhout and Bogdanov 2007) or by adding a biotinylated 
radiolabel to streptavidin modified viral particles (Raty et al. 2007). Dual in vivo imaging of 
rats was demonstrated for LVvectors coding for transferring and displaying streptavidin 
adaptors (M. U. Kaikkonen et al. 2009). In this case, enrichment of iron in cells upon 
transferrin expression was used to enable MRI, while radiolabels were attached to the 
displayed streptavidin molecules to allow for SPECT detection. For this study, deposition of 
adaptor molecules on viral particles was additionally used for targeting applications, 
demonstrating the versatile nature of adaptor systems. However, also approaches using 
fluorescent labeling molecules may additionally have a function in enrichment or 
concentration prior to transduction i.e. viral particles modified with proteins containing 
6xhis-tagged proteins can be enriched by using established immobilized metal ion affinity 
chromatography (IMAC) (Gaberc-Porekar and Menart 2001; Magnusdottir et al. 2009) or 
magnetic purification techniques (Franzreb et al. 2006) (see also section 3.3.).  
3.3 Purification/concentration  
Another important issue in gene therapy is generation of suitable vector preparations in 
terms of viral titer, purity, speed and costs. Cheap methods which allow for quick 
concentration and purification of RV/LV vectors after harvesting from producing cell lines 
are of great importance. Contaminants from producing cell cultures may inhibit 
transduction of target cells (Rodrigues et al. 2007). Additionally, with clinical use of vectors 
as a mid- to long-term aim, vector preparations need to be compliant with regulators’ 
standards. In nearly all cases, purification and concentration of viruses starts with a micro-
filtration step, using 0.45 μm filters to remove cells and cellular debris from culture 
supernatants. When large amounts of dead cells are present in the supernatant, 
centrifugation may be preferred for removal of micro-level contaminants. Subsequently, 
RV/LV particles are still concentrated and purified in most cases by ultra-centrifugation, 
often utilizing sucrose gradients to prevent mechanical damage to viruses. These methods 
are time-consuming and require the use of expensive equipment, i.e. high velocity 
centrifuges. Additionally, not all RV/LV vectors tolerate ultra-centrifugation well. Sucrose 
may need to be removed from preparations afterwards, adding another preparatory step. 
Additionally, high sucrose content can harm virus by change in osmotic pressure. Taken 
together these aspects lead to often quite significant reductions of infectivity (Rodrigues et 
al. 2007). Using VSV-G pseudotypes as well as ultra-centrifugation-resistant virus strains 
can improve yield after ultra-centrifugation (Burns et al. 1993). While acceptable for 
laboratory scale preparation, ultra-centrifugation is unsatisfactory for larger scale 
preparations. Alternatively viruses may be concentrated and purified by ultra-filtration or 
dialysis protocols, separating virus and contaminants according to size using semi-
permeable membranes. Conventional column based methods lead to problems regarding 
large-scale preparations, but use of tangential flow devices can circumvent this aspect 
(Geraerts et al. 2005; Kuiper et al. 2002).  
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What these methods have in common is that they do not rely on any modification of the 
virus. This is partially also true for purification strategies involving chromatography 
applications e.g. size exclusion or ion exchange approaches, both of which have been used 
for purification and concentration purposes (Rodrigues et al. 2007). Affinity 
chromatography is a very powerful tool for removal of contaminants. Using naturally 
occurring affinity tags for purification and concentration such as heparin can work well 
(Segura et al. 2008a; Segura et al. 2010). In such an application the tag should interfere 
minimally with the virus activity, be easily accessible for the purification matrix and, in 
most cases, a transient interaction would be preferred, allowing for removal of virus under 
mild conditions. An additional advantage would be, if the same strategy would be 
applicable for a broad spectrum of vectors. After all, the key property of a purification label 
would be its affinity and specificity for the purification matrices used. Approaches utilising 
either biotin-streptavidin interactions or IMAC have been reported (Williams et al. 2005a; 
Williams et al. 2005b; Ye et al. 2004). In the latter strategy, the affinity of complexed nickel or 
cobalt ions to stretches of histidine aminoacids is exploited. Viruses may be modified for 
application of the streptavidin/biotin system in numerous ways, as described in sections 2.5 
and 2.6. Direct chemical modification was chosen to biotinylate retroviral vectors prior to 
purification using a streptavidin coated stationary phase (Chan et al. 2005; Williams et al. 
2005a; Williams et al. 2005b). As a result of the strong interaction of biotin and 
avidin/streptavidin, removal of viral particles from the purification matrix can require 
harsh conditions, which will reduce yield and infectivity of viral preparations. While IMAC 
was used successfully on viral vectors containing histidine tags in the Env protein (Ye et al., 
2004), immediate dialysis of resulting samples is necessary to remove the chemicals 
necessary for desorption (imidazole, EDTA). These compounds would also need to be 
removed prior to any clinical application, as well as metal ions potentially leaking from the 
purification matrix, since both may lead to adverse side effects in patients (Rodrigues et al. 
2007). In addition to chromatography based methods, attachment of magnetic particles to 
the viral vectors may enable purification and concentration. Recently, attempts have been 
made to attach micro- or nanoparticles with magnetic properties to modified viral surfaces 
(R. Chen et al. 2010b; M. U. Kaikkonen et al. 2009; Nesbeth et al. 2006; S. Wong and Kwon 
2011). Again, avidin-biotin interactions were exploited to attach the magnetic particles. Such 
approaches are interesting due to their potential for up-scaling. Ideally, magnetic 
nanoparticles could be designed in such a way, that they may not have to be removed from 
viruses, but may serve additional function as contrast agents in detection via MRI. 
Generally, adaptor approaches can be considered most useful for labeling purposes, if only 
due to their versatility. Indeed, when an adaptor is present on a viral vector, it may as well 
be used for purification purposes in addition to the primary aim of modification, i.e. 
transduction targeting. Alternatively, quick post-exit approaches, such as viral painting with 
GPI-anchored proteins may be used, giving a great degree of flexibility, as they can be 
applied to a wide range of viral preparations, and again more than one objective may be 
achieved by a single modification i.e. by the use of a histidine-tagged, GPI-anchored 
immunomodulatory protein.  
3.4 Modulation of host functions 
Depending on the administration protocol planned, RV/LV vectors used in gene therapy may 
have to find their way to the target cells. During this journey, they will share contacts with 
both soluble and cell bound components of the host. Elements performing functions in the 
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chromatography is a very powerful tool for removal of contaminants. Using naturally 
occurring affinity tags for purification and concentration such as heparin can work well 
(Segura et al. 2008a; Segura et al. 2010). In such an application the tag should interfere 
minimally with the virus activity, be easily accessible for the purification matrix and, in 
most cases, a transient interaction would be preferred, allowing for removal of virus under 
mild conditions. An additional advantage would be, if the same strategy would be 
applicable for a broad spectrum of vectors. After all, the key property of a purification label 
would be its affinity and specificity for the purification matrices used. Approaches utilising 
either biotin-streptavidin interactions or IMAC have been reported (Williams et al. 2005a; 
Williams et al. 2005b; Ye et al. 2004). In the latter strategy, the affinity of complexed nickel or 
cobalt ions to stretches of histidine aminoacids is exploited. Viruses may be modified for 
application of the streptavidin/biotin system in numerous ways, as described in sections 2.5 
and 2.6. Direct chemical modification was chosen to biotinylate retroviral vectors prior to 
purification using a streptavidin coated stationary phase (Chan et al. 2005; Williams et al. 
2005a; Williams et al. 2005b). As a result of the strong interaction of biotin and 
avidin/streptavidin, removal of viral particles from the purification matrix can require 
harsh conditions, which will reduce yield and infectivity of viral preparations. While IMAC 
was used successfully on viral vectors containing histidine tags in the Env protein (Ye et al., 
2004), immediate dialysis of resulting samples is necessary to remove the chemicals 
necessary for desorption (imidazole, EDTA). These compounds would also need to be 
removed prior to any clinical application, as well as metal ions potentially leaking from the 
purification matrix, since both may lead to adverse side effects in patients (Rodrigues et al. 
2007). In addition to chromatography based methods, attachment of magnetic particles to 
the viral vectors may enable purification and concentration. Recently, attempts have been 
made to attach micro- or nanoparticles with magnetic properties to modified viral surfaces 
(R. Chen et al. 2010b; M. U. Kaikkonen et al. 2009; Nesbeth et al. 2006; S. Wong and Kwon 
2011). Again, avidin-biotin interactions were exploited to attach the magnetic particles. Such 
approaches are interesting due to their potential for up-scaling. Ideally, magnetic 
nanoparticles could be designed in such a way, that they may not have to be removed from 
viruses, but may serve additional function as contrast agents in detection via MRI. 
Generally, adaptor approaches can be considered most useful for labeling purposes, if only 
due to their versatility. Indeed, when an adaptor is present on a viral vector, it may as well 
be used for purification purposes in addition to the primary aim of modification, i.e. 
transduction targeting. Alternatively, quick post-exit approaches, such as viral painting with 
GPI-anchored proteins may be used, giving a great degree of flexibility, as they can be 
applied to a wide range of viral preparations, and again more than one objective may be 
achieved by a single modification i.e. by the use of a histidine-tagged, GPI-anchored 
immunomodulatory protein.  
3.4 Modulation of host functions 
Depending on the administration protocol planned, RV/LV vectors used in gene therapy may 
have to find their way to the target cells. During this journey, they will share contacts with 
both soluble and cell bound components of the host. Elements performing functions in the 
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host’s immune system will be of special interest, since in most patients, gene therapy vectors, 
including RV/LV vectors, will encounter an intact immune system. Navigating the immune 
system will be vital to any successful gene therapy approach. Interaction of virus particles with 
host molecules including immunological reactions are often mediated by molecules located in 
the envelope, thus modifying the envelope with immunologically competent molecules, e.g. 
cytokines or growth factors, allows for the manipulation of surrounding immune responses. 
This specifically includes protection of viral vectors from unwanted immune reactions such as 
complement activity. Immunoprotection can help to ensure efficient delivery to target cells by 
eliminating premature inactivation of vectors in gene therapy approaches. One example is the 
pegylation of VSV-G pseudotyped vectors (Croyle et al. 2004), as discussed in section 2.6. 
Other approaches to protect from complement activity include the introduction of 
complement regulatory factors such as CD55 or CD59 (Breun et al. 1999), if they are not 
already part of the envelope protein contents. In this case the presence of naturally occurring 
GPI-anchored proteins was exploited.  
Protection from the complement or neutralizing antibodies is only one aspect of immune-
modulation. Stimulation of immune responses may be a desired effect to augment 
therapeutic effect i.e. in cancer gene therapy or vaccine strategies. For example, presentation 
of antigen on the surface of virus-like particles (VLPs) is possible via the use of GPI-
anchored molecules. GPI-anchored cytokines engineered onto simian immunodeficiency 
virus (SIV) can enhance immunogenicity of the VLPs (Skountzou et al. 2007). VLPs can be 
used to modulate the immune system in several ways (Kueng et al. 2011). These aspects may 
be of more importance in the development of vaccines or specific adjuvants enhancing 
vaccine efficacy, but variations may also prove useful for gene therapy approaches. For 
example, early acting cytokines such as interleukin 6, stem cell factor or thrombopoietin, 
have been shown to enhance gene transfer using RV/LV vectors to haematopoietic stem 
cells (Santoni de Sio et al. 2006; Zielske and Gerson 2003). Attachment of such factors to viral 
surfaces as discussed above can help to achieve stronger local effects. This may be 
considered also in the context of “targeting by activation”, whereby efficient transduction is 
dependent on activation of the target cell by the ligand/receptor interaction (Verhoyen and 
Cosset 2004; see also section 3.5.).  
A further aspect of modulation of host cell function is inducing differentiation e.g. for tissue 
engineering purposes. Proof of principle was shown through differentiation of monocytes to 
dendritic cells (Kueng et al. 2007). Again, the GPI-anchored cytokines used were functional 
and elicited cellular responses such as differentiation and proliferation with similar 
efficiency as their soluble counterparts when co-cultured with the appropriate target cells. 
The major advantage of this approach is that stable transfection of RV/LV producer cell 
lines co- or super-transfected with GPI-anchored proteins can provide a long-term source of 
modified viral particles reproducibly. In addition, no post-exit steps that may reduce 
infectivity of viral vectors are required. Alternatively, viral painting may be used in cases 
where flexibility is required. Immunomodulation appears to be an area of great possibilities, 
allowing potentially for the “fine tuning” of gene therapy approaches, by enhancing 
distribution or transgene expression and  providing additional beneficial side effects such as 
increased tumor cell killing. 
3.5 Infection targeting 
A key element of successful and efficient gene therapy is the ability to target only a certain 
subset of cells for treatment after systemic administration. This constitutes both, a measure 
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to ensure safety, since (ideally) no non-target cells should become genetically modified, and 
enhance efficacy, since (again, ideally) all vector particles present should recognize and 
infect target cells. Targeted infection is an especially important feature when using 
replication-competent vectors. Such vectors can replicate in infected cells and produce 
progeny virus which in turn can infect new target cells. Whilst highly efficient, i.e. in the 
case of tumor gene therapy, safety of course is an important issue, as a form of viremia is 
part of the delivery strategy, which needs to be tightly controlled. Additionally, infection 
targeting is equally important for all in vivo  gene therapy approaches (as opposed to ex vivo 
approaches, were infection can be limited by other means), especially upon systemic 
administration. Here, viral vectors are introduced to the patient and non-specific infection is 
a definitive risk, especially considering integration of viral DNA into the host genome and 
the associated potential for insertional mutagenesis.  
In the case of RV/LV vectors, the viral glycoproteins located in the envelope function as 
recognition and entry devices to allow access to the target cells. The so called Env proteins 
consist of two subunits, the surface (SU) and transmembrane (TM), both with distinct 
functions. The Env protein complex is a hexamer consisting of 3 copies of each of the TM 
and SU subunits. SU mediates the first contact to the host cells by engaging the viral 
receptor and, eventually co-receptors. The binding specificity of the SU subunit therefore 
determines the host cell range of the virus. Upon this first contact, TM activates fusogenic 
properties, which allow viral and cellular membranes to fuse, resulting in viral entry. The 
interaction of SU and TM is highly sensitive to changes in SU and already small changes can 
disturb the activation of the TM activity (Zhao et al. 1999). Subsequently, modifications 
introduced to the Env proteins are tolerated badly, quite often leading to severe reduction in 
infectivity. Nevertheless, modification of these properties is crucial to achieve infection or 
transduction targeting – one of the most important goals of viral gene therapy. The choice of 
method being used for targeting applications may also be influenced by the specific target 
molecule, cell or tissue and the target’s distribution in the organism, since access to the 
targets will add additional obstacles to delivery/targeting, for example regarding the 
stability of the interaction between viral vector, targeting molecule and target. In targeting 
approaches, specificity is the most important parameter.  
A range of different strategies have been tested to change the infection tropism including the 
use of glycoproteins from heterologous viral species (pseudotyping) or chimeric envelope 
glycoproteins (Env fusion proteins) as well as bridging molecules (adaptors) (Waehler et al. 
2007). The application of pseudotyping for transduction targeting (Croyle et al. 2004; 
Engelstadter et al. 2001; Miller et al. 1991) is limited by the range of available glycoproteins 
with useful infection tropisms. A more versatile strategy is the use of chimeric envelope 
proteins in which parts of the protein responsible for receptor binding are replaced with 
peptides (Gollan and Green 2002), ligands (Cosset et al. 1995; Kasahara et al. 1994) or single-
chain antibodies (Anliker et al. 2010; Somia et al. 1995) conferring binding to the desired 
receptors for viral entry. Additionally, adaptors, which are capable of associating with both 
the viral glycoprotein and the cellular receptor, can be used to mediate between virus and 
target cell (Boerger et al. 1999; Snitkovsky et al. 2001).  
Another concept is targeting by activation. Retroviral vectors displaying the amphotropic 
MLV Env containing the original receptor binding domain and elements coding for IL2 
(Maurice et al. 1999) or hepatocyte growth factor (HGF) (T. H. Nguyen et al. 1998) were 
generated. These vectors would allow binding of and entry to a broad range of cells. However, 
only upon cell activation due to binding of IL2 or HGF to their cognate receptor would lead to 
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host’s immune system will be of special interest, since in most patients, gene therapy vectors, 
including RV/LV vectors, will encounter an intact immune system. Navigating the immune 
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cytokines or growth factors, allows for the manipulation of surrounding immune responses. 
This specifically includes protection of viral vectors from unwanted immune reactions such as 
complement activity. Immunoprotection can help to ensure efficient delivery to target cells by 
eliminating premature inactivation of vectors in gene therapy approaches. One example is the 
pegylation of VSV-G pseudotyped vectors (Croyle et al. 2004), as discussed in section 2.6. 
Other approaches to protect from complement activity include the introduction of 
complement regulatory factors such as CD55 or CD59 (Breun et al. 1999), if they are not 
already part of the envelope protein contents. In this case the presence of naturally occurring 
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of antigen on the surface of virus-like particles (VLPs) is possible via the use of GPI-
anchored molecules. GPI-anchored cytokines engineered onto simian immunodeficiency 
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used to modulate the immune system in several ways (Kueng et al. 2011). These aspects may 
be of more importance in the development of vaccines or specific adjuvants enhancing 
vaccine efficacy, but variations may also prove useful for gene therapy approaches. For 
example, early acting cytokines such as interleukin 6, stem cell factor or thrombopoietin, 
have been shown to enhance gene transfer using RV/LV vectors to haematopoietic stem 
cells (Santoni de Sio et al. 2006; Zielske and Gerson 2003). Attachment of such factors to viral 
surfaces as discussed above can help to achieve stronger local effects. This may be 
considered also in the context of “targeting by activation”, whereby efficient transduction is 
dependent on activation of the target cell by the ligand/receptor interaction (Verhoyen and 
Cosset 2004; see also section 3.5.).  
A further aspect of modulation of host cell function is inducing differentiation e.g. for tissue 
engineering purposes. Proof of principle was shown through differentiation of monocytes to 
dendritic cells (Kueng et al. 2007). Again, the GPI-anchored cytokines used were functional 
and elicited cellular responses such as differentiation and proliferation with similar 
efficiency as their soluble counterparts when co-cultured with the appropriate target cells. 
The major advantage of this approach is that stable transfection of RV/LV producer cell 
lines co- or super-transfected with GPI-anchored proteins can provide a long-term source of 
modified viral particles reproducibly. In addition, no post-exit steps that may reduce 
infectivity of viral vectors are required. Alternatively, viral painting may be used in cases 
where flexibility is required. Immunomodulation appears to be an area of great possibilities, 
allowing potentially for the “fine tuning” of gene therapy approaches, by enhancing 
distribution or transgene expression and  providing additional beneficial side effects such as 
increased tumor cell killing. 
3.5 Infection targeting 
A key element of successful and efficient gene therapy is the ability to target only a certain 
subset of cells for treatment after systemic administration. This constitutes both, a measure 
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to ensure safety, since (ideally) no non-target cells should become genetically modified, and 
enhance efficacy, since (again, ideally) all vector particles present should recognize and 
infect target cells. Targeted infection is an especially important feature when using 
replication-competent vectors. Such vectors can replicate in infected cells and produce 
progeny virus which in turn can infect new target cells. Whilst highly efficient, i.e. in the 
case of tumor gene therapy, safety of course is an important issue, as a form of viremia is 
part of the delivery strategy, which needs to be tightly controlled. Additionally, infection 
targeting is equally important for all in vivo  gene therapy approaches (as opposed to ex vivo 
approaches, were infection can be limited by other means), especially upon systemic 
administration. Here, viral vectors are introduced to the patient and non-specific infection is 
a definitive risk, especially considering integration of viral DNA into the host genome and 
the associated potential for insertional mutagenesis.  
In the case of RV/LV vectors, the viral glycoproteins located in the envelope function as 
recognition and entry devices to allow access to the target cells. The so called Env proteins 
consist of two subunits, the surface (SU) and transmembrane (TM), both with distinct 
functions. The Env protein complex is a hexamer consisting of 3 copies of each of the TM 
and SU subunits. SU mediates the first contact to the host cells by engaging the viral 
receptor and, eventually co-receptors. The binding specificity of the SU subunit therefore 
determines the host cell range of the virus. Upon this first contact, TM activates fusogenic 
properties, which allow viral and cellular membranes to fuse, resulting in viral entry. The 
interaction of SU and TM is highly sensitive to changes in SU and already small changes can 
disturb the activation of the TM activity (Zhao et al. 1999). Subsequently, modifications 
introduced to the Env proteins are tolerated badly, quite often leading to severe reduction in 
infectivity. Nevertheless, modification of these properties is crucial to achieve infection or 
transduction targeting – one of the most important goals of viral gene therapy. The choice of 
method being used for targeting applications may also be influenced by the specific target 
molecule, cell or tissue and the target’s distribution in the organism, since access to the 
targets will add additional obstacles to delivery/targeting, for example regarding the 
stability of the interaction between viral vector, targeting molecule and target. In targeting 
approaches, specificity is the most important parameter.  
A range of different strategies have been tested to change the infection tropism including the 
use of glycoproteins from heterologous viral species (pseudotyping) or chimeric envelope 
glycoproteins (Env fusion proteins) as well as bridging molecules (adaptors) (Waehler et al. 
2007). The application of pseudotyping for transduction targeting (Croyle et al. 2004; 
Engelstadter et al. 2001; Miller et al. 1991) is limited by the range of available glycoproteins 
with useful infection tropisms. A more versatile strategy is the use of chimeric envelope 
proteins in which parts of the protein responsible for receptor binding are replaced with 
peptides (Gollan and Green 2002), ligands (Cosset et al. 1995; Kasahara et al. 1994) or single-
chain antibodies (Anliker et al. 2010; Somia et al. 1995) conferring binding to the desired 
receptors for viral entry. Additionally, adaptors, which are capable of associating with both 
the viral glycoprotein and the cellular receptor, can be used to mediate between virus and 
target cell (Boerger et al. 1999; Snitkovsky et al. 2001).  
Another concept is targeting by activation. Retroviral vectors displaying the amphotropic 
MLV Env containing the original receptor binding domain and elements coding for IL2 
(Maurice et al. 1999) or hepatocyte growth factor (HGF) (T. H. Nguyen et al. 1998) were 
generated. These vectors would allow binding of and entry to a broad range of cells. However, 
only upon cell activation due to binding of IL2 or HGF to their cognate receptor would lead to 
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significant transduction, as introducing proliferation enabled the progress of MLV provirus to 
the nucleus and subsequent integration and transgene expression (Maurice et al. 1999). 
Although lentiviral vector can infect non-dividing cells, blocks to transduction occur, for 
example in monocytes (Kootstra et al. 2000; Neil et al. 2001) and resting T cells (Dardalhon et 
al. 2001). Activation targeting can help to overcome such blocks. Problems encountered in such 
approaches include differentiation of stimulated cells or background infection in rapidly 
dividing cells (Verhoeyen and Cosset 2004). What these approaches have in common is that 
they often lead to significantly reduced infection rates (Galanis et al. 2001).  
Progress in transduction targeting has been made by separating binding and fusion properties 
(Lin et al. 2001; L. Yang et al. 2006b). This is possible as in several viral species, binding and 
fusion properties are independent features and fusion activity is triggered by different stimuli, 
i.e. low pH after endocytosis (L. Yang et al. 2006b). Most promising candidates for the use as 
heterologous fusogenic proteins in RV are genetically engineered variants of the Sindbis virus 
(SIN) glycoprotein (Morizono et al. 2005; L. Yang et al. 2006b; L. Yang et al. 2008b; H. Yang et 
al. 2008a; Ziegler et al. 2008), the influenza virus hemagglutinin (Lin et al. 2001; L. Yang et al. 
2006b) and measles virus surface glycoproteins (Anliker et al. 2010). In such a case, the use of 
adaptor systems may help to construct flexible targeting systems, as well as deposition of 
specific binding factors by using GPI-anchored proteins, especially in cases where binding and 
entry of viral particles are mediated by independent proteins, i.e. in trans (Lin et al. 2001; L. 
Yang et al. 2006b). The same basic viral particle can be modified with a range of binding 
properties to suit the specific needs of the applications. Antibody molecules, for example, in 
the form of single-chain antibody molecules, engineered to contain a GPI anchor, can provide 
a vast range of binding specificities. Summing up, the use of non RV/LV viral surface 
glycoproteins capable of inducing virus/cell fusion independent of specific binding taken 
together with a flexible such as an adaptor system or viral painting seems currently the most 
promising candidates for targeting applications. 
4. Outlook and discussion 
Due to their average size of 100 nm, RV and LV particles can be considered as 
bionanotechnological devices. Modification thus becomes the – in the field of nanotechnology 
– more commonly used term “functionalisation”. Multiple modifications could lead to using 
viral vectors as multifunctional platforms for biomedicine combined with other 
nanotechnological elements. For example, magnetic micro- and nanoparticles are already 
commercially available to allow the purification of proteins containing tags such as the 
histidine tag or Flag tag. GPI-anchored proteins used for painting of enveloped viral vectors 
have also been engineered to contain histidine tags, allowing the particles to be coated with 
GPI-anchored protein and attached to the viral vectors by means of the GPI-anchor. Or, 
alternatively, biolinker proteins such as streptavidin can potentially be modified at the 
genetic level to contain a GPI signal sequences, and as such, after production in a suitable 
expression system, can be purified as reactive reagents to link up with biotinylated 
nanoparticles. In both cases the recombinant GPI-anchored protein acts as a linker or 
interface between the organic viral particles and inorganic nanomaterials, either magnetic or 
fluorescent capabilities (or both). With such a system in place to functionalise the surface of 
viral vectors without affecting the viral infectivity pathway, one can imagine many 
biomedical applications such as targeting of gene therapy vectors in vivo to tumours using 
magnetic force and tracking via bioimaging techniques based on magnetic field, i.e. MRI or 
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high-sensitivity camera in vivo fluorescence imaging. However, with all of this in mind one 
must not forget the safety issues as the effects of such materials cannot always be predicted 
in biological systems, an issue that has already emerged for carbon nanotubes which would 
not have been expected to be as toxic as has proven to be the case in many instances (Patlolla 
et al. 2010; van der Zande et al. 2011). Sometimes the speed of development can lead to 
rashness when translating into the clinic, a fate that already befell gene therapy in some 
regards (Sheridan 2011), so the same mistakes should be avoided when mixing together 
such new technologies with clinically used viral vectors (Subbiah et al. 2010).  
5. Conclusions / summary 
RV/LV vectors are already proving to be useful delivery vehicles for gene therapy 
applications but in order to establish more efficient vectors for in vivo delivery, the viral surface 
can potentially be modified to provide better means of preparation, purification, 
concentration, detection, tracking, imaging, and targeting in order to not only successfully 
manufacture the product but also to navigate interactions within the patient and  infect pre-
defined target cells selectively. To achieve this aim several techniques may be employed for 
surface engineering or RV/LV vectors. Table 3 provides a concise overview of these 
techniques and the applications for which they have been used and may conceivably be used 
in the future. Pseudotyping has been used for targeting applications, however, can only make 
use of a limited amount of targeting options. Chimeric proteins have been used for labeling 
and targeting applications, and can be useful for immunomodulation approaches. Enrichment 
may be achieved as a secondary objective. Modifications employing GPI-anchored proteins 
may prove to be versatile and efficient; however, further research will be necessary. A similar 
assessment can be made for the use of membrane-bound adaptor systems and direct chemical 
modifications. Finally, combining different strategies will allow broadening possibilities for 
the surface modification of viral vectors considerably. 
 
Modification Comment Labelling Enrichment Modulation Targeting 
Pseudotyping  
limited 






X (x) (x) X 
GPI 
Modifications 
via budding versatile, time-consuming  (x) X (x) 





(x) (x)  X 




maybe post-exit X X X X 
Table 3. Methods for engineering RV/LV vector surfaces and potential applications.  
X applications mentioned in the text; (x) potential for future applications. 
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example in monocytes (Kootstra et al. 2000; Neil et al. 2001) and resting T cells (Dardalhon et 
al. 2001). Activation targeting can help to overcome such blocks. Problems encountered in such 
approaches include differentiation of stimulated cells or background infection in rapidly 
dividing cells (Verhoeyen and Cosset 2004). What these approaches have in common is that 
they often lead to significantly reduced infection rates (Galanis et al. 2001).  
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entry of viral particles are mediated by independent proteins, i.e. in trans (Lin et al. 2001; L. 
Yang et al. 2006b). The same basic viral particle can be modified with a range of binding 
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the form of single-chain antibody molecules, engineered to contain a GPI anchor, can provide 
a vast range of binding specificities. Summing up, the use of non RV/LV viral surface 
glycoproteins capable of inducing virus/cell fusion independent of specific binding taken 
together with a flexible such as an adaptor system or viral painting seems currently the most 
promising candidates for targeting applications. 
4. Outlook and discussion 
Due to their average size of 100 nm, RV and LV particles can be considered as 
bionanotechnological devices. Modification thus becomes the – in the field of nanotechnology 
– more commonly used term “functionalisation”. Multiple modifications could lead to using 
viral vectors as multifunctional platforms for biomedicine combined with other 
nanotechnological elements. For example, magnetic micro- and nanoparticles are already 
commercially available to allow the purification of proteins containing tags such as the 
histidine tag or Flag tag. GPI-anchored proteins used for painting of enveloped viral vectors 
have also been engineered to contain histidine tags, allowing the particles to be coated with 
GPI-anchored protein and attached to the viral vectors by means of the GPI-anchor. Or, 
alternatively, biolinker proteins such as streptavidin can potentially be modified at the 
genetic level to contain a GPI signal sequences, and as such, after production in a suitable 
expression system, can be purified as reactive reagents to link up with biotinylated 
nanoparticles. In both cases the recombinant GPI-anchored protein acts as a linker or 
interface between the organic viral particles and inorganic nanomaterials, either magnetic or 
fluorescent capabilities (or both). With such a system in place to functionalise the surface of 
viral vectors without affecting the viral infectivity pathway, one can imagine many 
biomedical applications such as targeting of gene therapy vectors in vivo to tumours using 
magnetic force and tracking via bioimaging techniques based on magnetic field, i.e. MRI or 
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such new technologies with clinically used viral vectors (Subbiah et al. 2010).  
5. Conclusions / summary 
RV/LV vectors are already proving to be useful delivery vehicles for gene therapy 
applications but in order to establish more efficient vectors for in vivo delivery, the viral surface 
can potentially be modified to provide better means of preparation, purification, 
concentration, detection, tracking, imaging, and targeting in order to not only successfully 
manufacture the product but also to navigate interactions within the patient and  infect pre-
defined target cells selectively. To achieve this aim several techniques may be employed for 
surface engineering or RV/LV vectors. Table 3 provides a concise overview of these 
techniques and the applications for which they have been used and may conceivably be used 
in the future. Pseudotyping has been used for targeting applications, however, can only make 
use of a limited amount of targeting options. Chimeric proteins have been used for labeling 
and targeting applications, and can be useful for immunomodulation approaches. Enrichment 
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1. Introduction  
The hope that delivering genes to ailing tissues and organs can treat disease more effectively 
than drugs or surgery, has fueled the intense interest in gene therapy. Potential uses of gene 
therapy include replacing mutated genes with healthy ones, inactivating improperly 
functioning mutated genes, or introducing new genes into the body to help fight a specific 
disease. While the concept of gene therapy is easy to understand, technical difficulties have 
limited its practical use. Delivered genes that function admirably in cell culture may not 
function correctly in vivo, may have unexpected consequences on intracellular signaling 
pathways, or may transform cells raising the risk of iatrogenic malignancy. 
Retroviruses play a central role in gene delivery applications because they have a high 
infection efficiency and are able to induce stable mutagenesis in eukaryotic cells (Yi et al., 
2005; Somia & Verma, 2000; Thomas et al., 2003). Stable incorporation of retroviral DNA into 
the host genome is advantageous, since long-term expression of the transgene, usually a 
requirement for prolonged therapeutic efficacy, is possible. While they are currently being 
used for in vitro and (animal) in vivo studies, the clinical use of retroviral vectors to deliver 
genes is still in its infancy. Among the reasons for the slow progress in adapting retroviruses 
to deliver genes are the concerns over potential adverse events when introduced into 
humans and a limited understanding of the mechanisms that affect retroviral function and 
expression in infected (target) cells. 
Both wild type and genetically modified retroviruses rely on the host cell to assist during its 
life cycle. Retroviral infection of cells, followed by integration of its genome into the host 
genome, is not always a certain process, however, and cellular and extracellular processes 
can influence these events. Therefore, while retroviral gene delivery is generally successful, 
the impact of viral infections on target cells remains less predictable and can be considered, 
basically uncontrollable. Despite the care with which viral vectors are generated, researchers 
ultimately rely on random events that can yield both positive and negative outcomes. 
In most eukaryotic cells, steroid hormones regulate a wide variety of physiological functions 
ranging from inflammation to pregnancy. There are five major classes of steroid hormones: 
glucocorticoids, mineralocorticoids, estrogens, androgens, and progestins. Steroid hormones 
from each class can complex with their specific receptors, and often with other transcription 
factors, to recognize DNA sequences called response elements. This mechanism of gene 
regulation by steroids is so potent and universal throughout the biosphere that it is not 
surprising that retroviruses have exploited the host nuclear steroid receptor regulatory 
system to expand their own genomes and improve their overall functionality. 
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While most steroid hormone receptor systems could be utilized by retroviruses during 
target cell infection, the strongest evidence exists for an important role of the glucocorticoid 
receptor (GR) in this process. This review focuses on the role of the nuclear glucocorticoid 
receptor in controlling retroviral infection and function and highlights its potential 
importance in retroviral-based gene therapy applications. 
2. Retroviral vectors for gene therapy 
Retroviruses belong to the family Retroviridae which consists of a large and diverse group of 
viruses classified into seven genera. Within each genera retroviruses are structurally and 
functionally similar and further classified based on a computer analysis of their genome. 
Only two of them, gamma-retroviruses and lentiviruses, are commonly used as vectors for 
gene therapy, however. The murine leukemia virus (MLV) is the prototypical gamma-
retroviral backbone that has been modified to generate different gene delivery vectors, 
whereas the human immunodeficiency virus type 1 (HIV-1) provides the standard backbone 
for most lentiviral vectors. Both types of retroviruses (gamma-retroviruses and lentiviruses) 
have been used to generate stable genetic modification in host cells through the 
chromosomal integration of the transferred vector genomes. This ability to stably modify 
target cell genomes is useful not only for research purposes, but also for clinical gene 
therapy strategies intended to correct genetic defects. An important difference between 
gamma-retroviruses and lentiviruses is that gamma-retroviruses can only infect dividing 
cells whereas lentiviruses can infect both dividing and quiescent cells. To date, gamma-
retroviral and lentiviral vectors have been used in more than 300 clinical trials targeting 
various diseases (Telesnitsky, 2010). 
All retroviral genomes are non-segmented and typically consist of at least 4 genes: gag, pro, 
pol and env. The gag gene encodes the major structural polyprotein Gag which is both 
necessary and sufficient for the assembly of non-infectious and immature viral-like particles. 
The pro gene encodes the viral protease that is responsible for facilitating the maturation of 
viral particles. Products of the pol gene include reverse transcriptase, RNase H and 
integrase, all critical for the successful integration of the viral genome into the host genome. 
Env encodes the viral surface glycoprotein and transmembrane proteins that mediate 
cellular receptor binding and membrane fusion. There are additional genes (called accessory 
genes) that are present in some, but not all, gamma-retroviruses and lentiviruses. These 
accessory genes are involved in regulating the synthesis and processing of viral RNA and 
other replicative functions. For the HIV-1 based viruses, these additional genes include: Vif, 
Vpr, Vpu, Tat, Rev, and Nef (Malim & Emerman, 2008). 
The retroviral genome is flanked by two long terminal repeat (LTR) sequences at both the 5’- 
and 3’- ends. In the integrated virus (provirus) each LTR consists of three regions: 1) the R 
sequence, 2) the U3 region, and 3) the U5 region. The R region is a short (18-250nt) sequence 
which forms a direct repeat at both ends of the genome, and is flanked upstream by the U3 
region and downstream by the U5 region in the integrated virus. The U3 is a unique non-
coding segment of 200-1,200nt that forms the 5’ end of the virus after reverse transcription. It 
contains the enhancer elements responsible for transcription of the integrated virus. The U5 
is a unique, non-coding region of 75-250nt which is the first part of the genome to be reverse 
transcribed, forming the 3’ end of the provirus genome. Both U3 and U5 sequences are 
required for viral integration. The Primer Binding Site (PBS) is an 18nt sequence 
complementary to the 3' end of the specific tRNA primer used by the virus to begin reverse 
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transcription. Downstream from the PBS is the packaging signal (psi) sequence that allows 
completed RNA transcripts to be packaged into budding viral cores. Polypurine Tract (PPT) 
is a short (~10nt) run of A/G residues responsible for initiating (+)strand synthesis during 
reverse transcription. The 5’ LTR is the control center for gene expression and contains both 
promoter and regulatory elements that can be responsive to both viral and cellular trans-
activating factors. The 3’ LTR functions as a transcription terminator and a polyadenylation 
signal that leads to the development of a mature viral transcript. 
 
 
Fig. 1. Schematic representation of the retroviral genome. 
For gene delivery applications both gamma-retroviral and lentiviral genomes are initially 
modified to meet certain criteria (Lech & Somia, 2008). This includes removal of gag, pol and 
env to prevent the provirus from generating infectious particles in target cells. This makes 
them safer and therefore more suitable to deliver genes than wild type viruses. Other parts 
of the viral genome, such as PBS and PPT, cannot be removed if the vector is to remain 
functional, however. In addition, while both the LTRs and the psi sequence can be partially 
truncated or modified, they must be present for the virus to function. 
A critical difference therefore, between wild type retroviruses and modified retroviruses 
used in research applications, is the ability of the wild type to generate infectious particles, a 
trait the retroviral vectors lack. The modifications required to make retroviruses safer, 
however, can impact enhancer and promoter elements within the LTR and thus make direct 
comparisons between the behavior of wild type and modified retroviral vectors difficult. 
Specific to this review, modifications within the LTR promoter of both gamma-retroviruses 
and lentiviruses can alter the activity of the nuclear GR-regulatory pathway, yielding 
potentially conflicting experimental results depending on the vector and cell type.  
3. Glucocorticoid receptor regulatory system 
The glucocorticoid receptor (GR) is also known as NR3C1 (nuclear receptor subfamily 3, group 
C, member 1) and is encoded by the NR3C1 gene located on chromosome 5 (5q31) in humans 
(Hollenberg et al., 1985; Francke & Foellmer, 1989; Lu et al., 2006; Rhen & Cidlowski, 2005). The 
GR is expressed in almost every cell in the body and upon binding to glucocorticoids, 
regulates genes controlling development, metabolism, and immune response. 
In the absence of the glucocorticoid hormone, the GR resides, inactive, in the cytosol, 
complexed with a variety of proteins (Pratt et al., 2006). When glucocorticoids bind to the 
GR it can lead to either gene transactivation or gene transrepression (Buckingham, 2006; 
Hayashi et al., 2004). Transactivation usually involves homodimerization of the receptor 
followed by its translocation into the nucleus via active transport. The activated GR binds to 
specific DNA sequences called glucocorticoid response elements (GRE), which are short 
sequences of DNA within the promoter of a gene that are able to bind GR complexes and 
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sequences of DNA within the promoter of a gene that are able to bind GR complexes and 
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regulate transcription. The GRE’s sequence is most commonly a pair of inverted repeats 
separated by a short linker, indicating that the receptor binds as a homodimer. Half-sites 
GRE are also present and usually bind monomeric GR. These half-sites are only weakly 
activated by GR complexes, but can also have inhibitory effects, leading to transrepression. 
Nuclear factor-kappaB (NFκB) and the activator protein-1 (AP-1) are two important 
transcription factors that are negatively regulated by the nuclear GR signaling pathway. In 
the absence of activated GR, NFκB and AP-1 are able to translocate into the nucleus and 
transactivate target genes by binding to specific DNA sequences that correspond to each 
transcription factor. Activated GR can complex with either of these transcription factors, 
however, and prevent them from binding their target genes, repressing genes that are 
normally upregulated by NFκB or AP-1. GR-mediated transrepression of NFkB can also 
occur through GR’s binding to NFκB’s response elements, thus preventing transactivation 
(Hermoso & Cidlowski, 2003; Nissen & Yamamoto, 2000; Tuckermann et al., 1999). 
NFkB regulates the expression of well over 100 genes, the majority of which participate in 
the host immune response (Ghosh et al., 1998). These proteins include cytokines and 
chemokines, receptors required for immune recognition, proteins involved in antigen 
presentation, and adhesion receptors involved in transmigration across blood vessel walls. 
Because of its extensive role in immune action, NFkB has been termed the central mediator 
of the immune response (Hiscott et al., 2001). The ability of activated GR to block NFkB’s 
transactivation of these genes is likely important in mediating the immunosuppressive effect 
of glucocorticoids (Ito et al., 2001). 
GRE are present in the genomes of most gamma-retroviruses (Bruland et al., 2003a, 
Rodriguez & Goff, 2010, Pages et al., 1995) and HIV-1 based lentiviruses (Ghosh, 1992; Mitra 
et al., 1995; Hapgood & Tomasicchio, 2010). NFkB response elements are generally absent in 
gamma-retroviruses, but present in HIV-1, making GR-mediated regulation of lentiviral 
vectors derived from the HIV-1 backbone more complex. The presence of GRE and NFkB 
response elements in the retroviral genome suggests that glucocorticoids can exert influence 
on the viral-host cell interaction. Defining the role of GR on the retroviral lifecycle may not 
only provide clues on how to combat retroviral infections, but also provide alternate 
strategies for adapting retroviral vectors for gene delivery. 
4. Effects of activated glucocorticoid receptors on gamma-retroviral and 
lentiviral promoters 
The prominence of GRE in the gamma- and lentiviral genomes suggests that their life cycles 
are dependent on the host’s GR regulatory system (Rusmevichientong & Chow, 2010). 
Glucocorticoids stimulate gamma-retroviral promoter activity in multiple cell types. 
Synthetic corticosteroid hormones stimulated MLV transgene expression in primary bone 
marrow stromal cells (Jaalouk et al., 2000). The synthetic glucocorticoid, dexamethasone, 
increased gamma-retroviral LTR promoter activity in pulmonary artery endothelial and 
smooth muscle cells and also in 293 cells as evidenced by an increased expression of the 
reporter protein, GFP, in infected cells (Solodushko et al., 2009) Most published evidence 
suggests that the usual effect of glucocorticoids on gamma-retroviral promoter activity is 
positive (Mitra et al., 1995). 
The effect of GR on the lentiviral promoter is more complicated than its effect on gamma-
retroviruses, however. Activation of the GR can enhance lentivirus functionality. H9V3 cells 
transfected with the reporter HIV-1 LTR did show increased transgene expression in the 
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presence of glucocorticoids (Kolesnitchenko & Snart, 1992). HIV-1 infected lymphoid and 
monocytoid cell lines treated with cortisol or dexamethasone also increased HIV-1 gene 
expression and virus production in vitro, a process that required the presence of the GRE 
(Soudeyns et al., 1993). In addition, glucocorticoid administration has also been associated 
with increased HIV-1 promoter activity leading to increased virus replication and AIDS 
progression in infected individuals (Kino et al., 2000; Soudeyns et al., 1993). 
 
 
Fig. 2. Schematic representation of binding sites for activated GR in the LTR of MLV (gamma-
retrovirus) and HIV-1 (lentivirus). In MLV GR can bind GRE resulting in transactivation. In 
HIV-l GR can bind GRE1 generally resulting in transactivation and GRE2 and GRE3 (both half 
sites) leading to transrepression. Activated GR can also directly interact with HIV-1 NFkB 
binding sites resulting in transrepression of the viral promoter. 
Lentiviruses contain both stimulatory and inhibitory GRE sites though and therefore 
activated GR can cause different effects depending on the cell type. The first GRE (GRE1) is 
located between −264 and −259 relative to the transcriptional start site and can generally be 
considered a stimulatory GRE. The other GREs (GRE2 and 3) are half sites and are 
positioned between −6 and −1 and between +15 and +20, respectively, relative to the 
transcriptional start site (Mitra et al., 1995; Berkhout et al., 1989). Both GRE half-sites (2 and 
3) are shown to be negative regulators of the viral promoter (Meijsing et al., 2009). 
In addition to its ability to signal through the GRE, the GR signaling pathway can also 
regulate lentiviral (although not gamma-retroviral) behavior through its interaction with the 
NFkB and AP-1 pathway. Activated GR can interfere with NFkB signaling either by directly 
interacting with NFkB response sites or by binding with NFkB proteins (thus blocking its 
ability to enhance the lentiviral LTR). As shown in figure 2 two NFkB response sequences 
(NFkB1) in the HIV-1 U3 region are located between GRE1 and the TATA box. Wild type 
HIV-1 that lacks both of the NFkB binding sites is replication-incompetent; returning one or 
both NFkB elements restores the virus’s ability to replicate (Ross et al., 1991).  
The active binding sites for NFkB, however, are not limited to the enhancing region but can 
be found downstream of the transcription initiation site. In addition to this double NFkB site 
in the U3 region, another double NFkB binding site is present in the R region of the 
lentiviral LTR (NFκB2). This site is also active and contributes to the GR and NFκB response 
and is involved in activating the LTR in response to mitogenic stimuli (Mitra et al., 1995; 
Berkhout et al., 1989; Logan et al., 2004; Kilareski et al., 2009). The p50-p65-NFκB complex 
can bind both of these sites and enhance expression of HIV-1 genes. Further downstream, 
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lentiviral LTR (NFκB2). This site is also active and contributes to the GR and NFκB response 
and is involved in activating the LTR in response to mitogenic stimuli (Mitra et al., 1995; 
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three AP-1 binding sites in U5 may also potentiate NFkB-dependent responses in integrated 
proviruses (Logan et al., 2004; Kilareski et al., 2009). Figure 2 shows the only direct binding 
sites for GR in retroviral LTR.  
Thus the GR is a regulatory factor that can influence HIV-1 activity through multiple 
mechanisms, not only by its direct binding to the GRE, but also through its effects on NFkB 
and AP-1 signaling pathways. These influences can be both positive and negative. (Hapgood 
& Tomasicchio, 2010; Kino et al., 1999; Ayyavoo et al., 1997a; Mirani et al., 2002) The overall 
effect of glucocorticoids on lentiviral promoter activity, therefore, can be difficult to predict. 
This may explain the confusing, and often contradictory, results on the effect of glucocorticoids 
on HIV-1 progression obtained by different research groups (Kino et al., 2000). 
5. Viral protein R potentiates the effect of glucocorticoid receptor 
In contrast to the relatively simple ways that gamma-retroviruses induce host cell infection, 
lentiviruses have evolved multiple strategies to induce a persistent infection in host cells. 
HIV-1 in particular, employs several strategies that rely on an array of virally encoded 
accessory proteins, including Vif, Vpr, Vpu, and Nef.  Collectively, these proteins appear to 
manipulate host cell biology to ensure a favorable cellular environment for viral replication, 
transmission, dissemination, and immune evasion (Malim & Emerman, 2008). One of them 
in particular, the 14-kDa HIV-1 viral protein R (Vpr), down-regulates the expression of 
genes involved in cell cycle/proliferation, DNA repair, tumor antigen presentation by the 
host cell, and immune activation factors, and upregulates many ribosomal and structural 
proteins required for viral propagation (Janket et al., 2004; Levy et al., 1994; Wu et al., 1995, 
Sherman et al., 2000). These changes can occur in the absence of other viral gene products, 
suggesting that Vpr can mediate its proviral effects partially, or perhaps solely, through 
modulation of the target cell environment (Ayyavoo et al., 1997a). 
Vpr protein is present in high titers in the serum of AIDS patients and can be efficiently 
taken up from the extracellular medium by cells in vitro in a process that occurs independent 
of other HIV-1 proteins and also independent of cellular receptors. Following cellular 
uptake, Vpr can have multiple actions on the host cell GR signaling pathway, an interaction 
that can affect both the host cell and the virus. Two highly conserved leucine-rich domains 
within Vpr resemble the GR coactivator signature motif which allows Vpr to activate the GR 
in the absence in glucocorticoids (Sherman et al., 2000). As a result, the activated Vpr-GR 
complex translocates into the nucleus and induces the expression of glucocorticoid-
responsive genes in a similar direction to that seen with dexamethasone in either the host 
cell or the viral promoters (Muthumani et al., 2006). Vpr can also activate the HIV-1 
promoter without GR, directly binding to the viral SP-1 site in complexes with other 
activators (Kino et al., 2002, Kino et al., 2000, Amini et al., 2004). Thus, Vpr can stimulate the 
retroviral promoter leading to increased virus production and virion maturation. 
Experimentally it has been shown to induce virus expression in the peripheral blood 
mononuclear cells of HIV-infected individuals (Levy et al., 1994) and can directly induce T-
cell receptor-triggered apoptosis. This effect, central to the ability of HIV-1 to deplete T cells, 
can be prevented by the inhibitory steroid hormone mifepristone (Ayyavoo et al., 1997b; 
Fakruddin & Laurence, 2005). In addition to its effect on the lentiviral and the host cell 
promoters, Vpr also enhances expression of the beta-retroviral mouse mammary tumor 
virus (MMTV) promoter suggesting that Vpr could be used as an enhancer in retroviruses 
other than lentiviruses (Kino et al., 2002). 
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Vpr interaction with the host cell’s GR and subsequent ability to transactivate the HIV-1 LTR 
directly (i.e. in the absence of glucocorticoids), can be blocked by mifepristone. Mifepristone, 
also known as RU-486 is an abortifacient that has both anti-progestin and anti-glucocorticoid 
activity. It can bind and activate the GR-alpha primarily, but recent work suggests that it can 
also bind and translocate the GR-beta into the nucleus of Cos1 and U2OS cells, leading to 
upregulation of a number of genes (Lewis-Tuffin et al., 2007). In vitro, mifepristone was able to 
inhibit Vpr-mediated translocation of the HIV nucleoprotein preintegration complex into the 
host cell nucleus and block Vpr-induced apoptosis, cytokine production and T-cell 
proliferation (Schafer et al., 2006). This and other experimental observations led to the 
hypothesis that mifepristone could reduce viral synthesis in infected cells and therefore could 
reduce the pace of infection in vivo. A clinical trial examining the anti-HIV activity and safety 
of mifepristone on viral load, disease progression, and survival in HIV-1 infected individuals 
was begun in 2006 (Clinical trial number: NCT00352911). Final results of that trial have not yet 
been released, but interim results suggest no benefit of mifepristone in the primary endpoint of 
reducing HIV viral load at 28 days (Para et al., 2010).  
6. Role of glucocorticoid receptor in immune resonance, retroviral release 
and integration capability 
Glucocorticoids are among the most commonly prescribed drugs worldwide due to their 
profound anti-inflammatory and immunosuppressive activity (Herold et al., 2006; Kim et 
al., 2001; Janket et al., 2004). They control homeostasis of T cell monocytes/macrophages, 
osteoclasts, and dendritic cells by inducing their apoptosis or inhibiting maturation. Most, if 
not all, of these effects are mediated through their interactions with the GR (Herold et al., 
2006). Activated GR can interfere with the signaling pathways of AP-1 and NFκB, two key 
host transcription factors that regulate expression of pro-inflammatory genes and other 
genes involved in immune responses (Hapgood & Tomasicchio, 2010; De Bosscher et al., 
2003; Smoak & Cidlowski, 2004) 
Vpr enhances the immunosuppressive effect of endogenous and therapeutic glucocorticoids 
(Mirani et al., 2002; Kino et al., 1999). Vpr administered extracellularly potentiated the 
glucocorticoid-induced suppression of mRNA expression and secretion of IL-12 by dendritic 
cells (Kim et al., 2001). Vpr also potentiated the glucocorticoid-induced inhibition of other 
immunologically important cytokines such as IL-2, IL-10, TNF alpha and IL-4, all of which 
are NFκB –dependent (Fakruddin & Laurence, 2005). Both the GR and Vpr are involved in 
the apoptosis in T cells and dendritic cells (Hapgood & Tomasicchio, 2010; Bruland et al., 
2003b). In addition, patients with AIDS and normal cortisol secretion have manifestations 
compatible with glucocorticoid hypersensitivity of the immune system, such as suppression 
of innate and cellular immunity.  
Since the GR plays an important role in regulating viral promoter activity it is not surprising 
that it also affects viral particle production. Dexamethasone can stimulate the gamma-
retroviral promoter in viral producing cells (i.e. HEK 293 packaging cells) significantly 
increasing viral release into the cultured medium, a strategy that can be used to increase the 
viral titer for gene delivery applications (Solodushko et al., 2009). A similar effect can be 
seen with lentiviruses, but this is dependent on the formulation of glucocorticoid used and 
cell type infected. Hydrocortisone increased the efficacy of HIV-1 infection in fresh normal 
human peripheral blood mononuclear leukocytes whereas other corticosteroids 
(dexamethasone) and sex hormones, had no effect (Markham et al., 1986).  
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Fig. 3. A: The anti-glucocorticoid and anti-progestin agent, mifepristone, increased the 
integration efficiency of three gamma-retroviruses: moloney murine leukemia virus (MLV), 
murine stem cell virus (MSCV) and friend murine embryonic stem cell virus (FMEV). Target 
cells included: lung microvascular endothelial cells (expressing both functioning 
glucocorticoid (GR) and progesterone (PR) receptors), U87MG cells (lacking functioning GR) 
and T47D cells (lacking functioning PR). This effect was independent of viral titer. B: 
Infection efficiency of endothelial cells with MLV under four conditions: (C) control, no 
steroid treatment at time of virus propagation and infection; (D) virus was propagated and 
target cells were infected in the presence of glucocorticoid dexamethasone; (M) virus was 
propagated with no steroids and target cells were infected in the presence of mifepristone; 
(D+M) virus was propagated in the presence of dexamethasone followed by infection of 
target cells in the presence of dexamethasone and mifepristone. 
We and others have demonstrated that dexamethasone can stimulate the gamma-retroviral 
LTR promoter and increase viral particle production in packaging cell lines. This effect 
could be blocked by the progestin and glucocorticoid antagonist, mifepristone. In a novel 
observation, we demonstrated that mifepristone could increase the infection efficiency of 
gamma-retroviruses in a number of different target cells including (human, rat, and mouse) 
vascular endothelial and smooth muscle cells, and epithelial cells. This effect was 
independent of viral titer. Later studies demonstrated that mifepristone had no effect on 
viral entry, viral survival or viral DNA synthesis, but increased gamma-retroviral infection 
efficiency by facilitating viral integration into the host genome (figure 3A). This effect 
appeared to be due to mifepristone's anti-glucocorticoid, but not its anti-progestin, activity 
since T47D cells lacking functioning GR did not demonstrate increased infection efficiency 
in the presence of mifepristone, whereas U87MG cells lacking functional progesterone 
receptors, did. Mifepristone had no effect on lentiviral integration into host cells, however. 
These results suggest that inhibition of the GR enhances retroviral integration into the host 
genome and indicates that cells may have a natural protection again retroviral infection that 
may be reduced by glucocorticoid receptor antagonists (Solodushko & Fouty, 2010).  
Based on these observations, we demonstrated that gamma-retroviral infection of target 
cells can be maximized by first incubating packaging cells with dexamethasone to increase 
the viral titre in the supernatant and then incubating target cells with mifepristone to 
improve integration of virus into the host genome (figure 3B) (Solodushko & Fouty, 2010). 
The predominantly cytoplasmic localization of the GR appears to be a specific obstacle for 
HIV replication by preventing its migration into the nucleus where it can complete the 
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infectious process. The presence of both endogenous and exogenous glucocorticoids tends 
to increase the lentiviral infection efficiency of target cells. Resting peripheral mononuclear 
blood cells are not easily infected with HIV-1 due to a block, prior to integration, of the 
provirus into the host genome. Proviral integration increases after addition of a GR ligand 
(such as hydrocortisone or dexamethasone). This effect is confined to an early time period 
after incubation of the cells with the virus and requires the presence of the GR and the GR 
binding viral protein Vpr (Wiegers et al., 2008).  
7. Lessons for retroviral gene therapy 
Due to safety concerns, retroviral vectors are made replication incompetent by the removal 
of the gag, pol and env genes. As a result, while retroviral vectors are still capable of 
transducing cells and expressing the foreign (delivered) gene, they cannot produce 
infectious viral particles due to the lack of structural and enzymatic genes. To generate the 
retroviral vectors needed to deliver genes of interest to target cells, the gag, pol and env genes 
are stably introduced into retroviral-packaging (producing) cells. The presence of 
functioning LTRs, PBS, psi and PPT are required and sufficient for the proper function of 
most gamma-retroviral vectors whereas additional trans and cis elements are required for 
the proper function of lentiviruses. The genetic modifications required to transform wild 
type gamma-retroviruses and lentiviruses into vectors suitable for use in research and 
clinical trials can significantly alter their response to environmental signals. Since the 
retroviral life cycle is dependent somewhat on the function of the GR in host cells, retroviral 
gene delivery vectors derived from wild type retroviruses are also regulated by GR activity. 
While many regions of the wild type retroviral backbones genome can be altered to meet the 
demands of gene delivery, essential parts of the viral genome must be retained to allow 
transgene expression and vector (virus) production. An intact R and U5 regions of the LTR 
promoter are required for the virus to work. Parts of the U3 (enhancer) region of the promoter 
can be modified, deleted or replaced by other sequences, without significantly decreasing 
virus functionality, however. The U3 region of most retroviruses contains GRE and, in the case 
of lentiviruses, NFkB response elements as well. Removing these response elements will still 
allow the virus to function, but will alter its responsiveness to GR signaling pathways. 
Therefore vectors with full length LTR or truncated LTR that retain these GR responsive 
sequences, will behave like wild type viruses in response to GR activation whereas vectors in 
which they have been removed will appear non-responsive to GR activation. 
The promoters of gamma-retroviral vectors with completely functional GRE are strongly 
stimulated when exposed to GR. This enhancing effect of activated GR on the LTR promoter 
in gamma-retroviruses can be exploited to increase viral production by packaging cells and 
also to increase expression of reporter or therapeutic genes in target cells once the viral 
genome is integrated. The net effect of activated GR (due to either glucocorticoids or Vpr) on 
LTR activity in lentiviruses is less predictable, however, due to the opposing effects of GR 
on the GRE and NFkB regulatory segments. Published data indicate that glucocorticoids can 
have either positive or negative effects on the LTR promoter in lentiviruses depending on 
the cell type, glucocorticoid formulation, and vector being studied (Soudeyns et al., 1993; 
Kolesnitchenko & Snart, 1992; Kino et al., 2000; Mitra et al., 1995). 
For the HIV-1 based vector, most of the accessory genes (Vif, Vpr, Vpu, Nef ) as well as Tat 
and Rev have been deleted for safety reasons or separated from the packaging construct. 
Despite these deletions, this modified virus can still function as a gene delivery vector. 
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While the absence of Vpr does not interfere with infection efficiency in most cell types, this 
protein can potentiate transduction of macrophages (Amado & Chen, 1999; Heinzinger et 
al., 1994), muscle, and liver cells (Kafri et al., 1997; Blomer et al., 1997). In addition, Vpr is a 
known activator of lentiviral and cellular promoters and can also enhance activity of the 
MMLV LTR promoter by directly binding to p300/CBP coactivators (Kino et al., 2002). Since 
Vpr is deleted in most lentiviral vectors, its ability to enhance activation of the viral LTR and 
the host promoters is also eliminated. Vpr can enter cells independent of the virus, however, 
and can activate retroviral vectors even if it is not included in the vector. Vpr can block 
NFkB and AP-1 signaling, thus inducing immune suppression which increases the 
likelihood of successful retroviral stable infection of host cells in vivo. When using third 
generation lentiviral vectors which lack Vpr, some investigators have delivered Vpr 
separately to increase the chances of a successful infection.  
Self-inactivating (SIN) retroviral vectors are ones in which a region of the 3’LTR that 
contains an enhancing region of the viral promoter is deleted. The complementary region in 
the 5’LTR is replaced by a promoter to allow transcription of the full-length viral genome. 
After integration into the host genome, the retroviral LTR becomes inactive allowing 
increased transgene expression from another internal promoter. This allows the placement 
of a stronger promoter such as cytomegalovirus (CMV) to increase transgene expression, or 
alternatively, to allow site-specific activation of the transgene such as when the internal 
promoter is the endothelial promoter, Tie2, which will only allow transgene expression in 
endothelial cells.  Originally SIN vectors were thought to be safer for gene therapy because 
they lacked the retroviral enhancer element and therefore do not continue to replicate 
within the host genome. There is some debate about whether this is true or not, however 
(Bosticardo et al., 2009; Yu et al., 1986). 
In SIN vectors, the role of the GR on viral promoter activity is further reduced because the 
GREs within the U3 region are also removed. To combat this limitation, the excised GRE can 
be restored within the second internal promoter. Even without restoring GREs in SIN vectors, 
however, activated GR continue to have an effect on lentiviral behavior due to the presence of 
GRE and NFkB responsive sequences in regions other than U3 (Soudeyns et al., 1993; 
Hapgood & Tomasicchio, 2010; Mitra et al., 1995; Berkhout et al., 1989; Logan et al., 2004; 
Kilareski et al., 2009). GR, in cooperation with other regulatory proteins, can bind these sites 
and enhance AP-1 signaling since several AP-1 binding sites are present not only in U3, but in 
the U5 region of HIV-1 also. Since the R and U5 regions are not significantly altered in 
retroviral vectors due to their importance in viral function, these NFkB and AP-1 sites remain 
relatively intact even in SIN lentiviral vectors and therefore may contribute to residual LTR 
transcriptional activity (Logan et al., 2004; Kilareski et al., 2009; Logan et al., 2004) 
Depending on the type of internal promoter used in SIN vectors, their enhancers may also 
have GRE or NFkB response elements. The most robust and popular internal promoters 
used in lentiviral vectors (such as CMV or SV-40) may also contain NFkB binding sites that 
increase promoter activity when NFkB is bound (Ross et al., 1991). Lentiviral Vpr can also 
increase the activity of CMV, SV-40 and many other internal promoters (Hiscott et al., 2001; 
Roux et al., 2000; Kim et al., 2007). Glucocorticoids can have different effects on these 
internal retroviral promoters if they are used with an intact LTR promoter, however, and 
this appears to be a function of cell type. For example, in bone marrow cells infected with a 
retroviral construction that contains a full length LTR and a second internal SV-40 promoter 
(which does not contain the GRE), dexamethasone suppresses SV-40 promoter activity, 
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whereas in retrovirus-infected fibroblasts infected with the same retroviral vector, 
dexamethasone increased SV-40 activity  (Akahane et al., 2002). Therefore, retroviral vectors 
with internal promoters should be designed individually depending on the cell type that 
needs to be infected and the effect of glucocorticoids on these vectors needs to be tested in 
each cell type.  Understanding the distinct effects of modified vectors in different cell types 
is important for successful gene therapy (Derecka et al., 2006). 
8. Conclusions 
Gamma-retroviruses and lentiviruses are the most commonly used vectors for in vitro and 
in vivo gene delivery and both are responsive to activated GR. The GR signaling pathway is 
an important regulator of retroviral functionality through both its effects on the retrovirus 
and its effects on the target cell. In addition to its effects on the host cell and the retrovirus, 
glucocorticoids and activated GR can also dampen cellular immunity. This is particularly 
important when retroviruses are used as gene delivery vehicles in vivo. Once these wild type 
viruses are modified for gene delivery applications, however, the direction and magnitude 
of this GR response can be altered. Depending on what areas of the retroviral genome are 
changed, the effects of GR activation can vary greatly. In addition, the cell type infected 
contributes to the GR response making predictions about the effects of GR activators (i.e. 
glucocorticoids and Vpr) in specific cell types, difficult. Retroviral vectors therefore, need to 
be designed for a specific purpose and cell type and they must also be tested within the cell 
of interest under the conditions of interest to confirm the desired effect.  
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1. Introduction 
Adenoviruses (AdV) have been well delineated and made into suitable vectors for gene 
transfer by their somewhat benign nature, broad tissue tropism, and the relative ease of 
manipulation of their genome. These viruses readily transduce both quiescent and dividing 
cells, are adaptable for large scale production and have certified cell lines that have been 
developed for purification. Nevertheless, these vectors are not recommended for all 
purposes.  Currently, adenoviral vectors are more widely evaluated in applications where a 
short-term transgene expression is sought after (i.e., cancer and vaccines) (Jolly et al., 2008; 
Sharma et al., 2009b). 
Rowe and colleagues in 1953 were the first to isolate AdV from adenoidal tissue and to 
describe the spontaneous degeneration of primary cell lines from whence they were derived 
(Rowe WP et al., 1953). A similar virus was isolated from an epidemic of respiratory illness 
in U.S. military recruits in 1954 (Hilleman MR & Werner JH, 1954). In 1956, the viruses were 
named adenoviruses after the tissue from which they were isolated (Enders et al., 1956). 
Their anti-tumor potential was explored in the clinical treatment of cervical carcinoma 
following AdV inoculation not long after 1956 (Huebner et al., 1956).  Despite this initial use, 
it took several years following the advent of recombinant technology before the therapeutic 
potential of AdV was truly realized.  Since then, adenoviral vectors have received much 
attention as gene transfer agents and currently are being tested in a wide variety of gene 
therapy applications. 
There are more than 120 AdV that infect a wide host range including mammalian, avian, 
and reptile species.  AdV are divided into four genera: Atadenovirus, Aviadenovirus, 
Mastadenovirus, and Siadenovirus. Mastadenovirus serotypes which infect humans are 
placed in groups (A-F) or subgenera.  Initial parameters for grouping were based on 
patterns of hemagglutination from various animal species; now the grouping is based on 
DNA homology.  Some of these genera are being engineered for use as AdV vectors. 
The Adenoviridae family is characterized by a linear, double-stranded DNA genome that is 
encapsulated in an icosohedral shell of protein that measures 70 to 90 nm in diameter. 
Virions of AdV are comprised of 13% DNA and 87% protein (Rux & Burnett, 2004; San & 
Burnett, 2003).  Their genome is approximately 35-38 kilobases in size.   The majority of the 
viral capsid encompasses three proteins: fiber, penton base and hexon.  Fiber and penton 
base proteins are necessary for receptor binding and cell internalization, whereas hexon 
 5 
Adenoviral Vectors: Potential and  
Challenges as a Gene Delivery System 
Suresh K. Mittal, AnneMarie Swaim and Yadvinder S. Ahi 
Department of Comparative Pathobiology, Purdue University Center for Cancer Research, 
and Bindley Bioscience Center, Purdue University, West Lafayette, IN,  
USA 
1. Introduction 
Adenoviruses (AdV) have been well delineated and made into suitable vectors for gene 
transfer by their somewhat benign nature, broad tissue tropism, and the relative ease of 
manipulation of their genome. These viruses readily transduce both quiescent and dividing 
cells, are adaptable for large scale production and have certified cell lines that have been 
developed for purification. Nevertheless, these vectors are not recommended for all 
purposes.  Currently, adenoviral vectors are more widely evaluated in applications where a 
short-term transgene expression is sought after (i.e., cancer and vaccines) (Jolly et al., 2008; 
Sharma et al., 2009b). 
Rowe and colleagues in 1953 were the first to isolate AdV from adenoidal tissue and to 
describe the spontaneous degeneration of primary cell lines from whence they were derived 
(Rowe WP et al., 1953). A similar virus was isolated from an epidemic of respiratory illness 
in U.S. military recruits in 1954 (Hilleman MR & Werner JH, 1954). In 1956, the viruses were 
named adenoviruses after the tissue from which they were isolated (Enders et al., 1956). 
Their anti-tumor potential was explored in the clinical treatment of cervical carcinoma 
following AdV inoculation not long after 1956 (Huebner et al., 1956).  Despite this initial use, 
it took several years following the advent of recombinant technology before the therapeutic 
potential of AdV was truly realized.  Since then, adenoviral vectors have received much 
attention as gene transfer agents and currently are being tested in a wide variety of gene 
therapy applications. 
There are more than 120 AdV that infect a wide host range including mammalian, avian, 
and reptile species.  AdV are divided into four genera: Atadenovirus, Aviadenovirus, 
Mastadenovirus, and Siadenovirus. Mastadenovirus serotypes which infect humans are 
placed in groups (A-F) or subgenera.  Initial parameters for grouping were based on 
patterns of hemagglutination from various animal species; now the grouping is based on 
DNA homology.  Some of these genera are being engineered for use as AdV vectors. 
The Adenoviridae family is characterized by a linear, double-stranded DNA genome that is 
encapsulated in an icosohedral shell of protein that measures 70 to 90 nm in diameter. 
Virions of AdV are comprised of 13% DNA and 87% protein (Rux & Burnett, 2004; San & 
Burnett, 2003).  Their genome is approximately 35-38 kilobases in size.   The majority of the 
viral capsid encompasses three proteins: fiber, penton base and hexon.  Fiber and penton 
base proteins are necessary for receptor binding and cell internalization, whereas hexon 
 
Viral Gene Therapy 92
proteins form most of the viral capsid.  These three proteins are also crucial targets of virus 
neutralizing antibodies. 
AdV infections are common in humans and have relatively benign sequelae. Primarily, they 
are the etiologic agents that cause upper and lower respiratory infections. However, they do 
infect other tissues such as the eyes, gastrointestinal and urinary tracts, brain, heart, kidney, 
and liver where they pose minor health risks.  Individuals with a normal immune system 
have self-limiting infections without notable clinical sequelae. Yet immunocompromised 
individuals may develop conditions more frequently associated with uncommon variants 
(i.e., group B, serotype 35). During infection, adenoviral DNA is not usually integrated into 
host cell chromosomes thereby minimizing concerns regarding insertional mutagenesis or 
potential germ line risks.  The clinical mildness of a natural AdV infection is probably 
attributed to their immunogenicity which has made these viruses popular as gene transfer 
vectors.   In spite of this positive side of their immunogenicity, these viruses without 
considerable modifications may not be useful for applications that necessitate long-term 
expression since they do not incorporate into the host genome. 
1.1 Advantages of AdV vectors 
There are several factors that contribute to the advantages of AdV-based vectors.  The 
molecular mechanisms underlying the AdV genome and its life cycle have been extensively 
studied which has facilitated molecular manipulations of the viral genome in plasmid 
form.  Only the packaging signal and the inverted terminal repeat (ITR) (approximately 
300bp) are essential to package nearly 105% of the total AdV genome.  This facilitates a 
decrease in the occurrence of replication-competent recombinants while also permitting 
introduction of a large transgene cassette (up to approx. 35kb) into the AdV 
virion.  Additional benefits include relatively simple and reliable manufacturing methods, 
high levels of expression in various replicating and non-replicating tissues even at low 
temperatures, delineation of its toxicity profile, minimized risk of genomic insertional 
mutagenesis due to its episomal persistence in the nucleus, and extensive knowledge of the 
effects pertaining to vector genome uptake following a particular route of administration.  
Also, AdV vectors have demonstrated the ability to prime and boost T- and B-cell responses 
(Pinto et al., 2003; Vemula & Mittal, 2010). Most importantly, safety has been demonstrated 
in the therapeutic application of AdV vectors in a number of clinical trials (Sharma et al., 
2009b). 
AdV vectors can be generated to express multiple proteins from various expression cassettes 
located within the genome of the AdV. Vaccine formulations that exploit the advantages of 
these AdV vectors increase the potency and reduce the prospective costs.  Also the use of 
multi-gene expression technology permits flexibility in vaccine design regarding rapid 
antigen swapping after AdV vector development. A prerequisite for such an AdV vector is 
that it must adequately express multiple antigens (Jolly et al., 2008). Finally, while some may 
view the transient nature of AdV vectors to be a disadvantage, it does have beneficial 
medical applications. AdV vectors have demonstrated therapeutic potential in treating 
various forms of cancer, infectious disease, and tissue remodeling. 
1.2 Disadvantages of AdV vectors 
Transient expression of the transgene by AdV vectors can be a disadvantage for gene 
therapy applications where continous expression of the trangene is necessary for a desired 
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therapeutic effect. Due to the promiscuous nature of AdV biodistribution following systemic 
administration, targeting of the AdV vector to only a specific cell type is a considerable 
challenge. 
AdV vectors at a very high dose could lead to significant toxicity. Expression of  
viral proteins by the AdV vector and activation of innate immunity are partially 
responsible for this in vivo toxicity. The deadly potential of AdV in vivo toxicity was 
highlighted after the intravascular delivery of an AdV to a patient enrolled in a clinical 
trial in 1999. A large dose of vector was administered into the hepatic artery of the patient 
recruited in a partial ornithine transcarbamylase (OTC) deficiency clinical trial.  This large 
dose resulted in  liver dysfunction and death due to multiple organ failure (Raper et al., 
2003). The investigators concluded that the toxicity was due to the ‘extremely high dose’ 
(3.8 x 1013 virus particles) of AdV causing a saturation of the available AdV receptors on 
hepatocytes and the subsequent spread of the vector to other organs. The patient’s death 
was thought to be due to strong activation of an innate immune response. This 
unfortunate event has led to new guidelines for the validation of new technologies.   
AdV are a common human pathogen, especially human adenovirus 5 (HAdV5); therefore, in 
vivo delivery of AdV may be hampered due to pre-existing vector immunity in the majority 
of human population.  Although low levels of vector immunity can be quelled by increasing 
the dose of administered AdV vector  without increasing toxic side effects (Pratt et al., 2010), 
the issue of pre-existing vector immunity is a cause for concern.  Challenges also exist in 
correlating the protective outcomes of the quality of T cell responses over the quantity of T 
cells that are stimulated by different immunization protocols and vector strategies.  Priming 
with some AdV vectors stimulates transgene-specific immune responses that have a low 
correlation with type I interferon (IFN) production; the reduced levels are associated with 
reduced transgene expression. Reduced IFN also hampers quality T cell responses and B cell 
differentiation into effector plasma cells. However, too much type I IFN results in clearance 
by innate effector systems and poor transgene expression.  Thus, type I IFN responses must 
be rigidly controlled to attain therapeutic efficacy (Draper & Heeney, 2010). 
2. AdV induced innate immune response 
The AdV vector-mediated acute toxicity subsequent to intravascular inoculation is known to 
be a direct result of potent activation of the innate immune system - a desirable outcome for 
the purpose of vaccine development or cancer immunotherapy (Muruve, 2004). The 
activated immune system in these scenarios also results in the induction of a stronger 
immune response against the desired antigen or cancer cells. However, this strong immune 
reaction remains an obstacle for AdV-mediated gene therapy since the danger of severe 
toxicity prevents administration of the dose necessary to achieve the desirable therapeutic 
effect. The immune system activation follows a dose-dependent pattern and is independent 
of viral gene expression. Immune system activation is manifested as severe liver 
inflammation, thrombocytopenia, and systemic flu-like symptoms such as fever and 
myalgias (Raper et al., 2002). The severe inflammatory response is also associated with poor 
target cell tranduction and loss of viral genome and transgene expression within two to 
three weeks post administration (Yang et al., 1994). 
The initial host response to AdV vectors occurs within minutes after systemic 
administration and may last from several hours to days. It is characterized by elevated 
serum levels of proinflammatory cytokines such as tumor necrosis factor- α (TNF- α), IL-
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proteins form most of the viral capsid.  These three proteins are also crucial targets of virus 
neutralizing antibodies. 
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and liver where they pose minor health risks.  Individuals with a normal immune system 
have self-limiting infections without notable clinical sequelae. Yet immunocompromised 
individuals may develop conditions more frequently associated with uncommon variants 
(i.e., group B, serotype 35). During infection, adenoviral DNA is not usually integrated into 
host cell chromosomes thereby minimizing concerns regarding insertional mutagenesis or 
potential germ line risks.  The clinical mildness of a natural AdV infection is probably 
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AdV vectors can be generated to express multiple proteins from various expression cassettes 
located within the genome of the AdV. Vaccine formulations that exploit the advantages of 
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therapeutic effect. Due to the promiscuous nature of AdV biodistribution following systemic 
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(3.8 x 1013 virus particles) of AdV causing a saturation of the available AdV receptors on 
hepatocytes and the subsequent spread of the vector to other organs. The patient’s death 
was thought to be due to strong activation of an innate immune response. This 
unfortunate event has led to new guidelines for the validation of new technologies.   
AdV are a common human pathogen, especially human adenovirus 5 (HAdV5); therefore, in 
vivo delivery of AdV may be hampered due to pre-existing vector immunity in the majority 
of human population.  Although low levels of vector immunity can be quelled by increasing 
the dose of administered AdV vector  without increasing toxic side effects (Pratt et al., 2010), 
the issue of pre-existing vector immunity is a cause for concern.  Challenges also exist in 
correlating the protective outcomes of the quality of T cell responses over the quantity of T 
cells that are stimulated by different immunization protocols and vector strategies.  Priming 
with some AdV vectors stimulates transgene-specific immune responses that have a low 
correlation with type I interferon (IFN) production; the reduced levels are associated with 
reduced transgene expression. Reduced IFN also hampers quality T cell responses and B cell 
differentiation into effector plasma cells. However, too much type I IFN results in clearance 
by innate effector systems and poor transgene expression.  Thus, type I IFN responses must 
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The AdV vector-mediated acute toxicity subsequent to intravascular inoculation is known to 
be a direct result of potent activation of the innate immune system - a desirable outcome for 
the purpose of vaccine development or cancer immunotherapy (Muruve, 2004). The 
activated immune system in these scenarios also results in the induction of a stronger 
immune response against the desired antigen or cancer cells. However, this strong immune 
reaction remains an obstacle for AdV-mediated gene therapy since the danger of severe 
toxicity prevents administration of the dose necessary to achieve the desirable therapeutic 
effect. The immune system activation follows a dose-dependent pattern and is independent 
of viral gene expression. Immune system activation is manifested as severe liver 
inflammation, thrombocytopenia, and systemic flu-like symptoms such as fever and 
myalgias (Raper et al., 2002). The severe inflammatory response is also associated with poor 
target cell tranduction and loss of viral genome and transgene expression within two to 
three weeks post administration (Yang et al., 1994). 
The initial host response to AdV vectors occurs within minutes after systemic 
administration and may last from several hours to days. It is characterized by elevated 
serum levels of proinflammatory cytokines such as tumor necrosis factor- α (TNF- α), IL-
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6, IL-1β, IFN-γ, and chemokines such as macrophage inhibitory protein (MIP)-2, IFN-γ 
inducible protein 10 (IP-10), RANTES, MIP-1α, MIP-1β and monocyte chemoattaractant 
protein 1 ((MCP-1) (Muruve et al., 2004). Induction of inflammatory response to viral 
pathogens proceeds through opsonization, uptake of opsonized viral particles, antigen 
processing and presentation, and, finally, the release of inflammatory cytokines. Likewise, 
high doses of systemically administered AdV vectors result in activation of splenic 
dendritic cells (DCs) and macrophages inducing the production of inflammatory 
cytokines such as IL-6, IL-12 and TNF-α. Depletion of tissue macrophages and DCs 
prevents the production of the aforementioned cytokines, indicating a central role of these 
innate effectors in the acute inflammatory response (Kuzmin et al., 1997; Lieber et al., 
1997; Zhang et al., 2001). Recently, an in vitro study using co-culture of epithelial cells and 
macrophages demonstrated the dependence of AdV-induced inflammatory response on 
the activation of macrophages through interactions with epithelial cells where the 
activation was mediated by NF-κB. AdV infection of the co-culture resulted in 
cytotoxicity, expression of inflammatory cytokines and chemokines, NOS and ROS 
generation and activation of inflammatory transcription factors (Lee et al., 2010).  
However, the nature of macrophage and epithelial cell interaction and their implications 
during AdV infection in vivo remain to be elucidated.  
Neutrophils also seem to play an important role in AdV-induced acute inflammation. The 
chemokines, MCP-1, RANTES and MIP-1β, upregulate the neutrophil chemoattaractant 
chemokine MIP-2 which then recruits neutrophils to the liver. Recruitment of neutrophils 
and rapid induction of C-C and C-X-C chemokines correlates with acute liver injury and 
histopathological changes (Muruve et al., 1999). Moreover, AdV vectors are shown to 
activate endothelium in post-sinusoidal venules and promote P and E selectin-mediated 
rolling. This is followed by adhesion mediated through interactions between α4-integrin 
on the neutrophil surface and vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
cells (Li et al., 2002). Blocking of either leukocyte rolling and adhesion or neutrophil 
depletion results in lower expression of the proinflammatory gene expression implying a 
central role of neutrophils in AdV-induced liver inflammation (Liu et al., 2003b). The 
neutrophils are recruited to the liver where they take up AdV particles in a complement 
receptor 1 (CR1)- and Fc receptor-dependent manner sequestering the AdV particles away 
from target cells (Cotter et al., 2005). How the neutrophil sequestration of AdV particles 
affects the vector-induced innate immune response calls for further exploration. Although 
other types of leukocytes such as monocytes and macrophages are also recruited to the 
liver, neutrophils constitute more than 70% of the total leukocytes in the liver following 
systemic AdV administration. 
Natural killer (NK) cells are another cell type activated and populated to the liver following 
AdV infection and are directly associated with liver injury. Type 1 IFNs, produced in 
response to viral infection, promote activation of NK cells which mediate clearance of AdV 
genome and lowers transgene expression. Pre-treatment with anti-NK cells antibodies 
enhances AdV genome persistence, prolongs transgene expression and dampens the innate 
immune-mediated liver injury (Liu et al., 2003a; Zhu et al., 2007). A very interesting strategy 
to mitigate the impact of AdV-induced innate immune response would be to transiently 
remove the effector cells of the innate immune system, such as neutrophil and NK cells. 
Alternatively, in the light of evidence of IFN-γ-mediated NK cell activation, transient 
suppression of type 1 IFN response prior to AdV administration might also be beneficial 
(Zhu et al., 2007). 
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Several studies in the recent past have focused on delineating the molecular mechanisms 
governing AdV-mediated activation of the innate immune system. This system, being the 
first line of defense against invading pathogens, has evolved a highly conserved repertoire 
of ‘pattern recognition receptors (PRRs)’ which specifically identify ‘pathogen-associated 
molecular patterns (PAMPs)’ (Kumar et al., 2009). A variety of PRRs, including Toll-like 
receptors (TLRs), RIG-1-like receptors (RLRs) and Nod-like receptors (NLRs), are employed 
for the recognition of all types of pathogens ranging from bacteria, fungi, viruses and 
protozoa.  
2.1 Role of TLR signaling in AdV-induced innate immune response 
Depending on the cell type, the sensing of AdV by innate immune response is mediated by 
both TLR-dependent and independent pathways and appears to be very complex 
(Appledorn et al., 2008b; Cerullo et al., 2007; Nociari et al., 2007; Zhu et al., 2007).  Among 
the members of the TLR family, four are known to recognize viral nucleic acids: TLR3 
(dsRNA), TLR7, TLR8 (ssRNA) and TLR9 (dsDNA). The myeloid differentiation primary 
response gene 88 (MyD88), a TLR Adaptor protein for downstream activation of  signaling 
cascades such as MAPK and NF-κB pathways, is necessary to initiate an AdV-induced 
proinflammatory cytokine and chemokine response (Hartman et al., 2007a; Hartman et al., 
2007b). TLR9 is spatially and temporally co-localized with AdV as it is expressed in 
endosomes and is specifically upregulated during AdV infection. As a result, it effectively 
recognizes unmethylated CpG motifs in dsDNA released after proteolytic degradation of 
AdV particles within endosomes and initiates a signaling cascade through MyD88 in 
plasmacytoid DCs (pDCs).  This culminates with their maturation and the production of 
high levels of type 1 IFNs as witnessed during AdV infection. The type 1 IFN production in 
pDCs is TLR9/MyD88-dependent, as opposed to non-pDCs which recognize AdV DNA 
through a cytosolic sensor different from TLR9.  Significant amounts of type 1 IFNs are 
produced with an AdV infection. In addition to the activation of NK cells, the type 1 IFNs 
play a crucial role in the AdV-mediated activation of innate immune response by enhancing 
production of proinflammatory cytokines IL-6 and IL-12 (Zhu et al., 2007). TLR2 also plays a 
crucial role regulating AdV-induced innate immune response by mediating the rapid 
activation of MAPK and NF-kB pathways which are linked to induction of inflammatory 
cytokine and chemokine gene expression. Specifically, TLR2 is required for sustained late 
phase induction of these pathways; initial activation is TLR2 independent (Appledorn et al., 
2008b; Tibbles et al., 2002).  
The induction of chemokines MCP-1 and RANTES depends solely on TLR-9 within one 
hour post-infection (hpi), but relies on both TLR2 and TLR9 at eight hpi. Collectively, 
TLR2 and TLR9 play crucial roles through the differential induction of cytokines and 
chemokines. However, the induction of chemokines independent of both TLR2 and TLR9, 
was discovered to be MyD88-dependent at beth early and late time points suggesting the 
involvement of different MyD88- dependent sensors in the full spectrum induction of 
innate immune response (Appledorn et al., 2008b). 
As noted above, AdV infection of non-pDCs such as conventional DCs (cDCs), macrophages 
and fibroblasts stimulates production of significant amounts of type 1 IFNs, 
proinflammatory cytokines and chemokines through phosphorylation of interferon 
regulatory factor (IRF)-3. The activation of IRF-3 occurs as a result of the recognition of AdV 
DNA by a yet unidentified cytosolic DNA sensor which promotes phosphorylation of IRF-3. 
The phosphorylation initiates IRF-3 dimerization and translocation to the nucleus where it 
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neutrophils are recruited to the liver where they take up AdV particles in a complement 
receptor 1 (CR1)- and Fc receptor-dependent manner sequestering the AdV particles away 
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systemic AdV administration. 
Natural killer (NK) cells are another cell type activated and populated to the liver following 
AdV infection and are directly associated with liver injury. Type 1 IFNs, produced in 
response to viral infection, promote activation of NK cells which mediate clearance of AdV 
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DNA by a yet unidentified cytosolic DNA sensor which promotes phosphorylation of IRF-3. 
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causes transcriptional activation of several IRF-3 responsive inflammatory cytokine and 
chemokine genes (Hiscott, 2007; Nociari et al., 2007). However, AdV vectors can also induce 
IRF-3 phosphorylation directly through the capsid-cell membrane interactions prior to the 
endosomal escape of viral DNA, thereby providing an additional IRF-3 activation signal for 
stronger IFN and inflammatory response (Nociari et al., 2009).  Evidently, AdV infection 
induces type 1 IFN response through multiple pathways and, therefore, causes a very strong 
activation of IFN responsive genes which might explain the powerful induction of innate 
immune response following AdV infection. 
The NALP3 protein, a type of Nod-like receptor, plays an important role in cytosolic sensing 
of AdV DNA and the subsequent induction of proinflammatory IL-1β response. However, 
NALP3 is a general sensor for any kind of dsDNA including viral, bacterial, or even host 
(mammalian DNA) (Martinon et al., 2009). AdV DNA was shown in vitro to activate NALP3 
signaling events through apoptosis-associated speck-like protein containing caspase 
recruitment domain (ASC), the adaptor protein for NALP3, resulting in the recruitment of 
the inflammatory caspase-1 into the molecular complex called the inflammasome which 
activates caspase-1. The activated caspase-1 initiates the proteolytic cleavage of pro-IL-1β 
into an active and secreted form of IL-1β. A similar response was detected upon infection 
with first generation AdV vectors, helper-dependent (HD) AdV vectors, and by transfecting 
cells with AdV DNA implying that the nature of DNA did not affect inflammasome 
activation.  However, empty capsids failed to elicit a similar response suggesting that mere 
internalization of the capsid proteins was not enough for the inflammatory response. 
Furthermore, NALP-, ASC- and caspase-1-deficient mice systemically injected with AdV 
vectors developed only a blunted inflammatory response in the liver and showed a 
remarkable reduction in the expression of NF-kB regulated pro-inflammatory genes 
confirming the role of NALP3 and inflammasome in AdV-induced innate immune response 
(Muruve et al., 2008).  Furthermore, recognition of AdV DNA through endosomally 
expressed TLR9 upregulated expression of NALP3, ASC and pro-IL-1β thereby tuning the 
cellular environment for a stronger IL-1β response.(Barlan et al., 2011) 
2.2 AdV interactions with blood factors 
In addition to immune responses, successful gene therapy will depend on organ specific 
delivery and an adequate expression level of the gene of interest. Following intravascular 
delivery, AdV vectors first come in contact with blood and its components. Considering the 
diverse cell types and myriad of proteins with roles in processes as complex as immune 
response, coagulation, cell signaling and others, it is not surprising that interactions between 
AdV vectors and blood components are pivotal in shaping the biodistribution profile of 
intravascularly delivered AdV and, also, the complexity of the ensuing host immune 
response (Parker et al., 2008). Therefore, a thorough understanding of AdV and blood factor 
interactions is advantageous in devising novel strategies to preclude deleterious interactions 
and to efficiently target vector delivery to the organ. 
Based on in vitro experiments, the classical pathway for AdV internalization involves a 
primary interaction of fiber knob domain with Coxsackievirus and adenovirus receptor 
(CAR) resulting in viral attachment to cell surface, followed by a secondary interaction of 
the RGD motif on a penton base with integrins promoting internalization of the attached 
virus via receptor-mediated endocytosis. However, the in vivo biodistribution pattern cannot 
be attributed to knob-CAR interaction alone since CAR follows a ubiquitous expression 
profile, whereas the majority of intravascularly delivered AdV is sequestered primarily in 
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the liver. Further, HAdV5 vectors modified by inserting retargeting peptides and ablated for 
CAR binding fail to efficiently retarget to intended sites (Nicklin et al., 2005). These 
observations suggest involvement of CAR-independent pathways of cellular transduction in 
vivo by AdV. Heparan sulfate proteoglycans (HSPG) and LDL receptor-related proteins 
(LRP) were identified as alternative receptors for AdV transduction of liver cells. Initially, 
the blood coagulation factor IX and complement factor C4BP were shown to bind to HAdV5 
and HAdV35 fiber knobs and bridge them to HSPG and LRP, thereby providing a ‘CAR-
independent’ pathway of AdV infection in vivo.  
Transduction of Kupffer cells which sequester the majority of the AdV transducing the liver is 
CAR-independent; hepatocytes rely on CAR-dependent, as well as CAR-independent, 
pathways for AdV uptake (Shayakhmetov et al., 2005).  Consequently, abrogation of the factor 
IX- and factor C4BP-mediated AdV transduction can be an effective strategy for precluding 
AdV sequestration in Kupffer cells which contributes significantly to a proinflammatory 
cytokine and chemokine response to systemic administration of AdV vectors (Lieber et al., 
1997; Manickan et al., 2006). Preventing Kupffer cell transduction can simultaneously provide 
dual benefits for effective liver gene therapy by mitigating the innate immune response and 
enhancing hepatocyte transduction through greater bioavailability of the vector.  
The Vitamin K-dependent blood coagulation factors FVIII, FIX, FX and protein C also appear 
to play crucial roles in hepatocyte transduction through interactions with the HAdV5 viral 
capsid. Of note, these coagulation factors contain a conserved domain with an identical, 
defined structure comprising of a γ-carboxyglutamate (Gla)-EGF-1-EGF-2-serine protease 
domain which supposedly arose due to gene duplication. All of these factors significantly 
enhance hepatocyte transduction in vitro with factors FX and protein C being more efficient 
than factors FVIII and FIX through mediating interactions between the capsid, and the 
alternate AdV receptors, HSPGs and LRP. Interestingly, the factors did not exert an additive 
effect on transduction as they all seem to bind at a common site on the capsid and, therefore, 
might have an overlapping role in mediating AdV entry. Depletion of vitamin K-dependent 
blood coagulation factors in mice through warfarin treatment prior to intravascular AdV 
administration resulted in a remarkable reduction in hepatocyte transduction. This effect could 
be reversed by restoring physiological levels of factor FX just prior to AdV inoculation (Parker 
et al., 2006). The relevance of factor FX - hexon interaction to AdV vector biology is justified by 
swapping the hypervariable regions (HVRs) of HAdV5 with those from HAdV48, a non-factor 
FX-binding serotype, which absolutely abrogates the interaction and also decreases the 
hepatocyte transduction by more than 150-fold. The interaction between factor FX and the 
capsid hexon is calcium-dependent and mediated by the (Gla)-EGF1 domain of factor FX and 
the HVRs of hexons. No other capsid proteins play any role in the factor FX-capsid interaction. 
Furthermore, the hexon from all human AdV serotypes does not bind factor FX equally; 
serotypes 5, 2, 50 and 16 show strong binding, while serotypes 35 and 3 show weak binding, 
and serotypes 26 and 48 show no binding (Waddington et al., 2008). Construction of hexon 
swapped AdV vectors should be performed accordingly, keeping in mind the factor FX 
binding ability of the serotype and the intended clinical use of the vector. While constructing 
AdV vectors targeted to specific sites, tissue-specific fiber modifications must be accompanied 
by appropriate hexon HVR modifications large enough to ablate factor FX binding yet small 
enough to allow the chimeric virus rescue.  
A recent study suggested that AdV sequestration in the liver is a collective result of a defined 
set of molecular mechanisms occurring in a redundant, sequential and synergistic pathway (Di 
Paolo et al., 2009). In addition to the trapping of intravascular AdV by Kupffer cells and 
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stronger IFN and inflammatory response (Nociari et al., 2009).  Evidently, AdV infection 
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activates caspase-1. The activated caspase-1 initiates the proteolytic cleavage of pro-IL-1β 
into an active and secreted form of IL-1β. A similar response was detected upon infection 
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virus via receptor-mediated endocytosis. However, the in vivo biodistribution pattern cannot 
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profile, whereas the majority of intravascularly delivered AdV is sequestered primarily in 
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the liver. Further, HAdV5 vectors modified by inserting retargeting peptides and ablated for 
CAR binding fail to efficiently retarget to intended sites (Nicklin et al., 2005). These 
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vivo by AdV. Heparan sulfate proteoglycans (HSPG) and LDL receptor-related proteins 
(LRP) were identified as alternative receptors for AdV transduction of liver cells. Initially, 
the blood coagulation factor IX and complement factor C4BP were shown to bind to HAdV5 
and HAdV35 fiber knobs and bridge them to HSPG and LRP, thereby providing a ‘CAR-
independent’ pathway of AdV infection in vivo.  
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pathways for AdV uptake (Shayakhmetov et al., 2005).  Consequently, abrogation of the factor 
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and serotypes 26 and 48 show no binding (Waddington et al., 2008). Construction of hexon 
swapped AdV vectors should be performed accordingly, keeping in mind the factor FX 
binding ability of the serotype and the intended clinical use of the vector. While constructing 
AdV vectors targeted to specific sites, tissue-specific fiber modifications must be accompanied 
by appropriate hexon HVR modifications large enough to ablate factor FX binding yet small 
enough to allow the chimeric virus rescue.  
A recent study suggested that AdV sequestration in the liver is a collective result of a defined 
set of molecular mechanisms occurring in a redundant, sequential and synergistic pathway (Di 
Paolo et al., 2009). In addition to the trapping of intravascular AdV by Kupffer cells and 
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hepatocytes through interactions with blood factors, the AdV penton base-β3-integrin 
interaction becomes predominant in the absence of other virus clearance mechanisms. 
Combined treatment with chlodronate liposomes and warfarin removes Kupffer cells and 
inactivates vitamin K-dependent blood factor, prevents AdV entry into Kupffer cells and 
hepatocytes, and, therefore, might force AdV to accumulate in the liver sinusoidal space.  Here 
the interaction between penton base RGD motif and β3-integrin may promote AdV uptake by 
sinusoidal endothelial cells (Di Paolo et al., 2009). These observations led to the proposal of a 
three step, dose-dependent model of AdV sequestration in the liver. At low doses, Kupffer 
cells are the primary niche for AdV retained in the liver. When the dose is higher and exceeds 
Kupffer cell capacity, the excess AdV enter hepatocytes in a blood factor-dependent manner. 
At an even higher dose, both Kupffer cells and hepatocytes become fully loaded, and AdV 
start entering sinusoidal epithelial cells. Following these principles, complete elimination of  
liver retention of systemically delivered AdV through simultaneous blocking of all three 
mechanisms might enhance the bioavailability of AdV vectors for gene therapy applications of 
extrahepatic organs and preclude induction of innate immune-mediated hepatotoxicity from 
reaching dangerous levels. 
3. Adaptive immune responses to AdV vectors  
AdV vector-mediated transduction in vivo results in efficient but transient transgene 
expression in various organs with the exception of those in newborn, immunocompromised 
or immunodeficient animals. The loss of transgene expression is attributed to a low basal 
level expression of AdV proteins despite the absence of E1A and E1B (Yang et al., 1994). 
Apart from induction of a strong innate immune response, AdV vectors also elicit adaptive 
immune responses directed towards the capsid components. The induction of adaptive 
immunity is profoundly influenced by the activated innate immune response (Descamps & 
Benihoud, 2009). The AdV-specific cellular immune response is induced through the uptake 
of AdV particles by antigen-presenting cells such as macrophages and DCs and the 
presentation of peptides derived from capsid proteins through MHC class I and class II 
pathways. Subsequently, the CTLs recognize and destroy the host cells displaying AdV-
specific peptides, thereby leading to diminished transgene expression in immunocompetent 
hosts (Schagen et al., 2004). Macrophages also play a role in transporting AdV to draining 
lymph nodes, where AdV-specific B lymphocytes are activated resulting in an AdV-specific 
humoral immune response comprising of anti-AdV antibodies directed against capsid 
proteins (Junt et al., 2007).  
The HD-AdV vectors, due to a lack of all viral genes, effectively remain unseen by the 
immune system and consequently cause a severely attenuated adaptive immune response. 
However, a transgene-specific immune response can be induced causing elimination of the 
host cells expressing the target protein in addition to antibody-mediated clearance of 
secreted target protein from circulation. The problem of anti-transgene immunity is unique 
and no less confounding than vector-associated primary complications since immunity may 
vary with the nature of transgene, animal model or even individual (Brown et al., 2004). On 
the positive side, HD-AdV vector-based gene therapy studies in various mouse and rat 
models of diseases such as diabetes, hemophilia, familial hypercholesterolemia, ornithine 
transcarbamylase deficiency, and Crigler Najjar syndrome produced favorable results 
through long-term phenotypic correction implying transgene-specific immunity may not be 
a significant hindrance (Seiler et al., 2007).  
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3.1 Significance of pre-existing vector immunity 
More than 80% of the human population has been exposed to one or more serotypes among 
over fifty different serotypes of human AdV (Harvey et al., 1999; Xiang et al., 2006). The 
adjuvant effect of AdV results in development of strong anti-viral humoral and cellular 
immune responses in the pre-exposed individuals. These neutralizing antibodies are 
serotype-specific and are directed toward the viral capsid proteins.  Similarly, the AdV-
specific CD8+ T cells against both viral structural and non-structural proteins as well as the 
transgene will eliminate AdV-transduced cells (Tang et al., 2006). In the absence of pre-
existing immunity, re-administration of homologous vector mimics vector administration in 
the presence of pre-existing immunity. Therefore, first and second generation AdV vectors 
are not suitable for correction of disorders requiring multiple vector inoculations and are 
limited to only those applications requiring short-term transgene expression or 
circumvention of vector immunity, either natural or induced. The presence of anti-AdV 
antibodies also enhances AdV uptake by DCs and macrophages via interaction with the Fc-
receptor (FcR), but without a consequent increase in transgene expression. Pre-
immunization with homologous vectors has been shown to exacerbate vector-induced 
hepatotoxicity and increase mortality rates (Vlachaki et al., 2002) which might be the 
indirect consequences of stronger innate immune activation.  
4. Evolution of AdV vector systems 
Despite early observations, it took several years following the advent of recombinant 
technology before the therapeutic potential of AdV was truly realized.   The first 
generation AdV vectors (FGAdV) have a deleted early region (E) 1 (E1).  The E1 region 
has two subunits E1A and E1B (Dormond et al., 2009).  E1A deletions impair vector 
replication, down regulate transactivation of other early units, and deregulate cell cycle 
controls.  However, this deletion does permit transgene expression capacity up to 
5kb.  E1B primarily inhibits apoptotic cell signaling.  Most of these vectors also have a 
deletion in E3, which does not hinder in vitro growth but adds 3kb worth of transgene 
capacity. The different types of AdV vectors are described below and illustrated in  
Figure 1. 
The Frank Graham Laboratory in 1977 developed a human embryonic kidney-derived 293 
cell line that expresses the E1 gene products in trans thereby enabling the production of the 
first recombinant AdV (rAdV) in a helper-free environment (Graham et al., 1977). The 293 
cell line used in vector manufacturing has nucleotides 1-4344 of the left end of the AdV 
genome which provides considerable overlap in the sequences with conventional 
vectors.  These overlapping sequences within the cell promote homologous recombination 
between the vector and the AdV sequences which can generate replication-competent AdV 
(RCAdV) recombinants during the process of amplification.   
Currently, the FDA has ruled that there must be less than one RCA per 3 x 1010 vector 
particles (Jolly et al., 2008). New cell lines, such as PER.C6 (Fallaux et al., 1998) and SL0036 
(Howe et al., 2006), have been developed which abrogate sequence overlap and reduce 
RCAdV occurrence.  Another method to diminish sequence overlap and reduce RCAdV risk 
has been to transfer a protein encoding gene into the cell genome which encodes for pIX, a 
minor AdV capsid protein (Hehir et al., 1996). The introduction of stuffer DNA into the E3 
region is an additional method which increases the FGAdV DNA size but renders the 
system unpackageable in E1-recombined viral DNA progeny. 
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Fig. 1. Representative Diagram of the wild type AdV genome and different deletions in the 
various AdV vector constructs. E1 - E4: early transcription regions; L1 - L5: late transcription 
regions; ITRs: inverted terminal repeats; ψ: packaging signal; mE1: mutated E1;  
TSP: tumor-specific promoter. 
In order to reduce the in vivo toxicity associated with the FGAdV, the second generation 
AdV vectors (SGAdV) were developed with additional deletions in their vector 
constructs.  The initial E1 or E1/E3 deletions are supplemented with full or partial deletions 
in E2 and/or E4.  Complementing cell lines are designed to constitutively express the 
matching E2/E4 region, but isolating these cell lines is a time-consuming process.  The 
propagation of these vector constructs is less likely to generate RCAdV but will also have a 
lower yield.  Although production possesses its own problems, it ultimately limits effects on 
immunogenicity resulting in the loss of interest for these multiple regions-deleted vectors 
(Lusky et al., 1998; Morral et al., 2002; O'Neal et al., 1998).  Ultimately, long term expression 
and added safety were not attained with SGAdV (Dormond et al., 2009). 
The further deletions of viral encoding genes that were gradually introduced to address safety 
concerns gave rise to the third generation AdV vectors (TGAdV).  TGAdV lack all non-
essential viral sequences.  The TGAdV or helper-dependent AdV (HD-AdV) rely on helper-
dependent systems in order to be generated.  Along with the packaging signals, the inverted 
terminal repeats (ITRs) of AdV are required in cis to initiate replication (Grable & Hearing, 
1992). Non-coding stuffer DNA is introduced into the 36kb of space that is available for 
transgene insertion.  Helper functions are furnished by FGAdV which are also referred to as 
helper AdV.  Initially, this class of AdV yielded a low number of TGAdV and a high level of 
contamination from helper AdV (Kochanek, 1999; Mitani et al., 1995). The purification of 
TGAdV from FGAdV by density gradient is a difficult task (Kumar-Singh & Chamberlain, 
1996; Mitani et al., 1995; Parks & Graham, 1997). To facilitate better separation, the size of 
TGAdV should not exceed 32 kb which permits a better separation from the 36 kb FGAdV.   
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A recombinase system has been introduced into the TGAdV platform in order to reduce 
the amount of contamination (Hardy et al., 1997; Lieber et al., 1996; Parks et al., 
1996).  Adding a recombinase recognition site next to the packaging signal of the helper 
AdV yields an unpackageable FGAdV while co-infecting into HEK293 cells that 
constitutively express the respective recombinase.  Currently, three recombinase systems 
have been employed:  (1) Cre/LoxP, (2) FLP/frt and (3) C31/attB-attP (Alba et al., 2007; 
Ng et al., 2001; Umana et al., 2001).  The two latter systems possess similar potential for 
the removal of FGAdV (Ng et al., 2001; Umana et al., 2001). Certain sequences on the 
TGAdV genome influence the yield.  The stuffer DNA that is selected is of non-coding 
human DNA origin with minimized repeating sequences (Parks et al., 1999; Sandig et al., 
2000; Schiedner et al., 2002). A promoter in the E4 region has provided amplification 
enhancement to TGAdV (Sandig et al., 2000). Additional amplification has been 
accomplished by the strategic development of FGAdV (Zhou et al., 2002). Sequence 
homology between packaging signals of the FGAdV and TGAdV should be avoided in 
order to limit the recombination events (Hardy et al., 1997; Sandig et al., 2000).  
Complementary cell lines used in the production of TGAdV were derived from those that 
produce FGAdV and SGAdV.  Furthermore, these cell lines express the respective 
recombinase enzyme such as Cre, FLP, or C31 (Alba et al., 2007; Ng et al., 2001; Umana et al., 
2001). Generating competent cell lines that amplify TGAdV, while limiting FGAdV 
contamination has been difficult.  Investigators have demonstrated that FGAdV 
contamination is due to the AdV-mediated shutoff of the host cell (Hartigan-O'Connor et al., 
2002). The appearance of RCAs in TGAdV preparations has been attributed to a low level of 
FGAdV serving as helper AdV.  Yet, production methods that necessitate that two viral 
constructs be present during serial passages increases the incidence of RCA.  The use of 
PERC.6, a cell line which minimizes homology (Sakhuja et al., 2003), and the addition of 
stuffer DNA into the E3 region of FGAdV DNA (Parks et al., 1996) which limits 
encapsidation are useful solutions to minimizing RCAs. 
Some AdV constructs have been changed to focus on the targeting potential instead of 
deleting multiple regions. Various methods are based on the rationale of expanding the 
otherwise limited tropism of the AdV while also reducing the potential toxicity seen in non-
target tissue during over expression thereby improving the odds for systemic 
delivery.  There are two approaches used in targeting:  the modification of the virion to 
specifically transduce targeted cells or the use of gene regulation to restrict transgene 
expression to desired tissues.  Tissue restriction modifications can be accomplished by 
genetically modifying the fiber-knob structure or through the covalent binding of a 
“bridging” molecule to the virion (Fattori et al., 2006; Folgori et al., 2006; Gherardi et al., 
2003; Heeney et al., 2000; Lemckert et al., 2005; Liu et al., 2009; Shiver et al., 2002; Yu et al., 
2008). Modification possibilities are limitless and range from the addition of de novo 
peptides or fiber-knob hybrids that combine other human and nonhuman AdV to 
exploitation of common receptor-ligand interactions to variations in RGD or similar motifs 
(Jolly et al., 2008). The bridging molecule method is advantageous since multiple antibodies 
and ligands can be implemented to form bispecific (target and AdV) bridges between the 
vector and the target cell type.  Despite the advantages, each bispecific molecule and virion 
combination will possess unique effects, distribution, and toxicity profiles which will have 
to be defined both individually and as a constituent of a biological complex used in clinical 
data for drug trials. Retargeted or unique serotype vectors may prove efficacious in 
bypassing anti-vector immunity which could otherwise disturb transgene delivery used in 
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Fig. 1. Representative Diagram of the wild type AdV genome and different deletions in the 
various AdV vector constructs. E1 - E4: early transcription regions; L1 - L5: late transcription 
regions; ITRs: inverted terminal repeats; ψ: packaging signal; mE1: mutated E1;  
TSP: tumor-specific promoter. 
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in E2 and/or E4.  Complementing cell lines are designed to constitutively express the 
matching E2/E4 region, but isolating these cell lines is a time-consuming process.  The 
propagation of these vector constructs is less likely to generate RCAdV but will also have a 
lower yield.  Although production possesses its own problems, it ultimately limits effects on 
immunogenicity resulting in the loss of interest for these multiple regions-deleted vectors 
(Lusky et al., 1998; Morral et al., 2002; O'Neal et al., 1998).  Ultimately, long term expression 
and added safety were not attained with SGAdV (Dormond et al., 2009). 
The further deletions of viral encoding genes that were gradually introduced to address safety 
concerns gave rise to the third generation AdV vectors (TGAdV).  TGAdV lack all non-
essential viral sequences.  The TGAdV or helper-dependent AdV (HD-AdV) rely on helper-
dependent systems in order to be generated.  Along with the packaging signals, the inverted 
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2008). Modification possibilities are limitless and range from the addition of de novo 
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exploitation of common receptor-ligand interactions to variations in RGD or similar motifs 
(Jolly et al., 2008). The bridging molecule method is advantageous since multiple antibodies 
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data for drug trials. Retargeted or unique serotype vectors may prove efficacious in 
bypassing anti-vector immunity which could otherwise disturb transgene delivery used in 
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vaccine applications.  Promising preclinical data with canine and nonhuman primate AdV 
exists (Alejo et al., 2006; Beveridge et al., 2007; McElrath et al., 2008). 
Transcriptional targeting is achieved by placing a gene of interest under the control of a 
tissue- or tumor-specific promoter.  This construct possesses potential for desired long term 
gene expression especially when small levels of expression in nontargeted cells can 
significantly impact potency or toxicity.  One of the first constructs implemented in a human 
lung cancer cell line used the carcinoembryonic antigen promoter (CEA) to drive expression 
of the thymidine kinase gene derived from the herpes simplex virus (Liu et al., 2008a).  
Other promoters have been used which possess similar efficacy while simultaneously 
reducing the vector toxicity (Geiben-Lynn et al., 2008; Jego et al., 2003).  
Conditionally replicating AdV vectors (CRAdV) have been implemented in cancer 
therapeutics because lysis of solid tumor masses requires a replicating vector in order to 
penetrate and spread through the tumor cells (Everts & van der Poel, 2005). The first class of 
deletion mutant CRAdV was designed so that a portion of E1 remains intact. Either E1A or 
E1B are mutated in order to confer replicative capacity only in human tumor cells which 
possess an impaired retinoblastoma tumor suppressor (Rb) or p53 gene.  The second class of 
CRAdV possesses a tissue specific promoter upstream of E1A which restricts replication 
only in the target cells.  Class 1 and 2 CRAdV have been adequately produced in E1-
containing cell lines.  RCAdV-preventing cell lines such as HeLA or A549 have also been 
implemented in CRAdV production (Longley et al., 2005; Yuk et al., 2004). 
5. AdV vectors as a gene therapy tool 
One of the important applications of gene therapy is the treatment of patients with monogenic 
recessive disorders by delivery of the mutated or non-functional gene. Hemophilia, cystic 
fibrosis and muscular dystrophies are some of the several thousand inherited disorders that 
can, in principle, be corrected by gene therapy. The various techniques used for delivery of 
therapeutic genes include viral vectors, physical methods, chemical methods and naked 
nucleic acids.  A successful gene therapy program requires an efficient gene delivery system 
and targeting of a specific cell type without dissemination of the therapeutic gene to other cells 
thereby allowing longer persistence and adequate expression of the replaced gene. In the case 
of viral vectors, the host immune response may become a significant barrier to gene delivery 
and impede the overall success of the gene therapy effort.   
AdV-based vectors were initially thought to be very promising candidates for gene therapy 
applications for genetic disorders. However, the progress of AdV vectors have been 
hampered by vector immunity and the toxicity induced by AdV vectors following systemic 
administration. The pre-existing anti-AdV neutralizing antibodies in the majority of the 
human population induced following natural exposure to AdV clears the AdV vectors soon 
after systemic administration. In the absence of pre-existing anti-AdV antibodies, the AdV 
vectors persist longer following initial inoculation. Repeated administration results in 
development of a neutralizing antibody response similar to natural infection preventing 
subsequent inoculations with the same vector from being effective.  
The death of the patient in the ornithine transcarbamylase (OTC) clinical trial (Raper et al., 
2003) and the results of several subsequent pre-clinical trials shifted the focus of AdV 
research towards the molecular mechanisms underlying AdV-induced innate immune 
pathways leading to development of AdV vectors, such as HD-AdV vectors, particularly 
suited for gene therapy applications. These HD-AdV vectors, due to the deletion of most of 
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the viral genome, can accommodate inserts as large as 36 Kb, making them the vector of 
choice for delivering very large genes, multiple genes or ta tissue-specific regulatory 
promoter which may be very long (Shi et al., 2002; Shi et al., 2006). The host cells transduced 
by HD-AdV vectors do not express the viral proteins and, therefore, cells carrying HD-AdV 
are not recognized by the host immune system resulting in longer persistence and transgene 
expression. 
5.1 HD-AdV for liver gene therapy 
The liver is the most affected organ in several genetic diseases including Crigler-Najjar 
syndrome and OTC deficiency. HD-AdV vectors have shown tremendous promise for liver 
directed gene therapy in several pre-clinical studies in small and large animal models.   
Their abilities to support long-term transgene expression, low chronic toxicity, natural  
liver tropism of AdV vectors and the fenestrated structure of liver endothelium  
allowing efficient hepatocyte transduction are the main factors (Brunetti-Pierri et al., 2008; 
Dimmock et al., 2011; Toietta et al., 2005). HD-AdV vectors were shown to be very effective 
for liver gene therapy in Gunn rats, the animal model for Crigler-Najjar syndrome. A single 
injection of a HD-AdV vector expressing uridine diphospho-glucuronosyl transferase 1A1 
(UGT1A) was sufficient to induce life-long normalization of hyperbilirubinemia (Toietta et 
al., 2005). Similarly, an HD-AdV vector expressing canine glycogen-6-phosphatase was able 
to correct the hypoglycemia and prolong survival up to seven months in a mouse model of 
glycogen storage disease type 1 (Koeberl et al., 2007). Results of several other studies have 
supported the clinical utility of HD-AdV vectors in the gene therapy of liver diseases 
(Brunetti-Pierri et al., 2008; Gau et al., 2009; Hu et al., 2011; McCormack, Jr. et al., 2006; Oka 
et al., 2007). 
However, the prospects of liver directed gene therapy using HD-AdV vectors are hampered 
by the high vector doses necessary to result in efficient hepatocyte transduction. Such high 
doses may not be clinically relevant for human use. A non-linear relation is observed between 
the vector dose and hepatocyte transduction; at low doses, there is very little to undetectable 
transgene expression, yet there are disproportionately high levels of transgene expression 
when vector dose is increased (Morral et al., 2002; Sullivan et al., 1997) with the Kupffer cells 
sequestering more than 85% of the intravascularly administered AdV vectors. AdV vectors 
also associate with platelets, red blood cells and other binding components in circulation 
resulting in eventual elimination of the vector. Sequestration by Kupffer cells and binding to 
the blood components determines the ‘threshold dose’ which must be administered for 
efficient hepatocyte transduction. Unfortunately, such high doses precipitate acute toxicity due 
to activation of the innate immune system and might result in the death of patient as observed 
during the human clinical trial for gene therapy of OTC deficiency (Raper et al., 2003). This 
conundrum warrants a thorough understanding of mechanisms underlying AdV-mediated 
innate immune system induction and calls for development of novel strategies to achieve high 
level hepatocyte transduction at clinically relevant doses.  
5.2 HD-AdV for brain gene therapy 
Due to the complexity of tissue organization in the nervous system, treatment of 
neurological disorders imposes a huge challenge to both healthcare providers and clinical 
researchers alike.  HD-AdV gene therapy is currently being employed in preclinical trials as 
well as in animal models in the cases of brain cancer, sensory neuronopathies, 
neurodegenerative diseases, and multiple sclerosis, to name a few. Despite pre-exposure to 
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the viral genome, can accommodate inserts as large as 36 Kb, making them the vector of 
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by HD-AdV vectors do not express the viral proteins and, therefore, cells carrying HD-AdV 
are not recognized by the host immune system resulting in longer persistence and transgene 
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allowing efficient hepatocyte transduction are the main factors (Brunetti-Pierri et al., 2008; 
Dimmock et al., 2011; Toietta et al., 2005). HD-AdV vectors were shown to be very effective 
for liver gene therapy in Gunn rats, the animal model for Crigler-Najjar syndrome. A single 
injection of a HD-AdV vector expressing uridine diphospho-glucuronosyl transferase 1A1 
(UGT1A) was sufficient to induce life-long normalization of hyperbilirubinemia (Toietta et 
al., 2005). Similarly, an HD-AdV vector expressing canine glycogen-6-phosphatase was able 
to correct the hypoglycemia and prolong survival up to seven months in a mouse model of 
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by the high vector doses necessary to result in efficient hepatocyte transduction. Such high 
doses may not be clinically relevant for human use. A non-linear relation is observed between 
the vector dose and hepatocyte transduction; at low doses, there is very little to undetectable 
transgene expression, yet there are disproportionately high levels of transgene expression 
when vector dose is increased (Morral et al., 2002; Sullivan et al., 1997) with the Kupffer cells 
sequestering more than 85% of the intravascularly administered AdV vectors. AdV vectors 
also associate with platelets, red blood cells and other binding components in circulation 
resulting in eventual elimination of the vector. Sequestration by Kupffer cells and binding to 
the blood components determines the ‘threshold dose’ which must be administered for 
efficient hepatocyte transduction. Unfortunately, such high doses precipitate acute toxicity due 
to activation of the innate immune system and might result in the death of patient as observed 
during the human clinical trial for gene therapy of OTC deficiency (Raper et al., 2003). This 
conundrum warrants a thorough understanding of mechanisms underlying AdV-mediated 
innate immune system induction and calls for development of novel strategies to achieve high 
level hepatocyte transduction at clinically relevant doses.  
5.2 HD-AdV for brain gene therapy 
Due to the complexity of tissue organization in the nervous system, treatment of 
neurological disorders imposes a huge challenge to both healthcare providers and clinical 
researchers alike.  HD-AdV gene therapy is currently being employed in preclinical trials as 
well as in animal models in the cases of brain cancer, sensory neuronopathies, 
neurodegenerative diseases, and multiple sclerosis, to name a few. Despite pre-exposure to 
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AdV, the sustained transgene expression in the brain for at least one year (Barcia et al., 2007) 
and the ability to infect the cells of the central nervous system renders HD-AdV vectors 
particularly appealing for brain gene therapy. 
5.2.1 Gliomas  
The tumor originating from glial cells is called a glioma which is highly lethal and 
associated with a median survival of mere 9-12 months (Furnari et al., 2007). Among 
gliomas, Glioblastoma multiforme (GBM) is the most common and so far incurable; 
aggressive primary brain cancer in adults has a median survival time of 15-21 months 
(Grossman et al., 2010). GBM is highly invasive with a limited potential for complete 
resection and a high recurrence rate owing to its resistance towards conventional 
chemotherapy and radiotherapy. A combination of HD-AdV-TK (cytotoxic herpes simplex 
type 1 thymidine kinase/HSV1-TK) and HD-AdV vector encoding Flt3L (human soluble 
fms-like tyrosine kinase ligand 3) under the control of a tightly regulatable mCMV-TetOn 
expression system (HC-AdV-TetOn-Flt3L29–31) was tried in rats bearing GBM (Muhammad 
et al., 2010). As a result of intratumoral administration of HD-AdV vectors, tumor cells were 
rapidly removed from the brain, and ~70% of the animals showed a reduction in the tumor 
mass within thirty days of the treatment leading to a long-term survival rate. The treatment 
also ensured the safety of the protocol with a one-year follow-up indicating the lack of 
behavioral deficits, chronic inflammation in the brain or alteration in the brain architecture. 
Furthermore, in order to lower the vector dose and improve production yield, a bi-cistronic 
HD-AdV vector has been developed “that encodes both constitutively expressed HSV1-TK 
and inducible Flt3L from a single HD-AdV vector genome” - the first one of its kind (Puntel 
et al., 2010).  
5.2.2 Sensory neuronopathies 
Dorsal root ganglion (DRG) neuron dysfunction is commonly associated with a number of 
sensory neuronopathies, and therefore, DRG comprises the target of choice for their 
treatment. Undesirable side effects of conventional treatments can be minimized by targeted 
gene delivery towards DRG neurons (Waehler et al., 2007). Fiber modified HD-AdV vectors 
have been engineered to specifically target DRG neurons in mice (Terashima et al., 2009) 
and were also tested in Hexb–/– mice, an animal model exhibiting neurological impairment 
leading to death before the age of twenty weeks (Sango et al., 2002). DRG-targeted HD-AdV 
vectors were injected through an intra-thecal route and were shown to have a significantly 
higher transduction of DRG neurons compared to unmodified HD-AdV vectors. Testing in 
Hexb–/– mice also showed production of β-hexosaminidase in the original Hexb-deficient 
mice as well as a reversal of gangliosidosis and improvement in peripheral sensory 
dysfunction (Terashima et al., 2009).   
5.2.3 Neurodegenerative diseases 
A helper-dependent canine AdV (CAdV-2) vector was designed and tested by Soudais et al 
(2003) and was proposed to be useful in the treatment of neurodegenerative diseases 
(Soudais et al., 2004).  The advantages associated with this particular vector include 
preferential transduction of the neurons and retrograde transportation through the axons. 
Due to the chronic nature of neurodegenerative diseases, it is of particular interest whether 
the treatment can be offered over a long period of time. HD-AdV vectors have been 
administered into the cerebrospinal fluid (CSF) of non-human primates through lumbar 
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puncture, and it was shown that the intervention allowed a long-lasting (three months) 
infection of the neuroepithelial cells without any systemic or local toxicity (Butti et al., 2008).  
5.2.4 Multiple sclerosis 
The ability of HD-AdV vectors to express anti-inflammatory molecules can be useful in 
inflammatory disorders of the central nervous system. Experimental autoimmune 
encephalomyelitis (EAE) is an animal model of multiple sclerosis that has been adopted for 
pre-clinical studies. HD-AdV vectors expressing IL-4 were administered into the CSF of 
immunocompetent mice that allowed transduction of neuroepithelial cells and prolonged 
(five months) transgene expression without any adverse effects (Butti et al., 2008). 
6. AdV vectors for cancer therapy 
Not long after the discovery of existence of AdV, AdV were noted for their oncolytic  
nature in the clinical treatment of cervical carcinoma. Since that time, AdV have shown 
promise in the cancer vaccine field and currently offer a variety of methodologies which are 
being implemented to combat various forms of cancer (Table 1). The field of cancer 
vaccinology is fraught with complications since an effectively persistent immune response 
must be stimulated.  One complication lies in the fact that immune tolerance must be 
overcome against self-antigens.  These self-antigens, which are weak stimulators of the 
immune system or completely lack the ability to be immunogenic in an 
immunocompromised environment, pose quite a hurdle in the cancer vaccine 
development.   
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DC=dendritic cell; h=human; LMP= latent membrane protein; PEDF = pigment epithelium-derived 
factor protein; OTC:  ornithine transcarbamylase; r=recombinant; VEGF=Vascular Endothelial Growth 
Factor D; SSTR=somatostatin receptor type 2 
Table 1. Clinical Trials of AdV vectors 
6.1 Tumor suppressor therapies 
Several genes (p53, Rb,BRCA1, PTEN, etc) regulate the cell cycle and apoptotic 
pathways.  The cellular machinery can inhibit tumor formation by suppressing aberrant 
cellular proliferation.  Several malignancies have a loss-of-function mutation in one or more 
of the cell cycle control genes. Gene delivery can rescue a cell from a tumor phenotype by 
restoring the dysfunctional gene or a tumor-suppressor gene.  One of the most extensively 
studied tumor suppressor genes, p53, is mutated in more than 50% of all human 
malignancies.  The administration of wild-type p53 through gene transfer with a replication-
defective AdV has demonstrated significant tumor suppression (Roth, 2006). The repair of 
p53 activity also has impaired angiongenic activity, inhibited the growth of nontransduced 
cells and directed a local immune response against tumor cells.  In addition, replacement of 
p53 increased the vulnerability of tumor cells to chemotherapy and radiotherapy by 
reestablishing pro-apoptotic pathways.  Furthermore, the potency of an anti-tumor response 
is enhanced when p53 gene replacement therapy is supplemented with available cytotoxic 
chemotherapeutics (El-Deiry, 2003). The first AdV gene therapy construct for the treatment 
of cancer has been approved by the State Food and Drug Administration (SFDA) of 
China.  This AdV construct contains a p53 expression cassette in the deleted E1 region and 
has demonstrated remarkable synergistic effects when combined with radio-
/chemotherapy, surgery, or hyperthermia for the management of cancer (Peng, 2005). 
Another way to inhibit tumor growth is to manipulate ligand-receptor interactions. AdV 
have been engineered to deliver ligands to oncogenic receptors in the form of antibodies 
against the receptor or by mimicking natural interactions.  Peptides with either natural or 
recombined ligand moieties have been particularly efficacious in receptor-ligand mimicry 
(Pasquale, 2010).  Receptor-ligand interactions typically lead to down-regulation of that 
receptor either directly or through signal transduction complexes.  One example is the 
EphA2 receptor, a tyrosine kinase protein, which is elevated in breast (Zelinski et al., 2001), 
prostate (Walker-Daniels et al., 1999), pancreatic, (Van Geer et al., 2010) and many other 
cancers.  Thus, EphA2 is a good therapeutic candidate for treating cancer.  Under normal 
conditions, the EphA2 receptor is localized at intracellular junctions where it binds to its 
membrane-anchored ligand, EphrinA1, resulting in phosphorylation of the receptor.  E-
cadherin, a cell adhesion molecule, is also able to phosphorylate EphA2 and aid in proper 
localization of the receptor.  In many cancer cells, EphA2 is over expressed, 
unphosphorylated and unable to bind to its ligands due to its altered localization (Kinch & 
Carles-Kinch, 2003; Zantek et al., 1999).  Monoclonal antibodies directed against EphA2 have 
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been used in order to mimic ligand-induced downregulation.  These antibodies caused 
elevated levels of EphA2 phosphorylation which encouraged its degradation (Carles-Kinch 
et al., 2002). AdV-mediated delivery of the secretory form of EphrinA1 produced 
autophosphorylation, degradation, and subsequent inhibition of tumor growth and 
metastasis (Noblitt et al., 2004; Noblitt et al., 2005).  Likewise, AdV-mediated antibodies 
directed against ErbB2 (HER2/neu) demonstrated that ErbB2 down-regulation increased 
apoptosis and cytotoxicity both in vitro and in vivo (Arafat et al., 2002; Jiang et al., 2006). 
6.2 CRAdV therapy 
An effective approach to cancer therapy is the use of RCAdV that selectively replicate inside 
a tumor and ultimately kill tumor cells while leaving normal cells intact.  As previously 
mentioned, therapeutic CRAdV are either engineered by deletion mutagenesis or 
engineered for the tumor- or tissue-specific replication by use of transcriptional regulatory 
elements (TREs). 
6.2.1 Deletion mutation of CRAdV 
CRAdV have expanded our knowledge regarding AdV proteins and how they interact with 
cellular proteins.  E1 proteins of AdV adjust cell cycle controls in order to promote virus 
replication.  The product of the E1A gene binds to the wild type Rb protein which causes the 
release and activation of E2F, a transcription factor (Whyte et al., 1988). Once E2F is 
activated, the transcription of S phase entry genes facilitates the hijacking of cellular 
machinery involved in AdV replication (Flint & Shenk, 1997).  Additionally, E2F 
transactivates the p14ARF gene which increases p53 levels within the cell by inhibiting its 
degradation by murine double minute 2 (MDM2) (Bates et al., 1998).  Although increased 
p53 levels can cause cellular apoptosis or arrest of the cell cycle, it also inhibits viral 
replication.  To circumvent this replication inhibition, AdV E1B 55 kDa proteins work with 
E4 open reading from (ORF) 6 to bind to p53 and inactivate it preventing apoptosis and 
permitting virus replication and spread (Dobner et al., 1996; Yew & Berk, 1992).  A bcl-2-
related protein, E1B 19 kDa,  also prevents apoptosis stimulated by E1A (Boyd et al., 1994; 
Rao et al., 1992). This knowledge combined with known tumor suppressor genes (i.e., p53 
and Rb), tumor-associated antigens (CEA) or specialized promoters has facilitated the 
development of efficacious CRAdV. 
The first CRAdV to enter clinical trials was ONYX-15 (also known as dl1520), a E1B 
55kDa/E3B deleted vector.  This mutant CRAdV selectively replicates in cancer cells that 
possess a defective p53 while leaving cells with intact p53 alone.  It has undergone 
numerous clinical trials (Phase I to III) to test its therapeutic potential in head and neck 
squamous cell carcinoma, glioblastoma, hepatocellular carcinoma, colorectal carcinoma, 
sarcomas, ovarian, pancreatic, and hepatobiliary cancer (Aghi & Martuza, 2005; Kirn, 2001). 
Data indicate that ONYX-15 is safe and selective for cancer (Kirn & Thorne, 2009), but the 
strategy has failed to demonstrate extensive therapeutic effects or significant systemic 
spread (Liu et al., 2008b). Other oncolytic vectors that possess the same E1B/E3B mutations 
have exhibited the same capabilities, but only H101 was finally approved by the Chinese 
SFDA  for use in combination with chemotherapy to treat late-stage refractory 
nasopharyngeal cancer (Kirn et al., 2008; Liu et al., 2008b). 
There is a weak correlation between p53 status and cellular susceptibility to E1B/E3B 
mutant CRAdV (Geoerger et al., 2002; Hay et al., 1999; Rothmann et al., 1998).  Some 
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(Pasquale, 2010).  Receptor-ligand interactions typically lead to down-regulation of that 
receptor either directly or through signal transduction complexes.  One example is the 
EphA2 receptor, a tyrosine kinase protein, which is elevated in breast (Zelinski et al., 2001), 
prostate (Walker-Daniels et al., 1999), pancreatic, (Van Geer et al., 2010) and many other 
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conditions, the EphA2 receptor is localized at intracellular junctions where it binds to its 
membrane-anchored ligand, EphrinA1, resulting in phosphorylation of the receptor.  E-
cadherin, a cell adhesion molecule, is also able to phosphorylate EphA2 and aid in proper 
localization of the receptor.  In many cancer cells, EphA2 is over expressed, 
unphosphorylated and unable to bind to its ligands due to its altered localization (Kinch & 
Carles-Kinch, 2003; Zantek et al., 1999).  Monoclonal antibodies directed against EphA2 have 
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been used in order to mimic ligand-induced downregulation.  These antibodies caused 
elevated levels of EphA2 phosphorylation which encouraged its degradation (Carles-Kinch 
et al., 2002). AdV-mediated delivery of the secretory form of EphrinA1 produced 
autophosphorylation, degradation, and subsequent inhibition of tumor growth and 
metastasis (Noblitt et al., 2004; Noblitt et al., 2005).  Likewise, AdV-mediated antibodies 
directed against ErbB2 (HER2/neu) demonstrated that ErbB2 down-regulation increased 
apoptosis and cytotoxicity both in vitro and in vivo (Arafat et al., 2002; Jiang et al., 2006). 
6.2 CRAdV therapy 
An effective approach to cancer therapy is the use of RCAdV that selectively replicate inside 
a tumor and ultimately kill tumor cells while leaving normal cells intact.  As previously 
mentioned, therapeutic CRAdV are either engineered by deletion mutagenesis or 
engineered for the tumor- or tissue-specific replication by use of transcriptional regulatory 
elements (TREs). 
6.2.1 Deletion mutation of CRAdV 
CRAdV have expanded our knowledge regarding AdV proteins and how they interact with 
cellular proteins.  E1 proteins of AdV adjust cell cycle controls in order to promote virus 
replication.  The product of the E1A gene binds to the wild type Rb protein which causes the 
release and activation of E2F, a transcription factor (Whyte et al., 1988). Once E2F is 
activated, the transcription of S phase entry genes facilitates the hijacking of cellular 
machinery involved in AdV replication (Flint & Shenk, 1997).  Additionally, E2F 
transactivates the p14ARF gene which increases p53 levels within the cell by inhibiting its 
degradation by murine double minute 2 (MDM2) (Bates et al., 1998).  Although increased 
p53 levels can cause cellular apoptosis or arrest of the cell cycle, it also inhibits viral 
replication.  To circumvent this replication inhibition, AdV E1B 55 kDa proteins work with 
E4 open reading from (ORF) 6 to bind to p53 and inactivate it preventing apoptosis and 
permitting virus replication and spread (Dobner et al., 1996; Yew & Berk, 1992).  A bcl-2-
related protein, E1B 19 kDa,  also prevents apoptosis stimulated by E1A (Boyd et al., 1994; 
Rao et al., 1992). This knowledge combined with known tumor suppressor genes (i.e., p53 
and Rb), tumor-associated antigens (CEA) or specialized promoters has facilitated the 
development of efficacious CRAdV. 
The first CRAdV to enter clinical trials was ONYX-15 (also known as dl1520), a E1B 
55kDa/E3B deleted vector.  This mutant CRAdV selectively replicates in cancer cells that 
possess a defective p53 while leaving cells with intact p53 alone.  It has undergone 
numerous clinical trials (Phase I to III) to test its therapeutic potential in head and neck 
squamous cell carcinoma, glioblastoma, hepatocellular carcinoma, colorectal carcinoma, 
sarcomas, ovarian, pancreatic, and hepatobiliary cancer (Aghi & Martuza, 2005; Kirn, 2001). 
Data indicate that ONYX-15 is safe and selective for cancer (Kirn & Thorne, 2009), but the 
strategy has failed to demonstrate extensive therapeutic effects or significant systemic 
spread (Liu et al., 2008b). Other oncolytic vectors that possess the same E1B/E3B mutations 
have exhibited the same capabilities, but only H101 was finally approved by the Chinese 
SFDA  for use in combination with chemotherapy to treat late-stage refractory 
nasopharyngeal cancer (Kirn et al., 2008; Liu et al., 2008b). 
There is a weak correlation between p53 status and cellular susceptibility to E1B/E3B 
mutant CRAdV (Geoerger et al., 2002; Hay et al., 1999; Rothmann et al., 1998).  Some 
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researchers have observed that when E1B 55kDa binds to p53, AdV-mediated death is 
followed by a productive infection (Dix et al., 2000; Hall et al., 1998). Others argue that the 
preferential killing by ONYX-15 types may be due to infectivity variances of the vector, 
permissiveness, upregulation of AdV early proteins (Steegenga et al., 1999), p14ARF failure 
(Ries et al., 2000), mutation features of p53 (Hann & Balmain, 2003), or late export of viral 
RNA (O'Shea et al., 2004) rather than solely the status of p53 (Sharma et al., 2009b). 
Replication of ONYX-15 is attenuated when compared with wild-type virus (Dix et al., 2001) 
which may  be attributable to other E1B functions such as translation, nuclear exports of late 
viral mRNA, and compromised inhibition of host cell protein synthesis (Babiss & Ginsberg, 
1984).  Other mutations have been identified in the E1B 55 kDa protein that enhanced 
selectivity for tumors without hindering  viral replication (Shen et al., 2001). 
An alternative method involves the use of CRAdV mutants that possess a deletion in E1A 
and Rb-binding domain (CR-2) which ultimately targets cancers that have aberrant Rb 
pathways (Fueyo et al., 2000; Heise et al., 2000). When anti-tumor potential is compared 
between E1B mutations and CR-2 deletion vectors which do not inhibit vector replication in 
cancerous cells, the CR-2 vectors demonstrate better efficacy in vivo and in vitro (Alemany & 
Curiel, 2001).  There are safety concerns, however, that exist with CR-2 deletion vectors since 
their replication is not restricted to cancer cells alone (Heise et al., 2000).  Incorporation of 
tumor-specific promoters which restrict viral gene expression (i.e., ONYX-411) or the 
incorporation of Arg-Gly-Asp(RGD) motifs are beneficial to enhancing tumor cell selectivity 
and safety (Johnson et al., 2002; Page et al., 2007). 
CRAdV targeting CEA-expressing malignancies in the colon, lung, and breast tissues have 
been successful and are in Phase I clinical trials with HAd5[E1-,E2b-]-CEA(6D) or ETBX-011. 
The HAdV5 has been engineered to express the CEA protein which is found in some 
cancerous cells.  The goal is to direct the immune system to target cancer cells producing 
CEA. [http://clinicaltrials.gov/ct2/show/NCT01147965] 
6.2.2 Transcriptional regulation of CRAdV 
Another class of CRAdV replaces viral promoters that control vital transcriptional units 
with transcription regulating elements (TREs).  Transcriptional targeting drives selection 
according to the vector gene expression and replication parameters set in motion by the 
TREs. The most obvious gene to be selected for TRE regulation is E1A since it is responsible 
for viral replication and adaptations which favor virus replication in the host cell 
environment.  CN706 was the first TRE-regulated AdV to demonstrate potent anti-tumor 
effects (Rodriguez et al., 1997).  In this construct, E1A expression was under the control of 
the prostate-specific antigen (PSA)-derived minimal enhancer/promoter which permitted 
selective replication in PSA-expressing prostate cells.  Several promising TREs under 
investigation today include those that regulate expression of human telomerase reverse 
transcriptase (hTERT), transcription factor E2F, alpha-fetoprotein (AFP), and many more 
which tailor vector replication to be selective for a specific tumor phenotype. 
Leaky replication has been observed in normal cells even though a single essential viral 
gene is under exogenous control.  To improve tumor specificity and safety of CRADV, other 
essential viral genes (e.g., E1B, E2, E4) can be manipulated (Brunori et al., 2001; Doronin et 
al., 2001; Kawashima et al., 2004; Kuppuswamy et al., 2005; Li et al., 2005). A more complete 
list is available in a previous review (Sharma et al., 2009b). Other deletion mutations have 
been made in an effort to exploit specific oncolytic potentials while also retaining the 
replicative capacity of the virus.  However, more work is warranted in all areas of CRAdV 
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development before they can be used commercially.  Additional safety features should 
include external regulation of oncolytic CRAdV through activation of inducible promoter 
systems such as TET or MMTV promoters (Avvakumov & Mymryk, 2002; Chong et al., 
2002; Fechner et al., 2003). Furthermore, tissue-specific promoters can regulate where the 
vector replicates (Hernandez-Alcoceba et al., 2000; Hsieh et al., 2002). Radiation, chemical or 
heat-inducible promoters have also been employed  to restrict transgene expression (Lee et 
al., 2001; Rasmussen et al., 2002). 
Various regulatory elements have been fused in order to artificially design promoters which 
restrict TRE size while also preserving or amplifying rigid control of vector replication 
(Nettelbeck et al., 2000; Nettelbeck, 2008). In one artificial design, bidirectional promoters that 
simultaneously exert control over two key viral genes (i.e., E1A/E1B or E1A/E4) have been 
applied.  Another promoter concept includes a dual-specific hybrid with regulatory elements 
that react to a hypoxic environment and estrogen thereby conferring greater discriminatory 
capabilities to oncolytic CRAdV (Hernandez-Alcoceba et al., 2002). Engineering of these 
transcriptionally-regulated CRAdV is an onerous task and poses several limitations due to the 
variety of viral and non-viral factors which can influence the response of the heterologous 
promoter.   Safety concerns arise when cis-acting enhancer elements or cryptic transcription 
initiation sites lie in the left ITR or packaging signal. These regions that are upstream of E1A 
can influence transcriptional read-through of the E1A or transgene region even in the presence 
of a TRE (Yamamoto et al., 2003). Other elegant designs  which address the limitations include 
the insertion of additional transcriptional terminators or insulators which are upstream of 
heterologous promoters, orientation changes of the E1A expression cassette, or the 
translocation of the packaging signal from the left ITR to the right ITR. 
Post-transcriptional methods which control mRNA stability or translation are also under 
investigation for CRAdV development.  Within the tumor microenvironment, proliferative 
signals are the driving force for expression of specific tumor-associated proteins.  Expression 
of these proteins is boosted partially by the stabilization of mRNA by a 3'UTR which is 
regulated by an activated mitogen-activated protein kinase (P-MAPK ) pathway.  The 3’UTR 
regulates mRNA stability in several genes; hence, ligation of the 3’UTR with crucial AdV 
genes confers the vector with the ability to better target tumors (Sharma et al., 2009b). 
No CRAdV have currently been developed that completely lack the ability to replicate or 
cause some toxicity in normal cells.  They do however confer a great deal of selectivity and 
safety.  Future conceptions should involve the enhancement of tumor-specific replication. 
6.3 Suicide gene therapy 
Suicide gene therapy selectively orchestrates a gene-directed enzyme for prodrug therapy 
(GDEPT) to deliver chemotherapeutic moieties to specific tumors.  Nontoxic drugs (i.e., 
chemotherapeutic agents) are converted by AdV loaded with a GDEPT into cytotoxic agents 
within the tumor. Classic chemotherapy is often harmful to normal cells and, thus, promotes 
deleterious effects with the high doses needed for maintaining therapeutic indices. Since 
nontoxic prodrugs can be administered without harmful side effects to normal cells, this is a 
preferred methodology for chemotherapeutic delivery.    
Two suicide genes which have been well characterized include the herpes simplex virus, type I 
thymidine kinase (HSV-TK) and the Escherichia coli, cytosine deaminase (CD) genes. HSV-TK 
phosphorylates ganciclovir (GCV) which cooperates with DNA polymerase to interfere with 
DNA synthesis ultimately leads to cell death in rapidly dividing cells.  CD transforms 5-
fluorocytosine (5-FC) into a very toxic metabolite 5-fluorouracil (5-FU), which is a frequently 
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development before they can be used commercially.  Additional safety features should 
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signals are the driving force for expression of specific tumor-associated proteins.  Expression 
of these proteins is boosted partially by the stabilization of mRNA by a 3'UTR which is 
regulated by an activated mitogen-activated protein kinase (P-MAPK ) pathway.  The 3’UTR 
regulates mRNA stability in several genes; hence, ligation of the 3’UTR with crucial AdV 
genes confers the vector with the ability to better target tumors (Sharma et al., 2009b). 
No CRAdV have currently been developed that completely lack the ability to replicate or 
cause some toxicity in normal cells.  They do however confer a great deal of selectivity and 
safety.  Future conceptions should involve the enhancement of tumor-specific replication. 
6.3 Suicide gene therapy 
Suicide gene therapy selectively orchestrates a gene-directed enzyme for prodrug therapy 
(GDEPT) to deliver chemotherapeutic moieties to specific tumors.  Nontoxic drugs (i.e., 
chemotherapeutic agents) are converted by AdV loaded with a GDEPT into cytotoxic agents 
within the tumor. Classic chemotherapy is often harmful to normal cells and, thus, promotes 
deleterious effects with the high doses needed for maintaining therapeutic indices. Since 
nontoxic prodrugs can be administered without harmful side effects to normal cells, this is a 
preferred methodology for chemotherapeutic delivery.    
Two suicide genes which have been well characterized include the herpes simplex virus, type I 
thymidine kinase (HSV-TK) and the Escherichia coli, cytosine deaminase (CD) genes. HSV-TK 
phosphorylates ganciclovir (GCV) which cooperates with DNA polymerase to interfere with 
DNA synthesis ultimately leads to cell death in rapidly dividing cells.  CD transforms 5-
fluorocytosine (5-FC) into a very toxic metabolite 5-fluorouracil (5-FU), which is a frequently 
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used chemotherapeutic (Aghi et al., 1998).  Although direct toxicity is imparted by GDEPT-
mediated cell death, there is also significant growth inhibition/killing of uninfected 
neighboring tumor cells due to the transfer of the toxic drug.  The causes of this event are 
hypothesized to involve transfer via gap junctions or diffusion and stimulation of an anti-
tumor response against lysed tumor cells (Lumniczky & Safrany, 2006).  
Replication-defective AdV were initially used in GDEPT but demonstrated poor anti-tumor 
efficacy. RCAdV have had a better outcome, and the combination of suicide genes with 
standard therapies has further enhanced anti-tumor efficacy. However, GDEPT loaded  
AdV must be administered intratumorally in order to protect normal cells from cytotoxic 
events.   
Other methods have evolved which can be used alone or in combination with the methods 
described above. The transductional targeting of tumors, the selective expression of suicide 
genes, or the addition of tumor specific promoters to AdV essential genes have improved 
anti-tumor potential of AdV vectors.   These suicide gene/prodrug combinations are under 
investigation in both preclinical and clinical trials.  Better dosage regimens and vaccination 
protocols must be formulated in order to improve the therapeutic potential of this system.  
 Another approach to consider for improvement involves thorough documentation of the 
kinetics of the prodrug and vector transgene expression.  Timing prodrug administration in 
order to maximize benefits is of crucial importance.  One novel method that has been 
proposed involves sequential administration of prodrug 5-FC followed by GCV.  This 
double suicide gene therapy produced significant synergistic cytotoxicity.  Avoidance of 
premature cell death is of critical importance since AdV will not be able to replicate.  If virus 
proliferation is inhibited, yield will decrease markedly affecting the benefit of AdV-
mediated suicide gene therapy (Sharma et al., 2009b). 
6.4 Cancer immunotherapy 
An intact immune system is capable of recognizing and eliminating tumor cells in the body; 
however, cancer cells possess the ability to evade immune detection.   Tumor cells have several 
methods to avoid immune detection which include but are not limited to the release of 
immunosuppressive or anti-inflammatory proteins, flawed antigen presentation and 
processing caused by mutations within the mechanisms of antigen presentation or decreased 
expression of MHC molecules. The ineffectual anti-tumor immune response (humoral or cell-
mediated) along with the progression of immunosuppression during oncogenesis 
demonstrates how the immune system needs to be magnified and specificity-modified to 
target tumor cells and the process of oncogenesis.   The objective of cancer immunotherapy is 
to stimulate an endogenous immune response against already established or rapidly 
developing tumors.  AdV have been employed to promote an immune response against 
cancerous cells by transporting immunostimulatory molecules or by arming dendritic cells 
(DC) with the appropriate tumor-associated antigen (TAA) (Sharma et al., 2009b). 
6.4.1 Delivery of cytokines/co-stimulatory molecules via AdV 
The administration of cytokines augments the cytokine environment within the tumor cell 
while also rallying immune cells to elicit an anti-tumor response.  Many cytokines and 
membrane bound receptors (IL-12, IL-2, IFN-gamma, CD40L, etc) are very potent 
immunomodulators but elicit systemic toxicity during exogenous delivery.  They also have a 
short half-life in vivo and are maintained at subtherapeutic levels at the tumor site. AdV 
loaded with cytokine expressing genes which are delivered intratumorally have 
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demonstrated increased patient survival and decreased tumor growth.  IL-2 suppresses 
tumor growth by stimulating cell-mediated killing activities in cytotoxic T lymphocytes 
(CTLs), lymphokine-activated killer (LAK) cells, or tumor infiltrating lymphocytes (TILs) 
(Eberlein & Schoof, 1991). A few clinical trials have exploited the potential of IL-2 in order to 
build an immune response to eventually kill tumor cells.  IL-12 is another cytokine under 
investigation which elicits a potent anti-tumor response when administered locally by 
stimulating proliferation and cytotoxicity of CTLs and natural killer (NK) cells.   A 
replication defective AdV (AdV.TNF) which does not target any particular tumor-associated 
antigen but rather expresses TNF-α under a chemoradiation-inducible promoter is in Phase 
III of clinical trials. The AdV.TNF is administered intratumorally along with radiation and 5-
FU to induce an anti-tumor response.  Co-stimulatory molecules, such as CD40L, have also 
demonstrated an ability to suppress tumor growth and are in Phase I/II of clinical trials 
(Habib-Agahi et al., 2007; Kikuchi & Crystal, 1999; Loskog et al., 2004; Martinet et al., 2000; 
Xu et al., 2005; Yoshida et al., 2003).  
6.4.2 AdV Infection of DCs facilitate cancer immunotherapy 
DCs are efficient and specialized APCs which present MHC-tagged epitopes to T cells in 
order to generate a specific immune response.  These cells have been modified by AdV ex 
vivo so that the DCs either present TAA to effector cells of the immune system and/or 
introduce various immunomodulatory genes (i.e., cytokines or co-stimulatory 
receptors).  Several of the anti-cancer therapies utilizing AdV have coupled the vector with 
the DC’s abilities in order to generate an effective anti-tumor therapy.  This method offers 
several advantages: (1) the AdV demonstrates adjuvant activity and has the ability to 
activate DCs and promote maturation which facilitates the induction of strong anti-tumor 
response (Geutskens et al., 2000; Kanagawa et al., 2008) , (2) AdV expression of TAA within 
DCs permits processing and loading onto both MHCI and MHCII molecules which 
stimulates the appropriate and relatively persistent activation of CD8+/CD4+ responses 
(Xia et al., 2006), and (3) ex vivo treatment of DCs with AdV evades any potential problems 
with pre-existing vector immunity (Wan et al., 1999). 
7. AdV vaccines for infectious diseases 
Significant advancements have been made in recombinant viral-vaccine strategies for 
infectious disease. AdV vaccines have demonstrated remarkable levels of T cell 
immunogenicity. AdV possess the ability to prime the immune response to target a transgene. 
This immune response can be boosted to high levels with a second vector that is recombined 
with the target antigen or with a serotype from a heterologous AdV (Jolly et al., 2008). 
7.1 HIV vaccines  
HIV is a constantly evolving virus that is an imposing challenge in the realm of engineering 
vaccines.  The goal of HIV-1 vaccines is to reduce viral load, prolong survival, and minimize 
transmission. Vaccines that induce the HIV-1-specific cellular immune response have a 
delicate balance to maintain with regard to population preservation and selective 
stimulation. The vaccine construct should preserve the CD4+ T cell population and also 
increase the degree to which the CD8+ and CD4+ T cells recognize and bind HIV-1 antigens 
such as Gag and Pol.  In addition, an elevated titer of neutralizing antibodies which possess 
high-avidity for the native trimeric Env protein of the virus needs to be attained. 
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used chemotherapeutic (Aghi et al., 1998).  Although direct toxicity is imparted by GDEPT-
mediated cell death, there is also significant growth inhibition/killing of uninfected 
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genes, or the addition of tumor specific promoters to AdV essential genes have improved 
anti-tumor potential of AdV vectors.   These suicide gene/prodrug combinations are under 
investigation in both preclinical and clinical trials.  Better dosage regimens and vaccination 
protocols must be formulated in order to improve the therapeutic potential of this system.  
 Another approach to consider for improvement involves thorough documentation of the 
kinetics of the prodrug and vector transgene expression.  Timing prodrug administration in 
order to maximize benefits is of crucial importance.  One novel method that has been 
proposed involves sequential administration of prodrug 5-FC followed by GCV.  This 
double suicide gene therapy produced significant synergistic cytotoxicity.  Avoidance of 
premature cell death is of critical importance since AdV will not be able to replicate.  If virus 
proliferation is inhibited, yield will decrease markedly affecting the benefit of AdV-
mediated suicide gene therapy (Sharma et al., 2009b). 
6.4 Cancer immunotherapy 
An intact immune system is capable of recognizing and eliminating tumor cells in the body; 
however, cancer cells possess the ability to evade immune detection.   Tumor cells have several 
methods to avoid immune detection which include but are not limited to the release of 
immunosuppressive or anti-inflammatory proteins, flawed antigen presentation and 
processing caused by mutations within the mechanisms of antigen presentation or decreased 
expression of MHC molecules. The ineffectual anti-tumor immune response (humoral or cell-
mediated) along with the progression of immunosuppression during oncogenesis 
demonstrates how the immune system needs to be magnified and specificity-modified to 
target tumor cells and the process of oncogenesis.   The objective of cancer immunotherapy is 
to stimulate an endogenous immune response against already established or rapidly 
developing tumors.  AdV have been employed to promote an immune response against 
cancerous cells by transporting immunostimulatory molecules or by arming dendritic cells 
(DC) with the appropriate tumor-associated antigen (TAA) (Sharma et al., 2009b). 
6.4.1 Delivery of cytokines/co-stimulatory molecules via AdV 
The administration of cytokines augments the cytokine environment within the tumor cell 
while also rallying immune cells to elicit an anti-tumor response.  Many cytokines and 
membrane bound receptors (IL-12, IL-2, IFN-gamma, CD40L, etc) are very potent 
immunomodulators but elicit systemic toxicity during exogenous delivery.  They also have a 
short half-life in vivo and are maintained at subtherapeutic levels at the tumor site. AdV 
loaded with cytokine expressing genes which are delivered intratumorally have 
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demonstrated increased patient survival and decreased tumor growth.  IL-2 suppresses 
tumor growth by stimulating cell-mediated killing activities in cytotoxic T lymphocytes 
(CTLs), lymphokine-activated killer (LAK) cells, or tumor infiltrating lymphocytes (TILs) 
(Eberlein & Schoof, 1991). A few clinical trials have exploited the potential of IL-2 in order to 
build an immune response to eventually kill tumor cells.  IL-12 is another cytokine under 
investigation which elicits a potent anti-tumor response when administered locally by 
stimulating proliferation and cytotoxicity of CTLs and natural killer (NK) cells.   A 
replication defective AdV (AdV.TNF) which does not target any particular tumor-associated 
antigen but rather expresses TNF-α under a chemoradiation-inducible promoter is in Phase 
III of clinical trials. The AdV.TNF is administered intratumorally along with radiation and 5-
FU to induce an anti-tumor response.  Co-stimulatory molecules, such as CD40L, have also 
demonstrated an ability to suppress tumor growth and are in Phase I/II of clinical trials 
(Habib-Agahi et al., 2007; Kikuchi & Crystal, 1999; Loskog et al., 2004; Martinet et al., 2000; 
Xu et al., 2005; Yoshida et al., 2003).  
6.4.2 AdV Infection of DCs facilitate cancer immunotherapy 
DCs are efficient and specialized APCs which present MHC-tagged epitopes to T cells in 
order to generate a specific immune response.  These cells have been modified by AdV ex 
vivo so that the DCs either present TAA to effector cells of the immune system and/or 
introduce various immunomodulatory genes (i.e., cytokines or co-stimulatory 
receptors).  Several of the anti-cancer therapies utilizing AdV have coupled the vector with 
the DC’s abilities in order to generate an effective anti-tumor therapy.  This method offers 
several advantages: (1) the AdV demonstrates adjuvant activity and has the ability to 
activate DCs and promote maturation which facilitates the induction of strong anti-tumor 
response (Geutskens et al., 2000; Kanagawa et al., 2008) , (2) AdV expression of TAA within 
DCs permits processing and loading onto both MHCI and MHCII molecules which 
stimulates the appropriate and relatively persistent activation of CD8+/CD4+ responses 
(Xia et al., 2006), and (3) ex vivo treatment of DCs with AdV evades any potential problems 
with pre-existing vector immunity (Wan et al., 1999). 
7. AdV vaccines for infectious diseases 
Significant advancements have been made in recombinant viral-vaccine strategies for 
infectious disease. AdV vaccines have demonstrated remarkable levels of T cell 
immunogenicity. AdV possess the ability to prime the immune response to target a transgene. 
This immune response can be boosted to high levels with a second vector that is recombined 
with the target antigen or with a serotype from a heterologous AdV (Jolly et al., 2008). 
7.1 HIV vaccines  
HIV is a constantly evolving virus that is an imposing challenge in the realm of engineering 
vaccines.  The goal of HIV-1 vaccines is to reduce viral load, prolong survival, and minimize 
transmission. Vaccines that induce the HIV-1-specific cellular immune response have a 
delicate balance to maintain with regard to population preservation and selective 
stimulation. The vaccine construct should preserve the CD4+ T cell population and also 
increase the degree to which the CD8+ and CD4+ T cells recognize and bind HIV-1 antigens 
such as Gag and Pol.  In addition, an elevated titer of neutralizing antibodies which possess 
high-avidity for the native trimeric Env protein of the virus needs to be attained. 
 
Viral Gene Therapy 116 
A HAdV5-based HIV-1 vaccine was tested in humans in a Phase II trial to evaluate the risk 
for acquiring HIV infection. Unfortunately this trial was halted because the monitoring 
board determined that the vaccine was not able to demonstrate protection (Buchbinder et 
al., 2008; McElrath et al., 2008; Priddy et al., 2008). Future goals are focused on additional 
optimization of vaccine immunogens and technologies (Bradac & Dieffenbach, 2009). Since 
other researchers report the ability to induce a high level of cell-mediated immune response 
in non-HIV formulations, this is the time to apply this proof of principle to the area of HIV 
vaccine research.   
In other areas of research, an AdV vector with chimeric fiber is used to infect autologous T 
cells to facilitate HIV therapy.  This chimeric fiber contains both the HAdV5 fiber tail and 
the HAdV35 fiber shaft and knob domains (Perez et al., 2008). Due to its specificity to CCR5, 
CD4+ T-cells treated with this vector are relatively resistant to HIV infection.  The data, 
while preliminary, are encouraging.  Also, the modified CD4+ T cells treated with this 
vector are well-tolerated and engraft, replicate, and persist within the body after a single 
infusion.  They behave like unmodified T-cells in so much as they migrate to the gut mucosa 
where they undergo selective expansion (Barouch, 2010). When used in combination with 
conventional anti-HIV therapies, this strategy might prove beneficial. 
Different immunization strategies include a prime-boost approach with AdV-modified 
vaccinia virus Ankara (MVA) or heterologous HAdV5 and HAdV35 regimens or triple 
combinations which further elicit both T and B cell responses.  The use of HAdV26 and 
HAdV35 in a prime-boost approach has shown promise in avoiding pre-existing vector 
immunity (Barouch, 2010). Immunization with HAdV26-Gag and HAdV35-Gag resulted in 
increased levels of CD127, CD62L, and Bcl-2 on T cells compared to HAdV5-Gag 
inoculation.  These markers are indicative of improved functioning in T lymphocytes.  There 
is also increased proliferation potential as well as increased antigen specificity. 
7.2 Malaria vaccines 
Malaria is characterized by several molecular interactions between the parasite and host 
during the parasite’s incubation.  An effective malaria vaccine will vigorously induce 
protective antibody and T cell responses to various malaria antigens that are expressed 
during the parasite’s differentiation at the various life stages.  Currently a mixture of two 
HAdV-5 vectors which express the pre-erthrocytic-stage malaria antigen circumsporozoite 
protein (CSP) or blood-stage malaria antigen apical membrane antigen 1 (AMA1) have 
demonstrated some success and are in Phase I/II of clinical trials.  After immunization, 
human volunteers had a remarkable response to each antigen.  Depletion studies 
determined that the response was due to a mixed population of CD8+ and CD4+ T 
cells.   The CD8+ T cell lineage was five times greater than the CD4+phenotype when IFN-γ 
secreting cells were assayed within the response population (Draper & Heeney, 2010).   
Another malaria vaccine platform involves the use of rAdV of rarer human serotypes or of 
non-human origin.  These designs are engineered in such a way as to avoid pre-existing 
vector immunity against HAdV5. Some preclinical trials investigate priming with one AdV 
(i.e., HAdV5) and boosting with a heterologous AdV (i.e., HAdV35).  Another strategy uses 
chimpanzee AdV serotype 63 (AdVCh63).   AdVCh63 expresses the pre-erthrocytic-stage 
antigen thrombospondin-related adhesion protein combined with a multi-epitope string 
(ME-TRAP).  A preclinical study utilizing a HAdV5 vector for priming followed with a 
boost by a MVA vector to promote the antibody and T cell responses.  This particular 
HAdV5-MVA protocol used vectors that had been recombined with blood-stage malaria 
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antigen merozoite surface protein 1 (MSP1) which induces a T cell response which was 
partially effective against the liver-stage infection (Draper et al., 2009) and a protective 
antibody response effective against the blood-stage infection (Draper et al., 2008). Future 
studies will have to address the immunogenicity problems of the AdV system that may exist 
when it is used in a target population of African children between the ages of one and 
six.  This age group lives in a highly endemic region for malaria.  It has already been shown 
that vector immunogenicity, provided by sequential immunization with two attenuated 
poxvirus vectors, was less effective in affording protection when immunized children were 
compared with naturally immune adults in Africa and malaria-naïve volunteers from 
developed countries (Bejon et al., 2006).  
7.3 Tuberculosis (TB) vaccines 
AdV vaccine programs are being investigated for human TB, but these programs are slightly 
hindered due to the absence of a good experimental model for humans during 
challenge.   Currently, M. bovis BCG is being developed as a representative challenge for 
human M. tuberculosis (Draper & Heeney, 2010).  The AdV in clinical trials for M. tuberculosis 
aims to circumvent vector immunity by utilizing HAdV35 in place of HAdV5.  AERAS-402 
utilizes a live, replication-deficient rHAdV35 that expresses a fusion protein of three 
Mycobacterium tuberculosis antigens, 85A, 85B, and 10.4 (Radosevic et al., 2007).  This 
platform has demonstrated safety and efficacy in adults that were primed by BCG or 
recombinant BCG. The system intends to increase T cell-mediated immunity and, thus, 
protection from tuberculosis.  Preclinical studies are exploring the potential of aerosolized 
delivery for AERAS-402 in an attempt to intensify mucosal immunity to provide greater 
protection against M. tuberculosis infection.  However, in order to address these issues, more 
preclinical data needs to be collected from non-human primates. 
7.4 Influenza vaccines 
The establishment of an influenza vaccine that protects against multiple strains is a major 
undertaking and a long sought after goal.  Given the current circumstances of the seasonal 
emergence of new permutations of influenza, the past pandemic involving the 2009 H1N1 
influenza type A strain, and the possibility of highly pathogenic avian influenza to attain 
pandemic potential, accomplishing this goal is imperative. Inducing variant-specific 
antibody responses against the surface antigens, hemagglutinin and neuraminidase, is not 
the best way to combat influenza viruses which are constantly changing their surface 
proteins due to antigenic drift. Initiating a strong T cell response in addition to neutralizing 
antibody response to conserved T and B cell epitopes is important for protection against 
influenza variants.    
AdV-based influenza vaccines provide particular advantages over egg-based influenza 
vaccines due to their low production costs and the quick and easy manufacturing of a 
substantial amount in validated cell lines. Replication-competent as well as replication-
defective AdV vectors have been developed to express distinct influenza antigens.  Each 
construct has been evaluated for its immunogenicity and efficacy in a variety of animal 
models, and a few formulations have been evaluated for the safety and efficacy in clinical 
trials in humans.   
Immunization of mice with an AdV expressing the HA gene from swine influenza virus -
A/Swine/Iowa/1999 (H3N2) resulted in high levels of influenza-specific neutralizing 
antibodies.  Also, the immunization led to partial protection against a lethal challenge with a 
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A HAdV5-based HIV-1 vaccine was tested in humans in a Phase II trial to evaluate the risk 
for acquiring HIV infection. Unfortunately this trial was halted because the monitoring 
board determined that the vaccine was not able to demonstrate protection (Buchbinder et 
al., 2008; McElrath et al., 2008; Priddy et al., 2008). Future goals are focused on additional 
optimization of vaccine immunogens and technologies (Bradac & Dieffenbach, 2009). Since 
other researchers report the ability to induce a high level of cell-mediated immune response 
in non-HIV formulations, this is the time to apply this proof of principle to the area of HIV 
vaccine research.   
In other areas of research, an AdV vector with chimeric fiber is used to infect autologous T 
cells to facilitate HIV therapy.  This chimeric fiber contains both the HAdV5 fiber tail and 
the HAdV35 fiber shaft and knob domains (Perez et al., 2008). Due to its specificity to CCR5, 
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while preliminary, are encouraging.  Also, the modified CD4+ T cells treated with this 
vector are well-tolerated and engraft, replicate, and persist within the body after a single 
infusion.  They behave like unmodified T-cells in so much as they migrate to the gut mucosa 
where they undergo selective expansion (Barouch, 2010). When used in combination with 
conventional anti-HIV therapies, this strategy might prove beneficial. 
Different immunization strategies include a prime-boost approach with AdV-modified 
vaccinia virus Ankara (MVA) or heterologous HAdV5 and HAdV35 regimens or triple 
combinations which further elicit both T and B cell responses.  The use of HAdV26 and 
HAdV35 in a prime-boost approach has shown promise in avoiding pre-existing vector 
immunity (Barouch, 2010). Immunization with HAdV26-Gag and HAdV35-Gag resulted in 
increased levels of CD127, CD62L, and Bcl-2 on T cells compared to HAdV5-Gag 
inoculation.  These markers are indicative of improved functioning in T lymphocytes.  There 
is also increased proliferation potential as well as increased antigen specificity. 
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Malaria is characterized by several molecular interactions between the parasite and host 
during the parasite’s incubation.  An effective malaria vaccine will vigorously induce 
protective antibody and T cell responses to various malaria antigens that are expressed 
during the parasite’s differentiation at the various life stages.  Currently a mixture of two 
HAdV-5 vectors which express the pre-erthrocytic-stage malaria antigen circumsporozoite 
protein (CSP) or blood-stage malaria antigen apical membrane antigen 1 (AMA1) have 
demonstrated some success and are in Phase I/II of clinical trials.  After immunization, 
human volunteers had a remarkable response to each antigen.  Depletion studies 
determined that the response was due to a mixed population of CD8+ and CD4+ T 
cells.   The CD8+ T cell lineage was five times greater than the CD4+phenotype when IFN-γ 
secreting cells were assayed within the response population (Draper & Heeney, 2010).   
Another malaria vaccine platform involves the use of rAdV of rarer human serotypes or of 
non-human origin.  These designs are engineered in such a way as to avoid pre-existing 
vector immunity against HAdV5. Some preclinical trials investigate priming with one AdV 
(i.e., HAdV5) and boosting with a heterologous AdV (i.e., HAdV35).  Another strategy uses 
chimpanzee AdV serotype 63 (AdVCh63).   AdVCh63 expresses the pre-erthrocytic-stage 
antigen thrombospondin-related adhesion protein combined with a multi-epitope string 
(ME-TRAP).  A preclinical study utilizing a HAdV5 vector for priming followed with a 
boost by a MVA vector to promote the antibody and T cell responses.  This particular 
HAdV5-MVA protocol used vectors that had been recombined with blood-stage malaria 
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antigen merozoite surface protein 1 (MSP1) which induces a T cell response which was 
partially effective against the liver-stage infection (Draper et al., 2009) and a protective 
antibody response effective against the blood-stage infection (Draper et al., 2008). Future 
studies will have to address the immunogenicity problems of the AdV system that may exist 
when it is used in a target population of African children between the ages of one and 
six.  This age group lives in a highly endemic region for malaria.  It has already been shown 
that vector immunogenicity, provided by sequential immunization with two attenuated 
poxvirus vectors, was less effective in affording protection when immunized children were 
compared with naturally immune adults in Africa and malaria-naïve volunteers from 
developed countries (Bejon et al., 2006).  
7.3 Tuberculosis (TB) vaccines 
AdV vaccine programs are being investigated for human TB, but these programs are slightly 
hindered due to the absence of a good experimental model for humans during 
challenge.   Currently, M. bovis BCG is being developed as a representative challenge for 
human M. tuberculosis (Draper & Heeney, 2010).  The AdV in clinical trials for M. tuberculosis 
aims to circumvent vector immunity by utilizing HAdV35 in place of HAdV5.  AERAS-402 
utilizes a live, replication-deficient rHAdV35 that expresses a fusion protein of three 
Mycobacterium tuberculosis antigens, 85A, 85B, and 10.4 (Radosevic et al., 2007).  This 
platform has demonstrated safety and efficacy in adults that were primed by BCG or 
recombinant BCG. The system intends to increase T cell-mediated immunity and, thus, 
protection from tuberculosis.  Preclinical studies are exploring the potential of aerosolized 
delivery for AERAS-402 in an attempt to intensify mucosal immunity to provide greater 
protection against M. tuberculosis infection.  However, in order to address these issues, more 
preclinical data needs to be collected from non-human primates. 
7.4 Influenza vaccines 
The establishment of an influenza vaccine that protects against multiple strains is a major 
undertaking and a long sought after goal.  Given the current circumstances of the seasonal 
emergence of new permutations of influenza, the past pandemic involving the 2009 H1N1 
influenza type A strain, and the possibility of highly pathogenic avian influenza to attain 
pandemic potential, accomplishing this goal is imperative. Inducing variant-specific 
antibody responses against the surface antigens, hemagglutinin and neuraminidase, is not 
the best way to combat influenza viruses which are constantly changing their surface 
proteins due to antigenic drift. Initiating a strong T cell response in addition to neutralizing 
antibody response to conserved T and B cell epitopes is important for protection against 
influenza variants.    
AdV-based influenza vaccines provide particular advantages over egg-based influenza 
vaccines due to their low production costs and the quick and easy manufacturing of a 
substantial amount in validated cell lines. Replication-competent as well as replication-
defective AdV vectors have been developed to express distinct influenza antigens.  Each 
construct has been evaluated for its immunogenicity and efficacy in a variety of animal 
models, and a few formulations have been evaluated for the safety and efficacy in clinical 
trials in humans.   
Immunization of mice with an AdV expressing the HA gene from swine influenza virus -
A/Swine/Iowa/1999 (H3N2) resulted in high levels of influenza-specific neutralizing 
antibodies.  Also, the immunization led to partial protection against a lethal challenge with a 
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heterologous virus [A/HK/1/1968 (H3N2)] (Tang et al., 2002). Intranasal or epicutaneous 
immunization of humans with a replication-defective AdV encoding the HA gene of 
A/PR/8/1934 (H1N1) influenza virus resulted in a fourfold increase in hemagglutination 
inhibition (HI) titers in 83% of the participants (Van Kampen et al., 2005).  The presence of 
pre-existing vector immunity did not seem to have a significant impact on the resultant 
hemagglutinin (HA)-specific immune response.   
A replication defective HAdV5 influenza A (HAd-H5HA) vaccine containing the HA gene 
from HK/156/97 (H5N1) was evaluated for immunogenicity and protection in a mouse 
model (Hoelscher et al., 2006). The immunization resulted in the development of epitope-
specific CD8 T cells and virus neutralizing antibodies.  HAd-H5HA expresses HA from 
H5N1 influenza strain A/Hong Kong/156/1997 (HK/156/97) and is administered 
intramuscularly or intranasally.   This vaccine construct provided complete protection to 
mice when challenged with homologous (HK/156/97) or heterologous (VN/1203/04) 
H5N1 influenza virus challenge indicating that HAd-H5HA afforded cross-protection to 
antigenically distinct strains of highly pathogenic H5N1. Immunized mice with HAd-
H5HA were fully protected following challenge with a homologous H5N1 virus even 
after one year following immunization (Hoelscher et al., 2007). Inclusion of the HA genes 
from clade 1 and clade 2 H5N1 influenza viruses and the NP gene from one of the clades 
in the AdV-based vaccine resulted in expanded protection (Hoelscher et al., 2008). A 
replication-defective AdV vector expressing the HA gene from a H5N1 influenza virus 
has been tested in a Phase 1 clinical trial.  The replication competent HAdV4 vector-based 
vaccine containing the HA gene of a H5N1 virus induced both humoral and mucosal 
antibodies as well as a cellular immune response when administered in a enteric capsule 
(Palkonyay, 2009).  
An AdV vector provokes both humoral and cellular immune responses. If an AdV is 
engineered to carry multiple genes from different influenza strains, this will enhance the 
cross-protective efficacy against multiple strains. An AdV that is loaded with cross-reactive 
potential will provide a stockpiling option to address the vaccine need for a potential H5N1-
based pandemic influenza (Vemula & Mittal, 2010). 
7.5 Filovirus vaccine 
In the effort to battle Ebola and Marburg viruses, a Phase I study has been completed using 
a mixture of two replication-deficient, rAdV5 (Ebola-rAdV5) encoding glycoproteins (GP) 
from Zaire and Sudan-Gulu strains, as well as the nucleoprotein (NP) of filovirus. It 
demonstrated excellent pre-clinical results with 100% protection in monkeys, but, 
apparently, it did not do well in human clinical trials (Martin et al., 2006). Virus neutralizing 
antibodies that were specific for the virus strains used in the trial were undetectable in the 
persons vaccinated.  It was also determined that NP was not necessary for inclusion in the 
vaccine construct and may actually dampen the protective immune response (Sullivan et al., 
2006).  
8. Improving adenovirus based gene transfer- strategies for immune evasion 
Staggering innate and adaptive immune responses have undoubtedly limited the 
therapeutic potential of AdV based gene transfer. However, the extensive promise that Ad 
vectors offer for improving human and animal health has fueled tremendous interest in 
acquiring a deeper understanding of molecular mechanisms underlying the immune 
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activation. Several promising innovative strategies to eliminate or minimize the acute 
inflammatory responses induced by AdV vectors, as well as to circumvent the vector 
immunity in order to prolong the vector persistence in host are being developed. 
8.1 Immunosuppression and immunomodulation  
Elimination of a significant fraction of intravascularly administered AdV vectors within 
initial twenty-four hours is attributed to elements of non-specific innate immune response, 
particularly the liver Kupffer cells, acting as a buffer against invading pathogen. Hepatocyte 
transduction occurs only after the saturation of kupffer cells at higher doses (Di Paolo et al., 
2009). Removal of Kupffer cells is expected to result in higher hepatocyte transduction 
efficiency. In fact, transient depletion of macrophages prior to vector inoculation using pre-
treatment with gadolinium chloride (GdCl3) or dicholoromethylene bisphosphate (Cl2MBP) 
not only reduces the initial vector clearance, but also seem to prolong the long-term 
transgene expression, possibly through attenuating the vector-specific adaptive immune 
responses (Kuzmin et al., 1997; Lieber et al., 1997). Although an effective macrophage 
depletion strategy may not be able to prevent vector elimination entirely since other 
mechanisms are also involved, this strategy might be used effectively in combination with 
other immune suppression methods.    
The anti-vector humoral and cytotoxic immune responses are primarily responsible for 
preventing long-term transgene expression and act by eliminating the vector-transduced 
cells. Several studies have shown that treatment with non-specific immunosuppressive 
agents such as cyclosporine A, cyclophosphamide, deoxypergualin, dexamethasone and 
FK506 at the time of vector administration in presence of pre-existing immunity can 
suppress progression of humoral and/or cellular immune response and prolong the 
persistence of transgene in the host (Kaplan & Smith, 1997; Kuriyama et al., 2000; Seregin et 
al., 2009; Smith et al., 1996; Thomas et al., 2008). Similar effects can be obtained through 
transient immunosuppression by using specific antibodies targeted against molecules such 
as T lymphocyte antigens, CD4, CD40, or CD86 to block the receptor-ligand interaction 
(Chirmule et al., 2000; Haegel-Kronenberger et al., 2004; Ye et al., 2000). Many AdV vector 
applications require administration of high vector doses and, therefore, necessitate 
prevention or mitigation of an AdV-induced acute inflammatory response. Simultaneous 
administration of suppressor of cytokine signaling 1 (SOCS-1) results in generalized lower 
serum levels of cytokines, including IL-6, MCP-1, RANTES and TNF-α (Sakurai et al., 2008). 
Other studies have targeted suppression of specific cytokines, for example, TNF-α 
(Wilderman et al., 2006) and IFN-α/β (Zhu et al., 2007) resulted in significant reduction of 
the inflammatory response. Interestingly, a regimen for the inhibition of multiple cytokines 
at same time may have an additive or synergistic effect on inhibition of the inflammatory 
response. However, caution must be exercised for interpreting the results of such studies as 
species-specific variations may exist, and the observation made in animal models may not 
be replicated in humans. Each immunosuppressive or immunomodulatory approach needs 
to be thoroughly evaluated for potential side effects before their transition to clinical trials. 
Additionally, although transient, a generalized immunosuppression might render the 
patients more vulnerable to other diseases.  
8.2 Vector modifications  
Strategies involving vector modifications impose lesser risk to the host than those that 
involve attenuating or modifying host immune responses. Vector modifications can be 
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hemagglutinin (HA)-specific immune response.   
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H5HA were fully protected following challenge with a homologous H5N1 virus even 
after one year following immunization (Hoelscher et al., 2007). Inclusion of the HA genes 
from clade 1 and clade 2 H5N1 influenza viruses and the NP gene from one of the clades 
in the AdV-based vaccine resulted in expanded protection (Hoelscher et al., 2008). A 
replication-defective AdV vector expressing the HA gene from a H5N1 influenza virus 
has been tested in a Phase 1 clinical trial.  The replication competent HAdV4 vector-based 
vaccine containing the HA gene of a H5N1 virus induced both humoral and mucosal 
antibodies as well as a cellular immune response when administered in a enteric capsule 
(Palkonyay, 2009).  
An AdV vector provokes both humoral and cellular immune responses. If an AdV is 
engineered to carry multiple genes from different influenza strains, this will enhance the 
cross-protective efficacy against multiple strains. An AdV that is loaded with cross-reactive 
potential will provide a stockpiling option to address the vaccine need for a potential H5N1-
based pandemic influenza (Vemula & Mittal, 2010). 
7.5 Filovirus vaccine 
In the effort to battle Ebola and Marburg viruses, a Phase I study has been completed using 
a mixture of two replication-deficient, rAdV5 (Ebola-rAdV5) encoding glycoproteins (GP) 
from Zaire and Sudan-Gulu strains, as well as the nucleoprotein (NP) of filovirus. It 
demonstrated excellent pre-clinical results with 100% protection in monkeys, but, 
apparently, it did not do well in human clinical trials (Martin et al., 2006). Virus neutralizing 
antibodies that were specific for the virus strains used in the trial were undetectable in the 
persons vaccinated.  It was also determined that NP was not necessary for inclusion in the 
vaccine construct and may actually dampen the protective immune response (Sullivan et al., 
2006).  
8. Improving adenovirus based gene transfer- strategies for immune evasion 
Staggering innate and adaptive immune responses have undoubtedly limited the 
therapeutic potential of AdV based gene transfer. However, the extensive promise that Ad 
vectors offer for improving human and animal health has fueled tremendous interest in 
acquiring a deeper understanding of molecular mechanisms underlying the immune 
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activation. Several promising innovative strategies to eliminate or minimize the acute 
inflammatory responses induced by AdV vectors, as well as to circumvent the vector 
immunity in order to prolong the vector persistence in host are being developed. 
8.1 Immunosuppression and immunomodulation  
Elimination of a significant fraction of intravascularly administered AdV vectors within 
initial twenty-four hours is attributed to elements of non-specific innate immune response, 
particularly the liver Kupffer cells, acting as a buffer against invading pathogen. Hepatocyte 
transduction occurs only after the saturation of kupffer cells at higher doses (Di Paolo et al., 
2009). Removal of Kupffer cells is expected to result in higher hepatocyte transduction 
efficiency. In fact, transient depletion of macrophages prior to vector inoculation using pre-
treatment with gadolinium chloride (GdCl3) or dicholoromethylene bisphosphate (Cl2MBP) 
not only reduces the initial vector clearance, but also seem to prolong the long-term 
transgene expression, possibly through attenuating the vector-specific adaptive immune 
responses (Kuzmin et al., 1997; Lieber et al., 1997). Although an effective macrophage 
depletion strategy may not be able to prevent vector elimination entirely since other 
mechanisms are also involved, this strategy might be used effectively in combination with 
other immune suppression methods.    
The anti-vector humoral and cytotoxic immune responses are primarily responsible for 
preventing long-term transgene expression and act by eliminating the vector-transduced 
cells. Several studies have shown that treatment with non-specific immunosuppressive 
agents such as cyclosporine A, cyclophosphamide, deoxypergualin, dexamethasone and 
FK506 at the time of vector administration in presence of pre-existing immunity can 
suppress progression of humoral and/or cellular immune response and prolong the 
persistence of transgene in the host (Kaplan & Smith, 1997; Kuriyama et al., 2000; Seregin et 
al., 2009; Smith et al., 1996; Thomas et al., 2008). Similar effects can be obtained through 
transient immunosuppression by using specific antibodies targeted against molecules such 
as T lymphocyte antigens, CD4, CD40, or CD86 to block the receptor-ligand interaction 
(Chirmule et al., 2000; Haegel-Kronenberger et al., 2004; Ye et al., 2000). Many AdV vector 
applications require administration of high vector doses and, therefore, necessitate 
prevention or mitigation of an AdV-induced acute inflammatory response. Simultaneous 
administration of suppressor of cytokine signaling 1 (SOCS-1) results in generalized lower 
serum levels of cytokines, including IL-6, MCP-1, RANTES and TNF-α (Sakurai et al., 2008). 
Other studies have targeted suppression of specific cytokines, for example, TNF-α 
(Wilderman et al., 2006) and IFN-α/β (Zhu et al., 2007) resulted in significant reduction of 
the inflammatory response. Interestingly, a regimen for the inhibition of multiple cytokines 
at same time may have an additive or synergistic effect on inhibition of the inflammatory 
response. However, caution must be exercised for interpreting the results of such studies as 
species-specific variations may exist, and the observation made in animal models may not 
be replicated in humans. Each immunosuppressive or immunomodulatory approach needs 
to be thoroughly evaluated for potential side effects before their transition to clinical trials. 
Additionally, although transient, a generalized immunosuppression might render the 
patients more vulnerable to other diseases.  
8.2 Vector modifications  
Strategies involving vector modifications impose lesser risk to the host than those that 
involve attenuating or modifying host immune responses. Vector modifications can be 
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achieved through several different strategies, each with its own advantages and 
disadvantages, and will vary pertinent to the specific application. Vector modifications can 
consist of many alternatives such as (1) those intended to ablate interactions between AdV 
and its primary and/or secondary receptor, (2) fiber knob modifications to retarget vector to 
specific cell types, (3) replacement of fibers using serotype chimerism, (3) covalent 
modifications, (4) vector pseudotyping, and (5) vector microencapsulation. 
8.2.1 Fiber knob modification  
Binding of the HAdV5 fiber knob domain to CAR on the cell surface is the foremost step in 
virus entry. Multiple strategies are available for altering the natural biodistribution pattern 
of AdV vectors and retargeting them to specific cell types. Complexing the vector with a bi-
specific antibody for recognizing the fiber knob or a specific cell surface molecule will serve 
the dual purpose of ablating knob-CAR interaction and targeting the modified vector to an 
alternative receptor (Curiel, 1999; Mizuguchi & Hayakawa, 2004). Alternatively, the vector 
can be treated with a CAR ectodomain-single chain antibody targeted against a tissue-
specific antigen. The CAR ectodomain will bind to the fiber knob preventing interaction 
between CAR on cell surface. The single chain antibody will retarget the vector to the 
specific cell type (Li et al., 2009). In vivo, the fiber knob domain also interacts with 
coagulation factor IX and factor C4BP, targeting AdV vectors to HSPGs and LRP on 
hepatocytes and Kupffer cells. Consequently, fiber knob modifications might also ablate 
these interactions, thereby reducing liver transduction and subsequent hepatotoxicity 
(Shayakhmetov et al., 2005). 
8.2.2 Serotype chimerism 
Chimeric AdV vectors are most commonly constructed by replacing the knob domain or 
whole fiber with one from an alternative AdV serotype. Remarkable similarities among 
fibers of different Ad serotypes allows for the ‘fiber chimerism’. Since the subgroup B 
viruses use cell surface molecules other then CAR as their primary attachment receptor, it 
is credible to replace HAdV5 fiber knob with one of a subgroup B virus, or vice versa, and 
expect a shift in vector biodistribution. Expectedly, fibers from subgroup B AdV have 
been successfully used for constructing HAdV5-based fiber chimeric vectors with an 
altered biodistribution pattern compared to HAdV5 alone. For example, HAdV5 carrying 
a fiber knob from HAdV16p, a subgroup B virus, showed greater transduction of 
cardiovascular and synovial tissues (Havenga et al., 2001). Similarly, HAdV5 with fiber 
from HAdV35, another subgroup B virus, showed enhanced transduction of 
hematopoeitic cells and human pancreatic cancer cells in vitro (Shayakhmetov et al., 2000; 
Toyoda et al., 2008).  
Alternatively, the replacement of only the knob domain instead of the whole fiber has also 
been evaluated. A HAdV5 vector with fiber knob domain from HAdV3 proved to be 
remarkably efficient for gene transfer in animal models of breast cancer, ovarian cancer, 
gastric cancer and renal cancer and also showed good oncolytic ability (Ranki & Hemminki, 
2010). A recent study explained the possibility of exploiting non-human AdV vectors for 
constructing fiber chimerism. Replacing the HAdV5 shaft and knob domains of HAdV5 
with those from a bovine AdV ablated the vector interaction with blood factors IX and X and 
the subsequent HSPG-mediated hepatocyte transduction. As a result, serum levels of many 
of the pro-inflammatory cytokines and chemokines at early time points after the 
intravascular inoculation were significantly reduced (Rogee et al., 2010). 
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The major capsid protein hexon of HAdV5 interacts with factor X and mediates hepatocyte 
transduction. Being the most abundant capsid protein, it is expected to contribute 
significantly to non-CAR-dependent tropism. However, not all AdV serotypes bind factor X, 
and therefore, have variable hepatocyte transduction profiles in vivo. Chimeric HAdV5 27 
vectors whose HVRs were replaced with HVRs of HAdV26 or HAdV27, which do not bind 
factor X, ablated factor X binding and showed a reduced hepatocyte transduction at a 
comparatively high dose (1011 vp/mouse). However, a greater degree of macrophage 
transduction was observed, giving a possible reason for the concomitant higher degree of 
proinflammatory cytokine and chemokine response following intravascular administration 
of the hexon chimeric HAdV5 vector. Interestingly, inserting HAdV35 fiber in place of 
native fiber of this chimeric HAdV5 vector dramatically increased lung transduction by 
more than 16000 times compared to the vector with HAdV5 fiber (Alba et al., 2010). Such a 
vector may prove very useful for lung gene therapy applications. Furthermore, this study 
also highlighted an interesting possibility of combining hexon and fiber chimerism to 
construct novel vectors with decreased immunogenicity and suitability for a particular 
application. Recently, another study reported a chimeric HAdV5 vector with the hexon from 
HAdV3. This chimeric vector showed ablation for factor X binding, which translated into 
reduced liver transduction and enhanced anti-tumor activity, owing to greater 
bioavailability of the vector for tumor transduction (Short et al., 2010). 
8.3 Covalent modification of Ad capsid  
Covalent modification of AdV capsids is an attractive alternative to genetic modification for 
preventing induction of immune responses and the acute toxicity following systemic 
administration. Addition of chemical groups to AdV capsids masks the natural 
immunodominant epitopes and the molecular patterns required for interaction with Ad-
neutralizing antibodies along with the pattern recognition receptors, thereby preventing 
antibody-mediated vector clearance and induction of innate immune responses. Several 
standardized methods for covalent modifications are available for the generation of high 
titer stocks of modified vectors. Furthermore, simultaneous modification of a large number 
of capsid amino acids is feasible with covalent modification which may not be possible 
through genetic modification. Multiple studies have reported the so-called ‘stealth AdV 
vectors’ modified with synthetic polymers, for example, polyethylene glycol (PEG) (Kreppel 
& Kochanek, 2008). In accordance with the above principles, covalently modified AdV 
vectors have been shown to prevent or attenuate the induction of innate and adaptive 
immune responses, as well as, to evade pre-existing AdV-neutralizing antibodies (Croyle et 
al., 2002; Croyle et al., 2005). In addition, the use of bifunctional PEG allows for tissue-
specific targeting of AdV vectors by coupling one functional group to capsid proteins and 
another functional group to a ligand of a specific tissue receptor (Park et al., 2008).  
8.4 Alternative Ad vectors  
Since AdV-neutralizing antibodies are serotype-specific and the prevalence of some of the 
HAdV serotypes in the human population is rare, HAdV vectors derived from the rare 
HAdV serotypes can potentially circumvent the pre-existing vector immunity, and, 
therefore, be more effective than vectors derived from common HAdV serotypes such as 
HAdV5. Vector systems based on HAdV serotypes in all subgroups have been reported 
(Appledorn et al., 2008a). 
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achieved through several different strategies, each with its own advantages and 
disadvantages, and will vary pertinent to the specific application. Vector modifications can 
consist of many alternatives such as (1) those intended to ablate interactions between AdV 
and its primary and/or secondary receptor, (2) fiber knob modifications to retarget vector to 
specific cell types, (3) replacement of fibers using serotype chimerism, (3) covalent 
modifications, (4) vector pseudotyping, and (5) vector microencapsulation. 
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virus entry. Multiple strategies are available for altering the natural biodistribution pattern 
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specific antibody for recognizing the fiber knob or a specific cell surface molecule will serve 
the dual purpose of ablating knob-CAR interaction and targeting the modified vector to an 
alternative receptor (Curiel, 1999; Mizuguchi & Hayakawa, 2004). Alternatively, the vector 
can be treated with a CAR ectodomain-single chain antibody targeted against a tissue-
specific antigen. The CAR ectodomain will bind to the fiber knob preventing interaction 
between CAR on cell surface. The single chain antibody will retarget the vector to the 
specific cell type (Li et al., 2009). In vivo, the fiber knob domain also interacts with 
coagulation factor IX and factor C4BP, targeting AdV vectors to HSPGs and LRP on 
hepatocytes and Kupffer cells. Consequently, fiber knob modifications might also ablate 
these interactions, thereby reducing liver transduction and subsequent hepatotoxicity 
(Shayakhmetov et al., 2005). 
8.2.2 Serotype chimerism 
Chimeric AdV vectors are most commonly constructed by replacing the knob domain or 
whole fiber with one from an alternative AdV serotype. Remarkable similarities among 
fibers of different Ad serotypes allows for the ‘fiber chimerism’. Since the subgroup B 
viruses use cell surface molecules other then CAR as their primary attachment receptor, it 
is credible to replace HAdV5 fiber knob with one of a subgroup B virus, or vice versa, and 
expect a shift in vector biodistribution. Expectedly, fibers from subgroup B AdV have 
been successfully used for constructing HAdV5-based fiber chimeric vectors with an 
altered biodistribution pattern compared to HAdV5 alone. For example, HAdV5 carrying 
a fiber knob from HAdV16p, a subgroup B virus, showed greater transduction of 
cardiovascular and synovial tissues (Havenga et al., 2001). Similarly, HAdV5 with fiber 
from HAdV35, another subgroup B virus, showed enhanced transduction of 
hematopoeitic cells and human pancreatic cancer cells in vitro (Shayakhmetov et al., 2000; 
Toyoda et al., 2008).  
Alternatively, the replacement of only the knob domain instead of the whole fiber has also 
been evaluated. A HAdV5 vector with fiber knob domain from HAdV3 proved to be 
remarkably efficient for gene transfer in animal models of breast cancer, ovarian cancer, 
gastric cancer and renal cancer and also showed good oncolytic ability (Ranki & Hemminki, 
2010). A recent study explained the possibility of exploiting non-human AdV vectors for 
constructing fiber chimerism. Replacing the HAdV5 shaft and knob domains of HAdV5 
with those from a bovine AdV ablated the vector interaction with blood factors IX and X and 
the subsequent HSPG-mediated hepatocyte transduction. As a result, serum levels of many 
of the pro-inflammatory cytokines and chemokines at early time points after the 
intravascular inoculation were significantly reduced (Rogee et al., 2010). 
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The major capsid protein hexon of HAdV5 interacts with factor X and mediates hepatocyte 
transduction. Being the most abundant capsid protein, it is expected to contribute 
significantly to non-CAR-dependent tropism. However, not all AdV serotypes bind factor X, 
and therefore, have variable hepatocyte transduction profiles in vivo. Chimeric HAdV5 27 
vectors whose HVRs were replaced with HVRs of HAdV26 or HAdV27, which do not bind 
factor X, ablated factor X binding and showed a reduced hepatocyte transduction at a 
comparatively high dose (1011 vp/mouse). However, a greater degree of macrophage 
transduction was observed, giving a possible reason for the concomitant higher degree of 
proinflammatory cytokine and chemokine response following intravascular administration 
of the hexon chimeric HAdV5 vector. Interestingly, inserting HAdV35 fiber in place of 
native fiber of this chimeric HAdV5 vector dramatically increased lung transduction by 
more than 16000 times compared to the vector with HAdV5 fiber (Alba et al., 2010). Such a 
vector may prove very useful for lung gene therapy applications. Furthermore, this study 
also highlighted an interesting possibility of combining hexon and fiber chimerism to 
construct novel vectors with decreased immunogenicity and suitability for a particular 
application. Recently, another study reported a chimeric HAdV5 vector with the hexon from 
HAdV3. This chimeric vector showed ablation for factor X binding, which translated into 
reduced liver transduction and enhanced anti-tumor activity, owing to greater 
bioavailability of the vector for tumor transduction (Short et al., 2010). 
8.3 Covalent modification of Ad capsid  
Covalent modification of AdV capsids is an attractive alternative to genetic modification for 
preventing induction of immune responses and the acute toxicity following systemic 
administration. Addition of chemical groups to AdV capsids masks the natural 
immunodominant epitopes and the molecular patterns required for interaction with Ad-
neutralizing antibodies along with the pattern recognition receptors, thereby preventing 
antibody-mediated vector clearance and induction of innate immune responses. Several 
standardized methods for covalent modifications are available for the generation of high 
titer stocks of modified vectors. Furthermore, simultaneous modification of a large number 
of capsid amino acids is feasible with covalent modification which may not be possible 
through genetic modification. Multiple studies have reported the so-called ‘stealth AdV 
vectors’ modified with synthetic polymers, for example, polyethylene glycol (PEG) (Kreppel 
& Kochanek, 2008). In accordance with the above principles, covalently modified AdV 
vectors have been shown to prevent or attenuate the induction of innate and adaptive 
immune responses, as well as, to evade pre-existing AdV-neutralizing antibodies (Croyle et 
al., 2002; Croyle et al., 2005). In addition, the use of bifunctional PEG allows for tissue-
specific targeting of AdV vectors by coupling one functional group to capsid proteins and 
another functional group to a ligand of a specific tissue receptor (Park et al., 2008).  
8.4 Alternative Ad vectors  
Since AdV-neutralizing antibodies are serotype-specific and the prevalence of some of the 
HAdV serotypes in the human population is rare, HAdV vectors derived from the rare 
HAdV serotypes can potentially circumvent the pre-existing vector immunity, and, 
therefore, be more effective than vectors derived from common HAdV serotypes such as 
HAdV5. Vector systems based on HAdV serotypes in all subgroups have been reported 
(Appledorn et al., 2008a). 
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8.5 Non-human Ad vectors  
Vectors based on nonhuman AdV serotypes are very promising candidates to serve as gene 
delivery vehicles and are frequently derived from AdV infecting bovine, porcine, ovine and 
chimpanzee. The nonhuman AdV do not cause disease in humans and are not neutralized 
by the HAdV-specific neutralizing antibodies (Moffatt et al., 2000; Sharma et al., 2010; Singh 
et al., 2008). In addition, nonhuman AdV vectors have been shown to transduce human cells 
in culture and express transgene (Bangari et al., 2005; Bangari & Mittal, 2004; Farina et al., 
2001; Klonjkowski et al., 1997; Mittal et al., 1995; Rasmussen et al., 1999). Advances in the 
past decade signify the potential of nonhuman AdV vectors as effective gene delivery 
vehicles without any significant toxicity and interference from pre-existing immunity. A 
bovine AdV serotype 3 (BAdV3) vector has been shown to possess low liver tropism, 
prolonged vector genome persistence and, thereby, higher transgene expression than a 
HAdV5 vector in the heart, lungs, and kidneys of mice following intravenous inoculation 
(Sharma et al., 2009a). The humoral as well as cellular immune responses generated against 
various non-human AdV are expected to be non cross-neutralizing (Sharma et al., 2010). 
Sequential use of alternative non-human AdV-derived vectors  might prolong the transgene 
expression and, therefore, the desired therapeutic effect. 
9. Conclusion 
The future of AdV vectors is very promising.  Much research has been conducted on the 
various constructs of the vectors with the hope of finding therapies that will enable specific 
targeting of diseased cells or tumors thereby causing minimum harm to surrounding cells or 
organs.  With continued research on the mechanisms of AdV gene expression and tissue 
tropism, the medical and scientific communities have great reason to anticipate 
breakthroughs in cancer and vaccine therapies.  
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8.5 Non-human Ad vectors  
Vectors based on nonhuman AdV serotypes are very promising candidates to serve as gene 
delivery vehicles and are frequently derived from AdV infecting bovine, porcine, ovine and 
chimpanzee. The nonhuman AdV do not cause disease in humans and are not neutralized 
by the HAdV-specific neutralizing antibodies (Moffatt et al., 2000; Sharma et al., 2010; Singh 
et al., 2008). In addition, nonhuman AdV vectors have been shown to transduce human cells 
in culture and express transgene (Bangari et al., 2005; Bangari & Mittal, 2004; Farina et al., 
2001; Klonjkowski et al., 1997; Mittal et al., 1995; Rasmussen et al., 1999). Advances in the 
past decade signify the potential of nonhuman AdV vectors as effective gene delivery 
vehicles without any significant toxicity and interference from pre-existing immunity. A 
bovine AdV serotype 3 (BAdV3) vector has been shown to possess low liver tropism, 
prolonged vector genome persistence and, thereby, higher transgene expression than a 
HAdV5 vector in the heart, lungs, and kidneys of mice following intravenous inoculation 
(Sharma et al., 2009a). The humoral as well as cellular immune responses generated against 
various non-human AdV are expected to be non cross-neutralizing (Sharma et al., 2010). 
Sequential use of alternative non-human AdV-derived vectors  might prolong the transgene 
expression and, therefore, the desired therapeutic effect. 
9. Conclusion 
The future of AdV vectors is very promising.  Much research has been conducted on the 
various constructs of the vectors with the hope of finding therapies that will enable specific 
targeting of diseased cells or tumors thereby causing minimum harm to surrounding cells or 
organs.  With continued research on the mechanisms of AdV gene expression and tissue 
tropism, the medical and scientific communities have great reason to anticipate 
breakthroughs in cancer and vaccine therapies.  
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1. Introduction  
The concept of gene therapy is defined as a biomedical technology to treat diseases with 
functional genes or therapeutic genes by transferring these genes into cells. According to the 
most comprehensive source of information on worldwide gene therapy clinical trials 
available on the internet from “The Journal of Gene Medicine” clinical trial site 
(http://www.wiley.com/genmed/clinical), there are 1060 clinical trials (64.5%) for cancer 
treatment among the total 1644 trials updated June 2010, and most of them (23.8%) use 
adenovirus as vector. However, gene therapy goes through one of gains and losses since the 
very day of its naissance. Until late 2009, gene therapy received a series of great 
achievements after years of silence. The journal, Science, appraised 10 breakthroughs of the 
Year 2009, in which the seventh was gene therapy. It brings us a rekindled hope for 
overcoming the genetic diseases including cancer.  
Adenoviral vectors have been used extensively in cancer gene therapy (Su et al., 2008; Yang 
et al., 2007). Most of them are replication-deficient (Yang, 1995). The first generated 
replication-deficient adenovirus lacks the E1 and E3 regions. The second and third ones also 
contain E2 and/or E4 deletions (Andrews et al., 2001; Thomas et al., 2003). Because the 
replication-deficient adenoviruses can not replicate, they express the foreign therapeutic 
genes only in the cells that are initially infected. Synchronously, they also lack a specificity 
target to cancer cells (Kurihara et al., 2000). These problems may decrease the therapeutic 
effect on cancer cells and result in toxicity to normal cells. Therefore, development of a novel 
tumor-targeting adenoviral vector is needed to enhance the efficiency and specificity of 
transgene expression. Oncolytic adenoviruses are promising as therapeutic agents in cancer 
treatment. These viruses are genetically modified to target, infect and replicate in cancer 
cells causing them to lyse with an improved, superior efficacy compared to non-replicating 
adenoviral vector which lacks the E1 genes. Here, combined with the studies of our group 
(Fang et al., 2009, 2010; He et al., 2009, 2010; Hu et al., 2010; Ma et al., 2009; Su et al., 2004, 
2006a, 2006b, 2008a, 2008b), we review the development of oncolytic adenovirus-based gene 
therapy for cancer, and figured the potential prospects of gene therapy in cancer treatment. 
2. Adenovirus gene therapy 
The strategy of virotherapy, a method for the treatment of cancer with viruses, has been 
revitalized since the appearance of a series of novel conditionally replicating adenoviruses 
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(CRAds), also known as oncolytic adenoviruses (Alemany et al., 2000). These tumor-
selective replicating viruses were designed to replicate preferentially in cancer cells, but not 
in normal cells. The infection, replication and oncolytic abilities of CRAds were targeted 
specifically to cancer cells and had little or no influence on the normal cells (Kirn et al., 
2001). After infecting one cancer cell and replicating in it, the viruses replicate and lyse the 
infected cell, and the progeny virions are released and infect the rest neighboring cancer 
cells. These cycles of infections and replications carry on repeatedly, making a chain reaction 
to facilitate viral spread within the cancer tissues till all cancer cells are destroyed 
(Ramachandra et al., 2001).  
As antitumor therapeutic agents, CRAds are accordingly armed with incontestable 
advantages and is superior to replication-deficient adenovirus. There are a number of 
ongoing preclinical or clinical trials with oncolytic adenoviruses in treatment of a variety of 
cancers, such as OBP-301 (Telomelysin) in lung and prostate cancers, Ad-dl922-947, Ad-
Onyx-015, Ad-Onyx-017, Ad-vKH1 and AdEHE2F in breast, colon, head and neck cancers 
(Bazan-Peregrino et al., 2008; Ouchi et al., 2009). A product of Onyx Pharmaceuticals 
(Richmond, CA), ONYX-015, is a replicative virus studied in clinical trials for several years. 
It is a chimeric human group C adenovirus (Ad2 and Ad5) modified by deletion between 
nucleotides 2496 and 3323 in the E1B region encoding the 55-kDa protein which binds the 
tumor suppressor protein p53. ONYX-015 has an ability to selectively replicate in and kill 
many human malignant tumor cells with mutations of p53 gene (Bischoff et al., 1996; Khuri 
et al., 2000).  
Although the replicative viruses have many advantages to exert antitumor efficacy, they 
also have limitations in cancer therapy. Durable responses in clinical trials with replicative 
viruses, including ONYX-015, as single oncolytic agents have not been very encouraging 
(Ganly et al., 2000). It is not unexpected that a virus utilizing one of many mechanisms, such 
as p53 pathway, to promote its replication does not have enough power to destroy all cancer 
cells. This intrinsic limitation of targeted therapies mandates devotion to developing a series 
of selectively replicating viruses targeted to different tumorigenesis pathways, and to 
refining on replicative viruses with higher specificity, lower toxicity and stronger oncolytic 
efficacy for different tumors and different patients. 
In order that viruses will specifically infect cancer cells, and the viral replication can be 
carefully controlled for the purpose of killing cancer cells safely and effectively, a cancer-
specific expression and transportation system is required. One attempt to achieve CRAd is 
to modify adenovirus by partial deletion of viral genes (Biederer et al., 2002; Ring, 2002). The 
representative of this type of CRAd is ONYX-015. Moreover, many cancers have their own 
special markers whose expression is controlled by the particular cis-acting elements and 
trans-acting factors. Another attempt to achieve CRAd is to place viral replicative genes 
under the control of cancer-specific promoters. Although these tissue- or cancer-specific 
promoters can provide the restricted viral replication in cancer cells by controlling the 
expression of viral replicative genes, their shortcomings are obvious and cannot be ignored. 
Firstly, they are limited to a narrow range of cancers expressing the targeted tumor markers, 
and cannot be used for treatment of cancers of different origins. Secondly, most of them are 
much weaker than commonly used viral promoters such as cytomegalovirus (CMV) or SV40 
early promoter (Gu et al., 2002). The expression of the genes driven by these specific 
promoters is generally in lower levels, thus attenuating their effects in cancer therapy (Su et 
al., 2004). 
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Many attempts have been made to improve both the antitumor potency and biosafety of 
approaches combining viral oncolytic therapy and transgene therapy. Genetic re-
engineering of CRAds by incorporating therapeutic payloads may yield mutually 
supportive antitumor effects. CRAd replication selectively amplifies therapeutic transgene 
expression in cancer cells (Haviv et al., 2001; Nanda et al., 2001), and transgene expression 
synchronously increases the spread of viral progeny within a tumor cell mass (Hermiston & 
Kuhn, 2002; Van Beusechem et al., 2002). It has been shown that the approach combining 
gene therapy with oncolytic virotherapy is more effective than their use individually. Many 
therapeutic transgenes have exhibited antitumor efficacy in experimental models, including 
cytotoxic genes, suicide genes, tumor suppressor genes, apoptosis-inducing genes, 
angiogenesis-inhibiting genes and immunostimulatory genes (Haviv & Curiel, 2003; Lam & 
Breakefield, 2001). Some strategies have employed CRAds armed with immunostimulatory 
genes to enhance their overall antitumor activity. Heat shock proteins (HSPs) play 
important roles in eliciting innate and adaptive immunity by chaperoning peptides for 
antigen presentation to antigen-presenting cells and providing endogenous danger 
signalling. The recombinant oncolytic adenoviruses overexpressing the HSP70 protein can 
accordingly eradicate primary tumors, as well as inhibit the growth of established metastatic 
tumors in mice as a result of their capacity to induce individual tumor-specific immune 
responses (Huang et al., 2003). Although a few achievements have recently been made in the 
field of cancer gene therapy, great effort is still needed to select effective transgenes with 
more efficacy against cancers, and modify adenoviral vectors with more biosafety and 
specificity (Su et al., 2006a). 
2.1 Modification of adenovirus E1a gene for CRAds 
CRAds are genetically modified to express the wild type of E1a (wE1a) and showed good 
cytolytic effect in various human cancers (Hong et al., 2008; Liao et al., 2007; Su et al., 2006b, 
2008a, 2008b), which binds to cellular regulators and mediates a series of genetic events, for 
instance, suppression of transformation, tumorigenicity and cancer metastatic ability (Kim 
et al., 2007). In addition, the E1a antitumor effect may be involved in many genetic factors in 
cancer cells, including E1a-induced apoptosis (Radke et al., 2008), Ela-enhanced sensitivity 
to chemotherapeutics and radiation (Sánchez-Prieto et al., 1996), E1a-triggered accumulation 
of p53 product and the E1a-mediated down-regulation of the oncogene Neu (ErbB-2/HER2) 
expression (Bartholomeusz et al., 2005; Madhusudan et al., 2004). Neu protein is a member 
of epidermal growth factor receptor (EGFR) and is commonly overexpressed in many 
human solid cancers, eg. in breast and primary liver cancer. E1a-mediated down-regulation 
of Neu expression in cancer cells could inhibit cancer cell proliferation and progression. 
Indeed, E1a-targeted gene therapy has been tested in clinical trials in cancer patients (Yoo et 
al., 2001). Moreover, during adenovirus infection, E1a protein interacts with a number of 
cellular proteins, thereby has an important role in facilitating viral replication.  
The wE1a protein consists of three conserved regions (CR1, CR2, and CR3). These regions 
have different functions for viral antitumor effect and its replication. CR1 and CR2 are 
known to act through several cellular transcription factors, such as E2F, AP1, ATF, ETF, Sp1, 
CBP/p300, P/CAF, and USF, that interact with E1a-inducible promoters (Hale & 
Braithwaite, 1999). The N-terminus of CR1 is also required for the transcriptional activation, 
expression and stability of p53, and induces p53-dependent apoptosis (Itamochi et al., 2007). 
The CR2 domain binds to retinoblastoma tumor suppressor (Rb) protein, resulting in an 
inhibition of E2F transcription factors, and activating genes for cell cycle progression (Berk, 
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Many attempts have been made to improve both the antitumor potency and biosafety of 
approaches combining viral oncolytic therapy and transgene therapy. Genetic re-
engineering of CRAds by incorporating therapeutic payloads may yield mutually 
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antigen presentation to antigen-presenting cells and providing endogenous danger 
signalling. The recombinant oncolytic adenoviruses overexpressing the HSP70 protein can 
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field of cancer gene therapy, great effort is still needed to select effective transgenes with 
more efficacy against cancers, and modify adenoviral vectors with more biosafety and 
specificity (Su et al., 2006a). 
2.1 Modification of adenovirus E1a gene for CRAds 
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expression (Bartholomeusz et al., 2005; Madhusudan et al., 2004). Neu protein is a member 
of epidermal growth factor receptor (EGFR) and is commonly overexpressed in many 
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of Neu expression in cancer cells could inhibit cancer cell proliferation and progression. 
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The wE1a protein consists of three conserved regions (CR1, CR2, and CR3). These regions 
have different functions for viral antitumor effect and its replication. CR1 and CR2 are 
known to act through several cellular transcription factors, such as E2F, AP1, ATF, ETF, Sp1, 
CBP/p300, P/CAF, and USF, that interact with E1a-inducible promoters (Hale & 
Braithwaite, 1999). The N-terminus of CR1 is also required for the transcriptional activation, 
expression and stability of p53, and induces p53-dependent apoptosis (Itamochi et al., 2007). 
The CR2 domain binds to retinoblastoma tumor suppressor (Rb) protein, resulting in an 
inhibition of E2F transcription factors, and activating genes for cell cycle progression (Berk, 
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2005). The CR3 is a transcriptional activation domain that associates with CtIP, Sur2, CtBP 
(Bruton et al., 2007, 2008). However, any modification of the E1a gene which would optimise 
its antitumor efficacy without any significant negative effect on viral replication still needs 
to be investigated. 
For increasing the wE1a antitumor efficacy without decreasing its effect on viral replication, 
the 870-bp wE1a gene was modified by deleting parts of the E1a CR2 (amino acid residues 
125 to 128) and CR3 (amino acid residues 140 to 185) to yield a novel 720-bp truncated 
minimal-E1a gene (mE1a). The mE1a gene was introduced into an oncolytic adenoviral 
vector lacking the E1b genes, placing it under the control of human telomerase reverse 
transcriptase (hTERT) promoter, creating AdDC315-mE1a. The experiments showed that the 
vector was shown to give a high expression of mE1a protein in all cancer cell lines tested, 
including HepGII, A549, SGC-7901, Hela, MCF-7, HT-29, and also in HepGII xenograft 
models in nude mice where the expression was stable throughout the experiment (35 days). 
In AdDC315-mE1a treated cell lines and the xenografted tumors, the mE1a protein 
expression was selective in various cancer cell lines, but expression was negative or only 
weakly positive in the normal cells (Fang et al., 2009).  
The truncated mE1a gene was also proved to have capacities to down-regulate Neu 
expression, and also support adenoviral replication for the oncolytic vector as well as the 
wE1a gene. But there is a difference between the mE1a gene and wE1a gene, the mE1a 
gene can release Rb protein efficiently and preserve the Rb function. The Rb pathway is 
frequently defective by phosphorylation of Rb protein (pRb). When the cancer cells are 
infected with adenoviruses, the Rb protein also can be inactivated by combination with 
the E1a-CR2 domains (Nemajerova et al., 2008). Both the phosphorylation and 
combination of Rb protein resulted in the release of E2F factor, thus the E2F activity is 
high in cancer cells. The oncolytic adenovirus with a deletion of 24 bp in Rb-binding 
region of the E1a protein (amino acids 122–129) is sufficient to prevent binding to and 
inactivation of the Rb protein, but it has little effect on the functions of the E1a protein 
that are necessary for effective viral replication in cancer cells (Fueyo et al., 2000). The 
results demonstrated that the mE1a gene with a small deletion of 125-128 amino acid 
residules in Rb-binding region has a diminished binding affinity to Rb and can preserve 
Rb function.  
The adenovirus E1a can render the adenovirus-infected cells susceptible to DNA damage 
from chemotherapy and radiation. Interestingly, normal cells appear to be unaffected by E1a 
protein (Sánchez-Prieto et al., 1996). Most oncolytic adenoviruses have been engineered by 
holding E1a gene expression. Thereby, in addition to their oncolytic effects, E1a protein 
endows oncolytic adenovirus with higher antitumor potency. Since the 1990s, oncolytic 
adenoviruses with E1a expression were utilized to treat cancer patients from Phase I to 
Phase III. In 2004, China approved one kind of oncolytic adenovirus, H101, to market. 
Clinical data showed that H101 is well tolerable and has good efficacy when combined with 
chemotherapy in some cancer treatment modalities (Yu & Fang, 2007). For the purpose of 
optimizing the therapeutic efficacy of wE1a, the small truncated E1a variant, mE1A, is 
proved to be capable of down-regulating Neu expression and supporting adenovirus 
replication in the mE1a-expressed cancer cells. It has a particular strongpoint to boost Rb 
function differed from the wE1a gene. Thereby, the mE1a-supported oncolytic adenovirus is 
endowed with more effective effects on tumor growth suppression, cell cycle arrest and 
cancer cell apoptosis as demonstrated in hepatocarcinoma xenografts in nude mice (Fang et 
al., 2009). 
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2.2 Modification of tumor-selective promoters for CRAds 
Several tissue- and cell-specific promoters that are more active in the particular cancer cells, 
but inactive or only weakly active in the cancer-originating somatic cells, have been 
identified and exploited to construct CRAds or target gene transportation and expression in 
cancers, such as the carcinoembryonic antigen (CEA) promoter in colorectal and lung cancer 
(Osaki et al., 1994), the DF3/MUC1 antigen promoter in breast cancer (Kurihara et al., 2000), 
the E2F transcriptional factor promoter in cancers with a defective pRb/E2F/p16 pathway 
(Johnson et al., 2002; Ramachandra et al., 2001; Tsukuda et al., 2002), the α-fetoprotein 
promoter in hepatocellular cancer (Ohashi et al., 2001), the prostate-specific antigen (PSA) 
promoter in prostate cancer (Rodriguez et al., 1997) and the L-plastin promoter in ovarian 
and bladder cancers (Peng et al., 2001). These cancer-specific promoters can provide CRAds 
the selective replication in corresponding cancer cells and demonstrate antitumor activity in 
preclinical models and clinical trials. However, most of them limit to target a narrow range 
of cancers expressing the corresponding tumor antigen, thus attenuating their efficacy in 
cancer therapy. More efforts should be put in seek the tumor-selective promoters targeting a 
wide range of human cancers. 
2.2.1 The hTERT promoter-regulated CRAds 
A number of gene therapeutic approaches have been proposed to kill cancer cells or inhibit 
growth of caners by targeting telomerase (Hodes, 2001). Telomerase, a unique enzyme that 
synthesizes telomeric repeats, is highly activated in immortalized cell lines and most of the 
malignant tumors, but is inactive in normal somatic cells (Cong et al., 1999; Kim et al., 1994; 
Shay & Bacchetti, 1997). Telomerase activation has been regarded as a crucial step in cellular 
carcinogenesis, and it is the broadest spectrum molecular marker of malignancies found. 
More detailed analyses of telomerase activity in normal and malignant cells suggested that 
telomerase is active in most cancers, more than 85% of human primary cancers exhibit 
telomerase activity (Nowak et al., 2003; Saretzki et al., 2002), but not in normal tissues except 
hematopoietic stem cells and germ cells in the ovary and testis (Kim et al., 1994; Yui et al., 
1998). With these properties, telomerase is an ideal target for cancer gene therapy and has 
attracted an intense interest in recent years. The studies have established a possibility that 
the manipulation of telomerase function may have an important role in cancer therapeutic 
intervention. Based on the knowledge on the structure and function of telomere and 
telomerase, a number of approaches have been proposed to inhibit the growth and division 
of caner cells by targeting the telomerase (Hodes, 2001).  
Telomerase is a ribonucleoprotein complex composed of the telomerase RNA (hTR), the 
telomerase associated protein and the telomerase reverse transcriptase (hTERT). By 
cloning of the hTR and hTERT components to clarify the mechanism of telomerase 
activation, it has been demonstrated that hTR is expressed in both telomerase-positive 
and -negative cells, but hTERT is expressed only in telomerase-positive cells but not in 
telomerase-negative cells. Transferring hTERT gene into telomerase-negative cells can 
induce telomerase activation in these cells (Nakayama et al., 1998; Weinrich et al., 1997). A 
strong correlation is established between hTERT expression and telomerase activity. 
These findings strongly suggest that the hTERT component is the key determinant of 
human telomerase activity, and utilizing hTERT promoter to drive antitumoral genes in 
cancer gene therapy can target to and selectively kill the cancer cells with positive 
telomerase activity, without affecting the normal cells with negative telomerase activity 
(Koga et al., 2000; Poole et al., 2001). 
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The hTERT promoter has been cloned and identified (Cong et al., 1999; Horikawa et al., 
1999). It is highly G/C-rich and lacks TATA and CAAT boxes, and has several binding sites 
for transcriptional factors, including the transcriptional activating factors Myc (Eickbush, 
1997), SP1 (Kyo et al., 2000), and the transcriptional repressing factors Mad1 (Gunes et al., 
2000), p53 (Xu et al., 2000), MZF2 (Fujimoto et al., 2000). By measuring the transcriptional 
activity of a series of constructs containing unidirectionally deleted fragments of the hTERT 
promoter, some investigators discovered that a 181 bp fragment upstream of the 
transcriptional start site is the smallest core promoter essential for transcriptional activation 
of hTERT gene (Abdul-Ghani et al., 2000; Takakura et al., 1999). The expression of c-Myc 
oncoprotein markedly induces the transcriptional activity of the hTERT promoter in the 
endogenous hTERT-negative cells, and induces 3- to 7-fold increase of the hTERT promoter 
activity in the hTERT-positive cell lines (Horikawa et al., 1999). The mechanism of c-Myc 
protein up-regulating the hTERT promoter activity is probably through the E-box motifs 
(CACGTG) within the hTERT core promoter. It has been shown that although SP1 factor is 
over-expressed in the telomerase-negative normal somatic cells and its binding to the 
specific sites promotes the start of hTERT gene transcription, by comparison, the major 
determinant regulating the hTERT gene expression is the transcriptional factors that 
combined with E-box motifs. In addition to the E-box (-187 bp to -182 bp) upstream of the 
transcriptional start site (Horikawa et al., 1999), there is another E-box (+22 bp to +27 bp) 
downstream of the transcriptional start site (Horikawa et al., 2002). This downstream E-box 
mediates the activation or repression of hTERT gene transcription by binding c-Myc or 
Mad1 transcriptional factors, respectively (Greenberg et al., 1999; Gunes et al., 2000). The 
current research demonstrated that the downstream E-box is a target for down-regulating 
the hTERT activity in the telomerase-negative cells. But this downstream E-box changes to 
the binding site for up-regulating the hTERT gene transcription in the telomerase-positive 
cells when it combines with the transcriptional activating factors such as the upstream 
stimulatory factor (USF), a member of Myc family (Horikawa et al., 2002). Therefore, the 
expression of the hTERT gene determining the telomerase activity is firmly controlled by 
many factors including the transcriptional activating and repressing factors, and the 
regulatory sites mainly locate in the promoter region of the hTERT gene. 
Some current studies showed that the hTERT promoter which was used to construct CRAds 
by controlling the E1a gene demonstrated a sufficient activity for viral effective replication 
in cancer cells (Huang et al., 2003; Irving et al., 2004; Kawashima et al., 2004; Zou et al., 
2004). To further improve the specificity of hTERT promoter, the activity of hTERT core 
promoter could be enhanced significantly in the majority of the cancer cell lines by inserting 
the adenovirus E1a TATA box downstream of the hTERT promoter (Wirth et al., 2003). A 
CRAd, CNHK300, in which the hTERT promoter is used to replace the original regulatory 
elements of E1a gene and to control the E1a gene expression, can target to the telomerase-
positive cancer cells and replicate in them, resulting in oncolysis, when the progeny virions 
are released and infect the adjacent cancer cells, they will not affect the normal cells negative 
for telomerase activity. Another interesting approach developed an oncolytic adenovirus 
AdEHT2 in which a minimal dual-specificity promoter that responds to estrogens and 
hypoxia was used to control the viral E1a gene, and the hTERT core promoter was 
introduced into the E4 region of AdEHT2 (Hernandez-Alcoceba et al., 2002). Their 
experiments of viral replication and cytotoxicity showed that AdEHT2 was not attenuated 
in telomerase-negative cells when these cells were infected under hypoxia conditions. It was 
postulated that the good expression of the adenoviral E1a gene activated by hypoxia was 
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sufficient to promote the viral replication. They also held that the E1a protein can potentially 
stimulate the hTERT promoter in the E4 region directly or as a consequence of the cell cycle 
activation. Although the E4-deleted adenovirus was attenuated, a low level of the E4 open 
reading frame expression could support its replication under the condition that the rest 
transcriptional units of the virus were activated. Based on the published data and the 
current study, it is reasonable to conclude that the tight regulation of the adenoviral E1a 
gene is crucial for the replication of the virus.  
One of the major concerns was the potential toxicity of hTERT promoter-regulated CRAds 
to stem cells or other normal cells, although there were evidences suggesting that the toxic 
effects caused by the use of the hTERT promoter on normal cells may be transient (Chiu et 
al., 1996), and could be prevented by using the adenoviral vectors which infect stem cells 
poorly (Gu et al., 2000). The toxicity assay was performed in BALB/c mice by sequential 
intravenous injections of the hTERT promoter-regulated CRAds and the control virus (wild 
adenovirus type 5, wAd5). The main objective is to investigate whether the replicative 
adenovirus has toxicity to liver cells after systemic delivery. The results suggested that the 
hTERT promoter-regulated CRAds are less toxic than wAd5 after intravenous 
administration. They are well tolerated at a low dosage that was equal to the therapeutic 
dosage for the treatment of the transplantation tumors of nude mice. Even at a high dosage 
of hTERT promoter-regulated CRAds, mice showed no signs of toxicity in terms of 
mortality, liver enzyme levels and hepatocyte morphology, no replication of viruses was 
found in liver tissues by E1a immunohistochemistry, and only slight granular or hydropic 
degeneration of hepatocytes could be observed. Meanwhile, wAd5 displayed both a certain 
mortality and liver toxicity. All mice died at a high dosage of wAd5, and the therapeutic 
dosage induced an obvious increase of liver enzymes and evidence of cytopathic effects on 
liver tissues. Therefore, the toxic effect of hTERT promoter-regulated CRAds is much 
weakened compared with wAd5 by the use of the hTERT promoter (Su et al., 2004, 2006b, 
2008a; Wang et al., 2008).  
2.2.2 The E2F promoter-regulated CRAds 
The loose control of cell cycle is a key feature of cancer cell proliferation. Much evidence 
suggests that the Cyclin/Cyclin-dependent kinase (CDK)/P16/retinoblastoma protein 
(Rb)/E2F pathway is the major link for cell cycle control. Cyclin D1 activates CDK4 and 
promotes the phosphorylation of Rb protein, which makes the E2F transcriptional factor 
released from Rb-E2F complex. Then the E2F transcriptional factor activates the 
transcription of many important cell cycle regulatory genes, and promotes tumorigenesis. 
P16 is known as a negative regulator of cell cycle, which can block cell cycle progression 
from G1 to S phase by binding to CDK4 and inhibiting the action of Cyclin D1 (Coqueret, 
2002; Ortega et al., 2002). It was found that the inactivation of Cyclin D/ CDK/ P16/ Rb/ 
E2F pathway is a common characteristic of most solid cancers (Gemin et al., 2005; Johnson et 
al., 2002; Tsukuda et al., 2002). This pathway is an ideal target for cancer gene therapy and 
has attracted an intense interest in recent years.  
As described above, cancer cells with the deficiency of Cyclin /CDK/P16/Rb/E2F pathway 
have high activity of E2F transcriptional factor, thus this important factor is defined as a 
crucial target in cancer treatment. A CRAd, AdEHE2F, in which the expression of E4 gene is 
controlled by the E2F promoter, had been generated for breast cancer treatment (Post et al., 
2003). The tight regulation of E4 expression correlated with the viral ability to selectively 
replicate and kill cancer cells. Current study constructed an E2F promoter-regulated CRAd 
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sufficient to promote the viral replication. They also held that the E1a protein can potentially 
stimulate the hTERT promoter in the E4 region directly or as a consequence of the cell cycle 
activation. Although the E4-deleted adenovirus was attenuated, a low level of the E4 open 
reading frame expression could support its replication under the condition that the rest 
transcriptional units of the virus were activated. Based on the published data and the 
current study, it is reasonable to conclude that the tight regulation of the adenoviral E1a 
gene is crucial for the replication of the virus.  
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to stem cells or other normal cells, although there were evidences suggesting that the toxic 
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2.2.2 The E2F promoter-regulated CRAds 
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suggests that the Cyclin/Cyclin-dependent kinase (CDK)/P16/retinoblastoma protein 
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released from Rb-E2F complex. Then the E2F transcriptional factor activates the 
transcription of many important cell cycle regulatory genes, and promotes tumorigenesis. 
P16 is known as a negative regulator of cell cycle, which can block cell cycle progression 
from G1 to S phase by binding to CDK4 and inhibiting the action of Cyclin D1 (Coqueret, 
2002; Ortega et al., 2002). It was found that the inactivation of Cyclin D/ CDK/ P16/ Rb/ 
E2F pathway is a common characteristic of most solid cancers (Gemin et al., 2005; Johnson et 
al., 2002; Tsukuda et al., 2002). This pathway is an ideal target for cancer gene therapy and 
has attracted an intense interest in recent years.  
As described above, cancer cells with the deficiency of Cyclin /CDK/P16/Rb/E2F pathway 
have high activity of E2F transcriptional factor, thus this important factor is defined as a 
crucial target in cancer treatment. A CRAd, AdEHE2F, in which the expression of E4 gene is 
controlled by the E2F promoter, had been generated for breast cancer treatment (Post et al., 
2003). The tight regulation of E4 expression correlated with the viral ability to selectively 
replicate and kill cancer cells. Current study constructed an E2F promoter-regulated CRAd 
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which was armed with the p16 gene, AdE2F-p16. By controlling the E1a gene expression 
with the E2F promoter, AdE2F-p16 achieved a desired specificity to target cancer cells, while 
the normal cells were spared. The luciferase assay suggested that the E2F promoter had a 
high activity in cancer cells but not in normal cells. The data from in vitro experiments 
showed that AdE2F-p16 specifically replicated and induced E1a expression in cancer cells. 
Due to the viral replication, AdE2F-p16 more efficiently expressed P16 than the replication-
deficient adenovirus AdCMV-p16 in cancer cells. Thereby, AdE2F-p16 overcomes the 
disadvantages of low transfer rate and poor gene expression compared with the replication-
deficient adenovirus vectors. In summary, the E2F promoter-regulated, p16-armed CRAd 
can mediate the effective expression of transgene in cancer cells, and displays a satisfactory 
therapeutic effect for cancer (Ma et al., 2009). 
To further investigate the molecular mechanisms of P16-induced apoptosis, the 
consequential study found that the adenovirus-mediated P16 reactivation lead to an 
inhibition of Akt signaling pathway and a downregulation of survivin expression in 
hepatocellular carcinoma cells (Hu et al., 2010). P16 and survivin are a pair of incompatible 
factors in the cell cycle and cell apoptosis regulation. Cyclin D1 and P16 eventually regulate 
cell cycle by interacting with CDK4 (Ai et al., 2005). CDK4 and survivin are co-localized 
mainly in nuclei of the P16-deficient hepatocellular carcinoma cells. But when cancer cells 
re-express P16, the P16 protein competes with survivin for CDK4 binding and transports 
CDK4 from nuclei to cytoplasm. The translocation of CDK4 from nuclei to cytoplasm 
illuminates that its function to accelerate cell proliferation is weakened. Interestingly, it is 
found an important molecular event that the nuclear survivin is reduced obviously in cancer 
cells after P16 re-expressed. The localization of survivin in cancer cells exerts different 
functions. The nuclear survivin is involved in promoting cell proliferation, whereas the 
cytoplasmic survivin may participate in controlling cell survival (Connell et al., 2008; Li et 
al., 2005; Liu & Matsuura, 2005). Accordingly, survivin promotes cell proliferation and 
inhibits cell apoptosis by competitively interacting with CDK4, and the P16-induced 
decrease of the amount of survivin and CDK4 in nuclei contributes to the inhibition of cell 
cycle progression and induction of detachment-induced apoptosis (anoikis) in cancer cells. 
This new insight into P16 function would help in designing better strategies for cancer gene 
therapy. 
2.3 Utilization of antitumor transgenes 
CRAds can be designed to function as therapeutic gene delivery vehicles by incorporating 
antitumor transgenes, and their antitumor efficacy is thus increased by the combination of 
antitumor gene therapy and oncolytic viral therapy (Chen et al., 2005; Nagayama et al., 2003; 
Post et al., 2003; Su et al., 2006a). Previous studies confirmed the antitumor activity of 
various vectors carrying cytokine genes, such as interferons (Belardelli & Gresser, 1996), 
tumor necrosis factors (Zhang et al., 1996), drug-sensitive gene HSV-tk (Steele, 2000), 
antiangiogenesis genes (Fang et al., 2010). When these therapeutic genes were inserted into 
the genome of CRAds, they were selectively and highly expressed in cancer cells as a result 
of the cancer-selective replication of CARds, which further enhanced therapeutic effect 
targeting cancer cells without toxicity to normal tissues or cells. 
2.3.1 CRAd with interferon-gamma (IFN-γ) gene 
Interferons (IFNs) are the first cytokines to be applied clinically in treatment of human 
cancers, and have anti-proliferative effects and immune modulatory activity. They have also 
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been shown to inhibit angiogenesis and suppress tumor vascularization (Dvorak & Gresser, 
1989; Fathallah-Shaykh et al., 2000; Singh et al., 1995). Among IFNs, IFN-γ is vital to the 
promotion of tumor surveillance in immunocompetent hosts and activates macrophages to 
nonspecifically lyse cancer cells through various mechanisms (Baratin et al., 2001; Guadagni 
et al., 1994). IFN-γ can enhance antitumor immune response by upregulating major 
histocompatibility complex class I expression and accentuating the migration of specific and 
non-specific immune cells to necrotic areas which develop spontaneously in large tumors 
(Khorana et al., 2003; Merritt et al., 2004; Peyregne et al., 2004). Gene transfer of IFN-γ 
inhibits neovascularization of tumors by inducing apoptosis of endothelial cells (Kowalczyk 
et al., 2003), suggesting that IFN-γ represses tumor growth by the dual mechanisms of 
inhibition of angiogenesis and elicitation of an immunotherapeutic response.  
In clinical trials, only high concentration of IFN-γ product in tumor tissues yields 
antiangiogenic effects and immune response. Unfortunately, high concentration of IFN-γ 
product is associated with significant toxic effects, including fever, endocrine dysfunction, 
thrombocytopenia, and hepatic toxicity (Jonasch & Haluska, 2001). Therefore, its toxicity 
limits the administration of high concentration of this agent. Based on dual antitumor 
features of the IFN-γ gene and tumor-selective replication of viruses, CRAds armed with the 
IFN-γ gene could amplify transgene copies in tumor cells and produce high local 
concentration of IFN-γ product in tumor tissues. This strategy could thus yield multiple 
antitumor effects including oncolysis, antiangiogenesis, and induction of immune response. 
Even in immunodeficient animals, delivery of IFN-γ can partially restore significant 
immune activity (Wu et al., 2001).  
In tumor models of nude mice, the IFN-γ gene-armed CRAd exhibited efficient antitumor 
activity against tumor xenografts. Many extensive foci of necrosis appeared in virus-treated 
tumor specimens. Around the necrotic foci, there were cancer cells positive for adenoviral 
capsid protein in tumor tissues, suggesting the selective replication and oncolytic effect of the 
IFN-γ gene-armed CRAd in cancer cells. The number of microvessels was clearly decreased in 
tumor tissues, which may be one of the mechanisms of IFN-γ-mediated antitumor responses 
in mice. Since suppressing tumor angiogenesis could lead to tumor starvation and regression 
(Folkman, 1998), decreasing the number of microvessels in tumor tissues might strongly 
suppress tumor growth. The present study found that more effective antitumor immune 
responses were exhibited when the IFN-γ gene-armed CRAd was used in immunocompetent 
hosts than in immunodeficient animals, because the host immune system was intact to support 
the full function of IFN-γ. After treated with the IFN-γ gene-armed CRAd, the increase in 
numbers of LCA+, CD4+, and CD8+ lymphocytes and the ratio of CD4+/CD8+ in tumor 
tissues accounted for the enhancement of immune responses to cancer cells (Su et al., 2006a). It 
is hypothesized that the combination of oncolytic virotherapy and immune gene therapy 
would enhance antitumor efficacy in both immunodeficient and immunocompetent hosts, and 
obtained results strongly supporting this hypothesis.  
2.3.2 CRAd with antiangiogenesis gene 
Increasing evidence suggests that the solid tumors and their metastasis are angiogenesis 
dependent. Angiogenesis is a complex process that includes the activation, proliferation, 
and migration of endothelial cells. This process involves in the formation of vascular tubes 
and networks. Antiangiogenic therapy attempts to stop new microvessels from forming 
around tumors and to break up the existing network of abnormal capillaries that feed the 
cancerous mass, finally mediates the inhibition of cancer growth.  
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around tumors and to break up the existing network of abnormal capillaries that feed the 
cancerous mass, finally mediates the inhibition of cancer growth.  
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Endostatin, a 20-kDa C-terminal fragment of collagen XVIII, is the most potent angiogenesis 
inhibitor and specifically inhibits endothelial cell proliferation and migration, induces 
apoptosis of vascular endothelial cells (Lai et al., 2007; Li et al., 2008; Ning et al., 2008), and 
has been demonstrated to be with antitumor effect in many solid tumors, and without 
toxicity, immunogenesis or resistance. The adenovirus vector carrying a secretable form of 
mouse endostatin, Av3mEndo, mediated the secreted expression of endostatin from 
Av3mEndo-transduced mammalian cells and showed a potential inhibition of endothelial 
cell migration in vitro. A single intravenous administration of Av3mEndo in mice could 
result in prolonged and elevated levels of circulating endostatin, partial inhibition of 
vascular endothelial growth factor (VEGF)-induced angiogenesis, and in 25% of mice the 
complete prevention of tumor growth (Chen et al., 2000). The CRAd, AdSu-hE, in which a 
chimeric promoter of HER2 enhancer and hTERT promoter was used to drive the E1a gene, 
a cytomegalovirus promoter to control the human endostatin gene. In vivo intratumoral 
delivery of the CRAd to pre-established hepatocellular carcinoma tumors in nude mice 
induced a significant tumor reduction and, in some cases resulted in a complete tumor 
regression (Fang et al., 2010). 
Canstatin, a novel matrix-derived inhibitor of angiogenesis, was described as being at least 
10-fold more active than endostatin (Kamphaus et al., 2000; Narazaki & Tosato, 2006). 
Experiments demonstrated that recombinant canstatin can potently inhibit endothelial cell 
proliferation, migration, and induce apoptosis in vitro. Moreover, it can successfully 
suppress the growth of implanted human xenografts of renal cell carcinoma and prostate 
tumors through antiangiogenesis effect (Kamphaus et al., 2000). The canstatin gene was 
inserted into an E1B-55kDa-deleted adenovirus vector and constructed an adenovirus, 
CRAd-Cans. It showed markedly improved inhibitory effects on the growth of the 
pancreatic cancer in mice with a prolonged survival rate through the mechanisms of 
oncolytic and anti-angiogenesis effects (He et al., 2009).  
2.3.3 CRAd with tumor suppression gene 
P16 is known as a negative regulator of cell cycle, which can block cell cycle progression 
from G1 to S phase by binding to CDK4 and inhibiting the action of Cyclin D1 (Canepa et 
al., 2007; Coqueret, 2002). It was found that the P16 inactivation is a frequent molecular 
event in most cancers. The mechanisms of P16 inactivation include the homozygous 
deletion, point mutation and 5’-CpG island methylation (Ortega et al., 2002). Due to the P16 
inactivation, cancer cells show growth superiority and high malignancy. Reactivation of P16 
by transferring the p16 gene into cancer cells induced cell G1 arrest and apoptosis (Chen et 
al., 2005), suggesting that the p16 gene may have a good future application in cancer gene 
therapy. The E2F promoter-regulated CRAd armed with the p16 gene, AdE2F-p16, was 
constructed (Ma et al., 2009). With the selective replication of AdE2F-p16 under the control 
of the E2F promoter, AdE2F-p16 expressed P16 with high levels in cancer cells. The 
improved antitumor efficacy of AdE2F-p16 was shown in human gastric cancer model in 
nude mice. The viral selective replication resulted in enhanced oncolysis, and p16 
expression induced cancer cell apoptosis, suggesting that the combined effects led to the 
tumor growth inhibition in mouse models.  
The p53 gene is one of the most important tumor suppressor gene. It plays an important role 
in cancer gene therapy, which has received preclinical validation by developing anticancer 
agents that specifically reactivate P53 function (Martins et al., 2006). To explore the efficacy 
of wild type p53 reactivation as a tumor therapy, some investigators demonstrated that 
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restoring endogenous P53 expression in mice led to regression of autochthonous 
lymphomas through cellular apoptosis pathway and sarcomas through cellular senescence 
in mice, but without affecting normal tissues (Ventura et al., 2007). By RNA interference 
(RNAi) to conditionally regulate endogenous P53 expression in a mosaic mouse model of 
liver carcinoma, it was found that even brief reactivation of endogenous P53 in p53-deficient 
tumors could produce complete tumor regressions through the induction of a cellular 
senescence that was associated with differentiation and upregulation of inflammatory 
cytokines (Xue et al., 2007). These studies indicated that the p53-triggered tumor regression 
is not only due to the cellular apoptosis but the cellular senescence program, which is 
dependent on the tumor types. The transfer of wide type p53 gene is an important method 
to cure the p53-deficient cancers (Swisher & Roth, 2002; Weill et al., 2000). A previous study 
demonstrated the enhanced antitumor effect of CRAd with the wild type p53 gene in the 
treatment of glioma (Van Beusechem et al., 2002). The tumor-specific CRAds carrying the 
wide type p53 gene, SG600-p53, can selectively replicate in tumor cells, whereas hardly 
replicated in normal cell lines, suggesting that SG600-p53 has a high selectivity to cancer 
cells and a low toxicity to normal cells. SG600-p53 expressed P53 with high efficiency in 
cancer cells. Both the high selectivity of viral replication and high efficiency of P53 
expression ensured the efficient oncolytic effect and inhibition effect on cancer cells. In NCI-
H1299 tumor xenografts in nude mice, SG600-p53 achieved the significant antitumor 
efficacy. By pathological examination, administration of SG600-p53 resulted in cancer cell 
apoptosis. It is concluded that the CRAd carrying p53 gene, as a more potent and safer 
antitumor agent, could provide a new strategy for cancer biotherapy.  
3. Problems and prospects 
The achievements of success in adenovirus-based gene therapy bring forth new hope to treat 
cancer. Many countries worldwide invested heavily in cancer gene therapy, however, there 
are few products used in clinic because of their low efficacy. The differences between the in 
vitro and in vivo experiments, basic technology and clinical application should be further 
investigated. More worrying about the long-term toxicity of transgene vector also limits the 
wide utilization of gene therapy. These problems existed and exist, but they can not 
counteract the developments and prospects of gene therapy. The traditional strategies for 
cancer treatment, including surgery, chemotherapy and radiation, are difficult to eradicate 
the root of various cancers, the gene therapy absolutely searches for the roots cause of 
carcinogenesis, and corrects the genetic defects in transformed cells. Further investigations 
on the carcinogenesis mechanism, signal transduction and genetic characteristic of cancer 
cells will promote the development and breakthrough of cancer gene therapy in the future. 
4. References 
Abdul-Ghani, R., Ohana, P., Matouk, I., Ayesh, S., Ayesh, B., Laster, M., Bibi, O., Giladi, H., 
Molnar-Kimber, K., Sughayer, M. A., De Groot, N. & Hochberg, A. (2000). Use of 
transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective 
killing of cancer cells, Mol. Ther. 2(6): 539-544. 
Ai, M. D., Li, L. L., Zhao, X. R., Wu, Y., Gong, J. P. & Cao, Y. (2005). Regulation of survivin 
and CDK4 by Epstein-Barr virus encoded latent membrane protein 1 in 
nasopharyngeal carcinoma cell lines, Cell Res. 15(10):777-784. 
  
Viral Gene Therapy 
 
138 
Endostatin, a 20-kDa C-terminal fragment of collagen XVIII, is the most potent angiogenesis 
inhibitor and specifically inhibits endothelial cell proliferation and migration, induces 
apoptosis of vascular endothelial cells (Lai et al., 2007; Li et al., 2008; Ning et al., 2008), and 
has been demonstrated to be with antitumor effect in many solid tumors, and without 
toxicity, immunogenesis or resistance. The adenovirus vector carrying a secretable form of 
mouse endostatin, Av3mEndo, mediated the secreted expression of endostatin from 
Av3mEndo-transduced mammalian cells and showed a potential inhibition of endothelial 
cell migration in vitro. A single intravenous administration of Av3mEndo in mice could 
result in prolonged and elevated levels of circulating endostatin, partial inhibition of 
vascular endothelial growth factor (VEGF)-induced angiogenesis, and in 25% of mice the 
complete prevention of tumor growth (Chen et al., 2000). The CRAd, AdSu-hE, in which a 
chimeric promoter of HER2 enhancer and hTERT promoter was used to drive the E1a gene, 
a cytomegalovirus promoter to control the human endostatin gene. In vivo intratumoral 
delivery of the CRAd to pre-established hepatocellular carcinoma tumors in nude mice 
induced a significant tumor reduction and, in some cases resulted in a complete tumor 
regression (Fang et al., 2010). 
Canstatin, a novel matrix-derived inhibitor of angiogenesis, was described as being at least 
10-fold more active than endostatin (Kamphaus et al., 2000; Narazaki & Tosato, 2006). 
Experiments demonstrated that recombinant canstatin can potently inhibit endothelial cell 
proliferation, migration, and induce apoptosis in vitro. Moreover, it can successfully 
suppress the growth of implanted human xenografts of renal cell carcinoma and prostate 
tumors through antiangiogenesis effect (Kamphaus et al., 2000). The canstatin gene was 
inserted into an E1B-55kDa-deleted adenovirus vector and constructed an adenovirus, 
CRAd-Cans. It showed markedly improved inhibitory effects on the growth of the 
pancreatic cancer in mice with a prolonged survival rate through the mechanisms of 
oncolytic and anti-angiogenesis effects (He et al., 2009).  
2.3.3 CRAd with tumor suppression gene 
P16 is known as a negative regulator of cell cycle, which can block cell cycle progression 
from G1 to S phase by binding to CDK4 and inhibiting the action of Cyclin D1 (Canepa et 
al., 2007; Coqueret, 2002). It was found that the P16 inactivation is a frequent molecular 
event in most cancers. The mechanisms of P16 inactivation include the homozygous 
deletion, point mutation and 5’-CpG island methylation (Ortega et al., 2002). Due to the P16 
inactivation, cancer cells show growth superiority and high malignancy. Reactivation of P16 
by transferring the p16 gene into cancer cells induced cell G1 arrest and apoptosis (Chen et 
al., 2005), suggesting that the p16 gene may have a good future application in cancer gene 
therapy. The E2F promoter-regulated CRAd armed with the p16 gene, AdE2F-p16, was 
constructed (Ma et al., 2009). With the selective replication of AdE2F-p16 under the control 
of the E2F promoter, AdE2F-p16 expressed P16 with high levels in cancer cells. The 
improved antitumor efficacy of AdE2F-p16 was shown in human gastric cancer model in 
nude mice. The viral selective replication resulted in enhanced oncolysis, and p16 
expression induced cancer cell apoptosis, suggesting that the combined effects led to the 
tumor growth inhibition in mouse models.  
The p53 gene is one of the most important tumor suppressor gene. It plays an important role 
in cancer gene therapy, which has received preclinical validation by developing anticancer 
agents that specifically reactivate P53 function (Martins et al., 2006). To explore the efficacy 
of wild type p53 reactivation as a tumor therapy, some investigators demonstrated that 
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restoring endogenous P53 expression in mice led to regression of autochthonous 
lymphomas through cellular apoptosis pathway and sarcomas through cellular senescence 
in mice, but without affecting normal tissues (Ventura et al., 2007). By RNA interference 
(RNAi) to conditionally regulate endogenous P53 expression in a mosaic mouse model of 
liver carcinoma, it was found that even brief reactivation of endogenous P53 in p53-deficient 
tumors could produce complete tumor regressions through the induction of a cellular 
senescence that was associated with differentiation and upregulation of inflammatory 
cytokines (Xue et al., 2007). These studies indicated that the p53-triggered tumor regression 
is not only due to the cellular apoptosis but the cellular senescence program, which is 
dependent on the tumor types. The transfer of wide type p53 gene is an important method 
to cure the p53-deficient cancers (Swisher & Roth, 2002; Weill et al., 2000). A previous study 
demonstrated the enhanced antitumor effect of CRAd with the wild type p53 gene in the 
treatment of glioma (Van Beusechem et al., 2002). The tumor-specific CRAds carrying the 
wide type p53 gene, SG600-p53, can selectively replicate in tumor cells, whereas hardly 
replicated in normal cell lines, suggesting that SG600-p53 has a high selectivity to cancer 
cells and a low toxicity to normal cells. SG600-p53 expressed P53 with high efficiency in 
cancer cells. Both the high selectivity of viral replication and high efficiency of P53 
expression ensured the efficient oncolytic effect and inhibition effect on cancer cells. In NCI-
H1299 tumor xenografts in nude mice, SG600-p53 achieved the significant antitumor 
efficacy. By pathological examination, administration of SG600-p53 resulted in cancer cell 
apoptosis. It is concluded that the CRAd carrying p53 gene, as a more potent and safer 
antitumor agent, could provide a new strategy for cancer biotherapy.  
3. Problems and prospects 
The achievements of success in adenovirus-based gene therapy bring forth new hope to treat 
cancer. Many countries worldwide invested heavily in cancer gene therapy, however, there 
are few products used in clinic because of their low efficacy. The differences between the in 
vitro and in vivo experiments, basic technology and clinical application should be further 
investigated. More worrying about the long-term toxicity of transgene vector also limits the 
wide utilization of gene therapy. These problems existed and exist, but they can not 
counteract the developments and prospects of gene therapy. The traditional strategies for 
cancer treatment, including surgery, chemotherapy and radiation, are difficult to eradicate 
the root of various cancers, the gene therapy absolutely searches for the roots cause of 
carcinogenesis, and corrects the genetic defects in transformed cells. Further investigations 
on the carcinogenesis mechanism, signal transduction and genetic characteristic of cancer 
cells will promote the development and breakthrough of cancer gene therapy in the future. 
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1. Introduction 
Recombinant Adenoviruses (rAd) are widely used as gene delivery vectors in gene therapy 
and vaccination (Hall et al., 2010, Liu, 2010). These replication incompetent vectors have 
established safety in humans and possess a number of advantages, such as that high viral titres 
can be produced efficiently. Several different human rAd types are being intensively 
investigated in clinical trials for their usefulness. In addition, there is an ever-expanding body 
of literature covering basic virology of Ad and interactions with host immune and other cells. 
It is important to understand how rAd vectors interact with specific cells of the immune 
system in order to improve their clinical efficacy. In particular, studies on the interaction of 
rAd and professional antigen presenting cells (pAPC), which specialize in recognizing 
pathogens and initiating a cascade of events that lead to specific immunity, are highly relevant. 
The most potent type of pAPC are dendritic cells (DC) that possess a unique ability to prime 
adaptive immune responses (Palucka & Banchereau, 1999, Palucka et al., 2010). rAd vectors 
likely contact DC early following inoculation and thus these cells may play a major role in 
regulating immunity towards the vector itself and encoded transgenes. 
This chapter will include a review of the current literature on the interactions between DC 
and rAd vectors reported by ourselves and others, in addition to a presentation of novel 
data. We will first summarize the phenotype and function of specific human DC subsets and 
methods to isolate or differentiate DC, which are crucial tools to study the interplay of DC 
and rAd vectors in physiologically relevant systems. Further, we will discuss basic 
virological aspects of rAd including vector generation and cellular receptor usage among 
different rAd species. While a multitude of receptors have been described for rAd, we will 
focus on those relevant for DC. In addition to how rAd vectors bind and infect DC, the 
extent by which different rAd types infect different DC subsets will be examined. Finally we 
will give an overview of the functional response of DC to rAd vectors, including maturation, 
cytokine production, and antigen presentation. Understanding how human DC sense and 
respond to rAd vectors will assist in guiding the use of these gene delivery vehicles in their 
many different clinical applications.  
2. Human dendritic cells 
2.1 Function in innate and adaptive immunity 
DC participate centrally in the initiation of immune responses towards foreign antigen and 
in this way link the innate and adaptive arms of the immune system (Palucka & Banchereau, 
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and rAd vectors in physiologically relevant systems. Further, we will discuss basic 
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extent by which different rAd types infect different DC subsets will be examined. Finally we 
will give an overview of the functional response of DC to rAd vectors, including maturation, 
cytokine production, and antigen presentation. Understanding how human DC sense and 
respond to rAd vectors will assist in guiding the use of these gene delivery vehicles in their 
many different clinical applications.  
2. Human dendritic cells 
2.1 Function in innate and adaptive immunity 
DC participate centrally in the initiation of immune responses towards foreign antigen and 
in this way link the innate and adaptive arms of the immune system (Palucka & Banchereau, 
 




1999). During the steady state, DC have an immature phenotype, possess high endocytic 
capacity, and express a diverse array of pathogen recognition receptors (PRR) to sense 
extracellular and intracellular foreign antigen. Recognition of specific viral nucleic acid 
signatures by cytosolic and endosomal PRR enables DC to initiate downstream signalling 
cascades that lead to phenotypic maturation and production of cytokines such as type-1 
interferons (IFN) (Pichlmair & Reis e Sousa, 2007). DC activation is also characterized by 
upregulation of chemokine receptors that facilitate their migration from the periphery to the 
spleen or lymph nodes, the primary sites for presentation of antigens, to activate antigen-
naïve T lymphocytes. The morphological and phenotypic changes that occur upon 
maturation endow DC with a notable capacity to activate lymphocytes in an antigen specific 
manner (Steinman & Witmer, 1978). Specifically, DC have a unique capacity to present 
foreign peptides on MHC (major histocompatibility complex) I and II to activate both 
cytotoxic CD8+ T cells and helper CD4+ T cells, respectively. In addition to efficient 
induction of antigen-specific T cell responses, DC are also becoming increasingly 
appreciated for their role in shaping the function of innate immune cells such as NK cells 
(Medzhitov, 2007). Since DC have a multifaceted role in both innate and adaptive immunity, 
they likely respond to and influence the efficacy of rAd vector administration. While DC 
may facilitate the induction of systemic immunity towards vector transgenes, local immune 
responses may in contrast blunt the desired effect of the delivered gene. Part of the diversity 
in DC function is attributable to the presence of distinct DC subsets present in blood and 
other tissues.  
2.2 Overview of DC subsets, phenotype, and function 
Human DC are classified into subsets based on characteristics such as surface phenotype, 
anatomical location, cytokine and maturation profiles, and the capacity to present antigen to 
activate antigen specific lymphocytes. In this section, we will describe the phenotypes and 
functions of subsets of DC derived from human blood and skin.  
2.2.1 Blood DC subsets 
Human DC from blood can be broadly separated into three distinct subsets: plasmacytoid 
DC (pDC) and two types of myeloid DC (mDC) (Ueno et al., 2011, Ziegler-Heitbrock et al., 
2010) (Table I). These subsets are distinguished by their unique expression of different blood 
DC antigens (BDCA) (Dzionek et al., 2000, Palucka et al., 2010). mDC are CD1c+ (BDCA-1+), 
while pDC co-express CD303 (BDCA-2) and CD304 (BDCA-4) (Table I). Another recently 
identified mDC subset expressing CD141+ (BDCA-3) is notably adept at presenting 
exogenous foreign peptides on MHC I molecules, in a process termed cross-presentation 
(Bachem et al., 2010, Crozat et al., 2010, Jongbloed et al., 2010, Poulin et al., 2010). Because 
there is very limited data on the interaction of rAd vectors and the CD141+ mDC subsets 
this chapter will focus on pDC and CD1c+ mDC. While mDC and pDC are similar in that 
they share several classical DC functions, such as mechanisms for efficient uptake of 
antigen, expression of PRR, ability to phenotypically mature, migrate and activate naïve T 
cells, they also differ in a number of critical aspects. For example, their expression repertoire 
of PRR differs. mDC express toll like receptors (TLR) 1 through 8, and 10 whereas pDC 
express TLR 7 and 9. mDC are generally considered more potent antigen presenting cells, 
while pDC specialize in the production of rapid and copious type-1 IFN (IFNα/β) and may 
thus have a particularly important role in viral immunity (Liu, 2005). Both pDC and mDC 
are also defined as being mostly CD14- (Fig. 1). A surrogate for DC of myeloid lineage may 
 




also be differentiated in vitro from CD14+ monocytes (termed monocytes derived DC or 
MDDC). These cells lose CD14 expression, but concurrently gain expression of CD1a and 
DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) (Table I 
and Fig. 2). It is currently unclear whether MDDC represent any single primary DC subset, 
but recent a report indicates that they in part mimic skin resident interstitial dermal DC in 
that they produce similar cytokines and express DC-SIGN (Klechevsky et al., 2008). In 
section 2.3 we will briefly discuss the methods for differentiating MDDC in vitro and 
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2.2.2 Cutaneous DC subsets 
Cutaneous DC are commonly divided into two main subsets based on the tissue in which 
they reside in steady state conditions: dermal interstitial DC (dDC) resident in the dermal 
layer, and Langerhans cells (LC) resident in the epidermal layer. Both subsets express HLA-
DR and are of myeloid origin. LC are distinguished by expression of Langerin and CD1a, 
while dDC consist of a more diverse population based on differential expression of DC-
SIGN, CD1a and CD14 (Bond et al., 2009, Klechevsky et al., 2008). A more complete 
phenotypic characterization of these cells is provided in Table I. The unique roles that each 
of these skin DC play in detecting viral infection and initiating immune responses likely 
depends on both the route of inoculation and the nature of the particular virus (Palucka et 
al., 2010). It has been shown that dDC, in particular the CD14+ subset, stimulate humoral 
immunity (i.e. antibody producing B cells) while LC specialize at inducing cellular 
immunity (i.e. cytotoxic CD8+ T cells) (Klechevsky et al., 2008). The methods for isolating 
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while pDC specialize in the production of rapid and copious type-1 IFN (IFNα/β) and may 
thus have a particularly important role in viral immunity (Liu, 2005). Both pDC and mDC 
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2.3 Differentiation and isolation of DC from blood and skin 
2.3.1 Isolation of primary blood DC subsets 
We have developed methods that yield significant numbers of highly pure and immature 
CD303+ pDC and CD1c+ mDC (Adams et al., 2009, Douagi et al., 2009, Lore, 2004, Lore et 
al., 2003). These cells allow for studies of more physiologically relevant primary human DC 
than in vitro surrogate DC (i.e. MDDC). As discussed earlier, isolation of pDC and mDC is 
facilitated by differential BDCA expression. A series of sequential separations is necessary to 
yield sorted cells of high purity. We have developed two means of first enriching DC and 
monocytes from the total peripheral blood mononuclear cell (PBMC) population: (i) 
aphaeresis of donor leukocytes followed by counterflow centrifugation elutriation to 
separate monocytes and lymphocytes based on cell size and sedimentation density (Lore et 
al., 2003, Lore et al., 2005), or (ii) treatment of PBMC with RosetteSep CD14+ enrichment kit 
(Lambert et al., 2009). Both these methods result in a fraction of cells highly enriched of 
monocytes and DC, and depleted of lymphocytes. Subsequently, the pDC are positively 
selected by staining with anti-CD304 monoclonal antibodies (mAb) directly conjugated to 
magnetic microbeads (Miltenyi). Since a subset of B cells expresses CD1c, these cells are 
depleted by staining with anti-CD19 mAb directly conjugated to magnetic microbeads 
(Miltenyi). mDC may thereafter be positively selected with mAb against CD1c. Cell 
separation based on magnetic microbead conjugated mAb can be performed using either an 
AutoMacs instrument or manually with appropriate selection columns (Miltenyi). This 
sequential magnetic sorting procedure results in the isolation of highly pure CD123 
expressing CD304+ pDC and CD11c expressing CD1c+ mDC (Fig. 1). pDC and mDC are 
then cultured in complete media supplemented with IL-3 and GM-CSF, respectively. These 
rare subsets of DC isolated from blood display an immature phenotype that is consistent 
with the established literature (Ziegler-Heitbrock et al., 2010). Important to note is that 
although pDC may be isolated with anti-CD303 mAb, ligation of this receptor with the 
currently available clones (Miltenyi) attenuates type-1 IFN production (Dzionek et al., 2001), 
TLR9 induced phenotypic maturation, and optimal antigen presentation (Jahn et al., 2010). 
 
     
Fig. 1. Phenotype and purity of human pDC and mDC sorted from blood. 
pDC and mDC were positively selected on an AutoMacs after staining with anti-CD304 and 
anti-CD1c mAb conjugated directly to magnetic microbeads, respectively (Miltenyi). Freshly 
isolated pDC or mDC were stained with anti-CD123 or anti-CD11c, respectively, and anti-
CD14 mAbs (BD Biosciences). Surface expression was evaluated using flow cytometry (BD 
FACS Calibur) and data was analyzed with FlowJo software (Treestar). 
2.3.2 Differentiation of monocyte derived DC 
Due to the rarity of DC subsets in blood and skin an alternative method was developed to 
more readily study DC (Sallusto & Lanzavecchia, 1994). This method to in vitro generate 
 




MDDC from monocytes significantly accelerated investigations of human DC function. 
Here, primary monocytes are isolated from PBMC fractions. Highly pure CD14+ monocytes 
are obtained either by collection of plastic-adherent cells or treatment of PBMC with 
RosetteSep CD14+ enrichment kit (Stem Cell Technologies) (Adams et al., 2009, Lambert et 
al., 2009). Subsequent culture of monocytes with recombinant human interleukin (IL)-4 and 
granulocyte macrophage-colony stimulating factor (GM-CSF) at optimal concentrations over 
6 days induces monocytes to differentiate into MDDC that display CD1a, DC-SIGN, HLA-
DR, but lack CD14 (Fig. 2). 
 
 
Fig. 2. Phenotype of human DC differentiated from primary monocytes with GM-CSF and 
IL-4 over six days. 
Human PBMC were treated with RosetteSep CD14+ enrichment kit to isolate monocytes, 
which were then cultured for 6 days in the presence of IL-4 (4 ng/ml) and GM-CSF (4 
ng/ml). On day 6, the cells were washed, stained with anti-CD14, anti-DC-SIGN, anti-HLA-
DR, and anti-CD1a mAbs (BD Biosciences). Surface expression was evaluated using flow 
cytometry and data was analyzed with FlowJo software. 
2.3.3 Isolation of skin DC subsets 
We have recently described methods to isolate DC subsets from healthy skin tissue obtained 
after reconstructive plastic surgery (Bond et al., 2009). These methods employ a skin graft 
mesher (Zimmer) that mechanically expands skin in a net-like fashion and increases the 
accessibility of dispase, an enzyme that separates the dermal and epidermal layers, to 
penetrate the tissue. After dispase treatment, these layers can then be physically teased apart 
with forceps. This step is followed by incubation with collagenase, which enzymatically 
disrupts the collagen fibers and thereby the tissue integrity. After sequential filtering steps, 
this method results in single cell suspensions enriched for dDC and LC from the dermis and 
epidermis, respectively. In an alternative method to isolate skin DC, the separated layers are 
incubated with collagenase and GM-CSF, which induces the cells to migrate from the tissue 
and into the media. Suspensions of the cells typically consist of a higher percentage of DC, 
but which may display a more mature phenotype compared to DC isolated with collagenase 
alone. Regardless of maturation state, the harvested LC are identified by uniform and high 
expression of HLA-DR, CD1a and Langerin. dDC express HLA-DR, but exhibit differential 
expression of CD1a and CD14 (Bond et al., 2009). These techniques allow for efficient 
isolation of significant numbers of skin DC useful for investigations of rAd infection. 
3. Recombinant adenovirus vectors 
3.1 Background 
The family of human Adenoviruses (Adenoviridae) consists of at least 50 different subtypes 
divided into seven species and causes a diverse array of acute human diseases (Arnberg, 
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Fig. 2. Phenotype of human DC differentiated from primary monocytes with GM-CSF and 
IL-4 over six days. 
Human PBMC were treated with RosetteSep CD14+ enrichment kit to isolate monocytes, 
which were then cultured for 6 days in the presence of IL-4 (4 ng/ml) and GM-CSF (4 
ng/ml). On day 6, the cells were washed, stained with anti-CD14, anti-DC-SIGN, anti-HLA-
DR, and anti-CD1a mAbs (BD Biosciences). Surface expression was evaluated using flow 
cytometry and data was analyzed with FlowJo software. 
2.3.3 Isolation of skin DC subsets 
We have recently described methods to isolate DC subsets from healthy skin tissue obtained 
after reconstructive plastic surgery (Bond et al., 2009). These methods employ a skin graft 
mesher (Zimmer) that mechanically expands skin in a net-like fashion and increases the 
accessibility of dispase, an enzyme that separates the dermal and epidermal layers, to 
penetrate the tissue. After dispase treatment, these layers can then be physically teased apart 
with forceps. This step is followed by incubation with collagenase, which enzymatically 
disrupts the collagen fibers and thereby the tissue integrity. After sequential filtering steps, 
this method results in single cell suspensions enriched for dDC and LC from the dermis and 
epidermis, respectively. In an alternative method to isolate skin DC, the separated layers are 
incubated with collagenase and GM-CSF, which induces the cells to migrate from the tissue 
and into the media. Suspensions of the cells typically consist of a higher percentage of DC, 
but which may display a more mature phenotype compared to DC isolated with collagenase 
alone. Regardless of maturation state, the harvested LC are identified by uniform and high 
expression of HLA-DR, CD1a and Langerin. dDC express HLA-DR, but exhibit differential 
expression of CD1a and CD14 (Bond et al., 2009). These techniques allow for efficient 
isolation of significant numbers of skin DC useful for investigations of rAd infection. 
3. Recombinant adenovirus vectors 
3.1 Background 
The family of human Adenoviruses (Adenoviridae) consists of at least 50 different subtypes 
divided into seven species and causes a diverse array of acute human diseases (Arnberg, 
 




2009). The virion has an icosohedral non-enveloped capsid containing fibers spikes 
protruding from each vertice that encapsulates a double stranded linear DNA genome. The 
complete high resolution structure of the 150 megadalton Ad viron has recently been solved 
(Liu et al., 2010, Reddy et al., 2010) and provides critical insights into the virology of Ad. The 
genome organization and capsid structure are relatively conserved amongst Ad species, but 
receptor usage, cellular and tissue tropism, and activation of immune cells differs. 
Recombinant Adenoviruses (rAd), rendered replication incompetent by removal of viral 
early genes (e.g. E1, E3, and E4), have steadily gained prominence as vectors in various gene 
therapy and vaccine applications (Liu, 2010, Patterson et al., 2009). The use of rAd as gene 
delivery vehicles is driven largely by the extensive characterization of Ad virology and the 
ability to produce high titers of replication incompetent virus that encode for relatively large 
foreign gene inserts. Transduction of many cell types by rAd leads to transcription of the 
inserted transgene and high production of its encoded protein, especially when the 
transgene is under control of an optimized promoter element. Moreover, replication 
incompetent rAd vectors have proven safe in both pre-clinical toxicology and clinical trials 
(Catanzaro et al., 2006, Sheets et al., 2008). rAd type 5 (rAd5) of species C has been used 
most widely, but due to various limitations such as common pre-existing antibody mediated 
immunity, alternative Ad species (e.g. B) are now being investigated and employed (Abbink 
et al., 2007). Thus, investigation of these alternative Ad species, which are often less well 
characterized compared to rAd5 in terms of their specific receptor usage and ability to 
transduce different cells, is highly warranted and will hopefully expand their usefulness in 
gene therapy and vaccination. 
3.2 Generation of recombinant adenovirus vectors 
Replication incompetent rAd vectors can be efficiently generated in mammalian  
packing cells lines and are the type in common use (He et al., 1998). These vectors are 
rendered replication incompetent by genetic deletion of early genes, which are transcribed 
early in the virus life cycle and are required for viral replication. Numerous packaging cell 
lines, such as PER.C6 or 293-ORF6, have been developed that provide deleted early genes in 
trans. rAd5 and rAd35 vectors have capacity for foreign transgenes of up to 7.5 kb under 
control of a CMV promoter (McVey et al., 2010). This type of promoter has been found to be 
the most active in human DC (Papagatsias et al., 2008). However, these authors noted that 
promoter type strongly affected transgene expression, and promoter activity was dependent 
on cell type. Thus, cell lines may neither accurately represent promoter activity nor predict 
gene expression in primary immune cells. Viral expression cassettes typically also  
include SV40 polyadenylation signals to further enhance expression of the transgene. 
Transgenes encoding fluorescent proteins can be used to follow viral infection. These 
current methods result in the generation of high viral titre stocks with severely limited viral 
replication. 
3.3 Receptor usage 
3.3.1 Primary cellular attachment receptors 
Ad use a variety of cellular attachment receptors that are determined both by cell type 
and the virus species (reviewed by (Arnberg, 2009)). Furthermore, receptor usage may be 
substantially different depending on the host species; such as between human and mice. 
Therefore, for the purposes of this chapter, we will focus on the receptors expressed by 
human DC that have been or may be implicated in rAd infection. Table II provides an 
 




overview of described and potential receptors on human DC for selected Ad types. It is 
well established that species B Ad35 requires the complement regulatory protein CD46 to 
attach to and infect a variety of human cells (Gaggar et al., 2003). The trimeric fiber knob 
protein mediates high affinity and avidity binding of rAd35 to a region within the 
extracellular short consensus repeats (SCR)1 and 2 of CD46 (Nemerow et al., 2009, Wang 
et al., 2007, Wang et al., 2008). In fact, all species B rAd probably use CD46 except types 3 
and 7 (Marttila et al., 2005).  We have previously confirmed these findings by showing 
that rAd35 requires CD46 to infect pDC and mDC (Lore et al., 2007). Using anti-CD46 
mAb directed against the known binding regions of the rAd35 knobs we demonstrated 
that CD46 attachment was required for rAd35 infection. CD46 is ubiquitously expressed 
on all nucleated cells and it is therefore likely that rAd35 infects or at least binds to a 
range of cells. In addition to its role as a complement regulatory protein, CD46 regulates 
immune cell function through putative signalling domains within its cytoplasmic tails 
(Kemper & Atkinson, 2007, Wang et al., 2000). Thus, CD46 using rAd vectors, such as 
rAd35, may modulate immune cells through receptor interactions. For example, CD46 
engagement drives the differentiation of CD4+ T cells to a regulatory phenotype (Kemper 
et al., 2003).  
Contrary to rAd35, the receptors used by the species C Ad5 to infect human DC are less 
clear. While the coxsackie-adenovirus receptor (CAR) is the described receptor for rAd5 
on epithelial cells (Bergelson et al., 1997), blood DC were found to not express this 
receptor at levels detectable by flow cytometry (Lore et al., 2007). However, we have 
found that CAR plays a minor role in mediating rAd5 infection of skin DC, which express 
CAR (Adams et al., 2009). Thus, rAd5 may infect DC, especially blood DC, in a CAR-
independent manner. To this end, several CAR-independent pathways for rAd5 infection 
have been suggested. Lactoferrin (Lf), an iron-binding protein present in abundance at 
mucosal sites and in many bodily fluids, was shown to facilitate epithelial cell infection by 
species C Ad (Johansson et al., 2007). We expanded on this report and found that Lf 
strongly enhanced rAd5 infection of all tested blood and skin DC subsets (Adams et al., 
2009). Of particular interest in the application of rAd5 as a gene therapy or vaccine vector 
was the mechanism by which Lf facilitated infection. Lf species with high mannose type 
N-linked glycans mediated rAd5 infection via binding to DC-SIGN. As mentioned earlier, 
this receptor is expressed by both MDDC and a subset of skin resident dDC. Thus, Lf 
represents a mechanism to mediate rAd5 infection of CAR- human DC and may provide a 
means to enhance the infection of DC both in vitro and in vivo. Coagulation factors also 
play a critical role in mediating in vivo tropism of rAd5 vectors, especially after 
intravenous administration (Kalyuzhniy et al., 2008, Waddington et al., 2008). High 
affinity Ad5 hexon protein interactions with coagulation factor X (FX) mediate liver 
tropism through high efficiency transduction of hepatocytes in mice. These studies 
illustrate that cellular tropism may be determined by binding events that occur 
independent of the classical Ad knob-receptor interactions. It is currently unknown to 
what extent these soluble factors mediate infection of human DC in vivo, but this will be 
important to determine in future studies.  In murine DC, a region within the rAd5 fiber-
shaft facilitates infection in a heparin dependent manner (Cheng et al., 2007). It will be 
critical to determine whether this receptor usage also exists in DC. These authors also 
found that rAd5 mutants with ablated CAR binding retained their ability to infect murine 
DC, which supports our earlier findings that Ad5 infects human DC, albeit to a lesser 
extent than rAd35, in the absence of CAR. 
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Transgenes encoding fluorescent proteins can be used to follow viral infection. These 
current methods result in the generation of high viral titre stocks with severely limited viral 
replication. 
3.3 Receptor usage 
3.3.1 Primary cellular attachment receptors 
Ad use a variety of cellular attachment receptors that are determined both by cell type 
and the virus species (reviewed by (Arnberg, 2009)). Furthermore, receptor usage may be 
substantially different depending on the host species; such as between human and mice. 
Therefore, for the purposes of this chapter, we will focus on the receptors expressed by 
human DC that have been or may be implicated in rAd infection. Table II provides an 
 




overview of described and potential receptors on human DC for selected Ad types. It is 
well established that species B Ad35 requires the complement regulatory protein CD46 to 
attach to and infect a variety of human cells (Gaggar et al., 2003). The trimeric fiber knob 
protein mediates high affinity and avidity binding of rAd35 to a region within the 
extracellular short consensus repeats (SCR)1 and 2 of CD46 (Nemerow et al., 2009, Wang 
et al., 2007, Wang et al., 2008). In fact, all species B rAd probably use CD46 except types 3 
and 7 (Marttila et al., 2005).  We have previously confirmed these findings by showing 
that rAd35 requires CD46 to infect pDC and mDC (Lore et al., 2007). Using anti-CD46 
mAb directed against the known binding regions of the rAd35 knobs we demonstrated 
that CD46 attachment was required for rAd35 infection. CD46 is ubiquitously expressed 
on all nucleated cells and it is therefore likely that rAd35 infects or at least binds to a 
range of cells. In addition to its role as a complement regulatory protein, CD46 regulates 
immune cell function through putative signalling domains within its cytoplasmic tails 
(Kemper & Atkinson, 2007, Wang et al., 2000). Thus, CD46 using rAd vectors, such as 
rAd35, may modulate immune cells through receptor interactions. For example, CD46 
engagement drives the differentiation of CD4+ T cells to a regulatory phenotype (Kemper 
et al., 2003).  
Contrary to rAd35, the receptors used by the species C Ad5 to infect human DC are less 
clear. While the coxsackie-adenovirus receptor (CAR) is the described receptor for rAd5 
on epithelial cells (Bergelson et al., 1997), blood DC were found to not express this 
receptor at levels detectable by flow cytometry (Lore et al., 2007). However, we have 
found that CAR plays a minor role in mediating rAd5 infection of skin DC, which express 
CAR (Adams et al., 2009). Thus, rAd5 may infect DC, especially blood DC, in a CAR-
independent manner. To this end, several CAR-independent pathways for rAd5 infection 
have been suggested. Lactoferrin (Lf), an iron-binding protein present in abundance at 
mucosal sites and in many bodily fluids, was shown to facilitate epithelial cell infection by 
species C Ad (Johansson et al., 2007). We expanded on this report and found that Lf 
strongly enhanced rAd5 infection of all tested blood and skin DC subsets (Adams et al., 
2009). Of particular interest in the application of rAd5 as a gene therapy or vaccine vector 
was the mechanism by which Lf facilitated infection. Lf species with high mannose type 
N-linked glycans mediated rAd5 infection via binding to DC-SIGN. As mentioned earlier, 
this receptor is expressed by both MDDC and a subset of skin resident dDC. Thus, Lf 
represents a mechanism to mediate rAd5 infection of CAR- human DC and may provide a 
means to enhance the infection of DC both in vitro and in vivo. Coagulation factors also 
play a critical role in mediating in vivo tropism of rAd5 vectors, especially after 
intravenous administration (Kalyuzhniy et al., 2008, Waddington et al., 2008). High 
affinity Ad5 hexon protein interactions with coagulation factor X (FX) mediate liver 
tropism through high efficiency transduction of hepatocytes in mice. These studies 
illustrate that cellular tropism may be determined by binding events that occur 
independent of the classical Ad knob-receptor interactions. It is currently unknown to 
what extent these soluble factors mediate infection of human DC in vivo, but this will be 
important to determine in future studies.  In murine DC, a region within the rAd5 fiber-
shaft facilitates infection in a heparin dependent manner (Cheng et al., 2007). It will be 
critical to determine whether this receptor usage also exists in DC. These authors also 
found that rAd5 mutants with ablated CAR binding retained their ability to infect murine 
DC, which supports our earlier findings that Ad5 infects human DC, albeit to a lesser 
extent than rAd35, in the absence of CAR. 
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Table 2. Definitive and potential receptors on human DC for select Ad types. 
Finally, increased vector transduction of DC has been tested by genetically modifying rAd 
vectors to target DC expressing CD40 (Korokhov et al., 2005b) and DC-SIGN (Korokhov et 
al., 2005a, Maguire et al., 2006). Targeting DC in this manner led to greater transduction 
efficiency of DC by retargeted rAd vectors compared to unmodified vectors. These reports 
are reminiscent of how Lf  also enhanced infection through DC-SIGN (Adams et al., 2009). 
In conclusion, rAd vectors may be retargeted through genetic modification of the capsid 
structure or other soluble proteins to more efficiently infect DC, but it remains to be 
determined how effective such strategies are in vivo.  
3.3.2 Secondary cellular receptors 
A secondary interaction with cellular αv/β3 and αv/β5 integrins and RGD motifs of the Ad 
penton bases facilitates membrane penetration and internalization of Ad particles (Wickham 
et al., 1993). αvβ5 integrins may even be sufficient to allow rAd infection when CAR is not 
present (Lyle & McCormick, 2010). However, mutant rAd with ablated integrin binding 
retained their ability to infect murine DC, which indicates that such interactions are not 
necessary on DC (Cheng et al., 2007). It will be important to further elucidate the role of 
integrins in mediating rAd infection of DC, particularly since the expression may differ 
between DC subsets and host species. β3 integrins displayed by mouse macrophages are the 
major initiators of innate immune response towards Ad vectors in vivo (Di Paolo et al., 2009). 
In that study, binding of RGD motifs to integrins induce IL-1α independent of membrane 
penetration. This report highlights how Ad interactions with receptors may, in addition to 
mediating cellular attachment, influence immunity independent of infection (Shayakhmetov 
et al., 2010).    
3.3.3 Other potential cellular attachment receptors on DC 
The co-stimulatory receptors, CD80 and CD86, involved in the antigen presentation process 
have been implicated as receptors for Ad3 (Short et al., 2004, Short et al., 2006). These 
findings are relevant for DC since they display these markers whereas most other cells do 
not. As will be discussed in more detail in section 5.1, surface CD80 and CD86 levels 
increase on DC during phenotypic maturation. Whether CD80 and CD86 can act as 
candidate receptors for Ad3 on DC, needs to be confirmed. A recent report demonstrates 
 




that Ad3 binds the desmoglein receptor (Wang et al., 2011), although it is unknown if this 
receptor is expressed on DC and can facilitate infection. GD1a glycan was recently identified 
as the receptor for Ad37, although again the relevance of this receptor for DC infection has 
not yet been studied (Nilsson et al., 2011). Taken together, these data highlight the 
importance of understanding how rAd vectors used in gene therapy interact with immune 
cells. In particular, certain interactions with DC may have positive or negative consequences 
on immunity generated towards the rAd vector. 
4. Susceptibility of DC to rAd infection 
4.1 Methods for testing DC susceptibility in vitro 
As previously discussed, there is significant complexity in the receptor usage of rAd vectors 
derived from different species or types, which likely results in vast differences in their 
ability to infect DC. What particular cells are infected with rAd after vector delivery is 
largely unknown. Whether expression of vector transgenes in all or specific cells of the 
heterogeneic DC population is desired or not may also depend on the specific gene therapy 
or vaccine application. It is thus important to determine the susceptibility of primary human 
DC subsets to rAd. We have developed methods to monitor rAd infection in DC (Adams et 
al., 2009, Lore et al., 2007). In these assays, freshly isolated DC are exposed to rAd vectors 
encoding green fluorescence protein (GFP) reporter transgene. Following receptor binding 
and penetration of the cellular membrane, the virus traffics to and enters the nucleus where 
replication occurs. Since the vectors are optimized for expression of the transgene, GFP may 
be expressed in susceptible cells. GFP expression can then be used as a surrogate marker of 
productive rAd infection. We have included examples here to demonstrate how the method 
is performed and how it can be used to compare the capacity of different rAd types to infect 
MDDC (Fig. 3), mDC and pDC (Fig. 4A), and LC and dDC (Fig. 4B). In these experiments, 
the DC were exposed to different inocula of rAd types 35 or rAd5, or rAd26. After 24 h, the 
cells were stained for surface markers to examine phenotype simultaneously with GFP by 
 
 
Fig. 3. Flow cytometry analysis of GFP transgene expression in human MDDC. 
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findings are relevant for DC since they display these markers whereas most other cells do 
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increase on DC during phenotypic maturation. Whether CD80 and CD86 can act as 
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that Ad3 binds the desmoglein receptor (Wang et al., 2011), although it is unknown if this 
receptor is expressed on DC and can facilitate infection. GD1a glycan was recently identified 
as the receptor for Ad37, although again the relevance of this receptor for DC infection has 
not yet been studied (Nilsson et al., 2011). Taken together, these data highlight the 
importance of understanding how rAd vectors used in gene therapy interact with immune 
cells. In particular, certain interactions with DC may have positive or negative consequences 
on immunity generated towards the rAd vector. 
4. Susceptibility of DC to rAd infection 
4.1 Methods for testing DC susceptibility in vitro 
As previously discussed, there is significant complexity in the receptor usage of rAd vectors 
derived from different species or types, which likely results in vast differences in their 
ability to infect DC. What particular cells are infected with rAd after vector delivery is 
largely unknown. Whether expression of vector transgenes in all or specific cells of the 
heterogeneic DC population is desired or not may also depend on the specific gene therapy 
or vaccine application. It is thus important to determine the susceptibility of primary human 
DC subsets to rAd. We have developed methods to monitor rAd infection in DC (Adams et 
al., 2009, Lore et al., 2007). In these assays, freshly isolated DC are exposed to rAd vectors 
encoding green fluorescence protein (GFP) reporter transgene. Following receptor binding 
and penetration of the cellular membrane, the virus traffics to and enters the nucleus where 
replication occurs. Since the vectors are optimized for expression of the transgene, GFP may 
be expressed in susceptible cells. GFP expression can then be used as a surrogate marker of 
productive rAd infection. We have included examples here to demonstrate how the method 
is performed and how it can be used to compare the capacity of different rAd types to infect 
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Fig. 3. Flow cytometry analysis of GFP transgene expression in human MDDC. 
 




flow cytometry. GFP+ cells can be detected at earlier time points (≥ 8 hours), but the level of 
infection usually peaks around 24 hours. We have previously optimized these methods in 
pDC and mDC with similar results as presented here (Lore et al., 2007). Here, we confirmed 
these findings in all the mentioned DC (Fig. 3-4). In section 4.2 of this chapter we will 
discuss the major differences observed between the susceptibility of DC subsets to different 
rAd species. 
MDDC were exposed to rAd types 35, 26, and 5 encoding GFP at the indicated inocula 
(virus particles (vp) per cell). After 24 hours, the cells were washed and stained with directly 
conjugated anti-CD1a and anti-CD14 mAbs (BD Biosciences). Expression of surface markers 
and GFP was evaluated using flow cytometry and data was analyzed with FlowJo software. 
 
 
Fig. 4. Flow cytometry analysis of GFP transgene expression in human blood and skin DC 
subsets. 
Freshly isolated (A) mDC and pDC or (B) dDC and LC were exposed to rAd35 or 5 encoding 
GFP at the indicated inocula (infectious virus particles (ip) per cell). After 24 hours, the cells 
were washed and stained with directly conjugated anti-CD1a or anti-HLA-DR mAbs (BD 
Biosciences). Expression of surface marker and GFP was evaluated using flow cytometry 
and data was analyzed with FlowJo software. 
4.2 Notable differences in DC infection between rAd species 
There may be important implications for gene delivery vehicles that differentially target 
DC. We have reported previously on the capacity of rAd vectors to infect primary human 
DC and MDDC (Adams et al., 2009, Lore et al., 2007). In these studies we have compared 
the species C rAd5 and species B rAd35, which are widely used as gene delivery vehicles. 
As discussed in section 3.3, a major difference between these viruses is their receptor 
usage. rAd35 uses CD46 as a primary attachment receptor, while rAd5 uses CAR to infect 
CAR+ cells. A flow cytometric analysis of surface marker expression revealed that pDC, 
mDC, and MDDC express high levels CD46, but have undetectable levels of CAR (Adams 
et al., 2009, Lore et al., 2007). Moreover, exposure of rAd35 encoding GFP led to a greater 
frequency of GFP+ pDC and mDC when compared to rAd5 (Fig. 4A). These differences 
have been observed by others as well (Ophorst et al., 2004, Rea et al., 2001) and are in 
agreement with data presented here that rAd35 infects MDDC (Fig. 3) and the cutaneous 
dDC and LC (Fig. 4B) more efficiently than rAd5. Others have also found that rAd35 
infects skin emigrating DC more efficiently than rAd5 (de Gruijl et al., 2006). Here, we 
also show new data that species D rAd26 infected MDDC to about the same degree as 
 




rAd35 (Fig. 3). On this note, the specific receptor used by rAd26 for infection is still 
controversial and there are diverging reports implicating either CD46 (Abbink et al., 2007) 
or CAR (Chen et al., 2010). rAd5 infection of DC occurred in the absence of CAR 
expression and neutralizing anti-CAR mAb had no effect on infection (Lore et al., 2007). 
Unlike blood DC, subsets of cutaneous DC display CAR and blocking CAR has a 
noticeable but incomplete reduction of rAd5 infection (Adams et al., 2009). We also show 
here that dDC were substantially more susceptible to both rAd5 and 35 infection than 
donor matched LC (Fig. 4B). Another report found that LC were more susceptible to rAd 
infection compared to dDC when using skin DC differentiated from CD34+ 
haematopoietic stem cells in vitro (Rozis et al., 2005). These differing studies highlight the 
complexicity in comparing data generated using different sources of DC. It is criticial to 
perform detailed characterizations of the phenotypes and functions of the DC in each 
culture system to be able to relate it to how accurately they represent DC in vivo. The level 
of maturation should be carefully monitored since it may substantially affect DC 
susceptibility to rAd infection. Finally, even though rAd5 infects DC to a lesser extent 
than rAd35, it was recently shown that CD11c+ DC were indispensable for generating 
strong transgene specific CD8+ T cell responses in mice (Lindsay et al., 2010). This shows 
that DC recognition of rAd vectors plays a crucial role in mediating immunity and that it 
may be beneficial in gene therapy to retarget rAd to not infect DC in order to minimize 
insert specific immunity. 
5. rAd induced activation of DC 
5.1 Phenotypic maturation 
As mentioned earlier in this chapter, phenotypic maturation is an important differentiation 
step in which DC convert from an immature resting state to an activated state with 
increased capacity to process and present foreign antigen. Maturation licenses DC to 
activate naïve T cells through expression of co-stimulatory molecules concurrently with 
presentation of foreign peptides on MHC molecules. Mature DC upregulate activating 
members of the B7 family (CD80 and CD86) that provide co-stimulation through CD28 
engagement and optimally activate naïve T cells. DC also upregulate MHC class II (HLA-
DR) and CD40 that activates both T and B cells through CD40L. There are also many more 
molecules that positively and negatively regulate DC mediated activation of T cells that are 
outside the scope of this chapter. Flow cytometry analysis of these surface markers is the 
most common and instructive method to assess maturation as it quantifies the change in 
expression on the surface of DC, which is indicative of the strength by which DC can 
activate T cells. We have found that different rAd types have vastly different capacities to 
induce phenotypic maturation of DC. For example, the species B rAd35 was found to induce 
maturation of primary human DC subsets, while rAd5 was not (Lore et al., 2007). In fact, 
while very high doses of rAd5 did not induce differentiation, a dose of only a few rAd35 
particles per DC induced strong maturation. rAd35 induced upregulation of the maturation 
markers CD80, CD83, CD86, HLA-DR, and CD40 (Lore et al., 2007)(Adams and Loré, 
unpublished data). The maturation caused by rAd35 is comparable to that induced by 
strong maturation stimuli such as the TLR4 ligand lipopolysaccharide and the TLR7/8 using 
imidazoquinolines. While others have found rAd5 activates DC (Philpott et al., 2004), there 
may be important differences in the source of DC and viral dose between studies. Receptor 
usage may be linked to the capacity of different rAd types to induce maturation. Although 
 




flow cytometry. GFP+ cells can be detected at earlier time points (≥ 8 hours), but the level of 
infection usually peaks around 24 hours. We have previously optimized these methods in 
pDC and mDC with similar results as presented here (Lore et al., 2007). Here, we confirmed 
these findings in all the mentioned DC (Fig. 3-4). In section 4.2 of this chapter we will 
discuss the major differences observed between the susceptibility of DC subsets to different 
rAd species. 
MDDC were exposed to rAd types 35, 26, and 5 encoding GFP at the indicated inocula 
(virus particles (vp) per cell). After 24 hours, the cells were washed and stained with directly 
conjugated anti-CD1a and anti-CD14 mAbs (BD Biosciences). Expression of surface markers 
and GFP was evaluated using flow cytometry and data was analyzed with FlowJo software. 
 
 
Fig. 4. Flow cytometry analysis of GFP transgene expression in human blood and skin DC 
subsets. 
Freshly isolated (A) mDC and pDC or (B) dDC and LC were exposed to rAd35 or 5 encoding 
GFP at the indicated inocula (infectious virus particles (ip) per cell). After 24 hours, the cells 
were washed and stained with directly conjugated anti-CD1a or anti-HLA-DR mAbs (BD 
Biosciences). Expression of surface marker and GFP was evaluated using flow cytometry 
and data was analyzed with FlowJo software. 
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the species C rAd5 and species B rAd35, which are widely used as gene delivery vehicles. 
As discussed in section 3.3, a major difference between these viruses is their receptor 
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CAR+ cells. A flow cytometric analysis of surface marker expression revealed that pDC, 
mDC, and MDDC express high levels CD46, but have undetectable levels of CAR (Adams 
et al., 2009, Lore et al., 2007). Moreover, exposure of rAd35 encoding GFP led to a greater 
frequency of GFP+ pDC and mDC when compared to rAd5 (Fig. 4A). These differences 
have been observed by others as well (Ophorst et al., 2004, Rea et al., 2001) and are in 
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rAd35 (Fig. 3). On this note, the specific receptor used by rAd26 for infection is still 
controversial and there are diverging reports implicating either CD46 (Abbink et al., 2007) 
or CAR (Chen et al., 2010). rAd5 infection of DC occurred in the absence of CAR 
expression and neutralizing anti-CAR mAb had no effect on infection (Lore et al., 2007). 
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donor matched LC (Fig. 4B). Another report found that LC were more susceptible to rAd 
infection compared to dDC when using skin DC differentiated from CD34+ 
haematopoietic stem cells in vitro (Rozis et al., 2005). These differing studies highlight the 
complexicity in comparing data generated using different sources of DC. It is criticial to 
perform detailed characterizations of the phenotypes and functions of the DC in each 
culture system to be able to relate it to how accurately they represent DC in vivo. The level 
of maturation should be carefully monitored since it may substantially affect DC 
susceptibility to rAd infection. Finally, even though rAd5 infects DC to a lesser extent 
than rAd35, it was recently shown that CD11c+ DC were indispensable for generating 
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activate naïve T cells through expression of co-stimulatory molecules concurrently with 
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members of the B7 family (CD80 and CD86) that provide co-stimulation through CD28 
engagement and optimally activate naïve T cells. DC also upregulate MHC class II (HLA-
DR) and CD40 that activates both T and B cells through CD40L. There are also many more 
molecules that positively and negatively regulate DC mediated activation of T cells that are 
outside the scope of this chapter. Flow cytometry analysis of these surface markers is the 
most common and instructive method to assess maturation as it quantifies the change in 
expression on the surface of DC, which is indicative of the strength by which DC can 
activate T cells. We have found that different rAd types have vastly different capacities to 
induce phenotypic maturation of DC. For example, the species B rAd35 was found to induce 
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while very high doses of rAd5 did not induce differentiation, a dose of only a few rAd35 
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may be important differences in the source of DC and viral dose between studies. Receptor 
usage may be linked to the capacity of different rAd types to induce maturation. Although 
 




the mechanisms of cellular entry may differ between Ad species and cell type (Hall et al., 
2010), it is likely that viral nucleic acids could signal through endosomal or cytosolic 
expressed PRR and thereby initiate DC maturation. It is currently unclear why or how 
certain Ad species induce maturation while others do not. However, one potential 
explanation may be that species C and B Ads have different kinetics of endosomal retention 
and escape to the cytosol following receptor mediated endocytosis, which thereby affect 
PRR recognition in these compartments (Miyazawa et al., 2001). In vivo, maturation of mDC 
induced by rAd vectors was dependent on type-1 IFN signalling (Hensley et al., 2005), 
indicating that phenotypic maturation of DC may be induced directly through infection or 
facilitated indirectly through cytokine production. However, it is currently unknown what 
PRR are responsible for rAd mediated DC maturation. 
5.2 Cytokine induction 
In addition to phenotypic maturation, DC also produce numerous cytokines in response to 
foreign antigen exposure. In this regard, DC subsets differ in the specific cytokines they 
produce (Table I). Whereas mDC secrete IL-12p70, pDC possess a unique ability to rapidly 
secrete abundant type-1 interferons (IFNα/β) following viral infection (Swiecki et al., 2010). 
Like many other viruses Ads can potently induce systemic IFNα/β in vivo. We have 
previously used three methods to measure cytokines levels in DC: (i) enzyme-linked 
immunosorbent assay (ELISA), (ii) intracellular cytokine staining with flow cytometry, and 
(iii) quantitative RT-PCR (Douagi et al., 2009, Lore et al., 2007). DC cytokine production may 
also be measured in situ (Lore et al., 1998, Lore et al., 2001), but this method has not been 
combined with rAd infection. There are benefits and drawbacks to each of these techniques, 
which is why the appropriate method should be selected depending on the study aim. 
ELISA is highly sensitive and useful when the purity of the sorted cells is high, as is the case 
with sorted primary DC. This method quantifies secreted cytokines, but does not measure 
production on a per cell basis. Intracellular staining does allow for such assessment 
however. In this method the use of pharmacological inhibitors of protein secretion (e.g. 
Brefeldin A) enables detection of cytokines by causing their accumulation within the cells in 
which they are produced. Subsequent fixation and saponin-mediated cell membrane 
permeabilization enables staining of intracellular accumulated cytokines and detection by 
flow cytometry. This method is particularly useful for detecting cytokines in unsorted cell 
populations or when measuring GFP expression simultaneously (Fig. 5). Since several 
common pharmacological agents, such as monensin and chloroquine, may interfere with 
rAd infection or PRR signalling (Adams and Loré, unpublished data), they should be tested 
rigorously to avoid unwanted effects on DC function. 
 
 
Fig. 5. Simultaneous detection of rAd derived GFP and intracellular IFNα. 
 




pDC were exposed to rAd35-GFP, rAd5-GFP (100 ip/cell), or a TLR7/8-ligand (1 μg/ml) for 
8 hours with Brefeldin A present for the last 7 hours. The cells were then washed, fixed and 
permeabilized with BD cytofix/cytoperm kit, and stained for anti-CD123 (BD) and anti-
IFNα (Interferon Source). GFP expression was evaluated simultaneously with IFNα by flow 
cytometry (BD FACS LSR II) and data was analyzed with FlowJo software. 
Intracellular IFNα, accumulated during the last 7 hours of stimulation by Brefeldin A, can 
be readily detected in pDC exposed to rAd35 (Lore et al., 2007). To add to our previous 
study we show here the simultaneous detection of the frequencies of infected (GFP+) and 
IFNα producing cells (Fig. 5). rAd35 again induced almost as much IFNα as the positive 
control, a TLR7/8-ligand, whereas rAd5 neither infected nor induced IFNα in pDC. We 
also observed four distinct groups of pDC following rAd35 exposure: GFP-, GFP+, 
GFP+/IFNα+, or IFNα+ (Fig. 5). Since DC may be infected with rAd even though no GFP 
is detected, this may explain why PDC make IFNα in the absence of GFP expression. 
Differential kinetics of GFP and IFNα production may also partly explain the observed 
expression pattern. Nevertheless, the strong induction of IFNα by pDC is an important 
parameter to study in the context of rAd infection. Type-1 IFN induction in PBMC was 
shown to be a feature unique to CD46 using Ads (Iacobelli-Martinez & Nemerow, 2007). 
In that study, IFNα/β production was dependent on endosomal TLR9 signalling. While 
rAd35 induces IFNα/β in pDC in vitro, there may be multiple sources of systemic 
IFNα/β, especially for non-CD46 using Ads. For example, murine splenic mDC are the 
major source of IFNα/β in vivo following inoculation of Ad3 or Ad5, independent of TLR 
and cytosolic nucleic acid receptor (RIG-I like) signalling (Fejer et al., 2008). Moreover, 
virus associated RNA synthesized by RNA polymerase III may also contribute to systemic 
type-1 IFN production after rAd immunization (Yamaguchi et al., 2010). Nevertheless, 
potent transgene-specific CD8+ T cell responses are mounted in the absence of intact type-
1 IFN signalling (Hensley et al., 2005). IFNα likely has beneficial effects for vaccination in 
driving adaptive immunity, whereas in gene therapy antiviral properties of IFNα may 
blunt rAd mediated gene delivery. 
RT-PCR is an alternative and sensitive method to quantify cytokine gene transcription 
(Douagi et al., 2009). However, this method requires highly pure populations of sorted cells 
and does not allow for cytokine measurement on a per cell basis. In addition, it is important 
to consider that detection of RNA may not correlate with protein translation and functional 
cytokine secretion.   
5.3 Antigen presentation 
When rAd are used in either gene therapy or vaccine vector applications, it is crucial to 
determine the immune responses to the transgene. Following vaccination the goal is to 
induce strong transgene immunity, while for gene therapy such immune responses may 
blunt the intended effect of the transgene. As such, we have previously studied in vitro the 
capacity of rAd vectors to activate transgene specific memory T cells (Lore et al., 2007). To 
be able to measure antigen-presentation of the transgene we developed rAd5 or rAd35 
vectors encoding the immunodominant pp65 antigen of CMV. These rAd encoding pp65 
were exposed to freshly isolated pDC or mDC for 24 hours to allow for sufficient time for 
transgene presentation and the DC were then added to autologous sorted CD4+ or CD8+ T 
cells from donors with known pre-existing T cell responses to CMV pp65. We found that 
rAd exposed DC were able to activate antigen (pp65)-specific memory T cells equivalently 
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Fig. 5. Simultaneous detection of rAd derived GFP and intracellular IFNα. 
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to antigen matched overlapping pp65 peptide pools. Importantly, rAd35 vectors more 
efficiently activated memory T cells compared to rAd5. While infected DC likely display 
rAd-derived peptide on class I to activate CD8 T cells, the mechanisms for class II 
presentation to activate CD4+ T cells are less clear. Nevertheless, these studies indicate that 
rAd5 and rAd35 exposed DC are able to present Ad encoded antigen and stimulate antigen 
specific T cells. Future studies should also evaluate how rAd vectors influence DC priming 
of naive T cells. These findings have important implications in clinical applications and 
depend on whether immune responses towards the transgene are desired or not (Zaiss et al., 
2009).  
6. Conclusions 
In this chapter we have reviewed the basic concepts relating to the infection of primary 
human DC. Studying the interactions between clinically relevant rAd vectors and multiple 
subsets of pAPC is instructive for guiding the use of these delivery vectors in vivo. While 
studies in rodents, such as mice, may offer clues to how rAd vectors are recognized in vivo, 
there are notable biological differences between humans and mice (Mestas & Hughes, 2004). 
While receptors for viral nucleic acid may be similar in these species, the expression patterns 
within DC subsets are quite different. Additionally, the primary viral attachment receptors 
for human rAd species are likely different between their natural human hosts and mice; for 
example, mice do not express the species B receptor CD46. This likely has a significant 
impact on tissue and cellular tropism as well as innate viral recognition. For these reasons, it 
is crucial to study the interaction of rAd on immune cells from the host species (i.e. humans) 
with which the viruses co-evolved. To this end, isolating phenotypically immature primary 
human DC from both blood and skin tissue provides highly relevant cells with which to 
study the interactions between innate immune cells and different recombinant rAd species. 
Using GFP reporter transgenes, the susceptibility of different DC subsets can be monitored 
in vitro, as can the subsequent induction of DC activation (i.e. phenotypic maturation and 
cytokine production). Following infection and induction of maturation, DC become 
specialized to activate antigen-specific lymphocytes, which can also be tested in vitro. While 
it may be important to exploit the induction of innate immune responses to drive 
development of transgene specific adaptive immunity in a vaccine setting, the opposite is 
likely desired for locally targeted gene therapy. In both clinical applications it is evermore 
crucial to gain a more complete understanding of the human immune response raised 
against rAd vectors.  
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primates (NHPs)(Shiver et al., 2002). The failure of modified vaccinia Ankara (MVA) or DNA 
vectors to achieve similar results only served to underscore the potency of the adenoviral vector 
system. However, several reports both preceding and in particularly following the spectacular 
failure of the MERCK STEP trial have highlighted that adenoviral vectored vaccines may 
induces a substantial, yet functionally impaired T cell response (Tatsis et al., 2007a), that in 
many cases nevertheless provide highly significant protection (Yang et al., 2006). In that context 
it is pertinent to note, that adenoviral vaccination seems to induce T cells with a phenotype 
more resembling that associated with a chronic infection than with a resolved acute and self-
limiting infection. Importantly, although the kinetics and magnitude of the reported adenovirus 
induced CD8+ T cell responses vary considerably depending on the encoded antigen as well as 
the route and dose of immunization, the responses are unusually stable over time. Thus, 
memory T cell frequencies frequently stabilizes above 30% of the peak response, which contrast 
with the 5-10% usually found to be associated with acutely resolved infections (Abbink et al., 
2007; Holst et al., 2007; Holst et al., 2010b; Tatsis et al., 2007a) (See figure 2 for a cartoon of the 
different immune response patterns and their associated phenotypic properties).  
 
 
Fig. 1. The principal differences between replication competent and replication incompetent 
viral vectors with regard to source of antigens. Infection with a live replication competent 
vaccine vector (left side) or a replication incompetent vector (right side) differ markedly in the 
ability to present recombinant vaccine antigen. The replication competent vector has less 
cloning capacity (hence the small red fragment symbolizing recombinant antigen) and 
infection of a host cell results in many viral transcripts being produced, including those not 
containing the recombinant insert. On the positive side, the inoculum will be amplified 
(symbolized by the appearance of virus progeny), and present an ongoing infectious signature 
to the innate immune system. Replication incompetent vectors do not become amplified, but 
transcripts containing the recombinant insert dominate the transcription profile of the 
transduced cell. Other popular virus vectors such as vaccinia virus resemble replication 
competent adenovirus in the way in which they present antigen, whereas replication deficient 
variants, such as modified vaccinia Ankara (MVA), more resemble replication incompetent 
vectors (although with more non-recombinant gene expression)  
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Fig. 2. The principal time-course of antigen elimination and CD8+ T cell response after 
a self-limiting acute infection and an adenoviral vaccination. Infection with an acute 
viral infection (green lines)) takes days to reach maximal antigen presentation (dashed 
green line) as viral replication is needed to amplify the inoculum. There is rapid and 
nearly complete elimination of the virus after the peak by the induced CD8+ T cell 
response (full green line) the time-course of which mimics the antigen curve with a few 
days delay. Vaccination with a replication incompetent adenoviral vector (red lines) is 
representing a bolus injection and the peak of antigen expression (dashed red line) is 
reached shortly after virus inoculation. Subsequently antigen presentation gradually 
declines over a protracted time-period. T cell expansion is delayed (full red line) and 
slowly reaches a peak as the majority of the antigen has been eliminated. The response 
then slowly declines, but is maintained at a high level relative to the peak response. The 
relative differences in the resulting memory T cell phenotype is inserted between the lines 
with color coding identifying the two populations.   
2.1 Tissue transduction properties  
The key to untangle these conflicting reports regarding the immunological properties of 
adenovirus vectors may lie in a better understanding of the mechanisms underlying the 
remarkable immunogenicity of adenoviral vectors and its relationship to route, dose and 
antigen presentation. To aid in this understanding we will first consider the unusual 
features of the adenoviral gene delivery system. Adenoviral vectors are not unique in 
their ability to target relevant populations of antigen presenting cells (Lindsay et al., 
2010), but uniquely among all vaccine delivery technologies, adenoviral vectors have also 
received serious attention as vehicles of correctional or experimental gene therapy. Thus, 
adenoviral vectors can be used to transduce a large number of cell types, and intravenous 
or intramuscular application can lead to a situation where most liver cells or cells of the 
infected muscle are expressing vast amount of the transgene (Antinozzi et al., 1999; 
Jimenez-Chillaron et al., 1999; Okuyama et al., 1998). Thus, with the ability to transduce 
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perfectly equipped to induce combined direct and cross-presentation of antigen to CD8+ 
T cells. In agreement with this notion, ubiquitous, keratinocyte specific and alveolar 
epithelial cell specific promoters have been used to induce CD8+ T cell responses towards 
the encoded antigen, and remarkably, no differences in the response level have been 
observed provided the administration route targeted cells with the relevant promoter 
activity (Prasad et al., 2001). Paradoxically, adenoviruses are extremely potent inducers of 
CD8+ T cells directed against the inserted transgene, yet induce levels of CD4+ T cell 
activation similar to that of naked DNA vaccines, which are much less efficient in tissue 
transduction (Wu et al., 2005). This is surprising because the ability to cross-prime CD8+ T 
cells implies that substantial amount of antigen are being released from dying cells, and 
this antigen would normally be expected to represent a good sources of peptides for MHC 
class II restricted presentation to CD4+ T cells. The reasons for this limited ability to 
induce CD4+ T cell responses are currently not understood.  Unfortunately the study 
employing cell type specific promoters for antigen expression did not contain any data 
relating to the immunological potency, the kinetics of the response or the phenotype of 
the CD8+ T cells induced. This means, that while it is likely that both direct and cross-
presentation contribute in the induction of the response, it has until recently been  unclear 
what is the relative contribution of each type of antigen presentation pathway, how this 
contribution may differ between different antigens and how this may affect the 
phenotypes of the responding T cells. Recent work by our group (Holst et al., 2010b) and 
the group of Jonathan L. Bramson (Bassett et al., 2011; Finn et al., 2009; Yang et al., 2006) 
has now begun to address this issue in greater detail.  
2.2 The issue of dose  
Initially we discovered that increasing the dose of s.c. administered adenovirus from 109 to 
1010 or 1011 particles, caused most of the increased inoculum to enter the systemic circulation 
and transduce the cells of the liver and spleen at levels comparable to those found after an 
i.v. administration (Holst et al., 2010b) (see figure 3). Intravenous administration was found 
to induce a slow response and require more vector for initiating a transgene specific 
response (1010 particles i.v., while 109 or less sufficed for s.c. administration). This is 
consistent with the notion that a key to a potent immune response is efficient priming in the 
local environment of the lymph nodes draining the injection site, and we were able to 
substantiate this suggestion by observing markedly impaired responses in L-selectin 
deficient mice after peripheral immunization using a moderate dose of adenovirus vectored 
vaccine (Holst PJ, Thomsen AR and Christensen JP, unpublished) (see figure 4A). However, 
after a considerable delay, i.v. administered adenovirus did induce a transgene specific 
CD8+ T cell response, which eventually surpassed the response following s.c. immunization 
in terms of cell numbers generated.  For both routes of virus administration we found a 
positive correlation between the amount of vector reaching the systemic circulation and the 
magnitude of the response, whereas an inverse correlation was noted with regard to the 
quality of the response as measured by cytokine producing competence.  These observations 
led us to suggest that dissemination of the vector was responsible for the apparent reduction 
in T cell quality in i.v. immunized mice. Bramson and co-workers had early on 
demonstrated that transgene expression after injection of moderate virus doses 
intramuscularly (i.m.) in the thigh were confined to the injection site and the draining lymph 
nodes (Yang et al., 2003).  Recently, they took the mechanistic unraveling an important step 
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further and demonstrated by surgical removal of the nodes that the full response depended 
on intact draining lymph nodes for more than 7 days post infection, but after 20 days they 
were no longer required. These results by themselves could have been an artifact reflecting 
the removal of antigen-specific CD8+ T cells sequestered in the draining lymph nodes rather 
than the abrogation of antigen presentation; yet they are consistent with the conclusions we 
drew from our experiments with L-selectin deficient mice.  However, even in “denoded” 
mice, there was continuous T cell expansion for an additional 3 weeks, which could be 
abrogated by eliminating transcription of the transgene encoding gene using a doxycycline 
repressible system (Finn et al., 2009). This was interpreted by the authors to suggest that i.m. 
inoculation of adenovirus leads to extra nodal, but transgene expression dependent 
prolonged T cell expansion. To address this issue in detail they generated bone-marrow 
chimeric mice in which bone marrow cells from mice lacking the MHC element restricting 
the relevant transgene derived epitope was used for reconstitution of lethally irradiated WT 
mice. Using this system, they could confirm that epitopes restricted by MHC molecules only 
expressed by non-hematopoietic cells were driving late T cell expansion. This result was 
taken as evidence for non-hematopoietic antigen presentation by Bramson and co-workers 
and is referred to as such in the following; however, that this is the case has not been 
formally proven. Antigen could still be presented by professional antigen presenting cells 
which have acquired already peptide loaded MHC class I molecules from the surface of 
tissue resident, non-hematopoietic cells, a phenomenon coined by the phrase “cross-
dressing” (see figure 4C) (Dolan et al., 2006). Nevertheless, the T cells maintained 
exclusively by so-called non-hematopoietic antigen presentation showed marked 
deficiencies in particular with respect to cytokine production, but also featured a more 
pronounced effector memory surface phenotype as compared with T cells generated in 
context of both hematopoietic and non-hematopoietic antigen-presentation. These 
phenotypic differences were roughly identical to those we had previously observed when 
comparing responses elicited by i.v. administration with those elicited by s.c. 
administration. Importantly, the dysfunctional T cells, be they induced by i.v immunization 
or non-hematopoietic priming were quite capable of performing cytotoxic activity. We also 
found i.v. primed T cells to be efficient in protection against vaccinia challenge (Holst et al., 
2010b), whereas Bramson and co-workers found that non-hematopoietic primed T cells were 
partially effective against LCMV or melanoma (Bassett et al., 2011).  Importantly, we also 
found the T cells induced by i.v. administration to be less capable of secondary expansion 
(Holst et al., 2010b), whereas Bramson and co-workers found non-hematopoietic and 
hematopoietic priming equally efficient in inducing memory T cells capable of undergoing 
secondary expansion (Bassett et al., 2011). However, the secondary expansion and 
protection data reported by Bramson and co-workers requires careful evaluation. The 
experiments were performed in vaccinated chimeras with and without hematopoietic 
antigen presentation of the relevant epitopes, and thus the adenovirus induced T cell 
priming as well as the antigen presentation taking place during the challenge phase would 
be affected. This might not be important during melanoma challenge, but certainly would 
impact the effector phase of the responses to infections with rapidly replicating viruses such 
as LCMV, vaccinia virus or influenza. Furthermore, as the capacity for protection was 
evaluated through the challenge of intact animals rather than by adoptive transfers of 
primed donor cells into naïve hosts, we do not know the phenotype of the cells actually 
responding. Importantly, during early primary expansion of OVA specific T cells 
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the removal of antigen-specific CD8+ T cells sequestered in the draining lymph nodes rather 
than the abrogation of antigen presentation; yet they are consistent with the conclusions we 
drew from our experiments with L-selectin deficient mice.  However, even in “denoded” 
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inoculation of adenovirus leads to extra nodal, but transgene expression dependent 
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chimeric mice in which bone marrow cells from mice lacking the MHC element restricting 
the relevant transgene derived epitope was used for reconstitution of lethally irradiated WT 
mice. Using this system, they could confirm that epitopes restricted by MHC molecules only 
expressed by non-hematopoietic cells were driving late T cell expansion. This result was 
taken as evidence for non-hematopoietic antigen presentation by Bramson and co-workers 
and is referred to as such in the following; however, that this is the case has not been 
formally proven. Antigen could still be presented by professional antigen presenting cells 
which have acquired already peptide loaded MHC class I molecules from the surface of 
tissue resident, non-hematopoietic cells, a phenomenon coined by the phrase “cross-
dressing” (see figure 4C) (Dolan et al., 2006). Nevertheless, the T cells maintained 
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found i.v. primed T cells to be efficient in protection against vaccinia challenge (Holst et al., 
2010b), whereas Bramson and co-workers found that non-hematopoietic primed T cells were 
partially effective against LCMV or melanoma (Bassett et al., 2011).  Importantly, we also 
found the T cells induced by i.v. administration to be less capable of secondary expansion 
(Holst et al., 2010b), whereas Bramson and co-workers found non-hematopoietic and 
hematopoietic priming equally efficient in inducing memory T cells capable of undergoing 
secondary expansion (Bassett et al., 2011). However, the secondary expansion and 
protection data reported by Bramson and co-workers requires careful evaluation. The 
experiments were performed in vaccinated chimeras with and without hematopoietic 
antigen presentation of the relevant epitopes, and thus the adenovirus induced T cell 
priming as well as the antigen presentation taking place during the challenge phase would 
be affected. This might not be important during melanoma challenge, but certainly would 
impact the effector phase of the responses to infections with rapidly replicating viruses such 
as LCMV, vaccinia virus or influenza. Furthermore, as the capacity for protection was 
evaluated through the challenge of intact animals rather than by adoptive transfers of 
primed donor cells into naïve hosts, we do not know the phenotype of the cells actually 
responding. Importantly, during early primary expansion of OVA specific T cells 
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hematopoietic and non-hematopoietic antigen presentation worked synergistically to 
increase CD8+ T cell numbers, but only hematopoietic antigen presentation supported 
sustained functionality as measured by cytokine competence (Bassett et al., 2011). Notably, 
beyond 20 days post vaccination only extra-nodal expansion contributed to the T cell 
response. This method of antigen presentation is highly important during the early memory 
phase of the response as cessation of antigen expression by a doxycycline regulated vector 
drastically reduced the magnitude of late memory responses (Finn et al., 2009). Our tools 
did not allow detailed control of antigen expression, but we also observed a continuous 
expansion of memory T cells from 20 to 60 days post vaccination following high-dose i.v. 
adenovirus vector administration (Holst et al., 2010b).  
2.3 Model for adenovirus induced CD8+ T cell responses  
Although there are differences between the studies of Bramson and coworkers using 
doxycycline repressible presentation of the ovalbumine derived SIINFEKL epitope and our 
own using adenovirus encoded β-galactosidase, in particular with regard to the kinetics of 
the induced response, the conclusions drawn in these reports are consistent. Taken together, 
these studies allows us to propose a mechanism by which adenoviral vector delivered 
antigen primes an immune response in part by directly transducing the available tissue 
resident dendritic cells and in part by transduction of the local tissue resident, non-
hematopoietic cells. Regarding the antigen produced by cells at the injection site this may 
either be cross-presented via hematopoietic dendritic cells expressing the same MHC 
molecules as the tissue cells, be presented by the novel mechanism of “cross-dressing” 
described in Bassett et al.(Bassett et al., 2011), or be directly presented to the CD8+ T cells in 
situ (see figure 4 for a complete description of the different mechanisms potentially involved 
in the presentation of antigen). Increasing the inoculum leads to the systemic dissemination 
of viral vector and an altered balance between dendritic cell mediated lymph node 
presentation and presentation mediated by non-hematopoietic cells independent of the 
draining lymph nodes (see figure 3 for a description of the interrelation between virus dose 
and site of antigen presentation). This in turn leads to poorer cytokine producing 
competence. The relative importance of hematopoietic and non-hematopoietic antigen 
presentation at doses below ~109 particles is as yet undetermined, but some studies in mice 
and primates as well as humans have demonstrated the relative stability of the response 
within 10- fold variations of the inoculum (Bassett et al., 2011; Bett et al., 2010), and we have 
seen a plateau of the response between ~109 to ~108 particles administered s.c., with a 
gradual reduction of the magnitude of the response upon further dose reductions (Holst PJ, 
Thomsen AR and Christensen JP,unpublished and (Flatz et al., 2010)). A possible 
explanation for these plateaus could be that these doses are sufficient to target all the 
relevant professional antigen presenting cells present at the injection site, and that the major 
difference between the doses are in the degree of non-dendritic cell targeted transduction. 
As the non professional APC transduction leads to poorer cytokine producing competence 
and generation of more terminally differentiated cells, it is worth noticing that we have 
observed an increase in the ratio of CD127high cells compared to KLRG1high cells as the dose 
was further decreased (Holst PJ, Thomsen AR and Christensen JP, unpublished), and that 
termination of transgene expression after the acute response led to higher frequencies of 
central memory T cells, and higher CD27 expression, and a lower frequency of KLRG1 
expression on the responding T cells (Finn et al., 2009).  
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Fig. 3. Relative contribution of antigen presentation from different cell types driving  the  
CD8+ T cell expansion after peripheral administration of adenoviral vaccines. Injection of 
increasing amounts of adenoviral vaccine initially results in a gradual and dose-dependent 
increase in the transduction of professional antigen presenting cells (APC, represented by a 
ruffled cell placed above the line to the left) and tissue resident parenchymal cells 
(represented by an oval cell placed below the line). The peak level of APC transduction is 
reached at a lower dose than is the parenchymal cell transduction and thus the ratio of APC 
to parenchymal cell transduction gradually declines. Increasing the dose further leads to 
spill-over into the systemic circulation causing transduction of central organs, particularly 
the liver (represented by a hepatocyte inserted next to the line at the top right corner). 
The differences between the response patterns observed by us and by Bramson and co-
workers deserve some consideration. Most remarkably, we find i.v. administration of 1010 
particles (~2x108 IFU) of adenovirus to induce a response that becomes detectable in the 
spleen as late as between 30 and 60 days post vaccination whereas lower doses of virus 
given  i.v. fail to induce any detectable response. Subcutaneous immunization induces an 
earlier response at lower doses. Bramson and co-workers on the other hand detect a 
response in the blood and spleen at 10 to 20 days post i.m. immunization with 107-108 pfu of 
adenovirus encoding SIINFEKL fused to luciferase (Bassett et al., 2011; Finn et al., 2009). 
This difference in the kinetics of the response after i.v. as compared to i.m. administration is 
not likely to be due to differences in antigen as Flatz et al.(Flatz et al., 2010) also noted a 
profound attenuation of the response after intravenously administration of 2.5x108 pfu of 
adenovirus encoding the SIINFEKL containing ovalbumin sequence, whereas a potent 
response was observed at lower doses, all measured at 28 days post vaccination. Thus, 
whereas the difference between our report and the one of Flatz et al. (Flatz et al., 2010), who 
observed a strong response to low doses of ovalbumin encoding adenovirus, are likely due 
to the immunological potency of the encoded antigen (ovalbumin being a potent antigen, 
while β-galactosidase is a weak antigen), the differences between Flatz and Bramson must 
relate to the route of administration. In this regard it is interesting that we observed an early, 
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hematopoietic and non-hematopoietic antigen presentation worked synergistically to 
increase CD8+ T cell numbers, but only hematopoietic antigen presentation supported 
sustained functionality as measured by cytokine competence (Bassett et al., 2011). Notably, 
beyond 20 days post vaccination only extra-nodal expansion contributed to the T cell 
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molecules as the tissue cells, be presented by the novel mechanism of “cross-dressing” 
described in Bassett et al.(Bassett et al., 2011), or be directly presented to the CD8+ T cells in 
situ (see figure 4 for a complete description of the different mechanisms potentially involved 
in the presentation of antigen). Increasing the inoculum leads to the systemic dissemination 
of viral vector and an altered balance between dendritic cell mediated lymph node 
presentation and presentation mediated by non-hematopoietic cells independent of the 
draining lymph nodes (see figure 3 for a description of the interrelation between virus dose 
and site of antigen presentation). This in turn leads to poorer cytokine producing 
competence. The relative importance of hematopoietic and non-hematopoietic antigen 
presentation at doses below ~109 particles is as yet undetermined, but some studies in mice 
and primates as well as humans have demonstrated the relative stability of the response 
within 10- fold variations of the inoculum (Bassett et al., 2011; Bett et al., 2010), and we have 
seen a plateau of the response between ~109 to ~108 particles administered s.c., with a 
gradual reduction of the magnitude of the response upon further dose reductions (Holst PJ, 
Thomsen AR and Christensen JP,unpublished and (Flatz et al., 2010)). A possible 
explanation for these plateaus could be that these doses are sufficient to target all the 
relevant professional antigen presenting cells present at the injection site, and that the major 
difference between the doses are in the degree of non-dendritic cell targeted transduction. 
As the non professional APC transduction leads to poorer cytokine producing competence 
and generation of more terminally differentiated cells, it is worth noticing that we have 
observed an increase in the ratio of CD127high cells compared to KLRG1high cells as the dose 
was further decreased (Holst PJ, Thomsen AR and Christensen JP, unpublished), and that 
termination of transgene expression after the acute response led to higher frequencies of 
central memory T cells, and higher CD27 expression, and a lower frequency of KLRG1 
expression on the responding T cells (Finn et al., 2009).  
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this response seem to be associated with the transduction of liver cells, and it disappears 
before the systemic response can be measured in the spleen. The most likely explanation for 
this phenomenon is that the early transgene-specific T cell response is aborted within the 
liver parenchyma as previously reported for the adenovirus-specific response following i.v. 
immunization (Liu et al., 2001), and that systemic T-cell expansion can only occur after a 
reduction in transgene expression in the liver or when a lower inoculum has been used to 
induce the response as seen by Flatz et al.(Flatz et al., 2010). Based on our findings that 
peripheral virus administration leads to a marked increase in hepatic transduction when the 
dose is increased from 109 to 1010 particles, and that the entire increase in dose at 1011 
particles enters the systemic circulation, we would think that working with peripheral 
administration of adenovirus at doses above 109 particles in murine systems entails a major 
risk for variability in response magnitude, kinetics and quality. The report from Tatsis et 
al.(Tatsis et al., 2007a) can be seen to support this conclusion as i.v. administration of 1010 
adenoviral particles expressing LCMV glycoprotein gave a result midway between our 
results with i.v. administered β-gal at 1010 and s.c. administered β-gal at 1011 particles, 
whereas 1011 particles given  i.m. induced a biphasic response. Hypothetically, the 
elimination of the first phase could be due to intrahepatic sequestration. 
The delineation of adenovirus induced immune responses in hematopoietic and non-
hematopoietic is recent, and the mechanisms of the non-hematopoietic antigen presentation 
is unknown. However, although non-hematopoietic antigen presentation is a novel finding 
for adenovirus induced immunizations, it is not the only system in which it is described. 
Thus, during allogenic bone marrow transplantation, non-hematopoietic antigen 
presentation contributes both to induction of T cells incapable of recall responses and 
functional exhaustion of T cells already generated (Flutter et al., 2010). What is special about 
the adenoviral immunization after a low dose injection is that it is taking place at a defined 
site and should in theory by highly amendable for studying. In any case, more attention 
should now be directed towards the events taking place at the site of adenovirus 
inoculation, because these appear to be crucial for both the immunological potency of 
adenoviral vectors and for excessive differentiation of adenovirus primed CD8+ effector T 
cells.  
For non-hematopoietic antigen presentation to occur one must assume that either a local 
environment capable of causing naïve T cells activation is induced by the interaction of the 
immune system and persisting antigen, or that the antigen is transported to secondary 
lymphoid organs by macrophages or dendritic cells cross-dressed with loaded peptide/MHC 
complexes derived from dying (?) cells within the infected tissue (see figure 4 for an overview 
of potential mechanisms). Potentially, cross-dressing of APCs at the injection site could occur 
either through capture of exosomes by dendritic cells (Utsugi-Kobukai et al., 2003) or through 
a cell-contact dependent mechanism (Dolan et al., 2006), although it should be noted that 
recent studies have questioned the ability of exosomes to contribute to relevant responses 
against viral infections in vivo. However, in the latter case the antigens tested have been 
different and the sensitivity of the assays may have been rather low (Coppieters et al., 2009). 
That expression of foreign antigen following adenoviral vector injection contributes to an 
inflammatory infiltrate seems beyond question as no long term infiltrate can be seen following 
injection with vectors devoid of viral genes and a transgene which does not prime an immune 
response (Chen et al., 1997), yet the interest in such infiltrates have focused on their ability to 
clear gene therapy vectors rather than on their role in supporting immune responses. Thus, at 
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present, we know the infiltrates contain CD4+ and CD8+ T cells, few macrophages but little 
else. In other systems, chronic or extended inflammation has been seen to induce lymphoid 
like structures within parenchymatous  organs such as the CNS, kidneys (Moskophidis et al., 
1987) and bronchi (Moyron-Quiroz et al., 2004), and such changes could possibly also take 
place following adenovirus immunizations. A more thorough understanding of the events 
occurring at the injection site could perhaps lead to strategies impeding excessive T cell 
differentiation without removing antigen stimulation and thus result in generation of even 
more potent vaccines. 
 
 
Fig. 4. Overview of the potential antigen presentation mechanisms after adenoviral 
vaccination. All the cartoons feature an oval tissue resident parenchymal cell in the bottom, a 
ruffled professional antigen presenting cell in the middle and a lymph node with afferent 
lymphatic vessels to the left. CD8+ T cells are drawn with a dark blue nuclei and dark purple 
cytoplasm. MHC class I molecules are yellow, whereas the presented recombinant antigen is 
red. Replication incompetent vectors are hexagonal containing double stranded DNA. A) 
Direct presentation. Professional APCs are directly transduced by the adenoviral vector, 
migrate to the draining lymph nodes and presents antigen synthesized within themselves to 
the CD8+ T cells. B) Cross-presentation. Tissue resident parenchymal cells are transduced and 
professional APCs take up the antigen, process it, migrate to the draining lymph node and on 
their own MHC molecules present the antigen to the CD8+ T cells. C) Cross-dressing. Tissue 
resident cell process and initially presents the antigen. However, somehow MHC/peptide 
complexes are released and taken up by APCs, which migrate to the draining lymph node and 
present the antigen to the CD8+ T cells on MHC molecules synthesized within the 
parenchymal cells. D) Local presentation by APCs. Tissue resident cells are transduced, but 
the antigen remains at the injection site. Resident and inflammatory APCs present antigen to 
CD8+ T cells locally, either from processing of tissue debris or from presentation of MHC 
molecules already loaded with antigen in the parenchymal cells. E) Local presentation 
without APC’s. Tissue resident parenchymal cells are transduced, process the antigen and 
present it to CD8+ T cells locally on their own MHC class I molecules.  
2.4 The issue of quality 
The proposed model has profound implications for interpreting the existing literature and 
in appreciating the potential potency of adenoviral vectors for vaccination use. First of all, it 
partially explains why functionally exhausted T cells are a feature of increasing the dose 
beyond 109 particles (in mice). Secondly, as chronic non-hematopoietic antigen presentation 
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immune system and persisting antigen, or that the antigen is transported to secondary 
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present, we know the infiltrates contain CD4+ and CD8+ T cells, few macrophages but little 
else. In other systems, chronic or extended inflammation has been seen to induce lymphoid 
like structures within parenchymatous  organs such as the CNS, kidneys (Moskophidis et al., 
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2.4 The issue of quality 
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cannot be avoided, it may also help explain why adenovirus induced CD8+ T cells tend to 
be more terminally differentiated than are T cells induced by live viral vaccines or MVA 
vectors. As murine studies reporting an exhausted phenotype of adenovirus induced CD8+ 
T cells have typically involved virus doses in the range of 1010-1011 viral particles (Tatsis et 
al., 2007a; Yang et al., 2006), one might question the relevance of the results obtained when it 
comes to human or primate vaccination, where the virus dose is typically in the order of 
1010-1011 particles (Bett et al., 2010). In contrast to the studies using high doses of adenoviral 
vectors in mice, CD8+ T cells induced by adenoviral vaccination in primates and humans 
are cytokine competent and cytotoxic cells, but seemingly terminally differentiated effector- 
like cells are found in the circulation for extended periods of time. A key question in this 
respect is whether this should be of significant concern. In the opinion of these authors it 
should not. Under the premise that the adenoviral infection is not overdosed, the phenotype 
of adenovirus primed CD8+ T cells resemble that of T cells found in association with 
chronic, but well-controlled viral infections such as Epstein Barr virus infection in human 
(Ibegbu et al., 2005) and γ herpes virus-68 (MHV-68) infection in mice (Cush & Flano, 2011). 
A key cell surface marker in this context is KLRG1, the expression of which is often taken to 
indicate replicative senescence. However, in EBV infected humans it has been found that 
while KLRG1 is indeed expressed by terminally differentiated T cells, by no means all 
KLRG1high cells are end cells, but rather seem to represent a subset of memory cells 
associated with antigen persistence (Ibegbu et al., 2005). Along the same lines the meticulous 
study by Cush and Flãno (Cush & Flano, 2011) have clearly demonstrated that KLRG1high 
CD8+ T cells in MHV-68 infected mice are fully functional, can expand upon reactivation 
and provide even better protection against reinfection than do KLRG-1low cells with the 
same specificity. Furthermore, despite having predominantly an effector memory 
(CD62LlowCD43low) phenotype, KLRG1high CD8+ T cells may express receptors for 
homeostatic cytokines (IL-7 and IL-15) and can survive long-term in the absence of cognate 
antigen. Thus, although expression of KLRG1 may be associated with a decreasing potential 
for expansion, there are numerous observations indicating that these cells may be protective, 
and by way of their immediate effector capacity in fact could represent the most optimal 
type of vaccine-induced T-cell defence despite some limitations in proliferative capacity 
(Bachmann et al., 2005). An earlier study by the group of Rafi Ahmed investigating the 
responsiveness of mice undergoing repeated antigenic stimulation supports this view 
(Masopust et al., 2006). These authors found that increasing the number of antigenic 
challenges preferentially promoted the generation phenotypically similar memory cells that 
retained effector-like properties and showed preferential accumulation in non-lymphoid 
organs. Notably, neither the adenovirus primed CD8+ T cells nor those driven by repeated 
antigenic stimulation express the inhibitory receptor PD-1 typical of dysfunctional T cells 
(Barber et al., 2006; Bassett et al., 2011; Masopust et al., 2006).  
3. Increasing the potency of adenovirus vectors 
3.1 Improving antigen presentation  
Even though adenovirus vectored vaccines stand among the most potent vaccine platforms 
for induction of CD8 T cell responses, it is apparent that better vaccines are needed still. Be 
that in magnitude of the response, breadth or phenotype of the induced cells. It is clear that 
simply providing more vaccine or administering adenovirus multiple times provide 
minimal benefit compared to low dose immunization, at least with potent antigens, and 
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while awaiting a deeper understanding of non-hematopoietic antigen presentation, the goal 
is to do more with less (vaccine). Our group, and others in close pursuit, therefore set out to 
identify the mechanisms that would be rate limiting for adenovirus induced immune 
responses. We had prior experiences with enhancing the immune responses to DNA 
vaccines by covalently linking an ER exported minimal epitope to β-2 microglobulin as 
described (Uger et al., 1999; Uger & Barber, 1998), thereby presumably increasing the direct 
antigen presentation on DNA transduced cells (Bartholdy et al., 2003; Bartholdy et al., 2004). 
When the same antigen was cloned into an adenoviral vector and compared to full length 
LCMV glycoprotein, we saw an acceleration and augmentation of the response, and the 
transgene specific response which otherwise depended on CD4+ T cell help could now be 
induced in MHC class II deficient mice (Holst et al., 2007). We have since confirmed that the 
transgene works by loading the encoded antigen directly onto the MHC in a processing 
independent manner as TAP deficient cells transduced with adenoviral vectors expressing 
the β-2 microglobulin fused minimal epitope were fully competent in stimulating antigen 
specific T cells in vivo whereas an antigen expression system more potent in WT mice was 
not (Holst PJ and Bassi MR, unpublished).    
3.2 Increasing the breadth of the CD8+ T cell response 
We were surprised to find that the native LCMV glycoprotein induced a CD8+ T cell 
response which were severely limited in breadth and predominantly focused on the 
immunodominant GP33 epitope. In retrospect, the limited breadth of the induced response 
is perhaps not so surprising and tends to be a general draw-back of viral vectored vaccines. 
The vector backbone of adenoviruses, poxviruses and other systems encode many T cell 
epitopes which may compete with the transgene for the attention of the CD8+ T cells 
(Schirmbeck et al., 2008). In a search for adenovirus vaccine modifications which might lead 
to broader T cell responses, we decided to improve MHC class II restricted antigen 
presentation by covalently linking the encoded antigen to the MHC class II associated 
Invariant chain (Diebold et al., 2001; Holst et al., 2008; Rowe et al., 2006). Surprisingly, this 
strategy improved not only CD4+ T cell responses, but also the kinetics, breadth, magnitude 
and stability of the CD8+ T cell response via increased MHC class I presentation and 
independently of MHC class II (Holst et al., 2011). We have since then confirmed these 
findings with a variety of antigens and are able to conclude that the level of antigen 
presentation on the adenovirus transduced cell is a limiting factor with regard to the speed 
and breadth of CD8+ T cell responses (Hoegh-Petersen et al., 2009; Mikkelsen et al., 2011; 
Sorensen et al., 2009). Given the apparent dichotomy of fast hematopoietic and chronic non-
hematopoietic antigen presentation in adenoviral vaccination, this is highly consistent with 
the hypothesis that the above described strategies work at least in part to increase the first 
wave of antigen presentation mediated by dendritic cells directly transduced by the vector 
(see figure 2). Remarkably, the CD8+ T cell response induced by adenoviral vaccination 
with this type of modified construct seem to have acquired a normal contraction phase and 
the CD8+ T cell response typically stabilizes at approximately 10% of the level of the peak 
response (see figure 1). Though augmentation of direct early presentation should lead to an 
accelerated response, it is unclear if this would also result in reduced late phase presentation 
thereby allowing the return to a nearly normal contraction pattern. One could speculate that 
increased MHC class I restricted antigen presentation, also in the tissue resident cells, would 
result in more efficient antigen elimination at these sites by the antigen-specific CD8+ T 
cells, but it is also possible that CD4+ T cells and MHC class II restricted antigen 
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cannot be avoided, it may also help explain why adenovirus induced CD8+ T cells tend to 
be more terminally differentiated than are T cells induced by live viral vaccines or MVA 
vectors. As murine studies reporting an exhausted phenotype of adenovirus induced CD8+ 
T cells have typically involved virus doses in the range of 1010-1011 viral particles (Tatsis et 
al., 2007a; Yang et al., 2006), one might question the relevance of the results obtained when it 
comes to human or primate vaccination, where the virus dose is typically in the order of 
1010-1011 particles (Bett et al., 2010). In contrast to the studies using high doses of adenoviral 
vectors in mice, CD8+ T cells induced by adenoviral vaccination in primates and humans 
are cytokine competent and cytotoxic cells, but seemingly terminally differentiated effector- 
like cells are found in the circulation for extended periods of time. A key question in this 
respect is whether this should be of significant concern. In the opinion of these authors it 
should not. Under the premise that the adenoviral infection is not overdosed, the phenotype 
of adenovirus primed CD8+ T cells resemble that of T cells found in association with 
chronic, but well-controlled viral infections such as Epstein Barr virus infection in human 
(Ibegbu et al., 2005) and γ herpes virus-68 (MHV-68) infection in mice (Cush & Flano, 2011). 
A key cell surface marker in this context is KLRG1, the expression of which is often taken to 
indicate replicative senescence. However, in EBV infected humans it has been found that 
while KLRG1 is indeed expressed by terminally differentiated T cells, by no means all 
KLRG1high cells are end cells, but rather seem to represent a subset of memory cells 
associated with antigen persistence (Ibegbu et al., 2005). Along the same lines the meticulous 
study by Cush and Flãno (Cush & Flano, 2011) have clearly demonstrated that KLRG1high 
CD8+ T cells in MHV-68 infected mice are fully functional, can expand upon reactivation 
and provide even better protection against reinfection than do KLRG-1low cells with the 
same specificity. Furthermore, despite having predominantly an effector memory 
(CD62LlowCD43low) phenotype, KLRG1high CD8+ T cells may express receptors for 
homeostatic cytokines (IL-7 and IL-15) and can survive long-term in the absence of cognate 
antigen. Thus, although expression of KLRG1 may be associated with a decreasing potential 
for expansion, there are numerous observations indicating that these cells may be protective, 
and by way of their immediate effector capacity in fact could represent the most optimal 
type of vaccine-induced T-cell defence despite some limitations in proliferative capacity 
(Bachmann et al., 2005). An earlier study by the group of Rafi Ahmed investigating the 
responsiveness of mice undergoing repeated antigenic stimulation supports this view 
(Masopust et al., 2006). These authors found that increasing the number of antigenic 
challenges preferentially promoted the generation phenotypically similar memory cells that 
retained effector-like properties and showed preferential accumulation in non-lymphoid 
organs. Notably, neither the adenovirus primed CD8+ T cells nor those driven by repeated 
antigenic stimulation express the inhibitory receptor PD-1 typical of dysfunctional T cells 
(Barber et al., 2006; Bassett et al., 2011; Masopust et al., 2006).  
3. Increasing the potency of adenovirus vectors 
3.1 Improving antigen presentation  
Even though adenovirus vectored vaccines stand among the most potent vaccine platforms 
for induction of CD8 T cell responses, it is apparent that better vaccines are needed still. Be 
that in magnitude of the response, breadth or phenotype of the induced cells. It is clear that 
simply providing more vaccine or administering adenovirus multiple times provide 
minimal benefit compared to low dose immunization, at least with potent antigens, and 
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while awaiting a deeper understanding of non-hematopoietic antigen presentation, the goal 
is to do more with less (vaccine). Our group, and others in close pursuit, therefore set out to 
identify the mechanisms that would be rate limiting for adenovirus induced immune 
responses. We had prior experiences with enhancing the immune responses to DNA 
vaccines by covalently linking an ER exported minimal epitope to β-2 microglobulin as 
described (Uger et al., 1999; Uger & Barber, 1998), thereby presumably increasing the direct 
antigen presentation on DNA transduced cells (Bartholdy et al., 2003; Bartholdy et al., 2004). 
When the same antigen was cloned into an adenoviral vector and compared to full length 
LCMV glycoprotein, we saw an acceleration and augmentation of the response, and the 
transgene specific response which otherwise depended on CD4+ T cell help could now be 
induced in MHC class II deficient mice (Holst et al., 2007). We have since confirmed that the 
transgene works by loading the encoded antigen directly onto the MHC in a processing 
independent manner as TAP deficient cells transduced with adenoviral vectors expressing 
the β-2 microglobulin fused minimal epitope were fully competent in stimulating antigen 
specific T cells in vivo whereas an antigen expression system more potent in WT mice was 
not (Holst PJ and Bassi MR, unpublished).    
3.2 Increasing the breadth of the CD8+ T cell response 
We were surprised to find that the native LCMV glycoprotein induced a CD8+ T cell 
response which were severely limited in breadth and predominantly focused on the 
immunodominant GP33 epitope. In retrospect, the limited breadth of the induced response 
is perhaps not so surprising and tends to be a general draw-back of viral vectored vaccines. 
The vector backbone of adenoviruses, poxviruses and other systems encode many T cell 
epitopes which may compete with the transgene for the attention of the CD8+ T cells 
(Schirmbeck et al., 2008). In a search for adenovirus vaccine modifications which might lead 
to broader T cell responses, we decided to improve MHC class II restricted antigen 
presentation by covalently linking the encoded antigen to the MHC class II associated 
Invariant chain (Diebold et al., 2001; Holst et al., 2008; Rowe et al., 2006). Surprisingly, this 
strategy improved not only CD4+ T cell responses, but also the kinetics, breadth, magnitude 
and stability of the CD8+ T cell response via increased MHC class I presentation and 
independently of MHC class II (Holst et al., 2011). We have since then confirmed these 
findings with a variety of antigens and are able to conclude that the level of antigen 
presentation on the adenovirus transduced cell is a limiting factor with regard to the speed 
and breadth of CD8+ T cell responses (Hoegh-Petersen et al., 2009; Mikkelsen et al., 2011; 
Sorensen et al., 2009). Given the apparent dichotomy of fast hematopoietic and chronic non-
hematopoietic antigen presentation in adenoviral vaccination, this is highly consistent with 
the hypothesis that the above described strategies work at least in part to increase the first 
wave of antigen presentation mediated by dendritic cells directly transduced by the vector 
(see figure 2). Remarkably, the CD8+ T cell response induced by adenoviral vaccination 
with this type of modified construct seem to have acquired a normal contraction phase and 
the CD8+ T cell response typically stabilizes at approximately 10% of the level of the peak 
response (see figure 1). Though augmentation of direct early presentation should lead to an 
accelerated response, it is unclear if this would also result in reduced late phase presentation 
thereby allowing the return to a nearly normal contraction pattern. One could speculate that 
increased MHC class I restricted antigen presentation, also in the tissue resident cells, would 
result in more efficient antigen elimination at these sites by the antigen-specific CD8+ T 
cells, but it is also possible that CD4+ T cells and MHC class II restricted antigen 
 
Viral Gene Therapy 180 
presentation by tissue resident cells could play a role. Thus, the more efficient early 
induction of CD4+ T cells by the MHC class II associated Invariant chain linked constructs 
combined with local production of interferon-γ,  which could cause local MHC class II up-
regulation and antigen presentation, might together set the stage for CD4+ T cell mediated 
antigen elimination.  
3.3 Role of CD4+ T cell help 
Interestingly, we also found that while ordinary adenovaccine primed CD8+ T cell 
responses were CD4+ T-cell help dependent, neither of the tethered constructs required 
CD4+ T cells for induction of a primary CD8+ T-cell response (Holst et al., 2007; Holst et al., 
2011). However, as has previously been observed also with fully CD4+ T-cell helped CD8+ T 
cells, the functionality of the generated cells decreased faster in a CD4+ T-cell deficient 
environment  (Sun et al., 2004). Still, however, we saw significant protection against a high-
dose viral challenge in MHC class II deficient mice at 2 months post vaccination, which 
matched that found in wild type mice vaccinated with an ordinary adenovirus vaccine 
(Holst et al., 2007; Holst et al., 2011). This ability of our improved vaccine to induce an 
efficient acute and prolonged CD8+ T cell response in the absence of CD4+ T cells have clear 
implications as regards certain states of clinical immunodeficiency. Thus, in bone-marrow 
transplant recipients herpes virus infections represent a serious clinical problem. However, 
as the CD8+ T-cell population in these patients recovers faster than the CD4+ T cell 
population (Berger et al., 2008), this type of vaccine could be used to curtail such infections 
until the CD4+ T-cell population is restored.   
Although several strategies can increase the immune response resulting from DNA 
vaccination there are not many strategies that have been published to augment the response 
to adenovirus vectored vaccines (reviewed in Holst et al. 2010 (Holst et al., 2010a)). Whether 
this reflects that very few strategies have actually been tested or that they have not worked 
efficiently is a matter of speculation, but it is tempting to conclude that virus vectored 
vaccines contains sufficient pathogen- associated molecular patterns to substitute for many a 
cytokine co-administered with the vaccine. Exceptions to the general rule has been antigen 
linked to the herpes viral tegument protein VP22 and calreticulin, which have been tested in 
Sindbis virus replicon particles (Cheng et al., 2002) and vaccinia vectors (Hsieh et al., 2004), 
respectively, and the herpes viral glycoprotein D (gD), which has been tested using an 
adenoviral vector. Both VP22 and calreticulin are suggested to work by increasing antigen 
presentations, but the herpes viral glycoprotein D was postulated to work by competitive 
inhibition of the interaction between the herpes virus entry mediator (HVEM) and the B and 
T lymphocyte attenuator (BTLA) (Lasaro et al., 2008). Although herpes viral gD fused to 
antigen was convincingly showed to interact with HVEM, there were no experiments 
performed in animals or cells deficient in HVEM or BTLA, nor was antigen presentation 
measured following use of this strategy. Thus whether or not HVEM-BTLA interaction is 
important in the immune response to adenoviral vectors remains to be determined (see 
(Holst et al., 2010a) for a detailed comment on this study). The MHC class II associated 
invariant chain linked antigen concept was also tested as a DNA vaccine, and found to 
increase CD8+ T cell responses working both alone and as a primer for an adenoviral boost. 
Moreover, the MHC class II associated Invariant chain linked antigen concept was also 
beneficial when applied in the booster supporting the conclusion that increased direct 
presentation benefits adenovirus induced CD8+ T cell responses after the initial priming 
(Grujic et al., 2009).  
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4. Adenovirus vectored vaccines compared to other vaccine technologies 
4.1 Adenovirus induces unusually potent and protective CD8+ T cell responses 
With regard to sheer potency of long term CD8+ T cell induction there are only a few 
reports challenging the supremacy of adenovirus vectors, and none of these have been 
verified in humans. In primates, adenoviral vectors have been tested side-by-side with MVA 
and DNA vectors and matched studies have been performed in humans (Bett et al., 2010; 
Casimiro et al., 2003; Shiver et al., 2002). These studies have unequivocally shown that 
adenoviral vectors induce superior frequencies of CD8+ T cells and, importantly, induce 
better T cell mediated protection against simian human immunodeficiency virus challenge 
(SHIV) in NHP’s. However, other general findings include a low proliferative potential of 
induced T cells, effector memory rather than central memory phenotype of the induced T 
cells and a low frequency of IL-2 producing T cells (Tatsis et al., 2007a; Yang et al., 2006; 
Yang et al., 2007). Although several studies have addressed potency and immunogenicity of 
antigen presentation from various vectors, few direct comparisons exists between 
adenoviral vectors and other popular virus vectored vaccine candidates, most notably MVA 
and fowlpox vectors. A recent study has been made in mice comparing human adenovirus 
serotype 5, simian serotype C6, fowlpox vectors and MVA. These studies confirmed the 
tendencies reported above, but remarkably again demonstrated a superior protective 
efficacy of the adenoviral vector system. Thus, even though adenovirus vectors induce 
CD8+ T cells with functional and phenotypic properties most similar to those found in 
association with unresolved chronic infections, they still stand as superior vectors for T cell 
mediated protection against acute and chronic infections (Shiver et al., 2002; Sridhar et al., 
2008). A paradox which has caused confusion, but in the opinion of these authors, a paradox 
which can be easily be appreciated if one considers the impact of the acute phase of an 
infection as a major determinant of the course of the chronic phase of an infection. Also, the 
negative result of the STEP trial regarding clinical protection against HIV may have 
attracted much too negative attention to the adenoviral vector system. Recent follow- up 
data of infected vaccinees revealed that the infecting HIV strains have accumulated 
mutations matching the most immunogenic epitopes of the vaccine, thus demonstrating that 
the adenovirus vectored vaccine has exerted an efficient selection pressure upon the 
infecting virus (Rolland et al., 2011). In conclusion, the vaccine induced T cells did work, but 
as the vaccine induced T-cell responses were rather narrowly targeted  and raised against T-
cell epitopes that can readily be mutated, the induced response simply was not sufficient to 
permanently control infection with a rapidly mutating virus like HIV. Some improvement 
strategies to the immunogenicity of the adenovirus vaccines have been discussed above (see 
the “Increasing the potency of adenovirus vectors” section above), whereas the most 
commonly applied strategy, prime-boost regimens will be discussed below. 
4.2 Adenovirus induced antibody responses 
Although the major focus of this review is on adenovirus induced T cell responses, it should 
be noted that the benefits of adenoviral vectors for induction of antibody responses is less 
clear. It is noteworthy that adenoviral vectors, despite their capacity for induction of high 
titers of antibodies, may fall short of MVA vectors when it comes to induction of cross-
reacting antibodies against influenza and SIV. Thus, MVA vectors expressing the 
hemagglutinin antigen of influenza A H5N1/Vietnam/2004 provide efficient cross-clade 
protection against H5N1/Indonesia/2005 challenge in primates (Kreijtz et al., 2009), 
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presentation by tissue resident cells could play a role. Thus, the more efficient early 
induction of CD4+ T cells by the MHC class II associated Invariant chain linked constructs 
combined with local production of interferon-γ,  which could cause local MHC class II up-
regulation and antigen presentation, might together set the stage for CD4+ T cell mediated 
antigen elimination.  
3.3 Role of CD4+ T cell help 
Interestingly, we also found that while ordinary adenovaccine primed CD8+ T cell 
responses were CD4+ T-cell help dependent, neither of the tethered constructs required 
CD4+ T cells for induction of a primary CD8+ T-cell response (Holst et al., 2007; Holst et al., 
2011). However, as has previously been observed also with fully CD4+ T-cell helped CD8+ T 
cells, the functionality of the generated cells decreased faster in a CD4+ T-cell deficient 
environment  (Sun et al., 2004). Still, however, we saw significant protection against a high-
dose viral challenge in MHC class II deficient mice at 2 months post vaccination, which 
matched that found in wild type mice vaccinated with an ordinary adenovirus vaccine 
(Holst et al., 2007; Holst et al., 2011). This ability of our improved vaccine to induce an 
efficient acute and prolonged CD8+ T cell response in the absence of CD4+ T cells have clear 
implications as regards certain states of clinical immunodeficiency. Thus, in bone-marrow 
transplant recipients herpes virus infections represent a serious clinical problem. However, 
as the CD8+ T-cell population in these patients recovers faster than the CD4+ T cell 
population (Berger et al., 2008), this type of vaccine could be used to curtail such infections 
until the CD4+ T-cell population is restored.   
Although several strategies can increase the immune response resulting from DNA 
vaccination there are not many strategies that have been published to augment the response 
to adenovirus vectored vaccines (reviewed in Holst et al. 2010 (Holst et al., 2010a)). Whether 
this reflects that very few strategies have actually been tested or that they have not worked 
efficiently is a matter of speculation, but it is tempting to conclude that virus vectored 
vaccines contains sufficient pathogen- associated molecular patterns to substitute for many a 
cytokine co-administered with the vaccine. Exceptions to the general rule has been antigen 
linked to the herpes viral tegument protein VP22 and calreticulin, which have been tested in 
Sindbis virus replicon particles (Cheng et al., 2002) and vaccinia vectors (Hsieh et al., 2004), 
respectively, and the herpes viral glycoprotein D (gD), which has been tested using an 
adenoviral vector. Both VP22 and calreticulin are suggested to work by increasing antigen 
presentations, but the herpes viral glycoprotein D was postulated to work by competitive 
inhibition of the interaction between the herpes virus entry mediator (HVEM) and the B and 
T lymphocyte attenuator (BTLA) (Lasaro et al., 2008). Although herpes viral gD fused to 
antigen was convincingly showed to interact with HVEM, there were no experiments 
performed in animals or cells deficient in HVEM or BTLA, nor was antigen presentation 
measured following use of this strategy. Thus whether or not HVEM-BTLA interaction is 
important in the immune response to adenoviral vectors remains to be determined (see 
(Holst et al., 2010a) for a detailed comment on this study). The MHC class II associated 
invariant chain linked antigen concept was also tested as a DNA vaccine, and found to 
increase CD8+ T cell responses working both alone and as a primer for an adenoviral boost. 
Moreover, the MHC class II associated Invariant chain linked antigen concept was also 
beneficial when applied in the booster supporting the conclusion that increased direct 
presentation benefits adenovirus induced CD8+ T cell responses after the initial priming 
(Grujic et al., 2009).  
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4. Adenovirus vectored vaccines compared to other vaccine technologies 
4.1 Adenovirus induces unusually potent and protective CD8+ T cell responses 
With regard to sheer potency of long term CD8+ T cell induction there are only a few 
reports challenging the supremacy of adenovirus vectors, and none of these have been 
verified in humans. In primates, adenoviral vectors have been tested side-by-side with MVA 
and DNA vectors and matched studies have been performed in humans (Bett et al., 2010; 
Casimiro et al., 2003; Shiver et al., 2002). These studies have unequivocally shown that 
adenoviral vectors induce superior frequencies of CD8+ T cells and, importantly, induce 
better T cell mediated protection against simian human immunodeficiency virus challenge 
(SHIV) in NHP’s. However, other general findings include a low proliferative potential of 
induced T cells, effector memory rather than central memory phenotype of the induced T 
cells and a low frequency of IL-2 producing T cells (Tatsis et al., 2007a; Yang et al., 2006; 
Yang et al., 2007). Although several studies have addressed potency and immunogenicity of 
antigen presentation from various vectors, few direct comparisons exists between 
adenoviral vectors and other popular virus vectored vaccine candidates, most notably MVA 
and fowlpox vectors. A recent study has been made in mice comparing human adenovirus 
serotype 5, simian serotype C6, fowlpox vectors and MVA. These studies confirmed the 
tendencies reported above, but remarkably again demonstrated a superior protective 
efficacy of the adenoviral vector system. Thus, even though adenovirus vectors induce 
CD8+ T cells with functional and phenotypic properties most similar to those found in 
association with unresolved chronic infections, they still stand as superior vectors for T cell 
mediated protection against acute and chronic infections (Shiver et al., 2002; Sridhar et al., 
2008). A paradox which has caused confusion, but in the opinion of these authors, a paradox 
which can be easily be appreciated if one considers the impact of the acute phase of an 
infection as a major determinant of the course of the chronic phase of an infection. Also, the 
negative result of the STEP trial regarding clinical protection against HIV may have 
attracted much too negative attention to the adenoviral vector system. Recent follow- up 
data of infected vaccinees revealed that the infecting HIV strains have accumulated 
mutations matching the most immunogenic epitopes of the vaccine, thus demonstrating that 
the adenovirus vectored vaccine has exerted an efficient selection pressure upon the 
infecting virus (Rolland et al., 2011). In conclusion, the vaccine induced T cells did work, but 
as the vaccine induced T-cell responses were rather narrowly targeted  and raised against T-
cell epitopes that can readily be mutated, the induced response simply was not sufficient to 
permanently control infection with a rapidly mutating virus like HIV. Some improvement 
strategies to the immunogenicity of the adenovirus vaccines have been discussed above (see 
the “Increasing the potency of adenovirus vectors” section above), whereas the most 
commonly applied strategy, prime-boost regimens will be discussed below. 
4.2 Adenovirus induced antibody responses 
Although the major focus of this review is on adenovirus induced T cell responses, it should 
be noted that the benefits of adenoviral vectors for induction of antibody responses is less 
clear. It is noteworthy that adenoviral vectors, despite their capacity for induction of high 
titers of antibodies, may fall short of MVA vectors when it comes to induction of cross-
reacting antibodies against influenza and SIV. Thus, MVA vectors expressing the 
hemagglutinin antigen of influenza A H5N1/Vietnam/2004 provide efficient cross-clade 
protection against H5N1/Indonesia/2005 challenge in primates (Kreijtz et al., 2009), 
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whereas similar adenovirus vectors appear less potent, and infectious virus may still be 
detectable after homologous challenge (Gao et al., 2006). Direct comparisons are lacking. 
Similarly, in the SHIV system, Robinson and colleagues have developed a DNA and MVA 
based vaccine which uses the large cloning capacity of the poxvirus vector to 
simultaneously encode gp41 and gag and thus produce virus-like particles. Highly avid 
antibodies to native gp41 appear to constitute a correlate of protection against peak viremia 
which transcends into improved control in the chronic phase of the infection (Zhao et al., 
2009). Again, a similar strategy has not been tested with adenovirus vectors. Thus, there is 
suggestive evidence that MVA vectors are superior or at least as potent as adenovirus 
vectors with respect to induction of broadly reactive antibodies. Why adenovirus vectors 
induce superior CD8+ T cell responses, but only comparable antibody responses has not 
been systematically addressed. However, as vectors such as the MVA induce their 
associated immune response in considerable less time than do the adenoviral vectors, the 
former could be speculated to rely on the recruitment of more B cell precursors to reach the 
same levels as the adenovirus vectored vaccines and therefore induce more diverse 
responses. 
5. Use of adenovirus vaccines in prime-boost regimens 
5.1 Use of adenovirus in heterologous prime-boost regimens 
Pre-clinically, adenovirus vectors have been used rather successful as boosters for DNA 
immunizations, and paradoxically as they potentially induce memory T cells with a 
restricted proliferative potential, also as primers for poxvirus booster immunizations. The 
use of DNA priming is logical and results in a broadening of the CD4+ T cell response, an 
increase in the IL-2 competence of the primed CD8+ T cells and improved protection after 
SIV challenge (Casimiro et al., 2005; Cox et al., 2008; Wu et al., 2005). Please note that 
although some animal studies point to an improved immunogenicity of DNA primed 
adenovirus immunizations (Grujic et al., 2009), this has not been verified in humans (Bett et 
al., 2010). Although DNA primed adenovirus immunization have shown some promise, it 
pales in comparison to the recent pre-clinical results obtained using adenoviruses of 
different serotypes (Liu et al., 2009) or adenovirus as primers for MVA vectors (Reyes-
Sandoval et al., 2010). The use of such prime-boost regimens have improved the protective 
efficacy against SIV or rodent malaria compared to the use of either vector system alone, 
although it should be stressed that the reason for the improved protection is unclear. The 
heterologous adenovirus based immunization by Barouch and co-workers induced 
increased CD4+ T cell responses and CD8+ T cells of increased functionality, but the 
correlate of protection was with the breadth of the response (Liu et al., 2009). Similar 
phenotypic changes were seen in a rodent malaria model, yet here protection was correlated 
with the total numbers of IFN-γ producing CD8+ T cells (Reyes-Sandoval et al., 2010). As 
noted above, all these data strongly suggest that the T cells induced by adenoviral 
immunization are at least acutely protective. Notably, by documenting the ability of 
adenoviral vectors to prime for subsequent responses, these observations also questions the 
notion that adenovirus induced T cells necessarily have a limited proliferative capacity. Not 
only vaccines can boost adenovirus primed responses, also live LCMV infection in mice 
(Holst et al., 2011) or SIV in primates (Liu et al., 2009; Sun et al., 2008) cause massive post-
exposure expansion of adenovirus primed T cells. In this context it is noteworthy that direct 
analysis of the adenovirus primed T cells’ ability to proliferate have mostly been performed 
 
Harnessing the Potential of Adenovirus Vectored Vaccines 183 
following what seems likely to be represent inoculation of unreasonably high doses of virus 
(see above for details), and the obtained results may therefore not be very relevant to a more 
real-life vaccine situation. An additional factor explaining the discrepancy may be that ex 
vivo analysis of proliferative capacity is typically performed on either blood or spleen cells, 
whereas an infection or an immunization can boost any T cell population present in the 
challenged animal. The phenotype and tissue localization of T cells responding with 
proliferation in response to a secondary immunization or challenge infection remains 
unknown, and the most relevant cells may not be present in blood or spleen in significant 
quantities. 
5.2 Heterologous prime-boost regimens impact T cell quality 
The study of Barouch and co-workers revealed an impact of the particular adenoviral 
serotype used for priming, on the phenotype and functionality of the ensuing T cell 
response, and suggested that special rare serotypes may have unique properties (Liu et al., 
2008). However, as noted above, the heterologous prime-boost regimens in rodents using 
malaria antigens also reported an increased functionality of the induced CD8+ T cells 
(Reyes-Sandoval et al., 2010). An interesting observation in this regard was made when a 
triple sequential immunization was attempted using two different serotype of adenoviral 
vectors together with MVA. The third immunization induced further expansion of the CD8+ 
T cell response, increased their tissue homing and increased their cytokine producing 
competence (Tatsis et al., 2007b). Whereas expansion and increases in tissue homing 
capacity may be general phenomena following sequential immunization and has been seen 
in other systems as well as (Masopust et al., 2006), the increase in cytokine producing 
competence following the third immunization is harder to explain and has not been 
investigated. However, it is possible that the very strong response of transgene specific 
tissue homing CD8+ T cell may contribute to a rapid reduction of tissue localized vector, 
which would be in line with the notion that this pool of antigen contributes to induce CD8+ 
T cells of low cytokine producing competence. 
6. Disease indications where the attributes of adenoviral vectored vaccines 
are especially useful 
In principle adenoviral vectors would be useful wherever a strong and sustained antibody 
and/or CD8+ T cell response is readily inducible and contributing to protection. Acute 
infections such as avian influenza (Gao et al., 2006), Ebola (Richardson et al., 2009; Sullivan 
et al., 2003), foot-and-mouth disease virus (Pacheco et al., 2005) and rabies (Hu et al., 2006) 
are prime examples , but the list of published pre-clinical infections with high efficacy of 
adenovirus based vaccines essentially goes on and on. However, the more challenging 
vaccine targets are undoubtedly those involving infections with a propensity to become 
chronic such as HIV, HCV and the herpesviruses, or those where antibody inducing 
immunization may potentially exacerbate disease, such as dengue virus. These viruses have 
in common that sufficiently broad, high-titered and stable antibodies cannot readily be 
induced and that T cells therefore are needed to do the job. Accordingly, fairly solid pre-
clinical data using adenoviral vectors have been obtained in the SIV model system (Liu et 
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whereas similar adenovirus vectors appear less potent, and infectious virus may still be 
detectable after homologous challenge (Gao et al., 2006). Direct comparisons are lacking. 
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immunization are at least acutely protective. Notably, by documenting the ability of 
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adenovirus based vaccines essentially goes on and on. However, the more challenging 
vaccine targets are undoubtedly those involving infections with a propensity to become 
chronic such as HIV, HCV and the herpesviruses, or those where antibody inducing 
immunization may potentially exacerbate disease, such as dengue virus. These viruses have 
in common that sufficiently broad, high-titered and stable antibodies cannot readily be 
induced and that T cells therefore are needed to do the job. Accordingly, fairly solid pre-
clinical data using adenoviral vectors have been obtained in the SIV model system (Liu et 
al., 2009) and the chimpanzee model of HCV infection (Folgori et al., 2006). However, the 
scientific community is still debating how to improve this further and develop clinically 
useful vaccines. In this review we would offer a different opinion from that of the majority 
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regarding such diseases. Thus, while the focus have been on inducing immune responses 
capable of persisting during chronic infections, it is worth remembering that no actual 
intervention strategy succeeding in contributing to chronic virus control have done so 
without first reducing acute viral replication. An interesting case in this context is the SIV 
model for HIV infection. In this system, rapid application of highly active anti-retroviral 
therapy can lead to complete control of the virus and even protection against rechallenge 
(Lifson et al., 2001). This suggests that the rapidity of early virus control should be the goal 
for vaccine development. Another case supporting this suggestion is found in the MHV-68 
model. In this system, a potent adenovirus vectored vaccine capable of reducing the splenic 
viral load after 14 days, was unable to impact the level of the latent infection. However, local 
immunization using intranasal application of the vaccine resulted in enhanced acute control 
at 7 days after infection as well as in improved control of the latent infection (Hoegh-
Petersen et al., 2009). The lesson for vaccine development seems to be that increased efficacy 
can be expected against different disease targets by ensuring that CD8+ T cells are present 
and efficient at the site of virus entry/early virus replication and, furthermore, that these 
cells can rapidly acquire effector functions and reduce the viral load. Regarding the 
phenotype associated with acute control, adenovirus vaccines induce CD8+ T cells that for 
extended periods of time can exert immediate cytotoxic activity whereas immediate effector 
functions are quite limited in the less differentiated central memory T cells that seem to 
accumulate during controlled SIV or HIV infection. Also, regarding the ability to apply 
vaccines in manners that will induce local immunosurveillance at the likely site of virus 
entry or early replication, adenoviral vaccines have been found to be very useful. Thus, 
studies have suggested that local application can be used to augment mucosal CD8+ T cell 
memory (Belyakov et al., 2008; de Souza et al., 2007; Kaufman et al., 2010; Lemiale et al., 
2007), and also that parenteral immunization can be used to induce T cell homing to 
mucosal sites (Haut et al., 2010; Kaufman et al., 2010; Lin et al., 2007; Tatsis et al., 2007b). The 
ability to induce local T cell responses is not a quality unique to adenovirus vectors and 
local immunity can also be obtained by mucosal application of pox-viral vectors (Corbett et 
al., 2008). Unfortunately, direct comparisons of vector systems for induction of mucosal 
immune responses seem to be lacking. While it may seem encouraging that parenteral 
immunization induces efficient T cell memory at mucosal sites, it should be noted that the 
assays performed to document mucosal homing are typically performed using tissue 
fractions or whole tissue homogenates. When we attempted a clean sampling of CD8+ T 
cells patrolling the mucosal surface of the lungs and airways by harvesting the 
bronchioalveolar lavage (BAL), only minimal frequencies of antigen specific cells could be 
detected after s.c. immunization whereas robust responses were seen after a single 
intranasal immunization. It seems possibly that there may be a difference between inducing 
the migration of T cells into a tissue with a large mucosal surface and to actually make the 
cells dedicated with respect to patrolling this surface for infected cells. In support of a 
compartmentalized CD8+ T cell memory at mucosal organs, immune responses in the 
mesenteric lymph nodes,  which are frequently interpreted as a sign of induction of mucosal 
immunity in the gut, are efficiently induced following i.m. adenoviral immunization 
(Kaufman et al., 2010; Lin et al., 2007), whereas genuine mucosal immunization does not 
increase T cell frequencies in this site (Belyakov et al., 2008). Fortunately, concomitant 
subcutaneous and intranasal administration can induce T cell memory at both mucosal 
(BAL) (Hoegh-Petersen et al., 2009) and systemic (spleen) sites  (these authors and Mette 
Hoegh-Petersen, unpublished). 
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7. Future perspectives 
Apart from attempting to combat chronic infections prophylactically, the realization that 
adenovirus primes T cells for extended periods of time based on extra-nodal and perhaps 
even non-hematopoietic antigen presentation opens up an interesting avenue for further 
studies. Thus, as the understanding of extranodal priming increases, so will the ability to 
modulate it, for instance by co-encoding cytokines or inhibitors of immunomodulatory 
molecules. Adenovirus vectors could in this respect have unique qualities which could be 
exploited for therapeutic vaccines against cancer or chronic infection.    
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1. Introduction 
β-thalassemia is one of the most common monogenic disease due to mutation or deletion in 
the β-globin gene on chromosome 11, inherited in an autosomal recessive fashion, with a 
global estimated annual birth incidence of 40,000/year1. The disease is particularly 
prevalent among Mediterranean peoples, Middle Eastern and Southeast Asians 1. 
The severity of the disease depends on the production of functional β-globin chain.  
Mutations of β-globin gene cause reduced β-chain synthesis (β+) lead to β thalassemia minor 
or intermedia, while mutations cause no β-chain synthesis (βo) usually resulted in β- 
thalassemia major or Cooley's anemia2.  Lacking of β-chain causes ineffective production of 
oxygen-carrying protein haemoglobin, therefore results in anemia. The relative excess of α-
chains bind to the red blood cell membrane, undermine membrane, even form toxic 
aggregates, which aggravates anemia of patients. According to statistics, there are an 
estimated 80 million carriers of mutation of β-globin gene in the world3. The severe 
thalassemia is characterized by markedly ineffective erythropoiesis and severe anemia. 
The treatment for β-thalassemia major usually includes lifelong blood transfusion and 
allogeneic hematopoietic transplantation4. Chronic blood transfusion often causes iron 
overload, accumulated iron produces tissue damage in multiple organs, so that iron 
chelating treatment is required to prevent iron overload damage to the internal organs in 
patients.  To most of patients receiving the treatment, it is an expensive and inconvenience 
therapy for maintaining a long life. 
Bone marrow transplantation is the other effective therapy, which can eliminate a patient's 
dependence on blood transfusions5,6.  However, it is difficult to find the matching donors for 
the most of patients, which is only available for a minority of patients. 
Gene therapy is one potential novel therapeutic avenue for the treatment of inherited 
monogenic disorder.  It is a technology for correcting defective genes by introducing of the 
normal genes directly into patient’s cells.  This strategy mainly focuses on diseases caused 
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by single-gene defects, such as β-thalassemia.  For patients lacking a suitable bone marrow 
(BM) donor, gene therapy is not limited by the histocompatibility barrier and does not 
require immunosuppression.  
The general strategy for β-thalassemia gene therapy is to obtain hematopoietic stem cell 
(HSC) from patient’s bone marrow first, then, deliver a normal β-globin gene to patient’s 
HSC by recombinant viral vector in vitro, the transfected cells will be transplanted into 
patients, the exogenous normal β-globin gene would be expressed in erythroid lineage cells 
under the regulation of the promoter, the ratio of β-chain to α-chain in red cells will be 




Fig. 1. The general strategy for β-thalassemia gene therapy. 
To get a persistent expression of β-globin gene, CD34+ cells are usually selected to be the 
target of gene transfer and transplantation. CD34 is considered as a maker for hematopoietic 
cells which possess self-renew and multiple lineage differentiation potentials, covering not 
only stem cells but also earlier multipotent progenitors and later lineage-restricted 
progenitors8.  The success of transfecting exogenous β-globin gene into CD34+ cells is the 
precondition of β-thalassemia gene therapy, which ensures the long term expression of the 
β-globin gene due to CD34+ cells keeping differentiation into erythroid lineage cells, the 
erythroid lineage-specific expression of  β-globin gene will be induced and regulated in 
these cells9. 
Human β-globin locus is composed of five genes which includes β, δ, Aγ, Gγ, and ε globin 
gene, located on a short region of chromosome 11, arranged as the sequence of 5' –ε- Gγ- Aγ- 
δ- β - 3'.  Expression of all of these genes is controlled by single locus control region (LCR), 
and forms of hemoglobin expressed change during development.  Genes are expressed in 
the order in which they are arranged in the cluster10(Fig.2).  
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From Olivieri NF. The -thalassemias. The N Engl J Med 1999 341:99-109. 
Fig. 2. The β-Globin Gene Cluster on the Short Arm of Chromosome 11.  A, the  -globin–
like genes are arranged in the order in which they are expressed  during development.  
B, shows the timing of the normal developmental switching of human hemoglobin. 
2. Gene therapy for β-thalassemia 
As a classic gene model for human genetics,β-globin gene has been extensively studied in 
the fields of gene structure, gene evolution, gene transcription and regulation.  Gene therapy 
for β-thalassemia was started in 1980’.  The retrovirus is the earliest and the most frequently 
used vector.  It was reported in 1988 that the retrovirus (RV) containing β-globin gene 
successfully transfected HSC, although the erythroid lineage-specific expression of β-globin 
gene was low, only 1% of normal expression level11.  It is generally considered in current 
studies that there is a therapeutic meaning only after the expression of exogenous β-globin 
gene reaches 10-20% of normal endogenous expression level.  The discovering of the locus 
control region (LCR) in the range of 20 kb upstream of ε-gene greatly improved the 
erythroid lineage-specific expression of β-globin. LCR is composed of a series of 
hypersensitivities (HS) including HS1-HS512.  Sadelain et al. tried different HS combinations, 
reconstructed the RV vectors, got increased expression of β-globin gene, as high as 5 of 
normal β-globin gene expression level in mice13.  But 4 months later, the expression of β-
globin gene cannot be detected, suggested the gene silencing appeared.  Gene silencing is a 
phenomenon that the specific gene is not expressed in vivo for a variety of reasons.  
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and forms of hemoglobin expressed change during development.  Genes are expressed in 
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Fig. 2. The β-Globin Gene Cluster on the Short Arm of Chromosome 11.  A, the  -globin–
like genes are arranged in the order in which they are expressed  during development.  
B, shows the timing of the normal developmental switching of human hemoglobin. 
2. Gene therapy for β-thalassemia 
As a classic gene model for human genetics,β-globin gene has been extensively studied in 
the fields of gene structure, gene evolution, gene transcription and regulation.  Gene therapy 
for β-thalassemia was started in 1980’.  The retrovirus is the earliest and the most frequently 
used vector.  It was reported in 1988 that the retrovirus (RV) containing β-globin gene 
successfully transfected HSC, although the erythroid lineage-specific expression of β-globin 
gene was low, only 1% of normal expression level11.  It is generally considered in current 
studies that there is a therapeutic meaning only after the expression of exogenous β-globin 
gene reaches 10-20% of normal endogenous expression level.  The discovering of the locus 
control region (LCR) in the range of 20 kb upstream of ε-gene greatly improved the 
erythroid lineage-specific expression of β-globin. LCR is composed of a series of 
hypersensitivities (HS) including HS1-HS512.  Sadelain et al. tried different HS combinations, 
reconstructed the RV vectors, got increased expression of β-globin gene, as high as 5 of 
normal β-globin gene expression level in mice13.  But 4 months later, the expression of β-
globin gene cannot be detected, suggested the gene silencing appeared.  Gene silencing is a 
phenomenon that the specific gene is not expressed in vivo for a variety of reasons.  
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Studies show that the RV has the characteristics of random integrate into the host genome, 
while expression of β-globin gene is affected by the integrated position, which is called 
position effect variegation (PEV)14. The possible reason  
for both of PEV and gene silencing is that transduced gene located in other regions outside 
of a normal gene locus.  During the development of erythroid cells, over expressed mRNA 
from abnormal integrated position in chromosome may trigger specific mRNA degradation 
to prevent expression of the gene.  Other studies also showed that gene silencing caused by 
RV is relative with the DNA sequences of long terminal repeats (LTR) and frame of RV 
virus15. 
The transduction efficiency of RV in HSC is low due to retrovirus vector only can infect 
dividing cells, but most of the HSCs are in quiescent stage, lacking of  receptors for RV coat 
in HSC surface is also considered as one of the main reasons.  In recent years, it was found 
that the random integration features of RV creates the potential risk of activating oncogenes 
or inactivating tumor suppressor genes, so  application of RV in clinic is relatively limited16. 
The insufficiency of RV prompts people to try to develop new viral vectors for β-
thalassemia gene therapy, such as lentivirus (LV), adeno associated virus (AAV),et al.  The 
well-known lentivirus is human immunodeficiency virus (HIV 1).  Although LV 
belongs to retroviridae, it can effectively infect non-dividing cells. May et al. firstly obtained 
steady expression of β-globin gene in β-thalassemia mice by transducing HSCs with LV 
containing large fragment of LCR and β-globin gene, the expression of β-globin gene 
reached 10-20% of normal level, and lasted for more than 15 weeks without PEV effect, 
which showed preferable therapeutic action17.  It was reported recently that a severe 
transfusion dependent thalassemia patient who accept β-globin gene therapy through 
lentivirus became transfusion independent for 21 months18.  However, it is also noticeable 
that whether recombinant HIV-1 vector lost the pathogenicity completely so there will be no 
risk for patients to gain acquired immune deficiency syndrome (AIDS).  Therefore, the 
safety of vector still need be monitored and valued in a long term through more 
experiments in vivo19. 
3. AAV mediated β-thalassemia gene therapy 
Adeno-associated virus (AAV) is often found in cells that are simultaneously infected with 
adenovirus (Ad).  However, unlike Ad, AAV does not stimulate inflammation in the host; 
causes a very mild immune response has a wide range of host of human and non-human 
cells, which can be dividing and non-dividing cells; wild AAV inserts preferentially at a 
specific site on human chromosome 19.  AAV is not known to cause direct disease in 
humans and considered as the safest viral vector so far.  In the absence of helper virus, 
recombinant AAV will stably integrate into the host cell genome, mediating the long and 
stable expression of the transgene.  The main deficiency of AAV is the small packing 
capacity, only 4.5 kb20.   
AAV is a small (20 nm) replication-defective, nonenveloped virus, belongs to the genus 
Dependovirus, family Parvoviridae.  The genome of AAV is built of single-stranded 
deoxyribonucleic acid (ssDNA), comprises two open reading frames (ORFs), rep and cap, 
flanked by inverted terminal repeats (ITRs) at both ends of DNA strand.  The rep gene 
encodes 4 kinds of Rep proteins required for the AAV replication and rescue: Rep 78, Rep68, 
Rep52, Rep40.  And the cap gene contains nucleotide sequences of capsid proteins: VP1, VP2 
and VP3, which interact together to form a capsid of an icosahedral symmetry.  The ITR 
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sequences comprise 145 bases each, are required in cis for efficient virus replication, 
integration, rescue, and encapsidation21,22(Fig.3).   
 
 
From Blood, Vol. 94 No. 3 (August 1), 1999: pp. 864-874. Adeno-Associated Virus Vectors and 
Hematology . 
Fig. 3. Structure of wild-type and vector AAV genomes. A, Map of the wild-type AAV 
genome, including Rep (solid) and Cap (open) reading frames, promoters (p5, p19, and p40), 
polyadenylation site (pA), and inverted terminal repeats (ITR). The viral transcripts 
encoding the different Rep and Cap (VP1-3) proteins are shown below the genome. The 
smaller Rep proteins, VP2 and VP3, are translated from internal initiation sites. B, Map of a 
typical AAV vector, showing replacement of the viral Rep and Cap genes with a transgene 
cassette (promoter, transgene cDNA, and polyadenylation site). C, Secondary structure of 
the AAV ITR, with the locations of the Rep binding site (RBS) and terminal resolution site 
(TRS) indicated.  
There have been 11 AAV serotypes identified, of which serotype 2 (AAV2) has been the 
most extensively examined so far23.  AAV2 presents natural tropism towards skeletal 
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most extensively examined so far23.  AAV2 presents natural tropism towards skeletal 
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muscles, neurons, vascular smooth muscle cells and hepatocytes24.  Currently, the 
application of AAV serotype 2 in hemophilia B gene therapy gets a promising 
development25.  AAV2 is also studied in gene therapy for pulmonary cystic fibrosis, tumor 
and β-thalassemia.  Although AAV2 is the most popular serotype in various AAV studies, it 
has been shown that other serotypes can be more effective as gene delivery vectors for 
specific tissue.  Preliminary studies have demonstrated other AAV serotypes display 
different tissue tropisms26.  For instance, AAV6 has a higher efficiency in infecting airway 
epithelial cells compare to other serotypes27, AAV8 presents very high transduction rate of 
hepatocytes28, AAV1 and 5 were shown to be very efficient in gene delivery to vascular 
endothelial cells29.  The main reason causing the difference is there are distinctions among 
the capsid proteins of AAV serotypes, while the primary factor for virus entering into cells is 
the binding of capsid proteins with specific cell receptors.  For example, the receptors that 
mediate AAV2 entering into cells are 30, fibroblast growth factor receptor and the integrin 
α β531,32.  So  transduction efficiency of AAV serotypes is affected by distribution of 
specific AAV receptors in various tissues. 
In 1994, Srivastava et al. first reported successful transduction of CD34+ human primitive 
hematopoietic cells by recombinant AAV2 vectors at a relatively low vector:cell ratio of 
1,00033, indicated the potential of AAV2 in β-thalassemia gene therapy. Subsequently, AAV2 
mediated transduction of CD34 + cell were reported by a number of investigators 34-36. High 
transduction efficiency of AAV2-mediated transgene expression in HSCs was found when 
the AAV2 vector particle:cell exceeded 106 by some groups 35,36.  A few of groups concluded 
that human CD34+ cells were impervious to transduction by recombinant AAV2 vectors, 
and the transgene expression observed by others was due to ‘pseudo-transduction’ 
mediated by contaminants in the vector stocks37, which causes people focus more on the 
generation of rAAV. 
The helper virus or plasmid is required in production of recombinant AAV (rAAV) due to 
the AAV’s replication deficiency characteristic. The traditional rAAV production system 
involves transfecting HEK 293 cells with a recombinant AAV vector plasmid and an AAV 
helper plasmid in the presence of a helper virus function38,39. The vector plasmid contains 
AAV ITRs and a transgene cassette. The helper plasmid contains the AAV rep and cap gene, 
but not ITRs. Ad is the most used helper virus, which provides adequate function in helping 
the replication of the recombinant AAV. However, Ad contamination is liable to occur in the 
latter procedures of purify of AAV.  Thus, helper plasmid containing VA E2a and E4 gene 
of Ad genome is developed and used in many studies40-42.   
In our study, we constructed rAAV plasmid (pMT-2) containing genomic sequences of 
human β-globin gene and mini-cassette of locus control region (LCR) element, as described 
previously. The plasmid pAAV2-RC contains AAV2 rep and cap genes and plasmid 
pHelpers contains adenovirus-derived genes (i.e. the E2A, E4, and VARNA genes. The 
pMT-2 together with pAAV2-RC and pHelper were cotransfected into HEK 293 cells to 
generate rAAV2-β-globin virions. The packaged rAAV2 virions were purified using a 
single-step gravity-flow column43. The purity of recombinant virions was evaluated by 
sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE), and the titer of 
purified viral stock was determined by quantitative DNA dot-blots. The titer of rAAV2-β-
globin was near 1.3×1010 virus particles/ml, as determined by quantitative DNA slot blots 
.SDS-PAGE analysis revealed that rAAV2-β-globin contained VP1, VP2, and VP3 proteins at 
a ratio of approximately 1:1:10, suggesting high purity of rAAV2-β-globin. 
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To investigate the function of rAAV2-β-globin in β- thalassemia gene therapy, we first 
detected rAAV2 mediated transduction and β-globin gene expression in human fetal liver 
hematopoietic cells from aborted fetus, as the expression of β -globin gene in early fetal has 
not been initiated The results showed that rAAV2 efficiently transduced human fetal liver 
hematopoietic cells, and mediated expression of human β-globin gene in vivo, the detection 
of expression of β -globin gene was stopped at 2 weeks post transplanted considering the 
activation of endogenous β –globin gene. Following that, we investigated whether rAAV2 
could mediate the expression of normal β-globin gene in human hematopoietic cells from β-
thalassemia patients. We found that rAAV2-β-globin transduced human fetal hematopoietic 
cells, as determined by allele-specific PCR analysis. Furthermore, β-globin transgene 
expression was detected in human hematopoietic cells up to 70 days post-transplantation in 
the recipient mice. High pressure liquid chromatography (HPLC) analysis showed that 
human β-globin expression level increased significantly compared with control, as indicated 
by a 1.2–2.8 fold increase in the ratio of β/α globin chain.44,45 These novel data demonstrate 
that rAAV2 can transduce and mediate normal β-globin gene expression in fetal 
hematopoietic cells from β-thalassemia patients. Our findings further support the potential 
use of rAAV-based gene therapy in treatment of human β-thalassemia, How to improve the 
transfection efficiency of AAV mediated HSC transduction, however  is still an important 
issue.  
Recent article reported that mutation of tyrosine residues on AAV2 capsid greatly enhanced 
transduction efficiency of AAV2 in HSC.  They generated novel AAV vectors by mutating 7 
tyrosine residues on AAV2 capsid to phenylalanine, respectively, named 
Y252,Y272,Y444,Y500,Y700,Y704 and Y730. It was showed that the transduction efficiency of 
Y444F was 8-11 times higher than wt AAV2, next followed by Y500F and Y730F.  
Furthermore, the combination of mutations Y444 + Y500F+Y730F showed even more 
increased transduction efficiency (4 times) compare to Y444F.  The similar effect also was 
observed when the tyrosine residues on AAV6 capsid was mutated to phenylalanine.  They 
discovered that increased efficiency is relative with phosphorylation of tyrosine residues on 
AAV capsid.   Tyrosine residues exposed on AAV capsid surface could be phosphorylated 
by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) on cell surface, 
which has no effect on the steps of AAV entering into cells.46,47  However, phosphorylation 
of tyrosine residues on AAV capsid consequently triggered degradation of ubiquitin and 
proteasomal when AAV was present in cell plasma, which further caused the AAV 
degradation.  The degradation of AAV is successful avoided by mutation of tyrosine 
residues on AAV2 capsid to phenylalanine, thus improved transduction efficiency of AAV.  
Base on these encouraging results, we are trying to improve AAV transduction efficiency in 
HSC by mutating the single or combination of tyrosine residues on AAV capsid after 
analysis of sequence of AAV capsid protein, in order to facilitate the use of AAV in 
transduction of hematopoietic stem cells, and provide an effective therapeutic way for β-
thalassemia gene therapy. 
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Targeted viral vector-mediated gene transfer to specific population of neurons in the central 
nervous system (CNS) is a relatively novel, but fast developing approach to study gene 
function in a number of neurodegenerative diseases (reviewed in Korecka, Verhaagen, & 
Hol, 2007; Manfredsson & Mandel, 2010). Moreover, several early phase clinical trials based 
on viral vector-mediated therapeutic gene transfer have been completed or are underway 
for neurological disorders (Kaplitt et al., 2007; reviewed in Korecka et al., 2007; Marks, Jr. et 
al., 2010; Muramatsu et al., 2010; Tuszynski et al., 2005). Gene therapy is especially attractive 
for diseases where neuronal degeneration is largely restricted to a single neuronal 
population in a specific anatomical area. Parkinson disease (PD) is a neurodegenerative 
disease mainly characterized by a progressive degeneration of dopaminergic (DAergic) 
neurons in the Substantia Nigra (SN) (Dauer & Przedborski, 2003). It would be desirable to 
direct transgene expression to the dopaminergic neurons in animal models for 
neurodegenerative diseases, allowing for a range of investigations into the function of that 
gene in normal, adult DAergic neurons or following neurotoxic insult.  
Lentiviral vectors (LV) and adeno-associated viral vectors (AAV) are increasingly regarded 
as the two most useful gene therapy vectors for the CNS. Both vectors have been 
successfully used to express a foreign gene in a variety of brain regions and neuronal cell 
types (Lim, Airavaara, & Harvey, 2010; Manfredsson & Mandel, 2010; Papale, Cerovic, & 
Brambilla, 2009; Schneider, Zufferey, & Aebischer, 2008). LV vectors have been shown to 
direct long-lasting expression of a number of transgenes in the brain (Lundberg et al., 2008) 
including in neurons in the rat SN (Deglon et al., 2000). AAV vectors are considered to be 
the most appealing vectors for transgene expression in the CNS, due to their efficient 
neuronal transduction, their capacity to direct long-term transgene expression and their 
safety profile (Kaplitt et al., 2007; Mandel et al., 2006; McCown, 2005). The early AAV 
vectors were based on AAV serotype 2 (Kaplitt et al., 1994; Peel & Klein, 2000), but 
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disease mainly characterized by a progressive degeneration of dopaminergic (DAergic) 
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direct transgene expression to the dopaminergic neurons in animal models for 
neurodegenerative diseases, allowing for a range of investigations into the function of that 
gene in normal, adult DAergic neurons or following neurotoxic insult.  
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successfully used to express a foreign gene in a variety of brain regions and neuronal cell 
types (Lim, Airavaara, & Harvey, 2010; Manfredsson & Mandel, 2010; Papale, Cerovic, & 
Brambilla, 2009; Schneider, Zufferey, & Aebischer, 2008). LV vectors have been shown to 
direct long-lasting expression of a number of transgenes in the brain (Lundberg et al., 2008) 
including in neurons in the rat SN (Deglon et al., 2000). AAV vectors are considered to be 
the most appealing vectors for transgene expression in the CNS, due to their efficient 
neuronal transduction, their capacity to direct long-term transgene expression and their 
safety profile (Kaplitt et al., 2007; Mandel et al., 2006; McCown, 2005). The early AAV 
vectors were based on AAV serotype 2 (Kaplitt et al., 1994; Peel & Klein, 2000), but 
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subsequent vectors have been generated with novel serotypes that differ in their tissue and 
cellular tropism (Wu, Asokan, & Samulski, 2006). 
So far, three studies engaged in exploring the possibility of AAV transgene expression in the 
mouse SN. In two studies only AAV vectors based on serotype 2 were used inducing either 
alpha-synuclein (St Martin et al., 2007) or dual leucine zipper kinase (Chen et al., 2008) 
expression in the DAergic neurons of the mouse SN. In the third study AAV serotypes 1, 2, 5, 7 
and 8 were injected into the mouse SN and compared for their tropism for DAergic neurons 
(Taymans et al., 2007). Although, AAV1 and 5 displayed the most promising transduction 
rates, this data was qualitatively assessed.  In contrast, the rat dopaminergic system has been 
studied much more extensively with five studies investigating the performance of various 
AAV serotypes tropism.  These studies compared the levels of GFP expression in the rat SN 
after injection of AAV vector serotype 1, 2 and 5 (Burger et al., 2004; Paterna, Feldon, & Bueler, 
2004), AAV8 (Klein et al., 2006; McFarland, Lee, Hyman, & McLean, 2009), and AAV9 and 10 
(Klein, Dayton, Tatom, Diaczynsky, & Salvatore, 2008). A general conclusion for all these 
studies establishes AAV2 as the lowest transducing vector of dopaminergic neurons in the rat 
SN. Finally and most recently, one AAV serotype study has been performed in primate CNS, 
where AAV1 to 6 viral vectors were injected into the SN (Markakis et al., 2010). In the primate 
AAV5 displays the most promising transduction of neurons in this area.   
In the following study, we have compared multiple AAV serotypes for transduction of 
mouse and rat mesencephalic DAergic neurons. AAV vectors were developed to contain 
either a cytomegalovirus (CMV) promoter or the human synapsin 1 (SYN) promoter. We 
demonstrate that the synapsin promoter leads to higher nigral transduction compared to 
the CMV promoter in mice. Additionally we also show that in our setting, AAV serotype 
5 and 7 give the highest transduction rate of DAergic neurons in the mouse SN, where as 
rat SN can be equally well transduced with all serotypes tested. We compare our study 
with the published data and underline the differences in the methodology and outcome 
measures.  
2. Methods 
2.1 AAV constructs and production 
Lentiviral vectors were produced as described before (Hendriks, Eggers, Verhaagen, & Boer, 
2007). Two plasmids, designated pTRCGw and pTRUF20B-SEW, were used for the production 
of AAV. The pTRCGW plasmid contained inverted terminal repeats of AAV2 flanking a 
cytomegalovirus (CMV) promoter driving expression of GFP, a woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE), and a polyadenylation signal (Ruitenberg, 
Eggers, Boer, & Verhaagen, 2002). The second plasmid, designated pTRUF20B-SEW, was a 
generous gift from Prof. Deniz Kirik (Lund University, Sweden). This plasmid also contained 
two inverted terminal repeats of AAV2 flanking a human synapsin 1 (SYN) promoter driving 
expression of GFP, a WPRE, and a polyadenylation signal. For the production of different 
serotypes helper plasmids were used provided by J.A. Kleinschmidt (AAV1 to 6) (Grimm, 
Kay, & Kleinschmidt, 2003) and J.M. Wilson (AAV7 and 8) (Gao et al., 2002). For each serotype 
eight 15 cm petridishes containing 1x107 HEK293T cells were transfected with the use of 
polyethylenimine (PEI, MW25000; Polysciences Inc., Warrington, PA, USA). Cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and 
1% penicillin/streptomycin (GIBCO-Invitrogen Corp, New York, NY, USA). pTRCGW or 
pTRUF20B-SEW AAV plasmids were cotransfected with packaging plasmids in different 
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ratios as follows: AAV1 to 6 in a ratio of AAV plasmid over capsid plasmid 1:3 with a total 
amount of 50µg of DNA per plate, and AAV7 and 8 in a ratio of 1:2:2 of AAV plasmid over 
helper plasmid pAd∆F6 and capsid plasmid with total amount of 62.5µg of DNA per plate. 
Two days after the transfection cells were harvested in D-phosphate buffered saline (PBS) 
(Gibco) containing 10µg/ml DNAseI (Roche Diagnostics GmbH, Mannheim, Germany) and 
incubated for 1 hour at 37°C. Cells were lysed by three freeze-thaw cycles, spun down 30 min 
at 4000rpm and crude lysate was collected. Virus was purified by the iodixanol gradient ultra-
centrifugation method (Hermens et al., 1999; Zolotukhin et al., 1999), diluted in D-PBS/5% 
sucrose and concentrated using Amicon 100kDA MWCO Ultra-15 device (Millipore, Billerica, 
MA, USA). All AAV vectors were stored at -80°C until use. Titers were determined by 
repeated quantitative PCR for viral genomic copies extracted from DNAse-treated viral 
particles using WPRE directed primers (forward: CAGGTGTATTGCCACAAGACAAA and 
reverse: TGCACAGGTGAAGACCAAGCAA). Table 1 provides an overview of all viral stocks 
and their titers used in this study.  
 
 
Table 1. Viral vectors, titers and injection coordinates. All AAV batches have a similar range 
of titer with an exception of AAV5-SYN, which has a significantly higher titer than the other 
AAV-SYN viruses (after multiple testing, P<0.001, one way ANOVA). The injection 
coordinates are indicated for mice and rats respectively. Abbreviations: CMV- 
cytomegalovirus, SYN-synapsin, GCs/ml- genomic copies per milliliter, AP- Anterior 
Posterior, L- lateral, and VD- Ventral Dorsal distances from bregma. 
2.2 Experimental animals and surgical procedures 
A total of 43 male C57BL/6 mice weighing 20-25g and 16 female Sprague-Dawley rats 
weighing 200-250g were used (Harlan, Zeist, The Netherlands). Animals were housed with 
food and water ad libitum, with 12 hour light and dark cycles. All the experimental 
procedures and postoperative care was carried out in accordance with the local animal 
experimental ethical committee. 
The viral injections were carried out with the use of glass capillaries (0.78/1.0mm 
internal/external diameter; Harvard Apparatus, Holliston, MA, USA) with an 80µm tip. 
These glass capillaries were connected to Portex polyethylene tubing in turn connected to a 
Hamilton syringe fixed in a micro-infusion pump (PHD2000, Harvard Apparatus). The 
system was filled with water and a target volume of 1µl and an infusion rate of 0.2µl/min 
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subsequent vectors have been generated with novel serotypes that differ in their tissue and 
cellular tropism (Wu, Asokan, & Samulski, 2006). 
So far, three studies engaged in exploring the possibility of AAV transgene expression in the 
mouse SN. In two studies only AAV vectors based on serotype 2 were used inducing either 
alpha-synuclein (St Martin et al., 2007) or dual leucine zipper kinase (Chen et al., 2008) 
expression in the DAergic neurons of the mouse SN. In the third study AAV serotypes 1, 2, 5, 7 
and 8 were injected into the mouse SN and compared for their tropism for DAergic neurons 
(Taymans et al., 2007). Although, AAV1 and 5 displayed the most promising transduction 
rates, this data was qualitatively assessed.  In contrast, the rat dopaminergic system has been 
studied much more extensively with five studies investigating the performance of various 
AAV serotypes tropism.  These studies compared the levels of GFP expression in the rat SN 
after injection of AAV vector serotype 1, 2 and 5 (Burger et al., 2004; Paterna, Feldon, & Bueler, 
2004), AAV8 (Klein et al., 2006; McFarland, Lee, Hyman, & McLean, 2009), and AAV9 and 10 
(Klein, Dayton, Tatom, Diaczynsky, & Salvatore, 2008). A general conclusion for all these 
studies establishes AAV2 as the lowest transducing vector of dopaminergic neurons in the rat 
SN. Finally and most recently, one AAV serotype study has been performed in primate CNS, 
where AAV1 to 6 viral vectors were injected into the SN (Markakis et al., 2010). In the primate 
AAV5 displays the most promising transduction of neurons in this area.   
In the following study, we have compared multiple AAV serotypes for transduction of 
mouse and rat mesencephalic DAergic neurons. AAV vectors were developed to contain 
either a cytomegalovirus (CMV) promoter or the human synapsin 1 (SYN) promoter. We 
demonstrate that the synapsin promoter leads to higher nigral transduction compared to 
the CMV promoter in mice. Additionally we also show that in our setting, AAV serotype 
5 and 7 give the highest transduction rate of DAergic neurons in the mouse SN, where as 
rat SN can be equally well transduced with all serotypes tested. We compare our study 
with the published data and underline the differences in the methodology and outcome 
measures.  
2. Methods 
2.1 AAV constructs and production 
Lentiviral vectors were produced as described before (Hendriks, Eggers, Verhaagen, & Boer, 
2007). Two plasmids, designated pTRCGw and pTRUF20B-SEW, were used for the production 
of AAV. The pTRCGW plasmid contained inverted terminal repeats of AAV2 flanking a 
cytomegalovirus (CMV) promoter driving expression of GFP, a woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE), and a polyadenylation signal (Ruitenberg, 
Eggers, Boer, & Verhaagen, 2002). The second plasmid, designated pTRUF20B-SEW, was a 
generous gift from Prof. Deniz Kirik (Lund University, Sweden). This plasmid also contained 
two inverted terminal repeats of AAV2 flanking a human synapsin 1 (SYN) promoter driving 
expression of GFP, a WPRE, and a polyadenylation signal. For the production of different 
serotypes helper plasmids were used provided by J.A. Kleinschmidt (AAV1 to 6) (Grimm, 
Kay, & Kleinschmidt, 2003) and J.M. Wilson (AAV7 and 8) (Gao et al., 2002). For each serotype 
eight 15 cm petridishes containing 1x107 HEK293T cells were transfected with the use of 
polyethylenimine (PEI, MW25000; Polysciences Inc., Warrington, PA, USA). Cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and 
1% penicillin/streptomycin (GIBCO-Invitrogen Corp, New York, NY, USA). pTRCGW or 
pTRUF20B-SEW AAV plasmids were cotransfected with packaging plasmids in different 
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ratios as follows: AAV1 to 6 in a ratio of AAV plasmid over capsid plasmid 1:3 with a total 
amount of 50µg of DNA per plate, and AAV7 and 8 in a ratio of 1:2:2 of AAV plasmid over 
helper plasmid pAd∆F6 and capsid plasmid with total amount of 62.5µg of DNA per plate. 
Two days after the transfection cells were harvested in D-phosphate buffered saline (PBS) 
(Gibco) containing 10µg/ml DNAseI (Roche Diagnostics GmbH, Mannheim, Germany) and 
incubated for 1 hour at 37°C. Cells were lysed by three freeze-thaw cycles, spun down 30 min 
at 4000rpm and crude lysate was collected. Virus was purified by the iodixanol gradient ultra-
centrifugation method (Hermens et al., 1999; Zolotukhin et al., 1999), diluted in D-PBS/5% 
sucrose and concentrated using Amicon 100kDA MWCO Ultra-15 device (Millipore, Billerica, 
MA, USA). All AAV vectors were stored at -80°C until use. Titers were determined by 
repeated quantitative PCR for viral genomic copies extracted from DNAse-treated viral 
particles using WPRE directed primers (forward: CAGGTGTATTGCCACAAGACAAA and 
reverse: TGCACAGGTGAAGACCAAGCAA). Table 1 provides an overview of all viral stocks 
and their titers used in this study.  
 
 
Table 1. Viral vectors, titers and injection coordinates. All AAV batches have a similar range 
of titer with an exception of AAV5-SYN, which has a significantly higher titer than the other 
AAV-SYN viruses (after multiple testing, P<0.001, one way ANOVA). The injection 
coordinates are indicated for mice and rats respectively. Abbreviations: CMV- 
cytomegalovirus, SYN-synapsin, GCs/ml- genomic copies per milliliter, AP- Anterior 
Posterior, L- lateral, and VD- Ventral Dorsal distances from bregma. 
2.2 Experimental animals and surgical procedures 
A total of 43 male C57BL/6 mice weighing 20-25g and 16 female Sprague-Dawley rats 
weighing 200-250g were used (Harlan, Zeist, The Netherlands). Animals were housed with 
food and water ad libitum, with 12 hour light and dark cycles. All the experimental 
procedures and postoperative care was carried out in accordance with the local animal 
experimental ethical committee. 
The viral injections were carried out with the use of glass capillaries (0.78/1.0mm 
internal/external diameter; Harvard Apparatus, Holliston, MA, USA) with an 80µm tip. 
These glass capillaries were connected to Portex polyethylene tubing in turn connected to a 
Hamilton syringe fixed in a micro-infusion pump (PHD2000, Harvard Apparatus). The 
system was filled with water and a target volume of 1µl and an infusion rate of 0.2µl/min 
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was set for mice injections and target volume of 2µl and an infusion rate of 0.4 µl/min for 
rats. The glass needles were mounted on a stereotactic device (David Kopf Instruments, 
Tujunga, CA, USA). A total of 1.1µl of virus was loaded for mice and 2.3 µl for rats for each 
injection separately.  
Mice were intraperitoneally (IP) injected with FFM mix made of Hypnorm (0.1 mg/kg 
Fentanyl citrate/ 3.3 mg/kg Fluanisone HCl, Janssen Pharmaceuticals) and Dormicum (8.3 
mg/kg Midazolam, Roche) and placed into a stereotactic device where they were fixed and 
the skull was exposed. The skull was leveled based on the heights of bregma, lambda and 
two additional and very crucial lateral measurements of 2.0 mm from bregma. The injection 
coordinates were calculated from bregma with anterior posterior (AP) being -2.8 mm and 
lateral (L) -1.3 mm. Ventral dorsal (VD) coordinate was measured from the dura of either -
4.1, -4.2 or -4.3 mm depending on the viral injection (see table 1). Subsequently, the needle 
was lowered into the brain 0.1 mm below the VD coordinate and retracted back up to the 
correct level. After the infusion, the needle was left in place for 5min before retraction.  
Rats were anesthetized by intramuscular injection of 0.08ml/100g of Hypnorm and 
mounted in the stereotact. The skull level was controlled by measurement of bregma and 
lambda. 2µl of each AAV virus was injected at the following coordinates with VD being 
measured from dura: AP -5.2, L -2.0, and VD 7.2 (Ulusoy, Sahin, Bjorklund, Aebischer, & 
Kirik, 2009).   
All of the animals recovered on a heating pad at 37°C and were allowed to survive for 4 
weeks post surgery after which they were sacrificed by an IP overdose with Pentobarbital 
(50mg/µl) and transcardially perfused with 0.9% saline followed by 4% paraformaldehyde 
(PFA, Sigma-Aldrich Co., St. Louis, MO, USA) in PBS pH 7.4. The brains were further post-
fixed overnight and 4 series of 30µm thick coronal sections were cut on a vibratome. The 
sections were stored free-floating at 4°C in 1% PFA in PBS pH 7.6.  
2.3 Immunohistochemistry and histological quantification 
All immunohistochemical (IHC) stainings were performed on free-floating sections. Prior to 
the staining, one series of sections was pre-blocked in 1x tris buffered saline (TBS) (Sigma) 
with 2.5% fetal calf serum (FCS) and 0.2% Triton-X (Sigma) for 1 hour at room temperature. 
Sections were then incubated with anti-tyrosine hydroxilase (TH) rabbit polyclonal antibody 
(Institute Jacques Boy SA, Reims, France) at 1:1000 dilution in blocking buffer and anti-GFP 
(Millipore) chicken monoclonal antibody at 1:1000 for 1 hour at room temperature followed 
by overnight incubation at 4°C. Secondary goat anti-rabbit antibody Alexa 594 (1:400, 
Invitrogen, Carlsbad, CA, USA) was used for the detection of the TH antibody and donkey 
anti-chicken Alexa 488 (1:400, Invitrogen) for the detection of the GFP antibody. These 
antibodies were incubated for 1 hour at room temperature. Sections were then mounted on 
chrome-aluin and gelatin coated glass slides. 
Images were acquired with an Axioplan microscope (Zeiss, Sliedrecht, The Netherlands). 
Images for quantification of the transduced neurons of the SN were taken at 10x 
magnification for mice and 5x magnification for rats with fixed exposure times for both TH 
and GFP signal. The sections of the striatum area were photographed at 2.5x magnification 
also with fixed exposure times for both TH and GFP fluorescent signal. 
ImagePro Plus Fluorviewer software (Media cybernetics, Bethesda, MD, USA) was used for 
the SN transduction quantification. All TH-positive neurons were manually counted in a 
single-blinded setup. Furthermore, TH and GFP colocalization was assessed using cellular 
morphology and fluorescent intensity parameters. For each section the percentage of GFP-
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positive and TH-positive cells was determined, and all values from all of the sections were 
averaged to give the total percentage of colocalized cells in the whole structure. In the AAV-
SYN comparison study one animal in AAV8 group, which the injection had missed the SN 
structure, was excluded from further statistics unless specified. Caudate quantification was 
performed with the use of ImagePro Plus Measure Threshold macro. The striatal areas in both 
hemispheres were outlined based on the TH expression in the striatal fibers. The average GFP 
background signal measured in cortex areas in both hemispheres was subtracted from each 
ipsilateral striatum signal. Next, the recalculated intensity from the non-injected striatum was 
subtracted from the injected side. Finally, this average intensity value in the injected striatum 
was multiplied by the size of the area resulting in total GFP intensity of the measured area. 
3. All AAV serotype vectors with the CMV promoter direct poor transgene 
expression in DAergic neurons of the mouse SN 
Vectors based on AAV serotypes 1, 2, 5, 7, 8 and LV that contained the CMV-GFP expression 
cassette were injected into the mouse SN. Four weeks after the injection, the number of TH-
positive neurons expressing GFP was quantified. All AAV serotypes and the LV vector 
showed very low numbers of transduced TH-positive neurons (Figure 1B). AAV7 directs the 
highest transduction rate with 8% of the TH-positive SN cells expressing GFP. Most of the 
serotypes, with the exception of AAV2, showed high rates of cellular transduction in and 
around the SN, but the transduced neurons were TH-negative (Figure 1A). AAV1 and LV 
also transduced glial cells particularly in the area directly surrounding the injection site 
(data not shown). Glial transduction has not been observed with any other AAV serotypes.   
Three groups have reported on AAV-mediated gene transfer to the mouse SN (Chen et al., 
2008; St Martin et al., 2007; Taymans et al., 2007). Experimental details, including the 
serotype and promoter used in these studies are summarized in Table 2.  
 
 
Table 2. Summary of literature reports using AAV vectors for gene transfer in mouse SN.  
A comparative analysis of AAV1, 2, 5, 7 and 8 showed efficient transduction of cells in the 
SN area (Taymans et al., 2007).  AAV 1 and 5 showed robust GFP expression in the fibers of 
the striatum. In contrast AAV7 and 8 directed only low GFP levels in this projection area of 
the SN DAergic neurons. Additionally, a few GFP positive cells were observed in the 
striatum in all of the serotypes. Consistent with our observations, AAV2 showed poor 
transgene expression in the SN. The efficiency of AAV-CMV driven GFP expression was 
assessed qualitatively and no specification of the DAergic lineage of the transduced cells 
was performed. We have also found high numbers of GFP expressing cells with AAV-CMV 
vectors in and around the SN, however, quantification of the TH-positive GFP-labeled cells 
revealed very low numbers of GFP expressing DAergic neurons in the SN (Figure 1).  
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was set for mice injections and target volume of 2µl and an infusion rate of 0.4 µl/min for 
rats. The glass needles were mounted on a stereotactic device (David Kopf Instruments, 
Tujunga, CA, USA). A total of 1.1µl of virus was loaded for mice and 2.3 µl for rats for each 
injection separately.  
Mice were intraperitoneally (IP) injected with FFM mix made of Hypnorm (0.1 mg/kg 
Fentanyl citrate/ 3.3 mg/kg Fluanisone HCl, Janssen Pharmaceuticals) and Dormicum (8.3 
mg/kg Midazolam, Roche) and placed into a stereotactic device where they were fixed and 
the skull was exposed. The skull was leveled based on the heights of bregma, lambda and 
two additional and very crucial lateral measurements of 2.0 mm from bregma. The injection 
coordinates were calculated from bregma with anterior posterior (AP) being -2.8 mm and 
lateral (L) -1.3 mm. Ventral dorsal (VD) coordinate was measured from the dura of either -
4.1, -4.2 or -4.3 mm depending on the viral injection (see table 1). Subsequently, the needle 
was lowered into the brain 0.1 mm below the VD coordinate and retracted back up to the 
correct level. After the infusion, the needle was left in place for 5min before retraction.  
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All of the animals recovered on a heating pad at 37°C and were allowed to survive for 4 
weeks post surgery after which they were sacrificed by an IP overdose with Pentobarbital 
(50mg/µl) and transcardially perfused with 0.9% saline followed by 4% paraformaldehyde 
(PFA, Sigma-Aldrich Co., St. Louis, MO, USA) in PBS pH 7.4. The brains were further post-
fixed overnight and 4 series of 30µm thick coronal sections were cut on a vibratome. The 
sections were stored free-floating at 4°C in 1% PFA in PBS pH 7.6.  
2.3 Immunohistochemistry and histological quantification 
All immunohistochemical (IHC) stainings were performed on free-floating sections. Prior to 
the staining, one series of sections was pre-blocked in 1x tris buffered saline (TBS) (Sigma) 
with 2.5% fetal calf serum (FCS) and 0.2% Triton-X (Sigma) for 1 hour at room temperature. 
Sections were then incubated with anti-tyrosine hydroxilase (TH) rabbit polyclonal antibody 
(Institute Jacques Boy SA, Reims, France) at 1:1000 dilution in blocking buffer and anti-GFP 
(Millipore) chicken monoclonal antibody at 1:1000 for 1 hour at room temperature followed 
by overnight incubation at 4°C. Secondary goat anti-rabbit antibody Alexa 594 (1:400, 
Invitrogen, Carlsbad, CA, USA) was used for the detection of the TH antibody and donkey 
anti-chicken Alexa 488 (1:400, Invitrogen) for the detection of the GFP antibody. These 
antibodies were incubated for 1 hour at room temperature. Sections were then mounted on 
chrome-aluin and gelatin coated glass slides. 
Images were acquired with an Axioplan microscope (Zeiss, Sliedrecht, The Netherlands). 
Images for quantification of the transduced neurons of the SN were taken at 10x 
magnification for mice and 5x magnification for rats with fixed exposure times for both TH 
and GFP signal. The sections of the striatum area were photographed at 2.5x magnification 
also with fixed exposure times for both TH and GFP fluorescent signal. 
ImagePro Plus Fluorviewer software (Media cybernetics, Bethesda, MD, USA) was used for 
the SN transduction quantification. All TH-positive neurons were manually counted in a 
single-blinded setup. Furthermore, TH and GFP colocalization was assessed using cellular 
morphology and fluorescent intensity parameters. For each section the percentage of GFP-
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positive and TH-positive cells was determined, and all values from all of the sections were 
averaged to give the total percentage of colocalized cells in the whole structure. In the AAV-
SYN comparison study one animal in AAV8 group, which the injection had missed the SN 
structure, was excluded from further statistics unless specified. Caudate quantification was 
performed with the use of ImagePro Plus Measure Threshold macro. The striatal areas in both 
hemispheres were outlined based on the TH expression in the striatal fibers. The average GFP 
background signal measured in cortex areas in both hemispheres was subtracted from each 
ipsilateral striatum signal. Next, the recalculated intensity from the non-injected striatum was 
subtracted from the injected side. Finally, this average intensity value in the injected striatum 
was multiplied by the size of the area resulting in total GFP intensity of the measured area. 
3. All AAV serotype vectors with the CMV promoter direct poor transgene 
expression in DAergic neurons of the mouse SN 
Vectors based on AAV serotypes 1, 2, 5, 7, 8 and LV that contained the CMV-GFP expression 
cassette were injected into the mouse SN. Four weeks after the injection, the number of TH-
positive neurons expressing GFP was quantified. All AAV serotypes and the LV vector 
showed very low numbers of transduced TH-positive neurons (Figure 1B). AAV7 directs the 
highest transduction rate with 8% of the TH-positive SN cells expressing GFP. Most of the 
serotypes, with the exception of AAV2, showed high rates of cellular transduction in and 
around the SN, but the transduced neurons were TH-negative (Figure 1A). AAV1 and LV 
also transduced glial cells particularly in the area directly surrounding the injection site 
(data not shown). Glial transduction has not been observed with any other AAV serotypes.   
Three groups have reported on AAV-mediated gene transfer to the mouse SN (Chen et al., 
2008; St Martin et al., 2007; Taymans et al., 2007). Experimental details, including the 
serotype and promoter used in these studies are summarized in Table 2.  
 
 
Table 2. Summary of literature reports using AAV vectors for gene transfer in mouse SN.  
A comparative analysis of AAV1, 2, 5, 7 and 8 showed efficient transduction of cells in the 
SN area (Taymans et al., 2007).  AAV 1 and 5 showed robust GFP expression in the fibers of 
the striatum. In contrast AAV7 and 8 directed only low GFP levels in this projection area of 
the SN DAergic neurons. Additionally, a few GFP positive cells were observed in the 
striatum in all of the serotypes. Consistent with our observations, AAV2 showed poor 
transgene expression in the SN. The efficiency of AAV-CMV driven GFP expression was 
assessed qualitatively and no specification of the DAergic lineage of the transduced cells 
was performed. We have also found high numbers of GFP expressing cells with AAV-CMV 
vectors in and around the SN, however, quantification of the TH-positive GFP-labeled cells 
revealed very low numbers of GFP expressing DAergic neurons in the SN (Figure 1).  
  




Fig. 1. AAV-CMV-mediated GFP expression in the mouse Substantia Nigra. A. Confocal Z-
stack image of an immunohistochemical staining of the mouse SN showing GFP transgene 
expression in a small number of dopaminergic neurons identified by TH staining (arrows 
indicate the double labeled cells) but also in non-dopaminergic neurons (arrowheads) after 
AAV6-CMV injection. TH neurons are shown in red, GFP is shown in green. The scale bar 
indicates 50µm. B. Quantification of transduced DAergic neurons in the mouse SN (n=3) 
using LV-CMV-GFP and AAV-CMV-GFP viral vectors. The bars represent the percentage of 
TH positive neurons in the SN expressing GFP. AAV7 shows the highest transduction of 8% 
of DAergic neurons in the SN. Error bars indicate the SEM. 
The other two studies, performing AAV mediated gene transfer in mouse SN used only 
serotype 2. In the first study, injection of AAV2 into the SN showed between 10 and 80% of 
TH-positive neurons that express GFP in individual sections (St Martin et al., 2007). In the 
second study AAV2 was injected into the posterior SN, which resulted in transduction of 
71.1±6.0% of TH-positive neurons (Chen et al., 2008). The number of GFP transduced cells in 
both of these studies is much higher compared to our study, where AAV2-CMV led to the 
lowest transduction rate of SN neurons. Although both studies used slightly different 
injection coordinates than we did, it is unlikely that this caused significant differences in 
AAV2 transduction efficiencies. The most likely explanation for this difference is the use of 
the chicken β-actin (CBA) promoter, a promoter known to drive stronger and more 
persistent expression in several population of neurons (Fitzsimons, Bland, & During, 2002). 
Unfortunately there were no other serotypes used in these studies.  
4. AAV vectors that harbor the synapsin promoter direct high-level transgene 
expression in dopaminergic neurons of the mouse SN 
Based on our results and the available literature, the CMV promoter appears to direct less 
efficient transgene expression in different cell types, including striatal neurons (Jakobsson, 
Ericson, Jansson, Bjork, & Lundberg, 2003), cochlea cells (Liu et al., 2007), human embryonic 
stem cells (Orban et al., 2009) and finally rat SN neurons (Paterna, Moccetti, Mura, Feldon, & 
Bueler, 2000; Wang et al., 2005). Therefore we conclude that the CMV promoter leads to a 
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Fig. 2. GFP expression in AAV-SYN injected mouse SN. GFP stained (green) and TH stained 
(red) neurons are visualized in confocal images. Arrows point to examples of GFP positive 
and TH positive cells in all viral serotypes. A. AAV5-SYN-GFP; B. AAV6-SYN-GFP;  
C. AAV7-SYN-GFP; and D. AAV8-SYN-GFP. The scale of 50µm is represented by a bar in 
panel A. 
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indicate the double labeled cells) but also in non-dopaminergic neurons (arrowheads) after 
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indicates 50µm. B. Quantification of transduced DAergic neurons in the mouse SN (n=3) 
using LV-CMV-GFP and AAV-CMV-GFP viral vectors. The bars represent the percentage of 
TH positive neurons in the SN expressing GFP. AAV7 shows the highest transduction of 8% 
of DAergic neurons in the SN. Error bars indicate the SEM. 
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AAV2 transduction efficiencies. The most likely explanation for this difference is the use of 
the chicken β-actin (CBA) promoter, a promoter known to drive stronger and more 
persistent expression in several population of neurons (Fitzsimons, Bland, & During, 2002). 
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Fig. 2. GFP expression in AAV-SYN injected mouse SN. GFP stained (green) and TH stained 
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limited transduction in the mouse SN and may not be suitable to drive viral vector-
mediated transgene expression in the DAergic neurons of the mouse SN. The human 
synapsin 1 promoter, on the other hand, has been shown to be an excellent neuron specific 
promoter in co-cultured primary hippocampal neurons isolated from embryonic brain 
(Kugler, Lingor, Scholl, Zolotukhin, & Bahr, 2003), in primary dorsal root ganglion cultures 
(Sims et al., 2008) and in vivo following injection of an adenoviral vector in rat brain, 
including the SN (Hermening, Kugler, Bahr, & Isenmann, 2006; Kugler, Kilic, & Bahr, 2003; 
Kugler et al., 2003). We therefore produced 4 AAV vectors (AAV5, 6, 7 and 8) that harbored 
a GFP reporter gene under the human synapsin 1 promoter. The performance of these AAV 
vectors was tested in mice and rats after injection in the SN. 
4.1 AAV-synapsin-GFP drives transgene expression in tyrosine hydroxylase positive 
neurons 
Vectors based on AAV serotypes 5, 6, 7 and 8 that contained a SYN-GFP expression cassette 
were injected in the SN in the same fashion as the AAV-CMV-GFP viral vectors. All 
serotypes directed GFP expression in neurons throughout the midbrain, including the SN. 
AAV7 injected mice showed the most widespread viral transduction with GFP-positive 
neurons in multiple midbrain areas (data not shown).  
Subsequently, we specifically investigated the transduction efficiency of DAergic neurons of 
the SN. Immunohistochemical staining showed that all serotypes transduce TH positive 
neurons in the mouse SN (Figure 2). Interestingly, the level of GFP expression in the 
individual TH positive cells appears to be lower than in other TH-negative neurons in the 
SN area. This was also observed following transduction with AAV-CMV vectors.  In 
addition, large numbers of GFP positive fibers were observed in the SN. Based on cellular 
morphology, no other cell types expressed GFP. This indicates that the AAV-SYN-GFP 
construct drives neuron-specific expression.  
4.2 AAV5 and AAV7 mediate the highest transduction of TH positive neurons in the 
mouse SN 
Quantification of the number of TH-positive and GFP-positive neurons in the SN 
demonstrated a much higher proportion of double labeled neurons with all AAV-SYN 
vectors compared to the AAV-CMV vectors. AAV5 and AAV7 lead to significantly higher 
percentage of the GFP labeled DAergic neurons compared to AAV6 and AAV8. These two 
serotypes directed GFP expression in 76-80%of TH-positive neurons (Figure 3A). The 
homogeneous distribution of the TH and GFP-positive neurons from the posterior to the 
anterior side of the SN corroborates the superiority of AAV5 and AAV7 compared to 
AAV6 and AAV8 at each anatomical level (figure 3B, for more details see supplementary 
figure 1).  
In conclusion, AAV5-SYN and AAV7-SYN are the most effective vectors for transduction of 
DAergic neurons in mouse SN. Interestingly, even though AAV5 had a significantly higher 
titer in comparison to AAV7, it transduces a comparable number of DAergic neurons 
throughout the SN. In contrast, AAV8 injected animals, apart from a relatively low total 
percentage of TH and GFP-positive neurons, display a decrease in the number of these 
neurons in the anterior portion of the SN. AAV6 shows quite poor transduction efficiency 
throughout the SN. This is in accordance with the relative low overall percentage of TH-
positive neurons that express GFP (Figure 3A).  
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Fig. 3. AAV-SYN-GFP transduction of mouse SN. A. Quantification of TH positive (TH+) 
and GFP positive (GFP+) neurons in mouse SN transduced with different AAV serotypes. 
In the AAV5 and AAV7 groups, almost 80% of TH+ neurons express GFP, which is 
significantly higher than the AAV6 group where < 20% of the DAergic neurons are GFP 
positive (P<0.001), and the AAV8 group where 35% of the DAergic neurons express GFP 
(P<0.01). B. Quantification of GFP expressing TH+ cells per serotype in SN serial sections 
arranged according to the Allan Brain Atlas TH in situ hybridization (Lein et al., 2007) 
with 1 being most posterior and 8 being the most anterior part of the SN (supplementary 
figure 1). Throughout the groups there was no statistical significant difference between 
AAV5 and AAV7, however in section groups 2, 4, 5, 6 and 7 AAV7 showed significantly 
higher average of GFP+/TH+ cells than the other two serotypes (* P < 0.05, ** P < 0.01, *** 
P < 0.001), where as in section 3 only comparing to AAV6 (P < 0.01). AAV5 showed a 
significantly higher GFP expression in comparison to AAV6 and AAV8 serotypes in 
section groups 4, 5, 6, 7 and 8 and in section 2 and 3 to AAV6 only. AAV8 shows 
significantly higher GFP expression to AAV6 in group 3 and 4 (* P < 0.05, **P < 0.01,  
*** P < 0.001). 
4.3 AAV7 shows the most GFP positive fibers ascending through the nigrostriatal 
tract 
The DAergic neurons of the substantia nigra anatomically project to the striatum creating 
the nigral-striatal pathway. Accordingly, when the DAergic neurons in the substantia 
nigra are transduced their fibers in the striatum are expected to be GFP positive. To 
investigate this relationship, we have quantified the intensity of GFP fluorescent signal in 
the mouse striatum and compared this to the effectiveness of the AAV serotypes to target 
the DAergic neurons in the SN (Figure 4). While AAV5-SYN-GFP and AAV7-SYN-GFP 
display a high fluorescence intensity of GFP, AAV6-SYN-GFP and AAV8-SYN-GFP show 
a low level of GFP expression in the striatum. Furthermore, AAV7-SYN directs 
significantly higher levels of GFP expression in the striatum compared to AAV5-SYN 
(Figure 4 E). Moreover, we have found a significant correlation between the transduction 
efficiency of the SN and the labeling intensity of the fibers in the striatum (Figure 4F).  
This corroborates the superiority of the AAV7 and AAV5 serotypes in transducing 
DAergic neurons in the mouse SN. 
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limited transduction in the mouse SN and may not be suitable to drive viral vector-
mediated transgene expression in the DAergic neurons of the mouse SN. The human 
synapsin 1 promoter, on the other hand, has been shown to be an excellent neuron specific 
promoter in co-cultured primary hippocampal neurons isolated from embryonic brain 
(Kugler, Lingor, Scholl, Zolotukhin, & Bahr, 2003), in primary dorsal root ganglion cultures 
(Sims et al., 2008) and in vivo following injection of an adenoviral vector in rat brain, 
including the SN (Hermening, Kugler, Bahr, & Isenmann, 2006; Kugler, Kilic, & Bahr, 2003; 
Kugler et al., 2003). We therefore produced 4 AAV vectors (AAV5, 6, 7 and 8) that harbored 
a GFP reporter gene under the human synapsin 1 promoter. The performance of these AAV 
vectors was tested in mice and rats after injection in the SN. 
4.1 AAV-synapsin-GFP drives transgene expression in tyrosine hydroxylase positive 
neurons 
Vectors based on AAV serotypes 5, 6, 7 and 8 that contained a SYN-GFP expression cassette 
were injected in the SN in the same fashion as the AAV-CMV-GFP viral vectors. All 
serotypes directed GFP expression in neurons throughout the midbrain, including the SN. 
AAV7 injected mice showed the most widespread viral transduction with GFP-positive 
neurons in multiple midbrain areas (data not shown).  
Subsequently, we specifically investigated the transduction efficiency of DAergic neurons of 
the SN. Immunohistochemical staining showed that all serotypes transduce TH positive 
neurons in the mouse SN (Figure 2). Interestingly, the level of GFP expression in the 
individual TH positive cells appears to be lower than in other TH-negative neurons in the 
SN area. This was also observed following transduction with AAV-CMV vectors.  In 
addition, large numbers of GFP positive fibers were observed in the SN. Based on cellular 
morphology, no other cell types expressed GFP. This indicates that the AAV-SYN-GFP 
construct drives neuron-specific expression.  
4.2 AAV5 and AAV7 mediate the highest transduction of TH positive neurons in the 
mouse SN 
Quantification of the number of TH-positive and GFP-positive neurons in the SN 
demonstrated a much higher proportion of double labeled neurons with all AAV-SYN 
vectors compared to the AAV-CMV vectors. AAV5 and AAV7 lead to significantly higher 
percentage of the GFP labeled DAergic neurons compared to AAV6 and AAV8. These two 
serotypes directed GFP expression in 76-80%of TH-positive neurons (Figure 3A). The 
homogeneous distribution of the TH and GFP-positive neurons from the posterior to the 
anterior side of the SN corroborates the superiority of AAV5 and AAV7 compared to 
AAV6 and AAV8 at each anatomical level (figure 3B, for more details see supplementary 
figure 1).  
In conclusion, AAV5-SYN and AAV7-SYN are the most effective vectors for transduction of 
DAergic neurons in mouse SN. Interestingly, even though AAV5 had a significantly higher 
titer in comparison to AAV7, it transduces a comparable number of DAergic neurons 
throughout the SN. In contrast, AAV8 injected animals, apart from a relatively low total 
percentage of TH and GFP-positive neurons, display a decrease in the number of these 
neurons in the anterior portion of the SN. AAV6 shows quite poor transduction efficiency 
throughout the SN. This is in accordance with the relative low overall percentage of TH-
positive neurons that express GFP (Figure 3A).  
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Fig. 3. AAV-SYN-GFP transduction of mouse SN. A. Quantification of TH positive (TH+) 
and GFP positive (GFP+) neurons in mouse SN transduced with different AAV serotypes. 
In the AAV5 and AAV7 groups, almost 80% of TH+ neurons express GFP, which is 
significantly higher than the AAV6 group where < 20% of the DAergic neurons are GFP 
positive (P<0.001), and the AAV8 group where 35% of the DAergic neurons express GFP 
(P<0.01). B. Quantification of GFP expressing TH+ cells per serotype in SN serial sections 
arranged according to the Allan Brain Atlas TH in situ hybridization (Lein et al., 2007) 
with 1 being most posterior and 8 being the most anterior part of the SN (supplementary 
figure 1). Throughout the groups there was no statistical significant difference between 
AAV5 and AAV7, however in section groups 2, 4, 5, 6 and 7 AAV7 showed significantly 
higher average of GFP+/TH+ cells than the other two serotypes (* P < 0.05, ** P < 0.01, *** 
P < 0.001), where as in section 3 only comparing to AAV6 (P < 0.01). AAV5 showed a 
significantly higher GFP expression in comparison to AAV6 and AAV8 serotypes in 
section groups 4, 5, 6, 7 and 8 and in section 2 and 3 to AAV6 only. AAV8 shows 
significantly higher GFP expression to AAV6 in group 3 and 4 (* P < 0.05, **P < 0.01,  
*** P < 0.001). 
4.3 AAV7 shows the most GFP positive fibers ascending through the nigrostriatal 
tract 
The DAergic neurons of the substantia nigra anatomically project to the striatum creating 
the nigral-striatal pathway. Accordingly, when the DAergic neurons in the substantia 
nigra are transduced their fibers in the striatum are expected to be GFP positive. To 
investigate this relationship, we have quantified the intensity of GFP fluorescent signal in 
the mouse striatum and compared this to the effectiveness of the AAV serotypes to target 
the DAergic neurons in the SN (Figure 4). While AAV5-SYN-GFP and AAV7-SYN-GFP 
display a high fluorescence intensity of GFP, AAV6-SYN-GFP and AAV8-SYN-GFP show 
a low level of GFP expression in the striatum. Furthermore, AAV7-SYN directs 
significantly higher levels of GFP expression in the striatum compared to AAV5-SYN 
(Figure 4 E). Moreover, we have found a significant correlation between the transduction 
efficiency of the SN and the labeling intensity of the fibers in the striatum (Figure 4F).  
This corroborates the superiority of the AAV7 and AAV5 serotypes in transducing 
DAergic neurons in the mouse SN. 
  




Fig. 4. GFP expression in the mouse striatum after SN AAV transduction. A-D. Mouse 
striatal sections stained with anti-TH (red) and-GFP (green) antibody transduced with 
different AAV serotype. The scale bar represents 1mm. E. Quantification of GFP fluorescent 
intensity in all AAV-SYN serotypes. Each striatal section was measured for GFP intensity 
and corrected for the measured area (gray level*mm2). Statistical analysis indicates AAV7-
SYN-GFP result in the highest GFP expression in the striatum, with AAV5 inducing the 
second best expression (*P<0.05, **P< 0.01 and ***P<0.001). F. The percentage of TH+ 
neurons expressing GFP in the SN and the level of GFP fluorescence in the striatum are 
significantly correlated (Pearson correlation, R2=0.729, P<0.001). Each individual animal 
belonging to a specific AAV serotype injection group is depicted by different marker 
described in the figure legend. Animal with missed injection in AAV8-SYN group (as 
described in Methods section) was also included in this analysis. 
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Taken together, these observations demonstrate that AAV7-SYN is the best vector for the 
transduction of TH-positive neurons of mouse SN among the tested serotypes regarding the 
specificity and the transduction rate. Although both AAV5 and AAV7 effectively 
transduced large numbers of TH-positive neurons in the SN, AAV7 showed significantly 
higher GFP expression in the striatum. Injection of AAV7-SYN also resulted in a substantial 
transduction of other neurons in the midbrain. This indicates that AAV7 spreads further 
than other serotypes and/or has a more ubiquitous neuronal tropism in the mouse brain. It 
would be worthwhile to investigate whether it is possible to more specifically target only 
DAergic neurons in the SN by e.g. lowering the volume of the viral vector solution that is 
injected into the SN. Finally, we have not seen any signs of toxicity following the injection of 
high titer AAV vectors in the mouse brain.  
5. All AAV-vectors harboring the synapsin promoter direct similar level of 
transgene expression in the rat SN and the striatum 
5.1 All AAV-synapsin serotypes show similar GFP expression throughout the rat SN 
Female Sprague-Dawley rats were injected with AAV-SYN-GFP viral vectors 5, 6, 7 and  
8 into the SN. The viral stocks used were the same as in mouse SN injections. To estimate the 
transduction efficiency, the TH-positive and GFP-positive neurons of the SN were 
quantified in the same fashion as described in the mouse study. All AAV serotypes showed 
similar numbers of GFP-positive neurons in the rat SN (Figure 5A) with no significant  
 
 
Fig. 5. AAV-SYN-GFP transduction of rat SN. A. Quantification of TH positive (TH+) and GFP 
positive (GFP+) neurons in rat SN transduced by different AAV serotypes. All serotypes 
showed similar GFP expression in about 30-40%of DAergic neurons. B. Quantification of GFP 
expressing TH-positive cells per serotype in the SN serial sections arranged in posterior-distal 
direction accordingly to the ‘The rat brain atlas’ by Paxinos and Watson (2007) (arrangement 
was based on the stereotact anatomical slides and adjacent Acetylcholinesterase (AChE) 
stainings with 1 being most posterior area and 8 being the most anterior area of the SN 
(supplementary figure 2)). All of the serotypes show similar GFP distribution within the SN 
structure with two exceptions: section 1 shows AAV5 expressing significantly higher amount 
of GFP + in TH+ cells comparing to AAV7 (* P < 0.05) and section 8 where AAV7 has greater 
amount of GFP+ DAergic cells than AAV8 (* P < 0.05). 
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would be worthwhile to investigate whether it is possible to more specifically target only 
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injected into the SN. Finally, we have not seen any signs of toxicity following the injection of 
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Fig. 5. AAV-SYN-GFP transduction of rat SN. A. Quantification of TH positive (TH+) and GFP 
positive (GFP+) neurons in rat SN transduced by different AAV serotypes. All serotypes 
showed similar GFP expression in about 30-40%of DAergic neurons. B. Quantification of GFP 
expressing TH-positive cells per serotype in the SN serial sections arranged in posterior-distal 
direction accordingly to the ‘The rat brain atlas’ by Paxinos and Watson (2007) (arrangement 
was based on the stereotact anatomical slides and adjacent Acetylcholinesterase (AChE) 
stainings with 1 being most posterior area and 8 being the most anterior area of the SN 
(supplementary figure 2)). All of the serotypes show similar GFP distribution within the SN 
structure with two exceptions: section 1 shows AAV5 expressing significantly higher amount 
of GFP + in TH+ cells comparing to AAV7 (* P < 0.05) and section 8 where AAV7 has greater 
amount of GFP+ DAergic cells than AAV8 (* P < 0.05). 
  




Fig. 6. GFP expression in the rat striatum after SN AAV injection. A-D. Rat striatal sections 
stained with anti-TH (red) and-GFP (green) antibodies. The scale bar represents 1mm. E. 
GFP fluorescent intensity quantification in the striatum for all AAV-SYN serotypes. Whole 
striatum was cut, stained and each section was measured for GFP intensity and corrected for 
the measured area (gray level*mm2). Statistical analysis shows no differences in GFP 
expression levels between the different AAV serotypes. F. The percentage of TH+ neurons 
expressing GFP in the SN and the level of the GFP fluorescence in the striatum are 
significantly correlated (Pearson correlation R2=0.357, P<0.05). Each individual animal 
belonging to a specific AAV serotype injection group is depicted by different marker 
described in the figure legend. 
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differences between the serotypes. For AAV5 and AAV7 the proportion of transduced TH-
positive neurons is lower in the rat SN compared to the mouse SN. AAV6 directed 
transgene expression in a higher proportion of DAergic neurons in the rat SN (27%) than in 
mouse SN (16%), whereas AAV8 shows slightly higher number of GFP-positive neurons in 
the mouse SN (36%). These results suggest differential AAV tropism for DAergic neurons in 
rats comparing to mice.   
Analysis of the distribution of the GFP-positive neurons within the SN also shows no major 
differences between the AAV serotypes (Figure 5B) except for two anatomical levels where 
AAV5 shows significantly higher amount of TH-positive and GFP-positive cells when 
compared to AAV7 in section 1, and AAV7 shows more GFP-positive DAergic neurons 
when compared to AAV8 in section 8. Although significant, these differences are not 
prominent enough to allow us to speculate on either of the serotype superiority in 
transducing rat DAergic neurons. 
5.3 All AAV-SYN serotypes show GFP expression in the fibers of the rat striatum  
As in the mouse study, we have quantified the intensity of GFP signal in the rat striatum to 
compare the effectiveness of AAV serotype transduction of the rat SN anatomical projection 
(Figure 6). All AAV serotypes showed similar, relatively high levels of GFP expression in 
the striatum (Figure 6E). A correlation analysis revealed a significant correlation between 
the numbers of TH and GFP-positive neurons and the levels of GFP expression in striatum 
(Figure 4F). This further supports that all AAV serotypes are equally effective in targeting 
rat substantia nigra DAergic neurons. In addition, we have observed a transduction of the 
globus pallidus fibers by AAV5 and AAV7 serotypes. This may suggest more spread of 
these viral vectors in the rat brain.   
5.4 AAV7 viral vector injection decreases the amount of TH-positive cells in the rat SN 
We observed a > 50% decrease of number of TH-positive neurons in rat SN after AAV7 
injection when compared to the non injected contra-lateral side of the structure (Figure 7). 
We also studied the expression of vesicular monoamine transporter-2 (VMAT2), another 
DAergic phenotype marker, and found its protein levels also strongly decreased in the 
injected SN (data not shown).  Interestingly, the number of TH-positive and GFP-positive 
neurons in the SN is not less than in the other serotypes (Figure 5) as well as the intensity of 
GFP-positive fibers in the striatum (Figure 6).  
6. Discussion and concluding remarks 
Targeted gene delivery to mesencephalic DAergic neurons can be a very valuable approach 
to study the molecular mechanisms that underlie the development and progression of PD. 
Gene delivery to DAergic neurons has also a potential to evolve into a new therapeutic 
strategy for PD. In this study we have compared the capacity of multiple AAV serotypes to 
deliver a reporter gene to DAergic neurons in the adult mouse and rat SN. We have 
quantified the transduction efficiency of AAV vectors harboring two different promoters: 
the CMV and human synapsin 1 (SYN) promoter. We have demonstrated that following 
stereotactic injection of vectors containing the SYN promoter, a large number of DAergic 
neurons express GFP in the mouse as well as the rat SN. AAV7 is the most effective serotype 
for transduction of mouse SN DAergic neurons. AAV5 also displayed high transduction 
  




Fig. 6. GFP expression in the rat striatum after SN AAV injection. A-D. Rat striatal sections 
stained with anti-TH (red) and-GFP (green) antibodies. The scale bar represents 1mm. E. 
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differences between the serotypes. For AAV5 and AAV7 the proportion of transduced TH-
positive neurons is lower in the rat SN compared to the mouse SN. AAV6 directed 
transgene expression in a higher proportion of DAergic neurons in the rat SN (27%) than in 
mouse SN (16%), whereas AAV8 shows slightly higher number of GFP-positive neurons in 
the mouse SN (36%). These results suggest differential AAV tropism for DAergic neurons in 
rats comparing to mice.   
Analysis of the distribution of the GFP-positive neurons within the SN also shows no major 
differences between the AAV serotypes (Figure 5B) except for two anatomical levels where 
AAV5 shows significantly higher amount of TH-positive and GFP-positive cells when 
compared to AAV7 in section 1, and AAV7 shows more GFP-positive DAergic neurons 
when compared to AAV8 in section 8. Although significant, these differences are not 
prominent enough to allow us to speculate on either of the serotype superiority in 
transducing rat DAergic neurons. 
5.3 All AAV-SYN serotypes show GFP expression in the fibers of the rat striatum  
As in the mouse study, we have quantified the intensity of GFP signal in the rat striatum to 
compare the effectiveness of AAV serotype transduction of the rat SN anatomical projection 
(Figure 6). All AAV serotypes showed similar, relatively high levels of GFP expression in 
the striatum (Figure 6E). A correlation analysis revealed a significant correlation between 
the numbers of TH and GFP-positive neurons and the levels of GFP expression in striatum 
(Figure 4F). This further supports that all AAV serotypes are equally effective in targeting 
rat substantia nigra DAergic neurons. In addition, we have observed a transduction of the 
globus pallidus fibers by AAV5 and AAV7 serotypes. This may suggest more spread of 
these viral vectors in the rat brain.   
5.4 AAV7 viral vector injection decreases the amount of TH-positive cells in the rat SN 
We observed a > 50% decrease of number of TH-positive neurons in rat SN after AAV7 
injection when compared to the non injected contra-lateral side of the structure (Figure 7). 
We also studied the expression of vesicular monoamine transporter-2 (VMAT2), another 
DAergic phenotype marker, and found its protein levels also strongly decreased in the 
injected SN (data not shown).  Interestingly, the number of TH-positive and GFP-positive 
neurons in the SN is not less than in the other serotypes (Figure 5) as well as the intensity of 
GFP-positive fibers in the striatum (Figure 6).  
6. Discussion and concluding remarks 
Targeted gene delivery to mesencephalic DAergic neurons can be a very valuable approach 
to study the molecular mechanisms that underlie the development and progression of PD. 
Gene delivery to DAergic neurons has also a potential to evolve into a new therapeutic 
strategy for PD. In this study we have compared the capacity of multiple AAV serotypes to 
deliver a reporter gene to DAergic neurons in the adult mouse and rat SN. We have 
quantified the transduction efficiency of AAV vectors harboring two different promoters: 
the CMV and human synapsin 1 (SYN) promoter. We have demonstrated that following 
stereotactic injection of vectors containing the SYN promoter, a large number of DAergic 
neurons express GFP in the mouse as well as the rat SN. AAV7 is the most effective serotype 
for transduction of mouse SN DAergic neurons. AAV5 also displayed high transduction 
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efficiency for TH-positive neurons, but the GFP expression levels in the striatum were 
consistently lower when compared to AAV7. In the rat, all AAV-SYN vectors efficiently 
transduced DAergic neurons in the SN. AAV vectors containing the CMV promoter directed 
expression only in a small proportion of TH-positive SN neurons in mice, thereby 
demonstrating superiority of the synapsin promoter in this specific neuronal subtype. 
Collectively, these observations are useful for future experiments that aim to study the 
function of specific genes in the mesencephalic DAergic system. 
 
 
Fig. 7. AAV7 decrease of TH immunohistochemical signal in rat SN. All of the images were 
obtained from the same brain section. A. and C. Rat SN injected with AAV7-SYN-GFP B. 
Contra-lateral non injected side of the rat SN.  Section was stained for TH (red), a nuclear 
marker Hoechst (blue) and GFP (green). The scale bar in panel C represents 0.5mm. D. 
Quantification of the TH positive neurons in the rat SN after AAV7 transduction. TH 
positive neurons were counted in both the AAV7 injected side of the SN and the contra-
lateral side in each section. One way ANOVA indicated a significant decrease of TH+ 
neurons in the AAV7 injected SN (** P < 0.01). 
So far, one study has compared five AAV serotypes (AAV 1, 2, 5, 7 and 8) for gene delivery 
to the mouse SN (Taymans et al., 2007). All vectors, except for AAV2, showed positive 
transduction of the SN area, with AAV1 and AAV5 implicating to direct highest levels of 
GFP in the striatal fibers. This study did not show quantifications of the numbers of GFP 
and TH-positive neurons and GFP expression in striatal fibers, and can therefore not be 
directly compared to our study.  
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For the rat SN, the four tested AAV serotypes directed equally efficient transduction in 
DAergic neurons. In comparison, AAV5 and AAV8 appear to display the most consistent 
transduction efficiencies in the literature (Klein et al., 2006; McFarland et al., 2009; Paterna et 
al., 2004). Additionally, AAV9 and AAV10 have also been tested and indicated to have 
higher tau expression in the SN area and higher TH neuronal loss evoked by tau expression 
comparing to AAV2 and AAV8 (Klein et al., 2008).  These observations in combination with 
our results indicate that multiple AAV serotypes share relatively high tropism for DAergic 
neurons of the rat SN.  
In the mouse SN, AAV vectors with the SYN promoter were superior to the AAV vectors 
containing the CMV promoter. In contrast, in the rat, a range of promoters have been used 
very successfully to direct the transgene expression in the DAergic neurons of the SN via an 
AAV vector including the CMV (McFarland et al., 2009), CBA (Burger et al., 2004; Klein et 
al., 2006; Paterna et al., 2004; Ulusoy et al., 2009), CMV/CBA hybrid (Klein et al., 2008) and 
PDGV (Paterna et al., 2000)) promoters. This suggests that for experiments in the rat the 
choice of the promoter is not as critical as it appears to be for the mouse.  
Following AAV7-SYN-GFP injection, a dramatic decline in TH and VMAT2 expression 
occurred in the DAergic neurons in the rat SN. Klein et al. also observed a decrease in the 
number of TH-positive cells following high titer AAV8-GFP application, but not after 
AAV8-empty vector. Moreover, following the application of lower AAV8-GFP viral titer, no 
decrease of TH signal was noted. Therefore the authors suggest that the high concentrations 
of GFP can be neurotoxic to the DAergic neurons of the rat SN (Klein et al., 2006). Ulusoy et 
al. also reported a neurotoxic effect of high titer AAV5-GFP viral vectors. In this study not 
only TH was diminished, but also the expression of VMAT2. In subsequent experiments 
with low titer AAV5-GFP injections this effect was not seen anymore (Ulusoy et al., 2009). 
We speculate that in our case, the high tropism of AAV7 for DAergic neurons induces more 
GFP expression, and as a consequence causes DAergic neurotoxicity. We do not see this 
effect on TH expression in mice SN after the AAV7 injection.  
As presented here, the specifications of the delivery vehicle can be crucial for successful and 
accurate cellular transduction. We have demonstrated that targeting SN in the mouse is 
difficult and could only be successfully achieved in our set up with AAV serotypes 7 and 5 
harboring the SYN promoter. In contrast targeting rat SN can be efficiently achieved by 
multiple AAV viral vectors. It is therefore necessary to determine the vector potential for 
each animal species before pursuing genetic manipulation in the DAergic system. This can 
also be valid for human clinical PD gene therapy studies. So far AAV2 has been the only 
vector injected into the human brain as a delivery vehicle for PD gene therapy (Kaplitt et al., 
2007; Marks, Jr. et al., 2010; Muramatsu et al., 2010). As discussed before, AAV2 seams to be 
the least efficient vector in the transduction of DAergic neurons in the rodent brain. 
Understandably human serotype studies are not possible, but primate studies may shed 
more light on the transduction efficiency of different delivery vehicles and can improve the 
efficiency of the gene therapies dramatically. One such study has recently indicated AAV5 
to be the most efficient in transducing neurons in the area of SN but also glial cells, whereas 
glial transduction by AAV5 is not observed in the rodent brain (Markakis et al., 2010). This 
clearly illustrates the differences between viral vector transduction preferences between 
animal species.   
Another major concern at the moment in the field of gene therapy is the specification of the 
target area. Two of the above mentioned clinical studies have targeted the putamen of PD 
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efficiency for TH-positive neurons, but the GFP expression levels in the striatum were 
consistently lower when compared to AAV7. In the rat, all AAV-SYN vectors efficiently 
transduced DAergic neurons in the SN. AAV vectors containing the CMV promoter directed 
expression only in a small proportion of TH-positive SN neurons in mice, thereby 
demonstrating superiority of the synapsin promoter in this specific neuronal subtype. 
Collectively, these observations are useful for future experiments that aim to study the 
function of specific genes in the mesencephalic DAergic system. 
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al., 2004). Additionally, AAV9 and AAV10 have also been tested and indicated to have 
higher tau expression in the SN area and higher TH neuronal loss evoked by tau expression 
comparing to AAV2 and AAV8 (Klein et al., 2008).  These observations in combination with 
our results indicate that multiple AAV serotypes share relatively high tropism for DAergic 
neurons of the rat SN.  
In the mouse SN, AAV vectors with the SYN promoter were superior to the AAV vectors 
containing the CMV promoter. In contrast, in the rat, a range of promoters have been used 
very successfully to direct the transgene expression in the DAergic neurons of the SN via an 
AAV vector including the CMV (McFarland et al., 2009), CBA (Burger et al., 2004; Klein et 
al., 2006; Paterna et al., 2004; Ulusoy et al., 2009), CMV/CBA hybrid (Klein et al., 2008) and 
PDGV (Paterna et al., 2000)) promoters. This suggests that for experiments in the rat the 
choice of the promoter is not as critical as it appears to be for the mouse.  
Following AAV7-SYN-GFP injection, a dramatic decline in TH and VMAT2 expression 
occurred in the DAergic neurons in the rat SN. Klein et al. also observed a decrease in the 
number of TH-positive cells following high titer AAV8-GFP application, but not after 
AAV8-empty vector. Moreover, following the application of lower AAV8-GFP viral titer, no 
decrease of TH signal was noted. Therefore the authors suggest that the high concentrations 
of GFP can be neurotoxic to the DAergic neurons of the rat SN (Klein et al., 2006). Ulusoy et 
al. also reported a neurotoxic effect of high titer AAV5-GFP viral vectors. In this study not 
only TH was diminished, but also the expression of VMAT2. In subsequent experiments 
with low titer AAV5-GFP injections this effect was not seen anymore (Ulusoy et al., 2009). 
We speculate that in our case, the high tropism of AAV7 for DAergic neurons induces more 
GFP expression, and as a consequence causes DAergic neurotoxicity. We do not see this 
effect on TH expression in mice SN after the AAV7 injection.  
As presented here, the specifications of the delivery vehicle can be crucial for successful and 
accurate cellular transduction. We have demonstrated that targeting SN in the mouse is 
difficult and could only be successfully achieved in our set up with AAV serotypes 7 and 5 
harboring the SYN promoter. In contrast targeting rat SN can be efficiently achieved by 
multiple AAV viral vectors. It is therefore necessary to determine the vector potential for 
each animal species before pursuing genetic manipulation in the DAergic system. This can 
also be valid for human clinical PD gene therapy studies. So far AAV2 has been the only 
vector injected into the human brain as a delivery vehicle for PD gene therapy (Kaplitt et al., 
2007; Marks, Jr. et al., 2010; Muramatsu et al., 2010). As discussed before, AAV2 seams to be 
the least efficient vector in the transduction of DAergic neurons in the rodent brain. 
Understandably human serotype studies are not possible, but primate studies may shed 
more light on the transduction efficiency of different delivery vehicles and can improve the 
efficiency of the gene therapies dramatically. One such study has recently indicated AAV5 
to be the most efficient in transducing neurons in the area of SN but also glial cells, whereas 
glial transduction by AAV5 is not observed in the rodent brain (Markakis et al., 2010). This 
clearly illustrates the differences between viral vector transduction preferences between 
animal species.   
Another major concern at the moment in the field of gene therapy is the specification of the 
target area. Two of the above mentioned clinical studies have targeted the putamen of PD 
  
Viral Gene Therapy 
 
220 
patients (Marks, Jr. et al., 2010; Muramatsu et al., 2010) and one the subthalamic nucleus 
(Kaplitt et al., 2007). Depending on the function of the target gene, the location of the target 
area is crucial for successful therapeutic application. It is therefore rational to apply gene 
therapy for dopamine synthesis enzymes such as AADC to the putamen to increase the 
dopamine production at that area to alleviate the motor-related clinical symptoms 
(Muramatsu et al., 2010). On the other hand, it may not be as beneficial to induce an expression 
of a neurotrophic factor in the area not significantly affected by neuronal death (Marks, Jr. et 
al., 2010). It was therefore extensively discussed and suggested for the future to target the SN 
DAergic neurons when applying pro-survival and regenerative therapeutic agents (Benabid, 
2010; Marks, Jr. et al., 2010). Concluding, it is therefore necessary to apply the right vectors in 
the specific animal species and target the appropriate area of interest, depending on the 
function of the expression gene, for the most effective targeted gene delivery.  
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Supplementary Fig. 1. Quantitative overview of AAV-SYN-GFP transduction throughout 
the mouse SN in 4 different viral serotypes. A. The sorting of SN anatomical areas through 
section groups 1-8 is based on a TH in situ hybridization presented by the Allen Brain Atlas 
(Lein et al., 2007). Section group 1 is the most posterior group and section group 8 the most 
anterior. B-E. Quantification of SN AAV transduction throughout the structure in 4 different 
viral serotypes in individual animals. Values represent mean of all quantified sections 
belonging to the sorted section group and their SEM.   
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Supplementary Fig. 2. Quantitative overview of AAV-SYN-GFP transduction throughout 
the rat SN in 4 different viral serotypes. A. The sorting of SN anatomical areas through 
section groups 1-8 is based on the anatomical AChE stainings presented by ‘The rat brain 
atlas’ by Paxinos and Watson (2007). Section group 1 is the most posterior group and section 
group 8 the most anterior with indicated distances from the bregma. B-E. Quantification of 
SN AAV transduction throughout the structure in 4 different viral serotypes in individual 
animals. Values represent mean of all quantified sections belonging to the sorted section 
group and their SEM. 
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Molecular structure of the dystrophin-glycoprotein complex and related proteins 
superimposed on the sarcolemma and subsarcolemmal actin network (redrawn from 
Yoshida et al. (Yoshida et al., 2000), with modifications). cc, coiled-coil motif on 
dystrophin (Dys) and dystrobrevin (DB); SGC, sarcoglycan complex; SSPN, sarcospan; 
Syn, syntrophin; Cav3, caveolin-3; N and C, the N and C termini, respectively; G, G-
domain of laminin; asterisk indicates the actin-binding site on the dystrophin rod domain; 
WW, WW domain. 
The approximately 2.5-megabase dystrophin gene is the largest gene identified to date, and 
because of its size, it is susceptible to a high sporadic mutation rate. Absence of dystrophin 
and the dystrophin-glycoprotein complex (DGC) from the sarcolemma leads to severe 
muscle wasting (Figure 1). Whereas DMD is characterized by the absence of functional 
protein, Becker muscular dystrophy, which is commonly caused by in-frame deletions of the 
dystrophin gene, results in the synthesis of a partially functional protein. 
2. Gene-replacement strategies using virus vectors 
2.1 Choice of vector 
Successful therapy for DMD requires the restoration of dystrophin protein in skeletal and 
cardiac muscles. While various viral vectors have been considered for the delivery of genes 
to muscle fibers, the adeno-associated virus (AAV)-based vector is emerging as the gene 
transfer vehicle with the most potential for use in DMD gene therapies. The advantages of 
the AAV vector include the lack of disease associated with a wild-type virus, the ability to 
transduce non-dividing cells, and the long-term expression of the delivered transgenes 
(Okada et al., 2002). Serotypes 1, 6, 8 and 9 of recombinant AAV (rAAV) exhibit a potent 
tropism for striated muscles (Inagaki et al., 2006). Since a 5-kb genome is considered to be 
the upper limit for a single AAV virion, a series of rod-truncated micro-dystrophin genes is 
used in this treatment (Yuasa et al., 1998). 
Due to ingenious cloning and preparation techniques, adenovirus vectors are efficient 
delivery systems of episomal DNA into eukaryotic cell nuclei (Okada et al., 1998). The utility 
of adenovirus vectors has been increased by capsid modifications that alter tropism, and by 
the generation of hybrid vectors that promote chromosomal insertion (Okada et al., 2004). 
Also, gutted adenovirus vectors devoid of all adenoviral genes allow for the insertion of 
large transgenes, and trigger fewer cytotoxic and immunogenic effects than do those only 
deleted in the E1 regions (from bases 343 to 2270) (Hammerschmidt, 1999). Human artificial 
chromosomes (HACs) have the capacity to deliver a large gene (roughly 6-10 megabases) 
into host cells without integrating the gene into the host genome, thereby preventing the 
possibility of insertional mutagenesis and genomic instability (Hoshiya et al., 2008).  
A goal in clinical gene therapy is to develop gene transfer vehicles that can integrate 
exogenous therapeutic genes at specific chromosomal loci, so that insertional oncogenesis is 
prevented. AAV can insert its genome into a specific locus, designated AAVS1, on 
chromosome 19 of the human genome (Kotin et al., 1992). The AAV Rep78/68 proteins and 
the Rep78/68-binding sequences are the trans- and cis-acting elements needed for this 
reaction. A dual high-capacity adenovirus-AAV hybrid vector with full-length human 
dystrophin-coding sequences flanked by AAV integration-enhancing elements was tested 
for targeted integration (Goncalves et al., 2005).  
Gene correction is a process whereby sequence alterations in genes can be corrected by 
homologous recombination-mediated gene conversion between the recipient target locus 
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and a donor construct encoding the correct sequence (Klug, 2005). The introduction of a 
corrective sequence together with a site-specific nuclease to induce a double-stranded break 
(DSB) at sites responsible for monogenic disorders would activate gene correction. Pairs of 
designated zinc-finger protein with tandem DNA binding sites fused to the cleavage 
domain of the Fok1 protein were introduced into model systems or cell lines and produced 
corrections in 10–30% of cases tested (Porteus and Baltimore, 2003). 
2.2 Modification of the dystrophin gene and promoter 
Due to the large deletion in its genome, the gutted adenovirus vector can package 14-kb of 
full-length dystrophin cDNA. Multiple proximal muscles of seven-day-old 
utrophin/dystrophin double knockout mice (dko mice), which typically show symptoms 
similar to human DMD, were effectively transduced with the gutted adenovirus bearing 
full-length murine dystrophin cDNA (Kawano et al., 2008). However, further improvements 




Fig. 2. Structures of full-length and truncated dystrophin. 
Helper-dependent adenovirus vector can package 14-kb of full-length dystrophin cDNA 
because of the large-sized deletion in its genome. A mini-dystrophin is cloned from a patient 
with Becker muscular dystrophy, which is caused by in-frame deletions resulting in the 
synthesis of partially functional protein. A series of truncated micro-dystrophin cDNAs 
harboring only four rod repeats with hinge 1, 2, and 4 (CS1); the same components, except 
that the C-terminal domain is deleted (delta CS1); or one rod repeat with hinge 1 and 4 (M3), 
are constructed to be packaged in the AAV vector. 
A series of truncated dystrophin cDNAs containing rod repeats with hinge 1, 2, and 4 were 
constructed (Figure 2) (Yuasa et al., 1998). Although AAV vectors are too small to package 
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the full-length dystrophin cDNA, AAV vector-mediated gene therapy using a rod-
truncated dystrophin gene provides a promising approach (Wang et al., 2000). The 
structure and, particularly, the length of the rod are crucial for the function of micro-
dystrophin (Sakamoto et al., 2002). An AAV type 2 vector expressing micro-dystrophin 
(DeltaCS1) under the control of a muscle-specific MCK promoter was injected into the 
tibialis anterior (TA) muscles of dystrophin-deficient mdx mice (Yoshimura et al., 2004), 
and resulted in extensive and long-term expression of micro-dystrophin that exhibited 
improved force generation.  
The impact of codon usage optimization on micro-dystrophin expression and function in the 
mdx mouse was assessed to compare the function of two different configurations of codon-
optimized micro-dystrophin genes under the control of a muscle-restrictive promoter (Spc5-
12) (Foster et al., 2008). Codon optimization of micro-dystrophin significantly increased 
micro-dystrophin mRNA and protein levels after intramuscular and systemic 
administration of plasmid DNA or rAAV8. By randomly assembling myogenic regulatory 
elements into synthetic promoter recombinant libraries, several artificial promoters were 
isolated whose transcriptional potencies greatly exceed those of natural myogenic and viral 
gene promoters (Li et al., 1999).  
2.3 Use of surrogate genes 
An approach using a surrogate gene would bypass the potential immune responses 
associated with the delivery of exogenous dystrophin. Methods to increase expression of 
utrophin, a dystrophin paralog, show promise as a treatment for DMD. rAAV6 harboring a 
murine codon-optimized micro-utrophin transgene was intravenously administered into 
adult dko mice to alleviate the pathophysiological abnormalities (Odom et al., 2008). The 
paralogous gene efficiently acted as a surrogate for dystrophin. Myostatin is extensively 
documented as being a negative regulator of muscle growth. Systemic gene delivery of 
myostatin propeptide, a natural inhibitor of myostatin, enhanced body-wide skeletal muscle 
growth in both normal and mdx mice (Qiao et al., 2008). The delivery of various growth 
factors, such as insulin-like growth factor-I (IGF-I), has been successful in promoting skeletal 
muscle regeneration after injury (Schertzer and Lynch, 2006).  
Matrix metalloproteinases (MMPs) are key regulatory molecules in the formation, 
remodeling and degradation of all extracellular matrix (ECM) components in pathological 
processes. MMP-9 is involved predominantly in the inflammatory process during muscle 
degeneration (Fukushima et al., 2007). In contrast, MMP-2 is associated with ECM 
remodeling during muscle regeneration and fiber growth.  
3. AAV-mediated transduction of animal models 
3.1 Vector production 
When adenovirus helper plasmid is co-transfected into human embryonic kidney 293 cells 
along with a vector plasmid encoding the AAV vector and an AAV packaging plasmid 
harboring rep-cap genes, the AAV vector is produced as efficiently as when using 
adenovirus infection. A large-scale transduction method to produce AAV vectors with an 
active gassing system makes use of large culture vessels for labor- and cost-effective 
transfection in a closed system. Samples containing vector particles are further purified with 
a two-tier CsCl gradient or dual ion-exchange chromatography to obtain highly purified 
vector particles. 
 




Fig. 3. A scalable triple plasmid transfection system using active gassing.  
To gain acceptance as a medical treatment with a dose of over 1x1013 genome copies 
(g.c.)/kg body weight, AAV vectors require a scalable and economical production method. 
A production protocol of AAV vectors in the absence of a helper virus (Matsushita et al., 
1998) is widely employed for triple plasmid transduction of human embryonic kidney 293 
cells (Okada et al., 2002). The adenovirus regions that mediate AAV vector replication 
(namely, the VA, E2A and E4 regions) were assembled into a helper plasmid. When this 
helper plasmid is co-transfected into human embryonic kidney 293 cells along with 
plasmids encoding the AAV vector genome and rep-cap genes, the AAV vector is produced 
as efficiently as when using adenovirus infection (Figure 3). Importantly, contamination of 
most adenovirus proteins can be avoided in AAV vector stock made by this helper virus-
free method. Samples containing vector particles are further purified with a two-tier CsCl 
gradient or dual ion-exchange chromatography to obtain highly purified vector particles 
(Okada et al., 2002).  
Despite improvements in vector production, including the development of packaging cell 
lines expressing Rep/Cap, and of methods that induce the expression and regulation of 
Rep/Cap (Okada et al., 2001), maintaining such cell lines remains difficult, as the early 
expression of Rep proteins is toxic to cells. A scalable method, using active gassing and large 
culture vessels, was developed to transfect rAAV in a closed system, in a labor- and cost-
effective manner (Okada et al., 2005). This vector production system achieved a yield of 
more than 5x1013 g.c./flask by improving gas exchange to maintain the physiological pH in 
the culture medium. Recent developments in ion-exchange chromatography also suggest 
that vector production using transduction culture supernatant would be compatible with 
current good manufacturing practice and production on an industrial scale (Okada et al., 
2009). Moreover, AAV vector production in insect cells would be compatible with current 
good manufacturing practice production on an industrial scale (Cecchini et al., 2008).  
3.2 Animal models for the gene transduction study 
Dystrophin-deficient canine X-linked muscular dystrophy was found in a golden retriever 
with a 3’ splice-site point mutation in intron 6 (Valentine et al., 1988). The clinical and 
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pathological characteristics of dystrophic dogs are more similar to those of DMD patients 
than are those of mdx mice. A beagle-based model of canine X-linked muscular dystrophy, 
which is smaller and easier to handle than the golden retriever-based muscular dystrophy 
dog (GRMD) model, has been established in Japan, and is referred to as CXMDJ (Shimatsu et 
al., 2005). The limb and temporal muscles of CXMDJ are affected by two-month-old, which is 
the age corresponding to the second peak of serum creatine kinase. 
Interestingly, we found extensive lymphocyte-mediated immune responses to rAAV2-lacZ 
after direct intramuscular injection into CXMDJ dogs, despite successful delivery of the same 
viral construct into mouse skeletal muscle (Yuasa et al., 2007). In contrast to rAAV2, rAAV8-
mediated transduction of canine skeletal muscles produced significantly higher transgene 
expression with less lymphocyte proliferation than rAAV2 (Ohshima et al., 2008).  
It is increasingly important to develop strategies to treat DMD that consider the effect on 
cardiac muscle. The pathology of the conduction system in CXMDJ was analyzed to 
establish the therapeutic target for DMD (Urasawa et al., 2008). Although dystrophic 
changes of the ventricular myocardium were not evident at the age of 1 to 13 months, 
Purkinje fibers showed remarkable vacuolar degeneration when dogs were as young as 
four-months-old. Furthermore, degeneration of Purkinje fibers was coincident with 
overexpression of Dp71 at the sarcolemma. The degeneration of Purkinje fibers could be 
associated with the distinct deep Q waves present in ECGs and the fatal arrhythmias seen in 
cases of dystrophin deficiency (Urasawa et al., 2008). 
3.3 Immunological Issues of rAAV 
Neo-antigens introduced by AAV vectors evoke significant immune reactions in DMD 
muscle, since increased permeability of sarcolemma allows leakage of the transgene 
products from the dystrophin-deficient muscle fibers (Yuasa et al., 2002). rAAV2 transfer 
into skeletal muscles of normal dogs resulted in low and transient expression, together 
with intense cellular infiltration, and the marked activation of cellular and humoral 
immune responses (Yuasa et al., 2007). Furthermore, an in vitro interferon-gamma release 
assay showed that canine splenocytes respond to immunogens or mitogens more strongly 
than do murine splenocytes. In fact, co-administration of immunosuppressants, 
cyclosporine (CSP) and mycophenolate mofetil (MMF) improved rAAV2 transduction. 
The AAV2 capsids can induce a cellular immune response via MHC class I antigen 
presentation with a cross-presentation pathway, and rAAV2 has also been proposed to 
have an effect on human dendritic cells (DCs). In contrast, other serotypes, such as 
rAAV8, induced T-cell activation to a lesser degree (Ohshima et al., 2008). 
Immunohistochemical analysis revealed that the rAAV2-injected muscles showed higher 
rates of infiltration of CD4+ and CD8+ T lymphocytes in the endomysium than the rAAV8-
injected muscles (Ohshima et al., 2008).  
Resident antigen-presenting cells, such as DCs, myoblasts, myotubes and regenerating 
immature myofibers, might play a role in the immune response. A recent study also showed 
that mRNA levels of MyD88 and co-stimulating factors, such as CD80, CD86 and type I 
interferon, are elevated in both rAAV2- and rAAV8-transduced dog DCs in vitro (Ohshima 
et al., 2008). A brief course of immunosuppression with a combination of anti-thymocyte 
globulin (ATG), CSP and MMF was effective in permitting AAV6-mediated, long-term and 
robust expression of a canine micro-dystrophin in the skeletal muscle of a dog DMD model 
(Wang et al., 2007). 
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3.4 Intravascular vector administration by limb perfusion 
Although recent studies suggest that vectors based on AAV are capable of body-wide 
transduction in rodents, translating this finding into large animals remains a challenge. 
Intravascular delivery can be performed as a form of limb perfusion, which might bypass 
the immune activation of DCs in the injected muscle (Ohshima et al., 2008). We performed 
limb perfusion-assisted intravenous administration of rAAV8-lacZ into the hind limb of 
normal dogs and rAAV8-micro-dystrophin into the hind limb of CXMDJ dogs (Figure 4) 
(Ohshima et al., 2008). Administration of rAAV8-micro-dystrophin by limb perfusion 
produced extensive transgene expression in the distal limb muscles of CXMDJ dogs without 
obvious immune responses for as long as eight weeks after injection.  
 
 
Fig. 4. Intravascular vector administration by limb perfusion. 
(A) A blood pressure cuff is applied just above the knee of an anesthetized CXMDJ dog. A 
24-gauge intravenous catheter is inserted into the lateral saphenous vein, connected to a 
three-way stopcock, and flushed with saline. With a blood pressure cuff inflated to over 300 
mmHg, saline (2.6 ml/kg) containing papaverine (0.44 mg/kg, Sigma-Aldrich, St. Louis, 
MO) and heparin (16 U/kg) is injected by hand over a 10 second period. The three-way 
stopcock is connected to a syringe containing rAAV8 expressing micro-dystrophin (1 x 1014 
vg/kg, 3.8 ml/kg). The syringe is placed in a PHD 2000 syringe pump (Harvard Apparatus, 
Edenbridge, UK). Five minutes after the papaverine/heparin injection, rAAV8 is injected at 
a rate of 0.6 ml/sec. (B) Administration of rAAV8-micro-dystrophin by limb perfusion 
produces extensive transgene expression in the distal limb muscles of CXMDJ dogs without 
obvious immune responses at four weeks after injection. 
3.5 Global muscle therapies 
In comparison with fully dystrophin-deficient animals, targeted transgenic repair of skeletal 
muscle, but not cardiac muscle, paradoxically elicits a five-fold increase in cardiac injury 
and dilated cardiomyopathy (Townsend et al., 2008). Because the dystrophin-deficient heart 
is highly sensitive to increased stress, increased activity by the repaired skeletal muscle 
provides the stimulus for heightened cardiac injury and heart remodeling. In contrast, a 
single intravenous injection of AAV9 vector expressing micro-dystrophin efficiently 
transduces the entire heart in neonatal mdx mice, thereby ameliorating cardiomyopathy 
(Bostick et al., 2008). 
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pathological characteristics of dystrophic dogs are more similar to those of DMD patients 
than are those of mdx mice. A beagle-based model of canine X-linked muscular dystrophy, 
which is smaller and easier to handle than the golden retriever-based muscular dystrophy 
dog (GRMD) model, has been established in Japan, and is referred to as CXMDJ (Shimatsu et 
al., 2005). The limb and temporal muscles of CXMDJ are affected by two-month-old, which is 
the age corresponding to the second peak of serum creatine kinase. 
Interestingly, we found extensive lymphocyte-mediated immune responses to rAAV2-lacZ 
after direct intramuscular injection into CXMDJ dogs, despite successful delivery of the same 
viral construct into mouse skeletal muscle (Yuasa et al., 2007). In contrast to rAAV2, rAAV8-
mediated transduction of canine skeletal muscles produced significantly higher transgene 
expression with less lymphocyte proliferation than rAAV2 (Ohshima et al., 2008).  
It is increasingly important to develop strategies to treat DMD that consider the effect on 
cardiac muscle. The pathology of the conduction system in CXMDJ was analyzed to 
establish the therapeutic target for DMD (Urasawa et al., 2008). Although dystrophic 
changes of the ventricular myocardium were not evident at the age of 1 to 13 months, 
Purkinje fibers showed remarkable vacuolar degeneration when dogs were as young as 
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overexpression of Dp71 at the sarcolemma. The degeneration of Purkinje fibers could be 
associated with the distinct deep Q waves present in ECGs and the fatal arrhythmias seen in 
cases of dystrophin deficiency (Urasawa et al., 2008). 
3.3 Immunological Issues of rAAV 
Neo-antigens introduced by AAV vectors evoke significant immune reactions in DMD 
muscle, since increased permeability of sarcolemma allows leakage of the transgene 
products from the dystrophin-deficient muscle fibers (Yuasa et al., 2002). rAAV2 transfer 
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with intense cellular infiltration, and the marked activation of cellular and humoral 
immune responses (Yuasa et al., 2007). Furthermore, an in vitro interferon-gamma release 
assay showed that canine splenocytes respond to immunogens or mitogens more strongly 
than do murine splenocytes. In fact, co-administration of immunosuppressants, 
cyclosporine (CSP) and mycophenolate mofetil (MMF) improved rAAV2 transduction. 
The AAV2 capsids can induce a cellular immune response via MHC class I antigen 
presentation with a cross-presentation pathway, and rAAV2 has also been proposed to 
have an effect on human dendritic cells (DCs). In contrast, other serotypes, such as 
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Immunohistochemical analysis revealed that the rAAV2-injected muscles showed higher 
rates of infiltration of CD4+ and CD8+ T lymphocytes in the endomysium than the rAAV8-
injected muscles (Ohshima et al., 2008).  
Resident antigen-presenting cells, such as DCs, myoblasts, myotubes and regenerating 
immature myofibers, might play a role in the immune response. A recent study also showed 
that mRNA levels of MyD88 and co-stimulating factors, such as CD80, CD86 and type I 
interferon, are elevated in both rAAV2- and rAAV8-transduced dog DCs in vitro (Ohshima 
et al., 2008). A brief course of immunosuppression with a combination of anti-thymocyte 
globulin (ATG), CSP and MMF was effective in permitting AAV6-mediated, long-term and 
robust expression of a canine micro-dystrophin in the skeletal muscle of a dog DMD model 
(Wang et al., 2007). 
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3.4 Intravascular vector administration by limb perfusion 
Although recent studies suggest that vectors based on AAV are capable of body-wide 
transduction in rodents, translating this finding into large animals remains a challenge. 
Intravascular delivery can be performed as a form of limb perfusion, which might bypass 
the immune activation of DCs in the injected muscle (Ohshima et al., 2008). We performed 
limb perfusion-assisted intravenous administration of rAAV8-lacZ into the hind limb of 
normal dogs and rAAV8-micro-dystrophin into the hind limb of CXMDJ dogs (Figure 4) 
(Ohshima et al., 2008). Administration of rAAV8-micro-dystrophin by limb perfusion 
produced extensive transgene expression in the distal limb muscles of CXMDJ dogs without 
obvious immune responses for as long as eight weeks after injection.  
 
 
Fig. 4. Intravascular vector administration by limb perfusion. 
(A) A blood pressure cuff is applied just above the knee of an anesthetized CXMDJ dog. A 
24-gauge intravenous catheter is inserted into the lateral saphenous vein, connected to a 
three-way stopcock, and flushed with saline. With a blood pressure cuff inflated to over 300 
mmHg, saline (2.6 ml/kg) containing papaverine (0.44 mg/kg, Sigma-Aldrich, St. Louis, 
MO) and heparin (16 U/kg) is injected by hand over a 10 second period. The three-way 
stopcock is connected to a syringe containing rAAV8 expressing micro-dystrophin (1 x 1014 
vg/kg, 3.8 ml/kg). The syringe is placed in a PHD 2000 syringe pump (Harvard Apparatus, 
Edenbridge, UK). Five minutes after the papaverine/heparin injection, rAAV8 is injected at 
a rate of 0.6 ml/sec. (B) Administration of rAAV8-micro-dystrophin by limb perfusion 
produces extensive transgene expression in the distal limb muscles of CXMDJ dogs without 
obvious immune responses at four weeks after injection. 
3.5 Global muscle therapies 
In comparison with fully dystrophin-deficient animals, targeted transgenic repair of skeletal 
muscle, but not cardiac muscle, paradoxically elicits a five-fold increase in cardiac injury 
and dilated cardiomyopathy (Townsend et al., 2008). Because the dystrophin-deficient heart 
is highly sensitive to increased stress, increased activity by the repaired skeletal muscle 
provides the stimulus for heightened cardiac injury and heart remodeling. In contrast, a 
single intravenous injection of AAV9 vector expressing micro-dystrophin efficiently 
transduces the entire heart in neonatal mdx mice, thereby ameliorating cardiomyopathy 
(Bostick et al., 2008). 
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Since a number of muscular dystrophy patients can be identified through newborn 
screening, neonatal transduction may lead to an effective early intervention in DMD 
patients. After a single intravenous injection, robust skeletal muscle transduction with 
AAV9 vector throughout the body was observed in neonatal dogs (Yue et al., 2008). 
Systemic transduction was achieved in the absence of pharmacological intervention or 
immune suppression and lasted for at least six months, whereas cardiac muscle was barely 
transduced in the dogs.  
4. Safety and potential impact of clinical trials 
The initial clinical studies lay the foundation for future studies, providing important 
information about vector dose, viral serotype selection, and immunogenicity in humans. The 
first virus-mediated gene transfer for muscle disease was carried out for limb-girdle muscular 
dystrophy type 2D using rAAV1. The study, consisting of intramuscular injection of virus into 
a single muscle, was discharged to establish the safety of this procedure in phase I clinical 
trials (Rodino-Klapac et al., 2007). The first clinical gene therapy trial for DMD began in March 
2006 (Mendell et al., 2010). This was a Phase I/IIa study in which an AAV vector was used to 
deliver micro-dystrophin to the biceps of boys with DMD. The study was conducted on six 
boys with DMD, each of whom was transduced with mini-dystrophin genes in a muscle of one 
arm in the absence of serious adverse events. Interestingly, dystrophin-specific T cells were 
detected after treatment, providing evidence of transgene expression. The potential for T-cell 
immunity to self and nonself dystrophin epitopes should be considered in designing and 
monitoring experimental therapies for this disease. 
While low immunogenicity was considered a major strength supporting the use of rAAV in 
clinical trials, a number of observations have recently provided a more balanced view of this 
procedure (Manno et al., 2006). An obvious barrier to AAV transduction is the presence of 
circulating neutralizing antibodies that prevent the virion from binding to its cellular 
receptor (Scallan et al., 2006). This potential threat can be reduced by prescreening patients 
for AAV serotype-specific neutralizing antibodies or by performing procedures such as 
plasmapheresis before gene transfer. Another challenge recently revealed is the 
development of a cell-mediated cytotoxic T-cell (CTL) response to AAV capsid peptides. In 
the human factor IX gene therapy trial in which rAAV was delivered to the liver, only short-
term transgene expression was achieved and levels of therapeutic protein declined to 
baseline levels 10 weeks after vector infusion (Manno et al., 2006). This was accompanied by 
elevation of serum transaminase levels and a CTL response toward specific AAV capsid 
peptides. To overcome this response, transient immunosuppression may be required until 
AAV capsids are completely cleared. Additional findings suggest that T-cell activation 
requires AAV2 capsid binding to the heparan sulfate proteoglycan (HSPG) receptor, which 
would permit virion shuttling into a DC pathway, as cross-presentation (Vandenberghe et 
al., 2006). Exposure to vectors from other AAV clades, such as AAV8, did not activate 
capsid-specific T-cells. 
5. Challenges and limitations of related strategies 
5.1 Design of read-through drugs 
To suppress premature stop codon mutations, treatments involving aminoglycosides and 
other agents have been attempted. PTC124, a novel drug capable of suppressing premature 
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termination and selectively inducing ribosomal read-through of premature, but not normal, 
termination codons, was recently identified using nonsense-containing reporters (Welch et 
al., 2007). The selectivity of PTC124 for premature termination codons, its oral 
bioavailability and its pharmacological properties indicate that this drug may have broad 
clinical potential for the treatment of a large group of genetic disorders with limited or no 
therapeutic options.  
5.2 Modification of mRNA splicing 
By inducing the skipping of specific exons during mRNA splicing, antisense compounds 
against exonic and intronic splicing regulatory sequences were shown to correct the open 
reading frame of the DMD gene and thus to restore truncated yet functional dystrophin 
expression in vitro (Takeshima et al., 1995). Intravenous infusion of an antisense 
phosphorothioate oligonucleotide created an in-frame dystrophin mRNA via exon skipping 
in a 10-year-old DMD patient possessing an out-of-frame exon 20 deletion of the dystrophin 
gene (Takeshima et al., 2006). Moreover, the adverse-event profile and local dystrophin-
restoring effect of a single intramuscular injection of an antisense 2'-O-methyl 
phosphorothioate oligonucleotide, PRO051, in patients with DMD were explored (van 
Deutekom et al., 2007). Four patients received a dose of 0.8 mg of PRO051 in the TA muscle. 
Each patient showed specific skipping of exon 51 of dystrophin in 64 to 97% of myofibers, 
without clinically apparent adverse side effects.  
The efficacy and toxicity of intravenous injection of stable morpholino phosphorodiamidate 
(morpholino)-induced exon skipping were tested using CXMDJ dogs, and widespread 
rescue of dystrophin expression to therapeutic levels was observed (Yokota et al., 2009). 
Furthermore, a morpholino oligomer with a designed cell-penetrating peptide can 
efficiently target a mutated dystrophin exon in cardiac muscles (Wu et al., 2008).  
Long-term benefits can be obtained through the use of viral vectors expressing antisense 
sequences against regions within dystrophin gene. The sustained production of dystrophin at 
physiological levels in entire groups of muscles as well as the correction of muscular 
dystrophy were achieved by treatment with exon-skipping AAV1-U7 (Goyenvalle et al., 2004).   
5.3 Ex vivo gene therapy 
Transplantation of genetically corrected autologous myogenic cells is a possible treatment 
for DMD. Freshly isolated satellite cells transduced with lentiviral vectors expressing micro-
dystrophin were transplanted into the TA muscles of mdx mice, and these cells efficiently 
contributed to the regeneration of muscles with micro-dystrophin expression at the 
sarcolemma (Ikemoto et al., 2007). Mesoangioblasts are vessel-associated stem cells and 
might be candidates for future stem cell therapy for DMD (Sampaolesi et al., 2006). Intra-
arterial delivery of wild-type canine mesoangioblasts resulted in the extensive recovery of 
dystrophin expression, normal muscle morphology and function in the GRMD. Multipotent 
mesenchymal stromal cells (MSCs) are less immunogenic and have the potential to 
differentiate and display a myogenic phenotype (Dezawa et al., 2005).   
6. Future perspectives 
6.1 Pharmacological Intervention 
The use of a histone deacetylase (HDAC) inhibitor would likely enhance the utility of rAAV-
mediated transduction strategies in the clinic (Okada et al., 2006). In contrast to adenovirus-
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Since a number of muscular dystrophy patients can be identified through newborn 
screening, neonatal transduction may lead to an effective early intervention in DMD 
patients. After a single intravenous injection, robust skeletal muscle transduction with 
AAV9 vector throughout the body was observed in neonatal dogs (Yue et al., 2008). 
Systemic transduction was achieved in the absence of pharmacological intervention or 
immune suppression and lasted for at least six months, whereas cardiac muscle was barely 
transduced in the dogs.  
4. Safety and potential impact of clinical trials 
The initial clinical studies lay the foundation for future studies, providing important 
information about vector dose, viral serotype selection, and immunogenicity in humans. The 
first virus-mediated gene transfer for muscle disease was carried out for limb-girdle muscular 
dystrophy type 2D using rAAV1. The study, consisting of intramuscular injection of virus into 
a single muscle, was discharged to establish the safety of this procedure in phase I clinical 
trials (Rodino-Klapac et al., 2007). The first clinical gene therapy trial for DMD began in March 
2006 (Mendell et al., 2010). This was a Phase I/IIa study in which an AAV vector was used to 
deliver micro-dystrophin to the biceps of boys with DMD. The study was conducted on six 
boys with DMD, each of whom was transduced with mini-dystrophin genes in a muscle of one 
arm in the absence of serious adverse events. Interestingly, dystrophin-specific T cells were 
detected after treatment, providing evidence of transgene expression. The potential for T-cell 
immunity to self and nonself dystrophin epitopes should be considered in designing and 
monitoring experimental therapies for this disease. 
While low immunogenicity was considered a major strength supporting the use of rAAV in 
clinical trials, a number of observations have recently provided a more balanced view of this 
procedure (Manno et al., 2006). An obvious barrier to AAV transduction is the presence of 
circulating neutralizing antibodies that prevent the virion from binding to its cellular 
receptor (Scallan et al., 2006). This potential threat can be reduced by prescreening patients 
for AAV serotype-specific neutralizing antibodies or by performing procedures such as 
plasmapheresis before gene transfer. Another challenge recently revealed is the 
development of a cell-mediated cytotoxic T-cell (CTL) response to AAV capsid peptides. In 
the human factor IX gene therapy trial in which rAAV was delivered to the liver, only short-
term transgene expression was achieved and levels of therapeutic protein declined to 
baseline levels 10 weeks after vector infusion (Manno et al., 2006). This was accompanied by 
elevation of serum transaminase levels and a CTL response toward specific AAV capsid 
peptides. To overcome this response, transient immunosuppression may be required until 
AAV capsids are completely cleared. Additional findings suggest that T-cell activation 
requires AAV2 capsid binding to the heparan sulfate proteoglycan (HSPG) receptor, which 
would permit virion shuttling into a DC pathway, as cross-presentation (Vandenberghe et 
al., 2006). Exposure to vectors from other AAV clades, such as AAV8, did not activate 
capsid-specific T-cells. 
5. Challenges and limitations of related strategies 
5.1 Design of read-through drugs 
To suppress premature stop codon mutations, treatments involving aminoglycosides and 
other agents have been attempted. PTC124, a novel drug capable of suppressing premature 
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termination and selectively inducing ribosomal read-through of premature, but not normal, 
termination codons, was recently identified using nonsense-containing reporters (Welch et 
al., 2007). The selectivity of PTC124 for premature termination codons, its oral 
bioavailability and its pharmacological properties indicate that this drug may have broad 
clinical potential for the treatment of a large group of genetic disorders with limited or no 
therapeutic options.  
5.2 Modification of mRNA splicing 
By inducing the skipping of specific exons during mRNA splicing, antisense compounds 
against exonic and intronic splicing regulatory sequences were shown to correct the open 
reading frame of the DMD gene and thus to restore truncated yet functional dystrophin 
expression in vitro (Takeshima et al., 1995). Intravenous infusion of an antisense 
phosphorothioate oligonucleotide created an in-frame dystrophin mRNA via exon skipping 
in a 10-year-old DMD patient possessing an out-of-frame exon 20 deletion of the dystrophin 
gene (Takeshima et al., 2006). Moreover, the adverse-event profile and local dystrophin-
restoring effect of a single intramuscular injection of an antisense 2'-O-methyl 
phosphorothioate oligonucleotide, PRO051, in patients with DMD were explored (van 
Deutekom et al., 2007). Four patients received a dose of 0.8 mg of PRO051 in the TA muscle. 
Each patient showed specific skipping of exon 51 of dystrophin in 64 to 97% of myofibers, 
without clinically apparent adverse side effects.  
The efficacy and toxicity of intravenous injection of stable morpholino phosphorodiamidate 
(morpholino)-induced exon skipping were tested using CXMDJ dogs, and widespread 
rescue of dystrophin expression to therapeutic levels was observed (Yokota et al., 2009). 
Furthermore, a morpholino oligomer with a designed cell-penetrating peptide can 
efficiently target a mutated dystrophin exon in cardiac muscles (Wu et al., 2008).  
Long-term benefits can be obtained through the use of viral vectors expressing antisense 
sequences against regions within dystrophin gene. The sustained production of dystrophin at 
physiological levels in entire groups of muscles as well as the correction of muscular 
dystrophy were achieved by treatment with exon-skipping AAV1-U7 (Goyenvalle et al., 2004).   
5.3 Ex vivo gene therapy 
Transplantation of genetically corrected autologous myogenic cells is a possible treatment 
for DMD. Freshly isolated satellite cells transduced with lentiviral vectors expressing micro-
dystrophin were transplanted into the TA muscles of mdx mice, and these cells efficiently 
contributed to the regeneration of muscles with micro-dystrophin expression at the 
sarcolemma (Ikemoto et al., 2007). Mesoangioblasts are vessel-associated stem cells and 
might be candidates for future stem cell therapy for DMD (Sampaolesi et al., 2006). Intra-
arterial delivery of wild-type canine mesoangioblasts resulted in the extensive recovery of 
dystrophin expression, normal muscle morphology and function in the GRMD. Multipotent 
mesenchymal stromal cells (MSCs) are less immunogenic and have the potential to 
differentiate and display a myogenic phenotype (Dezawa et al., 2005).   
6. Future perspectives 
6.1 Pharmacological Intervention 
The use of a histone deacetylase (HDAC) inhibitor would likely enhance the utility of rAAV-
mediated transduction strategies in the clinic (Okada et al., 2006). In contrast to adenovirus-
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mediated transduction, the improved transduction with rAAV induced by the HDAC 
inhibitor is due to enhanced transgene expression rather than to increased viral entry. The 
enhanced transduction was proposed to be related to the histone-associated chromatin form 
of the rAAV concatemer in transduced cells. Since various HDAC inhibitors are currently 
being tested in clinical trials for many diseases, the use of such agents in rAAV-mediated 
DMD gene therapy is theoretically and practically reasonable.   
6.2 Capsid modification 
A DNA shuffling-based approach for developing cell type-specific vectors is an intriguing 
possibility to achieve altered tropism. Capsid genomes of AAV serotypes 1-9 were 
randomly reassembled using PCR to generate a chimeric capsid library (Li et al., 2008). A 
single infectious clone (chimeric-1829) containing genome fragments from AAV1, 2, 8, and 9 
was isolated from an integrin minus hamster melanoma cell line previously shown to have 
low permissiveness to AAV. 
7. Conclusion  
DMD remains an untreatable genetic disease that severely limits motility and life 
expectancy in affected children. The systemic delivery of rAAV to transduce truncated 
dystrophin is predicted to ameliorate the symptoms of DMD patients in the future. To 
translate gene transduction technologies into clinical practice, development of an effective 
delivery system with improved vector constructs as well as efficient immunological 
modulation must be established. A novel protocol that considers all of these issues would 
help improve the therapeutic benefits of DMD gene therapy.  
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mediated transduction, the improved transduction with rAAV induced by the HDAC 
inhibitor is due to enhanced transgene expression rather than to increased viral entry. The 
enhanced transduction was proposed to be related to the histone-associated chromatin form 
of the rAAV concatemer in transduced cells. Since various HDAC inhibitors are currently 
being tested in clinical trials for many diseases, the use of such agents in rAAV-mediated 
DMD gene therapy is theoretically and practically reasonable.   
6.2 Capsid modification 
A DNA shuffling-based approach for developing cell type-specific vectors is an intriguing 
possibility to achieve altered tropism. Capsid genomes of AAV serotypes 1-9 were 
randomly reassembled using PCR to generate a chimeric capsid library (Li et al., 2008). A 
single infectious clone (chimeric-1829) containing genome fragments from AAV1, 2, 8, and 9 
was isolated from an integrin minus hamster melanoma cell line previously shown to have 
low permissiveness to AAV. 
7. Conclusion  
DMD remains an untreatable genetic disease that severely limits motility and life 
expectancy in affected children. The systemic delivery of rAAV to transduce truncated 
dystrophin is predicted to ameliorate the symptoms of DMD patients in the future. To 
translate gene transduction technologies into clinical practice, development of an effective 
delivery system with improved vector constructs as well as efficient immunological 
modulation must be established. A novel protocol that considers all of these issues would 
help improve the therapeutic benefits of DMD gene therapy.  
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1. Introduction 
Gene therapy involves the insertion, removal or alteration of genes within cells and tissues 
of a living organism. Although it emerged as a tool to correct hereditary diseases due to a 
non-functional or missing protein, gene therapy also constitutes an experimental tool to 
investigate gene function. Since the 1960s, most gene therapy studies are aimed at cancer 
and hereditary diseases. As a research tool, the most traditional form of gene therapy 
involves the insertion of a functional gene at a specific location in the host genome in order 
to replace a mutated or missing gene. This is accomplished by isolating and amplifying the 
gene of interest, generating a construct containing the necessary elements for the right 
expression, and inserting this construct into the host organism. Another current approach to 
the study of gene function involves the genetic engineering of knock-out animals (generally 
mice), in which a specific gene is turned off through a targeted mutation. The resulting 
phenotype of a knock-out mouse may provide valuable information regarding the function 
of the missing gene. However, in some cases the targeted gene is necessary for the 
embryonic development, in which case the knock-out of that gene is not feasible. 
Alternatively, individual development may be directed towards compensating for that 
knock-down gene, in which case the phenotype would not provide much relevant 
information. Another research tool to study gene function is to create a transgenic organism, 
which can be a microbe, a plant, a fruit fly, a mouse, a zebrafish, a worm … in which 
foreign, recombinant DNA (i.e., a transgene) is transferred directly into embryos to result in 
modified or novel genes. The resulting phenotype can provide valuable information about 
the role of genes in development, physiology, and disease. Although a transgene integrates 
in the host cell in a chromosomal location different from the endogenous site, the pattern of 
expression usually mimics that of the endogenous gene. Transgenic organisms are broadly 
used for agriculture, production of pharmaceutical drugs and proteins such as insulin, 
biomedical research, and gene therapy in experimental medicine.  
Recent developments have provided us with different kinds of vectors to deliver, remove or 
modify genes within individual cells and tissues, bypassing undesirable effects of broad 
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knock-down or transgene expression. Basically, vectors used in gene therapy for release of 
specific genes can be viral or non-viral. Non-viral vectors include naked DNA, 
oligonucleotides, dendrimers, lipoplexes, and polyplexes, as well as nanoengineered, 
organically modified silicates. However, whereas artificial DNA transfer methods have very 
low efficiency and are not useful for some types of cells, natural selection and evolution 
have led viruses to naturally develop specialized molecular mechanisms to efficiently 
transport their genomes into the cells that they infect. Delivery of genetic material by a virus 
is called transduction, and the infected cells are termed as transduced. Actually, the earliest 
DNA transfer method for bacteria was bacteriophages, which are still commonly used in 
experimentation. For mammalian cells, the first viral vectors were based on the monkey 
tumor virus SV40, in which some viral genes can be replaced by foreign genes. Nonetheless, 
the advantages of viruses like SV40 are limited because only a few genes can be inserted into 
their genome before the length of the DNA molecule becomes too large to be packed into the 
viral coat. 
Additionally, the genetic material of SV40 is usually degraded after it infects the cells. 
Therefore, viral vectors experimentally designed for gene therapy are usually created from 
pathogenic viruses, whose infectivity is much more effective, but they are modified to 
minimize the biohazard. Modifications usually involve the elimination of part of the viral 
machinery necessary for their replication, so that the virus can efficiently infect the cells but 
lacks the necessary proteins for the production of new virions. Experimentally modified 
viral vectors also have low toxicity, which means minimal unwanted effects on the 
physiology and viability of the transduced cells. Additionally, lytic viruses, which kill the 
cells after replicating into them to propagate the infection, cannot be used as vectors. Thus, a 
limited number of nonlytic viruses modified from the retrovirus, adenovirus (AVV), and 
adeno-associated virus groups can be used in gene therapy to stably introduce a gene into a 
cell. Retroviruses insert the genetic material in the form of a RNA molecule, which will 
produce a DNA copy by the action of the enzyme reverse transcriptase. This viral DNA is 
efficiently inserted into the host genome as a provirus, where it permanently replicates 
together with host DNA at each cell division. However, most retroviruses can only infect 
dividing cells. Lentiviruses (LVVs, like HIV) are a subtype of retroviruses. AVVs and adeno-
associated viruses insert their genome in the form of a DNA molecule. Adeno-associated 
viruses, so named because they need the help of an adenovirus for replication, are small 
viruses whose genome consists of a single stranded DNA molecule. Once the adeno-
associated virus enters the nucleus, their single-stranded DNA becomes double-stranded 
and integrates into the host genome, like retroviruses. However, AVVs enter the nucleus but 
do not replicate, remaining as extrachromosomal double-stranded DNA molecules. As 
many differentiated cells in the brain and other tissues lack the capability to divide, LVVs, 
AVVs, and adeno-associated viruses are acquiring increasing popularity in gene therapy 
applications because they can transduce non-dividing cells. 
Currently, gene therapy is mainly being focused on the study of genetic disorders such as 
cancer, diabetes mellitus, cardiovascular diseases and nervous system pathologies, among 
others. More specifically, regarding the applications in the nervous system, this chapter 
will highlight the potential of viral vectors as tools for the investigation of the role of 
altered proteins in neuropathological processes and review our recently published 
findings (Sunico et al., 2008; 2010; Sunico & Moreno-López, 2010; Montero et al., 2010) in 
the context of the existing literature. Briefly, we have used AVVs and LVVs to study the 
function of 2 dysregulated proteins in pathological events occurring at the peripheral 
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(nerve) and central (motoneuron) levels after the severe crushing of a motor nerve in 
adult rats. The use of AVVs is proposed as a feasible gene therapy strategy for the 
enhancement of peripheral nerve regeneration in acquired peripheral neuropathies. 
Additionally, our outcomes support the promising benefits of gene therapy for the 
delivery of diverse genetic elements into specific populations of brain cells to treat several 
neurodegenerative disorders.  
2. The case of acquired motor neuropathies: an useful experimental model to 
analyze protein dysregulation in neuropathological conditions  
Most neurodegenerative disorders and prion diseases have common cellular and molecular 
mechanisms, including dysregulation of protein expression, function and/or aggregation. 
Alteration in the expression level of nitric oxide (NO) synthase (NOS) is a hallmark of 
Alzheimer (AD), Parkinson (PD), and Huntington diseases (HD), amyotrophic lateral 
sclerosis (ALS), multiple sclerosis (MS), and HIV dementia in humans and/or in animal 
models, as well as after peripheral and central traumatic lesions of the nervous system 
(Montero et al., 2010; Moreno-López et al., 2011). Subsequently, dysregulation of protein 
expression and/or function is a key event in a broad spectrum of neuropathological states. 
Unmasking the role of imbalanced proteins in anatomo-functional alterations of neurons in 
neurodegenerative disorders deserves attention. Our research has shown that viral vectors 
may be useful tools to explore the role of altered proteins in neuropathological processes. 
Using AVVs and LVVs, we studied the role of 2 NOS isoforms in pathological events 
occurring at the peripheral nerve and at the motoneuron after XIIth nerve crushing in adult 
rats. 
NO is a short-lived, bioactive free radical which, as a gaseous molecule, freely crosses 
plasma membrane. NO and L-citrulline are the products of hydroxylation of a guanidine 
nitrogen of L-arginine and subsequent oxidization of the Nω-hydroxy-L-arginine 
intermediate by NOS, a heme-containing enzyme that utilizes tetrahydrobiopterin (H4B) as a 
redox cofactor. Electron transfer reactions carried out by NOS are regulated by a Ca2+-
binding protein (calmodulin). NOS also needs NADPH as an electron donor and requires 
molecular oxygen to carry out the reaction. In their active form, the known NOS enzymes 
form dimers in which each NOS monomer is associated with a calmodulin molecule. Three 
major isoforms of NOS have been identified, coded by different genes and differing in 
localization, regulation, catalytic properties, and inhibitor sensitivity. The nNOS isoform 
was the first to be purified and cloned (also known as NOS-I) and is predominantly found in 
the neuronal tissue. Through their specialized postsynaptic density-95/disks large/zona 
occludens-1 domains, nNOS can physically associate with postsynaptic density protein-95 
(PSD-95). In turn, PSD-95 binds to motifs in the C-terminus of NMDA receptor NR2 
subunits. These molecular interactions may provide the mechanistic basis for a functional 
coupling between Ca2+ influx through NMDA receptors and NO production. The iNOS 
isoform (also known as NOS-II) is inducible in a wide range of cells and tissues, including 
activated macrophages and, astroglia and microglia in the pathological CNS. This isotype is 
Ca2+-independent and always catalytically active when expressed. However, iNOS is not the 
only isoform induced in pathological conditions. Finally, eNOS (or NOS-III) is the primary 
isoform found in vascular endothelial cells (Moreno-López et al., 2011). 
Injured nerve fibers in the peripheral nervous system maintain the capacity to regenerate 
even over long distances in adult mammals. However, after nerve transection, stumps of 
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redox cofactor. Electron transfer reactions carried out by NOS are regulated by a Ca2+-
binding protein (calmodulin). NOS also needs NADPH as an electron donor and requires 
molecular oxygen to carry out the reaction. In their active form, the known NOS enzymes 
form dimers in which each NOS monomer is associated with a calmodulin molecule. Three 
major isoforms of NOS have been identified, coded by different genes and differing in 
localization, regulation, catalytic properties, and inhibitor sensitivity. The nNOS isoform 
was the first to be purified and cloned (also known as NOS-I) and is predominantly found in 
the neuronal tissue. Through their specialized postsynaptic density-95/disks large/zona 
occludens-1 domains, nNOS can physically associate with postsynaptic density protein-95 
(PSD-95). In turn, PSD-95 binds to motifs in the C-terminus of NMDA receptor NR2 
subunits. These molecular interactions may provide the mechanistic basis for a functional 
coupling between Ca2+ influx through NMDA receptors and NO production. The iNOS 
isoform (also known as NOS-II) is inducible in a wide range of cells and tissues, including 
activated macrophages and, astroglia and microglia in the pathological CNS. This isotype is 
Ca2+-independent and always catalytically active when expressed. However, iNOS is not the 
only isoform induced in pathological conditions. Finally, eNOS (or NOS-III) is the primary 
isoform found in vascular endothelial cells (Moreno-López et al., 2011). 
Injured nerve fibers in the peripheral nervous system maintain the capacity to regenerate 
even over long distances in adult mammals. However, after nerve transection, stumps of 
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damaged nerves must be surgically joined to guide regenerating axons into the distal nerve 
stump. Even so, severe functional limitations persist after restorative surgery. Since most 
previous studies have used nerve transection, it is important to signal distinctions between 
different forms of nerve lesion. Regenerative and survival capacities could be differentially 
compromised in adult motoneurons following transection or avulsion of the peripheral 
nerve. However, crushing of a motor nerve causes an immediate and complete suppression 
of neuromuscular connectivity but, unlike transection, it preserves the endoneural tube, thus 
providing neurotrophic support and a physical guide for the growing proximal axonal 
endings (Moreno-López, 2010). A few weeks after nerve crushing, muscle re-innervation 
takes place without significant neuronal loss. Therefore, traumatic injury by crushing is a 
plausible model for the identification of molecules that regulate degenerative and 
regenerative processes after acquired peripheral neuropathies.  
2.1 A model of acquired motor neuropathy: the crushing of the XIIth nerve 
We have developed a model of acquired peripheral motor neuropathy induced by a 
traumatic insult that causes a well-characterized range of functional and synaptic 
impairments in the insulted motoneurons. This experimental model has been useful to test 
the role and effectiveness of diverse factors in degenerative/regenerative processes after 
nerve injury by means of functional and anatomical approaches. The hypoglossal system -
hypoglossal motoneurons (HMNs), XIIth nerve and their target muscle (the tongue)- has 
been well characterized by our group in physiological and pathological conditions 
(González-Forero et al., 2004; Montero et al., 2008; 2010; Sunico et al., 2005; 2008; 2010; 2011). 
This motor system offers several advantages, since muscle and motoneuron activities can be 
accurately measured and its peripheral and central partners are easily accessible to carry out 
damage strategies, local microinjections and electrophysiological recordings.  
Crushing the XIIth nerve immediately induces a complete suppression of neuromuscular 
connectivity, demonstrated by the complete absence in the tongue of the compound muscle 
action potential (CMAP) evoked by electrical stimulation of the injured nerve at the 
proximal portion (Fig. 1). CMAP was completely absent for 1, 3 or 7 days after crushing, 
even when supramaximal nerve stimulation was applied. These results indicate that our 
method of nerve crushing effectively disconnected most HMNs from their targets for at least 
1 week. Evidence of muscle re-innervation was obtained at 15 days after crushing. 
Subsequently, there was a slow and progressive recovery of CMAP and at 30 days after 
crushing its amplitude was similar to the control condition (Fig. 1). 
In the hypoglossal nucleus (HN), most motoneurons discharge bursts of action potentials 
synchronized with the inspiratory phase of breathing (Fig. 2). This characteristic activity 
persists even after animal decerebration and/or under anesthesia. The main alterations 
observed in the firing pattern of HMNs following XIIth nerve crushing were an overall 
reduction in firing rates and an almost complete loss of modulation by chemosensory 
afferents. The inspiratory activity of motoneurons was modulated by chemoreceptor-
driven changes in response to alterations in end tidal CO2 (ETCO2). The activity bursts of 
HMNs increased when ETCO2 rose and decreased when ETCO2 declined. One week after 
XIIth nerve crushing the chemosensory-mediated responsiveness of HMNs to ETCO2 
changes decreased (Fig. 2). Synaptic stripping of HMNs after nerve injury is at least 
partially responsible for reduced response of motoneurons to chemoreceptor-modulated 
inspiratory drive (Fig. 2). 
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Fig. 1. Experimental design and time course of neuromuscular function recovery after 
XIIth nerve crushing. (a) To evaluate the time course of the neuromuscular function 
recovery, the compound muscle action potential (CMAP), evoked by electrical stimulation 
(St.) of the XIIth nerve, was recorded using electrodes implanted in the genioglossus 
muscle. Inset: Photomicrograph of a sagittal section at the level of the crushing site 
extracted 3 h after injury, stained by neutral red. Note that axons are fully transected but 
endoneural tube is preserved. Scale bar: 500 m. (b) CMAPs evoked in the genioglossus 
muscle by single shock stimulation (arrowheads signal stimulus artifacts) of XIIth nerve in 
control and at 7, 15, 22, 30 and 45 days post-lesion. For comparison, CMAPs evoked by 
left (L, intact side) and right (R, crushed side) XIIth nerve stimulation are illustrated. Each 
trace represents an average of 10 individual traces. Dotted lines at 15 and 22 days 
represent how the  latency was calculated. Gray traces at 15 days represent the responses 
obtained in the same animal after injection of a neuromuscular blocker gallamine 
triethiodide in the genioglossus muscle. Note complete absence of CMAP on day 7 and 
the first signs of muscle re-innervation 15 days post-injury. Figure modified from Sunico 
et al., 2008 and Sunico & Moreno-López, 2010 (inset in (a)). © 2008 Elsevier Ltd and © 
2010 Elsevier Ireland Ltd, respectively.   
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even when supramaximal nerve stimulation was applied. These results indicate that our 
method of nerve crushing effectively disconnected most HMNs from their targets for at least 
1 week. Evidence of muscle re-innervation was obtained at 15 days after crushing. 
Subsequently, there was a slow and progressive recovery of CMAP and at 30 days after 
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In the hypoglossal nucleus (HN), most motoneurons discharge bursts of action potentials 
synchronized with the inspiratory phase of breathing (Fig. 2). This characteristic activity 
persists even after animal decerebration and/or under anesthesia. The main alterations 
observed in the firing pattern of HMNs following XIIth nerve crushing were an overall 
reduction in firing rates and an almost complete loss of modulation by chemosensory 
afferents. The inspiratory activity of motoneurons was modulated by chemoreceptor-
driven changes in response to alterations in end tidal CO2 (ETCO2). The activity bursts of 
HMNs increased when ETCO2 rose and decreased when ETCO2 declined. One week after 
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changes decreased (Fig. 2). Synaptic stripping of HMNs after nerve injury is at least 
partially responsible for reduced response of motoneurons to chemoreceptor-modulated 
inspiratory drive (Fig. 2). 
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Fig. 2. XIIth nerve crushing induces a reduction of HMNs CO2-modulated response and of 
their synaptic coverage. (a) Schematic diagram of the experimental preparation. Unitary 
discharge activity of HMNs and expired CO2 were obtained in decerebrated, vagotomized 
rats, which had been injected with a neuromuscular blocking agent and lightly anesthetized. 
Right, characterization of firing properties of HMNs. From top to bottom, traces represent 
the extracellularly recorded spike discharge for a control inspiratory HMN, the 
instantaneous firing rate (FR, in spikes/s) and the partial pressure of CO2 as a percentage of 
the expired air. Mean firing rate (mFR) per burst was measured and analyzed in relation to 
simultaneous ETCO2 measurements (dotted line in the middle trace). End-tidal CO2 (ETCO2) is 
indicated on the CO2 record as a dashed line. (b) Illustrative examples of the time courses of 
the mean firing rate modulation (mFR, in spikes (sp)/s/burst; right y-axis; gray trace) 
relative to ETCO2 levels (left y-axis; black trace) for a control HMN and a motoneuron 
recorded 7 days after XIIth nerve crushing. (c) Confocal high-magnification 
photomicrographs of HMNs identified by the presence of a tongue-injected retrograde 
tracer (FluoroGold; green) in sections immunostained for the synaptic marker 
synaptophysin (red) obtained from control animals or 7 days after XIIth nerve crushing. 
Scale bars: 10m. Figure modified, with permission, from Gonzalez-Forero et al., 2004 (a); 
Sunico et al., 2005 (c) and Montero et al., 2010 (b). © 2004 The Physiological Society, © 2005 
Society for Neuroscience and © 2010 The Physiological Society, respectively. 
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Up-regulation of NOS also happens as a consequence of different kinds of peripheral 
neuropathies. More specifically, after traumatic injury of a motor nerve, NOS expression is 
up-regulated at 3 different levels: in the damaged nerve, in the denervated muscle, and 
centrally at the injured motoneurons. In the distal stump of the affected nerve, all 3 major 
isoforms of NOS are up-regulated: iNOS is de novo expressed in dedifferentiated Schwann 
cells and in infiltrated macrophages, whereas nNOS is accumulated in the growing motor 
axons. However, eNOS, which is constitutively found in blood vessels, is overexpressed in 
vasa nervorum of the distal stump and around the injury site after the damage (Moreno-
López, 2010). At the central level, nNOS, but not iNOS, is expressed de novo in the soma of 
motoneurons after traumatic motor nerve injury (Sunico et al., 2005). nNOS is then 
outwardly transported, accumulating in growing axons at the peripheral level (Moreno-
López, 2010). However, eNOS induction has not been reported in injured motoneurons so 
far (Montero et al., 2010).  
2.2 Using an AVV to accelerate and improve muscle re-innervation after acquired 
motor peripheral neuropathy 
Evidences of NO as a harmful molecule for nerve regeneration show that systemic 
administration of N-nitro-L-arginine methyl ester (L-NAME), a nonselective NOS 
inhibitor, improved motor nerve regeneration in mice after sciatic nerve transection 
(Zochodne & Levy, 2005). L-NAME also protected motoneurons from death and 
substantially increased the number that re-innervated the target muscle after facial nerve 
transection and repair, accompanied by improved motor function recovery (Wang et al., 
2009). In the same direction, our studies showed that L-NAME treatment advanced the 
onset of neuromuscular reconnection after hypoglossal nerve crushing (Sunico et al., 
2008). However, the pattern and time course of expression of each NOS isoform (Moreno-
López, 2010) suggest that the NO from different origins could regulate diverse 
degenerative/regenerative processes after peripheral injury in a time-dependent manner. 
In nNOS or iNOS knockout mice, peripheral recovery was impaired after nerve injury due 
to delayed Wallerian degeneration, axon breakdown and Schwann cell reaction in the 
distal stump (Zochodne & Levy, 2005). Nevertheless, axon counts, myelination, and 
recovery of sensory and motor function in eNOS knockouts and wild-type mice were 
comparable after transection and reconstruction, although a delay of 2 days in 
revascularization was observed in eNOS knockout mice (Zochodne & Levy, 2005). The 
inherent risk of compensatory mechanisms for the disrupted enzyme during brain 
development is widespread in knockout animals. This may occur though a normally 
present redundant pathway and may be due to differences in expression of alternatively 
spliced isoforms of a particular NOS. For example, NOS catalytic activity levels in the 
brain of nNOS knockout mice are persistently low, which may mask the effect of nNOS 
deficiency (Moreno-López, 2010). Therefore, results obtained from knockouts, although 
useful, must be interpreted with caution. 
Systemic application of relatively isoform-specific NOS inhibitors is another strategy that 
has been used to study the role of each isoform in degenerative/regenerative processes after 
nerve injury. nNOS or iNOS inhibition by the relatively specific inhibitors for nNOS 7-
nitroindazole (7-NI), S-methyl-L-thiocitrulline (SMTC) and iNOS L-N6-(1-iminoethyl)-lysine 
hydrochloride (L-NIL), has contributed contradictory results. Whereas systemic 
administration of 7-NI, SMTC or L-NIL had beneficial effects on axonal regeneration after 
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Up-regulation of NOS also happens as a consequence of different kinds of peripheral 
neuropathies. More specifically, after traumatic injury of a motor nerve, NOS expression is 
up-regulated at 3 different levels: in the damaged nerve, in the denervated muscle, and 
centrally at the injured motoneurons. In the distal stump of the affected nerve, all 3 major 
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motoneurons after traumatic motor nerve injury (Sunico et al., 2005). nNOS is then 
outwardly transported, accumulating in growing axons at the peripheral level (Moreno-
López, 2010). However, eNOS induction has not been reported in injured motoneurons so 
far (Montero et al., 2010).  
2.2 Using an AVV to accelerate and improve muscle re-innervation after acquired 
motor peripheral neuropathy 
Evidences of NO as a harmful molecule for nerve regeneration show that systemic 
administration of N-nitro-L-arginine methyl ester (L-NAME), a nonselective NOS 
inhibitor, improved motor nerve regeneration in mice after sciatic nerve transection 
(Zochodne & Levy, 2005). L-NAME also protected motoneurons from death and 
substantially increased the number that re-innervated the target muscle after facial nerve 
transection and repair, accompanied by improved motor function recovery (Wang et al., 
2009). In the same direction, our studies showed that L-NAME treatment advanced the 
onset of neuromuscular reconnection after hypoglossal nerve crushing (Sunico et al., 
2008). However, the pattern and time course of expression of each NOS isoform (Moreno-
López, 2010) suggest that the NO from different origins could regulate diverse 
degenerative/regenerative processes after peripheral injury in a time-dependent manner. 
In nNOS or iNOS knockout mice, peripheral recovery was impaired after nerve injury due 
to delayed Wallerian degeneration, axon breakdown and Schwann cell reaction in the 
distal stump (Zochodne & Levy, 2005). Nevertheless, axon counts, myelination, and 
recovery of sensory and motor function in eNOS knockouts and wild-type mice were 
comparable after transection and reconstruction, although a delay of 2 days in 
revascularization was observed in eNOS knockout mice (Zochodne & Levy, 2005). The 
inherent risk of compensatory mechanisms for the disrupted enzyme during brain 
development is widespread in knockout animals. This may occur though a normally 
present redundant pathway and may be due to differences in expression of alternatively 
spliced isoforms of a particular NOS. For example, NOS catalytic activity levels in the 
brain of nNOS knockout mice are persistently low, which may mask the effect of nNOS 
deficiency (Moreno-López, 2010). Therefore, results obtained from knockouts, although 
useful, must be interpreted with caution. 
Systemic application of relatively isoform-specific NOS inhibitors is another strategy that 
has been used to study the role of each isoform in degenerative/regenerative processes after 
nerve injury. nNOS or iNOS inhibition by the relatively specific inhibitors for nNOS 7-
nitroindazole (7-NI), S-methyl-L-thiocitrulline (SMTC) and iNOS L-N6-(1-iminoethyl)-lysine 
hydrochloride (L-NIL), has contributed contradictory results. Whereas systemic 
administration of 7-NI, SMTC or L-NIL had beneficial effects on axonal regeneration after 
  
Viral Gene Therapy 
 
248 
facial nerve transection and repair (Wang et al., 2009), positive effects were not obtained 
after XIIth nerve crushing by treatment with 7-NI or aminoguanidine (AG), another iNOS 
inhibitor (Sunico et al., 2008). Strikingly, administration of the relatively specific eNOS 
inhibitor L-N(5)-(l-iminoethyl)ornithine (L-NIO) accelerated the onset of muscle re-
innervation after hypoglossal nerve crushing by promoting axonal regrowth (Sunico et al., 
2008). Contradictions can be explained by differences in the lesion model and in the dose 
and relative specificity of NOS inhibitors (Moreno-López, 2010). In any case, these results 
pointed to eNOS as the major source of detrimental NO in axonal regeneration, at least in 
the first week after nerve injury. 
In general, a strong consensus exists stating that NOS inhibition, at least during the first 
week after traumatic motor neuropathy, accelerates and improves motor function 
recovery. However, the administration route must be carefully taken into account. NO has 
important roles in the immunological, cardiovascular and nervous systems. Key 
physiological functions, such as learning, platelet aggregation, arterial blood pressure, 
and immune responses, could be disrupted by chronic and systemic NOS inhibition. NOS 
inhibition as a plausible treatment to improve functional recovery after nerve injury must 
bypass unwanted side effects of systemic administration of the inhibitors. The therapeutic 
strategy should entail specific inhibition of the proper NOS isoform that is detrimental to 
nerve regeneration and the selected NOS inhibitor should be locally administered 
(Moreno-López, 2010). Endothelial isoform has been described as having negative effects 
on functional recovery in the traumatic motor nerve injury model (Sunico et al., 2008), 
mainly inhibiting axonal regrowth. Due to the apparent involvement of eNOS in 
vasodilation of blood vessels and platelet aggregation, however, chronic systemic 
treatment with a specific eNOS inhibitor is not advised. Such a treatment can affect 
cardiovascular function, inducing hypertension and increasing the risk of thrombosis and 
atherosclerosis. Finally, systemic administration of NOS inhibitors is not advised because 
they cause motor deficits in mice and rats (Moreno-López, 2010). Feasible tools to improve 
motor function recovery after nerve injury without systemic side effects could involve 
local application of viral vectors. Promising results have been obtained by our group, 
which has reported that intraneural administration of an AVV expressing the dominant 
negative of eNOS (AVV-TeNOS) accelerated and improved motor function recovery after 
XIIth nerve crushing (Sunico et al., 2008). 
To elucidate the role of eNOS, recombinant protein expression has been induced by viral 
transfection. There are different approaches to induce a full or partial “loss of function” 
using viral transgenesis. In this chapter we illustrate the use of a dominant negative protein, 
which interferes with the target protein or its function. To suppress eNOS activity, a 
recombinant AVV was used to express a truncated form of eNOS (TeNOS) under the control 
of the human cytomegalovirus (hCMV) promoter (Kantor et al., 1996). TeNOS, which lacks 
catalytic activity, acts as a dominant negative inhibitor of wild-type eNOS by 
heterodimerization with the native protein (Liu et al., 2011). As a viral control, a 
recombinant AVV was used to express the enhanced green fluorescent protein (eGFP) 
directed by the hCMV (AVV-eGFP). This gene therapy strategy successfully revealed the 
involvement of eNOS from the nucleus tractus solitarii in hypertension of spontaneously 
hypertensive rats (Kasparov et al., 2004; Waki et al., 2003; Waki et al., 2006; Paton et al., 
2007). The expression of proteins under control of the hCMV promoter is characterized by a 
very rapid increase in expression, peaking 10 hr after transfection (Stokes et al., 2003). 
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Furthermore, when AVV-eGFP and AVV-TeNOS were injected in the nervous system, eGFP 
and TeNOS were expressed in glia and endothelial cells 7 days after transduction; 
expression diminished greatly at 14 days after vector injection (Waki et al., 2006). Therefore, 
a single intranerve injection of AVV-TeNOS could be expected to provide effective chronic 
inhibition of eNOS for at least 1 week in the transduced cells. It is noteworthy that this AVV 
did not retrogradely transduce motoneurons when injected into the nerve (Sunico et al., 
2008; Moreno-López, 2010).  
A single intranerve microinjection (3 l) of AVV-TeNOS (2.2 x 1010 infective units/ml) on the 
day of the XIIth nerve crushing accelerated the recovery of neuromuscular transmission, 
resulting in a measurable CMAP 1 week after the damage (Fig. 3). Furthermore, the CMAP 
was fully recovered 22 days after the damage, which is 1 week earlier than in the untreated 
or eGFP transduced animals (Sunico et al., 2008). Stability of recovery was confirmed by the 
recording of a control-like CMAP from animals administered with AVV-TeNOS and studied 
at 62 days post-injury (Fig. 3). These results demonstrated that a single intraneural injection 
of the AVV-TeNOS efficiently accelerates the functional recovery of the neuromuscular 
junction after nerve injury (Sunico et al., 2008). 
In addition, axonal regeneration was increased by AVV-TeNOS administration, compared 
with the AVV-eGFP treated group. Specifically, the number of retrogradely labeled 
motoneurons at 2 days after nerve crushing and intraneural injection of AVV-eGFP was 
significantly lower than that observed with AVV-TeNOS (Fig. 3). The number of 
retrogradely labeled HMNs at 7 days post-lesion in AVV-TeNOS-injected rats was similar to 
the control condition illustrating that AVV administration did not affect motoneuron 
viability (Sunico et al., 2008). Therefore, local eNOS inhibition with AVV-TeNOS speeds up 
neuromuscular functional recovery that is associated with accelerated axonal regeneration, 
among other possible mechanisms. 
2.2.1 Cellular mechanisms that speed up axonal regrowth after nerve injury in AVV-
TeNOS-treated animals 
Schwann cells (SC) play a very important role in promoting axonal regeneration through 
the distal stump. After peripheral nerve axotomy, Wallerian degeneration involves axonal 
degradation as well as myelin breakdown and clearance in the distal stump of the injured 
nerve. For the subsequent axonal regeneration, SC dedifferentiation is required (Jessen & 
Mirsky, 2008). Thus, following nerve axotomy, SCs change from a myelin-producing state 
to a dedifferentiated, proliferating non-myelin-forming state (Stoll & Muller, 1999). In this 
dedifferentiated state, SCs are characterized by the formation of strands called bands of 
Bungner, which are the cellular substrate to guide growing axons, together with the  
up-regulation of several regeneration associated proteins, such as cell adhesion molecules, 
cytokines, neurotrophins, and growth factors that promote axonal regeneration (Araki et 
al., 2001; Stoll & Muller, 1999). More specifically, the growth-associated protein 43 kDa 
(GAP-43) is strongly up-regulated in regenerating axons and in dedifferentiated SCs 
(Curtis et al., 1992; Plantinga et al., 1993; Scherer et al., 1994). As soon as 1 day after 
transection or crushing of sciatic nerve, GAP-43 mRNA is significantly increased in the 
distal stump, remaining at high levels for at least 4 weeks (Plantinga et al., 1993). Thus, 
GAP-43 protein, which is involved in cell shape plasticity and motility (Curtis et al., 1992; 
Scherer et al., 1994), contributes to SC reorganization to form bands of Bungner in the 
degenerative/regenerative processes that take place after nerve injury.  
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facial nerve transection and repair (Wang et al., 2009), positive effects were not obtained 
after XIIth nerve crushing by treatment with 7-NI or aminoguanidine (AG), another iNOS 
inhibitor (Sunico et al., 2008). Strikingly, administration of the relatively specific eNOS 
inhibitor L-N(5)-(l-iminoethyl)ornithine (L-NIO) accelerated the onset of muscle re-
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2008). Contradictions can be explained by differences in the lesion model and in the dose 
and relative specificity of NOS inhibitors (Moreno-López, 2010). In any case, these results 
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the first week after nerve injury. 
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recovery. However, the administration route must be carefully taken into account. NO has 
important roles in the immunological, cardiovascular and nervous systems. Key 
physiological functions, such as learning, platelet aggregation, arterial blood pressure, 
and immune responses, could be disrupted by chronic and systemic NOS inhibition. NOS 
inhibition as a plausible treatment to improve functional recovery after nerve injury must 
bypass unwanted side effects of systemic administration of the inhibitors. The therapeutic 
strategy should entail specific inhibition of the proper NOS isoform that is detrimental to 
nerve regeneration and the selected NOS inhibitor should be locally administered 
(Moreno-López, 2010). Endothelial isoform has been described as having negative effects 
on functional recovery in the traumatic motor nerve injury model (Sunico et al., 2008), 
mainly inhibiting axonal regrowth. Due to the apparent involvement of eNOS in 
vasodilation of blood vessels and platelet aggregation, however, chronic systemic 
treatment with a specific eNOS inhibitor is not advised. Such a treatment can affect 
cardiovascular function, inducing hypertension and increasing the risk of thrombosis and 
atherosclerosis. Finally, systemic administration of NOS inhibitors is not advised because 
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heterodimerization with the native protein (Liu et al., 2011). As a viral control, a 
recombinant AVV was used to express the enhanced green fluorescent protein (eGFP) 
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involvement of eNOS from the nucleus tractus solitarii in hypertension of spontaneously 
hypertensive rats (Kasparov et al., 2004; Waki et al., 2003; Waki et al., 2006; Paton et al., 
2007). The expression of proteins under control of the hCMV promoter is characterized by a 
very rapid increase in expression, peaking 10 hr after transfection (Stokes et al., 2003). 
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Furthermore, when AVV-eGFP and AVV-TeNOS were injected in the nervous system, eGFP 
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expression diminished greatly at 14 days after vector injection (Waki et al., 2006). Therefore, 
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distal stump, remaining at high levels for at least 4 weeks (Plantinga et al., 1993). Thus, 
GAP-43 protein, which is involved in cell shape plasticity and motility (Curtis et al., 1992; 
Scherer et al., 1994), contributes to SC reorganization to form bands of Bungner in the 
degenerative/regenerative processes that take place after nerve injury.  
  






























Fig. 3. Chronic intraneural inhibition of a dominant negative for eNOS using an AVV 
accelerates neuromuscular function recovery and axonal regeneration. (a)-(c) CMAPs 
evoked in the genioglossus muscle by single shock stimulation (arrowheads point to the 
stimulus artifact) of XIIth nerve at 7 (a), 22 (b), or 62 (c) days after intraneural injection of 
AVV-eGFP or AVV-TeNOS. For comparison, recordings obtained by stimulation of the left 
(intact) and right (crushed) XIIth nerve are illustrated. Each trace represents an average of 10 
individual responses. (d), (e) Photomicrographs of coronal sections of the right HN showing 
FluoroGold-labeled motoneurons in animals injected with AVV-eGFP (d) or AVV-TeNOS 
(e) on the crushing day. FluoroGold was applied on day 2 post-crushing and the animals 
were perfused 7 days after retrograde marker application. Scale bar = 100 µm. Figure 
modified from Sunico et al., 2008. © 2008 Elsevier Ltd. 
Given that AVV-TeNOS intraneural injection speeds up motor function recovery after XIIth 
nerve injury (Sunico et al., 2008), SCs were targeted to find out a feasible mechanism by 
which eNOS inhibition could enhance nerve regeneration, with the presumption that 
endothelial NO could be acting as a negative regulator of SC dedifferentiation after nerve 
crushing. To approach this issue, GAP-43 protein was analyzed in this study as a marker of 
regenerative processes, together with the density of SCs and bands of Bungner, in injured 
nerves after intraneural inhibition of eNOS. Indeed, our results indicate that endothelial NO 
confers a delaying action on SC dedifferentiation. As soon as 2 days following crushing of 
XIIth nerve together with AVV-TeNOS microinjection in the distal stump, GAP-43 
immunoreactivity increases compared to control treatment with AVV-eGFP (Fig. 4). The 
reason for this, at least in part, could be an increase in GAP-43-positive cells, presumably 
SCs, after eNOS inhibition. Formation of bands of Bungner is also favored by TeNOS 
(Sunico & Moreno-López, 2010). Thereafter, all these data indicate that eNOS inhibition 
enhances the number of SCs and the subsequent formation of bands of Bungner after 
peripheral nerve injury (Fig. 4). 
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To summarize, negative regulators for myelination, which activates the SC dedifferentiation 
program, involve many extrinsic and intrinsic signals (Jessen & Mirsky, 2008). It is a well 
established fact that injury-related signals from neighboring SCs and neurons accelerate and 
influence SC dedifferentiation in vivo (Jessen & Mirsky, 2008). However, these recent studies 
also identify endothelial NO as a negative regulator of SC dedifferentiation, thus pointing to 
the vascular system as a source of signals that regulate some of the degenerative/regenerative 
processes that take place after peripheral nerve injuries (Sunico & Moreno-López, 2010). For 
this reason, the local endothelium is cautiously proposed in this chapter as a gene therapy 
target in the acute events that take place in peripheral neuropathies, and virally mediated 




















































Fig. 4. TeNOS transgene increases the number of GAP-43 cells and bands of Bungner after 
XIIth nerve crushing. (a)-(c) GAP-43-immunoreactive (a) cells co-identified by Hoechst 
nuclear staining (b); the average number of GAP-43-positive cells (in thousands per cubic 
millimeter) at 4 and 5 mm distal to the injury site receiving the indicated adenoviruses is 
plotted (c). (d) Confocal high-magnification photomicrograph showing GAP-43-positive SCs 
forming two bands of Bunger disposed in parallel. (e)-(g) Confocal micrographs illustrating 
that after AVV-TeNOS injection the re-organization of SCs in bands of Bungner was more 
evident than in AVV-eGFP-treated injured nerves. The average number of bands of Bungner 
(in thousands per cubic millimeter) at 4 and 5 mm distal to the injury site receiving the 
indicated adenoviruses is plotted (g). Scale bars: (a), (b), (d), 10 m; (e), (f), 50 m. *P < 0.05; 
non-parametric Mann-Whitney U test. Figure modified from Sunico & Moreno-López, 2010. 
© 2010 Elsevier Ireland Ltd. 
2.3 Combinatory use of LVVs and AVVs to scrutinize the role of nNOS in central 
events occurring after traumatic nerve injury 
Disconnection of motoneurons from their target myocytes interrupts mutual trophic 
relations, leading to deep alterations in the structural and physiological properties of both 
motoneurons and muscle fibers. Axotomy provokes changes in axonal, synaptic and 
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established fact that injury-related signals from neighboring SCs and neurons accelerate and 
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events occurring after traumatic nerve injury 
Disconnection of motoneurons from their target myocytes interrupts mutual trophic 
relations, leading to deep alterations in the structural and physiological properties of both 
motoneurons and muscle fibers. Axotomy provokes changes in axonal, synaptic and 
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intrinsic membrane properties, including enhanced somato-dendritic excitability, 
decreased axonal conduction speed, considerable loss of afferent synaptic contacts, and 
disorders in the firing properties and recruitment order of motor units (González-Forero 
et al., 2004; 2007). Synapse loss is the major feature underlying cognitive impairment in 
patients and/or animal models of AD, PD, MS, HD, and HIV-related dementia (Sunico et 
al., 2010; Moreno-López et al., 2011). Interestingly, synaptic alteration, rather than 
neuronal death, is the main factor responsible for the age-related downturn in neuronal 
function. Synapse loss also happens in several motor maladies, including ALS, 
progressive muscular atrophy, and traumatically-injured motor axons (Sunico et al., 2005; 
2010). Interestingly, de novo expression of nNOS in motoneurons commonly occurs in 
response to the physical injury of a motor nerve and in the course of ALS. In both 
conditions, this event precedes synaptic withdrawal from motoneurons (Moreno-López et 
al., 2011). Changes in functional properties of injured cells also were prevented using 
various pharmacological agents targeting nNOS. NO-mediated disturbances involve 
changes in intrinsic membrane properties and anatomical synaptic deterioration that 
suggest a major pathological role of nNOS. However, nNOS is only one of the numerous 
proteins dysregulated after nerve damage. Therefore, the actual role for nNOS is less clear 
within the complex scenario created by multiple dysregulated proteins (Montero et al., 
2010). 
In an attempt to scrutinize whether nNOS up-regulation is sufficient to promote 
alterations after axonal injury on motoneurons, we have virally induced de novo 
expression of nNOS in non-axotomized HMNs together with complementary down-
regulation of nNOS expression using virally mediated gene knock-down (Montero et al., 
2010; Sunico et al., 2010). Replication-deficient recombinant AVVs (1010-1011 infective 
units/ml), directing the expression of enhanced green or monomeric red fluorescent 
proteins (eGFP and mRFP, respectively) or nNOS, were injected into the tongue to 
retrogradely transduce HMNs (Fig. 5). AVVs expressed eGFP, mRFP, or nNOS 
downstream the hCMV promoter. The AVV-eGFP and AVV-mRFP vectors were used as 
controls to test virally induced side effects. 
Neonatal HMNs were retrogradely transduced by injecting AVV-nNOS and/or AVV-eGFP 
into the genioglossus muscle. Ratiometric real-time NO imaging was used to record NO 
released around transduced HMNs in response to a glutamatergic stimulus (Fig. 5). For that 
purpose, the NO-sensitive fluorescent probe 1,2-diaminoanthraquinone sulphate (DAA) was 
perfused together with the reference dye Alexa 633. We found that the slope of DAA 
fluorescence increased around eGFP/nNOS-transduced motoneurons in response to 
glutamate, which was prevented by adding the NOS inhibitor L-NAME to the bath. This 
increase of NO created a gradient of concentration around the transduced HMNs, which in 
brain parenchyma showed a space constant of 12.3 µm. Thus, HMNs retrogradely 
transduced with AVV-nNOS express a functional enzyme that synthesizes NO in response 
to glutamatergic stimulation (Montero et al., 2010).    
Retrograde cotransduction of adult HMNs, after injection in the tongue of AVV-
eGFP/AVV-nNOS, induced a significant reduction in their synaptic coverage, as shown by 
immunohistochemistry and electron microscopy. Thus, nNOS transfection mimicked the 
effect of axonal injury on the synaptic coverage of HMNs. In this way, it seems clear that 
NO, synthesized by up-regulated nNOS in adult axotomized motoneurons, is not only 
necessary but also sufficient to trigger the molecular cascade leading to synapse withdrawal 
from HMN perikarya (Sunico et al., 2010; Moreno-López et al., 2011).  
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Fig. 5. AVV transfection of HMNs with functional nNOS. (a) Left, AVV injection into the tip of 
the tongue retrogradely transfected HMNs. Right, an illustrative example of a retrogradely 
cotransduced HMN after injection in the tip of the tongue of AVV-eGFP+AVV-mRFP. (b) 
Merged DIC and eGFP channels showing the tip of a pipette (arrow) ejecting dyes close to an 
eGFP-transfected HMN. The circle indicates the region of interest (ROI) used to construct the 
plot illustrated in (c). (c), (d) Time courses of the DAA/Alexa 633 ratio within a 5 μm diameter 
ROI placed just at the border of transfected HMNs by means of the indicated AVVs before and 
after addition to the perfusate of L-glutamate (500 μM; arrows). Slopes of the regression lines 
adjusted before (Sbglut) and after (Saglut) glutamate addition are indicated in (d). The slope 
increase after Glut application in (d) result from a rise in DAA relative to Alexa fluorescence. 
This indicates that NO synthesized by transduced HMN interacts with the NO-sensitive dye 
DAA. (e) Averaged Saglut–Sbglut was obtained from HMNs transfected with the specified AVVs 
and incubated with the indicated drugs. Drugs were added to the bath 5 min before glutamate. 
Inset, illustration signaling the location of ROIs analyzed per motoneuron. The average of Saglut–
Sbglut was taken as the representative HMN value. Prevention of the slope increase after Glut by 
pre-incubation with the NOS inhibitor L-NAME strongly suggests that the change in the slope 
is mediated by generation of NO. (f) NO gradient in brain tissue surrounding nNOS expressing 
HMNs. Average Saglut–Sbglut was obtained from HMNs transfected with the indicated AVVs 
relative to the distance from the center of the ROI to the motoneuron border. Measures have 
been normalized relative to the value obtained in the ROI nearest to the motoneuron. Inset 
illustrates how ROIs were located for this type of measure. (g) Data presented in (f) were well 
fitted to the exponential decay equation used to calculate the theoretical space constant of the 
NO gradient created around AVV-nNOS transfected motoneurons. Scale bars: 50 μm. Figure 
modified, with permission, from Montero et al., 2010 (a) and Sunico et al., 2010 (b-g). © 2010  
The Physiological Society and Society for Neuroscience, respectively. 
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Fig. 5. AVV transfection of HMNs with functional nNOS. (a) Left, AVV injection into the tip of 
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and incubated with the indicated drugs. Drugs were added to the bath 5 min before glutamate. 
Inset, illustration signaling the location of ROIs analyzed per motoneuron. The average of Saglut–
Sbglut was taken as the representative HMN value. Prevention of the slope increase after Glut by 
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For functional studies we injected AVV directly into the HN (Fig. 6). Five to 7 days after AVV 
administration, numerous neurons were identified as positively transfected at the injection 
site. Besides, a high number of astrocytes were also transfected, as confirmed by co-
immunostaining against the astroglial cell marker glial fibrillary acidic protein (GFAP). 
Inspection of brainstem slices did not reveal eGFP-positive cell bodies in areas that project to 
the HN, such as the ventrolateral reticular formation (VLRF; Fig. 6). This argues against the 


























Fig. 6. Specificity of viral injections and transfections. (a) Schematic diagram of viral 
administration. AVV and LVV were administered into the HN. (b) Epifluorescence 
photomicrograph of a coronal section at the level of the HN obtained 6 days after intranuclear 
injection of AVV-eGFP. Note that injection was almost fully restricted to the HN; cc, central 
canal. (c) Photomicrograph of a coronal section obtained 7 days after viral administration at 
the indicated distance from the injection site showing a broad number of eGFP-expressing 
hypoglossal neurons. At this level a high frequency of co-transfection was observed after 
intranuclear injection of AVV-eGFP/AVV-mRFP (right panels). (d) Low magnification 
photomicrograph of a coronal section at the level of AVV-eGFP injection site, obtained 7 days 
after viral administration. Note the absence of infected neurons in neighboring regions, such as 
the ventrolateral reticular formation (VLRF), which project directly to the HN. Asterisk points 
to the mark that identifies the right side of the brainstem. (e), (f) Photomicrographs from 
coronal sections at the level of the injection place obtained 7 days after intranuclear injection of 
LVV-miR-shRNA/nNOS in untreated animals (e) and those receiving doxycycline (Dox) in the 
drinking water (f). Scale bars: (b), (e), (f) 250 m; (c), (d) 500 m; (c) right panels 100 m. Figure 
modified from Montero et al., 2010. © 2010 The Physiological Society. 
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site. A large number of eGFP-positive neurons were identified, strictly within the HN, 
200-300 m rostrocaudal and ipsilateral to the injection site (Fig 6). Furthermore, astroglia 
was not transduced at these remote locations, as colocalization of eGFP and GFAP was 
absent there (Montero et al., 2010). Therefore, functional tests were performed in these 
areas away from the injection site to minimize any contaminating effects of nNOS 
transduction of astrocytes.  
Unilateral AVV-nNOS microinjection in the HN of adult rats induced axotomy-like changes 
in HMNs such as alterations in axonal conduction properties and reduction in the 
responsiveness to synaptic drive (Montero et al., 2010). In AVV-eGFP-transfected animals, 
as in controls, the majority of HMNs display a characteristic respiratory pattern of bursts of 
action potentials that is synchronized with the inspiratory stage of breathing. In contrast, the 
mean firing rate in basal conditions (ETCO2=4.8-5.2%) was considerably reduced after 
intranuclear microinjection of AVV-eGFP/AVV-nNOS (Fig. 7), likewise 1 week after 
hypoglossal nerve damage (Gonzalez-Forero et al., 2004). This reduction in the mean firing 
rate was prevented by chronic treatment with L-NAME or 7-NI, a relatively specific nNOS 
inhibitor. These results suggest that the reduction in the mean firing rate is evoked by NO 
synthesized by transduced nNOS in the HN.  
To gain specificity in nNOS activity inhibition, we used a neuron-specific LVV to knock-
down nNOS. This LVV system has been recently described (Liu et al., 2008; 2011). Briefly, 
for nNOS knock-down, we used a binary LVV system that requires co-operative action of 2 
viral vectors. The first vector expresses tetracycline-sensitive transactivator Tet-off under 
control of an enhanced synapsin-1 promoter (Liu et al., 2008; 2011). The second LVV harbors 
an expression cassette for a miRNA30 (miR30)-based short hairpin (shRNA) interference 
system (Stegmeier et al., 2005) under control of a Tet-sensitive promoter. The system 
expresses a miRNA30-like hairpin targeting the gene of choice as a fusion with the eGFP, 
which facilitates targeting of the RNA duplex into the RNA-induced silencing pathway. Tet-
off is able to bind tetracycline or similar molecules such as doxycycline (Dox); this renders it 
unable to bind to the Tet-sensitive promoter and blocks the expression of the hairpin (Fig. 6). 
This system is then referred to as LVV-miR-shRNA/nNOS.  
nNOS-induced effects on mean firing rate were fully prevented by administration of  
LVV-miR-shRNA/nNOS before AVV-nNOS injection into the HN, indicating that  
nNOS expression in neurons, but not in glial or endothelial cells, affects mean firing rate 
(Fig 7). 
In physiological conditions, the activity of HMNs increases when the ETCO2 rises, and 
decreases when the ETCO2 lowers. Axonal injury of HMNs induces a decrease in their 
response to chemoreceptor-modulated inspiratory drive (see Fig. 2; González-Forero et 
al., 2004) which was NO-mediated (Sunico et al., 2005). Strikingly, when HMNs are 
transduced with transgenic nNOS, their sensitivity to the chemoreceptor-modulated 
inspiratory drive is dramatically decreased, an alteration that was equivalent to the effects 
of crushing on motoneuron sensitivity to their afferent drive (Fig. 8). Chronic 
administration of L-NAME or 7-NI, as well as LVV-miR-shRNA/nNOS injection, 
protected against the changes in motoneuron sensitivity induced by de novo expression of 
nNOS. Altogether, these findings suggest that nNOS transgene-derived NO is sufficient to 
activate the molecular processes that lead to a decrease in motoneuron sensitivity to their 
afferent inputs. 
NO-mediated synaptic withdrawal from motoneurons is an underlying factor that is at least 
partially responsible for functional changes induced by axonal injury of motoneurons 
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For functional studies we injected AVV directly into the HN (Fig. 6). Five to 7 days after AVV 
administration, numerous neurons were identified as positively transfected at the injection 
site. Besides, a high number of astrocytes were also transfected, as confirmed by co-
immunostaining against the astroglial cell marker glial fibrillary acidic protein (GFAP). 
Inspection of brainstem slices did not reveal eGFP-positive cell bodies in areas that project to 
the HN, such as the ventrolateral reticular formation (VLRF; Fig. 6). This argues against the 


























Fig. 6. Specificity of viral injections and transfections. (a) Schematic diagram of viral 
administration. AVV and LVV were administered into the HN. (b) Epifluorescence 
photomicrograph of a coronal section at the level of the HN obtained 6 days after intranuclear 
injection of AVV-eGFP. Note that injection was almost fully restricted to the HN; cc, central 
canal. (c) Photomicrograph of a coronal section obtained 7 days after viral administration at 
the indicated distance from the injection site showing a broad number of eGFP-expressing 
hypoglossal neurons. At this level a high frequency of co-transfection was observed after 
intranuclear injection of AVV-eGFP/AVV-mRFP (right panels). (d) Low magnification 
photomicrograph of a coronal section at the level of AVV-eGFP injection site, obtained 7 days 
after viral administration. Note the absence of infected neurons in neighboring regions, such as 
the ventrolateral reticular formation (VLRF), which project directly to the HN. Asterisk points 
to the mark that identifies the right side of the brainstem. (e), (f) Photomicrographs from 
coronal sections at the level of the injection place obtained 7 days after intranuclear injection of 
LVV-miR-shRNA/nNOS in untreated animals (e) and those receiving doxycycline (Dox) in the 
drinking water (f). Scale bars: (b), (e), (f) 250 m; (c), (d) 500 m; (c) right panels 100 m. Figure 
modified from Montero et al., 2010. © 2010 The Physiological Society. 
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(Gonzalez-Forero et al., 2004; Sunico et al., 2005; 2010). We have recently reported that de 
novo synthesis of NO, induced by retrograde transduction of HMNs through muscle 
injection of AVV-nNOS, was sufficient to induce a withdrawal of synaptic boutons on 
HMNs (Sunico et al., 2010). This effect came together with a strong decline in the evoked 
excitatory postsynaptic potential on motoneurons in vitro (Sunico et al., 2010). Additionally, 
AVV-nNOS microinjection into the HN induced a reduction in the number of synaptic 
boutons apposed to HMNs, which could be prevented by preceding injection of LVV-miR-
shRNA/nNOS (Fig. 8). Taken together, these observations indicate that main functional 
alterations induced in motoneurons by nNOS transgene expression or axotomy involve NO-
directed synaptic re-arrangements. 
 
 
Fig. 7. AVV-nNOS injection into the HN mimics effects of XIIth nerve crushing on the basal 
firing activity of the HMNs. Representative examples show the discharge activity of HMNs 
recorded at basal conditions (ETCO2 = 4.8–5.2%) at the indicated conditions. For each panel, 
traces are the raw signals (top) of extracellularly recorded spike activity and the histogram 
of instantaneous firing rate (in spikes (sp)/s; bottom). Note that AVV-nNOS induced 
alterations in basal activity of HMNs were prevented by 7-NI or LVV-miR-shRNA/nNOS. 
Figure modified from Montero et al., 2010. © 2010 The Physiological Society. 
In summary, we suggest that de novo expression of nNOS creates a repulsive gradient of NO 
around the motoneurons in an activity-dependent manner that can alter their inherent 
membrane properties as well as their synaptic coating. These results further point to nNOS 
as a pivotal target for the development of tools for the treatment of peripheral neuropathies 
and neurodegenerative disorders characteristically accompanied by central up-regulation of 
nNOS. Additionally, this opens a line of research for a strategy to elucidate the role of 
dysregulated proteins in the neuronal impairment taking place in the course of several 
neuropathological situations. 
Viral Vectors as Tools to Investigate the Role of Dysregulated  


























































































Fig. 8. AVV-nNOS injection into the HN mimics effects of XIIth nerve crushing on the 
chemoreceptor-modulated inspiratory activity of HMNs and on their synaptic coverage. (a) 
Illustrative examples of the time courses of the mean firing rate modulation (mFR, in spikes 
(sp)/s/burst; right y-axis) relative to ETCO2 levels (left y-axis) for HMNs recorded 7 days 
after the injection of the indicated viruses into the HN. Figure modified from Montero et al., 
2010. © 2010 The Physiological Society.  
3. Conclusions 
Dysregulation of protein expression in specific cell populations of the central nervous 
system is a common hallmark in most neurodegenerative diseases. Ideally, this problem 
could be approached by somatic gene delivery targeted to specific cell types within a certain 
nucleus in order to increase or decrease the expression of a particular gene, with a precise 
control over the temporal expression of the transgenes. Transfection of cell lines with 
plasmids is a very efficient process, mainly thanks to the use of specific chemical reagents 
that increase the permeability of the cells. However, transfer of genes into a brain in vivo is 
still a challenging task. Nonetheless, gene delivery into brain cells using viral vectors has 
been successfully performed, even for long-term gene expression (Thomas et al., 2003; 
Papale et al., 2009). Likewise, viral vectors have been successfully used both in vitro and in 
vivo for the delivery of new genomic tools such as small interference RNAs (Snove and 
Rossi, 2006; Paddison, 2008). 
As supported by our outcomes using an experimental model of peripheral neuropathy, the 
re-establishment of a functional gene through the insertion, removal, or modification of 
genes within cells and tissues is a very promising therapeutic alternative to chemicals for the 
treatment of human genetic disorders. Unfortunately, although in theory it could be 
considered as the holy grail, in practice each type of gene therapy still poses many 
challenges for use as a routine medical practice.    
In germ line gene therapy, germ cells can be altered by the insertion of functional genes that 
integrate into their genomes, thus being inherited by later generations. However, numerous 
ethical, religious and technical reasons restrict this for application in human beings. 
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vivo for the delivery of new genomic tools such as small interference RNAs (Snove and 
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As supported by our outcomes using an experimental model of peripheral neuropathy, the 
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genes within cells and tissues is a very promising therapeutic alternative to chemicals for the 
treatment of human genetic disorders. Unfortunately, although in theory it could be 
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In germ line gene therapy, germ cells can be altered by the insertion of functional genes that 
integrate into their genomes, thus being inherited by later generations. However, numerous 
ethical, religious and technical reasons restrict this for application in human beings. 
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Conversely, in somatic gene therapy, the genes are introduced into somatic cells; therefore 
the effects will be restricted to the individual and will not be inherited by the offspring. 
However, we must be especially cautious with the vectors used for the gene delivery, 
particularly when viral vectors are used. Concerns about the risks of AVVs were raised 
during a gene therapy clinical trial in 1999, after an 18-year-old participant, Jesse Gelsinger, 
died because of a massive immune response triggered by the viral vector.  
In our view, gene therapy represents a very promising tool that may ameliorate many 
human genetic diseases and neuropathological conditions accompanied by protein 
dysregulation at the expression and/or functional levels in the future. However, the nature 
of the diseases themselves and their genetic links must be more deeply understood before 
applying gene therapy. In the same way, the biological consequences of gene therapy need 
further evaluation, including its short-range and long-term side effects. Nonetheless, 
although gene therapy is still in its infancy, it has already been used in vivo with some 
success. The recent findings related to the treatment of acquired motor neuropathies 
described in this chapter highlight the therapeutic potential of this novel genetic tool. 
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1. Introduction 
Gene therapy relies on the delivery of therapeutic genes into patients’ cells. The micro-
devices used to reach the cells and to transfer the gene payload are called gene vectors. Viral 
packaging machinery is often utilized to generate the particles transporting the cargo genes. 
Lentiviruses, a subgroup of retroviruses, are highly suitable for remodeling into gene 
transfer vectors because they offer the stability of transgene expression, the ability to reach 
the nuclei of the therapeutically important non-dividing cells and are known to have a low 
immunogenic profile. Well studied members of the lentiviruses include human 
immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2), feline immunodeficiency virus (FIV) 
and equine infectious anemia virus (EIAV). 
It is important not to confuse “gene delivery vectors” and “gene cloning vectors”. While the 
former are microparticles delivering genes, the latter are replicating vehicles for the 
amplification of nucleic acid sequences. “Gene delivery vectors” and “gene cloning vectors” 
coincide when the naked DNA of replicating bacterial plasmids or replication competent 
viruses is used for gene delivery into cells. Viral gene delivery vectors are normally non-
replicating and should correctly be referred to as “viral vectors”, not “viruses”. Particles of 
viral vectors can be referred to as “virions” or “transducing particles”, because viral gene 
transfer is traditionally described as “transduction”.  Replication deficient viral gene vector 
particles are similar to “defective interfering particles”, that is, faulty non-self-viable virions 
arising during natural viral infections and competing with non-defective virions, which 
were described in virology literature many years ago.  
Native lentiviral envelope proteins, which determine the cell range of viral infectivity 
(tropism) and mediate the fusion of viral and cellular membranes, are always composed 
from two non-covalently attached subunits, one of which (e.g. gp41 glycoprotein in HIV-1) 
is membrane-embedded and the other is an external subunit (e.g. gp120 glycoprotein in 
HIV-1).  This arrangement makes lentiviruses notoriously unstable because of their 
tendency to shed the external subunit of the envelope protein. As the virion’s stability is a 
pre-requisite for the effective purification and concentration of viral vector preparations, in 
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lentiviral gene vectors native lentiviral envelope proteins are routinely replaced with stable 
heterologous viral envelope glycoproteins, most commonly G-protein of Vesicular 
Stomatitis Virus (VSV) or, alternatively, G protein of Rabies Virus. Both VSV and Rabies 
Virus belong to the family of rhabdoviruses. VSV-G protein has a broad tropism towards 
lipid membranes while rabies G has a distinct tropism to neural cells. The interchangeable 
use of envelope proteins by viruses belonging to different groups is very common and is 
called “pseudotyping”. Lentiviral vectors can be pseudotyped with many other proteins, 
including artificially designed proteins, in order to improve infectivity for a particular cell 
type or, alternatively, to restrict the viral tropism. The rules of efficient pseudotyping are not 
yet completely clear, but one of the obvious requirements is the ability of the “cytoplasmic 
tails” of the membrane-embedded putative envelope proteins to fit into the available space 
between the viral capsid and the lipid envelope of the virion. Sometimes lentiviral vectors 
are pseudotyped by a cocktail of various viral, cellular or artificial membrane proteins. The 
structure of the lentiviral gene vector virion is presented in Figure 1. 
 
 
Fig. 1. A typical lentiviral vector particle 
Lentiviral vectors are a promising tool for both in vivo and ex vivo gene therapy 
(Srinivasakumar 2001; Maier, von Kalle et al. 2010). These vectors can be used for 
therapeutic strategies relying on both transgene expression and gene correction (Al-Allaf, 
Coutelle et al. 2010). In addition, lentiviral gene vectors are extensively used in basic 
biomedical research to deliver genes for the expression of proteins and RNAs, e.g. shRNAs 
for gene knockdown. Lentiviral gene vectors are also being investigated as vaccines for 
immunization.  
In some situations the use of classical lentiviral vectors can be compounded by the following 
problems: 1) insertional mutagenesis with a potential for malignant transformation; 2) 
relative difficulty of obtaining high titre concentrated viral vector preparations and the 
related problem of transduction inhibitors in the viral preparations; 3) toxicity of the 
commonly used VSV-G envelope protein at high multiplicity of infection; 4) limited insert 
 
Designing Lentiviral Gene Vectors 
 
265 
capacity because of the RNA size packaging constraints specified by the lentiviral Gag 
complex.  
Some of the above problems can be overcome. For example, contamination of lentiviral 
vector preparations with some inhibitors of infection can be avoided by the viral 
preparation concentration and purification by chromatography methods, which can be 
sufficiently gentle in comparison to ultracentrifugation based methods, which often result in 
a substantial fraction of the viral vector particles becoming inactivated. The reduction of  
viral vector losses during concentration is important, in particular because defective virions 
can compete with the functional virions and inhibit transduction  (Geraerts, Willems et al. 
2006). Perhaps the most dramatic improvement of the lentiviral vectors was the introduction 
of non-integrating lentiviral vectors, which do not cause genomic mutations arising via the 
random genomic integration of the classical lentiviral vectors (Section 5 of this review). 
Lentiviral vectors can be assembled through transient co-transfection of the lentiviral vector 
backbone plasmid with helper plasmids expressing viral packaging functions or by stably 
transfected packaging cell lines. The first production method is currently a preferred choice 
because of its greater flexibility. A small undesirable possibility of reconstitution of the 
replication competent virus in the cells used for the lentiviral vector packaging can 
compromise safety. So, the chances of formation of a complete viral genome are customarily 
reduced by splitting genes for helper packaging functions between separate plasmids. For 
example, a common three-plasmid transient co-transfection packaging system employs a 
helper plasmid with genes for the structural Gag polyprotein, the catalytic GagPol 
polyprotein and the accessory HIV-1 Rev and Tat proteins (e.g. psPAX2) plus a helper 
plasmid for an envelope protein (e.g. VSV-G plasmid pMD2G). In a four-plasmid packaging 
system the genes for the Gag and GagPol functions on the one hand and the Rev function on 
the other hand are split between two different helper plasmids (with the Tat function 
missing altogether). Universally used cell lines for the packaging of lentiviral vectors in 
transient co-transfection are HEK293 cell line and its derivatives. HEK293 cells were 
produced by selecting an individual immortalised clone among a mixed population of 
human embryonic kidney cells transformed with DNA fragments of adenovirus type 5. 
HEK293 cells can be efficiently transfected by the calcium phosphate method, protocols 
involving cationic lipids (e.g. Fugene 6 and Fugene HD) or electroporation. Contamination 
of plasmid DNA with co-purifying bacterial lypopolysaccharides should be avoided, as 
these endotoxins can substantially reduce the efficiency of transfection. HEK293T cells, 
which were derived from HEK293 cells and stably express large Simian Virus 40 (SV40) 
large T-antigen, are purported to generate retroviral and lentiviral vector preparations with 
particularly high titres. Thus, at present HEK293T and closely related HEK293FT cells are 
predominantly used for lentiviral vector production via transient co-transfection of the 
backbone vector plasmid and the helper plasmids. The abundance of lentiviral vector 
genomic RNA and levels of expression of VSV-G protein, Gag and GagPol polyproteins plus 
the accessory protein Rev in the packaging cells are of paramount importance for the 
resultant lentiviral vector titre. The ratio of a lentiviral backbone vector plasmid DNA and 
non-vector helper packaging plasmids is used to regulate the relative amount of genomic 
RNA and packaging proteins. In part, the optimal balance depends on the known toxicity of 
the excess VSV-G protein to mammalian cells. Clontech-Takara and ThermoFisherScientific-
OpenBiosystems offer mixtures of plasmids with tetracycline-inducible expression of the 
trans-acting packaging functions. As an alternative to plasmids, adenoviral vectors (Kuate, 
Stefanou et al. 2004) or baculoviral vectors (Lesch, Laitinen et al. 2011) can be used to deliver 
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DNA cassettes for the transient expression of lentiviral packaging proteins and the lentiviral 
vector backbone modules. Clearly, this method can broaden the range of cell lines suitable 
for lentiviral packaging, as receptors for adenoviruses are commonly expressed by different 
types of cells.  
The process of cell transduction by a viral vector follows the infection pathway of the 
cognate virus. There are several parameters characterizing the transduction of cells with a 
viral vector. Firstly, efficiency of transduction, defined as percentage of transduced cells out 
of all cells treated with a viral vector preparation, is a common and readily-obtained read-
out quantity in transduction experiments. The second commonly used parameter is end-
point titre, which is the number of “transduction units” per volume of the viral vector 
preparation with the number of transduced cells (corresponding to the “transduction units”) 
estimated when one of the highest dilutions of the viral preparation is used to infect the 
cells. The third important parameter describing transduction by a viral vector is the 
multiplicity of infection, that is, the average number of functional transducing particles 
infecting one cell. The infection of a cell by a lentiviral vector normally results in the 
establishment of one or several copies of the corresponding provirus. The efficiency of the 
transduction of the cell population by a retroviral vector, which is a function of the 
multiplicity of infection, correlates with a number of proviruses in the genome of the 
infected cell (Kustikova, Wahlers et al. 2003). Thus, the obtained transgene copy number 
reflects the multiplicity of infection. Expression of retroviral envelope proteins is known to 
block superinfection (i.e. extra-infection by the same virus) of the infected cells through the 
depletion of the cognate cellular receptor molecules during their intracellular transport. This 
mechanism, though, does not apply to VSV-G protein pseudotyped lentiviral vectors, which 
neither have protein cellular receptors, nor code for an envelope protein under typical 
circumstances. Therefore, it is possible to increase the number of the lentiviral vector 
proviruses and, hence, transgene copy number by repeated rounds of superinfection.  
As an alternative to gene delivery with packaged lentiviral vectors, the cargo genes within 
lentiviral vector DNA sequences can be transferred in situ “on the back” of other viral gene 
vectors, such as adenoviral or herpes virus based vectors. These, “dual-viral systems”, e.g. 
adenovirus-retrovirus hybrid vectors, can deliver attenuated lentiviral vectors competent for 
replication and packaging in order to achieve “a booster effect” due to lentiviral vector 
spread in situ (Dalba, Bellier et al. 2007). In addition, such delivery systems allow for the 
exploitation of the cellular tropism of some well-established non-lentiviral vectors, 
particularly vectors based on non-enveloped viruses which lack membrane-imbedded anti-
receptors suitable for pseudotyping (Soifer, Higo et al. 2002).  
The stable maintenance of lentiviral vectors makes them a highly suitable tool for various 
cell-fate mapping studies and also as sensors of cell differentiation. Tracing cells with a 
specific differentiation status is important in biomedical research, e.g. in stem cell studies 
(Gallo, Grimaldi et al. 2008). The packaging size constraints make it a challenge to avoid 
cross-talk between various elements within lentiviral vectors and, therefore, require the 
thoughtful design of lentiviral vectors with tissue specific transgene expression (Hager, 
Frame et al. 2008).  
2. Elements of lentiviral vector backbone plasmids 
The lentiviral vector genome has the size of about 10 kb and can be conveniently amplified 
by cloning its complete or partial DNA copy in the bacterial plasmid cloning vectors. Such 
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lentiviral vector  backbone plasmids are similar to other vector plasmids for mammalian 
gene expression, which were recently reviewed (Tolmachov 2009). The immediate purpose 
of the lentiviral vector backbone plasmid is to serve as a template for the transcription 
generating viral vector genomic RNA, which can be packaged into the lentiviral vector 
particles. The bacterial portion of the vector plasmid is not transcribed and, therefore, is not 
included in the genomic RNA of the viral vector. Thus, a typical lentiviral vector backbone 
plasmid consists of a bacterial plasmid portion, lentiviral elements required for viral vector 
RNA packaging and intracellular transport, a marker gene and/or a cargo gene and 
elements for their regulation, optional chromatin-control elements and sites for convenient 
plasmid DNA re-engineering (Figure 2). 
 
 
CMVp – the immediate early CMV promoter; delta 5’-LTR and delta 3’-LTR – the long terminal repeats 
with some deletions; Psi & RRE – the packaging sequence ψ and the Rev Response Element (RRE); 
PGKp – the mouse phosphoglycerol kinase promoter; EGFP-NLS – the gene for nuclear targeted 
enhanced GFP protein; ori-pMB1 – the multicopy origin of replication originating from the wild type 
plasmid pMB1; Ap-R – the ampicillin resistance marker, the gene for β-lactamase. 
Fig. 2. A typical lentiviral vector backbone plasmid 
Evolution has shaped both bacterial plasmid and viral genomes as mosaic assemblies, which 
can be disassembled into individual functional units that can then be assembled back into new 
chimeras. Thus, the genomes of lentiviral vectors consist of a number of genetic elements, of 
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lentiviral vector  backbone plasmids are similar to other vector plasmids for mammalian 
gene expression, which were recently reviewed (Tolmachov 2009). The immediate purpose 
of the lentiviral vector backbone plasmid is to serve as a template for the transcription 
generating viral vector genomic RNA, which can be packaged into the lentiviral vector 
particles. The bacterial portion of the vector plasmid is not transcribed and, therefore, is not 
included in the genomic RNA of the viral vector. Thus, a typical lentiviral vector backbone 
plasmid consists of a bacterial plasmid portion, lentiviral elements required for viral vector 
RNA packaging and intracellular transport, a marker gene and/or a cargo gene and 
elements for their regulation, optional chromatin-control elements and sites for convenient 
plasmid DNA re-engineering (Figure 2). 
 
 
CMVp – the immediate early CMV promoter; delta 5’-LTR and delta 3’-LTR – the long terminal repeats 
with some deletions; Psi & RRE – the packaging sequence ψ and the Rev Response Element (RRE); 
PGKp – the mouse phosphoglycerol kinase promoter; EGFP-NLS – the gene for nuclear targeted 
enhanced GFP protein; ori-pMB1 – the multicopy origin of replication originating from the wild type 
plasmid pMB1; Ap-R – the ampicillin resistance marker, the gene for β-lactamase. 
Fig. 2. A typical lentiviral vector backbone plasmid 
Evolution has shaped both bacterial plasmid and viral genomes as mosaic assemblies, which 
can be disassembled into individual functional units that can then be assembled back into new 
chimeras. Thus, the genomes of lentiviral vectors consist of a number of genetic elements, of 
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which lentiviral elements per se are only a fraction (often less than 30% of the vector genome). 
Lentiviral sequences essential for lentiviral gene vectors are Long Terminal Repeats (LTRs, 
which can be complete or partially deleted) for proviral integration and the packaging ψ 
sequence within the genome region proximal to the 5’-LTR. A viral life cycle involving tight 
nucleic acid packaging into protein shells (capsids) requires compactness from the viral genetic 
elements. Thus, terse genetic elements from various unrelated viruses are particularly suitable 
for employment within lentiviral vector constructs. Various cargo genes can be delivered with 
lentiviral vectors. Because of the lentiviral packaging size constraints, the shorter, cDNA-
based, versions of the genes are normally preferable. As the space within the lentiviral capsid 
is limited, one would only include an intron within a lentiviral vector born cargo gene if it 
provides an important regulatory function for the gene’s expression.  
Other regulatory genetic elements within lentiviral vectors include viral or cellular 
promoters and enhancers, splicing control elements if an intron is included, RNA stabilizing 
components like Woodchuck hepatitis virus Post-transcriptional Regulatory Element 
(WPRE) and, with a pinch of salt, polyadenylation signals (see discussion in Section 2.4). 
Thus, the lentiviral vector backbone plasmid normally includes a bacterial plasmid segment, 
cis-elements of the lentiviral packaging machinery and an elective strong promoter to drive 
the synthesis of lentiviral vector’s genomic RNA, cargo genes (e.g. marker genes, 
therapeutic genes) and genetic elements for their control. Optionally, lentiviral vector 
backbone plasmids can also contain sites for efficient transport of vector RNA from nucleus, 
for episomal maintenance of proviruses, site-specific genomic integration and also sites 
alleviating plasmid manipulation, e.g. polylinkers with restriction enzyme recognition sites. 
2.1 Bacterial plasmid segment  
Lentiviral vector backbone plasmids are propagated in bacteria and hence need to contain a 
bacterial origin of replication to drive the DNA amplification.  Plasmid origins of replication 
are traditionally classified into a “stringent control of the plasmid copy number” group and 
a “relaxed control of the plasmid copy number” group. High number of plasmid copies per 
cell, which is typical for the “relaxed control” group, insures the high yield of the plasmid 
DNA. However a high plasmid copy number can place substantial stress onto the host cells, 
thereby decreasing their growth rate and, thus, resulting in occasional accumulation of cells 
with the shortened, “deletion”, plasmid mutants or cells lacking the plasmid altogether.  In 
contrast, replicons from a “stringent control” group have a lower number of plasmid copies 
per cell and hence comparatively small plasmid DNA yields, however plasmids driven by 
these replicons only rarely place a selective disadvantage onto their host cells. In addition, 
stable maintenance of the stringent control replicons is insured by their “partition” 
functions, which are responsible for the faithful distribution of plasmids between daughter 
cells after cell divisions. Classic relaxed control replicons are derived from plasmids ColE1 
and pMB1, while typical stringent control replicons originate from plasmids RSF1010, 
pSC101, F-factor, and bacteriophage P1.  A particularly convenient replication system, 
which is used in the lentiviral vector backbone plasmids, is borrowed from the plasmid R6K. 
This plasmid has several origins of replication, all dependent on the Π-protein encoded by 
the plasmid’s pir gene. Thus, a lentiviral backbone plasmid with R6Kγ replicon can replicate 
only in the bacterial strains expressing the Π-protein. The copy number of ori-R6Kγ-driven 
plasmids can be increased substantially if the plasmid is transferred to an array of strains 
expressing various “copy-up” mutant versions of the Π-protein, thus giving the flexibility to 
choose the optimal copy number for a particular lentiviral backbone plasmid. 
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To select bacterial tranformants during plasmid modifications and to prevent plasmid loss 
using selective pressure for plasmid-containing cells, the bacterial plasmid segment should 
include a suitable selection marker. The standard solution is to employ an antibiotic 
selection gene such as the ampicillin resistance gene for β-lactamase or the chloramphenicol 
resistance gene for chloramphenicol acetyl transferase. Large scale preparations of plasmid 
DNA with antibiotic resistance genes might lead to the undesirable escape of these genes 
into environment. Thus, genetic systems, which rely on a short RNA-expressing gene as a 
plasmid selection marker, can be contrived (Luke, Carnes et al. 2009).  
Regrettably, it is relatively common for lentiviral vector backbone plasmids to suffer from 
structural and maintenance instability in bacteria. There are several common factors 
contributing to this instability. Lentiviral vector backbone plasmids are necessarily greater 
than 9 kb in size; if their replication is driven by a replication origin with “relaxed 
control” of the plasmid copy number, spontaneously arising deletion mutants have a 
propensity to replicate faster and, as a result, tend to establish dominance in the mixed 
plasmid population. Plasmid deletions can occur through homologous or illegitimate 
recombination between inverted repeats of the lentiviral LTRs. A mosaic of eukaryotic 
sequences within the lentiviral vector backbone plasmid might contain cryptic bacterial 
promoters, which could be able to drive the expression of toxic RNAs and polypeptides 
creating a negative selection pressure on the population of bacterial cells harbouring the 
desired plasmids. It should be noted that the ampicillin resistance gene coding for β-
lactamase, which is often used in the commercially available lentiviral backbone plasmids 
as a selection marker, is poorly suited for long-term bacterial selection in liquid cultures. 
This is because wild type β-lactamase is secreted in Escherichia coli and can destroy 
ampicillin before the bacterial culture is fully grown. Thus, if a particular lentiviral 
backbone plasmid would have a maintenance problem, the overgrowth of plasmidless 
cells in liquid culture would not be stopped by ampicillin. In such a situation, the use of 
alternative non-ampicillin-based selection marker is recommended. Alternatively, as 
much bacterial cultivation as possible should be performed on a solid agar medium 
containing ampicillin, where the spread of ampicillin-destroying β-lactamase is slower. 
For example, a seeding stock for a liquid plasmid maxi-preparation culture can be grown 
from an individual colony on agar plates with ampicillin instead of a liquid overnight 
culture. Non-secreted, cytosolic, mutant versions of β-lactamase were described and can 
be used for efficient selection of bacteria harbouring maintenance-compromised lentiviral 
vector backbone plasmids.  
2.2 Cis-acting elements of the lentiviral molecular machinery 
The standard purpose of lentiviral vector backbone plasmids is to provide a template for the 
synthesis of lentiviral vector genomic RNA, which can be successfully packaged into lentiviral 
vector virions, reverse transcribed and integrated within the cellular genome. The Ψ-sequence 
close to the 5’-LTR is strictly required for the packaging of RNA by the Gag polyprotein. A 
substantial portion of the sequences within the LTRs of the lentiviral genome is required for 
chromosomal integration. However, some sequences within the LTRs can be removed without 
reduction in the integration efficiency. Wild-type retroviral and lentiviral genomes contain a 
promoter within their 5’-LTR to drive expression of genomic RNA. The promoter sequences 
can be deleted from the 5’-LTR DNA segment in the lentiviral vector backbone plasmids and a 
strong constitutive promoter capable of directing synthesis of the vector genomic RNA, e.g. 
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which lentiviral elements per se are only a fraction (often less than 30% of the vector genome). 
Lentiviral sequences essential for lentiviral gene vectors are Long Terminal Repeats (LTRs, 
which can be complete or partially deleted) for proviral integration and the packaging ψ 
sequence within the genome region proximal to the 5’-LTR. A viral life cycle involving tight 
nucleic acid packaging into protein shells (capsids) requires compactness from the viral genetic 
elements. Thus, terse genetic elements from various unrelated viruses are particularly suitable 
for employment within lentiviral vector constructs. Various cargo genes can be delivered with 
lentiviral vectors. Because of the lentiviral packaging size constraints, the shorter, cDNA-
based, versions of the genes are normally preferable. As the space within the lentiviral capsid 
is limited, one would only include an intron within a lentiviral vector born cargo gene if it 
provides an important regulatory function for the gene’s expression.  
Other regulatory genetic elements within lentiviral vectors include viral or cellular 
promoters and enhancers, splicing control elements if an intron is included, RNA stabilizing 
components like Woodchuck hepatitis virus Post-transcriptional Regulatory Element 
(WPRE) and, with a pinch of salt, polyadenylation signals (see discussion in Section 2.4). 
Thus, the lentiviral vector backbone plasmid normally includes a bacterial plasmid segment, 
cis-elements of the lentiviral packaging machinery and an elective strong promoter to drive 
the synthesis of lentiviral vector’s genomic RNA, cargo genes (e.g. marker genes, 
therapeutic genes) and genetic elements for their control. Optionally, lentiviral vector 
backbone plasmids can also contain sites for efficient transport of vector RNA from nucleus, 
for episomal maintenance of proviruses, site-specific genomic integration and also sites 
alleviating plasmid manipulation, e.g. polylinkers with restriction enzyme recognition sites. 
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are traditionally classified into a “stringent control of the plasmid copy number” group and 
a “relaxed control of the plasmid copy number” group. High number of plasmid copies per 
cell, which is typical for the “relaxed control” group, insures the high yield of the plasmid 
DNA. However a high plasmid copy number can place substantial stress onto the host cells, 
thereby decreasing their growth rate and, thus, resulting in occasional accumulation of cells 
with the shortened, “deletion”, plasmid mutants or cells lacking the plasmid altogether.  In 
contrast, replicons from a “stringent control” group have a lower number of plasmid copies 
per cell and hence comparatively small plasmid DNA yields, however plasmids driven by 
these replicons only rarely place a selective disadvantage onto their host cells. In addition, 
stable maintenance of the stringent control replicons is insured by their “partition” 
functions, which are responsible for the faithful distribution of plasmids between daughter 
cells after cell divisions. Classic relaxed control replicons are derived from plasmids ColE1 
and pMB1, while typical stringent control replicons originate from plasmids RSF1010, 
pSC101, F-factor, and bacteriophage P1.  A particularly convenient replication system, 
which is used in the lentiviral vector backbone plasmids, is borrowed from the plasmid R6K. 
This plasmid has several origins of replication, all dependent on the Π-protein encoded by 
the plasmid’s pir gene. Thus, a lentiviral backbone plasmid with R6Kγ replicon can replicate 
only in the bacterial strains expressing the Π-protein. The copy number of ori-R6Kγ-driven 
plasmids can be increased substantially if the plasmid is transferred to an array of strains 
expressing various “copy-up” mutant versions of the Π-protein, thus giving the flexibility to 
choose the optimal copy number for a particular lentiviral backbone plasmid. 
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To select bacterial tranformants during plasmid modifications and to prevent plasmid loss 
using selective pressure for plasmid-containing cells, the bacterial plasmid segment should 
include a suitable selection marker. The standard solution is to employ an antibiotic 
selection gene such as the ampicillin resistance gene for β-lactamase or the chloramphenicol 
resistance gene for chloramphenicol acetyl transferase. Large scale preparations of plasmid 
DNA with antibiotic resistance genes might lead to the undesirable escape of these genes 
into environment. Thus, genetic systems, which rely on a short RNA-expressing gene as a 
plasmid selection marker, can be contrived (Luke, Carnes et al. 2009).  
Regrettably, it is relatively common for lentiviral vector backbone plasmids to suffer from 
structural and maintenance instability in bacteria. There are several common factors 
contributing to this instability. Lentiviral vector backbone plasmids are necessarily greater 
than 9 kb in size; if their replication is driven by a replication origin with “relaxed 
control” of the plasmid copy number, spontaneously arising deletion mutants have a 
propensity to replicate faster and, as a result, tend to establish dominance in the mixed 
plasmid population. Plasmid deletions can occur through homologous or illegitimate 
recombination between inverted repeats of the lentiviral LTRs. A mosaic of eukaryotic 
sequences within the lentiviral vector backbone plasmid might contain cryptic bacterial 
promoters, which could be able to drive the expression of toxic RNAs and polypeptides 
creating a negative selection pressure on the population of bacterial cells harbouring the 
desired plasmids. It should be noted that the ampicillin resistance gene coding for β-
lactamase, which is often used in the commercially available lentiviral backbone plasmids 
as a selection marker, is poorly suited for long-term bacterial selection in liquid cultures. 
This is because wild type β-lactamase is secreted in Escherichia coli and can destroy 
ampicillin before the bacterial culture is fully grown. Thus, if a particular lentiviral 
backbone plasmid would have a maintenance problem, the overgrowth of plasmidless 
cells in liquid culture would not be stopped by ampicillin. In such a situation, the use of 
alternative non-ampicillin-based selection marker is recommended. Alternatively, as 
much bacterial cultivation as possible should be performed on a solid agar medium 
containing ampicillin, where the spread of ampicillin-destroying β-lactamase is slower. 
For example, a seeding stock for a liquid plasmid maxi-preparation culture can be grown 
from an individual colony on agar plates with ampicillin instead of a liquid overnight 
culture. Non-secreted, cytosolic, mutant versions of β-lactamase were described and can 
be used for efficient selection of bacteria harbouring maintenance-compromised lentiviral 
vector backbone plasmids.  
2.2 Cis-acting elements of the lentiviral molecular machinery 
The standard purpose of lentiviral vector backbone plasmids is to provide a template for the 
synthesis of lentiviral vector genomic RNA, which can be successfully packaged into lentiviral 
vector virions, reverse transcribed and integrated within the cellular genome. The Ψ-sequence 
close to the 5’-LTR is strictly required for the packaging of RNA by the Gag polyprotein. A 
substantial portion of the sequences within the LTRs of the lentiviral genome is required for 
chromosomal integration. However, some sequences within the LTRs can be removed without 
reduction in the integration efficiency. Wild-type retroviral and lentiviral genomes contain a 
promoter within their 5’-LTR to drive expression of genomic RNA. The promoter sequences 
can be deleted from the 5’-LTR DNA segment in the lentiviral vector backbone plasmids and a 
strong constitutive promoter capable of directing synthesis of the vector genomic RNA, e.g. 
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immediate early CMV promoter, can be placed externally to the bracket of the lentiviral 
sequences within the plasmids. As the accessory lentiviral protein Tat is required for the 
activation of the promoter within the wild type 5’-LTR of HIV-1, the use of an external 
promoter for genomic RNA synthesis allows exclusion of the Tat gene from the packaging 
system with the consequent reduction in the probability for the re-constitution of the 
replication competent virus and the corresponding improvement in safety (Dull, Zufferey et al. 
1998). A substantial fraction of the currently used lentiviral vectors are “self-inactivating” 
(SIN) due to a deletion within their 3’-LTR. Indeed, as the DNA-copy of the 5’-LTR of the 
vector provirus is always synthesized by reverse transcription from the template of the 3’-LTR, 
proviruses of the SIN vectors lack sequences required for the re-constitution of the lentiviral 
promoter within the 5’-LTR segment of the vector provirus and the synthesis of the lentiviral 
vector genomic RNA from the provirus template. Thus, the SIN-vectors cannot be re-
distributed from the target cells, which is beneficial for their safety profile.  
Lentiviruses possess molecular machinery to enter into the nuclei of postmitotic, non-
dividing cells with an intact nuclear envelope. Lentiviral nuclear-penetration apparatus is in 
part dependent on the triple-stranded structure created during reverse transcription of the 
lentiviral genomic RNA, “the central DNA flap” (Riviere, Darlix et al. 2010). Central 
Polypurine Tract (cPPT) and Central Termination Sequence (CTS) are required for the 
formation of “the flap”. Therefore, DNA sequences for cPPT and CTS need to be present in 
the plasmid template of the nuclear penetrating lentiviral vectors. 
Rev protein of HIV-1 is known to increase lentiviral vector titres by promoting the export of 
genomic RNA from the nucleus. This export depends on the Rev Response Element (RRE) 
sequence within genomic RNA. Therefore, the RRE sequence is a desirable building block 
for inclusion into the lentiviral vector backbone plasmids. 
2.3 Marker genes for mammalian cells 
The concentration of lentiviral vector particles can be assessed by their ability to transduce 
cells and by physical measurements estimating the number of virions in a volume. A 
substantial number of virions in lentiviral preparations can be infection defective, so 
transduction data are vital for the evaluation of the titre of functional lentiviral vector particles. 
Convenient markers for the assessment of efficiency of transduction and for the fate mapping of 
transduced cells include genes for fluorescent proteins, drug resistance proteins, luciferase and 
cell surface antigens. More practical markers are easily detected in live cells, while others 
require fixation of the live material. Enzyme coding genes, such as the lacZ gene for bacterial β-
galactosidase, can be used as transduction markers, but lost some of their initial popularity 
because of the need to fix and, thus, to kill the transduced cells before colour reaction with 
enzymatic substrates. In addition, the lacZ gene is large (3075 bp), and occupies a substantial 
portion of the permissible payload size within lentiviral vectors. Similarly, detection of 
intracellular proteins by immunostaining requires cells to be killed by permeabilization of their 
membranes and fixation. Thoughtful choice of the viral vector marker is important for the 
straightforward collection of data and their faithful interpretation. Most marker proteins are 
small and do not illicit a substantial immune reaction in vivo. It is important to plan a 
convenient intracellular localization of the marker proteins as this can affect their activity and 
can minimize background signal. Genetic determinants used to direct proteins to a specific 
subcellular compartment include nuclear localization signals (NLS), chromosome binding 
moieties (e.g. histon H2B) and domains for plasma membrane association, endoplasmic 
 
Designing Lentiviral Gene Vectors 
 
271 
reticulum retention, targeting to mitochondria, peroxisomes, Golgi-apparatus, actin filaments 
and microtubules. Fused signal sequences or protein domains must not interfere with the 
marker protein multimer formation if the quaternal protein structure is required for its activity. 
Drug resistance (normally antibiotic resistance) genes are especially suitable for tasks 
requiring the establishment of stably transduced cell clones originating from individual 
transduced cells. The choice of a particular drug resistance gene can be affected by its size. 
The gene for blasticidin resistance, bsr, is 423 bp long and is particularly compact. In 
contrast, the gene for hygromycin resistance is 1038 bp long, and, therefore, is a less 
attractive choice if the available space within the lentiviral vector is limited. Different drugs 
cause cell death with dissimilar rates and their minimal inhibitory concentrations vary for 
different types of cells. The number of surviving transduced cell clones is typically higher at 
lower drug concentrations. Other frequently used antibiotic resistance markers include 
genes for resistance to zeocin, puromycin and neomycin analogue G418. Drug sensitivity 
genes, such as HSV thymidine kinase (TK), can also be delivered by lentiviral vectors. These 
genes are highly instrumental for cell suicide systems in cancer gene therapy, but are 
difficult to use as transduction markers.  
Fluorescent proteins are remarkably convenient as gene transfer markers because they can 
be detected both in live and fixed cells. The largest family of fluorescent proteins originates 
from the green fluorescent protein (GFP) of jellyfish Aequoria victoria.  Systematic protein 
engineering efforts produced mutant derivatives of GFP with increased brightness and 
widely different excitation and emission spectra (e.g. blue, cyan and yellow fluorescent 
proteins). Similarly, dsRed protein of coral Discosoma sp. was used to create a family of 
proteins including the orange fluorescent protein mOrange and the far-red fluorescent 
protein E2-Crimson. A number of specialized versions of fluorescent proteins were 
obtained, e.g. reduced half-life GFP for the collection of dynamic gene expression data. 
Fluorescently activated cell sorting (FACS) is the method of choice both for analytical 
analysis of the transduced fluorescent cells and for their preparative isolation. Fluorescence-
based microscopy is another convenient and informative method; however, 3-D imaging of 
fluorescent material is complicated by the extinction of both excitation and emission light in 
the thick slices. Still, the image data collected from thin slices can be assembled into 3-D 
images using computational algorithms. Computational algorithms can be also applied for 
“image de-convolution” in order to achieve some improvement of image quality using 
fluorescence data obtained directly on the thick specimens. 
The titre of a lentiviral vector depend to a large degree on the type of the marker used for 
analysis. Indeed, the titre determined by detecting the fluorescent transduction markers is 
usually higher than the titre obtained by counting drug resistant cell clones.  
Genes for luminescence proteins can be transferred by lentiviral vectors and used as cell 
tracers (Reumers, Deroose et al. 2008). Luciferases from North American firefly Photinus 
pyralis and sea pansy Renilla reniformis are commonly used. The two luciferases use different 
substrates for light production, this can be exploited to create internal control for 
luminescence in “dual luciferase reporter assays” used, e.g., for promoter strength testing or 
shRNA/siRNA analysis. The “baseline” luciferase marker (normally Renilla luciferase) can 
be delivered for expression on a separate vector or on the same vector. A version of firefly 
luciferase with enhanced expression in mammalian cells (luc2) was developed by Promega 
by codon optimization (as discussed in Section 2.4) and elimination of predicted 
transcription factor binding sites within the reporter gene sequence. On the basis of luc2, 
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immediate early CMV promoter, can be placed externally to the bracket of the lentiviral 
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portion of the permissible payload size within lentiviral vectors. Similarly, detection of 
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substrates for light production, this can be exploited to create internal control for 
luminescence in “dual luciferase reporter assays” used, e.g., for promoter strength testing or 
shRNA/siRNA analysis. The “baseline” luciferase marker (normally Renilla luciferase) can 
be delivered for expression on a separate vector or on the same vector. A version of firefly 
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by codon optimization (as discussed in Section 2.4) and elimination of predicted 
transcription factor binding sites within the reporter gene sequence. On the basis of luc2, 
  
Viral Gene Therapy 
 
272 
Promega developed luciferases with a higher rate of degradation such as luc2P (containing 
PEST protein degradation signal (“degron”) on the C-terminus or luc2CP (containing CL1 
and PEST protein degrons on the C-terminus). PEST is a 40 amino acid sequence present in 
the C-terminal region of mouse ornithine decarboxylase. CL1 is a 16 amino acid degron 
from yeast. This signal was also optimized for expression in mammalian cells. Versions of 
luciferase with the degradation signals improve responsiveness to factors enhancing or 
inhibiting luciferase expression. Other specialized versions of luciferases are available. For 
example, secreted firefly luciferase is convenient to measure the luciferase activity of live 
cells in tissue culture. Renilla luciferase-neoR fusion protein was generated and can be used 
for both cell clone selection and as an internal luminescence control. In vivo “whole animal” 
detection of luminescence is a common approach with no excitation light being required and 
with the efficient amplification of emitted photons. However, low spatial resolution limits 
due to light dispersion in the animal restrict the expediency of this approach. 
Surface antigen markers, e.g. extracellular domain of CD4, truncated low-affinity nerve 
growth factor (LNGFR) or truncated mouse MHC class I molecule H-2Kk can be used as cell 
markers for antibody-mediated conjugation with paramagnetic particles, which can be used 
for both magnetic cell sorting and magnetic resonance imaging (So, Hotee et al. 2005). The 
intracellular domains of these proteins are removed to avoid signal transduction and the 
extracellular domains are supplied with GPI-lipidation signal for plasma-membrane 
anchoring (as in Miltenyi Biotec MAC SelectTM system). Background signal during whole-
animal imaging can be avoided by using species-specific monoclonal antibodies for the cell 
surface marker proteins in a heterologous host organism. 
2.4 Genetic elements for controlling the expression of marker genes and cargo genes 
in lentiviral vectors 
In general, cis-acting elements strictly required for gene expression in eukaryotes are a 
minimal promoter and a transcription terminator. Genes coding for proteins (cistrons) also 
necessarily contain: 1) the translation start codon ATG with the surrounding Kozak consensus 
sequence controlling translation initiation; 2) the protein coding sequence; 3) the stop codon.  
Protein-encoding genes are transcribed by eukaryotic Polymerase II from Polymerase II 
specific promoters. The sequence of the Polymerase II promoters is variable; however, “TATA-
box” with the consensus sequence 5’-TATAAAA-3’ is normally found 20-25 bp upstream of 
the transcription start site. In addition, minimal Polymerase II promoters often contain “CAT-
box” with the consensus sequence 5’-GGCCAATCT-3’ at the position -70 relative to the 
transcription start site. The Kozak consensus sequence is important for expression of protein-
coding transgenes born on lentiviral vectors. The DNA template for one of the strong versions 
of the Kozak sequence can be written down as 5’-gccaccATGgcg-3’. 
The Polymerase II transcripts, e.g. mRNAs, are nearly always modified by the addition of 7-
methylguanosine (the “cap”) to their 5’-ends and the addition of the homopolymeric tail of 
adenosine nucleotides to their 3’-ends. Polyadenylation of eukaryotic mRNAs is important 
for their protection from exonucleolytic attack and for their export out of nucleus. It also 
serves as a means of transcription termination. For mRNA to be polyadenylated, it should 
contain a specific signal sequence downstream of its polypeptide coding sequence. In 
general, a DNA sequence for the functional “polyadenylation signal” (pA signal), which is 
suitable for insertion into lentiviral vector backbone plasmids, is several hundred 
nucleotides long and is borrowed from a mammalian gene or a viral genome. Commonly 
 
Designing Lentiviral Gene Vectors 
 
273 
used pA signal sites are taken from the rabbit β-globin gene, human growth hormone gene 
and human herpes virus (HSV) thymidine kinase (TK) gene. The sequence 5’-AAUAAA-3’ 
located 10-30 nucleotides upstream of the cleavage site is highly conserved but is not strictly 
required for the polyadenylation of mammalian mRNAs. A very important feature of the 
lentiviral vector backbone is the pA signal in its 3’-LTR. This signal functions as a terminator 
for wild type lentiviral RNAs including complete lentiviral genomic RNA. As the 3’-LTR 
sequence itself is strictly required for chromosomal integration in lentiviruses, any foreign 
pA signals which can cause premature termination of the genomic RNA are bound to 
reduce the amount of transductionally active genomic RNA, and, therefore, to diminish 
drastically the titre of the functional lentiviral vector particles (Hager, Frame et al. 2008). 
Thus, foreign pA signals within lentiviral vectors should be either avoided altogether, or 
weakened, or positioned to terminate the transcription of the anti-genomic DNA strand 
only. With this challenge in view, it should be noted that while most pA signal sites act 
unidirectionally, a pA signal borrowed from SV40 viral genome is known to terminate RNA 
and to promote polyadenylation irrespective of transcription direction. A brief look at the 
transcription map of SV40 can explain this fluke. Indeed, two opposing transcription waves 
of SV40 meet and terminate at its polyadenylation signal site, which is, therefore, an overlap 
of two opposing polyadenylation signals. 
Natural Polymerase II promoters are nearly always supplemented with one or several 
“enhancers”, that is, genetic elements, which up-regulate the activity of the promoter 
through binding to specific nuclear proteins, so-called “transcription factors”. Size 
limitations of the lentiviral payload and insufficiently precise enhancer localization data 
restrict the use of enhancers in the lentiviral vectors. However, small enhancer elements can 
still be used where, for example, tissue-specific or inducible transgene expression is desired.  
A typical eukaryotic protein-coding gene is a patchwork of coding exons and non-coding 
introns, so that the translation-grade mRNA is produced by the splicing of the primary     
transcript. The result of the splicing is the establishment of the phosphodiester bond 
between the AG dinucleotide at the 3’-end of the preceding exon and the G nucleotide at the 
5’-end of the subsequent exon within the transcript (Hiller and Platzer 2008). The interlacing 
sequences, the introns, are flanked with a “splice-donor” consensus sequence 5’-GTRAGT-3’ 
at their 5’-ends and a “splice-acceptor” sequence 5-YAG-3’ at their 3’-ends (where R is A or 
G, Y is C or T). In addition, introns contain a “branch point” 5’-YTRAY-3’ and a 
polypyrimidine tract, which are functionally important for successful splicing. As the 
payload space within the lentiviral vectors is limited, the standard practice is to include the 
genes in their complementary DNA (cDNA) form, that is, as spliced versions without 
introns. The introns, however, are not entirely inert genetically and occasionally take part in 
the regulation of gene expression. In such situations, the inclusion of small regulatory 
introns within lentiviral vectors can be considered (Le Hir, Nott et al. 2003).  
Coding sequences delivered by lentiviral vectors are often derived from non-mammalian 
organisms where the translation machinery is adapted to a non-mammalian profile of codon 
frequencies. Unusual codons, also called “hungry codons”, can cause undesirable pauses 
during translation and reduce the efficiency of gene expression. Therefore, the optimization 
of codon frequencies for the genes, which are born on the lentiviral vectors, is often 
advantageous. If the frequencies in a coding sequence are adapted to the human codon 
usage profile, the sequence is said to be “humanized” (Zeeberg 2002; Burgess-Brown, 
Sharma et al. 2008).  
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used pA signal sites are taken from the rabbit β-globin gene, human growth hormone gene 
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pA signals which can cause premature termination of the genomic RNA are bound to 
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Thus, foreign pA signals within lentiviral vectors should be either avoided altogether, or 
weakened, or positioned to terminate the transcription of the anti-genomic DNA strand 
only. With this challenge in view, it should be noted that while most pA signal sites act 
unidirectionally, a pA signal borrowed from SV40 viral genome is known to terminate RNA 
and to promote polyadenylation irrespective of transcription direction. A brief look at the 
transcription map of SV40 can explain this fluke. Indeed, two opposing transcription waves 
of SV40 meet and terminate at its polyadenylation signal site, which is, therefore, an overlap 
of two opposing polyadenylation signals. 
Natural Polymerase II promoters are nearly always supplemented with one or several 
“enhancers”, that is, genetic elements, which up-regulate the activity of the promoter 
through binding to specific nuclear proteins, so-called “transcription factors”. Size 
limitations of the lentiviral payload and insufficiently precise enhancer localization data 
restrict the use of enhancers in the lentiviral vectors. However, small enhancer elements can 
still be used where, for example, tissue-specific or inducible transgene expression is desired.  
A typical eukaryotic protein-coding gene is a patchwork of coding exons and non-coding 
introns, so that the translation-grade mRNA is produced by the splicing of the primary     
transcript. The result of the splicing is the establishment of the phosphodiester bond 
between the AG dinucleotide at the 3’-end of the preceding exon and the G nucleotide at the 
5’-end of the subsequent exon within the transcript (Hiller and Platzer 2008). The interlacing 
sequences, the introns, are flanked with a “splice-donor” consensus sequence 5’-GTRAGT-3’ 
at their 5’-ends and a “splice-acceptor” sequence 5-YAG-3’ at their 3’-ends (where R is A or 
G, Y is C or T). In addition, introns contain a “branch point” 5’-YTRAY-3’ and a 
polypyrimidine tract, which are functionally important for successful splicing. As the 
payload space within the lentiviral vectors is limited, the standard practice is to include the 
genes in their complementary DNA (cDNA) form, that is, as spliced versions without 
introns. The introns, however, are not entirely inert genetically and occasionally take part in 
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The stability of genomic RNA of lentiviral vectors is crucial for attaining high lentiviral 
vector titres and stability of the lentiviral vector encoded mRNAs is important for efficient 
transgene expression. It was discovered that an element from Woodchuck Hepatitis Virus 
(WHV) genome can operate at a post-transcriptional level to improve transgene expression. 
The sequence, called WHV Post-transcriptional Regulatory Element (WPRE) is thought to 
act by expediting the export of RNA from the nucleus with the concomitant reduction of the 
intra-nuclear RNA degradation. WPRE and a similar element from Human Hepatitis Virus 
(HBV) are extensively used in lentiviral vectors, where they are normally positioned 
immediately upstream from the 3’-LTR, primarily because of their vector titre enhancing 
properties. WPRE, as defined originally, was known to cause tumours in rodents, therefore, 
a safer version of WPRE with deleted sequences for the WHV X protein and its promoter 
was generated (Schambach, Bohne et al. 2006).  
Cistrons are not the only cargo genes delivered by the lentiviral vectors. Other payload 
genes include the genes for RNAi-exploiting “micro” RNAs (miRNAs) or their artificial 
analogues, “short hairpin” RNAs (shRNAs). These genes are transcribed by RNA 
Polymerases III or I from the corresponding promoters. The benefits of the lentiviral vectors, 
such as the relative stability of transgene expression and the ability to transduce postmitotic 
cells, considerably broaden the versatility of gene knock-down experiments with shRNAs 
(Rubinson, Dillon et al. 2003). A range of suitable lentiviral vectors, exploiting the high 
activity of hybrid miRNA-30-shRNA design, are offered by ThermoFisherScientific-
OpenBiosystems (Silva, Li et al. 2005).  
In summary, cis-acting elements regulating gene expression act in concert and in a cell-type-
specific manner. The inherent mosaicism of lentiviral genetic organization allows 
interchangeable use of an extensive array of genetic elements for the generation of new 
lentiviral vectors. However, some combinations of genetic determinants are less functional 
than others, so the optimization of the lentiviral vector set-up is usually required.  
2.5 Genetic elements for epigenetic maintenance of transgene expression 
It is a relatively common occurrence for transgene expression to die out both in terms of the 
reduction of the fraction of expressing cells and the decrease of the efficiency of expression. 
Integrated lentiviral proviruses are faithfully maintained in mammalian cells, so the reasons 
for the shutdown of transgene expression are mostly epigenetic. Malfunction of the 
transgene expression control elements is often blamed, indeed, the phenomenon is 
sometimes referred to as “promoter shut down”. Certainly, different promoters have 
various capabilities to maintain long-term transgene expression. In particular, some 
promoters tend to turn off in cell populations where they are not normally active. The 
shutdown of transgene expression is particularly common in cell populations undergoing 
differentiation (Bagchi, Kumar et al. 2006). Natural chromosomal integration of lentiviruses 
tends to occur in transcriptionally active areas of the genome where heterochromatin and 
DNA methylation are unlikely to interfere with transgene expression. However, as the cells 
differentiate, the pattern of heterochromatization and DNA methylation changes and some 
of the proviruses find themselves in the transcriptionally silent areas of the genome. 
There are many levels at which the longevity of transgene expression can be addressed 
through the lentiviral vector design, including: 1) control of the provirus amenity to 
methylation (e.g. purposeful exclusion of the methylation-prone CpG islands); 2) chromatin 
re-modeling control via cis-acting proviral elements; 3) choice of non-immunogenic 
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transgene products to prevent cell elimination via immune reaction in vivo; 4) choice of a 
suitable tissue-specific promoter-enhancer combination; 5) achieving the high copy number 
of proviruses; 6) control of the provirus integration sites via the preferences of the viral 
integrase or via harnessing the site-specific integration systems.  
In principle, the protection of proviruses from heterochromatin can be achieved with 
genomic insulators or other similar anti-heterochromatin elements. However, experiments 
with known insulators show that their effects on transgene expression from lentiviral 
proviruses are multi-vectorial depending on the cell context (Grandchamp, Henriot et al. 
2011). Ideally, targeting proviruses to a continuously active locus (e.g. human homologue of 
the mouse Rosa 26 locus) can resolve the transgene expression shutdown problem. An 
alternative solution is to escape chromatin-remodeling events by creating episomally 
maintained lentiviral proviruses (Section 5). 
2.6 Elements alleviating manipulation of lentiviral vector backbone plasmids 
The fairly large size of the lentiviral vector backbone plasmids means they contain a limited 
number of unique sites for restriction nucleases. Thus, it is often desirable to introduce 
artificial clusters of suitable unique restriction sites (polylinkers) to simplify the 
modification of these plasmids. Alternatively, selection schemes involving site-specific 
recombination can be used for repetitive modifications, e.g. for marker exchange or 
promoter exchange. In this scenario, the introduction of suitable site-specific recombination 
sites into the lentiviral vector backbone plasmid is required.  
As discussed in Section 2.1, lentiviral vector backbone plasmids are occasionally structurally 
unstable and/or poorly maintained. These plasmids are particularly vulnerable during 
initial establishment in bacteria. Instability of nascent recombinant plasmids can result in a 
practical unfeasibility of seemingly straightforward DNA cloning strategies. For example, 
the generation of new lentiviral vector backbone plasmids through inefficient ligation of two 
DNA fragments with blunt ends is normally very challenging. In such situations we 
recommend splitting the DNA cloning procedure into separate cloning steps, each one 
relying on either effective positive selection of new recombinant plasmids or on efficient 
ligation. For example, the insertion of additional DNA sequences into lentiviral vector 
backbone plasmids can take advantage of the “pop-in-pop-out” cloning strategy. In this 
approach, a plasmid containing the desired insert and marked with antibiotic resistance 
marker 1 is first fused with the lentiviral vector backbone plasmid marked with antibiotic 
resistance marker 2 using positive selection of the co-integrate plasmid with two antibiotics. 
The desired new lentiviral vector backbone plasmid is then obtained by removing the 
unwanted plasmid sequences from the resultant bi-replicon plasmid using restriction 
digestion and efficient intra-molecular ligation reaction. Clearly, this strategy for insertions 
into a lentiviral vector backbone plasmid requires the thoughtful placement of restriction 
sites conveniently accommodating both the “pop-in” step and the “pop-out” step. 
3. Engineering lentiviral vectors for the concomitant expression of several 
transgenes 
The genome sizes of non-defective wild type HIV-1 isolates are close to 9.5 kb. The lentiviral 
packaging size constraints are dictated by the geometry of the viral capsid and are thought 
to be fairly permissive of the smaller than wild type genome versions, but remarkably 
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intolerant of the larger than wild type variants. As lentiviral sequences required for genomic 
RNA packaging and chromosomal integration constitute about 2 kb, the available gene 
payload space within HIV-1 based lentiviral vectors should not be much more than 7.5 kb. 
Thus, the insert size capacity of the lentiviral vectors is completely appropriate for the vast 
majority of the monogenic applications but can present a challenge in situations where the 
delivery of several genes by a single vector is required. Therefore, various possible methods 
of gene cargo reduction have been explored.   
The expression of two or more cistrons from a single promoter can be achieved by the 
employment of internal ribosome entry site (IRES) elements, which are normally borrowed 
from viral genomes (Fux, Langer et al. 2004). The IRES sequences (about 0.5 kb) are inserted 
between the coding frames to facilitate translation of the downstream coding frames from 
the same transcript. IRES efficiency is not absolute and it is a common occurrence for the 
subsequent gene in the expression cassette to be expressed at a lower level than the 
preceding gene. As the length of the intercistronic inserts is an important factor in the IRES 
efficiency, the expression of the downstream genes can be improved by increasing or 
decreasing the sizes of the IRES inserts (Attal, Theron et al. 1999).  
Another common method used to compress the gene expression cassettes is to produce gene 
products as polyproteins, that is, large polypeptides, which are split into individual proteins 
by proteases recognizing the appropriate amino acid sequence cleavage motifs between the 
protein modules. In fact, lentiviruses use the same principle themselves as the Gag 
polyprotein is proteolytically processed inside the viral particles to form nucleocapsid, 
capsid, matrix proteins and the GagPol polyprotein is processed to form additionally viral 
protease, integrase and reverse transcriptase. The usual proteolytic signal, 2A, which is used 
in recombinant lentiviral gene vectors, is, however, borrowed not from lentiviruses but from 
the Foot-and-Mouth Disease Virus belonging to the family of picornaviruses. Multiple 
copies of the 2A sequence can be successfully used to indicate the desired break-up of the 
polyproteins. The method has its limitations as protein misfolding might occur, which 
would require some extra chaperone support.  
Quite often there is no need to separate several proteins as they can perform several 
functions remaining as a single polypeptide chain. In general, multifunctional fusion 
proteins are produced by the fusion of the coding sequences in the same translation frame. 
Some spacer peptides might be used to intercalate between the fused polypeptides to 
improve folding and to facilitate the functional activity of the individual protein domains. 
There are two common methods to achieve protein fusion: 1) the stop codon of the upstream 
coding unit is deleted and the start codon of the downstream coding unit is retained to 
obtain alternative translation starts; 2) both the stop codon of the upstream coding unit and 
the start codon of the downstream coding unit are deleted. It is important to remember that 
many proteins are naturally proteolytically processed and this processing can be upset by 
protein fusion or can interfere with the desired fusion. For example, many proteins are 
secreted into the lumen of the endoplasmic reticulum (ER) with the concomitant cleavage of 
the leader peptide by the signal peptidase. If incorporated within the downstream portion of 
the fusion protein, the signal peptide cleavage sequence can cause undesired fission of the 
fusion protein. Thus, potential problems associated with building of novel fusion proteins 
include protein misfolding, incorrect intracellular localization and unexpected sensitivity to 
a protease attack. In addition, in vivo use of fusion proteins might be impeded by unwanted 
immunogenicity of the newly-created epitopes. 
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Mimicking wild type lentiviruses, splicing signals can be exploited to generate multiple 
mRNAs for different proteins from a single primary transcript (Zhu, Chung et al. 2001). 
However, internal splicing signals reduce the amount of the full size genomic RNA of the 
lentiviral vectors and, therefore, are bound to be detrimental for the vectors’ titres. 
On some occasions several cargo genes within one lentiviral vector can be arranged to be 
driven by their individual promoters. This option is discussed in the following Section 4. 
4. Multiple transcription modules in lentiviral vectors  
The most straightforward way to arrange two transcription cassettes within the lentiviral 
vector is to assemble them in a tandem with the orientation coinciding with the transcription 
direction for the primary genomic RNA (that is, from 5’-LTR to 3’-LTR). Extreme caution is 
recommended in the employment of foreign pA signals in both cassettes, as they can 
interfere with the production of functional genomic RNA of the lentiviral vector. The 
production of functional genomic RNA and transcription from the two gene expression 
cassettes  can all rely on the pA signal within 3’-LTR and a postranscriptional enhancer, 
such as WPRE, positioned immediately upstream from the 3’-LTR. Such tandem 
arrangement of two gene expression units is prone to overriding any regulatory features of 
the downstream promoter by the topmost upstream promoter. Thus, a regulated promoter 
(e.g. a tissue specific promoter) should be positioned in the upstream gene expression unit 
while a constitutive and ubiquitous promoter should be positioned downstream (Gallo, 
Grimaldi et al. 2008; Kita-Matsuo, Barcova et al. 2009). As the lentiviral promoter in the 5’-
LTR can override any regulatory features of the downstream promoters, versions of the 
lentiviral vectors with a deleted 5’-LTR promoter are preferable for tandem assemblies of 
expression cassettes, which include a regulated promoter. There are multiple situations, 
both in gene therapy and in general biomedical research, where an induced transgene 
expression is required. In particular, heat (Vilaboa and Voellmy 2006), light 
(Schoenenberger, Gerosa et al. 2009; Deisseroth 2011) and gas-born acetaldehyde (Weber, 
Rimann et al. 2004) were used for induction of gene expression in mammalian cells 
(Goverdhana, Puntel et al. 2005).  
An alternative solution for the arrangement of two expression cassettes within a lentiviral 
vector genome is an assembly with the divergent orientation of the transcription. The 
advantage of the divergent orientation of the promoters is that it excludes any cross-talk 
between two gene expression units. Therefore, two highly regulated promoters can be 
employed in the same vector. An expression cassette positioned along the transcription of 
the genomic RNA can still use pA signal in 3’-LTR while a counter-genomic-transcription 
unit requires its own pA signal. Care should be taken to use an exclusively unidirectional 
pA signal and not to use a DNA fragment with two opposing pA signals, which can cause 
the disruption of the functional genomic RNA production.  
Lentiviral vectors with tissue-specific promoters can be used for the long-term expression of 
transgenes in gene therapy and also as sensors of cell differentiation, an important task in 
stem-cell-based therapy. There are two principal types of genetic sensors: a “responsive” 
type with a real-time reaction to the cell’s state and a “fate-mapping” type, which, once 
activated, can permanently retain the sensor state during any epigenetic changes happening 
while cells differentiate or react to outside stimuli. As promoters and enhancers are pivotal 
elements of the gene expression control, the ability of lentiviral vectors to accommodate 
several transcription cassettes is an important consideration in the gene vector choice.  
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There are two common methods to achieve protein fusion: 1) the stop codon of the upstream 
coding unit is deleted and the start codon of the downstream coding unit is retained to 
obtain alternative translation starts; 2) both the stop codon of the upstream coding unit and 
the start codon of the downstream coding unit are deleted. It is important to remember that 
many proteins are naturally proteolytically processed and this processing can be upset by 
protein fusion or can interfere with the desired fusion. For example, many proteins are 
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A flexible way to regulate gene expression is via cistron inversion relative to a promoter 
(Atasoy, Aponte et al. 2008; Sohal, Zhang et al. 2009). Thus, a site-specific recombinase, such 
as Cre-recombinase, can react with the cognate recombination sites within lentiviral vector 
provirus to activate or to block gene expression. Similarly, controlled excision or inversion 
of a transcription terminator can be used as a regulatory contrivance. The expression of 
some genes, e.g. cell suicide genes in cancer gene therapy, requires extra tight control, which 
can be achieved via a parallel or cascade arrangement of two control elements such as an 
inducible promoter and a cistron-inversion system (Sektas, Hasan et al. 2001). Lentiviral 
vectors seem to be particularly suited for the assembly of complex gene expression control 
systems destined for delivery to postmitotic cell populations as their packaging size 
constraints are less prohibitive than the packaging size constraints of competing Adeno-
Associated Virus (AAV) based gene vectors.  
5. Generating non-integrating lentiviral vectors 
One of the current trends in vectorology is for viral vectors to acquire some of the 
advantageous features of non-viral vectors and for non-viral vectors to borrow attractive 
bits of the viral machinery. A clear example of that trend is the rapid coming to the fore of 
non-integrating lentiviral vectors, which are transducing particles still bearing a substantial 
resemblance to lentiviruses and yet deficient in typical for retroviruses random 
chromosomal integration of their proviruses (Nightingale, Hollis et al. 2006; Philippe, Sarkis 
et al. 2006; Yanez-Munoz, Balaggan et al. 2006; Apolonia, Waddington et al. 2007; Philpott 
and Thrasher 2007; Bayer, Kantor et al. 2008; Sarkis, Philippe et al. 2008; Rahim, Wong et al. 
2009). Importantly, non-integrating lentiviral vectors retain the nuclear-penetrating ability, 
the flexibility of virion envelope engineering and capacity to package nucleic acids of the 
therapeutically relevant size that are otherwise characteristic of the lentiviral gene vectors 
(Wanisch and Yanez-Munoz 2009). The benefits of the non-integrative vectors for gene 
therapy arise from the absence of malignancy provoking insertional mutagenesis, which can 
occur because of the disruption of the tumour supressor genes or activation of expression of 
the oncogenes after proviral integration. 
Non-integrating lentiviral vectors are prepared with modified lentiviral packaging systems, 
which employ a modified GagPol polyprotein containing mutations specifically inactivating 
the lentiviral integrase function. If a regular lentiviral vector backbone plasmid is used in the 
packaging procedure, the resultant vector virions can deliver transgenes to the nucleoplasm, 
where the transgenes can stay and be expressed until they are diluted out in cell divisions. 
Therefore, such vectors are suitable either for transient transduction of dividing cells or for 
relatively stable transduction of non-dividing cells, where the lentiviral vector genomes can 
persist. To achieve better maintenance of the transgenes, non-integrating lentiviral vectors 
have to be supplemented with either site-specific integration machinery (Lombardo, 
Genovese et al. 2007; Moldt, Staunstrup et al. 2008) or episomal maintenance apparatus 
(Wong, Argyros et al. 2009; Argyros, Wong et al. 2011).  
Provirus integration can be made harmless by its targeting to a benign locus within the 
target cell genome (Moldt, Staunstrup et al. 2008). The lentiviral integrase itself can be 
engineered into a site-directed recombination enzyme by its fusion with site-specific 
“tethering” domains (Ferris, Wu et al. 2010). Robust and error-free site-specific integration 
into mammalian cells lacking pre-engineered integration sites is, however, difficult to 
achieve. Thus, compact episomal replicons from SV40, polyoma, papilloma viruses or 
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EBNA1-Rep1 DNA segment of Epstein-Barr virus (EBV) can be used to support 
maintenance of non-integrating lentiviral vectors in the nucleoplasm of dividing cells. Viral 
replicons are often completely adequate for research use of gene vectors, however they are 
rarely acceptable for therapeutic applications. Indeed, expression of the large SV40 T-
antigen and, hence, malignant transformation of the recipient host cells is required for SV40-
origin-based replication. EBNA1 expression does not result in a typical malignant 
transformation but can still tilt the cells towards the undesired immortalisation (Humme, 
Reisbach et al. 2003). Alternative benign episomal replicons are being sought; 
encouragingly,  the scaffold/matrix attachment region (S/MAR) from the human β-
interferon gene was reported to support episomal replication (Wong, Argyros et al. 2011).  
6. How to enhance the transduction of cells with lentiviral vectors 
The titre of lentiviral vector particles in the cell culture supernatant hardly ever exceeds 
1x108 TU/ml and, depending on a particular lentiviral vector backbone, is often much 
lower. Therefore, the use of concentrated lentiviral vector preparations is a popular, even 
though relatively involved, approach to achieve high efficiency of transduction with small 
volumes of the applied viral vector suspension. In addition to increased titres, concentrated 
lentiviral vector preparations benefit from concomitant purification of viral vector particles 
from transduction inhibitors, which are commonly present in the cell culture supernatants. 
Ultracentrifugation is a traditional method to concentrate lentiviral vector virions, however 
it is often accompanied by the loss of a substantial fraction of the active lentiviral vector 
particles. The particles are, in part, inactivated because of the contact between the vector 
pellet and air. To make the pellet more compact, ultracentrifugation is performed in swing-
out bucket rotors and conical-bottom tubes supplemented with appropriate adaptors.  
Centrifugal force can also cause deterioration of sedimenting vector particles, so a bottom 
layer of dense sucrose solution is recommended as a “cushion” for better survival of the 
vector virions. The cushion is also important because a considerable portion of the lentiviral 
vector preparation can be lost due to incomplete wash-off of the viral vector pellet from the 
tube or its poor re-suspension.  VSV-G pseudotyped lentiviral vectors have relatively short 
half-life of 8-9 hrs at 37 oC and are better stored at -80 oC. 
Similarly to other virions, lentiviral vector particles can be precipitated using “molecular 
crowding” agents such as polyethylene glycol (PEG), which can soak up water molecules 
and create micro-pockets with an extra-high virion concentration. Thus, precipitation of 
virions can be achieved by a proprietary reagent “Lenti-XTM concentrator” supplied by 
Clontech-Takara. Precipitated lentiviral vector particles can be pelleted by low-speed 
centrifugation and re-suspended in a smaller volume. However, some non-lentiviral 
material from cell culture supernatants tends to co-precipitate with virions complicating the 
re-suspension step. Therefore, additional viral vector purification is required, which is often 
performed by ion exchange chromatography. Lentiviral vector particles are eluted from the 
ion exchange column in a high salt solution, which can be toxic to cells. Therefore, the 
medium for lentiviral vector particles should be exchanged to the desired one using dialysis, 
gel filtration or ultrafiltration. Ultrafiltration also provides a means for additional 
concentration of the viral vector.  
A completely different strategy for the lentiviral vector concentration is to bind the vector 
particles to a coated plastic surface, which can then be used as a substrate for the cells to be 
infected. A recombinant derivative of human fibronectin called RetroNectinTM, which was 
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originally used for surface immobilisation of amphotropic retroviral vectors, can be used to 
trammel VSV-G pseudotyped lentiviral vectors on a plastic surface (Clontech-Takara). 
Lentiviral vector virions can also be concentrated, including directly at the recipient cell 
surfaces, after conjugation to paramagnetic particles and attraction by magnet.  
Receptors for VSV-G protein are ubiquitous, but still poorly defined. Various types of cells 
are transduced by VSV-G-pseudotyped lentiviral vectors with different efficiency. A higher 
efficiency of transduction can often be achieved by a better match of the recipient cells’ type 
and the type of the envelope protein used to pseudotype lentiviral vector particles. 
Lentiviral transduction is normally dramatically enhanced by polycations, such as 
hexadimethrine bromide (Polybrene), presumably because they modify the electrostatic 
interaction between the cells and the vector particles. The polycations’ transduction 
enhancer activity is highly cell specific. Alternative polycations, such as positively charged 
lipid dioctadecylamidoglycylspermine (DOGS), can be more effective than Polybrene for 
specific cell populations (Tolmachov, Ma et al. 2006). Transduction efficiency can be further 
increased by a very unusual and poorly understood method called “spinfection”. The 
recipient cells are overlaid by a viral vector suspension and centrifuged at low speed for 45 
min or more. In most circumstances, such a centrifugation step results in a distinct increase 
in the transduction efficiency, perhaps because of the changes in the trajectories of vector-
laden endosomal vesicles due to the centrifugal force. 
Lentiviral vectors are able to transduce non-dividing cells. However, higher efficiencies of 
transduction are achieved with dividing cells, indicating that the nuclear envelope still 
constitutes a difficult barrier to negotiate for the entering lentiviral vector particles. 
Therefore, growth factors that stimulate cell division can be applied to increase the 
efficiency of the lentiviral transduction.  
In addition to the measurement of the transduction activity, a lentiviral vector titre can be 
estimated using physical methods such as electron microscopy or enzyme-linked 
immunosorbent assay (ELISA) for capsid protein (such as “p24-antigen” of HIV-1). The titre 
of viral vector particles can be inferred from the concentration of genomic RNA determined 
by quantitative (real time) PCR. As the proportion of defective viral vector particles can vary 
depending on the procedures used to isolate and to concentrate the vector, such projections 
should rely on individually built calibration plots relating the physical titre and the 
transduction-based titre for a specific set of the viral vector production protocols. 
7. Conclusion 
Lentiviral gene vectors are generated by the packaging of the RNA transcribed in 
mammalian cells from vector backbone plasmids propagated in bacteria. Such plasmids 
contain bacterial and eukaryotic sets of elements. The bacterial set is comprised of a plasmid 
origin of replication, a bacterial selection marker, an optional partition region for stable 
maintenance in bacteria and plasmid DNA manipulation prop-ups like multiple cloning 
sites and site-specific recombination sites. The eukaryotic set consists of the lentiviral cis-
acting determinants for nuclear export of vector genomes, their packaging, entry into the 
target nuclei and chromosomal integration, plus a cargo gene or multiple cargo genes with 
their regulatory elements, an optional marker gene and the elements required for stable 
maintenance of transgenes in human cells. The bacterial set of elements is lost after vector 
genome RNA is produced and packaged into lentiviral transducing particles. Different 
cargo genes can be delivered with lentiviral vectors including genes for proteins, shRNA 
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and miRNA. Currently lentiviral vectors are packaged in mammalian cells only (Lesch, 
Laitinen et al. 2011). The development of straightforward lentiviral vector production 
systems in easily cultured insect cells and yeast would be desirable (Tolmachov 2006).  
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originally used for surface immobilisation of amphotropic retroviral vectors, can be used to 
trammel VSV-G pseudotyped lentiviral vectors on a plastic surface (Clontech-Takara). 
Lentiviral vector virions can also be concentrated, including directly at the recipient cell 
surfaces, after conjugation to paramagnetic particles and attraction by magnet.  
Receptors for VSV-G protein are ubiquitous, but still poorly defined. Various types of cells 
are transduced by VSV-G-pseudotyped lentiviral vectors with different efficiency. A higher 
efficiency of transduction can often be achieved by a better match of the recipient cells’ type 
and the type of the envelope protein used to pseudotype lentiviral vector particles. 
Lentiviral transduction is normally dramatically enhanced by polycations, such as 
hexadimethrine bromide (Polybrene), presumably because they modify the electrostatic 
interaction between the cells and the vector particles. The polycations’ transduction 
enhancer activity is highly cell specific. Alternative polycations, such as positively charged 
lipid dioctadecylamidoglycylspermine (DOGS), can be more effective than Polybrene for 
specific cell populations (Tolmachov, Ma et al. 2006). Transduction efficiency can be further 
increased by a very unusual and poorly understood method called “spinfection”. The 
recipient cells are overlaid by a viral vector suspension and centrifuged at low speed for 45 
min or more. In most circumstances, such a centrifugation step results in a distinct increase 
in the transduction efficiency, perhaps because of the changes in the trajectories of vector-
laden endosomal vesicles due to the centrifugal force. 
Lentiviral vectors are able to transduce non-dividing cells. However, higher efficiencies of 
transduction are achieved with dividing cells, indicating that the nuclear envelope still 
constitutes a difficult barrier to negotiate for the entering lentiviral vector particles. 
Therefore, growth factors that stimulate cell division can be applied to increase the 
efficiency of the lentiviral transduction.  
In addition to the measurement of the transduction activity, a lentiviral vector titre can be 
estimated using physical methods such as electron microscopy or enzyme-linked 
immunosorbent assay (ELISA) for capsid protein (such as “p24-antigen” of HIV-1). The titre 
of viral vector particles can be inferred from the concentration of genomic RNA determined 
by quantitative (real time) PCR. As the proportion of defective viral vector particles can vary 
depending on the procedures used to isolate and to concentrate the vector, such projections 
should rely on individually built calibration plots relating the physical titre and the 
transduction-based titre for a specific set of the viral vector production protocols. 
7. Conclusion 
Lentiviral gene vectors are generated by the packaging of the RNA transcribed in 
mammalian cells from vector backbone plasmids propagated in bacteria. Such plasmids 
contain bacterial and eukaryotic sets of elements. The bacterial set is comprised of a plasmid 
origin of replication, a bacterial selection marker, an optional partition region for stable 
maintenance in bacteria and plasmid DNA manipulation prop-ups like multiple cloning 
sites and site-specific recombination sites. The eukaryotic set consists of the lentiviral cis-
acting determinants for nuclear export of vector genomes, their packaging, entry into the 
target nuclei and chromosomal integration, plus a cargo gene or multiple cargo genes with 
their regulatory elements, an optional marker gene and the elements required for stable 
maintenance of transgenes in human cells. The bacterial set of elements is lost after vector 
genome RNA is produced and packaged into lentiviral transducing particles. Different 
cargo genes can be delivered with lentiviral vectors including genes for proteins, shRNA 
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and miRNA. Currently lentiviral vectors are packaged in mammalian cells only (Lesch, 
Laitinen et al. 2011). The development of straightforward lentiviral vector production 
systems in easily cultured insect cells and yeast would be desirable (Tolmachov 2006).  
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The basic principle of current gene therapy is to deliver genetic material to a population of 
cells in the body, thereby preventing a disease or improving the clinical status of a patient. 
One of key factors for successful gene therapy is the development of effective delivery. To 
date, a plethora of gene delivery systems, termed “vectors”, have been developed, and these 
fall into two broad categories: nonviral and viral vectors. Basically, the nonviral vector 
systems involve delivery of naked DNA or RNA into target cells with the aid of physical or 
chemical mediators such as cationic lipids. In terms of their simplicity, producibility, and 
immunogenicity, nonviral vector systems hold advantages over viral vector systems. 
However, in terms of the efficiency of gene delivery and expression, the viral vector systems 
are considered as more ideal (Goverdhana et al., 2005; Verma & Weitzman, 2005). 
Although a variety of gene-transfer vectors based on RNA and DNA viruses have been 
adapted to deliver foreign genes to target cells in vitro and in vivo, most viral vectors are 
derived from adenoviruses and retroviruses. Adenoviruses are DNA viruses that are 
characterized by a nonenveloped icosahedral virion containing a double-stranded linear 
DNA genome of 30-36 kb (Berk, 2007). The virus enters the target cell by endocytosis via 
interactions between the fiber protein on the virion and the adenoviral receptor on the cell 
surface followed by the subsequent binding of a second virion protein, penton, to a 
cellular integrin protein. Inside the cell, uncoating of virions takes place in the cytoplasm 
where the viral DNA genome remains associated with a core-derived protein that 
promotes efficient nuclear entry of the viral genome. Within the nucleus, viral DNA exists 
as an episome, consequently replication of the viral genome takes place in the nucleus 
(Leopold et al., 1998). Adenovirus genes are mainly divided into two classes, early and 
late, based on the time of expressions during the replication. Many of the recombinant 
adenovirus vectors used in gene transfer have been generated by the deletion and/or 
mutation of the early genes which are mostly involved in the activation of other viral 
genes, replication of the viral DNA genome, modulation of host immune responses, and 
inhibition of host cell apoptosis (Armentano et al., 1995; Armentano et al., 1999; Bett et al., 
1994; Brough et al., 1997; Danthinne& Imperiale, 2000; Fallaux et al., 1996; Flint & Shenk, 
1997; Gao et al., 1996; Graham et al., 1977; Imler et al., 1996; Wang et al., 1995; Yeh et al., 
1996). More recently, the helper-dependent adenoviral vectors, so-called “gutted” vectors, 
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have been created by removing most of the viral genes from adenoviral genome 
(Kochanek et al., 1996; Lowenstein et al., 2002; Ng et al., 2001; Parks et al., 1996; Umana et 
al., 2001). Although the gutted vectors need to employ a helper virus that provides all the 
viral proteins necessary for vector production (Kochanek et al., 1996; Lowenstein et al., 
2002; Ng et al., 2001; Parks et al., 1996; Umana et al., 2001), defect of all the viral-coding 
sequences theoretically allows the cloning of large DNA fragments up to 36 kb 
(Goverdhana et al., 2005). Although their tropism for the airway epithelial cells meant that 
adenovirus-based vectors were originally developed for the treatment of genetic lung 
diseases such as cystic fibrosis (Flotte et al., 2007), one of the major advantages of 
adenoviral vectors is that they are able to infect a wide variety of cells in a cell-cycle 
independent manner (Bergelson et al., 1997; Cullen, 2001; Tomko et al., 1997; Whittaker et 
al., 2000). However, one limitation is the persistence of transgene expression; adenoviral 
vector-mediated gene expression is short-term, ranging from two weeks to a few months. 
Thus, this vector is more appropriate for use in treatment of diseases that require high 
and transient gene expression (Robbins & Ghivizzani, 1998). 
In contrast with adenoviral vectors, retroviruses have a substantial advantage as vectors for 
the sustained expression of a transgene in target cells (Verma & Weitzman, 2005). 
Retroviruses are enveloped RNA viruses belonging to the Retroviridae family. The retroviral 
particle contains two copies of linear, positive sense, single-stranded RNA of 7-13 kb in 
length. All members of the Retroviridae family harbors at the minimum three essential genes: 
gag for structural proteins, pol for enzymes, and env for envelope. In the retroviral genome, 
the gag gene is positioned upstream of the pol gene, and the Pol polyprotein is generated as a 
fusion protein with the Gag polyprotein (Gag-Pol). As we shall see in the next section, the 
viral RNA genome is converted into a double-stranded DNA copy by reverse transcriptase 
(RT), a processing product of Pol, soon after the entry into the target cell (reverse 
transcription). Subsequently, the viral DNA is transported to the nucleus and covalently 
joined with cellular chromatin. This joining step is called integration and it is catalyzed by 
integrase (IN), another processing product of Pol. The integration step as well as the reverse 
transcription is hallmark of retroviral infection. Once integrated, the viral DNA serves as a 
template for the transcription of viral genes, enabling sustained gene expression in infected 
cells. The integrated viral DNA also contains cis-acting sequences termed the long terminal 
repeat (LTR) at its termini, which consist of 3’ unique elements (U3), repeat elements (R), 
and 5’ unique elements (U5). The 5’ LTR sequence functions as the promoter sequence for 
gene expression, in which viral RNA transcription is initiated at the U3-R, and the 
transcripts are polyadenylated at the R-U5 boundary of the 3’ LTR. The development of 
retrovirus as a gene transfer vector was first achieved with oncoretroviruses in the 1980s 
(Mann et al., 1983; Miller & Rosman, 1989; Shimotohno & Temin, 1981; Tabin et al., 1982; 
Watanabe & Temin, 1983; Wei et al., 1981); nowadays Moloney murine leukemia virus 
(MoMLV), one of the well characterized oncoretroviruses, is commonly used for therapeutic 
applications (Anderson et al., 1990; Blaese et al., 1993; Guild et al., 1988; Levine& Friedmann, 
1991; Miller, 1992a, b). However, the important limitation of the MoMLV-derived vector is 
its cell cycle dependency: this virus lacks the ability to infect non-dividing cells (Harel et al., 
1981; Hatziioannou & Goff, 2001; Lewis & Emerman, 1994; Miller et al., 1990; Roe et al., 
1993). Unlike the MoMLV, lentiviruses, a separate genus of the Retroviridae family including 
human immunodeficiency virus type-1 (HIV-1), can infect both dividing and non-dividing 
cells (Bukrinsky et al., 1992; Hatziioannou & Goff, 2001; Lewis et al., 1992; Lewis & 
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Emerman, 1994). The ability to infect non-dividing cells is not restricted to in vitro cell 
culture as lentivirus-derived vectors are capable of transducing certain quiescent or 
terminally differentiated cells such as macrophages and microglia (Miyake et al., 1998; 
Naldini et al., 1996; Weinberg et al., 1991). This property makes the lentivirus an attractive 
choice for gene transfer vector (Suzuki & Craigie, 2007). 
It is well known that HIV-1 is the causative agent for acquired immunodeficiency syndrome 
(AIDS). Currently, the standard AIDS treatment, termed highly active antiretroviral therapy 
(HAART), is to use cocktail of antiretroviral drugs that targets different HIV-1 enzymes 
including reverse transcriptase and protease. However, although it successfully causes 
suppression of HIV-1 RNA detected in plasma for a prolonged period of time and dramatic 
decrease of patient mortality (Palella et al., 1998; Volberding & Deeks, 2010), this 
pharmacological therapy is facing problems such as drug resistance and side effects in 
administrated individuals (Meadows & Gervay-Hague, 2006; Richman, 2001). Hence, viral 
vector-based gene therapy should offer a new approach to supplement the need for current 
drug regimens for the treatment of HIV/AIDS (Poluri et al., 2003; Strayer et al., 2005). 
Genetic modification of HIV-susceptible cells or hematopoietic stem cells (HSCs) by 
expressing anti-HIV transgenes should be one of the goals of the HIV gene therapy (Kitchen 
et al., 2011). In this regard, the lentiviral vector has the potential advantage for transduction 
because of its ability to infect quiescent cells including HSC (Miyoshi et al., 1999). However, 
incorporation of anti-HIV genes into an HIV-based lentiviral vector can create problems for 
production of the vector itself; expression of the anti-HIV trans gene in the producer cells 
can interfere with vector production (Banerjea et al., 2003; Li et al., 2003; Mautino & Morgan, 
2002c). One way to avoid this difficulty is to introduce a gene regulatable system in which 
the target transgene is kept silent during vector production and expression is subsequently 
induced on following infection of the vector in target cells. 
Several regulatable gene expression systems have been developed and applied to viral 
vectors including lentiviral vectors (Goverdhana et al., 2005; Weber & Fussenegger, 2004). In 
this chapter, we focus on recent development of the gene-regulatable lentiviral vectors and 
discuss the suitability of the vectors for anti-HIV therapy. 
2. Biology of HIV-1 replication 
2.1 Genomic organization and gene expression 
Lentiviruses, as represented by HIV-1, are also called complex retroviruses, which are 
characterized by a set of additional regulatory and accessory genes encoded in the viral 
genome (Cullen, 1991; Frankel & Young, 1998). In the case of HIV-1, the DNA genome 
converted from the RNA genome is about 9.7 kb and contains nine ORFs; in addition to the 
gag, pol, and env genes that are typical of all retroviruses, there are two regulatory (tat and 
rev) and four accessory (vif, vpr, vpu, and nef) genes (Fig. 1). These protein-coding regions are 
flanked by 5’ and 3’ LTR that are required for reverse transcription, integration, and gene 
expression steps. 
The complexity of HIV-1 is also characterized by its specific pattern of viral gene regulation 
(Kingsman & Kingsman, 1996). The HIV-1 LTR harbors several cis-acting sequences 
required for the initiation of viral RNA expression. The U3 region of the LTR is composed of 
a series of control elements that recruit a variety of transcription factors (Brady & Kashanchi, 
2005), and consequently, transcription of viral RNA initiates at the U3-R junction. However, 
the transcription activity of the U3 is basically low, and trans-acting proteins are required to 
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have been created by removing most of the viral genes from adenoviral genome 
(Kochanek et al., 1996; Lowenstein et al., 2002; Ng et al., 2001; Parks et al., 1996; Umana et 
al., 2001). Although the gutted vectors need to employ a helper virus that provides all the 
viral proteins necessary for vector production (Kochanek et al., 1996; Lowenstein et al., 
2002; Ng et al., 2001; Parks et al., 1996; Umana et al., 2001), defect of all the viral-coding 
sequences theoretically allows the cloning of large DNA fragments up to 36 kb 
(Goverdhana et al., 2005). Although their tropism for the airway epithelial cells meant that 
adenovirus-based vectors were originally developed for the treatment of genetic lung 
diseases such as cystic fibrosis (Flotte et al., 2007), one of the major advantages of 
adenoviral vectors is that they are able to infect a wide variety of cells in a cell-cycle 
independent manner (Bergelson et al., 1997; Cullen, 2001; Tomko et al., 1997; Whittaker et 
al., 2000). However, one limitation is the persistence of transgene expression; adenoviral 
vector-mediated gene expression is short-term, ranging from two weeks to a few months. 
Thus, this vector is more appropriate for use in treatment of diseases that require high 
and transient gene expression (Robbins & Ghivizzani, 1998). 
In contrast with adenoviral vectors, retroviruses have a substantial advantage as vectors for 
the sustained expression of a transgene in target cells (Verma & Weitzman, 2005). 
Retroviruses are enveloped RNA viruses belonging to the Retroviridae family. The retroviral 
particle contains two copies of linear, positive sense, single-stranded RNA of 7-13 kb in 
length. All members of the Retroviridae family harbors at the minimum three essential genes: 
gag for structural proteins, pol for enzymes, and env for envelope. In the retroviral genome, 
the gag gene is positioned upstream of the pol gene, and the Pol polyprotein is generated as a 
fusion protein with the Gag polyprotein (Gag-Pol). As we shall see in the next section, the 
viral RNA genome is converted into a double-stranded DNA copy by reverse transcriptase 
(RT), a processing product of Pol, soon after the entry into the target cell (reverse 
transcription). Subsequently, the viral DNA is transported to the nucleus and covalently 
joined with cellular chromatin. This joining step is called integration and it is catalyzed by 
integrase (IN), another processing product of Pol. The integration step as well as the reverse 
transcription is hallmark of retroviral infection. Once integrated, the viral DNA serves as a 
template for the transcription of viral genes, enabling sustained gene expression in infected 
cells. The integrated viral DNA also contains cis-acting sequences termed the long terminal 
repeat (LTR) at its termini, which consist of 3’ unique elements (U3), repeat elements (R), 
and 5’ unique elements (U5). The 5’ LTR sequence functions as the promoter sequence for 
gene expression, in which viral RNA transcription is initiated at the U3-R, and the 
transcripts are polyadenylated at the R-U5 boundary of the 3’ LTR. The development of 
retrovirus as a gene transfer vector was first achieved with oncoretroviruses in the 1980s 
(Mann et al., 1983; Miller & Rosman, 1989; Shimotohno & Temin, 1981; Tabin et al., 1982; 
Watanabe & Temin, 1983; Wei et al., 1981); nowadays Moloney murine leukemia virus 
(MoMLV), one of the well characterized oncoretroviruses, is commonly used for therapeutic 
applications (Anderson et al., 1990; Blaese et al., 1993; Guild et al., 1988; Levine& Friedmann, 
1991; Miller, 1992a, b). However, the important limitation of the MoMLV-derived vector is 
its cell cycle dependency: this virus lacks the ability to infect non-dividing cells (Harel et al., 
1981; Hatziioannou & Goff, 2001; Lewis & Emerman, 1994; Miller et al., 1990; Roe et al., 
1993). Unlike the MoMLV, lentiviruses, a separate genus of the Retroviridae family including 
human immunodeficiency virus type-1 (HIV-1), can infect both dividing and non-dividing 
cells (Bukrinsky et al., 1992; Hatziioannou & Goff, 2001; Lewis et al., 1992; Lewis & 
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Emerman, 1994). The ability to infect non-dividing cells is not restricted to in vitro cell 
culture as lentivirus-derived vectors are capable of transducing certain quiescent or 
terminally differentiated cells such as macrophages and microglia (Miyake et al., 1998; 
Naldini et al., 1996; Weinberg et al., 1991). This property makes the lentivirus an attractive 
choice for gene transfer vector (Suzuki & Craigie, 2007). 
It is well known that HIV-1 is the causative agent for acquired immunodeficiency syndrome 
(AIDS). Currently, the standard AIDS treatment, termed highly active antiretroviral therapy 
(HAART), is to use cocktail of antiretroviral drugs that targets different HIV-1 enzymes 
including reverse transcriptase and protease. However, although it successfully causes 
suppression of HIV-1 RNA detected in plasma for a prolonged period of time and dramatic 
decrease of patient mortality (Palella et al., 1998; Volberding & Deeks, 2010), this 
pharmacological therapy is facing problems such as drug resistance and side effects in 
administrated individuals (Meadows & Gervay-Hague, 2006; Richman, 2001). Hence, viral 
vector-based gene therapy should offer a new approach to supplement the need for current 
drug regimens for the treatment of HIV/AIDS (Poluri et al., 2003; Strayer et al., 2005). 
Genetic modification of HIV-susceptible cells or hematopoietic stem cells (HSCs) by 
expressing anti-HIV transgenes should be one of the goals of the HIV gene therapy (Kitchen 
et al., 2011). In this regard, the lentiviral vector has the potential advantage for transduction 
because of its ability to infect quiescent cells including HSC (Miyoshi et al., 1999). However, 
incorporation of anti-HIV genes into an HIV-based lentiviral vector can create problems for 
production of the vector itself; expression of the anti-HIV trans gene in the producer cells 
can interfere with vector production (Banerjea et al., 2003; Li et al., 2003; Mautino & Morgan, 
2002c). One way to avoid this difficulty is to introduce a gene regulatable system in which 
the target transgene is kept silent during vector production and expression is subsequently 
induced on following infection of the vector in target cells. 
Several regulatable gene expression systems have been developed and applied to viral 
vectors including lentiviral vectors (Goverdhana et al., 2005; Weber & Fussenegger, 2004). In 
this chapter, we focus on recent development of the gene-regulatable lentiviral vectors and 
discuss the suitability of the vectors for anti-HIV therapy. 
2. Biology of HIV-1 replication 
2.1 Genomic organization and gene expression 
Lentiviruses, as represented by HIV-1, are also called complex retroviruses, which are 
characterized by a set of additional regulatory and accessory genes encoded in the viral 
genome (Cullen, 1991; Frankel & Young, 1998). In the case of HIV-1, the DNA genome 
converted from the RNA genome is about 9.7 kb and contains nine ORFs; in addition to the 
gag, pol, and env genes that are typical of all retroviruses, there are two regulatory (tat and 
rev) and four accessory (vif, vpr, vpu, and nef) genes (Fig. 1). These protein-coding regions are 
flanked by 5’ and 3’ LTR that are required for reverse transcription, integration, and gene 
expression steps. 
The complexity of HIV-1 is also characterized by its specific pattern of viral gene regulation 
(Kingsman & Kingsman, 1996). The HIV-1 LTR harbors several cis-acting sequences 
required for the initiation of viral RNA expression. The U3 region of the LTR is composed of 
a series of control elements that recruit a variety of transcription factors (Brady & Kashanchi, 
2005), and consequently, transcription of viral RNA initiates at the U3-R junction. However, 
the transcription activity of the U3 is basically low, and trans-acting proteins are required to 
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enhance the viral RNA synthesis from the 5’ LTR. Viral regulatory protein, Tat is one of 
these transactivators (Brady & Kashanchi, 2005). Tat interacts not with DNA, but with an 
RNA bulge of a stem-loop structure formed at the 5’ end of nascent transcripts, which is 
known as the transactivation response region (TAR) (Berkhout et al., 1989; Feng & Holland, 
1988). Binding of Tat to the TAR then recruits an active transcription elongation complex 
consisting of cyclin T1 (CycT1), CDK9, and some other factors (Brady & Kashanchi, 2005). 
Subsequently, CDK9 leads the hyperphosphorylation of the C-terminal domain of RNA 
polymerase II, in turn resulting in a dramatic stimulation of transcriptional processivity 
(Brady & Kashanchi, 2005). 
More than 30 species of RNA are transcribed from the integrated HIV-1 DNA; these fall into 
three size classes of mRNA based on the pattern of splicing: unspliced, partially spliced, and 
multiply spliced RNAs. (Kingsman & Kingsman, 1996; Purcell & Martin, 1993; Schwartz et al., 
1990). The unspliced transcript is full-length RNA (about 9 kb) that is packaged as the viral 
genome into new viral particles but it also functions as mRNA to produce Gag and Gag-Pol 
polyproteins. The partially spliced transcripts (about 4 kb) encode Vif, Vpr, Vpu, and Env 
proteins. At early times after infection, however, the multiply spliced RNAs are predominant, 
and their encoded proteins, Tat, Rev, and Nef are highly produced (Kim et al., 1989).  
 
 
Fig. 1. Organization of the HIV-1 genome. 
2.2 Replication cycle 
HIV-1 infection begins with the binding of the viral envelope (Env) glycoprotein gp120 
(surface envelope protein: SU) to the CD4 receptor molecule on the surface of host cells. 
Consequently, the main target cells for HIV-1 infection are the CD4+ subset of helper T cells 
and monocyte/macrophage lineages (Dalgleish et al., 1984; Landau et al., 1988; Stevenson, 
2003). The gp120-CD4 interaction triggers a conformational change in the gp120 that 
facilitates subsequent binding to a secondary cellular receptor (coreceptor). While most HIV-
1 strains use either the α-chemokine receptor CXCR4 or the β-chemokine receptor CCR5 as 
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the coreceptor, other chemokine receptors or related proteins have been reported to serve as 
coreceptors for HIV-1 infection (Berger et al., 1999). This coreceptor usage is the basis for the 
differential cell-type tropism of HIV-1 strains. Formation of the gp120-CD4-coreceptor 
complex then induces refolding of the gp41 subunit of the Env (transmembrane envelope 
protein: TM), which allows the membrane fusion process between the virus and target cell 
(Melikyan, 2008). 
After penetrating the cell membrane, the viral nucleoprotein core, which contains genomic 
RNA, is released into the cytoplasm, followed by the uncoating of the viral core that is 
required for the formation of the reverse transcription complex (RTC) (Arhel, 2010; 
Bukrinskaya et al., 1998; Fassati & Goff, 2001). Reverse transcription, one of the defining 
steps of retrovirus infection, takes place in the RTC and it is initiated from the 3’ end of the 
tRNALys3 that is annealed to the primer binding site (PBS) near the 5’ end of the viral RNA 
genome. During the reverse transcription reaction, RT firstly synthesizes the minus-strand 
DNA along with the concomitant degradation of the RNA template by its RNase H activity 
(Basu et al., 2008). Subsequent synthesis of plus-strand DNA involves priming from two 
polyprine tracts (PPT), short RNA segments resistant to RNase H digestion, at the 3’ 
terminus (3’ PPT) and the center (central PPT: cPPT) of the HIV-1 genome. Once the 3’ end 
of the plus-strand DNA reaches the 5’ end of the cPPT, DNA synthesis proceeds by 
displacing the existing DNA fragments and stops at a central termination sequence (CTS) in 
the minus-strand DNA, resulting in a 99 bp triple-strand DNA structure in the center of the 
HIV-1 DNA (Arhel, 2010; Charneau et al., 1992; Charneau et al., 1994). 
The newly synthesized full-length viral DNA remains associated with viral and cellular 
proteins in a large nucleoprotein complex called the preintegration complex (PIC) 
(Engelman, 2003). The HIV-1 PIC has been shown to contain RT, IN, matrix (MA), 
nucleocapsid (NC), and Vpr proteins (Lewinski & Bushman, 2005; Suzuki & Craigie, 2007). 
In addition to viral proteins, several cellular proteins have been reported as components of 
the HIV PIC (Suzuki & Craigie, 2007). As mentioned above, unlike many oncoretroviruses, 
HIV-1 is able to infect non-dividing cells. Thus, the HIV-1 PIC is believed to carry 
karyophilic signals that direct transport across an intact nuclear membrane in non-dividing 
cells. Although the molecular mechanisms underlying the active transport of HIV-1 PIC into 
the nucleus is still poorly understood, several viral and cellular factors have been shown to 
be implicated in the nuclear import of the HIV-1 PIC (Fassati, 2006; Suzuki & Craigie, 2007; 
Yamashita & Emerman, 2006). Cell cycle-independent infection of HIV-1 is particularly 
important in the pathogenesis of the virus and the development of HIV-1-based lentiviral 
vectors (Blankson et al., 2002; Kaul et al., 2001; Somia & Verma, 2000). 
Following nuclear transport of the PIC, integration of viral DNA into the host chromatin 
takes place. IN is a key component of the PIC that catalyzes the integration. This reaction 
proceeds via three coordinated steps: 3’ end processing of the viral DNA, joining to the 
target DNA, and repairing of the gaps between viral DNA and target DNA. IN is 
responsible for the 3’ end processing and DNA joining steps, but the gap repair step is likely 
to be carried out by yet-to-be-identified cellular enzymes (Engelman, 2003) (Fig. 2). 
The integrated DNA, called the provirus, is acted upon by cellular transcription factors to 
express viral genes. Early populations of the transcripts are the multiply spliced class of 
mRNA that encodes Tat, Rev, and Nef proteins (Kingsman & Kingsman, 1996). Tat enhances 
production of viral mRNAs by more than two log via interaction with TAR and a cellular 
elongation complex (Brady & Kashanchi, 2005). There is then an increase in the partially 
spiced and unspliced mRNAs along with a concomitant decrease in the multiply spliced 
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enhance the viral RNA synthesis from the 5’ LTR. Viral regulatory protein, Tat is one of 
these transactivators (Brady & Kashanchi, 2005). Tat interacts not with DNA, but with an 
RNA bulge of a stem-loop structure formed at the 5’ end of nascent transcripts, which is 
known as the transactivation response region (TAR) (Berkhout et al., 1989; Feng & Holland, 
1988). Binding of Tat to the TAR then recruits an active transcription elongation complex 
consisting of cyclin T1 (CycT1), CDK9, and some other factors (Brady & Kashanchi, 2005). 
Subsequently, CDK9 leads the hyperphosphorylation of the C-terminal domain of RNA 
polymerase II, in turn resulting in a dramatic stimulation of transcriptional processivity 
(Brady & Kashanchi, 2005). 
More than 30 species of RNA are transcribed from the integrated HIV-1 DNA; these fall into 
three size classes of mRNA based on the pattern of splicing: unspliced, partially spliced, and 
multiply spliced RNAs. (Kingsman & Kingsman, 1996; Purcell & Martin, 1993; Schwartz et al., 
1990). The unspliced transcript is full-length RNA (about 9 kb) that is packaged as the viral 
genome into new viral particles but it also functions as mRNA to produce Gag and Gag-Pol 
polyproteins. The partially spliced transcripts (about 4 kb) encode Vif, Vpr, Vpu, and Env 
proteins. At early times after infection, however, the multiply spliced RNAs are predominant, 
and their encoded proteins, Tat, Rev, and Nef are highly produced (Kim et al., 1989).  
 
 
Fig. 1. Organization of the HIV-1 genome. 
2.2 Replication cycle 
HIV-1 infection begins with the binding of the viral envelope (Env) glycoprotein gp120 
(surface envelope protein: SU) to the CD4 receptor molecule on the surface of host cells. 
Consequently, the main target cells for HIV-1 infection are the CD4+ subset of helper T cells 
and monocyte/macrophage lineages (Dalgleish et al., 1984; Landau et al., 1988; Stevenson, 
2003). The gp120-CD4 interaction triggers a conformational change in the gp120 that 
facilitates subsequent binding to a secondary cellular receptor (coreceptor). While most HIV-
1 strains use either the α-chemokine receptor CXCR4 or the β-chemokine receptor CCR5 as 
 
Gene Regulatable Lentiviral Vector System 
 
289 
the coreceptor, other chemokine receptors or related proteins have been reported to serve as 
coreceptors for HIV-1 infection (Berger et al., 1999). This coreceptor usage is the basis for the 
differential cell-type tropism of HIV-1 strains. Formation of the gp120-CD4-coreceptor 
complex then induces refolding of the gp41 subunit of the Env (transmembrane envelope 
protein: TM), which allows the membrane fusion process between the virus and target cell 
(Melikyan, 2008). 
After penetrating the cell membrane, the viral nucleoprotein core, which contains genomic 
RNA, is released into the cytoplasm, followed by the uncoating of the viral core that is 
required for the formation of the reverse transcription complex (RTC) (Arhel, 2010; 
Bukrinskaya et al., 1998; Fassati & Goff, 2001). Reverse transcription, one of the defining 
steps of retrovirus infection, takes place in the RTC and it is initiated from the 3’ end of the 
tRNALys3 that is annealed to the primer binding site (PBS) near the 5’ end of the viral RNA 
genome. During the reverse transcription reaction, RT firstly synthesizes the minus-strand 
DNA along with the concomitant degradation of the RNA template by its RNase H activity 
(Basu et al., 2008). Subsequent synthesis of plus-strand DNA involves priming from two 
polyprine tracts (PPT), short RNA segments resistant to RNase H digestion, at the 3’ 
terminus (3’ PPT) and the center (central PPT: cPPT) of the HIV-1 genome. Once the 3’ end 
of the plus-strand DNA reaches the 5’ end of the cPPT, DNA synthesis proceeds by 
displacing the existing DNA fragments and stops at a central termination sequence (CTS) in 
the minus-strand DNA, resulting in a 99 bp triple-strand DNA structure in the center of the 
HIV-1 DNA (Arhel, 2010; Charneau et al., 1992; Charneau et al., 1994). 
The newly synthesized full-length viral DNA remains associated with viral and cellular 
proteins in a large nucleoprotein complex called the preintegration complex (PIC) 
(Engelman, 2003). The HIV-1 PIC has been shown to contain RT, IN, matrix (MA), 
nucleocapsid (NC), and Vpr proteins (Lewinski & Bushman, 2005; Suzuki & Craigie, 2007). 
In addition to viral proteins, several cellular proteins have been reported as components of 
the HIV PIC (Suzuki & Craigie, 2007). As mentioned above, unlike many oncoretroviruses, 
HIV-1 is able to infect non-dividing cells. Thus, the HIV-1 PIC is believed to carry 
karyophilic signals that direct transport across an intact nuclear membrane in non-dividing 
cells. Although the molecular mechanisms underlying the active transport of HIV-1 PIC into 
the nucleus is still poorly understood, several viral and cellular factors have been shown to 
be implicated in the nuclear import of the HIV-1 PIC (Fassati, 2006; Suzuki & Craigie, 2007; 
Yamashita & Emerman, 2006). Cell cycle-independent infection of HIV-1 is particularly 
important in the pathogenesis of the virus and the development of HIV-1-based lentiviral 
vectors (Blankson et al., 2002; Kaul et al., 2001; Somia & Verma, 2000). 
Following nuclear transport of the PIC, integration of viral DNA into the host chromatin 
takes place. IN is a key component of the PIC that catalyzes the integration. This reaction 
proceeds via three coordinated steps: 3’ end processing of the viral DNA, joining to the 
target DNA, and repairing of the gaps between viral DNA and target DNA. IN is 
responsible for the 3’ end processing and DNA joining steps, but the gap repair step is likely 
to be carried out by yet-to-be-identified cellular enzymes (Engelman, 2003) (Fig. 2). 
The integrated DNA, called the provirus, is acted upon by cellular transcription factors to 
express viral genes. Early populations of the transcripts are the multiply spliced class of 
mRNA that encodes Tat, Rev, and Nef proteins (Kingsman & Kingsman, 1996). Tat enhances 
production of viral mRNAs by more than two log via interaction with TAR and a cellular 
elongation complex (Brady & Kashanchi, 2005). There is then an increase in the partially 
spiced and unspliced mRNAs along with a concomitant decrease in the multiply spliced 
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mRNAs, which is caused by the accumulation of Rev protein. Rev is also required for the 
nuclear export of partially spliced and unspliced mRNAs. These classes of viral RNAs 
contain a highly structured cis-acting element termed Rev response element (RRE) that is 
located in the env coding region. Rev bears a leucine-rich nuclear export signal (NES) and, 
via association with the RRE, mediates nuclear-to-cytoplasmic transport of the partially 
spliced and unspliced RNAs, resulting in production of Gag, Gag-Pol, Env, and accessory 
proteins (Pollard & Malim, 1998). 
Following the synthesis of the full-length viral RNA genome and the viral proteins, these 
components are assembled together to produce new viruses. In HIV-1, the assembly process 
takes place at the plasma membrane (Ono, 2010). Gag protein plays a central role in the 
formation of virions; this protein is synthesized as a 55 kDa precursor protein for matrix (MA), 
capsid (CA)), and nucleocapsid (NC) proteins. The Gag precursor proteins are rapidly targeted 
to the plasma membrane where they multimerize. Although the multimerization of the Gag is 
sufficient to give rise to virus like particles, incorporation of Gag-Pol proteins is integral to the 
formation of infectious virions (Wu et al., 1997). Gag-Pol is a 160 kDa multidomain protein 
consisting of RT, IN, and protease (PR), and it too relocates to the plasma membrane, where 
Gag and Gag-Pol are assembled into virus particles. In the HIV-1 genome, Gag and Pol are 
encoded by overlapping ORF; Gag-Pol is generated by a ribosomal frameshifting during 
translation of the gag gene. This translation mechanism limits intracellular synthesis of Gag-Pol 
at 10- to 20-fold-lower than Gag (Haraguchi et al., 2010). Env glycoprotein, which is 
synthesized in the rough endoplasmic reticulum (ER), reaches the cell surface and is 
incorporated into virus particles. The MA domain of Gag has been suggested to be important 
for the recruitment of Env into virions (Ono, 2010). Encapsidation of the viral genomic RNA is 
directed by an interaction between the NC domain of Gag and the packaging signal (or ψ-site 
located in the 5’ region of the gag initiation codon. The ψ sequence also acts as a dimerization 
signal for the viral RNA genome. Eventually, the virus particle is pinched off the host cell 
membrane (budding). Recent evidence has revealed that a number of cellular proteins in the 
vacuolar protein sorting (VPS) pathway are involved in the HIV-1 budding process. After 
release from the plasma membrane, virus particles undergo a maturation step, in which Gag 
and Gag-Pol precursor proteins are cleaved by the viral PR to yield the functional mature 
proteins of infectious HIV-1 (Vogt, 1996) (Fig. 2). 
Accessory proteins (i.e. Vif, Vpr, Vpu, and Nef) are dispensable for viral replication in many 
in vitro cell culture systems, but these proteins are likely to be required for efficient 
replication and pathogenicity of HIV-1 in vivo (Malim & Emerman, 2008). 
3. Development of HIV-1-derived lentiviral vectors 
Although retrovirus vectors derived from oncoretroviruses were introduced first, in recent 
years, attention of the viral vector research has been focused on lentiviruses such as HIV-1 and 
equine infectious anemia virus (EIAV) due to their ability to infect non-dividing cells. In 
particular, HIV-1 should be one of the most practical gene transfer vectors for gene therapy 
applications because this is the best studied retrovirus. However, HIV-1 is a human pathogen 
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replication competent lentiviruses (RCL). Earlier development of lentiviral vectors was 
achieved by transient transfection of human embryonic kidney (HEK293T) cells with three 
separate plasmid DNAs encoding i) the lentiviral vector genome which was composed of the 
wild-type 5’ and 3’ LTR, a part of the gag gene corresponding to the ψ sequence, a part of the 
env gene containing the RRE, an internal promoter, and the desired gene (transfer vector 
plasmid), ii) the HIV-1 genome containing all viral genes with the exception of the env gene 
(packaging plasmid), and iii) the vesicular stomatitis virus G protein (VSV-G) that improves 
the stability and broadens the cellular tropism of lentiviral vectors (Burns et al., 1993; Naldini et 
al., 1996). However, in this vector production system, there is a potential risk for the generation 
of RCL; a recombination event would occur during subsequent reverse transcription in 
transduced cells between two RNAs that are derived from the transfer vector plasmid and the 
packaging plasmid and incidentally copackaged within the same virion (Fig. 3A).  
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Fig. 3. Schematic representation of HIV-1-derived lentiviral vector packaging constructs. The 
first-generation lentiviral vectors (A) are produced by three separate plasmid DNAs 
encoding the vector genome, all HIV-1 genes except for env gene, and Env protein (VSV-G). 
To reduce the potential risk of the generation of replication competent viruses, all accessory 
genes (vif, vpr, vpu, and nef) are removed from (or mutated in) the packaging plasmids in 
second-generation lentiviral vectors (B). In third-generation lentiviral vectors, the 
enhancer/promoter unit is deleted from the U3 region of the 3’ LTR (ΔU3) in transfer vector 
plasmids (SIN vector). Additionally the U3 region of the 5’ LTR is replaced with the CMV 
promoter, enabling Tat-independent production of the lentiviral vectors (C). LTR, long 
terminal repeat; ψ, packaging signal; RRE, Rev response element. 
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3.2 Second-generation lentiviral vectors 
The second-generation lentiviral vectors basically employ a similar three-plasmid system as 
the first generation vectors. Yet, in order to overcome the safety issue attributable to the 
first-generation vectors, the second-generation lentiviral vectors were generated without 
production of all accessory proteins (Vif, Vpr, Vpu, and Nef) via mutation or deletion of 
these genes from the packaging plasmid (Gasmi et al., 1999; Kim et al., 1998; Zufferey et al., 
1997) (Fig. 3B).  
3.3 Third-generation lentiviral vectors 
The second-generation vectors, however, still carry the transcriptionally active LTR 
elements that could induce the homologous recombination between the vector genome and 
wild-type HIV-1. This would be particularly problematic if the lentiviral vectors are used for 
gene therapy of HIV/AIDS. Thus, further improvements were made in the third-generation 
lentiviral vectors. To minimize the transcriptional activity of the LTR in transduced cells, the 
enhancer/promoter unit was deleted from the U3 region of the 3’ LTR in transfer vector 
plasmids. During reverse transcription in the transduced cells, this deletion is transferred to 
the 5’ LTR of the lentiviral DNA, thereby reducing promoter activity of the integrated 
provirus (self-inactivating [SIN] vector) (Miyoshi et al., 1998; Zufferey et al., 1998). 
Additionally, the U3’region of the 5’ LTR in the transfer vector plasmid was replaced with 
the cytomegalovirus (CMV) promoter, which enabled Tat-independent transcription of the 
lentiviral vector genome in producer cells (Dull et al., 1998; Miyoshi et al., 1998). In these 
SIN vectors, there is no compete HIV-1 U3 sequence. Moreover, expression of Rev protein is 
directed by a separate plasmid, but not by the packaging plasmid encoding gag and pol 
genes (Wagner et al., 2000) (Fig. 3C). Currently, third-generation SIN lentiviral vector 
system offers the best safety profile in terms of generation of RCL because this vector 
requires only three HIV-1 genes (gag, pol, and rev) for production, however safety 
improvement in the design of HIV-1-derived lentiviral vectors is still one of the challenging 
areas in gene therapy study 
4. Incorporation of regulatable gene expression systems in HIV-1-derived 
lentiviral vectors 
Lentiviral vectors hold great promise for a gene therapy approach to inherited and 
acquired diseases. In these particular clinical settings, it would be more beneficial to 
reversibly control transgene expression in a dose and time dependent manner as 
illustrated in the field of angiogenesis and Parkinson’s disease (Ma et al., 2002; 
Yancopoulos et al., 2000). To meet the standards required for clinical applications, a 
number of regulatable gene expression systems have been developed, and some of them 
are indeed incorporated into viral vectors including HIV-1-derived lentiviral vectors 
(reviewed in Goverdhana et al., 2005). 
Although early development of the regulatable gene expression systems was based on 
naturally occurring inducible cellular promoters that respond to exogenous signals, these 
types of systems had limitations due to the pleiotropic effects of the inducer, high levels of 
“leaky” background expression and poor performance in inducibility. Therefore, recent 
efforts have been mostly focused on the development of chimeric gene regulatable systems 
derived from prokaryotic, eukaryotic, and viral elements, which are designed to enhance 
specificity and activity of transgene expression (Fussenegger, 2001). 
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4.1 Tetracycline-regulated system 
The most widely used inducible system in lentiviral vectors is the tetracycline (Tet)-
regulated system. This system was originally based on binding of the Tet-controlled 
repressor (tetR), a 23.6 kDa protein of Escherichia coli (E. coli), to the operator sequence of E. 
coli Tet resistance gene (Baron & Bujard, 2000), but further developed to be operated in 
mammalian cells by the generation of a chimeric protein in which tetR is fused with herpes 
simplex virus (HSV) VP16 protein, a eukaryotic transactivator (Tet-controlled transactivator: 
tTA) (Gossen & Bujard, 1992). In the absence of Tet or its derivatives such as doxycycline 
(Dox), the tTA binds the Tet-response element (TRE) that is composed of seven tandem 
copies of Tet operator (tetO) sequences and placed upstream of the CMV minimal promoter 
(Baron & Bujard, 2000). This type of original Tet-regulated system, called Tet-off system, has 
been incorporated into HIV-1-derived lentiviral vectors (Gascon et al., 2008; Haack et al., 
2004; Kafri et al., 2000; Vigna et al., 2002) (Fig. 4A). In the first study that employed the Tet-
off system in the context of a lentiviral vector, transgene induction by the withdrawal of Dox 
resulted in a more than 500-fold increase in the expression level of a GFP reporter gene 
(Kafri et al., 2000). Of note, the Dox-dependent regulation of GFP expression was also 
confirmed in the brain cells of rats that had been transduced by the lentiviral vector and 
then administered Dox through drinking water, indicating applicability of the gene 
regulatable lentiviral vectors in vivo (Kafri et al., 2000). However, even in the presence of 
Dox, high levels of basal GFP expression was observed, which would be attributed to the 
transcriptional interference arising from the neighboring CMV promoter or the wild-type 
HIV-1 LTR. 
In addition to the background activity in the repressed state, the major limitation of the Tet-
off system is the requirement of continuous administration of Tet or Dox to suppress 
transgene expression. To overcome this limitation, another type of Tet-controlled gene 
expression system was established by introduction of several permutations in the tTA 
protein of the Tet-off system. The mutant tTA binds the tetO sequences only in the presence 
of Tet/Dox: it exhibits opposite function (Gossen et al., 1995). Because this modified version 
of regulatable system, the so-called Tet-on system, shows rapid kinetics of gene 
upregulation compared to Tet-off system, several HIV-1-derived lentiviral vectors have been 
constructed using the Tet-on system as well (Johansen et al., 2002; Koponen et al., 2003; 
Pluta et al., 2005; Reiser et al., 2000; Vogel et al., 2004) (Fig. 4B). 
One more approach to permit tight control of transgenes in the context of a lentiviral vector 
is demonstrated in the Tet-regulated system that employs a chimeric tetR fused with the 
Krüppel-associated box (KRAB) domain, a transcriptional regulator found in many DNA 
binding zinc-finger proteins (Szulc et al., 2006; Wiznerowicz & Trono, 2003). Binding of the 
KRAB domain-containing repressor protein to DNA recruits various heterochromatin-
inducing factors, thereby suppressing activity of cellular RNA polymerases (RNAPs) II and 
III. This transcriptional silencing can be exerted no farther than 2-3 kb away from the 
repressor binding site. In the new design of Tet-regulated lentiviral vector system, the tetO 
site was inserted upstream of the RNAP III promoter-driven small hairpin RNA (shRNA) 
expression cassette which was located in the U3 region of lentiviral vector genome, and the 
activity of tetO-linked shRNA expression unit was tightly suppressed in the presence of 
KRAB-fused tTA and in the absence of Dox. The KRAB-fused tTA/Dox-dependent 
inhibition of transcriptional activity was also observed in the internal RNAP II promoter for 
a reporter transgene within the same vector genome. However, when the transduced cells 
were treated with Dox, shRNA was produced to achieve RNA interference, which was 
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correlated with the expression of the reporter transgene (Szulc et al., 2006; Wiznerowicz & 
Trono, 2003). 
One drawback of the Tet-regulated system is that there is a requirement to deliver two distinct 
expression units into a target cell: one is for transactivator (e.g. tTA) expression and the other is 
for transgene expression. In a binary lentiviral vector approach in which tTA and transgene 
expression cassettes are cloned into separate vectors, a population cells that is singly 
transduced with either tTA or transgene would be produced, resulting in low inducibility as a 
whole. This can be a bottleneck, particularly in relevant applications of the Tet-regulated 
lentiviral vector systems in clinical use. Single vector systems that contain the entire 
regulatable component in a unique vector is one of the solutions to guarantee simultaneous 
expression of the two expression units in the target gene, and these have indeed been 
established (Gascon et al., 2008; Kafri et al., 2000; Szulc et al., 2006; Vogel et al., 2004). 
4.2 Mifepristone-inducible system 
This gene regulatable system (also called GeneSwitch system) is based on a mutated human 
progesterone receptor that responds to the synthetic progestin antagonist but fails to bind 
natural progestins or other steroids (Burcin et al., 1999; Wang et al., 1994). Similar to Tet-
regulated system, this system requires two components: the regulator (transactivator) 
protein and the inducible promoter sequence that drives transgene expression. The 
regulator is a hybrid protein consisting of a GAL4 DNA-binding domain from Saccharomyces 
cerevisiae, a ligand-binding domain of mutant progesterone receptor, and an activation 
domain of the p65 subunit of human NF-κB (Burcin et al., 1999). The inducible transgene 
expression unit contains six copies of the GAL4 upstream activating sequences (UAS) and 
the TATA box sequence in its promoter (Abruzzese et al., 1999). The progestin antagonist 
commonly used as an inducer for the GeneSwitch system is mifepristone (MFP, RU486). The 
regulator protein initially exists as an inactive monomeric form. However, in the presence of 
MFP, it binds to the MFP and undergoes a conformational change, causing the regulator 
protein to become an active homodimer. The active form of the regulator is able to bind to 
GAL4 UAS and induce transgene expression (Nordstrom, 2003) (Fig. 4C). 
Sirin and Park have incorporated the MFP-inducible gene expression system into HIV-1-
derived lentiviral vectors (Sirin & Park, 2003). In their design, two different SIN lentiviral 
vectors were constructed, in which either the regulator protein expression unit or the 
inducible transgene expression unit was cloned. When human cell lines (HeLa and Huh7 
cells) were infected with both lentiviral vectors, up to a 275-fold increase in the number of 
reporter fluorescent protein-positive cells was observed at 48 hours following MFP 
treatment. Similar effective induction was also detected in cells transduced by a lentiviral 
vector expressing the human α1-antitrypsin (hAAT) with an extremely low level of basal 
hAAT expression (Sirin & Park, 2003). 
Although an in vitro study using adenovirus vector expressing the chloramphenicol acetyl 
transferase (CAT) as a reporter transgene gene demonstrates that induction level of the 
GeneSwitch system is lower than that of the Tet-regulated (Tet-on) system (Molin et al., 
1998), the GeneSwitch system holds some advantages in its application to human gene 
therapy. The majority of components of the regulator protein are derived from human 
proteins, which has less impact on cell viability and immunogenicity. In addition, MFP has 
been approved by the Food and Drug Administration (FDA) for use in humans (Ulmann et 
al., 1995), and the concentration of MFP need for transgene induction is significantly lower 
than the concentration for its anti-progesterone effect (Nordstrom, 2003).  
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Fig. 4. Diagrams of two regulatable gene expression systems. The Tetracycline-regulated 
system is the most widely used inducible system in lentiviral vectors. In a Tet-off system 
(A), the Tet-controlled transactivator (tTA), a chimeric protein of E. Coli Tet-controlled 
repressor (tetR) and HSV VP16, binds the Tet-response element (TRE) upstream of the CMV 
promoter in the absence of Tet or Dox. On the other hand, in the Tet-on system (B), several 
mutations are introduced into the tTA (rtTA) so that this transactivator binds the TRE in the 
presence of Dox. The Mifepristone-inducible system (GeneSwitch) has been also 
incorporated into HIV-1-derived lentiviral vectors. In this system, the transactivator is a 
chimeric protein that comprises the GAL4 DNA-binding domain from Saccharomyces 
cerevisiae fused to the ligand-binding domain of a mutant progesterone receptor (hPR LBD 
Δ19) and the activation domain of the p65 subunit of human NF-kB. In the presence of 
mifepristone (MFP), the chimeric transactivator binds to the six copies of GAL4 upstream of 
the activating sequences and induce transgene expression (C). TATA, TATA box sequence. 
4.3 Ecdysone-regulated system 
The Drosophila melanogaster ecdysone receptor (EcR)-based gene regulatable system has been 
adapted to lentiviral vectors (Galimi et al., 2005). EcR is a member of the nuclear receptor 
superfamily that mediates a cascade of morphological changes in Drosophila, triggered by 
the steroid hormone ecdysone. Ecdysone regulates gene expressions by interacting with the 
functional EcR, which in turn induces binding of the EcR to DNA regulatory elements 
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EcREs) near target genes (No et al., 1996). The ecdysone-regulated gene expression system 
incorporated into lentiviral vectors employed two elements: i) the dimeric regulator protein 
of the EcR fused with HSV VP16 activation domain (VgEcR) and the retinoid X receptor 
(RXR), and ii) the hybrid promoter between the glucocorticoid response element and that of 
type II nuclear receptors (E/GRE) (Galimi et al., 2005). Upon exposure to ecdysone or 
synthetic analogues such as ponasterone A, the VgECR/RXR heterodimer binds to the 
E/GRE, resulting in induction of transgene expression (Saez et al., 2000). One advantage of 
the ecdysone-regulated gene expression system is the pharmacological profile of the inducer 
that allows for fast distribution and clearance after administration in vivo (Saez et al., 2000). 
Additionally, the inducible promoter is not responsive to natural nuclear receptors (No et 
al., 1996). 
In the single vector approach, the inducible GFP expression cassette containing E/GRE as 
well as a CNV promoter-driven bicistronic unit for VgEcR and RXR expressions were cloned 
into an HIV-1-derived SIN lentiviral vector. However, this ecdysone-regulated system was 
also applicable to the binary vector system, in which the VgEcR/RXR expression unit was in 
one lentiviral vector and the inducible transgene expression unit was in the second vector. 
The latter approach would be of value in deliver of longer transgene. These lentiviral vectors 
have been shown to successfully deliver the ponA-inducible GFP expression units in vitro 
and ex vivo (Galimi et al., 2005). 
4.4 Other regulatable systems 
Besides the Tet- MFP-, and ecdysone-regulated systems, different types of inducible 
lentiviral vectors have been generated based on the other chimeric regulatable systems, 
which include streptogramin-adjustable expression system derived from Streptomyces 
coelicolor (Mitta et al., 2004) and gaseous acetaldehyde-inducible expression system derived 
from Aspergillus nidulans (Hartenbach & Fussenegger, 2005). Although some endogenous 
cellular elements that respond to exogenous signals or stress have been adapted to HIV-1- 
and EIAV-derived lentiviral vectors (Beutelspacher et al., 2005; Hurttila et al., 2008; Parker et 
al., 2009), the pleiotropic effects exerted by the inducing agent would be a drawback in a 
human therapeutic context (Fussenegger, 2001). 
5. Application of a gene regulatable lentiviral vector for HIV-1 inhibition 
Lentiviral vector-mediated gene therapy has the potential to improve the clinical state of a 
patient with HIV-1. This goal would be accomplished by ex vivo transduction of anti-HIV 
genes into CD4+ virus target cells such as helper T cells and macrophages or CD34+ 
progenitor cells (HSCs), making them resistant to HIV-1 infection (intracellular 
immunization approach) (Baltimore, 1988; Kitchen et al., 2011). So far, various studies have 
reported the delivery of anti-HIV genes by HIV-1-based lentiviral vectors in vitro and in vivo, 
and the anti-HIV genes can be categorized as either RNA- or protein-based (Mukhtar et al., 
2000) (Banerjea et al., 2003; Dropulic et al., 1996; Klimatcheva et al., 2001; Li et al., 2003; 
Mautino et al., 2001; Mautino & Morgan, 2002a, b, c). Among the RNA-based anti-HIV genes 
include a ribozyme that cleaves the U5 region of HIV-1 RNA by its enzymatic activity 
(Dropulic et al., 1996), an antisense RNA that hybridizes the transcripts of HIV-1 env gene to 
inhibit translation of Env (Mautino & Morgan, 2002a, c), and small interfering RNA (siRNA) 
that induces sequence-specific degradation of HIV-1 RNA (Banerjea et al., 2003). In the 
protein-based approach, the transdominant negative mutant of Rev (TdRev) is best 
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described as an anti-HIV gene used in the setting of lentiviral vectors (Klimatcheva et al., 
2001; Mautino et al., 2001; Mautino & Morgan, 2002c; Mukhtar et al., 2000). The TdReV 
named RevM10 is a derivative of HIV-1 Rev in which two amino acid mutations are 
introduced in the C-terminus activation domain, and hampers nuclear export of HIV-1 
mRNAs via the formation of inactive multimers with WT Rev (Hope et al., 1992; Malim et 
al., 1989). It should be noted that RevM10 has been already tested in phase I clinical trials to 
treat HIV infection via transduction of the gene into CD34+ cells with MoMLV-derived 
retroviral vectors (Kang et al., 2002; Kitchen et al., 2011; Podsakoff et al., 2005). 
Although a promising approach for HIV gene therapy, constitutive expression of anti-HIV 
genes in the context of HIV-1-derived lentiviral vectors could encounter a problem of self-
inhibition of the vector particle production, resulting in significant decrease of viral 
infectious titer (Mautino & Morgan, 2002b). This problem of self-inhibition can be solved by 
several means. If the anti-HIV gene targets specific sequences in the HIV-1 RNA, one 
strategy to avoid the self-inhibition would be to engineer nucleotide sequences of lentiviral 
vector genome and packaging genes in order that anti-HIV gene will exclusively recognize 
wild-type virus in transduced cells. As for TdRev, the inhibition of vector production could 
be overcome by replacement of the HIV-1 Rev-dependent nuclear export element (e.g. RRE) 
with the one derived from another lentiviruses, conferring Rev-independent property on the 
lentiviral vectors (Mautino et al., 2001; Taylor et al., 2008). But, if the anti-HIV genes are 
designed to target HIV-1 at more fundamental process such as virion formation and 
budding processes, an ideal strategy would be the incorporation of regulatable transgene 
expression system into lentiviral vectors, in which expression of the anti-HIV gene is “OFF” 
during vector production and turned “ON” in the target cells. 
In order to assess the availability of gene regulatable systems in inhibition of HIV-1, we have 
generated HIV-1-derived lentiviral vectors harboring the MFP-inducible transgene 
expression unit (Shinoda et al., 2009). In the study, two SIN lentiviral vectors were designed 
to incorporate the MFP-inducible unit in either the forward or the reverse orientation with 
respect to the direction of transfer vector genome (designated as forward and reverse 
vectors, respectively), since it has been reported that promoter activity of the internal gene 
expression unit could be affected by its orientation and/or the presence of adjacent LTR 
(Chen et al., 1992; Reiser et al., 2000; Sirin & Park, 2003). When firefly luciferase gene, which 
does not interfere with HIV-1 production, was inserted into the MFP-inducible lentiviral 
vectors, substantial levels of infectious vectors could be yielded from the forward and 
reverse vector systems by co-transfection with packaging plasmid DNAs in HEK293T cells. 
However, the infectious titer obtained by the forward vector was more than 10-fold higher 
than reverse vector, and even in the absence of transactivator and inducer, significant level 
of the leaky expression of luciferase was observed in the forward vector plasmid 
transfected-cells, but not in the reverse vector-transfected cells (Shinoda et al., 2009). It can 
be speculated that the higher background activity in the forward vector was due to the 
enhancement of gene expression by orientation-dependent cis-acting element such as the 
woodchuck post-regulatory element (WPRE) and/or the weak promoter activity of the  
5’ LTR. Importantly, this tight suppression of inducible unit in the reverse vector was 
reflected in its ability to produce infectious vectors when a transdominant negative mutant 
of human VPS4B protein in the VPS pathway, which inhibits budding process of HIV-1, was 
used as a transgene. Transfection of the reverse vector plasmid containing VPS4B dominant-
negative mutant yielded infectious lentiviral vector, transfection of the forward vector could 
not generate infectious vectors, demonstrating the self-inhibition by the leaky expression of 
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VPS4B dominant-negative mutant from the forward vector plasmid in vector producing 
cells (Shinoda et al., 2009). As expected, subsequent transduction of the transactivator-
expressing cells with the infectious reverse vector bearing the VPS4B mutant resulted in 
significant inhibition of wild-type HIV-1 production only in the presence of MFP (Shinoda 
et al., 2009). Thus, this previous study demonstrates that the gene regulatable lentiviral 
vector system has the capability to transduce anti-HIV gene and subsequently block HIV-1 
budding without the problem of self-inhibition during vector production. 
6. Conclusion and future direction 
Lentiviral vectors derived from HIV-1 are attractive gene delivery vehicles in terms of stable 
and long-term transgene expression in dividing and non-dividing cells. Although strong 
promoters used to achieve high levels of transgene expression are put into general use in the 
lentiviral vectors, incorporation of regulatable gene expression system confers 
transcriptional flexibility to the vector, which expands the potential of the lentiviral vectors 
for a wide array of gene transfer applications, particularly when undesired side effect would 
be expected by the constitutive expression of transgene. Nevertheless, many obstacles must 
be overcome for the clinical application of gene regulatable lentiviral vectors in gene 
therapy. One of the obstacles is that all the components of a regulatory system should be 
incorporated into a single vector, limiting the cloning capacity for transgene. Another issue 
is that there is no gene regulatory system approved by the FDA for clinical use. However, if 
their safety and efficacy are validated, development of gene regulatable lentiviral vector 
systems will be a next promising step toward achieving successful gene therapy for 
otherwise incurable diseases. 
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1. Introduction 
Professional antigen presenting cells, in particular dendritic cells (DCs) are central players in 
the immune response (Steinman & Banchereau 2007). Their function is dual; on the one hand 
DCs evoke strong immune responses against antigens that are considered hazardous, on the 
other hand DCs induce tolerance against self-antigens. To that end, DCs need to present 
antigen-derived peptides in the context of MHC class I or class II molecules to CD8+ and CD4+ 
T cells, respectively. It is the context in which these peptides are presented that determines the 
outcome of the immune response, immune activation versus tolerance. Consequently, DCs 
have become targets for immunotherapy against not only cancer and infectious disease, but 
also autoimmune diseases and transplantation rejection (Palucka et al.).   
Key to successful DC-based immunotherapy is the delivery of the antigen of interest, be it 
cancer, viral or auto-antigens, to DCs, as well as the delivery of molecules that dictate the 
immune stimulatory capacity of the DCs. Therefore, it is not surprising that much effort has 
been put in the development of vectors for genetic modification of DCs (Breckpot et al. 
2004c). Of these lentiviral vectors (LVs), often derived from human immunodeficiency virus 
type 1 (HIV-1) are amongst the most efficient gene delivery vehicles, for both in vitro and in 
vivo modification of DCs (Escors & Breckpot ; Breckpot et al. 2007a). In addition, these LVs 
were demonstrated to activate the innate immune system through interaction with amongst 
others Toll-like receptors (TLRs), a characteristic that makes LVs even better suited for 
immunotherapeutic approaches against cancer and infectious diseases (Breckpot et al. ; 
Brown et al. 2006a). As immune activation of DCs is critical for the induction of antigen-
specific immunity, several strategies have been developed to further strengthen the immune 
response by introduction of immune modulating molecules or by modulation of well-
known activation pathways such as the nuclear factor-kappaB (NF-κB), mitogen activated 
protein kinase (MAPK) p38 and MAPK c-Jun N-terminal kinases (JNK) pathways (Breckpot 
& Escors 2009a). Although LVs inherently activate DCs, they have also been evaluated for 
their ability to switch of the stimulatory capacity of DCs, thus to generate tolerogenic DCs. 
The strategies exploited therefore are similar to the strategies employed to activate DCs and 
include introduction of single inhibitory molecules and modulation of pathways that 
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regulate the tolerogenic potential of DCs, such as the MAPK extracellular signal-regulated 
kinase (ERK) pathway (Arce et al. ; Gould & Favorov 2003).   
In the remainder of this chapter, we will give a comprehensive overview on how DCs have 
evolved to the cell type of choice for manipulation of the immune system, why LVs are 
successful for the genetic modification of DCs and which developments have led to the use 
of LVs to generate stimulatory or tolerogenic DCs. We will further touch upon the concerns 
that are raised in terms of translating the use of LVs to the clinic, i.e. the biosafety of LVs, 
summarizing strategies to avoid off-target transduction, and linked herewith insertional 
mutagenesis. Finally, we will conclude this chapter with our view on the future perspectives 
for the use of LVs to manipulate DCs, hence the immune system. 
2. Dendritic cells 
Dendritic cells (DCs) as we know them today were described during the mid 1970s by Ralph 
Steinman and co-workers as a rare subset of accessory cells, which are characterized by 
stellate cytoplasmatic protrusions. It was this tree-like morphology that led to their name 
(Dendron is Greek for tree) (Steinman & Cohn 1973). DCs are a heterogeneous population 
for which individual DC subtypes have been described. These DC subtypes differ in tissue 
distribution, surface marker expression and their capacity to stimulate T cells (Palucka et al.). 
Moreover, DCs have a remarkable functional plasticity. On the one hand DCs can induce 
immune responses against invading pathogens (non-self). On the other hand DCs can 
induce T cell anergy/depletion, and regulatory T cells (Treg) to avoid unwanted immune 
reactions against auto-antigens (self) (Fig. 1). This Janus-like functional behaviour is 
correlated with complex decision-making processes, triggered by the presence or absence of 
so called danger signals, hence resulting in the expression of stimulatory and/or inhibitory 
molecules, respectively (Coquerelle & Moser). Although, we are still deciphering the DC 
system in its complexity, DCs have entered the clinic as a cellular therapeutic. 
2.1 Dendritic cell subsets 
Originally it was thought that DCs were of myeloid origin. Studies demonstrating in vitro 
generation of DCs from monocytes (Sallusto & Lanzavecchia 1994), and in vivo studies 
demonstrating the differentiation of phagocytic monocytes to DCs (Randolph et al. 1999) 
supported this idea. Later on, the existence of lymphoid DCs was evidenced (Wu et al. 1996; 
Wu et al. 1998). These CD11c+ MHC class II+ myeloid and lymphoid DC subtypes were 
afterwards termed CD8- DCs or CD8+ DCs, respectively. Together they are called 
conventional DCs (cDCs). Importantly, it was demonstrated in several in vivo studies that 
both CD8- and CD8+ DC subsets could be generated from either lymphoid (Martin et al. 
2000; Traver et al. 2000), or myeloid progenitors (Traver et al. 2000), mounting the question 
whether these subsets are really distinct or represent different developmental states. cDCs 
can be found within lymph nodes, spleen, and thymus, but not in bone marrow (Steinman & 
Cohn 1973). They are believed to cross-present antigens to T cells (den Haan & Bevan 2002), 
as such stimulate a T helper type 2 (TH2, humoral) and type 1 (TH1, cellular) immune 
response (Maldonado-Lopez et al. 1999). In humans, DCs expressing BDCA-1 (CD1c) and 
BDCA-3 (CD141) are considered the counterparts of mouse cDCs. However, these human 
DC subsets are often termed myeloid instead of conventional. Human myeloid DCs are 
characterized by their ability to produce high amounts of interleukin (IL)-12 in response to 
several stimuli (van Duin et al. 2006), thus to induce cellular immunity.   
 




Fig. 1.  Schematic representation of DC subsets and their functional plasticity. Generally 
DC subsets are divided into cDCs (blue) and pDCs (grey). These DC subsets differ in tissue 
distribution, expression of PRRs, hence their ability to sense pathogens and subsequently 
stimulate appropriate T cell responses. Dependent on the stimuli these DCs encounter they 
will become tolerogenic or immunogenic, hence induce tolerance (Treg, red) or immunity 
(effector T cells, green), respectively. 
Another DC subset, the plasmacytoid DCs (pDCs) were described a decade ago (Siegal et al. 
1999). Whereas mouse pDCs express CD11c, human pDCs express low to undetectable 
levels of CD11c. Instead, human pDCs are characterized by the expression of CD4, CD45RA, 
as well as the expression of high levels of CD123 (IL-3 receptor) and the c-type lectin 
receptor BDCA2. Recently, it was described that pDCs can be further divided into 
subclasses based on the expression of CD2 (Matsui et al. 2009). pDCs reside in the same 
tissues as cDCs, and can moreover be found in bone marrow (Nakano et al. 2001), where 
they are believed to be a precursor for cDCs (Soumelis & Liu 2006; Segura et al. 2009). 
Nonetheless, pDCs, isolated from mice and humans, are functionally distinct from cDCs. In 
their resting state, pDCs play an important role in the induction of tolerance (Martin et al. 
2002). However, pDCs are best known for the ability to produce high amounts of type I 
interferon (IFN) in response to viral infection (O'Keeffe et al. 2002; Fitzgerald-Bocarsly et al. 
2008). In fact, pDCs control the progress of a virus infection at various levels: (i) through 
non-specific blockade of viral replication by type I IFN, (ii) by promoting the maturation of 
pDCs as well as other DC subsets (Fonteneau et al. 2004), and (iii) through the specific 
stimulation of adaptive anti-viral CD8+ T cell responses (Di Pucchio et al. 2008). 
The last DC subset to be discussed, the epidermal Langerhans’ cells (LCs), was in fact 
described in 1868 by Paul Langerhans (Merad & Manz 2009), almost a century before the 
description of cDCs (Steinman & Cohn 1973). LCs are characterized by the expression of 
Langerin and Birbeck granules. Furthermore, they are characterized by their long life span 
(weeks) when compared to other DC types (3-10 days) (Kamath et al. 2002). Upon activation 
LCs migrate through the dermis into regional lymph nodes to present antigens to T cells 
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several stimuli (van Duin et al. 2006), thus to induce cellular immunity.   
 




Fig. 1.  Schematic representation of DC subsets and their functional plasticity. Generally 
DC subsets are divided into cDCs (blue) and pDCs (grey). These DC subsets differ in tissue 
distribution, expression of PRRs, hence their ability to sense pathogens and subsequently 
stimulate appropriate T cell responses. Dependent on the stimuli these DCs encounter they 
will become tolerogenic or immunogenic, hence induce tolerance (Treg, red) or immunity 
(effector T cells, green), respectively. 
Another DC subset, the plasmacytoid DCs (pDCs) were described a decade ago (Siegal et al. 
1999). Whereas mouse pDCs express CD11c, human pDCs express low to undetectable 
levels of CD11c. Instead, human pDCs are characterized by the expression of CD4, CD45RA, 
as well as the expression of high levels of CD123 (IL-3 receptor) and the c-type lectin 
receptor BDCA2. Recently, it was described that pDCs can be further divided into 
subclasses based on the expression of CD2 (Matsui et al. 2009). pDCs reside in the same 
tissues as cDCs, and can moreover be found in bone marrow (Nakano et al. 2001), where 
they are believed to be a precursor for cDCs (Soumelis & Liu 2006; Segura et al. 2009). 
Nonetheless, pDCs, isolated from mice and humans, are functionally distinct from cDCs. In 
their resting state, pDCs play an important role in the induction of tolerance (Martin et al. 
2002). However, pDCs are best known for the ability to produce high amounts of type I 
interferon (IFN) in response to viral infection (O'Keeffe et al. 2002; Fitzgerald-Bocarsly et al. 
2008). In fact, pDCs control the progress of a virus infection at various levels: (i) through 
non-specific blockade of viral replication by type I IFN, (ii) by promoting the maturation of 
pDCs as well as other DC subsets (Fonteneau et al. 2004), and (iii) through the specific 
stimulation of adaptive anti-viral CD8+ T cell responses (Di Pucchio et al. 2008). 
The last DC subset to be discussed, the epidermal Langerhans’ cells (LCs), was in fact 
described in 1868 by Paul Langerhans (Merad & Manz 2009), almost a century before the 
description of cDCs (Steinman & Cohn 1973). LCs are characterized by the expression of 
Langerin and Birbeck granules. Furthermore, they are characterized by their long life span 
(weeks) when compared to other DC types (3-10 days) (Kamath et al. 2002). Upon activation 
LCs migrate through the dermis into regional lymph nodes to present antigens to T cells 
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(Romani et al. 2003). Because of this migration they are categorized as migratory DCs, a 
category, which also comprises other non-lymphoid tissue residing DCs, amongst which 
dermal DCs. LCs and dermal DCs are often grouped as skin DCs. It is generally accepted 
that these have a potent T cell stimulatory capacity (Romani et al. 2003; Larregina & Falo 
2005; He et al. 2006). Nevertheless, as for pDCs and cDCs, a possible tolerogenic capacity has 
been reported for skin DCs (Grabbe et al. 1995; Kaplan et al. 2005).  
2.2 Dendritic cells and the regulation of immune responses  
In addition to subsets with functional specialization, DCs are endowed with a remarkable 
functional plasticity. The hypothesis is that distinct DC activation stages play a role in the 
induction of tolerance versus immunity. This is correlated with the two-signal model of T cell 
stimulation, in which it is proposed that a productive T cell response requires recognition of 
MHC/peptide complexes by the T cell receptor (TCR) (signal 1) along with signalling 
through co-stimulatory molecules (signal 2). Indeed, steady-state cDCs and pDCs, have 
been described to induce T cell tolerance (Jonuleit et al. 2001; Mahnke et al. 2002; Martin et al. 
2002), whereas both activated DC types have been shown to induce immunity (Salio et al. 
2003; Cerundolo et al. 2004; Salio et al. 2004). 
Immature DCs efficiently take up pathogens, apoptotic cells and particulate antigens from the 
environment by phagocytosis, macropinocytosis, or endocytosis; process these but are 
considered inefficient in presenting these to T cells (Wilson et al. 2004). Hence, immature DCs 
are believed to induce tolerance (Steinbrink et al. 1997; Lutz & Schuler 2002). Indeed, in steady-
state conditions DCs remain immature and tissue-resident, express small amounts of MHC 
and co-stimulatory molecules hence induce T cell anergy instead of T cell activation upon DC-
T cell interaction (Hawiger et al. 2001). Furthermore, injection of immature DCs in humans 
induces tolerance (Dhodapkar et al. 2001; Jonuleit et al. 2001; Dhodapkar & Steinman 2002). In 
contrast, activated DCs are considered to be immunogenic. Maturation of DCs can be induced 
by a variety of signals, such as microorganisms (Rescigno et al. 2000; Beyer et al. 2001), 
cytokines (Jonuleit et al. 1997), interaction with CD4+ TH cells (Caux et al. 1994; Mackey et al. 
1998a; Mackey et al. 1998b) and chemicals like haptens (Aiba et al. 1997; Aiba & Tagami 1998; 
Aiba & Tagami 1999). DC maturation is associated with several coordinated events, including: 
(i) loss of endocytic and phagocytic receptors; (ii) changes in morphology; (iii) up-regulation of 
MHC and co-stimulatory molecules, such as CD40, CD80 and CD86, adhesion molecules and 
chemokine receptors, such as CCR7 (Tuyaerts et al. 2007a). The latter is one of the first changes 
and enables DCs to migrate from the periphery to the T cell areas of draining lymphoid organs 
(Forster et al. 2008). Here DCs present antigenic peptides in the context of MHC molecules to T 
cells. The phenotypic changes, high expression of antigen presenting, co-stimulatory and 
adhesion molecules, make mature DCs potent inducers of T cell immunity. However, the view 
that immature DCs induce tolerance and mature DCs induce immunity is simplified. It has 
been demonstrated that mature DCs can contribute to T cell tolerance through the induction of 
Treg (Verhasselt et al. 2004). It was suggested that the maturation trigger dictates the T cell 
polarizing or tolerating immune functions of the DCs. Some stimuli have been demonstrated 
to promote induction of TH1 responses, hence cellular immunity, whereas others hamper full 
DC maturation and cytokine production, hence promote tolerance.   
2.3 Stimulatory dendritic cells  
The immune system is constantly faced with choices. When confronted with a microbe, it 
must first decide whether to respond or not. If it chooses to respond, then it must decide 
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what kind of response to launch. A hallmark of the mammalian immune system is its ability 
to launch qualitatively distinct types of responses against different pathogens (Pulendran et 
al. 2008). Immune responses against T cell-dependent antigens can be divided in (i) CD4+ 
TH1 responses, which are characterized by high secretion of IFN-γ, and induced against 
intracellular microbes, (ii) CD4+ TH2 responses, which are characterized by the secretion of 
cytokines, such as IL-5 and IL-13, and induced against extracellular pathogens, (iii) CD4+ 
TH17 responses, characterized by the secretion of IL-17, and induced against fungi (Bettelli et 
al. 2007; Reiner 2007), and finally (iv) Treg responses, with suppressive activity, and which 
are essential to maintain tolerance to host antigens (Wing & Sakaguchi). Treg can also be 
induced by some microbial stimuli (Belkaid 2007), and are abundantly present in the blood, 
lymphoid organs and tumours of cancer patients (Vence et al. 2007; Ahmadzadeh et al. 2008), 
as such Treg enable evasion from the immune system.   
For the treatment of cancer and infectious diseases, a CD4+ TH1 response is required to 
induce a strong CD8+ cytotoxic T cell (CTL) response (Breckpot & Escors 2009a). These CTLs 
will then kill the target cells. To activate T cells, at least two signals are required (i) antigen 
recognition and (ii) co-stimulation. In the presence of tolerogenic mechanisms, as it is the 
case in cancer, an additional third signal is required. This is obtained by triggering of innate 
sensing pathways (Breckpot & Escors 2009a). As co-stimulatory molecules are not expressed 
by immature DCs, it goes without saying that DC activation (maturation) is a key event that 
determines the T cell stimulatory potential of DCs.  
Differentiation of immature to mature DCs requires pathogen recognition. Groups of 
pathogens express similar structures such as bacterial and viral nucleic acids or repetitive 
elements in the bacterial cell wall or within the viral envelope, enabling the recognition of a 
wide variety of pathogens. These structures are called pathogen-associated molecular patterns 
(PAMPs) and are recognized on DCs by pathogen recognition receptors (PRRs). The best-
studied PRRs are the TLRs, although other PRRs, such as Nod-like receptors, RIG-I-like 
receptors, as well as some members of the C-type lectin family, are described. Distinct 
pathogens express different PAMPs and this combination works as a fingerprint that triggers a 
specific set of PRRs (Akira et al. 2006; Barton & Kagan 2009; Geijtenbeek & Gringhuis 2009). As 
such complex signalling networks are activated. These cooperate, integrate and finally 
converge into a few pathways, of which the NF-κB and the MAPK pathways are examples 
(Rescigno et al. 1998; Sato et al. 1999; Re & Strominger 2001; Caparros et al. 2006; Kawai & Akira 
2008). These are described in detail elsewhere (Breckpot & Escors 2009c).  
The concept of co-stimulation was first introduced by Kevin Lafferty and co-workers 
(Lafferty et al. 1979). In the last decades, a large number of co-stimulatory molecules have 
been identified, which can be divided in members of the (i) B7 and (ii) tumour necrosis 
factor (TNF) type family. B7.1 (CD80) and B7.2 (CD86) are textbook examples of the B7 
family. These transmit strong co-stimulatory signals to T cells through interactions with 
CD28 on T cells (Greenwald et al. 2005). Recently, this group was expanded with a number 
of new members including ICOS ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3 and B7-H4. 
All these molecules are expressed on DCs. The corresponding CD28 members that are 
inducible expressed on T cells are ICOS, PD-1 and BTLA. It is important to mention that not 
all B7 family members are co-stimulatory. In fact, many of these new members have been 
linked to induction of tolerance hence they are discussed in the next section. The TNF type 
family of co-stimulatory molecules, includes CD70, OX40L, GITRL and 4-1BBL, which are 
expressed on DCs and their corresponding receptors CD27, OX40 (CD134), GITR and 4-1BB 
(CD137), expressed on T cells (Watts 2005). Some co-stimulatory molecules exemplified by 
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(Romani et al. 2003). Because of this migration they are categorized as migratory DCs, a 
category, which also comprises other non-lymphoid tissue residing DCs, amongst which 
dermal DCs. LCs and dermal DCs are often grouped as skin DCs. It is generally accepted 
that these have a potent T cell stimulatory capacity (Romani et al. 2003; Larregina & Falo 
2005; He et al. 2006). Nevertheless, as for pDCs and cDCs, a possible tolerogenic capacity has 
been reported for skin DCs (Grabbe et al. 1995; Kaplan et al. 2005).  
2.2 Dendritic cells and the regulation of immune responses  
In addition to subsets with functional specialization, DCs are endowed with a remarkable 
functional plasticity. The hypothesis is that distinct DC activation stages play a role in the 
induction of tolerance versus immunity. This is correlated with the two-signal model of T cell 
stimulation, in which it is proposed that a productive T cell response requires recognition of 
MHC/peptide complexes by the T cell receptor (TCR) (signal 1) along with signalling 
through co-stimulatory molecules (signal 2). Indeed, steady-state cDCs and pDCs, have 
been described to induce T cell tolerance (Jonuleit et al. 2001; Mahnke et al. 2002; Martin et al. 
2002), whereas both activated DC types have been shown to induce immunity (Salio et al. 
2003; Cerundolo et al. 2004; Salio et al. 2004). 
Immature DCs efficiently take up pathogens, apoptotic cells and particulate antigens from the 
environment by phagocytosis, macropinocytosis, or endocytosis; process these but are 
considered inefficient in presenting these to T cells (Wilson et al. 2004). Hence, immature DCs 
are believed to induce tolerance (Steinbrink et al. 1997; Lutz & Schuler 2002). Indeed, in steady-
state conditions DCs remain immature and tissue-resident, express small amounts of MHC 
and co-stimulatory molecules hence induce T cell anergy instead of T cell activation upon DC-
T cell interaction (Hawiger et al. 2001). Furthermore, injection of immature DCs in humans 
induces tolerance (Dhodapkar et al. 2001; Jonuleit et al. 2001; Dhodapkar & Steinman 2002). In 
contrast, activated DCs are considered to be immunogenic. Maturation of DCs can be induced 
by a variety of signals, such as microorganisms (Rescigno et al. 2000; Beyer et al. 2001), 
cytokines (Jonuleit et al. 1997), interaction with CD4+ TH cells (Caux et al. 1994; Mackey et al. 
1998a; Mackey et al. 1998b) and chemicals like haptens (Aiba et al. 1997; Aiba & Tagami 1998; 
Aiba & Tagami 1999). DC maturation is associated with several coordinated events, including: 
(i) loss of endocytic and phagocytic receptors; (ii) changes in morphology; (iii) up-regulation of 
MHC and co-stimulatory molecules, such as CD40, CD80 and CD86, adhesion molecules and 
chemokine receptors, such as CCR7 (Tuyaerts et al. 2007a). The latter is one of the first changes 
and enables DCs to migrate from the periphery to the T cell areas of draining lymphoid organs 
(Forster et al. 2008). Here DCs present antigenic peptides in the context of MHC molecules to T 
cells. The phenotypic changes, high expression of antigen presenting, co-stimulatory and 
adhesion molecules, make mature DCs potent inducers of T cell immunity. However, the view 
that immature DCs induce tolerance and mature DCs induce immunity is simplified. It has 
been demonstrated that mature DCs can contribute to T cell tolerance through the induction of 
Treg (Verhasselt et al. 2004). It was suggested that the maturation trigger dictates the T cell 
polarizing or tolerating immune functions of the DCs. Some stimuli have been demonstrated 
to promote induction of TH1 responses, hence cellular immunity, whereas others hamper full 
DC maturation and cytokine production, hence promote tolerance.   
2.3 Stimulatory dendritic cells  
The immune system is constantly faced with choices. When confronted with a microbe, it 
must first decide whether to respond or not. If it chooses to respond, then it must decide 
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what kind of response to launch. A hallmark of the mammalian immune system is its ability 
to launch qualitatively distinct types of responses against different pathogens (Pulendran et 
al. 2008). Immune responses against T cell-dependent antigens can be divided in (i) CD4+ 
TH1 responses, which are characterized by high secretion of IFN-γ, and induced against 
intracellular microbes, (ii) CD4+ TH2 responses, which are characterized by the secretion of 
cytokines, such as IL-5 and IL-13, and induced against extracellular pathogens, (iii) CD4+ 
TH17 responses, characterized by the secretion of IL-17, and induced against fungi (Bettelli et 
al. 2007; Reiner 2007), and finally (iv) Treg responses, with suppressive activity, and which 
are essential to maintain tolerance to host antigens (Wing & Sakaguchi). Treg can also be 
induced by some microbial stimuli (Belkaid 2007), and are abundantly present in the blood, 
lymphoid organs and tumours of cancer patients (Vence et al. 2007; Ahmadzadeh et al. 2008), 
as such Treg enable evasion from the immune system.   
For the treatment of cancer and infectious diseases, a CD4+ TH1 response is required to 
induce a strong CD8+ cytotoxic T cell (CTL) response (Breckpot & Escors 2009a). These CTLs 
will then kill the target cells. To activate T cells, at least two signals are required (i) antigen 
recognition and (ii) co-stimulation. In the presence of tolerogenic mechanisms, as it is the 
case in cancer, an additional third signal is required. This is obtained by triggering of innate 
sensing pathways (Breckpot & Escors 2009a). As co-stimulatory molecules are not expressed 
by immature DCs, it goes without saying that DC activation (maturation) is a key event that 
determines the T cell stimulatory potential of DCs.  
Differentiation of immature to mature DCs requires pathogen recognition. Groups of 
pathogens express similar structures such as bacterial and viral nucleic acids or repetitive 
elements in the bacterial cell wall or within the viral envelope, enabling the recognition of a 
wide variety of pathogens. These structures are called pathogen-associated molecular patterns 
(PAMPs) and are recognized on DCs by pathogen recognition receptors (PRRs). The best-
studied PRRs are the TLRs, although other PRRs, such as Nod-like receptors, RIG-I-like 
receptors, as well as some members of the C-type lectin family, are described. Distinct 
pathogens express different PAMPs and this combination works as a fingerprint that triggers a 
specific set of PRRs (Akira et al. 2006; Barton & Kagan 2009; Geijtenbeek & Gringhuis 2009). As 
such complex signalling networks are activated. These cooperate, integrate and finally 
converge into a few pathways, of which the NF-κB and the MAPK pathways are examples 
(Rescigno et al. 1998; Sato et al. 1999; Re & Strominger 2001; Caparros et al. 2006; Kawai & Akira 
2008). These are described in detail elsewhere (Breckpot & Escors 2009c).  
The concept of co-stimulation was first introduced by Kevin Lafferty and co-workers 
(Lafferty et al. 1979). In the last decades, a large number of co-stimulatory molecules have 
been identified, which can be divided in members of the (i) B7 and (ii) tumour necrosis 
factor (TNF) type family. B7.1 (CD80) and B7.2 (CD86) are textbook examples of the B7 
family. These transmit strong co-stimulatory signals to T cells through interactions with 
CD28 on T cells (Greenwald et al. 2005). Recently, this group was expanded with a number 
of new members including ICOS ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3 and B7-H4. 
All these molecules are expressed on DCs. The corresponding CD28 members that are 
inducible expressed on T cells are ICOS, PD-1 and BTLA. It is important to mention that not 
all B7 family members are co-stimulatory. In fact, many of these new members have been 
linked to induction of tolerance hence they are discussed in the next section. The TNF type 
family of co-stimulatory molecules, includes CD70, OX40L, GITRL and 4-1BBL, which are 
expressed on DCs and their corresponding receptors CD27, OX40 (CD134), GITR and 4-1BB 
(CD137), expressed on T cells (Watts 2005). Some co-stimulatory molecules exemplified by 
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CD83, which is expressed on mature DCs, but also on T cells, can’t be classified in either 
group. So far, no receptor has been identified for this molecule (Hirano et al. 2006; Aerts-
Toegaert et al. 2007; Prechtel et al. 2007).   
Initial activation of naive T cells generally occurs through interactions with CD28, after 
which they differentiate into effector T cells, and up-regulate other co-stimulatory 
molecules. Depending on the stimulus, expression of co-stimulatory ligands on DCs will 
vary. Their relative expression will ultimately determine the quality of the T cell stimulation 
hence the T cell function. It has to be mentioned that the importance of co-stimulatory 
molecules is not limited to the stimulation of effector T cells, but can moreover involve 
modulation of Treg, as described for GITRL and OX40L. It has been shown that triggering of 
GITR results in alleviation of Treg suppression of effector T cells. Although Treg 
constitutively express GITR, the effect of GITR-GITRL interactions is not mediated through 
functional impairment of Treg, but rather protection of effector T cells against Treg 
(Stephens et al. 2004). However, whether these observations in mice can be translated to a 
human setting remains unclear (Tuyaerts et al. 2007b). Direct inhibitory effects on Treg 
suppression have been shown for OX40L (Valzasina et al. 2005), which upon binding with 
OX40 on Treg mediates down-regulation of Foxp3 and the Tregs’ suppressive capacity (Vu 
et al. 2007). For other co-stimulatory molecules (CD70 and 4-1BBL), of which its receptors are 
also expressed on Treg, no unequivocal effect on Treg function has been described.  
2.4 Tolerogenic dendritic cells  
In physiological conditions, the organism is in direct contact with millions of innocuous 
antigens of different origins.  Many of them are bacterial antigens, such as those present 
within the gut. Others vary from pollen, yeast, dust mites and chemicals of all sorts. Until 
recently, it was thought that the immune system was constantly and restlessly fighting 
potentially dangerous organisms and antigens. This view has certainly become obsolete, and 
it is not inaccurate to consider the immune system in a kind of steady-state in which 
tolerance is the default outcome and has to be maintained at all costs, except when a real 
threat arises. Therefore, several tolerogenic mechanisms are constantly in place.   
One of the first mechanisms to be described is central tolerance, in which auto-reactive T 
cells are eliminated in the thymus by clonal deletion (Griesemer et al. 2010). Although this 
mechanism is essential to eliminate most auto-reactive T cells, it can’t explain the aetiology 
of autoimmune disorders in which self-antigens are clearly recognised. Even though clonal 
deletion is efficient, it does not eliminate all auto-reactive T cells. Interestingly, many auto-
reactive T cells that survive clonal deletion further differentiate into natural Foxp3+ CD4+ 
Treg (Sakaguchi et al. 2008; Griesemer et al. 2010). These are strong and intrinsic 
immunosuppressive, and are part of the central tolerance. Research on Treg has recently 
exploded, although ample experimental evidence of their existence was provided during the 
1970s (Rich & Pierce 1973; Ha et al. 1974; Taussig 1974). However, early studies were 
abandoned partly by the inexistence of specific cell markers associated with suppressive T 
cells. Nevertheless, Sakaguchi and colleagues demonstrated that high expression of CD25 
and Foxp3 was characteristic for natural Treg (Hori et al. 2003; Sakaguchi 2003), which re-
awakened research into this fundamental T cell type. Importantly, many of the early studies 
drew similar conclusions to more recent studies on Treg (Basten et al. 1974; Kirchner et al. 
1974; Polak & Turk 1974). Even so, clonal deletion and natural Treg activity can’t explain 
tolerance towards many other auto- and foreign antigens, which are not present in the 
thymus. Theoretically strong immune responses should constantly arise towards a wide 
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variety of antigens. However, this is not the case, and the organism still remains tolerant 
towards most antigens. Differentiation of inducible Treg specific for peripheral antigens can 
partially fill this experimental and conceptual gap. Inducible Treg derive from naïve CD4+ T 
cells and can be broadly classified into Tr1 (CD4+ CD25+ IL-10+ or TGF-β+) and TH3 (CD4+ 
CD25+ Foxp3+) cells (Mahnke et al. 2003; O'Garra et al. 2004; Peng et al. 2004; Arce et al. 2011). 
For differentiation of inducible Treg to occur, antigens have to be captured, processed and 
presented in a tolerogenic context. DCs, which induce Treg differentiation and inhibition of 
effector T cell expansion, are termed tolerogenic DCs.  
There is no compelling evidence demonstrating that tolerogenic DCs are a truly specialised cell 
type that is exclusively devoted to suppress immune responses. In fact, tolerogenic DCs 
encompass a wide range of DCs which acquire immune suppressive activities in particular 
circumstances. Firstly, it is well known that steady state DCs can capture antigens in 
peripheral tissues and migrate to secondary lymphoid organs. Antigen presentation by 
immature DCs leads to T cell inactivation (anergy), apoptosis and Treg differentiation 
(Dhodapkar et al. 2001; Hawiger et al. 2001; Bonifaz et al. 2002; Kretschmer et al. 2005). 
Secondly, DCs located in certain anatomical parts such as the mucosa and gut, are intrinsically 
tolerogenic. Interestingly, retinoic-acid (vitamin A) metabolising enzymes are critical in their 
suppressive functions. Mucosal DCs in contact with many microbial-derived antigens are 
potently immunosuppressive, particularly after TLR2 signal transduction (Dillon et al. 2006; 
Ilarregui et al. 2009; Manicassamy et al. 2009). Treatment of DCs with lectin ligands such as 
galectin 1 or potent immunosuppressive cytokines also renders them tolerogenic (Corinti et al. 
2001; Ghiringhelli et al. 2005; Dillon et al. 2006; Rutella et al. 2006; Ilarregui et al. 2009; Arce et al. 
2011). Importantly, certain types of specialised myeloid-derived cells with very potent intrinsic 
immunosuppressive capacities have been found in recent years. These cells are known as 
myeloid-derived suppressor cells and inhibit T cell proliferation through a variety of 
mechanisms (Li et al. 2009; Srivastava et al. 2010). In addition, certain types of monocytes are 
immunosuppressive cells, and are involved in establishing tolerance after organ 
transplantation (Garcia et al. 2010). According to the expression of surface molecules, 
tolerogenic DCs are generally considered to be immature. This is characterised by low levels of 
MHC and co-stimulatory molecules (Rutella et al. 2006; Escors et al. 2008; Breckpot & Escors 
2009b; Arce et al. 2010). It is believed that because of their immature phenotype antigen 
presentation is inefficient, and expansion of effector T cells is hampered. However, 
phenotypical mature DCs can also be potently tolerogenic. These mature tolerogenic DCs exert 
their suppressive activities through secretion of high levels of immunosuppressive cytokines 
(Rutella et al. 2006).  
The mechanisms by which tolerogenic DCs exert their activity are certainly varied in nature, 
and it is likely that several of these take place simultaneously. As mentioned, tolerogenic 
immature DCs are thought to lead to inefficient antigen presentation to naive T cells. 
Therefore, expansion of effector T cells is, if not prevented, at least severely reduced. However, 
there is evidence that these DCs do present antigens, although the interaction between 
immature DCs and T cells is transient and leads to T cell anergy, apoptosis or Treg 
differentiation (Rothoeft et al. 2006). An important characteristic that seems to be common in 
all tolerogenic DCs is the secretion of potent immunosuppressive cytokines during antigen 
presentation (Ghiringhelli et al. 2005; Dillon et al. 2006; Escors et al. 2008; Ilarregui et al. 2009; 
Arce et al. 2010; Saraiva & O'Garra 2010). In fact, at least in the presence of TGF-β, strong TCR 
stimulation during antigen presentation greatly enhances Foxp3+ Treg differentiation. 
Tolerogenic DCs can also secrete high amounts of IL-10, a potent immunosuppressive 
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CD83, which is expressed on mature DCs, but also on T cells, can’t be classified in either 
group. So far, no receptor has been identified for this molecule (Hirano et al. 2006; Aerts-
Toegaert et al. 2007; Prechtel et al. 2007).   
Initial activation of naive T cells generally occurs through interactions with CD28, after 
which they differentiate into effector T cells, and up-regulate other co-stimulatory 
molecules. Depending on the stimulus, expression of co-stimulatory ligands on DCs will 
vary. Their relative expression will ultimately determine the quality of the T cell stimulation 
hence the T cell function. It has to be mentioned that the importance of co-stimulatory 
molecules is not limited to the stimulation of effector T cells, but can moreover involve 
modulation of Treg, as described for GITRL and OX40L. It has been shown that triggering of 
GITR results in alleviation of Treg suppression of effector T cells. Although Treg 
constitutively express GITR, the effect of GITR-GITRL interactions is not mediated through 
functional impairment of Treg, but rather protection of effector T cells against Treg 
(Stephens et al. 2004). However, whether these observations in mice can be translated to a 
human setting remains unclear (Tuyaerts et al. 2007b). Direct inhibitory effects on Treg 
suppression have been shown for OX40L (Valzasina et al. 2005), which upon binding with 
OX40 on Treg mediates down-regulation of Foxp3 and the Tregs’ suppressive capacity (Vu 
et al. 2007). For other co-stimulatory molecules (CD70 and 4-1BBL), of which its receptors are 
also expressed on Treg, no unequivocal effect on Treg function has been described.  
2.4 Tolerogenic dendritic cells  
In physiological conditions, the organism is in direct contact with millions of innocuous 
antigens of different origins.  Many of them are bacterial antigens, such as those present 
within the gut. Others vary from pollen, yeast, dust mites and chemicals of all sorts. Until 
recently, it was thought that the immune system was constantly and restlessly fighting 
potentially dangerous organisms and antigens. This view has certainly become obsolete, and 
it is not inaccurate to consider the immune system in a kind of steady-state in which 
tolerance is the default outcome and has to be maintained at all costs, except when a real 
threat arises. Therefore, several tolerogenic mechanisms are constantly in place.   
One of the first mechanisms to be described is central tolerance, in which auto-reactive T 
cells are eliminated in the thymus by clonal deletion (Griesemer et al. 2010). Although this 
mechanism is essential to eliminate most auto-reactive T cells, it can’t explain the aetiology 
of autoimmune disorders in which self-antigens are clearly recognised. Even though clonal 
deletion is efficient, it does not eliminate all auto-reactive T cells. Interestingly, many auto-
reactive T cells that survive clonal deletion further differentiate into natural Foxp3+ CD4+ 
Treg (Sakaguchi et al. 2008; Griesemer et al. 2010). These are strong and intrinsic 
immunosuppressive, and are part of the central tolerance. Research on Treg has recently 
exploded, although ample experimental evidence of their existence was provided during the 
1970s (Rich & Pierce 1973; Ha et al. 1974; Taussig 1974). However, early studies were 
abandoned partly by the inexistence of specific cell markers associated with suppressive T 
cells. Nevertheless, Sakaguchi and colleagues demonstrated that high expression of CD25 
and Foxp3 was characteristic for natural Treg (Hori et al. 2003; Sakaguchi 2003), which re-
awakened research into this fundamental T cell type. Importantly, many of the early studies 
drew similar conclusions to more recent studies on Treg (Basten et al. 1974; Kirchner et al. 
1974; Polak & Turk 1974). Even so, clonal deletion and natural Treg activity can’t explain 
tolerance towards many other auto- and foreign antigens, which are not present in the 
thymus. Theoretically strong immune responses should constantly arise towards a wide 
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variety of antigens. However, this is not the case, and the organism still remains tolerant 
towards most antigens. Differentiation of inducible Treg specific for peripheral antigens can 
partially fill this experimental and conceptual gap. Inducible Treg derive from naïve CD4+ T 
cells and can be broadly classified into Tr1 (CD4+ CD25+ IL-10+ or TGF-β+) and TH3 (CD4+ 
CD25+ Foxp3+) cells (Mahnke et al. 2003; O'Garra et al. 2004; Peng et al. 2004; Arce et al. 2011). 
For differentiation of inducible Treg to occur, antigens have to be captured, processed and 
presented in a tolerogenic context. DCs, which induce Treg differentiation and inhibition of 
effector T cell expansion, are termed tolerogenic DCs.  
There is no compelling evidence demonstrating that tolerogenic DCs are a truly specialised cell 
type that is exclusively devoted to suppress immune responses. In fact, tolerogenic DCs 
encompass a wide range of DCs which acquire immune suppressive activities in particular 
circumstances. Firstly, it is well known that steady state DCs can capture antigens in 
peripheral tissues and migrate to secondary lymphoid organs. Antigen presentation by 
immature DCs leads to T cell inactivation (anergy), apoptosis and Treg differentiation 
(Dhodapkar et al. 2001; Hawiger et al. 2001; Bonifaz et al. 2002; Kretschmer et al. 2005). 
Secondly, DCs located in certain anatomical parts such as the mucosa and gut, are intrinsically 
tolerogenic. Interestingly, retinoic-acid (vitamin A) metabolising enzymes are critical in their 
suppressive functions. Mucosal DCs in contact with many microbial-derived antigens are 
potently immunosuppressive, particularly after TLR2 signal transduction (Dillon et al. 2006; 
Ilarregui et al. 2009; Manicassamy et al. 2009). Treatment of DCs with lectin ligands such as 
galectin 1 or potent immunosuppressive cytokines also renders them tolerogenic (Corinti et al. 
2001; Ghiringhelli et al. 2005; Dillon et al. 2006; Rutella et al. 2006; Ilarregui et al. 2009; Arce et al. 
2011). Importantly, certain types of specialised myeloid-derived cells with very potent intrinsic 
immunosuppressive capacities have been found in recent years. These cells are known as 
myeloid-derived suppressor cells and inhibit T cell proliferation through a variety of 
mechanisms (Li et al. 2009; Srivastava et al. 2010). In addition, certain types of monocytes are 
immunosuppressive cells, and are involved in establishing tolerance after organ 
transplantation (Garcia et al. 2010). According to the expression of surface molecules, 
tolerogenic DCs are generally considered to be immature. This is characterised by low levels of 
MHC and co-stimulatory molecules (Rutella et al. 2006; Escors et al. 2008; Breckpot & Escors 
2009b; Arce et al. 2010). It is believed that because of their immature phenotype antigen 
presentation is inefficient, and expansion of effector T cells is hampered. However, 
phenotypical mature DCs can also be potently tolerogenic. These mature tolerogenic DCs exert 
their suppressive activities through secretion of high levels of immunosuppressive cytokines 
(Rutella et al. 2006).  
The mechanisms by which tolerogenic DCs exert their activity are certainly varied in nature, 
and it is likely that several of these take place simultaneously. As mentioned, tolerogenic 
immature DCs are thought to lead to inefficient antigen presentation to naive T cells. 
Therefore, expansion of effector T cells is, if not prevented, at least severely reduced. However, 
there is evidence that these DCs do present antigens, although the interaction between 
immature DCs and T cells is transient and leads to T cell anergy, apoptosis or Treg 
differentiation (Rothoeft et al. 2006). An important characteristic that seems to be common in 
all tolerogenic DCs is the secretion of potent immunosuppressive cytokines during antigen 
presentation (Ghiringhelli et al. 2005; Dillon et al. 2006; Escors et al. 2008; Ilarregui et al. 2009; 
Arce et al. 2010; Saraiva & O'Garra 2010). In fact, at least in the presence of TGF-β, strong TCR 
stimulation during antigen presentation greatly enhances Foxp3+ Treg differentiation. 
Tolerogenic DCs can also secrete high amounts of IL-10, a potent immunosuppressive 
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cytokine, resulting in differentiation of mainly Tr1 cells (Kuhn et al. 1993; Saraiva & O'Garra 
2010). In addition IL-10 autocrine and paracrine activities keep DCs in an immature stage 
(Takayama et al. 1998; Corinti et al. 2001). DCs can also up-regulate surface expression of 
molecules with T cell inhibitory activities. This is the case for some members of the B7 family. 
One of the most extensively studied immunosuppressive members is PD-L1, the ligand of the 
T cell inhibitory receptor PD-1. Binding of PD-L1 to PD-1 on T cells, especially in the case of 
chronic antigen exposure, renders T cells inactive (exhausted) (Sakuishi et al. 2010). This is a 
critical mechanism by which many tumour cells exert their immunosuppressive activities 
towards effector CD8+ T cells. PD-L1 is expressed ubiquitously, but it is likely that its 
expression on DCs and other professional antigen presenting cells has a more specific role. 
Importantly, binding of PD-L1 expressed on DCs to CD80 on T cells has been shown to be 
required for TGF-β dependent antigen-specific Treg differentiation (Wang et al. 2008). A 
second PD-1 ligand was described that is specifically expressed on DCs and macrophages, 
termed PD-L2. However, it is unclear whether PD-L2 is truly immunosuppressive 
(Radhakrishnan et al. 2009). Recently, other B7 family members have also been shown to exert 
immunosuppressive activities (Sica et al. 2003). Finally, another interesting mechanism is up-
regulation of amino acid-metabolising enzymes. Intriguingly, many of these are triggered by 
TGF-β (Belladonna et al. 2009). It has been known for some time that increased arginase 
activity in DCs suppresses immune responses (Munder 2009; Norian et al. 2009). Indoleamine 
2,3-dioxygenase up-regulation, a tryptophan-metabolising enzyme, suppresses immune 
responses (Fallarino et al. 2002; Mellor & Munn 2004). Interestingly, Tregs can induce DCs to 
up-regulate several of these metabolic enzymes, resulting in infectious tolerance that amplifies 
the suppressive capacities of regulatory DCs and T cells (Cobbold et al. 2009).  
3. Lentiviral vectors 
Viruses are excellent candidates for the development of efficient gene delivery systems. As 
intracellular obligate parasites, they are specialized in the delivery of their genome to cells. 
Therefore it is no surprise that viruses have always been of interest for gene therapeutic 
applications. Nowadays a large number of viruses have been evaluated, e.g. adenovirus, 
adeno-associated virus, herpes virus, poxvirus, retrovirus, lentivirus, et cetera (Escors & 
Breckpot 2010). The first human gene therapy trial was performed in the 1970s and applied an 
arginase encoding Shope papilloma virus to treat hyperargininemia (Friedmann & Roblin 
1972). By 1985, gene transfer with viral vectors to mammalian cells was performed routinely 
and the use of the γ-retroviral Murine leukaemia virus for gene delivery was introduced 
(Mann et al. 1983). This seemed promising as these viruses integrate their cargo into the host 
genome. It was Brenner et al (Brenner et al. 1993) who demonstrated the proof-of-principle of γ-
retroviral gene transfer in hematopoietic stem cells (HSCs). The first clinical trial using γ-
retroviral vectors (RVs) was carried out by Anderson and colleagues to correct severe 
combined immunodeficiency (SCID) in 1991 (Anderson et al. 1990). The majority of clinical 
gene therapy trials today use γ-RVs, despite their relative low stability, the low titers and their 
inability to transduce quiescent cells. More importantly, worrisome incidents of RV induced 
insertional mutagenesis were reported (Pincha et al. 2010).  Lentiviruses, which as γ-
retroviruses are members of the Retroviridae, were suggested to be an attractive alternative, 
since they are capable of transducing both dividing and non-dividing cells (Bukrinsky et al. 
1993; Lewis & Emerman 1994). Moreover, their integration into the host genome is, in contrast 
to γ-retroviruses, associated with lower genotoxicity (Montini et al. 2006). 
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At the end of the 1990s, the use of recombinant LVs was boosted, especially for transduction 
of non-dividing cells (Akkina et al. 1996; Naldini et al. 1996a; Naldini et al. 1996b; Reiser et al. 
1996).  Another 10 years later the first clinical trial using LV modified cells for the treatment 
of HIV infection was completed (Lu et al. 2004). 
3.1 Development of recombinant lentiviral vectors  
Lentiviruses are characterized by a diploid 7-12 kb single stranded RNA genome with 
positive polarity that is reverse transcribed to double stranded DNA upon host cell entry 
(Coffin 1997).  Diploidy permits genetic recombination, which accounts partially for their 
success as procreators of the acquired immunodeficiency syndrome, a disease that develops 
by slowly affecting the immune systems’ function (lenti meaning slow).  Lentiviruses 
include primate and non-primate retroviruses, e.g. HIV and simian immunodeficiency virus, 
and caprine arthritis-encephalitis virus, equine infectious anaemia virus, Maedi-visna virus, 
feline immunodeficiency virus and bovine immunodeficiency virus, respectively (Breckpot 
et al. 2008; Escors & Breckpot 2010).  The spherical virion measures about 80-120 nm in 
diameter, has a mass of 2.5 x 105 kDA and a density of 1.16 g/ml in sucrose density gradient. 
Its envelope consists of a plasma membrane derived phospholipid bilayer loaded with 
surface (SU) and transmembranary (TM) glycoproteins and is supported on the inside by 
the non-glycosylated structural matrix (MA) proteins (Fig. 2). Within the envelope the 
nucleocapsid, comprised of capsid (CA) proteins, surrounds the viral genome, which is 
packaged together with nucleocapsid (NC) proteins and a few copies of the enzymes reverse 
transcriptase (RT), integrase (IN) and protease (PR). 
 
 
Fig. 2. Schematic representation of a retroviral particle. The viral envelope consists of a 
lipid bilayer loaded with viral proteins. These are composed of TM and SU components, 
linked via a disulphide bridge and encoded by de env genes. Internal non-glycosylated 
proteins are coded by the gag region of the viral genome and comprise MA, CA and NC 
proteins. The products of the pol – coding region are the RT and IN, while the PR is coded by 
the pro gene that resides between the gag and the pol gene. 
The replication cycle of lentiviruses starts with the attachment of the viral envelope proteins to 
specific receptors on the host cell surface (Flint S.J. 2009). This interaction defines the tropism 
and results in conformational changes of SU and TM, which allows the hydrophobic fusion 
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cytokine, resulting in differentiation of mainly Tr1 cells (Kuhn et al. 1993; Saraiva & O'Garra 
2010). In addition IL-10 autocrine and paracrine activities keep DCs in an immature stage 
(Takayama et al. 1998; Corinti et al. 2001). DCs can also up-regulate surface expression of 
molecules with T cell inhibitory activities. This is the case for some members of the B7 family. 
One of the most extensively studied immunosuppressive members is PD-L1, the ligand of the 
T cell inhibitory receptor PD-1. Binding of PD-L1 to PD-1 on T cells, especially in the case of 
chronic antigen exposure, renders T cells inactive (exhausted) (Sakuishi et al. 2010). This is a 
critical mechanism by which many tumour cells exert their immunosuppressive activities 
towards effector CD8+ T cells. PD-L1 is expressed ubiquitously, but it is likely that its 
expression on DCs and other professional antigen presenting cells has a more specific role. 
Importantly, binding of PD-L1 expressed on DCs to CD80 on T cells has been shown to be 
required for TGF-β dependent antigen-specific Treg differentiation (Wang et al. 2008). A 
second PD-1 ligand was described that is specifically expressed on DCs and macrophages, 
termed PD-L2. However, it is unclear whether PD-L2 is truly immunosuppressive 
(Radhakrishnan et al. 2009). Recently, other B7 family members have also been shown to exert 
immunosuppressive activities (Sica et al. 2003). Finally, another interesting mechanism is up-
regulation of amino acid-metabolising enzymes. Intriguingly, many of these are triggered by 
TGF-β (Belladonna et al. 2009). It has been known for some time that increased arginase 
activity in DCs suppresses immune responses (Munder 2009; Norian et al. 2009). Indoleamine 
2,3-dioxygenase up-regulation, a tryptophan-metabolising enzyme, suppresses immune 
responses (Fallarino et al. 2002; Mellor & Munn 2004). Interestingly, Tregs can induce DCs to 
up-regulate several of these metabolic enzymes, resulting in infectious tolerance that amplifies 
the suppressive capacities of regulatory DCs and T cells (Cobbold et al. 2009).  
3. Lentiviral vectors 
Viruses are excellent candidates for the development of efficient gene delivery systems. As 
intracellular obligate parasites, they are specialized in the delivery of their genome to cells. 
Therefore it is no surprise that viruses have always been of interest for gene therapeutic 
applications. Nowadays a large number of viruses have been evaluated, e.g. adenovirus, 
adeno-associated virus, herpes virus, poxvirus, retrovirus, lentivirus, et cetera (Escors & 
Breckpot 2010). The first human gene therapy trial was performed in the 1970s and applied an 
arginase encoding Shope papilloma virus to treat hyperargininemia (Friedmann & Roblin 
1972). By 1985, gene transfer with viral vectors to mammalian cells was performed routinely 
and the use of the γ-retroviral Murine leukaemia virus for gene delivery was introduced 
(Mann et al. 1983). This seemed promising as these viruses integrate their cargo into the host 
genome. It was Brenner et al (Brenner et al. 1993) who demonstrated the proof-of-principle of γ-
retroviral gene transfer in hematopoietic stem cells (HSCs). The first clinical trial using γ-
retroviral vectors (RVs) was carried out by Anderson and colleagues to correct severe 
combined immunodeficiency (SCID) in 1991 (Anderson et al. 1990). The majority of clinical 
gene therapy trials today use γ-RVs, despite their relative low stability, the low titers and their 
inability to transduce quiescent cells. More importantly, worrisome incidents of RV induced 
insertional mutagenesis were reported (Pincha et al. 2010).  Lentiviruses, which as γ-
retroviruses are members of the Retroviridae, were suggested to be an attractive alternative, 
since they are capable of transducing both dividing and non-dividing cells (Bukrinsky et al. 
1993; Lewis & Emerman 1994). Moreover, their integration into the host genome is, in contrast 
to γ-retroviruses, associated with lower genotoxicity (Montini et al. 2006). 
 
Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy 
 
317 
At the end of the 1990s, the use of recombinant LVs was boosted, especially for transduction 
of non-dividing cells (Akkina et al. 1996; Naldini et al. 1996a; Naldini et al. 1996b; Reiser et al. 
1996).  Another 10 years later the first clinical trial using LV modified cells for the treatment 
of HIV infection was completed (Lu et al. 2004). 
3.1 Development of recombinant lentiviral vectors  
Lentiviruses are characterized by a diploid 7-12 kb single stranded RNA genome with 
positive polarity that is reverse transcribed to double stranded DNA upon host cell entry 
(Coffin 1997).  Diploidy permits genetic recombination, which accounts partially for their 
success as procreators of the acquired immunodeficiency syndrome, a disease that develops 
by slowly affecting the immune systems’ function (lenti meaning slow).  Lentiviruses 
include primate and non-primate retroviruses, e.g. HIV and simian immunodeficiency virus, 
and caprine arthritis-encephalitis virus, equine infectious anaemia virus, Maedi-visna virus, 
feline immunodeficiency virus and bovine immunodeficiency virus, respectively (Breckpot 
et al. 2008; Escors & Breckpot 2010).  The spherical virion measures about 80-120 nm in 
diameter, has a mass of 2.5 x 105 kDA and a density of 1.16 g/ml in sucrose density gradient. 
Its envelope consists of a plasma membrane derived phospholipid bilayer loaded with 
surface (SU) and transmembranary (TM) glycoproteins and is supported on the inside by 
the non-glycosylated structural matrix (MA) proteins (Fig. 2). Within the envelope the 
nucleocapsid, comprised of capsid (CA) proteins, surrounds the viral genome, which is 
packaged together with nucleocapsid (NC) proteins and a few copies of the enzymes reverse 
transcriptase (RT), integrase (IN) and protease (PR). 
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proteins. The products of the pol – coding region are the RT and IN, while the PR is coded by 
the pro gene that resides between the gag and the pol gene. 
The replication cycle of lentiviruses starts with the attachment of the viral envelope proteins to 
specific receptors on the host cell surface (Flint S.J. 2009). This interaction defines the tropism 
and results in conformational changes of SU and TM, which allows the hydrophobic fusion 
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peptide of TM to insert in the cellular membrane, as such allowing the release of the 
nucleocapsid complex in the cytoplasm (Schaffer et al. 2008). The reverse transcription process 
sets off by primer binding of a viral tRNA and produces successively the negative and positive 
linear DNA strands till the DNA molecule called provirus is formed. Important are its cis-
acting ends called long terminal repeats (LTRs) that are shown juxtaposed in preparation for 
integration (Fig. 3). As a unique characteristic of lentiviruses, viral DNA and IN gain access to 
the nucleus by formation of a pre-integration complex. Therefore, the lentiviral genome 
contains not only a 3’ polypurine tract (PPT), as other retroviruses, but also a central PPT (Fig. 
3) (Charneau & Clavel 1991). The latter sequence together with a central termination sequence 
(CTS) controls the formation of a stable 99-nucleotide long plus strand overlap in the linear 
DNA molecule in cis, which enables active pro-viral nuclear import (Follenzi et al. 2000; 
Zennou et al. 2000). The subsequent integrative recombination is catalyzed by the IN, which 
uses the outer att sequences on the LTRs to grab the pro-viral DNA and results in random 
insertion of the viral DNA in the host genome. Transcription of the integrated provirus is 
mediated by cellular RNA polymerase II and results in different subsets of RNA molecules 
namely: mRNA molecules and new viral single stranded RNA genomes. The most important 
viral genes encoding mRNA molecules are: (i) the env (envelope) gene which encodes SU and 
TM; (ii) the gag (group specific antigen) gene which encodes the internal structural proteins MA, 
CA and NC; (iii) the pol (polymerase) gene which codes for the enzymes IN and RT including a 
DNA polymerase as well as its associated RNase H activity and finally (iv) the pro (protease) 
gene which encodes PR. Based on genomic organization retroviruses can be divided in simple 
and complex viruses. The simple viral genomes only encode the three genes, gag, pol, and env, 
common to all retroviruses, such as α-, β-, and γ-retroviruses. In contrast, complex viruses have 
a genome that encodes several accessory genes that affect viral gene expression and/or 
pathogenesis. Lentiviruses encode not only two extra regulatory genes tat and rev but also 
several accessory genes such as vpr, vpu, vif and nef.  After transcription of the unspliced full-
length viral RNA and translation of the mRNA encoding viral proteins, everything is 
transported to the cytoplasm where virion maturation occurs.  The cis-acting packaging signal, 
ψ (psi), is required to ensure viral genome packaging and subsequent budding of the particle 
from the cell to give rise to infectious virions. 
 
 
Fig. 3. Schematic representation of the pro-viral HIV-1 genome. All genes of the provirus 
(gag, pol, pro, vif, vpr, vpu, rev, tat, env and nef) are flanked on either side by identical ‘long 
terminal repeats’ (LTRs) that consist of a U3, R and U5 fragment. The pro-viral 
transcriptional control elements like the actual promoter and enhancer sequences can be 
found in the U3 regions. Ψ represents the encapsidation signal. Unlike most retroviruses, 
HIV and other LVs have two copies of the PPT, one at the border of the 3’LTR (3’ polypurine 
tract) and the other located within the pol-coding region (central polypurine tract [red line] 
together with a central termination sequence [green line]). 
Given the fact that lentiviruses are pathogenic, it is crucial to develop a recombinant LV that is 
replication deficient, safe and efficient in transduction of target cells. Therefore, LVs have been 
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vigorously modified, which has contributed to their widespread use as a gene delivery shuttle. 
A safety concern is the possible generation of replication-competent LVs (RCLs) as a 
consequence of genetic recombination (Wu et al. 2000). Therefore, LVs are produced by 
transient transfection of producer cells (HEK 293T) with at least three plasmids. This allows 
separation of cis- and trans-acting sequences. Generally the following plasmids are used: (i) a 
packaging, (ii) a transfer, and (iii) an envelope plasmid. All plasmids have been scrutinized to 
enhance their performance in terms of safety and efficacy (Breckpot et al. 2007a).   
The packaging plasmid provides all viral structural and enzymatic sequences, encoded by 
gag and pol, to make an infective virion in trans. Based on the packaging plasmid 
recombinant LVs can be divided into different generations. The first generation is 
represented by a plasmid encoding the entire gag and pol sequence in trans to enable 
packaging of the transfer construct together with the viral regulatory genes tat and rev and 
the virulence genes vif, vpr, vpu and nef. The second generation plasmid is multiply 
attenuated by removal of the four virulence genes without any negative effect on 
transduction efficacy as these genes seemed dispensable for the efficient generation of HIV-
derived LVs (Zufferey et al. 1997). In the third generation, the rev gene is expressed from a 
separate plasmid (Dull et al. 1998). Furthermore also the tat sequence could be removed by 
insertion of a strong constitutional promoter in the 5’ LTR of the transfer vector. More 
recently the importance of the development of non-integrating LVs (NILVs) has been 
brought to the attention because of the oncogene transactivation incidents in some clinical 
trials with γ-RVs. Although the LV integration profile seems more favourable than that of γ-
RVs (Montini et al. 2009), several groups tested the transduction efficacy of NILVs by 
mutating the catalytic triad within the IN gene of the packaging plasmid (Wanisch & Yanez-
Munoz 2009). Improved safety without major reduction in efficacy was demonstrated (Negri 
et al. 2007; Karwacz et al. 2009; Wanisch & Yanez-Munoz 2009). Downsides are the lower 
titers, higher doses needed and the fact that there still is a chance for integration of about 0.1 
to 2.3% (Apolonia et al. 2007). An alternative to IN deficiency is site-specific integration into 
a safe harbour sequence of the target cell. Several strategies have been described, e.g. Cre-
loxP carrying LVs, use of the zinc finger nuclease or meganuclease technology, et cetera 
(Matrai et al. 2010; Michel et al. 2010; Silva et al. 2011). Furthermore, the discovery that the 
LEDGF/p75 protein controls the site of integration of HIV-derived LVs presents new 
possibilities to control mutagenesis (Ciuffi 2008; Silvers et al. 2010). 
The transfer plasmid is the only plasmid derived from the viral genome where all viral 
coding regions are replaced by the expression cassette. An important improvement for 
safety was the development of so called self-inactivating (SIN) vectors (Zufferey et al. 1998). 
These rely on the introduction of a deletion in the U3 region of the 3’ LTR.  This deletion will 
be transferred to the 5’ LTR of the pro-viral DNA during reverse transcription, which 
abolishes production of full-length vector RNA in transduced cells. This has several 
advantages: (i) it minimizes the risk for emerging RCLs, (ii) it reduces the chance that 
cellular coding sequences located adjacent to the integrated pro-viral sequence will be 
aberrantly expressed due to the promoter activity in the 3’ LTR and (iii) it prevents 
transcriptional interference between the LTRs and an internal promoter. As the expression 
of genes delivered by LVs is often inefficient, several strategies were developed to 
ameliorate this. Firstly, the promoter within the expression cassette can be varied. Instead of 
using strong constitutive promoters, such as the promoter of cytomegalovirus or spleen 
focus forming virus, one can choose a cell-specific promoter as these are less sensitive to 
promoter inactivation and less likely to activate the host-cell defence machinery (Liu et al. 
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peptide of TM to insert in the cellular membrane, as such allowing the release of the 
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mediated by cellular RNA polymerase II and results in different subsets of RNA molecules 
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vigorously modified, which has contributed to their widespread use as a gene delivery shuttle. 
A safety concern is the possible generation of replication-competent LVs (RCLs) as a 
consequence of genetic recombination (Wu et al. 2000). Therefore, LVs are produced by 
transient transfection of producer cells (HEK 293T) with at least three plasmids. This allows 
separation of cis- and trans-acting sequences. Generally the following plasmids are used: (i) a 
packaging, (ii) a transfer, and (iii) an envelope plasmid. All plasmids have been scrutinized to 
enhance their performance in terms of safety and efficacy (Breckpot et al. 2007a).   
The packaging plasmid provides all viral structural and enzymatic sequences, encoded by 
gag and pol, to make an infective virion in trans. Based on the packaging plasmid 
recombinant LVs can be divided into different generations. The first generation is 
represented by a plasmid encoding the entire gag and pol sequence in trans to enable 
packaging of the transfer construct together with the viral regulatory genes tat and rev and 
the virulence genes vif, vpr, vpu and nef. The second generation plasmid is multiply 
attenuated by removal of the four virulence genes without any negative effect on 
transduction efficacy as these genes seemed dispensable for the efficient generation of HIV-
derived LVs (Zufferey et al. 1997). In the third generation, the rev gene is expressed from a 
separate plasmid (Dull et al. 1998). Furthermore also the tat sequence could be removed by 
insertion of a strong constitutional promoter in the 5’ LTR of the transfer vector. More 
recently the importance of the development of non-integrating LVs (NILVs) has been 
brought to the attention because of the oncogene transactivation incidents in some clinical 
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mutating the catalytic triad within the IN gene of the packaging plasmid (Wanisch & Yanez-
Munoz 2009). Improved safety without major reduction in efficacy was demonstrated (Negri 
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coding regions are replaced by the expression cassette. An important improvement for 
safety was the development of so called self-inactivating (SIN) vectors (Zufferey et al. 1998). 
These rely on the introduction of a deletion in the U3 region of the 3’ LTR.  This deletion will 
be transferred to the 5’ LTR of the pro-viral DNA during reverse transcription, which 
abolishes production of full-length vector RNA in transduced cells. This has several 
advantages: (i) it minimizes the risk for emerging RCLs, (ii) it reduces the chance that 
cellular coding sequences located adjacent to the integrated pro-viral sequence will be 
aberrantly expressed due to the promoter activity in the 3’ LTR and (iii) it prevents 
transcriptional interference between the LTRs and an internal promoter. As the expression 
of genes delivered by LVs is often inefficient, several strategies were developed to 
ameliorate this. Firstly, the promoter within the expression cassette can be varied. Instead of 
using strong constitutive promoters, such as the promoter of cytomegalovirus or spleen 
focus forming virus, one can choose a cell-specific promoter as these are less sensitive to 
promoter inactivation and less likely to activate the host-cell defence machinery (Liu et al. 
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2004). Secondly, the incorporation of the cPPT and CTS into the transfer plasmid not only 
improved LV yields, but also provided enhanced transgene expression by mediating active 
nuclear import of the provirus (Follenzi et al. 2000; Sirven et al. 2000). Addition of 
posttranscriptional regulatory elements such as the Woodchuck hepatitis virus regulatory 
element (WPRE) has also been explored (Zufferey et al. 1999). Although some groups 
demonstrated improved gene expression by modification of polyadenylation, RNA export 
and/or translation, others reported only a negligible benefit (Breckpot et al. 2003). Another 
issue is epigenetic silencing and heterochromatin formation nearby the inserted provirus, 
which hampers its transcription. This silencing process can be avoided by the insertion of 
insulators or with vectors containing an enhancer-less ubiquitously acting chromatin-
opening element (Zhang et al. 2007; Nielsen et al. 2009). To improve safety, the incorporation 
of a suicide-gene has been proposed to eliminate cells that are transformed as a consequence 
of LV integration (Tseng et al. 2009). Finally the discovery of RNA interference opens novel 
possibilities for LVs in terms of stable gene silencing (Gu et al. ; Arrighi et al. 2004), as well as 
for LV de-targeting strategies (Brown et al. 2006b). 
Last but not least also the envelope plasmid is variable. Since wild-type HIV-1 glycoproteins 
have a restricted tropism and do not allow production of high titer LV preparations, 
heterologous glycoproteins are used for LV production. This process is termed 
pseudotyping and most commonly the envelope of the vesicular stomatitis virus (VSV.G) is 
used. This rhabdovirus envelope glycoprotein interacts with an ubiquitous receptor and 
subsequently confers a broad host-cell range and high vector particle stability (Burns et al. 
1993; Marsac et al. 2002; Schaffer et al. 2008). 
3.2 Lentiviral vectors for the in vitro modification of dendritic cells  
Efficient transduction of human DCs with transgenic vectors has been challenging for 
several reasons.  Human DCs are usually generated from peripheral blood-derived 
quiescent CD14+ progenitors or from mitotically hypoactive primitive CD34+-derived 
progenitor cells. Therefore, the capacity of LVs to transduce quiescent and non-dividing 
cells turned out to be an important asset for DC transduction. The first successful 
transduction of human monocyte-derived DCs with LVs was described by Unutmaz et al 
(Unutmaz et al. 1999) in 1999. Since then, several research groups have reported successful 
transduction of human monocyte-derived (Gruber et al. 2000; Schroers et al. 2000; Dyall et al. 
2001; Firat et al. 2002; Breckpot et al. 2003; Lizee et al. 2004), human CD34+-derived DCs 
(Salmon et al. 2000; Oki et al. 2001; Sumimoto et al. 2002) and mouse bone marrow-derived 
DCs (Metharom et al. 2001; Breckpot et al. 2003) with varying efficiencies. Transgene 
expression was found to be stable in monocyte-derived DCs (Gruber et al. 2000; Breckpot et 
al. 2003) and CD34+-derived DCs (Oki et al. 2001). However, for mouse DCs, the kinetics are 
somewhat more complicated, due to a process which is called pseudotransduction (Dullaers 
et al. 2004), and which results in a wrong estimation of the transduction efficiency when 
analyzed early after transduction. Nevertheless, DCs can be modified at high efficiency 
(Breckpot et al. 2003). Importantly, there is quite some variability in transduction efficiency 
among different reports. This most likely reflects the diversity in DC sources, techniques 
and vectors used for transduction (Breckpot et al. 2004a). 
3.3 Lentiviral vectors for the in vivo modification of dendritic cells  
As broad-tropism LVs efficiently transduced mouse and human DCs in vitro, it was next 
questioned whether these LVs can be used to transduce DCs in vivo, as such circumvent the 
 
Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy 
 
321 
labour-intensive, time- and money-consuming procedure of generating DCs ex vivo. 
Dullaers et al (Dullaers et al. 2006) used a PCR-based method to demonstrate the presence of 
the LV delivered transgene in the draining lymph node at days 2 and 10, but not day 25 post 
administration of LVs in the footpad. These data were confirmed in flow cytometry, 
demonstrating that the PCR signal correlated with a small percentage (less than 1%) of 
transduced CD11c+ cells (unpublished data Dullaers et al).  Using the same injection route, 
Esslinger et al (Esslinger et al. 2003) showed transduction of CD11c+ cells in the lymph node 
by immunohistochemical analysis, whereas He et al (He & Falo 2006) were able to 
demonstrate by flow cytometry that transduced DCs present in the lymph node after 
footpad injection of GFP encoding LVs originated from locally transduced migratory skin 
DC. More recently, a new imaging technique, in vivo bioluminescence imaging, was used to 
visualize cells transduced in situ with Firefly luciferase encoding LVs upon footpad injection 
(Breckpot et al.). Intravenous administration of LVs also leads to transduction of DCs in the 
spleen (VandenDriessche et al. 2002; Palmowski et al. 2004; Arce et al. 2009). These studies 
indicate that LVs, independent of the route of administration transduce DCs in situ and have 
instigated the exploration of LVs as an off-the-shelf vaccine. 
4. Exploitation of lentivirally transduced dendritic cells in anti-cancer 
immunotherapy 
Active anti-tumour immunotherapy is based on the delivery of tumour antigens (Boon & 
van der Bruggen 1996) in a way that induces therapeutic immunity. As several tumour-
induced tolerogenic mechanisms are in place it is not sufficient to stimulate effector T cells, 
it is moreover critical to circumvent suppressive immune cells, such as Treg.  Such anti-
tumour immunity can only be induced by professional antigen presenting cells, in particular 
DCs, and requires presentation of the tumour antigen-derived peptides to both CD4+ and 
CD8+ T cells in the context of strong co-stimulation. As mentioned previously LVs have 
been tested as vehicles, for ex vivo and in vivo antigen delivery to DCs.  In the following 
section we will discus the induction of potent T cell mediated immune responses that can 
control tumour growth by ex vivo, as well as in situ LV transduced DCs.  Finally, we will 
discuss some strategies that have been explored to enhance the performance of LV-based 
vaccines. 
4.1 Evaluation of ex vivo lentiviral vector transduced dendritic cells as a cellular anti-
tumour vaccine 
Since the beginning of the millennium, several reports on the use of tumour antigen 
encoding LVs for the ex vivo modification of DCs have been published.  As it is of 
paramount importance that tumour antigen-derived peptides are efficiently processed and 
presented on the DC surface in order to efficiently prime and activate tumour antigen-
specific T cells, it was first evaluated whether LV transduced DCs activate established T cell 
lines.  Note, strategies in which the tumour antigen encoding genetic sequence is fused to 
the sequence encoding class II targeting signals, such as the first 80 amino acids of the 
invariant chain (Ii80), were employed to obtain not only presentation of antigenic peptides 
in MHC class I, but furthermore in MHC class II in order to activate CD8+ and CD4+ T cells, 
respectively (Bonehill et al. 2005).  As mentioned before, the activation of IFN-γ producing 
CD4+ TH1 cells supports priming and maintenance of CTLs, moreover in anti-tumour 
immunotherapy, it has been shown that these CD4+ TH1 cells mediate tumour rejection 
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2004). Secondly, the incorporation of the cPPT and CTS into the transfer plasmid not only 
improved LV yields, but also provided enhanced transgene expression by mediating active 
nuclear import of the provirus (Follenzi et al. 2000; Sirven et al. 2000). Addition of 
posttranscriptional regulatory elements such as the Woodchuck hepatitis virus regulatory 
element (WPRE) has also been explored (Zufferey et al. 1999). Although some groups 
demonstrated improved gene expression by modification of polyadenylation, RNA export 
and/or translation, others reported only a negligible benefit (Breckpot et al. 2003). Another 
issue is epigenetic silencing and heterochromatin formation nearby the inserted provirus, 
which hampers its transcription. This silencing process can be avoided by the insertion of 
insulators or with vectors containing an enhancer-less ubiquitously acting chromatin-
opening element (Zhang et al. 2007; Nielsen et al. 2009). To improve safety, the incorporation 
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have a restricted tropism and do not allow production of high titer LV preparations, 
heterologous glycoproteins are used for LV production. This process is termed 
pseudotyping and most commonly the envelope of the vesicular stomatitis virus (VSV.G) is 
used. This rhabdovirus envelope glycoprotein interacts with an ubiquitous receptor and 
subsequently confers a broad host-cell range and high vector particle stability (Burns et al. 
1993; Marsac et al. 2002; Schaffer et al. 2008). 
3.2 Lentiviral vectors for the in vitro modification of dendritic cells  
Efficient transduction of human DCs with transgenic vectors has been challenging for 
several reasons.  Human DCs are usually generated from peripheral blood-derived 
quiescent CD14+ progenitors or from mitotically hypoactive primitive CD34+-derived 
progenitor cells. Therefore, the capacity of LVs to transduce quiescent and non-dividing 
cells turned out to be an important asset for DC transduction. The first successful 
transduction of human monocyte-derived DCs with LVs was described by Unutmaz et al 
(Unutmaz et al. 1999) in 1999. Since then, several research groups have reported successful 
transduction of human monocyte-derived (Gruber et al. 2000; Schroers et al. 2000; Dyall et al. 
2001; Firat et al. 2002; Breckpot et al. 2003; Lizee et al. 2004), human CD34+-derived DCs 
(Salmon et al. 2000; Oki et al. 2001; Sumimoto et al. 2002) and mouse bone marrow-derived 
DCs (Metharom et al. 2001; Breckpot et al. 2003) with varying efficiencies. Transgene 
expression was found to be stable in monocyte-derived DCs (Gruber et al. 2000; Breckpot et 
al. 2003) and CD34+-derived DCs (Oki et al. 2001). However, for mouse DCs, the kinetics are 
somewhat more complicated, due to a process which is called pseudotransduction (Dullaers 
et al. 2004), and which results in a wrong estimation of the transduction efficiency when 
analyzed early after transduction. Nevertheless, DCs can be modified at high efficiency 
(Breckpot et al. 2003). Importantly, there is quite some variability in transduction efficiency 
among different reports. This most likely reflects the diversity in DC sources, techniques 
and vectors used for transduction (Breckpot et al. 2004a). 
3.3 Lentiviral vectors for the in vivo modification of dendritic cells  
As broad-tropism LVs efficiently transduced mouse and human DCs in vitro, it was next 
questioned whether these LVs can be used to transduce DCs in vivo, as such circumvent the 
 
Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy 
 
321 
labour-intensive, time- and money-consuming procedure of generating DCs ex vivo. 
Dullaers et al (Dullaers et al. 2006) used a PCR-based method to demonstrate the presence of 
the LV delivered transgene in the draining lymph node at days 2 and 10, but not day 25 post 
administration of LVs in the footpad. These data were confirmed in flow cytometry, 
demonstrating that the PCR signal correlated with a small percentage (less than 1%) of 
transduced CD11c+ cells (unpublished data Dullaers et al).  Using the same injection route, 
Esslinger et al (Esslinger et al. 2003) showed transduction of CD11c+ cells in the lymph node 
by immunohistochemical analysis, whereas He et al (He & Falo 2006) were able to 
demonstrate by flow cytometry that transduced DCs present in the lymph node after 
footpad injection of GFP encoding LVs originated from locally transduced migratory skin 
DC. More recently, a new imaging technique, in vivo bioluminescence imaging, was used to 
visualize cells transduced in situ with Firefly luciferase encoding LVs upon footpad injection 
(Breckpot et al.). Intravenous administration of LVs also leads to transduction of DCs in the 
spleen (VandenDriessche et al. 2002; Palmowski et al. 2004; Arce et al. 2009). These studies 
indicate that LVs, independent of the route of administration transduce DCs in situ and have 
instigated the exploration of LVs as an off-the-shelf vaccine. 
4. Exploitation of lentivirally transduced dendritic cells in anti-cancer 
immunotherapy 
Active anti-tumour immunotherapy is based on the delivery of tumour antigens (Boon & 
van der Bruggen 1996) in a way that induces therapeutic immunity. As several tumour-
induced tolerogenic mechanisms are in place it is not sufficient to stimulate effector T cells, 
it is moreover critical to circumvent suppressive immune cells, such as Treg.  Such anti-
tumour immunity can only be induced by professional antigen presenting cells, in particular 
DCs, and requires presentation of the tumour antigen-derived peptides to both CD4+ and 
CD8+ T cells in the context of strong co-stimulation. As mentioned previously LVs have 
been tested as vehicles, for ex vivo and in vivo antigen delivery to DCs.  In the following 
section we will discus the induction of potent T cell mediated immune responses that can 
control tumour growth by ex vivo, as well as in situ LV transduced DCs.  Finally, we will 
discuss some strategies that have been explored to enhance the performance of LV-based 
vaccines. 
4.1 Evaluation of ex vivo lentiviral vector transduced dendritic cells as a cellular anti-
tumour vaccine 
Since the beginning of the millennium, several reports on the use of tumour antigen 
encoding LVs for the ex vivo modification of DCs have been published.  As it is of 
paramount importance that tumour antigen-derived peptides are efficiently processed and 
presented on the DC surface in order to efficiently prime and activate tumour antigen-
specific T cells, it was first evaluated whether LV transduced DCs activate established T cell 
lines.  Note, strategies in which the tumour antigen encoding genetic sequence is fused to 
the sequence encoding class II targeting signals, such as the first 80 amino acids of the 
invariant chain (Ii80), were employed to obtain not only presentation of antigenic peptides 
in MHC class I, but furthermore in MHC class II in order to activate CD8+ and CD4+ T cells, 
respectively (Bonehill et al. 2005).  As mentioned before, the activation of IFN-γ producing 
CD4+ TH1 cells supports priming and maintenance of CTLs, moreover in anti-tumour 
immunotherapy, it has been shown that these CD4+ TH1 cells mediate tumour rejection 
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(Bonehill et al. 2003). Both human and mouse LV transduced DCs were able to activate 
established CD8+ and CD4+ T cell lines specific for epitopes derived from various relevant 
tumour antigens, such as MAGE-3 (Breckpot et al. 2003), Melan-A (Firat et al. 2002; 
Sumimoto et al. 2002) and tyrosinase (Lizee et al. 2004) in the human system and for the 
surrogate antigen ovalbumin (OVA) (Breckpot et al. 2003; He et al. 2005), as well as for TRP-2 
(Metharom et al. 2001) in the murine system.  
Moreover, several groups reported on the in vitro priming of naive T cells against tumour 
antigens using LV transduced human DCs. Firat et al (Firat et al. 2002) stimulated CD8+ T 
cells in bulk with monocyte-derived DCs that were transduced with LVs encoding a 
melanoma poly-epitope and demonstrated expansion of tetramer+ CD8+ T cells, which 
could specifically lyse gp100 and Melan-A peptide-pulsed targets. We showed priming of 
both CD8+ and CD4+ T cells against the poorly immunogenic melanoma antigen MAGE-
A3 after in vitro stimulation with DCs transduced with LVs encoding the fusion protein 
Ii80MAGEA3 (Breckpot et al. 2003). The primed CD8+ T cells were further cloned and 
characterized enabling the identification of a novel HLA-Cw7 restricted MAGE-A3 
peptide (Breckpot et al. 2004b). A number of groups evaluated the potential of mouse DCs 
transduced with LVs as a cellular anti-tumour vaccine in vivo.  Herein, the induced 
immune response was characterized and tested for protection against tumour growth. We 
showed that immunization with DCs transduced with OVA encoding LVs induced a 
strong CTL response, resulting in specific lyses of OVA-expressing tumour cells after in 
vitro restimulation (Breckpot et al. 2003) or in vivo upon delivery of autologous OVA 
peptide-pulsed spleen cells (Dullaers et al. 2006). He et al (He et al. 2005) confirmed these 
data. It was moreover demonstrated that these CTL responses were protective against a 
subsequent challenge with a lethal dose of OVA-expressing B16 melanoma cells and 
slowed down the outgrowth of pre-existing tumours (He et al. 2005; Dullaers et al. 2006). 
Later on, it was shown with endogenous tumour antigens that the results obtained with 
the strong immunogenic OVA were not an overestimation of the potential of LV 
transduced DCs as a cellular therapeutic. Tumour antigens such as TRP-2 (Metharom et al. 
2001) and erbB2 (mouse analogue of human Her-2/neu) (Mossoba et al. 2008) were used 
to demonstrate induction of strong CTL responses and decreased tumour growth. 
Importantly, Wang et al. (Wang et al. 2006) extended these data in a mouse hepatoma 
model, immunized with LV transduced DCs expressing three hepatoma-associated 
antigens, which are self-antigens that are highly expressed in tumour cells, demonstrating 
CD4+ and CD8+ T cell responses against all three hepatoma antigens, as well as regression 
of established tumours.  Delivery of multiple tumour antigens might overcome the 
problem of tumour escape due to antigen loss (Dullaers et al. 2006). Finally, it has to be 
noted that several groups compared DCs transduced with LVs to DCs pulsed with 
(tumour) antigen-derived peptides (He et al. 2005; Metharom et al. 2005) or electroporated 
with mRNA (Dullaers et al. 2004), two strategies that were approved in the clinic, 
demonstrating that LV modified DCs elicited stronger and longer-lasting anti-tumour T 
cell responses.  
These studies suggest that ex vivo LV transduced DCs are effective in therapeutic treatment 
of cancer.  However, this strategy has important drawbacks common to all DC-based 
vaccination approaches. Because the vaccine is patient-specific it requires specialized 
personnel and facilities for vaccine production. Consequently, there is a high cost and 
considerable time required for vaccine production and quality control. It is for that reason 
that direct administration of LVs in vivo has gained substantial interest.  
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4.2 Evaluation of lentiviral vectors as an off-the-shelf anti-tumour vaccine 
For LVs to be an effective vaccine they have to transduce DCs in situ, a pre-requisite that 
is fulfilled.  Furthermore, the in vivo transduced DCs need to process the transgene, have 
to be activated so they migrate to lymphoid organs, where they subsequently present 
transgene-derived epitopes in the context of MHC molecules and strong co-stimulation to 
T cells. Hence, the degree of tumour antigen-specific CTL induction can be considered as 
a reliable measure for the value of direct administration of tumour antigen encoding LVs 
in tumour immunology. Antigen-specific CTLs could be generated upon direct 
administration of LVs using HLA-Cw3 as a model antigen (Esslinger et al. 2003). Similar 
results were obtained in HLA-A transgenic mice using a LV encoding a minigene 
containing the dominant human Melan-A HLA-A*0201 epitope (Chapatte et al. 2006) or 
human telomerase reverse transcriptase (hTERT) (Adotevi et al. ; Rusakiewicz et al.). 
Using OVA as an antigen, it was confirmed that direct administration of LVs resulted in a 
higher number of IFN-γ producing CD8+ T cells, which had a higher lytic capacity as 
compared to those primed with ex vivo transduced DCs (Dullaers et al. 2006). Memory 
CTL responses were also significantly stronger upon LV administration. Other studies 
with tumour antigens such as NY-ESO (Palmowski et al. 2004), TRP-2 (Kim et al. 2005), 
TRP-1 (Liu et al. 2009) and CEA (Loisel-Meyer et al. 2009), have also shown potent 
immune responses upon vaccination with LVs. Comparison of in vivo administration of 
LVs to the peptide or DNA vaccination strategy was performed in a HLA-A transgenic 
mice, by Chapatte et al (Chapatte et al. 2006) and Rusakiewicz et al (Rusakiewicz et al.), 
demonstrating that stronger tumour-specific immune responses were elicited when 
immunization was performed with LVs. 
 
Reference Dose Route Antigen 
Esslinger et al 2 x 107 EFU sc (footpad, tail base) Cw3, mini Melan-A 
Palmowski et al 1 x 106 PFU iv (tail vein) NY-ESO 
Kim et al 1.6 x 106 PFU sc (footpad) TRP-2 
Rowe et al 1 x 107 IU iv (tail vein) OVA 
Dullaers et al 2 x 107 TU sc (footpad) OVA 
He et al 1 x 106 TU sc ( footpad ) OVA 
Chapatte et al 2 x 107 EFU sc (tail base) Melan-A 
Liu et al 2.5 x 107 TU sc (footpad) TRP-1 
Loisel-Meyer 0.15 × 106 TU sc (footpad) CEA 
Rusakiewicz et al 1 x 107 TU sc (footpad) hTERT 
Table 1. Summary of the studies evaluating LVs as an off-the-shelf vaccine. 
Although CD4+ T cell responses were shown to be necessary for the priming and 
maintenance of CTLs when DCs are used for vaccination, not much data is available on the 
role of CD4+ T cell help in the induction of CTLs upon immunization with LVs. Esslinger et 
al (Esslinger et al. 2003) showed that CD4 depletion reduces the primary CTL response upon 
direct administration of LVs. Similarly, we (Dullaers et al. 2006) showed that although there 
was a larger requirement for CD4+ T cell help during the primary response in case of 
immunization with ex vivo transduced DCs compared to direct administration of LVs; CD4+ 
T cell depletion strongly reduced the capacity to mount a recall CTL response in both cases. 
Interestingly, Marzo et al (Marzo et al. 2004) showed that in the case of a VSV infection, a 
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(Bonehill et al. 2003). Both human and mouse LV transduced DCs were able to activate 
established CD8+ and CD4+ T cell lines specific for epitopes derived from various relevant 
tumour antigens, such as MAGE-3 (Breckpot et al. 2003), Melan-A (Firat et al. 2002; 
Sumimoto et al. 2002) and tyrosinase (Lizee et al. 2004) in the human system and for the 
surrogate antigen ovalbumin (OVA) (Breckpot et al. 2003; He et al. 2005), as well as for TRP-2 
(Metharom et al. 2001) in the murine system.  
Moreover, several groups reported on the in vitro priming of naive T cells against tumour 
antigens using LV transduced human DCs. Firat et al (Firat et al. 2002) stimulated CD8+ T 
cells in bulk with monocyte-derived DCs that were transduced with LVs encoding a 
melanoma poly-epitope and demonstrated expansion of tetramer+ CD8+ T cells, which 
could specifically lyse gp100 and Melan-A peptide-pulsed targets. We showed priming of 
both CD8+ and CD4+ T cells against the poorly immunogenic melanoma antigen MAGE-
A3 after in vitro stimulation with DCs transduced with LVs encoding the fusion protein 
Ii80MAGEA3 (Breckpot et al. 2003). The primed CD8+ T cells were further cloned and 
characterized enabling the identification of a novel HLA-Cw7 restricted MAGE-A3 
peptide (Breckpot et al. 2004b). A number of groups evaluated the potential of mouse DCs 
transduced with LVs as a cellular anti-tumour vaccine in vivo.  Herein, the induced 
immune response was characterized and tested for protection against tumour growth. We 
showed that immunization with DCs transduced with OVA encoding LVs induced a 
strong CTL response, resulting in specific lyses of OVA-expressing tumour cells after in 
vitro restimulation (Breckpot et al. 2003) or in vivo upon delivery of autologous OVA 
peptide-pulsed spleen cells (Dullaers et al. 2006). He et al (He et al. 2005) confirmed these 
data. It was moreover demonstrated that these CTL responses were protective against a 
subsequent challenge with a lethal dose of OVA-expressing B16 melanoma cells and 
slowed down the outgrowth of pre-existing tumours (He et al. 2005; Dullaers et al. 2006). 
Later on, it was shown with endogenous tumour antigens that the results obtained with 
the strong immunogenic OVA were not an overestimation of the potential of LV 
transduced DCs as a cellular therapeutic. Tumour antigens such as TRP-2 (Metharom et al. 
2001) and erbB2 (mouse analogue of human Her-2/neu) (Mossoba et al. 2008) were used 
to demonstrate induction of strong CTL responses and decreased tumour growth. 
Importantly, Wang et al. (Wang et al. 2006) extended these data in a mouse hepatoma 
model, immunized with LV transduced DCs expressing three hepatoma-associated 
antigens, which are self-antigens that are highly expressed in tumour cells, demonstrating 
CD4+ and CD8+ T cell responses against all three hepatoma antigens, as well as regression 
of established tumours.  Delivery of multiple tumour antigens might overcome the 
problem of tumour escape due to antigen loss (Dullaers et al. 2006). Finally, it has to be 
noted that several groups compared DCs transduced with LVs to DCs pulsed with 
(tumour) antigen-derived peptides (He et al. 2005; Metharom et al. 2005) or electroporated 
with mRNA (Dullaers et al. 2004), two strategies that were approved in the clinic, 
demonstrating that LV modified DCs elicited stronger and longer-lasting anti-tumour T 
cell responses.  
These studies suggest that ex vivo LV transduced DCs are effective in therapeutic treatment 
of cancer.  However, this strategy has important drawbacks common to all DC-based 
vaccination approaches. Because the vaccine is patient-specific it requires specialized 
personnel and facilities for vaccine production. Consequently, there is a high cost and 
considerable time required for vaccine production and quality control. It is for that reason 
that direct administration of LVs in vivo has gained substantial interest.  
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4.2 Evaluation of lentiviral vectors as an off-the-shelf anti-tumour vaccine 
For LVs to be an effective vaccine they have to transduce DCs in situ, a pre-requisite that 
is fulfilled.  Furthermore, the in vivo transduced DCs need to process the transgene, have 
to be activated so they migrate to lymphoid organs, where they subsequently present 
transgene-derived epitopes in the context of MHC molecules and strong co-stimulation to 
T cells. Hence, the degree of tumour antigen-specific CTL induction can be considered as 
a reliable measure for the value of direct administration of tumour antigen encoding LVs 
in tumour immunology. Antigen-specific CTLs could be generated upon direct 
administration of LVs using HLA-Cw3 as a model antigen (Esslinger et al. 2003). Similar 
results were obtained in HLA-A transgenic mice using a LV encoding a minigene 
containing the dominant human Melan-A HLA-A*0201 epitope (Chapatte et al. 2006) or 
human telomerase reverse transcriptase (hTERT) (Adotevi et al. ; Rusakiewicz et al.). 
Using OVA as an antigen, it was confirmed that direct administration of LVs resulted in a 
higher number of IFN-γ producing CD8+ T cells, which had a higher lytic capacity as 
compared to those primed with ex vivo transduced DCs (Dullaers et al. 2006). Memory 
CTL responses were also significantly stronger upon LV administration. Other studies 
with tumour antigens such as NY-ESO (Palmowski et al. 2004), TRP-2 (Kim et al. 2005), 
TRP-1 (Liu et al. 2009) and CEA (Loisel-Meyer et al. 2009), have also shown potent 
immune responses upon vaccination with LVs. Comparison of in vivo administration of 
LVs to the peptide or DNA vaccination strategy was performed in a HLA-A transgenic 
mice, by Chapatte et al (Chapatte et al. 2006) and Rusakiewicz et al (Rusakiewicz et al.), 
demonstrating that stronger tumour-specific immune responses were elicited when 
immunization was performed with LVs. 
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Esslinger et al 2 x 107 EFU sc (footpad, tail base) Cw3, mini Melan-A 
Palmowski et al 1 x 106 PFU iv (tail vein) NY-ESO 
Kim et al 1.6 x 106 PFU sc (footpad) TRP-2 
Rowe et al 1 x 107 IU iv (tail vein) OVA 
Dullaers et al 2 x 107 TU sc (footpad) OVA 
He et al 1 x 106 TU sc ( footpad ) OVA 
Chapatte et al 2 x 107 EFU sc (tail base) Melan-A 
Liu et al 2.5 x 107 TU sc (footpad) TRP-1 
Loisel-Meyer 0.15 × 106 TU sc (footpad) CEA 
Rusakiewicz et al 1 x 107 TU sc (footpad) hTERT 
Table 1. Summary of the studies evaluating LVs as an off-the-shelf vaccine. 
Although CD4+ T cell responses were shown to be necessary for the priming and 
maintenance of CTLs when DCs are used for vaccination, not much data is available on the 
role of CD4+ T cell help in the induction of CTLs upon immunization with LVs. Esslinger et 
al (Esslinger et al. 2003) showed that CD4 depletion reduces the primary CTL response upon 
direct administration of LVs. Similarly, we (Dullaers et al. 2006) showed that although there 
was a larger requirement for CD4+ T cell help during the primary response in case of 
immunization with ex vivo transduced DCs compared to direct administration of LVs; CD4+ 
T cell depletion strongly reduced the capacity to mount a recall CTL response in both cases. 
Interestingly, Marzo et al (Marzo et al. 2004) showed that in the case of a VSV infection, a 
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functional CD8+ T cell memory response can be generated in the absence of CD4+ T cells, 
this in contrast to an infection with Listeria monocytogenes. These authors suggest that the 
difference might be due to the fact that VSV can directly infect DC whereas L. monocytogenes 
antigens need to be cross-presented. Since, the currently applied LVs are pseudotyped with 
VSV envelopes, it needs to be further examined to what extent the CTL response is CD4+ T 
cell-dependent.  
The generation of specific T cell responses is a convenient read-out for the success of a 
vaccination strategy however; there are many examples of discrepancies between immune 
responses and anti-tumour responses (Rosenberg et al. 2005). Therefore, it is critical to 
evaluate the effect of LV vaccination on tumour growth. Rowe et al (Rowe et al. 2006) 
showed significantly improved protection of mice vaccinated with LVs encoding OVA 
against a subsequent tumour challenge. Similarly, Dullaers et al (Dullaers et al. 2006) showed 
that direct administration of LVs offers increased protection to a subsequent tumour 
challenge compared to DC vaccination and a significantly improved survival of tumour 
bearing mice. Other studies using TRP-2 (Kim et al. 2005), TRP-1 (Liu et al. 2009) or CEA 
(Loisel-Meyer et al. 2009) as tumour antigen, demonstrated improved survival of tumour 
bearing mice receiving LVs encoding these tumour antigens.  Liu et al (Liu et al. 2009) 
showed that this type of immunization could result in complete regression of small 
subcutaneous tumours, which correlated with enhanced numbers of functional CD8+ T cells 
in the tumour environment. Therefore, these studies highlight the potential of LVs encoding 
tumour antigens as an anti-cancer therapeutic. 
These studies demonstrate that administration of LVs doesn’t provoke immunological 
tolerance, but rather elicits powerful CTL responses against transgene-encoded proteins. 
This suggests a certain degree of immunogenicity of LVs or components within LV 
preparations, leading to activation of innate viral-sensing pathways and as a consequence 
induction of strong adaptive immunity. Therefore, it is not surprising that several studies 
addressed the immunogenicity of LVs. LVs are generally derived from HIV-1, for which 
activation of pDCs through TLR7 triggering has been demonstrated (Fonteneau et al. 2004; 
Beignon et al. 2005). It was demonstrated in vivo that activation of pDCs by recombinant LVs 
is mediated by several mechanisms. Brown et al. (Brown et al. 2006a) reported a TLR7-
dependent type I IFN response, whereas a role for TLR9 was demonstrated by Pichlmair et 
al (Pichlmair et al. 2007), who demonstrated that VSV.G pseudotyped LV preparations 
contain tubulovesicular structures of cellular origin, which carry nucleic acids. These 
structures triggered TLR9 in pDCs, whereas LVs pseudotyped with a γ-retroviral envelope 
didn’t (Lopes et al. 2008), suggesting that this particular mechanism is not necessary for 
potent immune stimulation. More recently, Rossetti et al (Rossetti et al.) demonstrated that 
also human blood-derived pDCs are activated in a TLR7/9-dependent way by LVs in vitro. 
These observations were not surprising as the pDC subset is the DCs subset that is best 
equipped to sense viral infections. However, recombinant LVs also target cDCs. Therefore, 
this DC subset should not be neglected when the LV immunogenicity is discussed. Gruber et 
al (Gruber et al. 2000) reported that transduction of cDCs at low MOI didn’t result in DC 
activation, whereas Tan et al. (Tan et al. 2005) described that transduction of cDCs at high 
MOI results in up-regulation of adhesion, stimulatory and antigen presenting molecules. 
Furthermore, these DCs displayed enhanced allo-stimulatory capacities and an altered 
cytokine secretion pattern. To clarify these results, we (Breckpot et al. 2007b) transduced 
DCs with LVs at varying MOI, confirming that transduction of DCs with LVs at low MOI 
results in considerable transgene delivery, without activation, whereas transduction at high 
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MOI indeed leads to DC maturation. A role for protein kinase R, a cytosolic receptor that 
interacts with double stranded RNA during LV replication, and several TLRs was suggested 
(Breckpot et al. 2007b). In our recent in vivo study, we demonstrated that cDCs are activated 
upon LV infection. More importantly, we showed that this activation was dependent on 
retroviral reverse transcription and critically dependent on the signal adaptor molecules 
MyD88 and TRIF, hence TLR signalling. Experiments with TLR knock out DCs 
demonstrated that both TLR3 and TLR7 are involved in the DC activation (Breckpot et al.).   
It is important to stress that induction of therapeutic anti-tumour immunity is critically 
dependent on an inflammatory environment in order to overcome tolerance, and active 
inhibitory mechanisms exerted by suppressive immune cells, such as Treg, as well as 
tumour cells. Such an inflammatory environment can be achieved by strong activation of the 
innate arm of the immune system, in particular through the engagement of TLRs. This was 
highlighted by Yang et al (Yang et al. 2004) and by Lang et al (Lang et al. 2005), who 
demonstrated that tolerance of antigen-specific CTLs could be broken by persistent TLR 
ligation. In that respect, we demonstrated that DCs activated by LVs via TLR3 and TLR7, 
efficiently expanded antigen-specific CTLs, whereas DCs lacking either TLR lacked this CTL 
inducing capacity (Breckpot et al.). Furthermore, it has been described that signalling 
through certain combinations of TLRs on DCs not only provided a synergy with respect to 
the production of stimulatory cytokines such as IL-12, which is essential in the 
differentiation of CD4+ T cells to a TH1 phenotype (Gautier et al. 2005; Napolitani et al. 2005), 
but also offered protection from suppressive Treg that actively quench the anti-tumour 
immune response (Warger et al. 2006). As a consequence, much research efforts have been 
put in designing approaches that enhance the intrinsic immunogenicity of LV-based 
vaccines. Some of these will be discussed in the next section. 
4.3 Engineering lentiviral vectors to enhance the immune stimulatory capacity of 
dendritic cells  
To enhance the immunogenic potential of LVs, and concomitantly prevent the actions of 
tolerogenic mechanisms over transduced DCs, LVs can be engineered to not only deliver the 
tumour antigen but also deliver molecules that enhance DC activation. Based on our 
growing knowledge on the importance of TLRs for DC activation and which activation 
pathways are triggered by these TLRs, several TLR-based strategies have been developed to 
enhance the immune stimulatory capacity of DCs upon LV transduction.  
Over the years LPS, which binds to TLR4 has been extensively used to activate DCs in vitro 
(Ardeshna et al. 2000; Arrighi et al. 2001; da Silva Correia et al. 2001). LPS-mediated 
activation remarkably enhances stimulation of DC-mediated immune responses in vitro, and 
overcomes suppression by Treg, a critical factor in anti-tumour immunology (Pasare & 
Medzhitov 2003). However, its clinical use is limited by its cytotoxicity. Therefore, the 
feasibility of using RVs encoding a constitutive active TLR4 (caTLR4) for DC maturation has 
been evaluated (Xu et al. 2007). This was achieved by linking the cytoplasmic domain of 
TLR4 to the extracellular single-chain immunoglobulin anti-erbB2. However, no activation 
of an immortalized DC line, JAWSII was observed, although a similar strategy, i.e. 
electroporation with mRNA encoding caTLR4, was recently shown to activate human DCs, 
resulting in priming of Melan-A CTL responses (Bonehill et al. 2008). Using a similar cloning 
strategy Xu et al (Xu et al. 2007) generated RVs encoding MyD88 or IRAK-1, two major 
adaptor molecules in TLR triggered activation pathways. Again they used the JAWSII DC 
line to evaluate the chimeric proteins, demonstrating that only the IRAK-1 chimera 
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functional CD8+ T cell memory response can be generated in the absence of CD4+ T cells, 
this in contrast to an infection with Listeria monocytogenes. These authors suggest that the 
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VSV envelopes, it needs to be further examined to what extent the CTL response is CD4+ T 
cell-dependent.  
The generation of specific T cell responses is a convenient read-out for the success of a 
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showed that this type of immunization could result in complete regression of small 
subcutaneous tumours, which correlated with enhanced numbers of functional CD8+ T cells 
in the tumour environment. Therefore, these studies highlight the potential of LVs encoding 
tumour antigens as an anti-cancer therapeutic. 
These studies demonstrate that administration of LVs doesn’t provoke immunological 
tolerance, but rather elicits powerful CTL responses against transgene-encoded proteins. 
This suggests a certain degree of immunogenicity of LVs or components within LV 
preparations, leading to activation of innate viral-sensing pathways and as a consequence 
induction of strong adaptive immunity. Therefore, it is not surprising that several studies 
addressed the immunogenicity of LVs. LVs are generally derived from HIV-1, for which 
activation of pDCs through TLR7 triggering has been demonstrated (Fonteneau et al. 2004; 
Beignon et al. 2005). It was demonstrated in vivo that activation of pDCs by recombinant LVs 
is mediated by several mechanisms. Brown et al. (Brown et al. 2006a) reported a TLR7-
dependent type I IFN response, whereas a role for TLR9 was demonstrated by Pichlmair et 
al (Pichlmair et al. 2007), who demonstrated that VSV.G pseudotyped LV preparations 
contain tubulovesicular structures of cellular origin, which carry nucleic acids. These 
structures triggered TLR9 in pDCs, whereas LVs pseudotyped with a γ-retroviral envelope 
didn’t (Lopes et al. 2008), suggesting that this particular mechanism is not necessary for 
potent immune stimulation. More recently, Rossetti et al (Rossetti et al.) demonstrated that 
also human blood-derived pDCs are activated in a TLR7/9-dependent way by LVs in vitro. 
These observations were not surprising as the pDC subset is the DCs subset that is best 
equipped to sense viral infections. However, recombinant LVs also target cDCs. Therefore, 
this DC subset should not be neglected when the LV immunogenicity is discussed. Gruber et 
al (Gruber et al. 2000) reported that transduction of cDCs at low MOI didn’t result in DC 
activation, whereas Tan et al. (Tan et al. 2005) described that transduction of cDCs at high 
MOI results in up-regulation of adhesion, stimulatory and antigen presenting molecules. 
Furthermore, these DCs displayed enhanced allo-stimulatory capacities and an altered 
cytokine secretion pattern. To clarify these results, we (Breckpot et al. 2007b) transduced 
DCs with LVs at varying MOI, confirming that transduction of DCs with LVs at low MOI 
results in considerable transgene delivery, without activation, whereas transduction at high 
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MOI indeed leads to DC maturation. A role for protein kinase R, a cytosolic receptor that 
interacts with double stranded RNA during LV replication, and several TLRs was suggested 
(Breckpot et al. 2007b). In our recent in vivo study, we demonstrated that cDCs are activated 
upon LV infection. More importantly, we showed that this activation was dependent on 
retroviral reverse transcription and critically dependent on the signal adaptor molecules 
MyD88 and TRIF, hence TLR signalling. Experiments with TLR knock out DCs 
demonstrated that both TLR3 and TLR7 are involved in the DC activation (Breckpot et al.).   
It is important to stress that induction of therapeutic anti-tumour immunity is critically 
dependent on an inflammatory environment in order to overcome tolerance, and active 
inhibitory mechanisms exerted by suppressive immune cells, such as Treg, as well as 
tumour cells. Such an inflammatory environment can be achieved by strong activation of the 
innate arm of the immune system, in particular through the engagement of TLRs. This was 
highlighted by Yang et al (Yang et al. 2004) and by Lang et al (Lang et al. 2005), who 
demonstrated that tolerance of antigen-specific CTLs could be broken by persistent TLR 
ligation. In that respect, we demonstrated that DCs activated by LVs via TLR3 and TLR7, 
efficiently expanded antigen-specific CTLs, whereas DCs lacking either TLR lacked this CTL 
inducing capacity (Breckpot et al.). Furthermore, it has been described that signalling 
through certain combinations of TLRs on DCs not only provided a synergy with respect to 
the production of stimulatory cytokines such as IL-12, which is essential in the 
differentiation of CD4+ T cells to a TH1 phenotype (Gautier et al. 2005; Napolitani et al. 2005), 
but also offered protection from suppressive Treg that actively quench the anti-tumour 
immune response (Warger et al. 2006). As a consequence, much research efforts have been 
put in designing approaches that enhance the intrinsic immunogenicity of LV-based 
vaccines. Some of these will be discussed in the next section. 
4.3 Engineering lentiviral vectors to enhance the immune stimulatory capacity of 
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To enhance the immunogenic potential of LVs, and concomitantly prevent the actions of 
tolerogenic mechanisms over transduced DCs, LVs can be engineered to not only deliver the 
tumour antigen but also deliver molecules that enhance DC activation. Based on our 
growing knowledge on the importance of TLRs for DC activation and which activation 
pathways are triggered by these TLRs, several TLR-based strategies have been developed to 
enhance the immune stimulatory capacity of DCs upon LV transduction.  
Over the years LPS, which binds to TLR4 has been extensively used to activate DCs in vitro 
(Ardeshna et al. 2000; Arrighi et al. 2001; da Silva Correia et al. 2001). LPS-mediated 
activation remarkably enhances stimulation of DC-mediated immune responses in vitro, and 
overcomes suppression by Treg, a critical factor in anti-tumour immunology (Pasare & 
Medzhitov 2003). However, its clinical use is limited by its cytotoxicity. Therefore, the 
feasibility of using RVs encoding a constitutive active TLR4 (caTLR4) for DC maturation has 
been evaluated (Xu et al. 2007). This was achieved by linking the cytoplasmic domain of 
TLR4 to the extracellular single-chain immunoglobulin anti-erbB2. However, no activation 
of an immortalized DC line, JAWSII was observed, although a similar strategy, i.e. 
electroporation with mRNA encoding caTLR4, was recently shown to activate human DCs, 
resulting in priming of Melan-A CTL responses (Bonehill et al. 2008). Using a similar cloning 
strategy Xu et al (Xu et al. 2007) generated RVs encoding MyD88 or IRAK-1, two major 
adaptor molecules in TLR triggered activation pathways. Again they used the JAWSII DC 
line to evaluate the chimeric proteins, demonstrating that only the IRAK-1 chimera 
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mediated IL-12 and TNF-α secretion, and enhanced OVA-specific CD4+ T cell responses. 
Akazawa et al (Akazawa et al. 2007) expressed MyD88 and TRIF, another major TLR signal 
transduction molecule in mouse DCs using LVs. MyD88-modified DCs produced IL-6 and 
IL-12, but didn’t up-regulate phenotypic markers, whereas TRIF expression stimulated IFN-
β production and increased levels of CD86. Both MyD88 and TRIF increased the allo-
stimulatory capacity of the modified DCs, and tumour outgrowth was delayed after 
immunization with these DCs.   
Introduction of MyD88 or IRAK-1 in DCs activates the NF-κB pathway. NF-κB is a well-
studied transcription factor that targets genes associated with DC maturation. Sustained NF-
κB activation in DCs using LVs has been achieved by expressing Kaposi’s sarcoma 
associated human herpes virus vFLIP (Rowe et al. 2009). In this case, DC maturation was 
enhanced by up-regulation of MHC, adhesion (ICAM-1) and co-stimulatory molecules 
(CD80, CD86, CD40), and increased secretion of TNF-α and IL-12. vFLIP-modified DCs 
significantly increased antigen-specific CTL responses resulting in enhanced anti-tumour 
immunity (Karwacz et al. 2009; Rowe et al. 2009). Another effective approach leading to 
sustained NF-κB activation consists of down-regulating the negative feedback molecule, A20 
of which the expression is under the immediate control of NF-κB. A20 deactivates several 
adaptor molecules of the TNFR, IL-1/TLR signalling pathways by ubiquitinating/de-
ubiquitinating activity (Vereecke et al. 2009). Therefore, A20 down-regulation could result in 
prolonged NF-κB activation, resulting in DCs with enhanced stimulatory capacity. LV 
delivered A20-targeted shRNA (Song et al. 2008) and direct introduction of siRNA (Breckpot 
et al. 2009) were applied to down-regulate A20 in mouse and human DCs, respectively. 
These approaches showed that A20 controls DC maturation, cytokine production and 
immunostimulatory potency. Human DCs with down-regulated A20 expression had an 
increased NF-κB activity and showed enhanced and sustained IL-10 and IL-12 secretion. 
These DCs were more potent in stimulating Melan-A CTL responses (Breckpot et al. 2009). 
Mouse DCs with down-regulated A20 expression showed enhanced expression of co-
stimulatory molecules and pro-inflammatory cytokines. Moreover, these DCs hyper-
activated tumour-specific CTL and TH cells, which were refractory to Treg suppression 
(Song et al. 2008).  
Besides LVs that target the NF-κB pathway, LVs have been engineered to increase the DC’s 
immunogenicity by introducing specific genes that modulate intracellular MAPK pathways. 
p38 was activated by expressing MKK6 mutants containing glutamate and aspartate 
residues in their activation loop, mimicking phosphorylated serine or threonine residues 
(Raingeaud et al. 1996). A fusion protein between MKK7 and JNK1 was expressed to achieve 
constitutive JNK1 phosphorylation (Escors et al. 2008). Expression of constitutive activators 
prevents inactivation by phosphatase-dependent negative feedback mechanisms, which 
may counteract tolerogenic mechanisms in anti-tumour immunity. In the absence of TLR 
stimulation, p38 activation resulted in a DC maturation phenotype different from full 
maturation as achieved by LPS treatment (Escors et al. 2008). Particularly, there was specific 
up-regulation of co-stimulatory molecules and absence of significant secretion of pro-
inflammatory cytokines (Escors et al. 2008). Interestingly, co-expression of OVA with the p38 
activator in DCs significantly increased antigen-specific CD4+ and CD8+ T cell responses 
leading to increased anti-tumour immunity (Escors et al. 2008; Karwacz et al. 2009).  
Additionally, MAPK p38 constitutive activation also increased CD8+ T cell responses to 
human tumour antigens NY-ESO in a humanized HLA-A2 mouse model and Melan-A in a 
human DC-T cell culture (Escors et al. 2008). Specific activation of JNK1 in DCs showed only 
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a moderate up-regulation of co-stimulatory molecules and no significant secretion of pro-
inflammatory cytokines, confirming previous studies, which suggested that JNK marginally 
controls DC maturation (Nakahara et al. 2004; Escors et al. 2008).  On the other hand, 
increased antigen-specific CD8+ T cell expansion was achieved in mice after subcutaneous 
vaccination with LV expressing MKK7-JNK1, suggesting that JNK1 may play a subtle but 
important role in DCs in vivo (Escors et al. 2008). 
5. Exploitation of lentivirally transduced dendritic cells for the induction of 
tolerance 
There are many ways in which DCs have been utilised for the treatment of autoimmune 
disorders.  This chapter will focus on genetic modification using LVs, rather than providing 
an extensive review of all DC-based methods.  Because the achievement of immune 
suppression is more challenging than inducing activation, there are a limited number of 
reports on the use of LVs as immunosuppressive (tolerogenic) therapeutic agents.  
An obvious approach to genetically modify DCs for the treatment of autoimmune disorders 
is to express potent immunosuppressive cytokines. In fact, there are a few reports of DC 
modification using mainly RVs expressing immunosuppressive cytokines for the treatment 
of inflammatory diseases (Lee et al. 1998; Takayama et al. 1998; Morita et al. 2001). The 
equivalent approach has been undertaken by transduction of DCs using LVs expressing IL-
10 in an OVA-dependent model of experimental asthma (Henry et al. 2008). In vivo 
intratracheal injection of OVA-pulsed DCs modified with LVs expressing IL-10 effectively 
inhibited airway inflammation and asthma-associated symptoms.  Interestingly, it was 
demonstrated that host IL-10 expression was absolutely required for the IL-10 DCs to inhibit 
asthma (Henry et al. 2008). Therefore, IL-10 expression from DCs was playing an indirect 
role in inhibiting disease. Interestingly, a significant increase in Foxp3+ Treg expressing IL-
10 were expanded, and their adoptive transfer prevented OVA-sensitized mice from 
eosinophilia after OVA challenge (Henry et al. 2008). 
An attractive option for programming tolerogenic DCs is to modulate signalling pathways 
involved in differentiation of immunosuppressive DCs. This approach regulates expression 
of gene clusters, which act in a concerted action in physiological functional tolerogenic DCs. 
There is quite a wide range of experimental evidence linking MAPK ERK activation to 
immune suppression and tolerance (Agrawal et al. 2006; Caparros et al. 2006; Dillon et al. 
2006; Escors et al. 2008). Constitutive activation of the ERK pathway can be readily achieved 
by expression of constitutively active MEK1 mutants, the upstream ERK kinase (Pages et al. 
1994; Raingeaud et al. 1996; Escors et al. 2008; Anastasaki et al. 2009).  Particularly, DCs 
modified with a LV expressing a MEK1 mutant with a deletion in the coding region of the 
nuclear export signal, together with two activating mutations resulted in DCs with a marked 
immature phenotype (Escors et al. 2008). ERK-activated mouse and human DCs showed a 
pronounced CD40 down-regulation and secretion of significant amounts of TGF-β (Escors et 
al. 2008; Arce et al. 2010). These DCs were strongly immunosuppressive, leading to 
differentiation of antigen-specific Foxp3+ Treg in vivo and in vitro (Arce et al. 2010). These 
differentiated Treg strongly proliferated after a second antigen encounter in inflammatory 
conditions. A LV vaccine based on an ERK activator was successfully applied for the 
treatment of inflammatory arthritis in a mouse model (Arce et al. 2010). This therapeutic 
approach could be applied even when the specific arthritogenic antigen was not specifically 
targeted. Application in human therapy could follow a similar approach in which 
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mediated IL-12 and TNF-α secretion, and enhanced OVA-specific CD4+ T cell responses. 
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stimulatory capacity of the modified DCs, and tumour outgrowth was delayed after 
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inflammatory cytokines (Escors et al. 2008). Interestingly, co-expression of OVA with the p38 
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human DC-T cell culture (Escors et al. 2008). Specific activation of JNK1 in DCs showed only 
 
Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy 
 
327 
a moderate up-regulation of co-stimulatory molecules and no significant secretion of pro-
inflammatory cytokines, confirming previous studies, which suggested that JNK marginally 
controls DC maturation (Nakahara et al. 2004; Escors et al. 2008).  On the other hand, 
increased antigen-specific CD8+ T cell expansion was achieved in mice after subcutaneous 
vaccination with LV expressing MKK7-JNK1, suggesting that JNK1 may play a subtle but 
important role in DCs in vivo (Escors et al. 2008). 
5. Exploitation of lentivirally transduced dendritic cells for the induction of 
tolerance 
There are many ways in which DCs have been utilised for the treatment of autoimmune 
disorders.  This chapter will focus on genetic modification using LVs, rather than providing 
an extensive review of all DC-based methods.  Because the achievement of immune 
suppression is more challenging than inducing activation, there are a limited number of 
reports on the use of LVs as immunosuppressive (tolerogenic) therapeutic agents.  
An obvious approach to genetically modify DCs for the treatment of autoimmune disorders 
is to express potent immunosuppressive cytokines. In fact, there are a few reports of DC 
modification using mainly RVs expressing immunosuppressive cytokines for the treatment 
of inflammatory diseases (Lee et al. 1998; Takayama et al. 1998; Morita et al. 2001). The 
equivalent approach has been undertaken by transduction of DCs using LVs expressing IL-
10 in an OVA-dependent model of experimental asthma (Henry et al. 2008). In vivo 
intratracheal injection of OVA-pulsed DCs modified with LVs expressing IL-10 effectively 
inhibited airway inflammation and asthma-associated symptoms.  Interestingly, it was 
demonstrated that host IL-10 expression was absolutely required for the IL-10 DCs to inhibit 
asthma (Henry et al. 2008). Therefore, IL-10 expression from DCs was playing an indirect 
role in inhibiting disease. Interestingly, a significant increase in Foxp3+ Treg expressing IL-
10 were expanded, and their adoptive transfer prevented OVA-sensitized mice from 
eosinophilia after OVA challenge (Henry et al. 2008). 
An attractive option for programming tolerogenic DCs is to modulate signalling pathways 
involved in differentiation of immunosuppressive DCs. This approach regulates expression 
of gene clusters, which act in a concerted action in physiological functional tolerogenic DCs. 
There is quite a wide range of experimental evidence linking MAPK ERK activation to 
immune suppression and tolerance (Agrawal et al. 2006; Caparros et al. 2006; Dillon et al. 
2006; Escors et al. 2008). Constitutive activation of the ERK pathway can be readily achieved 
by expression of constitutively active MEK1 mutants, the upstream ERK kinase (Pages et al. 
1994; Raingeaud et al. 1996; Escors et al. 2008; Anastasaki et al. 2009).  Particularly, DCs 
modified with a LV expressing a MEK1 mutant with a deletion in the coding region of the 
nuclear export signal, together with two activating mutations resulted in DCs with a marked 
immature phenotype (Escors et al. 2008). ERK-activated mouse and human DCs showed a 
pronounced CD40 down-regulation and secretion of significant amounts of TGF-β (Escors et 
al. 2008; Arce et al. 2010). These DCs were strongly immunosuppressive, leading to 
differentiation of antigen-specific Foxp3+ Treg in vivo and in vitro (Arce et al. 2010). These 
differentiated Treg strongly proliferated after a second antigen encounter in inflammatory 
conditions. A LV vaccine based on an ERK activator was successfully applied for the 
treatment of inflammatory arthritis in a mouse model (Arce et al. 2010). This therapeutic 
approach could be applied even when the specific arthritogenic antigen was not specifically 
targeted. Application in human therapy could follow a similar approach in which 
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simultaneous ERK activation and expression of an endogenous antigen could be used to 
inhibit arthritis even though the arthritogenic antigens are not well characterized and may 
vary between patients. 
Interestingly, constitutive activation of the type I IFN signalling pathway was also 
immunosuppressive in DCs. Expression of a constitutively active IRF3 mutant (IRF3 2D) in 
mouse DCs induced expression of high levels of IL-10 (Escors et al. 2008). Interestingly, 
vaccination with a LV co-expressing IRF3 2D with an OVA-containing transgene resulted in 
systemic expansion of OVA-specific Foxp3+ Treg (Escors et al. 2008). In physiological 
conditions, phosphorylated IRF3 dimerizes and translocates to the nucleus where it 
transactivates type I IFN promoters, leading to IFN-β production, a potent antiviral cytokine 
(Fitzgerald et al. 2003). Interestingly, it has been known for some time that components of 
the type I interferon pathway are in fact immunosuppressive (Chang et al. 2007). This is also 
the basis of the use of type I IFNs for the treatment of multiple sclerosis (Comabella et al. 
2002; Billiau 2006). Very interestingly, production of both IFN-β and IL-10 share a common 
pathway when activated by TLR signalling (Hacker et al. 2006; Chang et al. 2007). It has been 
proposed that phosphorylated IRF3 may link IFN-β production with IL-10 secretion through 
a MyD88-dependent pathway (Escors et al. 2008). Taking advantage of this, activators of the 
type I IFN pathway could be expressed in DCs for the treatment of autoimmune disorders 
such as multiple sclerosis.  
An alternative to constitutive activation of immunosuppressive pathways is to specifically 
inhibit pro-inflammatory signalling pathways.  Possibly, one of the major pro-inflammatory 
pathways in DCs is NF-κB (Breckpot & Escors 2009b). Consequently, silencing of 
components from the NF-κB pathway could theoretically prevent DC maturation and 
induce immune suppression and tolerance. For instance, this has been successfully applied 
by silencing Rel-B in DCs by delivery of a specific shRNA using LVs (Zhang et al. 2009). Rel-
B silencing was sufficient to confer DCs resistance to TLR-derived maturation signals and to 
inhibit experimental autoimmune myasthenia gravis in a mouse model (Zhang et al. 2009). 
Interestingly, just by inhibiting NF-κB, DCs acquired tolerogenic activities characterised by 
inhibition of T cell proliferation and differentiation of Foxp3+ Treg.  
Another interesting approach is the exploitation of naturally occurring negative feedback 
mechanisms of pro-inflammatory pathways. This has been achieved by over-expressing 
suppressor of cytokine signalling 3 (SOCS-3) in DCs using LVs (Li et al. 2006). SOCS comprise 
a family of cytoplasmic proteins induced by cytokine-mediated signal transduction. They form 
part of a negative feedback mechanism that limits cytokine-induced signalling. Expression of 
SOCS3 in mouse DCs results in immature DCs with down-regulated MHC molecules and 
reduced CD86 (Li et al. 2006). These modified DCs exhibit an impaired signalling by IL-12 and 
IL-23, and reduced expression of these cytokines. More importantly, enhanced secretion of IL-
10 was observed, which polarised T cell responses towards a TH2 type.  Interestingly, SOCS3-
expressing DCs could efficiently inhibit the development of EAE, an experimental model for 
human multiple sclerosis (Li et al. 2006). 
Recently, a LV-based shRNA delivery system was successfully applied for the treatment of 
experimental collagen-induced arthritis without specific targeting of the arthritogenic 
antigen (collagen) (Lai Kwan Lam et al. 2008). Direct administration of a LV encoding a 
siRNA specific for B cell activating factor (BAFF) to the inflamed joint was sufficient to 
inhibit arthritis. BAFF is a member of the TNF family which is mainly involved in regulating 
B cell maturation and functions (Batten et al. 2000; Yang et al. 2010). Interestingly, elevated 
BAFF levels have been found in the serum of patients suffering from several autoimmune 
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disorders including rheumatoid arthritis. Very interestingly, it was demonstrated that LVs 
preferentially transduced DCs in the inflamed joint, and that BAFF silencing in these DCs 
interfered with DC maturation. Local BAFF silencing inhibited pro-inflammatory T cell 
development and inhibited production of pro-inflammatory cytokines such as IL-17, IL-23 
and IL-6 (Lai Kwan Lam et al. 2008). Importantly, these authors clearly demonstrated that (i) 
LVs can be directly administered to the site of inflammation, (ii) they preferentially 
transduce local DCs and (iii) it is not strictly necessary to target the arthritogenic antigen. 
In addition to manipulation of signalling pathways, there are small peptides with broad 
activities including immune suppression. Direct intraperitoneal immunisation with a LV 
encoding vasointestinal peptide (VIP) reduced the severity of collagen-induced arthritis in a 
mouse model (Delgado et al. 2008). Interestingly, vaccination with this LV significantly 
inhibited the secretion of a wide array of pro-inflammatory cytokines both systemically and 
in the joint. This tolerogenic LV-vaccination expanded Foxp3+ Treg (Delgado et al. 2008). 
However, VIP has a variety of physiological functions apart from its immunosuppressive 
properties. Therefore, in this case, it would be desirable to modify DCs ex vivo with a VIP-
expressing LV followed by in vivo transfer (Toscano et al. 2010). In fact, VIP expression in 
DCs was sufficient to keep them in an immature stage, leading to secretion of high levels of 
IL-10 (Toscano et al. 2010). In vivo administration of VIP-expressing DCs had beneficial 
therapeutic effects in EAE mice and in the cecal ligation and puncture model, both models 
relevant for multiple sclerosis and sepsis in humans (Toscano et al. 2010). 
6. Limitations of lentiviral vectors for direct in vivo application  
Although the HIV-based vector system is by far the best developed among the various LVs, 
a variety of quality, safety, efficacy, regulatory and ethical concerns slacken the frequent 
employment of HIV-based vectors in a clinical setting. In view of DC modulation, the scope 
of this review will be limited to the biological risks and immunogenic consequences of LV-
based vaccination. Safety seems the most pressing issue as LVs are derived from an 
integrating pathogenic agent, lethal in humans. As mentioned, one of the main adverse 
events to consider is the potential generation of RCLs. However, to date no RCLs have been 
reported for LV packaging systems. This can be partially explained by the separation of cis-
and trans-acting sequences during LV production, but also by the fact that SIN LVs are less 
likely to produce RCLs (Pauwels et al. 2009). A major setback for viral gene therapy clinical 
trials was caused by the development of leukaemia in five patients of two separate γ-RV 
gene therapy trials for X-linked SCID as a consequence of insertional activation of the LMO2 
gene (proto-oncogene) by the LTR enhancer. As genomic integration is common to all 
retroviruses, the associated risk of insertional mutagenesis and/or transactivation of 
adjacent sequences must be taken into account for LVs as well (Howe et al. 2008). However, 
as these observations were made with γ–RV it would be to hasty to extrapolate this risk to 
the multiply attenuated recombinant LV system used today. An in vitro mapping study 
comparing RV and LV integration in transduced human HSCs revealed that RV but not LV 
hot spots were highly enriched in proto-oncogenes, cancer-associated and growth-
controlling genes, suggesting that LVs have a lower propensity for integrating in potentially 
dangerous regions within the human genome (Cattoglio et al. 2007). Furthermore, an in vivo 
genotoxicity assay using a tumour-prone murine model, also showed differences in the 
oncogenic potential of RVs and LVs. Herein, it was shown that LTRs co-determine the 
vector’s genotoxic potential, supporting the choice of SIN LVs (Montini et al. 2009). Recently, 
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simultaneous ERK activation and expression of an endogenous antigen could be used to 
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IL-23, and reduced expression of these cytokines. More importantly, enhanced secretion of IL-
10 was observed, which polarised T cell responses towards a TH2 type.  Interestingly, SOCS3-
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Recently, a LV-based shRNA delivery system was successfully applied for the treatment of 
experimental collagen-induced arthritis without specific targeting of the arthritogenic 
antigen (collagen) (Lai Kwan Lam et al. 2008). Direct administration of a LV encoding a 
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disorders including rheumatoid arthritis. Very interestingly, it was demonstrated that LVs 
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development and inhibited production of pro-inflammatory cytokines such as IL-17, IL-23 
and IL-6 (Lai Kwan Lam et al. 2008). Importantly, these authors clearly demonstrated that (i) 
LVs can be directly administered to the site of inflammation, (ii) they preferentially 
transduce local DCs and (iii) it is not strictly necessary to target the arthritogenic antigen. 
In addition to manipulation of signalling pathways, there are small peptides with broad 
activities including immune suppression. Direct intraperitoneal immunisation with a LV 
encoding vasointestinal peptide (VIP) reduced the severity of collagen-induced arthritis in a 
mouse model (Delgado et al. 2008). Interestingly, vaccination with this LV significantly 
inhibited the secretion of a wide array of pro-inflammatory cytokines both systemically and 
in the joint. This tolerogenic LV-vaccination expanded Foxp3+ Treg (Delgado et al. 2008). 
However, VIP has a variety of physiological functions apart from its immunosuppressive 
properties. Therefore, in this case, it would be desirable to modify DCs ex vivo with a VIP-
expressing LV followed by in vivo transfer (Toscano et al. 2010). In fact, VIP expression in 
DCs was sufficient to keep them in an immature stage, leading to secretion of high levels of 
IL-10 (Toscano et al. 2010). In vivo administration of VIP-expressing DCs had beneficial 
therapeutic effects in EAE mice and in the cecal ligation and puncture model, both models 
relevant for multiple sclerosis and sepsis in humans (Toscano et al. 2010). 
6. Limitations of lentiviral vectors for direct in vivo application  
Although the HIV-based vector system is by far the best developed among the various LVs, 
a variety of quality, safety, efficacy, regulatory and ethical concerns slacken the frequent 
employment of HIV-based vectors in a clinical setting. In view of DC modulation, the scope 
of this review will be limited to the biological risks and immunogenic consequences of LV-
based vaccination. Safety seems the most pressing issue as LVs are derived from an 
integrating pathogenic agent, lethal in humans. As mentioned, one of the main adverse 
events to consider is the potential generation of RCLs. However, to date no RCLs have been 
reported for LV packaging systems. This can be partially explained by the separation of cis-
and trans-acting sequences during LV production, but also by the fact that SIN LVs are less 
likely to produce RCLs (Pauwels et al. 2009). A major setback for viral gene therapy clinical 
trials was caused by the development of leukaemia in five patients of two separate γ-RV 
gene therapy trials for X-linked SCID as a consequence of insertional activation of the LMO2 
gene (proto-oncogene) by the LTR enhancer. As genomic integration is common to all 
retroviruses, the associated risk of insertional mutagenesis and/or transactivation of 
adjacent sequences must be taken into account for LVs as well (Howe et al. 2008). However, 
as these observations were made with γ–RV it would be to hasty to extrapolate this risk to 
the multiply attenuated recombinant LV system used today. An in vitro mapping study 
comparing RV and LV integration in transduced human HSCs revealed that RV but not LV 
hot spots were highly enriched in proto-oncogenes, cancer-associated and growth-
controlling genes, suggesting that LVs have a lower propensity for integrating in potentially 
dangerous regions within the human genome (Cattoglio et al. 2007). Furthermore, an in vivo 
genotoxicity assay using a tumour-prone murine model, also showed differences in the 
oncogenic potential of RVs and LVs. Herein, it was shown that LTRs co-determine the 
vector’s genotoxic potential, supporting the choice of SIN LVs (Montini et al. 2009). Recently, 
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immune-deficient mice received LV transduced HSCs, and were followed for 2-6 months. 
No LV-associated adverse events were observed, and none of the mice had detectable levels 
of HIV p24 antigen in their sera (Bauer et al. 2008). More recently also the concept of clonal 
dominance came forward for LVs in a phase I/II clinical trial using HSCs transduced by a 
SIN LV with chromatin insulators (Bank et al. 2005). This clonal dominance seems to be due 
to growth and/or survival advantage conferred by gene-activating or -suppressing effects of 
the integrated LV. Importantly, such induced clonal dominance didn’t lead to malignant 
transformation (Fehse & Roeder 2008). Additional potential adverse events are 
seroconversion of the subject to components of the HIV-1 vector, mobilization and 
subsequent spread of mobilized vector particles to previously untransduced cells and 
tissues, and transmission of exogenous DNA to cells of the germ line (Romano et al. 2003). 
In view of LV based vaccination, the induced innate and adaptive immune reactions 
against the LV particle, transduced cells and/or its transgene product, act as a double-
edged sword. This immunogenicity may aggravate a robust immune reaction, which is 
possibly advantageous in the context of e.g. anti-tumour immunotherapy. However, 
unwanted immune responses may curtail the induction of tolerance, which is desired for 
the treatment of e.g. transplantation rejection or autoimmune diseases. As broad tropism 
LVs are capable of transducing DCs but also other cell types, this can have important 
consequences in view of the immunological outcome. On the one hand transgene 
expression by non-DCs could lead to uptake of cellular remains from these cells by DCs 
followed by antigen presentation in the context of MHC class II and via cross-presentation 
in the context of MHC class I. In this way not only a CTL response is triggered, but also 
TH cells, which are important to induce a proper CTL response (Matrai et al. 2010). On the 
other hand DCs also play an important role in the induction and maintenance of 
peripheral tolerance against self-antigens (Steinman 2007). In this context, persistent 
expression of the transgene by a non-DC, as a consequence of LV integration in a 
terminally differentiated long-living cell, could also lead to induction of peripheral 
tolerance (Follenzi et al. 2004). Thus, upon broad tropism LV vaccination, the antigen-
specific immune response could be initiated by transduced DCs (direct priming), and 
theoretically by non-lymphoid cells (cross-priming). However, the latter might also 
counteract the envisaged immune response, which makes it hard to predict the 
immunological outcome. Therefore, targeting of LVs to DCs, the cell type of choice to 
induce immunity or tolerance has been explored. Two different approaches have been 
successfully attempted (i) transcriptional targeting in which DC-specific promoters are 
exploited and (ii) transductional targeting in which DC-specific LV entry is achieved. 
Transcriptional targeting has been extensively discussed by Frecha et al (Frecha et al. 
2008). 
We believe that transductional targeting of LVs to DCs is a very interesting strategy to tackle 
safety and efficacy concerns all at once, since: (i) DCs have a relative short half-life, which 
decreases the chance for malignant transformation after insertional mutagenesis, since this is 
a multi-step process (Fehse & Roeder 2008), (ii) there is no risk for transmission of 
exogenous DNA to the germ line, (iii) non-DC transduction is prevented which can 
overcome unwanted interference with the desired immune response, (iv) DC subset-specific 
targeting paves the way to fundamental research on the exact role of each DC subset in the 
development of diseases, as well as their therapeutic importance.  
As the LV tropism is determined by the envelope glycoprotein, pseudotyping allows the 
generation of LVs with a specific transduction pattern. To date, there is no natural DC-
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specific envelope glycoprotein identified. In first instance, it was attempted to modify 
existing envelope proteins by means of genetic engineering to obtain DC-specific binding 
without disrupting membrane fusion. An example of this application is the construction of a 
LV where the VSV.G envelope is replaced by a chimeric version of a scFv, coupled to a (i) N-
terminal end of the VSV.G protein (Dreja & Piechaczyk 2006), (ii) the amphotrophic MLV 
protein (Gennari et al. 2009), (iii) the sindbis virus envelope protein  (Morizono et al. 2009; 
Zhang et al. 2010) or (iv) the H-protein of the measle virus envelope, which is than combined 
with its F-protein (Ageichik et al.). However, these manipulations result in viral particles 
with low stability and limited binding- and fusion capacities. Alternatively, the sindbis 
glycoprotein can be mutated in its heparin sulphate receptor (HSR) binding part whereby it 
exclusively binds to DC-SIGN, a DC-specific glycoprotein (Yang et al. 2008). Importantly, 
with this strategy DC-specific transduction could be demonstrated in vivo. It was moreover 
demonstrated that a strong T cell response could be generated that induced tumour 
regression. An alternative method to target LVs to specific cell types was proposed by 
Chandrashekran et al (Chandrashekran et al. 2004). Since RVs and LVs obtain their envelope 
after budding from the cell membrane of the producer cell line, every glycoprotein that is 
expressed on this membrane, will be incorporated in the viral envelope. Through this 
mechanism a membrane bound form of stem cell factor (mbSCF) was incorporated in the 
membrane of a RV producing cell line, which produced ecotropic RVs. This envelope 
doesn’t allow transduction of human cells. However, binding of the mbSCF onto its 
receptor, c-kit, resulted in the transduction of human c-kit+ cells by the mbSCF-containing 
and ecotropic envelope pseudotyped RVs. This strategy was later on expanded by Yang et al 
to LVs (Yang et al. 2006). They incorporated a fusogenic protein (derived from influenza A 
or sindbis virus), as well as an antibody against CD20 in the plasmamembrane of the LV 
producing cell line. Subsequently LVs were produced, which transduced B cells both in vitro 
and in vivo. Importantly, Zhang et al (Zhang et al.) engineered a truncated version of VSV.G 
(VSV.GS), which resulted in a binding-defective, but fusogenic envelope, which still confers 
vector stability hence allows production of high titer LVs. It was shown that LVs that 
incorporate the VSV.GS together with mbSCF in their viral surface efficiently transduced c-
kit+ cells. This strategy could be translated to DCs, where DC-specific molecules, such as 
BDCA-2 or DEC-205 are targeted (Dzionek et al. 2001; Bonifaz et al. 2004; Yang et al. 2008).  
As molecular cloning of classic antibodies or fragments thereof is challenging, alternatives 
have been explored. One of these is the use of antibodies from members of the family of 
Camilidae (i.e. dromedaries, camels, llamas), which produce a unique class of antibodies 
composed of two identical heavy chains as opposed to the conventional (four-chain) 
antibody repertoire (Hamers-Casterman et al. 1993). The antigen-binding part of the 
molecule is composed of only one single variable region (termed VHH, or Nanobody, Nb). 
These antigen-specific antibody fragments offer many advantages: (i) they are highly 
soluble, (ii) they can refold after denaturation whilst retaining their binding capacity, (iii) 
cloning and selection of antigen-specific Nbs obviate the need for construction and 
screening of large libraries, (iv) as Nbs can be fused to other proteins, it should be possible 
to present them on the cell membrane of a producer cell line, thus generating LVs that 
incorporated a DC-specific Nb in their envelope during budding as described above . 
7. Conclusion and future perspectives 
To date, numerous studies have demonstrated that LVs are excellent candidates for the 
treatment of immunological pathologies such as cancer and infectious diseases. This can be 
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immune-deficient mice received LV transduced HSCs, and were followed for 2-6 months. 
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to growth and/or survival advantage conferred by gene-activating or -suppressing effects of 
the integrated LV. Importantly, such induced clonal dominance didn’t lead to malignant 
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seroconversion of the subject to components of the HIV-1 vector, mobilization and 
subsequent spread of mobilized vector particles to previously untransduced cells and 
tissues, and transmission of exogenous DNA to cells of the germ line (Romano et al. 2003). 
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edged sword. This immunogenicity may aggravate a robust immune reaction, which is 
possibly advantageous in the context of e.g. anti-tumour immunotherapy. However, 
unwanted immune responses may curtail the induction of tolerance, which is desired for 
the treatment of e.g. transplantation rejection or autoimmune diseases. As broad tropism 
LVs are capable of transducing DCs but also other cell types, this can have important 
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expression by non-DCs could lead to uptake of cellular remains from these cells by DCs 
followed by antigen presentation in the context of MHC class II and via cross-presentation 
in the context of MHC class I. In this way not only a CTL response is triggered, but also 
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generation of LVs with a specific transduction pattern. To date, there is no natural DC-
 
Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy 
 
331 
specific envelope glycoprotein identified. In first instance, it was attempted to modify 
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protein (Gennari et al. 2009), (iii) the sindbis virus envelope protein  (Morizono et al. 2009; 
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glycoprotein can be mutated in its heparin sulphate receptor (HSR) binding part whereby it 
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To date, numerous studies have demonstrated that LVs are excellent candidates for the 
treatment of immunological pathologies such as cancer and infectious diseases. This can be 
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explained by their capacity to transduce DCs in vivo, which is followed by efficient 
expression, processing and presentation of the introduced transgenes via MHC class I and 
class II molecules, thereby (re) activating an effector and TH1 response, respectively. 
Although LVs comprise an intrinsic immunogenic potential, crucial for effective activation 
of transduced DCs, they have been exploited as a means to induce antigen-specific tolerance 
for the treatment of diseases with an autoimmune aetiology and transplantation rejection as 
well. Although this seems contradictory, this duality endows the LV with the potential to 
become the vaccine tool of choice with an infinite number of application possibilities. 
Although we are convinced of the LVs’ potential as an immunotherapeutic, we give a 
concise overview of the extra improvements we believe are necessary to moderate the 
translation of the LVs from bench to bedside.  
 
 
Fig. 4. Schematic representation of what we believe is the ultimate strategy to successfully 
exploit the advantageous of LVs and DCs for immunotherapeutic purposes. Herein, LVs 
encoding antigen and immune modulating molecules are pseudotyped with a binding-
defective but fusogenic envelope glycoprotein, as well as a DC-specific Nb (1).  The latter 
will dictate binding of the LVs to DCs, after which the envelope mediates fusion (2). 
Subsequently, the DCs are rendered immunogenic or tolerogenic, depending on the 
envisaged therapy, and the DCs present antigen-derived peptides in the context of MHC 
class I and class II molecules, hence induce effector T cells or Treg (3).  
A first improvement will be the overall use of third generation LVs to curtail the risk of 
RCLs. Secondly, the use of NILVs is believed to be an inevitable strategy to diminish the 
LVs’ potential to induce insertional mutagenesis. A third improvement to increase both 
safety and efficacy lies within transductional targeting of the LV to DCs in vivo. Therefore 
we propose to exploit the Nb display technology to target LVs to DCs in combination with 
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LV-based modulation of two signal transduction pathways within the DCs (Fig. 4). The Nb 
display technology is based on the natural budding mechanism of LVs as they are released 
from the LV producing cell. This mechanism allows the incorporation of a binding-defective 
but fusogenic glycoprotein together with a DC-specific Nb in the plasmamembrane of the 
LV producer cells and subsequently in the viral envelope. The DC-specific Nb will bind to 
its antigen on the DC surface whereupon the fusogenic envelope induces transduction. In 
this way LVs shuttle their cargo into the DC. Subsequently DCs can be conditioned to 
become either stimulatory or tolerogenic for the introduced transgene(s). For this purpose 
we can modulate adaptor molecules, such as the MAPK ERK, which switches on a 
tolerogenic pathway (Arce et al.) or A20, which inhibits the stimulatory NF-κB pathway 
(Song et al. 2008). Down-regulation of both will elevate the DC’ immunogenic potential, 
whereas their up-regulation could ameliorate its tolerogenic potential. We strongly believe 
that this strategy can pave the way toward a safe and multifunctional LV toolbox. 
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envisaged therapy, and the DCs present antigen-derived peptides in the context of MHC 
class I and class II molecules, hence induce effector T cells or Treg (3).  
A first improvement will be the overall use of third generation LVs to curtail the risk of 
RCLs. Secondly, the use of NILVs is believed to be an inevitable strategy to diminish the 
LVs’ potential to induce insertional mutagenesis. A third improvement to increase both 
safety and efficacy lies within transductional targeting of the LV to DCs in vivo. Therefore 
we propose to exploit the Nb display technology to target LVs to DCs in combination with 
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LV-based modulation of two signal transduction pathways within the DCs (Fig. 4). The Nb 
display technology is based on the natural budding mechanism of LVs as they are released 
from the LV producing cell. This mechanism allows the incorporation of a binding-defective 
but fusogenic glycoprotein together with a DC-specific Nb in the plasmamembrane of the 
LV producer cells and subsequently in the viral envelope. The DC-specific Nb will bind to 
its antigen on the DC surface whereupon the fusogenic envelope induces transduction. In 
this way LVs shuttle their cargo into the DC. Subsequently DCs can be conditioned to 
become either stimulatory or tolerogenic for the introduced transgene(s). For this purpose 
we can modulate adaptor molecules, such as the MAPK ERK, which switches on a 
tolerogenic pathway (Arce et al.) or A20, which inhibits the stimulatory NF-κB pathway 
(Song et al. 2008). Down-regulation of both will elevate the DC’ immunogenic potential, 
whereas their up-regulation could ameliorate its tolerogenic potential. We strongly believe 
that this strategy can pave the way toward a safe and multifunctional LV toolbox. 
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1. Introduction 
Retroviral vectors derived from the mouse moloney leukemia virus (MLV) are widely used 
for gene therapy of blood disorders because they are capable of permanently integrating a 
therapeutic gene into hematopoietic cells and achieving long-term expression. However, a 
limitation of MLV retroviral vectors is the inability to infect growth-arrested cells. It has 
been demonstrated that a passage through mitosis of infected cells is required for 
productive infection of MLV (Lewis & Emerman 1994). The breakdown of the nuclear 
membrane at mitosis may be necessary for nuclear transport of the oncoretroviral 
preintegration complex which is too large to enter a nuclear pore in the intact nuclear 
membrane. Because most of the target cells of gene therapy such as hematopoietic stem cells 
and lymphocytes are quiescent or rarely dividing, the requirement for cell division limits the 
use of MLV vectors for therapeutic gene transfer. 
For clinical trial of gene therapy, the best-established therapeutic vector is a gamma 
retroviral vector. This retroviral vector system has successfully been used for gene transfer 
to hematopoietic cells to treat X-linked severe combined immunodeficiency (X-SCID) and 
adenosine deaminase deficiency (ADA-SCID). However, in these successful clinical trials, 
genotoxicity mediated by integrated vector proviruses has led to clonal expansion, and in 5 
of 20 of these X-SCID patients have developed T-cell leukemia (Hacein-Bey-Abina et al. 
2008; Hacein-Bey-Abina et al. 2003; Howe et al. 2008). Molecular analyses of the leukemia 
cases showed that these retroviral vectors were integrated into a small number of T-cell 
proto-oncogenes, especially LMO2, leading to its aberrant and high-level expression caused 
by the strong enhancer elements located in the U3 region of the MLV long-terminal repeat 
(LTR). Moreover, the 2 patients with X-linked chronic granulomatous disease (X-CGD) 
exhibited striking clonal dominance with most of their gene-corrected cells having insertions 
into or near of the MDS1-EVI1, PRDM16, or SETBP1 loci (Ott et al. 2006). These retroviral 
vector genotoxicity emphasize that next-generation vectors should further improve the 
safety and the genotoxicity of retroviral integration is a relevant factor to be considered in 
designing vectors for future clinical trials. 
Human immunodeficiency virus type-1 (HIV-1), an etiological agent of acquired 
immunodeficiency syndrome (AIDS), is a member of lentivirinae which is a subfamily of 
retroviruses. We have previously established a packaging system which generates helper 
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free recombinant HIV vectors (Shimada et al. 1991). Compared with widely used 
amphotrophic retroviral vectors, HIV vectors have several interesting features. First, since 
the major receptor for HIV infection is the CD4 molecules of helper T lymphocytes, the HIV 
vectors are capable of targeted gene transfer into CD4+ cells (Miyake et al. 1996; Shimada et 
al. 1991). Second, since gene expression from the HIV-LTR is dependent upon the HIV 
encoded transacting factor TAT (Sodroski et al. 1984), in the presence of TAT, the HIV-LTR 
functions as a very strong promoter. However, because there is no TAT molecule in target 
cells, the HIV-LTR of the integrated provirus is inactive. Inactivation of the LTR of the 
retroviral vector is thought to be important to minimize the chance of insertional activation 
of cellular proto-oncogenes and promoter interference between the LTR and the internal 
promoter. Third, unlike oncoretroviruses, HIV and other lentiviruses have the ability to 
infect and integrate in non-dividing cells. Therefore, HIV based vectors can be used for gene 
transfer into non-dividing cells (Miyake et al. 1998). This possibility is particularly 
important, because none of the current vectors can efficiently integrate into chromosome of 
non-dividing cells. 
In this chapter, we describe about HIV vector pseudotyped with HIV envelopes. 
Replication-incompetent HIV vectors pseudotyped with HIV envelopes (BH10 or SF162) 
were developed and were shown to be capable of targeted gene transfer into CD4+ T cells 
and macrophages. This strict T cell tropism is important for the development of gene 
therapy of AIDS or adult T-cell leukemia (ATL). We also developed an improved strategy 
for preparation of high titer HIV vectors. Since primary un-stimulated T cells and terminally 
differentiated macrophages were transduced with high titer HIV vectors efficiently, HIV 
vectors are useful for the manipulation of gene expression in HIV infectable cells and the 
development of gene therapy targeting lymphocytes and macrophages. Finally, we present 
the application of HIV vectors for AIDS and ATL. 
2. Production and concentration of HIV vectors 
2.1 Plasmid construction 
The first generation packaging plasmid (pCGPE) provided all gag and pol sequences, the 
viral regulatory genes tat and rev and the accessory genes vif, vpr and vpu from T-cell 
tropic HIV strain (BH10) (Ratner et al. 1987). To improve the safety, the single packaging 
plasmid (pCGPE) was divided into two plasmids. One is the pCAGgpR, which contains the 
CAG promoter and HIV gag, pol and RRE; another one is the T-cell tropic HIV env 
expression vector (penvBH10). We also developed macrophage tropic HIV env expression 
vector (penvSF162), which contains the macrophage tropic HIV env fragment from SF162 
(Collman et al. 1989)(Figure 1A).  
The transfer plasmid consists of an expression cassette and the HIV cis-acting factors 
necessary for packaging together with the packaging signal (Ψ). pHXN transfer vector 
plasmid contains the TK promoter and neomycin resistance gene (neoR). To improve the 
packaging efficiency and safety, we modified splicing donor (SD) site (TGGT -> TCGC) and 
initiation codon of gag gene (ATG -> ATC) (pHXNm). Since promoter activity of HIV-LTR is 
Tat dependent, we also developed Tat independent transfer vector by replacement of 5’ U3 
region to CMV promoter (pCHXN). To improve the safety, self-inactivating (SIN) transfer 
vector was developed by deletion of 3’ U3 region (κB-κB-sp1-sp1-sp1-TATA) (pCHXN∆) 
(Figure 1B). 
 






Fig. 1. Construction of recombinant HIV packaging (A) and transfer vector (B) plasmids. 
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2.2 Production of HIV vectors 
Recombinant HIV vectors were prepared by transiently transfecting Cos cells (2x106 cells/10 
cm dish) with 10 µg of packaging plasmid (pCGPE) and 10 µg of transfer vector plasmid 
(pHXN) using the CaPO4 coprecipitation method described previously (Miyake et al. 1996; 
Shimada et al. 1991). For a separate packaging system, 7 µg of pCAGgpR, 7 µg of penvBH10 
or penvSF162, and 7 µg of vector plasmids were used. After 48 h, the supernatant was 
collected, passed through a 45-µm filter to remove cell debris. The conditioned medium of 
transfected Cos cells were used as the HIV vector stock (Figure 2). To assess the 
transduction efficiency and cell specificity of the vectors, HeLa, CD4H (CD4+ HeLa), and 
CD4H5 (CD4+ and CCR5+ HeLa) cells were incubated with various dilutions of the viral 
supernatants and cultured in the presence of 1,000 µg/ml active G418 for two weeks. G418 
resistant colonies were calculated and the titer of HIV vector was presented as colony 




Fig. 2. Production of HIV vector pseudotyped with HIV envelope. 
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2.3 Concentration of HIV vectors 
The titer of the HIV vector in Cos cell supernatants is approximately 104 cfu/ml when 
assayed on CD4H cells. This titer is too low to transduce primary CD4+ cells. To overcome 
this problem, we concentrated HIV vectors using sulfonated cellulose column 
chromatography, thereby increasing the titer more than 20-fold (Matsuoka et al. 1998). For 
further improvement, among several possible procedures, we found that ultrafiltration 
using CENTRIPREP columns was highly effective to concentrate HIV particles (Miyake et 
al. 2007b). The titer could be increased four orders of magnitudes (Figure 3). The total 
recovery was more than 80 %. No replication competent cytopathic HIV was detected in 
concentrated vector preparation when assayed on MT2 cell-based syncytium formation 





Fig. 3. Concentration of HIV vectors by ultrafiltration. By repeating the concentration step 
several times, we were able to obtain highly concentrated HIV vectors. 
3. Characterization of HIV vectors 
3.1 Targeted gene transfer into CD4-positive cells and macrophages 
To examine the tissue specificity of the vectors, CD4- parental HeLa, CD4H, and  
CD4H5 (CCR5+ CD4H) cells were incubated with the T-cell tropic HIV vector containing 
the neoR gene (HXN-T) or the macrophage tropic HIV vector (HXN-M). The T-cell  
tropic HIV vector selectively transduced CD4+ and CXCR4+ HeLa cells, while the 
macrophage tropic HIV vector transduced CD4+ and CCR5+ HeLa cells. Thus, the HIV 
vector has the same tissue specificity as wild type virus. The titer of HIV vectors 
generated from split packaging plasmids were slightly lower than those generated from 
single packaging plasmids (Table 1). Figure 4 shows the result of transduction of CD4H 
cells with MLV or HIV vector expressing enhanced green fluorescent protein (EGFP) gene 
(MLVG or HXG-T). Selective CD4+ cells were transduced by HXG-T compared to MLVG 
vector. 
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 HeLa CD4H CD4H5 
CD4 - + + 
CXCR4 - + + 
CCR5 - - + 
pCGPE 0 1.2x104 1.1x104 
pCAGgpR+penvBH10 0 0.8x104 0.7x104 
pCAGgpR+penvSF162 0 0 0.4x104 
Table 1. Selective transduction of CD4-positive HeLa cells by HIV vectors 
 
 
Fig. 4. Transduction of CD4-positive HeLa cells by MLV and HIV vectors expressing GFP. 
We next attempted to transduce human primary cells using the high titer HIV vector 
carrying the EGFP gene. After enrichment of CD4+ cells, the cells were stimulated with IL2 
and PHA. Two days after stimulation, transduction was performed using the concentrated 
T-cell tropic HIV vector (HXG-T), and up to 84% of the stimulated T cells were found to be 
transduced. Samples of these transduced lymphocytes were analyzed to determine the 
duration of GFP expression, which was detected for more than one month with no decline in 
the percentage of GFP+ cells (Miyake et al. 2007b). It thus appears that HIV vectors were 
integrated into the chromosomes, and the growth rate of vector-transduced cells was the 
same as that of non-transduced cells, making this highly concentrated HIV vector 
potentially useful for gene transfer into human primary lymphocytes.  
We have reported that HIV vectors are capable of mediating gene transfer into non-dividing 
cells (Miyake et al. 1998). Therefore, we next attempted to transduce freshly isolated, un-
stimulated CD4+ T cells and terminally differentiated macrophages. The un-stimulated T cells 
were also efficiently transduced by HXG-T, with from 20 % to 54 % of the un-stimulated T cells 
being GFP positive, while these un-stimulated T cells could not transduced by MLV based 
retroviral vector. In addition, approximately 20 % of terminally differentiated, monocyte-
derived macrophages were transduced using concentrated the macrophage tropic HIV vector 
expressing EGFP (HXG-M), indicating that macrophage trophic HIV vector should also be 
useful for targeted gene transfer into macrophages (Miyake et al. 2007b). We also construct 
HIV vectors containing LacZ gene and transduced with primary CD4+ T cells and 
macrophages. Figure 5 shows the result of transduction of CD4+ T cells and macrophages with 
HIV vector expressing LacZ gene. X-gal staining showed that both primary T cells and 
macrophages are efficiently transduced by HIV vectors. 
 




Fig. 5. Transduction of CD4+ T cells and macrophages with HIV vector expressing LacZ gene 
3.2 In vivo targeted gene transfer 
Targeted gene transfer is essential for safe and efficient gene therapy. Systemic injection of 
targeting vector is considered to be an ideal method of gene transfer. Since HIV vector was 
capable of targeted and efficient gene transfer into CD4+ human cells including non-
stimulated primary CD4+ T-cells, it should be potentially useful for in vivo gene transfer into 
T lymphocytes. To analyze whether the HIV vector could be used for in vivo targeting gene 
transfer, Hu-PBL-NOD-scid mice were prepared by intraperitoneal injection of 1 x 107 
human PBL into NK depleted NOD-scid mice. One ml of the HIV vector stock (HXG-T: 1 x 
108 transduction unit (TU)/ml) was inoculated into the intraperitoneal cavity, and the 
mouse was sacrifices after 10 days. FACS analysis showed that 2-4 % of CD4+ T-cells 
recovered from the peritoneal cavity, peripheral blood, and spleen were transduced with the 
HXG-T vector (Figure 6).  
 
 
Fig. 6. In vivo targeted gene transfer by HIV vector. One ml of the HIV vector containing 
GFP stock (1 x 108 TU/ml) was inoculated into the intraperitoneal cavity of Hu-PBL-NOD-
scid mice, and the mouse was sacrifices after 10 days. Expression of CD4 and GFP were 
analyzed by FACS. 
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These results indicate that HIV vector could be used for in vivo targeted gene transfer into 
CD4+ T-cells. Lymphocytes are important target cells for gene therapy of various disorders. 
Targetable and injectable HIV vectors would greatly facilitate the development of such gene 
therapy strategies. 
4. Applications of HIV vectors 
4.1 Gene therapy for AIDS 
A number of gene therapeutic strategies have been proposed for the treatment of AIDS.  
One approach, intracellular immunization (Baltimore 1988), entails rendering otherwise 
HIV-1-permissive cells resistant to HIV-1 infection by introducing such anti-HIV 
molecules as siRNA, antisense RNAs, ribozymes, RNA decoys, and trans-dominant 
negative mutants.  A second approach entails vaccination using expression vectors for 
viral proteins, and a large scale clinical trial based on MLV vector-mediated transfer of the 
HIV-1 env and rev genes was examined. Finally, a third approach entails the use of a 
suicide gene to induce the death of HIV-1 infected cells, thereby preventing virus spread. 
The herpes simplex virus thymidine kinase (HSV-TK) gene is a most used typical suicide 
gene. HSV-TK acting in concert with cellular kinase specifically converts the prodrug 
gancyclovir (GCV) into highly toxic GCV-triphosphate, which causes DNA polymerase 
chain termination and eventually cell death. To minimize unwanted side effects, it is 
essential to develop a technique that enables tissue-specific gene transfer and expression 
only in targeted cells. 
HIV vectors transduce only human CD4+ lymphocytes and macrophages. Further, when 
used in conjunction with the HIV-LTR, an inducible promoter dependent on the virus 
encoded trans-activator Tat, HIV-based vectors pseudotyped with HIV envelope have the 
potential to mediate targeted gene transfer into HIV-1-permissive cells and for specific 
expression in HIV-1 infected cells. This would appear to make such vectors ideal for use in 
gene therapies against AIDS. Advantages of HIV vector for gene therapy of AIDS are 
summarized in Table 2. 
 
1. Specific gene transfer into HIV infectable cells 
2. Inducible expression on HIV infected cells 
3. HIV vector sequences were packaged into newly synthesized virions 
4. Useful for in vivo targeting gene transfer 
Table 2. Advantages of HIV vector for gene therapy of AIDS 
We constructed an HIV-based vector pseudotyped with HIV envelope containing the 
HSV-TK suicide gene under the control of the inducible HIV-LTR promoter (Figure 7A). 
This vector was selectively transferred into CD4+ cells, and the HSVTK gene was 
subsequently expressed only in HIV-1-infected cells. Consequently, subsequent exposure 
to GCV selectively killed HIV-1 infected cells (Figure 7B). After transduction of H9 cells 
with HXTKN (HXTKN/H9), GCV-sensitivity was analyzed by MTT assay. Prior to HIV-1 
infection, the GCV IC50 in HXTKN/H9 cells was approximately 100 µg/ml. On the other 
hand, HXTKN/H9 cells became highly sensitive to GCV after infection with HIV-1. The 
GCV IC50 of HIV-1-infected HXTKN/H9 cells were 0.1 µg/ml or about 1,000 times greater 
than in uninfected cells (Figure 7C). We next tested the extent to which HIV-1 replication 
was inhibited by the selective suicide of HIV-1-infected cells.  In a model experiment, 
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HIV-1 infected HXTKN/H9 cells were mixed with uninfected HXTKN/H9 cells to a ratio 
of 1:100, and virus replication was studied by measuring p24 (Figure 7D). High levels of 
p24 were detected when the mixed cells were grown in the absence of GCV, but the 
amount of detected p24 declined dramatically following addition of 10 µg/ml GCV, 
indicating that selective suicide of HIV-infected cells effectively inhibited spread of the 
virus. In addition, on HIV-1 infection, HIV vector sequences were packaged into newly 
synthesized virions that were transferred into surrounding untransduced cells. These 
results support the rationale for treatment of HIV infection with HIV-based vectors 





Fig. 7. Selective killing of HIV infected cells. (A) Inducible HIV vectors containing the HSV-
TK suicide gene. (B) Rationale for treatment of HIV infection with HIV-based vectors. (C) 
HXTKN transduced H9 cells were incubated for 5 days with various concentrations of GCV 
(0.001-100 µg/mL), after which cell growth was estimated by MTT assay. (D) Effect of GCV 
on HIV-1 replication. A mixture of HIV-1-infected and uninfected HXTKN/H9 cells (1:100) 
were cultured with or without 10 µg/ml GCV. After 7 days, p24 levels in the culture 
supernatant were measured by ELISA. 
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These results indicate that HIV vector could be used for in vivo targeted gene transfer into 
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1. Specific gene transfer into HIV infectable cells 
2. Inducible expression on HIV infected cells 
3. HIV vector sequences were packaged into newly synthesized virions 
4. Useful for in vivo targeting gene transfer 
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We also investigated the utility of the HIV vector by intracellular immunization strategy. 
The chemokine receptors, CXCR4 and CCR5 (Alkhatib et al. 1996; Deng et al. 1996; Feng et 
al. 1996), have been identified as co-receptors for HIV-1 infection (Figure 8A). These cellular 
genes are attractive targets for intracellular immunization, because the mutation rate of the 
cellular gene is much less than that of the viral genome. We examined the feasibility of 
antisense inhibition of CXCR4 expression using HIV vector. We constructed the HIV vector 
containing the antisense sequence (738-429 nt) of CXCR4 driven by the CAG promoter and 
transduced CEM cells (Figure 8B). The level of CXCR4 in antisense expressing (HXCXAN-
transduced) CEM cells was reduced up to 20 % of that in control (HXN-transduced) cells 
(Figure 8C). Inhibition of T-cell trophic HIV replication also observed in transduced CEM 
cells (Figure 8D). These results suggest that antisense inhibition of CXCR4 expression is 





Fig. 8. Suppression of HIV-1 replication by HIV vector containing antisense CXCR4. (A) 
CXCR4 or CCR5 is a co-receptor of HIV-1 infection. (B) Construction of HIV vector 
expressing antisense CXCR4. (C) Expression of CXCR4 on HXN (control) or HXCXAN-
transduced CEM cells. Expression of CXCR4 was analyzed by FACS. (D) Effect of antisense 
CXCR4 on HIV-1 replication. After HIV-1-infected HXN- or HXCXAN-transduced CEM 
cells were cultured for 7 days, p24 levels in the culture supernatant were measured by 
ELISA. 
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4.2 Development of selective transduction of HIV-1-infected cells 
HIV based vectors bind specifically to the CD4 antigen and are capable of targeted gene 
transfer into CD4+ cells. The strict cell specificity of HIV vectors should be important for 
development of gene therapy of AIDS. However, HIV vectors may not be useful for gene 
transfer into cells already infected with HIV-1, because CD4 expression is usually down-
regulated and in contrast, the HIV envelope glycoprotein (HIV-Env) is overexpressed in 
such cells (Hoxie et al. 1986; Maddon et al. 1986). Therefore, using a special feature of the 
HIV vectors, we have developed a novel strategy for targeted gene transfer into HIV-1 
infected cells based on two-step gene transfer. Figure 9A shows the concept of two-step gene 
transfer. The first step involves the stable introduction of the HIV vector containing the 




Fig. 9. Targeted gene transfer into HIV-1 infected cells. (A) Concept of two-step gene 
transfer for selective transduction of HIV-1 infected cells. (B) Inducible expression of EcoRec 
on HXERN transduced CEM cells. The cells were infected (HIV(+)) or uninfected (HIV(-)) 
with HIV-1. (C) HXERN transduced CEM cells were infected (HIV(+)) or uninfected (HIV(-)) 
with HIV-1 and then, transduced with the ecotrophic retroviral vectors containing LacZ 
gene. Expressions of β-galactosidase were assessed by X-gal staining. 
Since the HIV-LTR is Tat-inducible, it is expected that EcoRec is expressed only after HIV-1 
infection. High levels of EcoRec expression were observed only in HIV-1 infected cells. 
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These cells became highly susceptible to ecotrophic MLV infection and therefore, in the 
second step, HIV-1 infected cells were selectively transduced with ecotrophic MLV vectors.  
CEM cells were transduced with the HIV vector containing the EcoRec gene under the 
control of the HIV-LTR (HXERN). Inducible expression of EcoRec in transduced cells was 
studied by the virus binding assay. Prior to HIV-1 infection, no detectable EcoRec was 
observed on the cell surface. However, after HIV-1 infection, high levels of induced EcoRec 
expression were detected by FACS analysis (Figure 9B). These findings indicated that 
HXERN transduced cells were ecotrophic MLV non-permissive, but became highly sensitive 
to ecotrophic MLV infection, once infected with HIV-1. In the next step, HXERN transduced 
cells were incubated with the ecotrophic MLV vector containing the beta-galactosidase gene 
(MLVLacZ). X-gal staining showed that HXERN transduced cells were totally resistant to 
retroviral infection. However, HIV-1 infected HXERN transduced cells were selectively 
transduced with MLVLacZ (Figure 9C). These findings indicate that this two-step method 
can be used for efficient, selective and stable gene transfer into HIV-1 infected cells (Sakai et 
al. 2001). 
A possible clinical application of this strategy is as follows. Targets should be HIV 
seropositive but disease free patients. Most CD4+ T cells in these patients are HIV negative.  
HXERN is stably inserted into these T cells (1st step). After a variable asymptomatic period, 
the virus apparently starts replication and spreads within the whole body. During this stage, 
EcoRec is expressed on the surface of only HIV-1 infected cells. Therefore, HIV-1 infected 
cells can be selectively attacked with the ecotrophic MLV vector carrying the therapeutic 
gene. 
4.3 Gene therapy for ATL 
Adult T cell leukemia (ATL) is a malignant disease etiologically associated with human T 
cell leukemia virus type I (HTLV-I). The prognosis of acute- or lymphoma-type ATL is far 
worse than that of other lymphoid malignancies, and effective therapy has not been 
established. HIV based vectors are capable of targeted and highly efficient gene transfer into 
CD4+ T cells regulated by the HIV envelope glycoprotein gp120 and CD4 interaction.   
Because almost all ATL cells express CD4, HIV based vectors are useful for targeting 
therapeutic genes to ATL cells. We investigated the potential efficacy of treating ATL cells 
using a gene therapeutic approach involving the use of an HSV-TK-mediated suicide 
system.  HIV vectors containing the HSV-TK gene under the control of CMV promoter 
(Figure 10A) were constructed to achieve targeted gene transfer into CD4+ ATL cells, after 
which the transduced cells were selectively killed by treatment with GCV. To examine the 
utility of HIV vectors in vivo, ATL-NOD-SCID mice were prepared by intraperitoneal 
injection of 1×107 MT2 cells into NK-depleted NOD-SCID mice. Thereafter, 1 ml of 
concentrated HIV vector expressing HSV-TK (HXCTKN) or GFP (HXG) stock was injected 
into the intraperitoneal cavity, and GCV was administered twice a day for 5 days (Figure 
10B). After three weeks, plasma sIL2-Rα levels, which are indicator of growth of MT2 cells, 
were significantly lower in mice administered HXCTKN than in those administered control 
HXG. Moreover, HXCTKN-injected mice survived significantly longer than HXG-injected 
mice (Miyake et al. 2007a) (Figure 10C). Taken together, these findings suggest that HIV 
vectors could be used for in vivo targeted gene transfer into ATL cells and thus could serve 
as the basis for the development of effective new therapies for the treatment ATL. 
 






Fig. 10. Selective killing of ATL cells by HIV vector expressing HSV-TK gene. (A) 
Construction of HIV vector containing the HSV-TK suicide gene. (B) Experimental design of 
in vivo model for ATL. ATL model mice were prepared by intraperitoneal injection of 1×107 
MT2 cells into NK-depleted NOD-SCID mice. Two days after treatment by HIV vectors 
(HXG or HXCTKN), GCV was administered twice a day for 5 days. (C) Survival curve of 
HIV vector treated ATL model mice. Mice administered HXCTKN-injected survived 
significantly longer than those injected with HXG (p=0.002). 
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5. Summary and future developments 
Tissue-specific gene transfer and expression are crucial for the development of safe and 
effective gene therapy protocols. In that context, HIV-based retroviral vectors pseudotyped 
with HIV envelope have several advantages compared to MLV or VSV pseudotyped HIV 
vector. We succeeded in concentration of HIV vectors and primary CD4+ cells were 
efficiently transduced with high titer HIV vectors. Moreover, HIV vector is potentially 
useful for in vivo gene transfer into T lymphocytes. These findings strongly suggest that 
concentrated HIV vectors should be useful in gene therapies targeting lymphocytes and 
macrophages.  
HIV based retroviral vectors were originally designed for gene therapy in the treatment of 
AIDS. And HIV vector have a lot of advantages of for gene therapy of AIDS (Table. 2). 
Therefore, we developed novel gene therapy strategy for AIDS using our original HIV 
vectors. Tissue specific transduction into HIV-infectable cells and inducible expression of 
HIV-infected cells were achieved by using HIV vector. We used an HIV vector containing 
the HSV-TK gene to selectively kill HIV-1-infected cells and to inhibit HIV-1 replication.  
Although this system may not represent a complete cure for AIDS, combining gene therapy 
with other anti HIV-1 therapies may be useful for the long-term control of the disease.  
Currently, recombinant HIV vectors were prepared by transiently transfecting Cos cells 
with packaging plasmid and transfer vector plasmid using the CaPO4 coprecipitation 
method. Therefore, to make a high titer HIV vector, a large number of cell plate and a lot of 
plasmids are need. A stable packaging system for producing HIV vectors may be useful for 
future clinical applications using HIV vectors. 
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1. Introduction 
Gene transfer vectors derived from neurotropic viruses provide a powerful tool for gene 
therapy of a variety of neurological diseases. The lentiviral vector system permits the 
efficient transfer of genes into non-dividing cells in the central nervous system and sustains 
long-term expression of the genes (Naldini et al., 1996; Reiser et al., 1996; Mochizuki et al., 
1998; Mitrophanous et al., 1999). This vector system has been used for gene therapy trials in 
animal models for neurological diseases (for reviews, see Azzouz et al., 2004a; Wong et al., 
2006; Lundberg et al., 2008). Axonal transport in the retrograde direction, as observed in the 
case of some viral vectors, has a considerable advantage for transferring genes into neuronal 
cell bodies situated in regions remote from the injection sites of the vectors (see Fig. 1). 
These viral vectors, when injected into the striatum, deliver the genes through retrograde 
transport into nigrostriatal dopamine neurons that are the major target for gene therapy of 
Parkinson’s disease (Zheng et al., 2005; Barkats et al., 2006). Intramuscular injection of the 
vectors also delivers retrogradely the genes into motor neurons that are the target for gene 
therapy of motor neuron diseases (Baumgartner & Shine, 1998; Perrelet et al., 2000; 
Mazarakis et al., 2001; Sakamoto et al., 2003; Azzouz et al., 2004b).  
To enhance the gene transfer of a human immunodeficiency virus type-1 (HIV-1)-based 
vector via retrograde transport, we have previously generated the HIV-1 vector 
pseudotyped with a selective variant of rabies virus glycoprotein (RV-G) (Kato et al., 2007). 
Injection of this RV-G-pseudotyped vector into the mouse striatum yields an increase in 
gene transfer into neuronal populations in the cerebral cortex, thalamus, and ventral 
midbrain, each of which innervates the striatum. Injection of the RV-G pseudotype into the 
monkey striatum (caudate and putamen) results in increased gene transfer into the 
nigrostriatal dopamine neurons. The RV-G pseudotyping of the HIV-1 vector enhances the 
efficiency of gene transfer through retrograde axonal transport in the rodent and nonhuman 
primate brains. However, because large-scale application of gene therapy trials requires 
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high-titer stocks of the vector, a lentiviral vector system that produces more efficient 
retrograde gene transfer is needed. 
Recently, we developed a novel vector system for highly efficient retrograde gene transfer 
(designated as HiRet vector) by pseudotyping the HIV-1 vector with fusion glycoprotein B 
type (FuG-B), in which the cytoplasmic domain of RV-G was substituted by the 
corresponding part of the vesicular stomatitis virus glycoprotein (VSV-G) (Kato et al., 2011).  
The HiRet vector shifts the transducing property of the lentiviral vector and promotes the 
retrograde gene transfer into different brain regions innervating the striatum with greater 
efficiency than that of the RV-G pseudotype in both rodent and nonhuman primate brains. 
In the present chapter, we describe the development and property of the HiRet vector as 
well as the retrograde gene transfer of the vector into target neurons for gene therapy of 
neurological diseases, such as Parkinson’s and motor neuron diseases. 
 
 
Fig. 1. Schematic illustration of gene transfer process through retrograde axonal transport.  
The viral vectors enter synaptic terminals and are transported within axons in the 
retrograde direction to neuronal cell bodies where transgene expression is induced. 
2. Development and characterization of HiRet vector 
2.1 Pseudotyping with fusion envelope glycoprotein 
To develop the HiRet vector, we tested two kinds of fusion glycoprotein (termed FuG-A and 
FuG-B), both of which are composed of the RV-G and VSV-G segments, for the 
pseudotyping of the HIV-1 vector. FuG-A contains the extracellular domain of RV-G fused 
to the transmembrane and cytoplasmic domains of VSV-G, whereas FuG-B contains the 
extracellular and transmembrane domains of RV-G connected to the VSV-G cytoplasmic 
domain (Fig. 2A). HIV-1-based lentiviral vectors carrying transgene encoding green 
fluorescent protein (GFP) were produced by pseudotyping with RV-G, FuG-A, or FuG-B. 
When the functional titer (transducing unit) in HEK293T cells was measured by flow 
cytometry, the titer of the FuG-B pseudotype was 13 times greater than that of the RV-G 
pseudotype, whereas the titer of the FuG-A pseudotype in this cell line showed only a 
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moderate increase compared with the RV-G vector titer (Fig. 2B). The functional titer of the 
FuG-B pseudotype, when measured in neuronal cell lines (Neuro2A and N1E-115 cells), was 
also the highest among the three vector pseudotypes (Fig. 2B). In contrast, the concentration 
of physical particles (or RNA copy number) of the vectors, when estimated by quantitative 
reverse transcription-PCR analysis, showed no remarkable change among the three 
pseudotypes (data not shown). Therefore, the HIV-1 vector pseudotyped with FuG-B 
exhibited a greatly increased efficacy of transduction into cultured cells. 
 
 
Fig. 2. Production of vector pseudotypes with fusion glycoproteins. 
(A) Structure of the fusion glycoproteins FuG-A and FuG-B composed of different 
combinations of the N-terminal and C-terminal segments from RV-G and VSV-G. Amino 
acid sequences around the junction (arrowhead) between the RV-G and VSV-G segments 
are indicated. S, signal peptide; TM, transmembrane domain. (B) Functional titer of the 
vector pseudotypes. HEK293T cells (eighteen 10-cm-diameter tissue culture dishes) were 
transfected, and the conditioned medium was collected. Vector particles were pelleted by 
ultracentrifugation and resuspended in PBS (1 ml). HEK293T, Neuro2A, and N1E-115 cells 
were transduced with viral vectors, and the functional titer was determined by flow 
cytometry. Values were obtained from four independent experiments. *p < 0.001, significant 
difference from the titer of the RV-G or FuG-A pseudotype (ANOVA, Tukey HSD test). 
(Data from Kato et al., 2011) 
2.2 Promoted efficiency of retrograde gene transfer 
To characterize the in vivo gene transfer of the pseudotyped lentiviral vectors, we injected 
the vectors into the dorsal striatum of mice, and studied gene expression in the brain regions 
that innervate the striatum, including the primary motor cortex (M1), primary 
somatosensory cortex (S1), parafascicular thalamic nucleus (PF), and substantia nigra pars 
compacta (SNc). The number of GFP-positive cells in each brain region was prominently 
increased in the FuG-B vector-injected mice over that in the RV-G vector-injected mice  
(Fig. 3A); and the increases in the cell number were 12-, 12-, 8-, and 14-fold in the M1, S1, PF, 
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and SNc, respectively (Fig. 3B). In contrast, the cell number in each brain region was 
comparable between the FuG-A and RV-G vector-injected animals (Fig. 3A, B). Therefore, 
the FuG-B pseudotyping of the HIV-1 vector greatly enhanced the efficiency of retrograde 
gene transfer into the brain regions innervating the dorsal striatum. Based on these in vivo 
data, we designated the FuG-B pseudotype as the HiRet vector.  
In the HiRet vector, the cytoplasmic domain of RV-G was substituted by the corresponding 
part of VSV-G, which resulted in the enhancement of transduction of cell lines and  
 
 
Fig. 3. Efficiency of retrograde gene transfer by the pseudotyped vectors. 
Lentiviral vectors pseudotyped with RV-G, FuG-A or FuG-B with equivalent copy numbers 
of viral RNA (1.2 x 1010 copies/ml, 1.0 μl x 2 sites) were injected into the mouse striatum, 
and four weeks later sections were used for GFP immunostaining. (A) Transgene expression 
through retrograde transport in the primary motor cortex (M1), primary somatosensory 
cortex (S1), parafascicular thalamic nucleus (PF), and substantia nigra pars compacta (SNc). 
fr, fasciculus retroflexus. Scale bars: 200 μm. (B) The cell number in the various brain 
regions. The number of GFP-positive cells per section was counted (n = 4). *p < 0.01, **p < 
0.001, significant differences from the RV-G or FuG-A pseudotype (ANOVA/Tukey HSD 
test). (Data from Kato et al., 2011) 
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retrograde gene transfer. The cytoplasmic domain differs in length between RV-G (44 amino 
acids) and VSV-G (29 amino acids), and their amino acid sequences do not show any 
particular homology (Rose et al., 1982). To test whether the length of the cytoplasmic 
sequence may be involved in the enhancement of retrograde gene transfer, we constructed 
deletion mutants of the RV-G cytoplasmic domain consisting of 10 or 20 amino acids, and 
used them for the pseudotyping of the HIV-1 vector. Analysis of the in vivo gene transfer 
indicated that shorter cytoplasmic domain of RV-G increased the efficiency of gene transfer 
through retrograde transport, but that the VSV-G cytoplasmic domain induced most 
efficiently the retrograde gene transfer (data not shown). The results suggest the importance 
of both the length and sequence of the glycoprotein cytoplasmic domain in the retrograde 
gene transfer of the HiRet vector. Based on our titration experiments using the pseudotyped 
vectors, the viral RNA titration displayed no significant change in the yield of physical 
particles between the pseudotyped vectors. Modification of the cytoplasmic domain of a 
viral glycoprotein thus seemed to shift the property of gene transduction of the 
pseudotyped vectors into the host cells, although the efficacy of formation or budding of the 
particles appeared to be unaffected. 
The host range of lentiviral vectors is altered by pseudotyping with distinct envelope 
glycoproteins (for review, see Cronin et al., 2005). RV-G interacts with certain neuronal 
receptors, such as the nicotinic acetylcholine receptor α-subunit, low-affinity nerve growth 
factor receptor, and neural cell adhesion molecule (Hanham et al., 1993; Gastka et al., 1996; 
Thoulouze et al., 1998; Tuffereau et al., 1998). Substitution of the cytoplasmic domain of a 
viral glycoprotein may influence incorporation of the glycoprotein into vector particles or 
cause conformational changes in the glycoprotein structure involved in binding to receptor 
molecules or membrane fusion of the pseudotyped vector. These changes may affect the 
mechanism involved in vector entry into synaptic terminals or the transduction level of the 
vector, resulting in the enhanced retrograde gene transfer.  
3. Retrograde gene delivery by HiRet vector into target neurons for gene 
therapy 
3.1 Nigrostriatal dopamine neurons 
We investigated the capability of the HiRet vector to introduce retrograde gene transfer into 
target neurons for gene therapy of neurological diseases. Nigrostriatal dopamine neurons 
are the major target for the therapy of Parkinson’s disease (Zheng et al., 2005; Barkats et al., 
2006). Retrograde gene transfer of the HiRet vector into the dopamine neurons in the mouse 
SNc was less efficient, although transfer of the vector into cortical and thalamic neurons was 
greatly increased (see Fig. 3). We thus tested the retrograde gene transfer of the HiRet vector 
into the SNc of the monkey. The pseudotyped vectors were injected into the striatum 
(caudate nucleus and putamen) of crab-eating monkeys, and sections through the SNc were 
stained immunohistochemically for GFP. Injection of the HiRet vector (FuG-B pseudotype) 
resulted in the appearance of a larger number of GFP-positive cells in the SNc as compared 
with that of the RV-G pseudotype (Fig. 4A), and the increase was 10-fold of the RV-G 
pseudotype control (Fig. 4B). The GFP transgene was expressed in a majority of the 
dopamine neurons (74.8%, n = 2), which were identified by immunostaining for tyrosine 
hydroxylase (TH), a key enzyme of dopamine biosynthesis (Fig. 4C). The HiRet vector thus 
achieved highly efficient delivery of genes through retrograde transport into the 
nigrostriatal dopamine system in the nonhuman primate brain. 
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particles appeared to be unaffected. 
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mechanism involved in vector entry into synaptic terminals or the transduction level of the 
vector, resulting in the enhanced retrograde gene transfer.  
3. Retrograde gene delivery by HiRet vector into target neurons for gene 
therapy 
3.1 Nigrostriatal dopamine neurons 
We investigated the capability of the HiRet vector to introduce retrograde gene transfer into 
target neurons for gene therapy of neurological diseases. Nigrostriatal dopamine neurons 
are the major target for the therapy of Parkinson’s disease (Zheng et al., 2005; Barkats et al., 
2006). Retrograde gene transfer of the HiRet vector into the dopamine neurons in the mouse 
SNc was less efficient, although transfer of the vector into cortical and thalamic neurons was 
greatly increased (see Fig. 3). We thus tested the retrograde gene transfer of the HiRet vector 
into the SNc of the monkey. The pseudotyped vectors were injected into the striatum 
(caudate nucleus and putamen) of crab-eating monkeys, and sections through the SNc were 
stained immunohistochemically for GFP. Injection of the HiRet vector (FuG-B pseudotype) 
resulted in the appearance of a larger number of GFP-positive cells in the SNc as compared 
with that of the RV-G pseudotype (Fig. 4A), and the increase was 10-fold of the RV-G 
pseudotype control (Fig. 4B). The GFP transgene was expressed in a majority of the 
dopamine neurons (74.8%, n = 2), which were identified by immunostaining for tyrosine 
hydroxylase (TH), a key enzyme of dopamine biosynthesis (Fig. 4C). The HiRet vector thus 
achieved highly efficient delivery of genes through retrograde transport into the 
nigrostriatal dopamine system in the nonhuman primate brain. 
 




Fig. 4. Retrograde gene transfer into nigrostriatal dopamine neurons. 
Lentiviral vectors pseudotyped with RV-G or FuG-B with equivalent copy numbers of viral 
RNA (8.5 x 109 copies/ml, 7.5 μl x 14 sites) were stereotaxically injected into the caudate and 
putamen, and four weeks later a series of sections were used for histological analysis. (A) 
GFP staining of sections through the SNc. Photos at the right denote magnified views of the 
rectangular boxes in the left ones. (B) Average number of GFP-positive cells per SNc section 
(n = 2). (C) Double immunofluorescence staining for GFP and TH in the SNc. GFP-positive 
signals, TH-positive signals, and merged images are presented in green, red, and yellow, 
respectively. SNr, substantia nigra pars reticulata. Scale bars, 1 mm (A) and 50 μm (C). 
(Data from Kato et al., 2011) 
3.2 Hindbrain/spinal motor neurons 
Motor neurons are the target for gene therapy of motor neuron diseases (Baumgartner & 
Shine, 1998; Perrelet et al., 2000; Mazarakis et al., 2001; Sakamoto et al., 2003; Azzouz et al., 
2004b). Therefore, we studied retrograde gene transfer of the HiRet vector into motor 
neurons in the hindbrain and spinal cord. The vector was injected into the tongue or 
hindlimb muscles in mice, and sections through the hindbrain (hypoglossal nerve) or spinal 
cord (lumbar level) were stained for GFP immunohistochemistry. Such injections labeled 
cells in the hypoglossal nucleus of the posterior hindbrain and in the ventral horn of the 
spinal cord at the lumbar level (Fig. 5A). Double immunofluorescence histochemistry for 
GFP and the motor neuronal marker choline acetyltransferase confirmed GFP expression in 
the hypoglossal and spinal motor neurons that innervate the injected muscles (Fig. 5B). The 
HiRet vector thus enabled us to induce retrograde gene delivery into motor neurons. The 
extent of motor neuron transfer of the HiRet vector will be compared with that of the RV-G 
pseudotype elsewhere. 
 




The lentiviral vector system based on HIV-1 has been extensively applied to gene therapy 
trials for neurological diseases. Retrograde axonal transport of viral vectors offers a great 
advantage to the delivery of genes into neuronal cell bodies that are located in brain areas 
distant from the injection site. The pseudotyping of HIV-1-based vectors with selective 
variants of RV-G increases gene transfer via retrograde transport into the central nervous 
system. Since the large-scale application for gene therapy trials requires high-titer stocks of 
the vector, the pseudotyping of a lentiviral vector that generates a greater efficiency of 
retrograde transport was needed. Therefore, we developed the HiRet vector for highly 
efficient retrograde gene transfer by pseudotyping an HIV-1 vector with a fusion envelope 
glycoprotein FuG-B, in which the cytoplasmic domain of RV-G was substituted by the 
corresponding part of VSV-G. The HiRet vector shifted the transducing property of the  
 
 
Fig. 5. Retrograde gene transfer into motor neurons. 
(A) GFP expression in the hindbrain and spinal cord after the FuG-B vector injection  
(2.4 X 109 transduction units/ml). Sections through the posterior hindbrain containing the 
hypoglossal nucleus and the lumbar spinal cord were prepared from the injected animals 
and stained by using GFP immunohistochemistry. (B) GFP expression in motor neurons. 
The sections were used for double immunofluorescence staining for GFP and choline 
acetyltransferase (ChAT), a marker of motor neurons. GFP-positive signals, ChAT-positive 
signals, and merged images are shown in green, red, and yellow, respectively. cc, central 
canal. Scale bar: 50 μm. 
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lentiviral vector and enhanced the retrograde transport-mediated gene transfer into 
different brain regions. In particular, its transfer efficiency into the brain regions innervating 
the striatum attained 8- to 14-fold increases over the efficiency of the RV-G pseudotype. In 
addition, intrastriatal injection of the HiRet vector in the monkey brain resulted in gene 
transfer into a large number of nigrostriatal dopamine neurons that are the major target for 
gene therapy of Parkinson’ disease. Furthermore, intramuscular injection of the HiRet vector 
achieved gene transfer into motor neurons in the hindbrain and spinal cord that are the 
target for gene therapy of motor neuron diseases. Our strategy with the HiRet vector 
provides a powerful tool for the treatment of certain neurological diseases by promoting 
retrograde gene delivery of this viral vector. 
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18 
Herpes Simplex Virus Type 1  
for Use in Cancer Gene Therapy:  
Looking Backward to Move Forward 




Herpes simplex virus type 1 (HSV-1) belongs to the Herpesviridae family, Alphaherpesvirinae 
subfamily. HSV-1 is a human pathogen associated with keratitis and cold sores, the 
formation of which is exacerbated by periods of elevated stress, corticosteroid use and 
immunosuppression. HSV-1 is an enveloped double stranded DNA (dsDNA) virus which 
following primary infection in epithelial cells follows a retrograde course to establish 
latency in sensory nerves of the sacral ganglia. Upon reactivation, HSV-1 travels 
anterograde from latently infected neurons to epithelial cells at the site of primary infection. 
Antiherpetic drugs such as Acyclovir (ACV) and Gancyclovir (GCV) are used to control 
herpes virus infection by inhibiting virus replication.  
The mature HSV-1 virion consists of an envelope containing 13 different glycoproteins 
embedded in a lipid bilayer. An icosahedral nucleocapsid encases the dsDNA genome and 
consists of three different proteins; VP5 forms both hexameric and pentameric complexes 
that are supported by VP19C/VP23 trimers. The tegument lies between the envelope and 
capsid and contains viral and cellular proteins, some of which are essential for virus 
replication. Following cellular entry, capsids dock at the nuclear pore and the genome exits 
the capsid via channels, which are controlled by tegument proteins.  
The HSV-1 genome is ~152 kbp and consists of long and short regions which are covalently 
linked (Figure 1). Each region is comprised of unique and repeated sequences. Terminal 
repeat sequences with single nucleotide overhangs allow for circularization during 
replication and latency. Homologous recombination between these regions produces four 
isomers in equimolar concentrations (Shen & Nemunaitis, 2006). Overall, the HSV-1 genome 
codes for approximately 90 proteins, some of which are dispensable for virus replication in 
vitro and some of which are present in more than once copy, making HSV-1 diploid for 
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1.1 Cellular entry 
Initial attachment of HSV-1 involves binding of glycoprotein B (gB) and/or gC to heparin 
sulphate proteoglycans on the cellular surface in a low-affinity interaction. This interaction 
induces a conformational change in gD, relieving steric hindrance of its N-terminal domain 
and exposing a flexible hairpin loop which binds Herpesvirus entrance mediators (HVEMs) 
in a high-affinity interaction (Heldwein & Krummenacher, 2008). Members of the 
immunoglobulin superfamily, nectin-1 and nectin-2, bind via a separate site at tyrosine 28 of 
gD (Heldwein & Krummenacher, 2008). The binding sites of HVEM and nectin do not 
overlap and thus require different conformations of gD for binding to occur. Downstream 
signalling cascades induce a conformational change in gB and/or gC and the gH/gL 
complex to bring about full fusion of the virus envelope with the cellular membrane. The 
viral capsid is released into the cytoplasm, and along with several tegument proteins, travels 
to the nucleus via the microtubular network (Shen & Nemunaitis, 2006). The HSV-1 genome 
enters the nucleus via nuclear pores to initiate virus replication. While HSV-1 has also been 
shown to enter cells via endocytosis, the factor(s) which dictate this method of entry remain 
uncertain. 
1.2 Virus replication 
Upon entry into the nucleus the HSV-1 genome is transcribed in a highly regulated cascade 
proceeding from immediate early (IE) genes, to early (E), then late (L) genes. Each gene 
functions as an independent transcriptional unit through a separate promoter. In general, 
genes are clustered based on function, not on the order in which they are transcribed. For a 
comprehensive review, please refer to Roizman & Sears (1996).  
Transcription is initiated through association of VP16, a L gene product which resides in 
the tegument, with the cellular DNA-binding protein Oct-1, which binds the 
“TATGARAT box” within the enhancer region of IE promoters. The C-terminus of VP16 is 
a potent transcriptional activating domain which enhances RNA polymerase II (RNA Pol 
II) activity. There are five IE genes, ICP0, ICP4, ICP22, ICP27 and ICP47, four of which 
have functions as regulatory factors to initiate lytic infection, while the fifth, ICP47, 
functions in immune evasion. ICP4 is a major transcriptional activator essential to viral 
replication. ICP0 acts along with ICP4 to enhance E gene transcription and is also 
involved in countering the host antiviral response. In addition, ICP22 and ICP27 enhance 
viral gene transcription by regulating activation of RNA Pol II and modulating post-
transcriptional events, respectively. When sufficient levels of IE genes have been 
transcribed, ICP4 inhibits IE gene expression and activates E gene expression. This switch 
is mediated by the activation of host RNA Pol II by IE gene products and results in the 
expression of proteins essential for viral replication such as DNA polymerase, single-
strand DNA binding proteins, helicase-primase complex and ori-binding proteins. The 
accumulation of E gene products results in viral DNA replication at replication 
compartments located in the nucleus. Lastly, L genes are transcribed following DNA 
replication and code for structural proteins such as those included in the nucleocapsid 
and viral envelope. Rolling circle replication produces concatemers which are cleaved by 
pac1/2 enzymes at specific sequences forming monomers which are then packaged into a 
nucleocapsid. At this time several tegument proteins associate with the newly formed 
nucleocapsid and help direct budding through the inner nuclear membrane, resulting in 
acquisition of an immature envelope. The immature envelope is lost and a new one is 
formed as the virion fuses and passes through the outer nuclear membrane into the 
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cytoplasm. Additional tegument proteins, such as VP16, associate with the nucleocapsid 
to direct formation of the mature envelope, which is acquired as the virion passes through 
the Golgi complex to the cellular membrane. Incorporation of glycoproteins into the 
envelope occurs at the Golgi and functions to direct the virus to the cellular membrane 
from which the new virion will bud.   
1.3 Latency 
HSV-1 is a neurotropic virus which establishes life-long latency within the neurons of its 
host. Primary infection occurs in epithelial cells after which the nucleocapsid and tegument 
are transported retrograde along sensory neurons at the site of infection. During latency, 
viral DNA associates with histones to form an episome and active replication does not occur 
(Shen & Nemunaitis, 2006). However, latency-associated transcripts (LATs) are abundantly 
transcribed during latency and are antisense (in part) to the gene transcript which encodes 
ICP0, suggesting it may interfere with ICP0 synthesis to prevent productive gene expression 
from occurring in latently infected neurons. Furthermore, LATs do not code for protein 
products but rather are alternatively spliced RNA species forming two different transcripts 
(2 and 1.5 kb) of varying abundance (Shen & Nemunaitis, 2006). LATs have also been shown 
to protect neuronal cells from apoptosis by inhibiting both extrinsic and intrinsic apoptosis 
pathways by blocking caspase 8 and 9 activity, respectively (Ahmed et al., 2002; Henderson 
et al., 2002). Reactivation from latency occurs following cellular stress, increases in 
corticosteroid and/or hormone levels and immunosuppression, resulting in limited 
productive gene expression and viral replication. Newly formed virus travels anterograde to 
re-infect epithelial cells within the site of primary infection.  
1.4 Host defense mechanisms 
From the moment HSV-1 infects host cells at the site of primary infection, viral mechanisms 
are in place to counteract host immune responses. The innate immune response is the first 
line of defense against HSV-1 infection followed by high-affinity adaptive responses. HSV-1 
encodes proteins which function to evade the host interferon (IFN) response (Paladino & 
Mossman, 2009), elude complement system opsonisation (Wakimoto et al., 2003), inhibit 
antigen presentation on MHC I molecules (Hill et al., 1995), block synthesis of host proteins 
(Shen & Nemunaitis, 2006), hinder apoptosis, and impede maturation of dendritic cells 
(DCs) (Kobelt et al., 2003).  
Innate cytokines including IFN are produced in response to HSV-1 infection. There are three 
types of IFN, type I, II and III, with type I and III comprising multiple species. Type I and III 
IFN are expressed by many different cell types, however type II IFN is primarily produced 
by activated T cells and natural killer (NK) cells. The effects of IFN are pleiotropic and 
include antiproliferative, antiviral and immunoregulatory functions executed through the 
expression of interferon stimulated genes (ISGs) (Sen & Sarkar, 2007). Overall, IFN 
signalling serves to expand the repertoire of immune effectors involved in the antiviral 
response and thereby regulates viral replication and spread. The production of IFN in most 
cell types occurs in three phases: sensitization, induction and amplification. During the 
sensitization phase, pathogen-associated molecular patterns are recognized by pattern 
recognition receptors including members of the toll-like receptor (TLR) and retinoic acid-
inducible gene-I receptor families. Recognition results in the activation of several cellular 
transcription factors, including interferon regulatory factor 3 (IRF3) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB), and the subsequent expression of 
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IFNβ. During the inductive phase, secreted IFNβ functions in a positive feedback 
mechanism by binding its cognate receptor. This leads to expression of additional ISGs via 
the Janus-activated kinase and signal transducer and activator of transcription (STAT) 
pathway. The interferon stimulated gene factor 3 (ISGF3) complex, consisting of STAT1, 
STAT2 and IRF9, translocates to the nucleus and binds the promoter of ISGs, including IRF7. 
Once activated, the IRF3-IRF7 heterodimer induces expression of additional ISGs including 
IFNα species. Lastly, during the amplification phase IFNα/β stimulate the production of 
ISGs such as dsRNA-dependent protein kinase receptor (PKR) and oligoadenylate 
synthetase (OAS) pathways, which function to inhibit viral protein synthesis and degrade 
viral RNA, respectively. Due to the pleiotropic effects of IFN during infection, HSV-1 has 
evolved mechanisms by which to inhibit this potent antiviral response.  
Infected cell protein 0 (ICP0) is an IE gene product which is pivotal in counteracting the IFN 
response. HSV-1 ICP0-null mutants are hypersensitive to IFN such that production of viral 
mRNA and resultant protein is diminished, leading to reduced plaque forming ability 
(Mossman et al., 2000). The diverse mechanisms by which ICP0 counteracts the IFN 
response include inhibition of IRF3, IRF7, and STAT1 activation, and degradation of 
promyelocytic leukemia protein (PML) (Paladino & Mossman, 2009; Lin et al., 2004; Halford 
et al., 2006; Everett et al., 1998; Sobol & Mossman, 2006). Although the E3 ubiquitin ligase 
activity of the RING finger domain of ICP0 has been implicated in the inhibition of 
cytoplasmic IRF3, this mechanism has been shown to be proteasome-independent (Paladino 
et al., 2010). In addition to ICP0, the IE gene ICP27 functions in IFN evasion by repressing 
host transcription, translation, mRNA splicing and induces mRNA degradation. Through 
these mechanisms ICP27 inhibits IRF3 and STAT1 activation (Melchjorsen et al., 2006; Lin et 
al., 2004; Melroe et al., 2004; Johnson et al., 2008). However, it should be noted that the 
ability of ICP27 to inhibit IRF3 may be cell type specific. Deletion of ICP27 does not result in 
an increase in ISG production in primary human fibroblasts, while the opposite was 
observed in human macrophages (Melroe et al., 2004; Melchjorsen et al., 2006).  
Furthermore, several L proteins including ICP34.5, Us11, virion host shutoff (vhs) and 
Us3 inhibit the IFN response. ICP34.5 acts in concert with the IRF3 kinase TBK-1 to inhibit 
IRF3 activation (Verpooten et al., 2009) and with the cellular phosphatase PP1 to reverse 
PKR-induced inhibition of viral protein synthesis (Chou et al., 1995; He et al., 1997). Us11 
inhibits PKR activation by binding PKR itself, or activators of PKR such as dsRNA and 
PACT (Peters et al., 2002). Us11-mediated inhibition of PKR has been found to enhance 
the growth of ICP34.5-null HSV-1 (Poppers et al., 2000).  Conversely, PKR activation 
levels in Us11-null HSV-1 infected cells are reduced in comparison to levels in wild type 
HSV-1 infected cells (Mulvey et al., 2003). Together these data demonstrate an additive 
effect of Us11 in PKR inhibition. The ability of Us11 to bind dsRNA at late phases of 
infection prevents the synthesis of 2’-5’ oligoadenylates by inhibiting OAS activation 
(Cayley et al., 1984; Sanchez & Mohr, 2007). It has been shown that Us11 and OAS directly 
interact at RNA-containing complexes and can bind the same RNA molecules (Sanchez & 
Mohr, 2007). The vhs protein is integral in counteracting the host antiviral response, in 
particular the type I and II IFN signalling cascades. In addition to its roles in inhibiting 
host protein synthesis by degrading mRNA and disrupting polyribosomes, vhs regulates 
the expression of ISG transcripts. A study by Leib et al. (1999) found that vhs-null HSV-1 
replication was severely reduced in non-dividing cells in vitro as well as in vivo, resulting 
in viral clearance within 24 hours. Moreover, vhs mutants are hypersensitive to IFN 
(Pasieka et al., 2008) and in comparison to wild type HSV-1 show a marked increase in 
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ISG accumulation (Lin et al., 2004). vhs has also been shown to induce the degradation of 
IFNγ-specific transcripts, thereby inhibiting type II IFN signalling. Furthermore, vhs 
inhibits STAT-1 activation and formation of the ISGF3 complex following IFNγ treatment 
of human DCs (Eisemann et al., 2007; Chee & Roizman, 2004). Lastly, Us3 functions as a 
protein kinase to impede apoptosis thereby promoting viral gene expression (Leopardi et 
al., 1997). With respect to the type I and II IFN response, Us3 alters TLR3-mediated 
signalling by decreasing TLR3 mRNA expression, resulting in depleted IRF3 
homodimerization (Peri et al., 2008). Additionally, Us3 post-translationally modifies type 
II IFN receptors via phosphorylation, resulting in decreased expression of IFNγ-
dependent genes (Liang & Roizman, 2008). 
The complement system is activated in response to HSV-1 infection leading to formation of 
a membrane attack complex and lysis of the infected cell. By-products of the complement 
system recruit inflammatory cells to the site of infection resulting in opsonisation by 
macrophages. To evade the complement system, HSV-1 gC binds to and inactivates C3, the 
central convertase in the complement cascade, as well as other components such as C5 and 
properdin (Wakimoto et al., 2003). This response is variable due to differences in the binding 
efficiency of gC to its’ targets between different strains of virus (Wakimoto et al., 2003). In 
addition, activity of virus-specific antibodies has been shown to enhance the antiviral 
activity of the complement system by aiding in activation of the classical pathway 
(Wakimoto et al., 2003).  
Activation of cellular immune effectors is critical to controlling infection, as well as 
determining the type and strength of the adaptive immune response. Macrophages, NK, 
DC, cytokines and chemokines control the initial infection and prevent its spread to other 
tissues (Wakimoto et al., 2003). Persistence of CD8+ T cells in infected neuronal tissue has 
been implicated in controlling HSV-1 during latency and reactivation (Knickelbein et al., 
2008). DCs are potent antigen presenting cells as they are able to induce naïve T cells which 
in turn stimulate maturation of B cells resulting in production of HSV-1-specific antibodies. 
HSV-1 is able to infect DCs and thereby block maturation via the IE protein ICP27 (Kobelt et 
al., 2003). This results in the inability of DCs to induce a potent immune response and 
antiviral T cell stimulation. HSV-1 ICP47 blocks transporter associated with antigen 
processing (TAP) preventing translocation of peptides to the endoplasmic reticulum (ER) 
and thus MHC I formation, ultimately leading to a decrease in activation of CD8+ T cells. 
Furthermore, vhs reduces expression of MHC I & II, IL-1β and IL-8 and activation of DCs 
(Eisemann et al., 2007; Chee & Roizman, 2004; Suzutani et al., 2000). Due to repressed CD8+ 
T cell activity, CD4+ T cells migrate to the area of infection where they secrete cytokines to 
activate NK cells. This culminates in secretion of IFNγ which increases MHC I production 
and thus CD8+ T cell activation. 
2. Oncolytic virotherapy 
The use of viruses to target and lyse cancer cells is a novel approach to cancer therapy that 
lacks the toxic side effects of many cancer treatments that are currently used.  Furthermore, 
virotherapy has been used in cases where cancer cells have become apoptosis-resistant and 
are refractory to common treatment modalities.  Although the safety and potential benefit of 
using viruses has been addressed in phase I and II clinical trials, the efficacy remains poor 
(Ries & Brandts, 2004). Thus, the search for new cancer therapy approaches with a high 
therapeutic index but limited pathogenicity continues.    
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ISG accumulation (Lin et al., 2004). vhs has also been shown to induce the degradation of 
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dependent genes (Liang & Roizman, 2008). 
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2. Oncolytic virotherapy 
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virotherapy has been used in cases where cancer cells have become apoptosis-resistant and 
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using viruses has been addressed in phase I and II clinical trials, the efficacy remains poor 
(Ries & Brandts, 2004). Thus, the search for new cancer therapy approaches with a high 
therapeutic index but limited pathogenicity continues.    
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Oncolytic virotherapy is based on the observation that some viruses preferentially replicate 
in and kill cancer cells while having minimal detrimental effects on normal cells (Cervantes-
García et al., 2008). It holds potential as a successful avenue of gene therapy given its two-
pronged approach, the destruction of cancer cells as a direct result of viral replication, and 
induction of tumour-specific immunity (Vaha-Koskela et al., 2007). Oncolytic viruses lack 
the widespread toxicity of chemotherapeutics with local replication of the virus amplifying 
the input dose and resulting in spread to adjacent tumor cells. 
Oncolytic viruses can be divided into two groups, wild type viruses that are naturally 
oncolytic and do not require mutations to render them oncotropic and those that require 
genetic modification for selective oncolysis. HSV-1 was the first virus used to demonstrate 
that a genetic mutation can render a virus oncolytic (Jia & Zhou, 2005, Shen & Nemunaitis, 
2006).  In fact, HSV-1 has been studied extensively as an oncolytic virus due to the many 
advantages it possesses for use in virotherapy. A brief section on natural oncolytic viruses 
has been included and will be followed by a detailed discussion of genetically modified 
HSV-1 vectors.   
2.1 Natural oncolytic viruses 
Wild type viruses including, but not limited to, reovirus, measles virus (MV), Newcastle 
disease virus (NDV), myxoma virus (MYXV), vesicular stomatitis virus (VSV), and Bovine 
herpesvirus type 1 (BHV-1) do not require a mutation to selectively replicate in tumor cells. 
These viruses exploit biochemical differences between normal and tumour cells to allow for 
preferential replication in cancer cells (Vaha-Koskela et al., 2007). In addition, species-specific 
viruses have gained popularity for use in oncolytic virotherapy due to the absence of pre-
existing immunity to these viruses. This lack of immunity prevents premature neutralization 
through antibody-mediated opsonisation and may also allow for systemic delivery of the 
virus, therefore improving the therapeutic potential against metastatic lesions.  
The selective replication of oncolytic viruses is the result of a collection of gain- or loss-of-
function mutations in a given cancer type (Vaha-Koskela et al., 2007). An example of one 
essential modification and hallmark of most malignant cancer types is the evasion of 
apoptosis (Hanahan & Weinberg, 2000). This is often the result of gain-of-function 
mutations in cellular signalling pathways, such as in constituents of the Ras signalling 
cascade (Ayllon & Rebollo, 2000). Activating mutations in Ras inhibit 
autophosphorylation of PKR, an important effector molecule in the IFN-mediated 
antiviral and apoptotic response (Everts & van der Poel, 2005). Wild type viruses that are 
sensitive to the effects of PKR, such as reovirus and NDV, can infect and replicate in cells 
with a Ras activating mutation, such as in cancer cells, while remaining inhibited in 
normal cells (Strong et al., 1998). In addition to its function as a cell cycle and apoptosis 
regulatory protein, p53 also functions as a potent tumor suppressor. In fact, p53 is the 
most commonly mutated oncogene in human cancers with over 50% of tumor cells 
carrying a mutation in p53 (Morris et al., 2002). Furthermore, p53 amplifies innate 
immune responses to virus infection through such mechanisms as enhancing IFN-
dependent responses and increasing IRF9 gene transcription (Muñoz-Fontela et al., 2008). 
Therefore, disruption of p53 is thought to dampen antiviral defense mechanisms 
conferring heightened sensitivity of cells to infection (Carroll, P.E. et al., 1999). Reovirus 
and MYXV replicate to higher levels in cancer cells with reduced expression of p53, and 
although this is not the major determinant dictating their selective replication in tumor 
cells, it enhances efficiency of infection (Kim et al., 2010). 
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Another feature of cancer cells that is often exploited by oncolytic viruses is an impaired IFN 
response. Upon binding to cellular receptors, IFN induces the expression of ISGs, many of 
which function to block viral replication (Platanias, 2005; Everts & van der Poel, 2005).  A 
well characterized ISG involved in blocking viral replication is PKR, as discussed previously 
(Sadler & Williams, 2008; Everts & van der Poel, 2005).  In addition to antiviral functions, 
many ISGs have been identified as tumour suppressors, including PML, ribonuclease 
(RNase) L, and ISG15 (Everts & van der Poel, 2005; Bernardi & Pandolfi, 2003; Salomoni & 
Pandolfi, 2002).  Furthermore, IRFs have been shown to possess tumour suppressive 
functions (Pitha et al., 1998; Taniguchi et al., 2001; Shen & Nemunaitis, 2006).  For example, 
IRF-1 has been implicated in cell cycle regulation and apoptosis (Tamura et al., 2008), and 
the development of some cancers, such as breast (Connett et al., 2005) and hepatocellular 
carcinoma (Moriyama et al., 2001), is correlated with decreases or loss of IRF-1 expression.  
Other pathways involved in IFN production, such as NFκB, have been implicated in tumour 
suppression (Everts & van der Poel, 2005; Chen & Castranova, 2007).  Given the diverse 
antitumorigenic functions of IFN signalling it is common for tumour cells to harbour defects 
in these pathways, and oncolytic viruses that are sensitive to IFN, such as VSV and NDV, 
preferentially replicate in tumor cells over normal cells (Jia & Zhou, 2005; Ries & Brandts, 
2004; Everts & van der Poel, 2005). 
2.1.1 Reovirus 
Reovirus is a non-enveloped dsRNA virus which has minimal pathogenicity in humans but 
can cause gastrointestinal and respiratory symptoms. Selective replication of reovirus occurs 
in tumor cells harbouring activating mutations in the Ras pathway (Strong et al., 1998; 
Coffey et al., 1998), as outlined above. Reovirus has shown promise in pre-clinical studies 
with selective replication in tumors of breast (Strong et al., 1996; Norman et al., 2002; 
Hirasawa et al., 2002), colon (Kinzler & Vogelstein, 1996), ovarian (Hirasawa et al., 2002), 
and lymphoid (Alain et al., 2002) origins. Combination therapy involving the 
immunosuppressant cyclosporine A or anti-CD4+/CD8+ antibodies enhances the oncolytic 
ability of reovirus in systemic treatment of metastatic malignancies (Hirasawa et al., 2002). A 
phase I open-label dose-escalation trial with reovirus type 3 Dearing (RT3D) in combination 
with radiotherapy was performed on twenty-three patients with advanced or metastatic 
solid tumors (Harrington et al., 2010a). Patients received intralesional injections of RT3D 
(1x108 pfu up to 1x1010 pfu) and were monitored for tumor regression and adverse events. 
Treatment was well tolerated with no adverse effects associated with virus treatment. 
Overall, seven patients achieved partial response and seven achieved stable disease. Results 
of this and other clinical trials using reovirus for the treatment of malignancies support 
development of this virus as a therapeutic option. 
2.1.2 Measles virus 
Measles virus (MV) is an enveloped (-)ssRNA virus that causes rash, fever, cough and 
conjunctivitis in infected humans. Several cases of spontaneous tumor regression have 
occurred in individuals with MV infection, suggesting an oncolytic attribute for the virus. 
However, the cellular receptor SLAM, which is used by wild type MV for cellular entry, is 
not commonly expressed on tumor cells. A live attenuated measles strain with no 
pathogenicity in humans has been generated by serially passaging the virus in tissue 
culture. This virus has adapted to use CD46, an inhibitor of complement activation, for 
cellular entry (Peng et al., 2003a). The CD46 receptor is expressed in higher abundance on 
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human tumor cells than on their non-transformed counterparts, rendering the attenuated 
strain oncolytic. Attenuated MV has been used to treat B cell malignancies such as non-
Hodgkin’s lymphoma and myeloma (Grote et al., 2001; Peng et al., 2001). In these studies the 
formation of multinucleated syncytia increased viral spread and thus the efficacy of virus 
treatment. In addition, a MV expressing an antibody against CD38, a cell marker highly 
expressed on myeloma cells, induced cell-cell fusion and cytopathic effects in mouse 
xenografts resulting in inhibition of tumor growth and prolonged survival (Peng et al., 
2003b).   
2.1.3 Newcastle disease virus 
Newcastle disease virus (NDV) is an enveloped (-)ssRNA avian paramyxovirus that is non-
pathogenic to humans. Like reovirus, NDV is unable to counter the effects of PKR and thus 
requires activated Ras to replicate in tumor cells. While Ras is the main factor determining 
NDV tropism, mutations in the IFN signalling pathway also confer sensitivity to NDV. Live 
attenuated strains of NDV have shown efficacy in mouse models of fibroblastoma (Lorence 
et al., 1994a), neuroblastoma (Lorence et al., 1994b; Reichard et al., 1993), colon (Schulze et 
al., 2009), prostate (Phuangsab et al., 2001), melanoma (Zamarin et al., 2009), large cell lung 
(Phuangsab et al., 2001) and breast carcinoma (Zhao et al., 2008; Janke et al., 2007). 
Moreover, live attenuated NDV strains MTH-68/H and PV701 are currently in clinical trials 
for high-grade gliomas (HGG) and advanced solid cancer, respectively (Csatary et al., 2004; 
Pecora et al., 2002). 
2.1.4 Vesicular stomatitis virus 
Vesicular stomatitis virus (VSV) is an enveloped (-)ssRNA virus that is non-pathogenic to 
humans. VSV is exquisitely sensitive to the effects of IFN signalling and as such selectively 
replicates in tumor cells harbouring mutations in IFN and its signalling effectors (Stojdl et 
al., 2000). The oncolytic ability of VSV has been demonstrated in in vivo models of melanoma 
(Luo et al., 2010; Galivo et al., 2010), colon, and hepatocellular carcinoma (Shinozaki et al., 
2004). In a recent study, recombinant VSV expressing human dopachrome tautomerase 
(hDCT) was used as an immune boost resulting in enhanced efficacy in the B16-F10 model 
of melanoma. Results indicate the efficacy of VSV in augmenting the antitumor immune 
response (Bridle et al., 2009). 
2.1.5 Myxoma virus 
Myxoma virus (MYXV) is an enveloped dsDNA virus that is non-pathogenic in humans. It 
causes Myxomatosis in European rabbits, which is uniformly fatal due to 
immunomodulation by several virus-encoded proteins (Stanford et al., 2007). Even in cases 
of routine exposure to the virus humans do not seroconvert (Stanford & McFadden, 2007). 
MYXV is restricted from normal mouse cells due to the IFN response, and from normal 
human cells due to IFN and tumour necrosis factor (TNF) responses (Lun et al., 2005). 
MYXV has been shown to selectively replicate in human cancer cells of various histological 
origins (Sypula et al., 2004; Lun et al., 2005, Wang et al., 2008).  The cellular tropism of 
MYXV for human tumor cells largely depends on the interaction of a viral host range factor 
(M-T5) and cellular Akt, a protein kinase with roles in cellular proliferation, migration, 
transcription and apoptosis (Wang et al., 2006). This interaction has been shown to induce 
the kinase activity of Akt resulting in MYXV replication. In a xenograft model of human 
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glioma in immunocompromised mice, intracranial injection of MYXV was well-tolerated 
and caused regression of the injected tumor. Regression in distal tumors was not observed 
but virus replication was sustained long term (Lun et al., 2005). Combination therapy trials 
using rapamycin, an immune and tumor suppressant which upregulates Akt activation via 
the mTOR pathway, resulted in increased MYXV replication in select tumor types (Werden 
et al., 2010).    
2.1.6 Bovine herpesvirus type 1 
Bovine herpesvirus type 1 (BHV-1) is a member of the Herpesviridae family, and 
Alphaherpesviridae subfamily. BHV-1 causes infectious bovine rhinotracheitis (IBR) in 
cattle, manifesting in symptoms such as ocular and nasal secretions, lesions on mucosal 
surfaces, anorexia, dyspnoea, conjunctivitis, and abortions (Turin et al., 1999, Hushur et 
al., 2003). In approximately 10% of affected animals bacterial superinfection occurs, 
resulting in bronchopneumonia (Turin et al., 1999). However, in the absence of 
bronchopneumonia the infection is self-limiting due to the immune response, and 
recovery occurs within 1 to 2 weeks (Turin et al., 1999). BHV-1 is a neurotropic virus 
which establishes life-long latency in neurons, with reactivation of the virus resulting 
from parturition, pregnancy, transport, entrance into a new herd, concomitant bacterial or 
viral infections, poor living conditions, deficient diet and increases in corticosteroids 
(Turin et al., 1999, Jones & Chowdhury, 2007).  
The structure of BHV-1 is similar to that of HSV-1, however some important differences 
exist. BHV-1 binds attachment and entry receptors used by HSV-1, such as heparan sulfate 
and nectin-1 (Campadelli-Fiume et al., 2000). However, it is unable to bind nectin-2, but 
binds CD155 instead (Campadelli-Fiume et al., 2000). CD155 is a poliovirus receptor 
associated with tumour cell migration and invasion, and has been shown to be up-regulated 
in human cancers (Merrill et al., 2004; Pende et al., 2005). Genes expressed by BHV-1 are 
generally named after the coinciding HSV-1 gene, which often have similar activities 
although there are some functional differences. For example, bICP0 is similar to HSV-1 ICP0 
in that it is an IE gene product which acts as a transcriptional activator and possesses E3 
ubiquitin ligase activity inherent to the RING-finger domain. However, bICP0 differs from 
HSV-1 ICP0 in that it promotes proteasomal-dependent degradation of IRF-3 (Henderson et 
al., 2005, Saira et al., 2007). Furthermore, while ICP0 induces disruption of PML nuclear 
bodies (PML-NB) by degrading SUMO-modified forms of PML, bICP0 does not decrease 
steady-state levels of PML but rather degrades sp100, another major component of PML-
NBs (Everett et al., 2010).  
Of particular interest is the narrow host range of BHV-1, as it is unable to productively infect 
mice and normal human cells (Hushur et al., 2003). Also, cattle farmers whom are routinely 
exposed to the virus do not seroconvert. Rodrigues et al. (2010) showed that human 
transformed and phenotypically normal immortalized cell types are permissive to BHV-1, 
while normal primary cell types are relatively resistant to BHV-1 infection (Figure 2). BHV-1 
induces cytopathic effects (CPE) and decreases cellular metabolism in immortalized and 
transformed cells from the lung, mammary, bone and prostate origins with varying 
efficiency.  
Naturally occurring oncolytic viruses such as VSV, MYXV and NDV are sensitive to the 
effects of type I IFN signalling.  However, this is not the case for BHV-1 as cellular IFN-
responsiveness does not correlate with sensitivity to BHV-1 (Table 1) (Rodriguez et al., 
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efficiency.  
Naturally occurring oncolytic viruses such as VSV, MYXV and NDV are sensitive to the 
effects of type I IFN signalling.  However, this is not the case for BHV-1 as cellular IFN-
responsiveness does not correlate with sensitivity to BHV-1 (Table 1) (Rodriguez et al., 
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2010). IFN production was also absent in BHV-1 infected cells. These observations suggest 







Fig. 2. BHV-1gfp replication and cellular viability in normal, immortalized and transformed 
human cells. Virus replication, as a function of GFP fluorescence, was quantified two days 
post infection using a Typhoon Bioanalyzer (Amersham Biosciences). Virus replication is 
represented in absolute fluorescence units (FU). Cellular metabolism was measured using 
Alamar blue and is represented as a fold change over uninfected controls. (*) indicates loss 
of fluorescence due to the absence of viable cells. Data is expressed as the mean from three 
independent experiments. (Rodriguez et al., 2010) 
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Table 1. IFN responsiveness for normal, immortalized and transformed cells from a variety 
of histological origins. Cells were treated with human IFNα for 24 hours prior to infection 
with VSV-GFP. VSV replication was used to assess the IFN responsiveness of each cell line, 
as cells responsive to IFN will be unable to support VSV replication. The effective 
concentration of IFN required to inhibit 50% of GFP fluorescence (EC50) was calculated to 
compare IFN responsiveness between cell lines. Cytopathic effect (CPE) scoring was 
performed by infecting cells with BHV-1 at an MOI 0.5, 1. 2.5, 5 or 10. Three days pi cell 
monolayers were stained with Giemsa to evaluate CPE. (- indicates a non-permissive cell 
type, no visible CPE; + indicates a cell type that is not very permissive, 50% CPE at MOI 
>2.5; ++ indicates a moderately permissive cell type, 50% CPE between MOI 1 and 2.5; +++ 
indicates a highly permissive cell, 50% CPE at MOI <1) (Rodriguez et al., 2010). 
These data suggest that BHV-1 holds promise for use in broad spectrum oncolytic 
virotherapy. The non-pathogenic nature of BHV-1 and lack of pre-existing immunity in 
humans, as well as the potential for systemic treatment with increased safety offers an 
advantage over current HSV-1 vectors. 
2.2 Engineered oncolytic viruses: HSV-1 vectors 
Genetically modified tumor-selective oncolytic viruses are often generated from the deletion 
of genes that are required for replication in normal cells, but are dispensable in tumor cells. 
A wide variety of viruses have been engineered for oncolytic virotherapy, including but not 
limited to, HSV-1, adenovirus, vaccinia virus, poliovirus, and influenza virus. Pathways 
commonly mutated in tumor cells, such as those involved in regulation of cell cycle and 
proliferation, are often those exploited by viruses. For example, cell cycle checkpoint 
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proteins p53 and retinoblastoma (Rb), and the Ras family of proteins and their downstream 
effectors, are commonly mutated in solid and hematologic cancers (Ayllon & Rebollo, 2000). 
Thus, oncolytic viruses have been generated to selectively replicate in tumor cells possessing 
these and other mutations. This section will focus on discussion of engineered HSV-1 
oncolytic viruses.  
2.2.1 First generation vectors 
HSV-1 was the first virus used to demonstrate that a genetic mutation can render a virus 
oncolytic (Jia & Zhou, 2005; Shen & Nemunaitis, 2006).  In fact, HSV-1 has been studied 
extensively as an oncolytic virus due to the many advantages it possesses for use in 
virotherapy.  Its large dsDNA genome (~150 kbp) allows for the insertion of multiple 
transgenes, up to 30 kbp in length (Everts & van der Poel, 2005; Shen & Nemunaitis, 2006).  
HSV-1 has been shown to infect a broad number of cell types due to the ubiquitous 
expression of its receptor in human tissues.  The virus is able to kill infected cells as a result 
of lytic replication and does not insert its DNA into the host genome, reducing the risk of 
insertional mutagenesis (Varghese & Rabkin, 2002; Shen & Nemunaitis, 2006).  Moreover, 
HSV-1 rarely causes severe illness in immunocompetent adults (Varghese & Rabkin, 2002; 
Shen & Nemunaitis, 2006) and antiherpetic drugs, such as ACV and GCV, can be used to 
control viral replication.  
Common mutations in HSV-1 oncolytic viruses are in the genes that encode for thymidine 
kinase (tk) and ribonucleotide reductase, also known as ICP6. These genes are responsible 
for synthesis of deoxynucleotide triphosphates (dNTPs) and are required for virus 
replication. Cellular synthesis of dNTPs is upregulated during G1 and S phases of the cell 
cycle but otherwise remain low. Thus, mutation of the genes encoding tk and ICP6 restrict 
replication to rapidly proliferating tumor cells. However, studies of the tk-null mutant 
dlsptk (Table 1) in severe combined immunodeficient (SCID) mice indicated the spread of 
the virus to normal tissue (Valyi-Nagy et al., 1994). Presence of an intact tk gene can serve as 
a safe guard against unwanted replication through the use of antiherpetic drugs, such as 
ACV and GCV. The HSV-1 recombinant hrR3 (Table 1), which is deleted for ICP6, 
selectively replicates in tumor cells with active ribonucleotide reductase due to their high 
rate of proliferation. ICP6-null mutants retain sensitivity to ACV and GCV, adding to their 
safety profile. This mutant has shown promising antitumor effects in animal models of brain 
(Mineta et al., 1994), pancreas (Kasuya et al., 1999), colon (Yoon et al., 2000; Carroll, N.M. et 
al., 1996), and liver (Pawlik et al., 2000) carcinoma. In combination therapy trials, co-
administration of cyclophosphamide (CPA) or cobra venom factor (CVF) and hrR3 resulted 
in enhanced antineoplastic effects (Ikeda et al., 2000). 
The leaky L gene ICP34.5 is a neurovirulence factor, which when deleted inhibits virus 
replication in neurons and other cells with a slow doubling time. ICP34.5 also functions to 
reverse PKR-mediated inhibition of viral protein synthesis. A wide variety of ICP34.5-null 
HSV-1 mutants have been described which preferentially replicate in cancer cells with Ras 
gain-of-function mutations (Davis & Fang, 2005; Farassati et al., 2001; Shen & Nemunaitis, 
2006). The HSV-1 mutant HSV1716 (Table 1), deleted for both copies of ICP34.5, has shown 
promise in animal models of glioma (Andreansky et al., 1996), mesothelioma (Kucharczuk et 
al., 1997), melanoma (Randazzo et al., 1995; Randazzo et al., 1997), and lung carcinoma 
(Lambright et al., 1999). HSV1716 treatment caused significant tumor regression and 
prolonged survival. Clinical trials have been initiated for many ICP34.5-null HSV-1 vectors 
including HSV1716, the details of which will be discussed in section 3. 
Herpes Simplex Virus Type 1 for Use in  
Cancer Gene Therapy: Looking Backward to Move Forward 
 
393 
Virus Gene(s) Mutated Transgene Description Reference 
First Generation
dlsptk TK  TK gene deletion Martuza  et al., 1991 
hrR3 ICP6 LacZ LacZ gene insertion within ICP6 coding region
Mineta 
 et al., 1994 






TK deletion of UL24, UL56, one copy of ICP34.5 exogenous TK under control of ICP4 promoter 
Advani  
et al., 1999 
G207 ICP34.5 (2), ICP6 LacZ 
deletion of both copies of ICP34.5 LacZ gene insertion 
within ICP6 coding region
Mineta  
et al., 1995 
G47∆ ICP47, ICP34.5 (2) LacZ 
deletion of ICP47 and both copies of ICP34.5 LacZ 
gene insertion within ICP6 coding region 
Todo  
et al., 2001b 
Transcriptional Targeting
G92A TK, US3, UL24 
LacZ 
Alb-ICP4
based on HSV-1 d120 backbone LacZ gene insertion 
within TK coding regioninsertion of albumin 
promoter-ICP4 transgene within TK coding region 
Miyatake  
et al., 1999 
d12.CALP TK, US3, UL24 
LacZ 
Cal-ICP4
based on HSV-1 d120 backbone E. coil LacZ gene 
insertion within TK coding region insertion of the 
CALP promoter-ICP4 transgene within TK coding 
region
Yamamura  
et al., 2001 
DF3γ34.5 ICP34.5 (2) DF3/Muc1-ICP34.5 
deletion of both copies of ICP34.5 insertion of 
exogenous ICP34.5 gene under control of DF3-MUC1 
promoter
Chung  
et al., 1999 
Transgene-expressing/Immunostimulatory
rRp450 ICP6 CYP2B1 cytochrome p450 oxidase gene insertion within ICP6 coding region
Pawlik  
et al., 2001 
HSV1γCD ICP6 CDAFP
CD gene insertion within ICP6 coding region AFP 
gene insertion within ICP6 coding region
Nakamura  
et al., 2001 
dvB7Ig ICP34.5 (2),ICP6 
LacZ 
B7-1 
deletion in both copies of ICP34.5 LacZ gene insertion 
within ICP6 coding region B7-1Ig inserted within the 
ICP6 coding region
Ino  
et al., 2006 
NV1034 ICP47, UL56 LacZ GM-CSF
deletion of ICP47 and UL56 LacZ gene insertion 
within ICP47 coding region GM-CSF under control of 
ICP6-TK hybrid promoter
Wong  
et al., 2001 




deletion of ICP47, UL56, and one copy of ICP34.5
LacZ gene insertion within ICP47 coding region 
Rescue of TK expression through insertion of a 5.2kb 
sequence of HSV-2 origin at the L-S junction mIL-12 
under control of the ICP6 promoter
Wong  




ICP34.5 (2) GM-CSF 
deletion of ICP47 deletion of both copied of ICP34.5 
GM-CSF expressed under control of the ICP47 
promoter 
Hu  
et al., 2006 
Table 2. Oncolytic HSV-1 Vectors and their corresponding mutations (ICP: infected cell 
protein, CALP: calponin, MUC1: mucin-1, CD: cytosine deaminase, AFP: alphafetoprotein, 
GM-CSF: granulocyte macrophage colony-stimulating factor, IL: interleukin, TK: thymidine 
kinase)  
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Concerns over safety of using single gene deletion mutants are centered on observations of 
residual replication and toxicity in normal cells. The development of HSV-1 oncolytic 
viruses containing mutations in multiple genes increases their safety profile while also 
decreasing the risk of reversion to wild type. These viruses are referred to as second 
generation oncolytic vectors. 
2.2.2 Second generation vectors 
The second generation mutant G207 (Table 1) is at the forefront of oncolytic virotherapy. 
G207 contains deletions in both copies of ICP34.5 and a lacZ gene insertion within the 
ICP6 coding region. This virus selectively replicates in human tumor cells over normal 
cells while retaining sensitivity to antiherpetic drugs. Also, the lacZ gene insertion 
encodes an easily detectible histochemical maker for virus replication and spread. The 
safety of G207 has been demonstrated in animal models of liver (Kooby et al., 1999), 
ovarian (Coukos et al., 2000), melanoma (Todo et al., 2002), breast (Toda et al., 1998), 
colon, gallbladder, gastric (Todo et al., 2002), head and neck (Wong et al., 2001), 
pancreatic, prostate (Todo et al., 2002) and cervical carcinoma (Blank et al., 2002). G207 is 
currently in clinical trials for treatment of malignant glioma (Markert et al., 2000). Another 
second generation mutant, NV1020 (Table 1), is deleted for tk and one copy of ICP34.5. TK 
function is provided by insertion of a 5.2 kb fragment of HSV-2 DNA under the control of 
the ICP4 promoter (Shen & Nemunaitis, 2006). Therefore, NV1020 retains sensitivity to 
ACV and GCV. The efficacy of NV1020 has been demonstrated in animal models of 
pancreatic (McAuliffe et al., 2000), head and neck (Wong et al., 2001), and hormone-
resistant prostate carcinoma (Advani et al., 1999) with the virus replicating to higher 
levels in comparison to mutants deleted for both copies of ICP34.5 (Bennett et al., 2002; 
McAuliffe et al., 2000; Advani et al., 1999). Clinical trials are currently underway using 
NV1020 to treat colon carcinoma liver metastases via intrahepatic arterial delivery 
(Kemeny et al., 2006). Furthermore, immunostimulatory HSV-1 vectors and mutants 
deleted for viral proteins involved in counteracting the immune response have been 
developed to augment antiviral and antitumor immune responses aiding in tumor 
regression. G47∆ (Table 1) is a derivative of G207 with an additional deletion in ICP47. 
Since ICP47 decreases expression of MHC I molecules through inhibition of TAP, its 
absence promotes tumor antigen presentation and increased antitumor immune responses 
(Todo et al., 2001b). In comparison to G207, G47∆ conferred enhanced inhibition of tumor 
growth in both immunodeficient and immunocompetent animal models while retaining 
the same safety profile (Todo et al., 2001b).       
2.3 Transcriptional targeting 
Another method of restricting virus replication to tumor cells involves insertion of tissue 
and/or tumor-specific promoters to drive the expression of genes which are essential to 
virus replication in tumor cells. This is referred to as transcriptional targeting and has 
shown promise as an efficient restriction mechanism. The HSV-1 mutant G92A (Table 1) 
places expression of the IE gene ICP4 under the control of the albumin-enhancer promoter 
to direct tropism to the liver and hepatocellular carcinomas (Miyatake et al., 1999). Another 
HSV-1 vector, d12.CALP (Table 1) expresses ICP4 under the control of the calponin 
promoter and selectively replicates in smooth muscle and bone tumors (Yamamura et al., 
2001). In addition, a similar virus DF3γ34.5 (Table 1) expresses ICP34.5 under the control of 
the DF3/MUC1 enhancer/promoter and is limited to tumors expressing the DF3/MUC1 
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antigen, such as breast carcinomas (Kasuya et al., 2004). In an effort to direct the tropism of 
oncolytic herpesvirus KeM34.5 to gliomas, Kanai et al. (2007) used the musashi1 promoter to 
control expression of ICP34.5. Musashi1 is a neural RNA-binding protein which is used as a 
molecular marker for malignant glioma. In comparison to its parental vector G207, KeM34.5 
showed enhanced cytotoxic ability in vitro as well as increased tumor regression in a murine 
glioma model. Recently, an oncolytic HSV-1 vector (oHSV-MDK-34.5) was developed to 
treat malignant peripheral nerve sheath tumors (MPNST) by fusing the human midkine 
(MDK) promoter to the ICP34.5 gene (Maldonado et al., 2010). Selective replication of oHSV-
MDK-34.5 in MDK-positive MPNSTs resulted in antitumor effects and prolonged survival 
of MPNST-bearing nude mice. Oncolytic adenoviruses have been engineered with restricted 
expression of E1A and E1B genes by placing them under the control of the prostate-specific 
antigen (PSA) and probasin promoters in CV706 and CV787 respectively (Chen et al., 2001; 
Yu et al., 1999). For instance, the replication of CV706 was found to be highest in PSA-
producing tissues and was able to induce cytotoxic effects in infected tumor cells (Rodriguez 
et al., 1997). 
The differential expression of micro-RNAs (miR) between normal and tumor cell types has 
been exploited to generate oncolytic HSV-1 vectors which selectively replicate in the absence 
of select miRs. The expression of miR-143 and miR-145 is significantly down-regulated in 
prostate carcinomas in comparison to normal healthy tissue. Target sequences for miR-143 
or miR-145 were incorporated into the 3’-untranslated region of ICP4 to generate the 
oncolytic HSV-1 vectors CMV-ICP4-143T and CMV-ICP4-145T (Lee et al., 2009). Tumor-
specific replication resulted in significant reductions in tumor volume and enhanced 
survival in mice bearing LNCaP human prostate tumors. 
2.4 Cellular targeting 
Modification of viral entry proteins, referred to as cellular targeting, is another method by 
which the replication of oncolytic vectors can be restricted to certain tissues and tumor cells. 
The recombinant HSV-1 virus, R5141, was engineered to enter cells solely via the IL-13Rα2 
receptor (Zhou et al., 2006). Briefly, the natural binding sites for HSPGs in gB and gC were 
replaced with the amino acid sequences encoding IL-13. Multiple amino acid substitutions 
were made in and around the HveA and nectin-1 binding sites to abolish their interaction 
with gD. An additional vector developed by the same group, R5181, enters cells via the 
urokinase plasminogen activator receptor. These studies demonstrate the application of this 
method to multiple receptor classes (Kamiyama et al., 2006). Although the mechanism of 
HSV-1 entry has not been fully elucidated, the upregulation of receptors on cancer cells, 
such as epidermal growth factor receptor (EGFR), folate receptor, CD44, CD38 and others, 
provides the basis for this approach but requires further study to achieve full tumor 
selectivity.  
2.5 Armed oncolytic vectors 
Although oncolytic vectors show promise as novel cancer therapeutics, studies indicate that 
in the majority of cases virus replication on its own is insufficient to induce full tumor 
regression. Thus, enhanced cytotoxic effects are desired and have been achieved through the 
expression of ‘suicide’ and immunostimulatory genes.  
Introduction of genes encoding immunostimulatory molecules and prodrug-converting 
enzymes have been used to enhance the cytolytic ability of oncolytic viruses and augment 
the antitumor immune response leading to increased tumor regression and survival. Initial 
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antigen, such as breast carcinomas (Kasuya et al., 2004). In an effort to direct the tropism of 
oncolytic herpesvirus KeM34.5 to gliomas, Kanai et al. (2007) used the musashi1 promoter to 
control expression of ICP34.5. Musashi1 is a neural RNA-binding protein which is used as a 
molecular marker for malignant glioma. In comparison to its parental vector G207, KeM34.5 
showed enhanced cytotoxic ability in vitro as well as increased tumor regression in a murine 
glioma model. Recently, an oncolytic HSV-1 vector (oHSV-MDK-34.5) was developed to 
treat malignant peripheral nerve sheath tumors (MPNST) by fusing the human midkine 
(MDK) promoter to the ICP34.5 gene (Maldonado et al., 2010). Selective replication of oHSV-
MDK-34.5 in MDK-positive MPNSTs resulted in antitumor effects and prolonged survival 
of MPNST-bearing nude mice. Oncolytic adenoviruses have been engineered with restricted 
expression of E1A and E1B genes by placing them under the control of the prostate-specific 
antigen (PSA) and probasin promoters in CV706 and CV787 respectively (Chen et al., 2001; 
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were made in and around the HveA and nectin-1 binding sites to abolish their interaction 
with gD. An additional vector developed by the same group, R5181, enters cells via the 
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2.5 Armed oncolytic vectors 
Although oncolytic vectors show promise as novel cancer therapeutics, studies indicate that 
in the majority of cases virus replication on its own is insufficient to induce full tumor 
regression. Thus, enhanced cytotoxic effects are desired and have been achieved through the 
expression of ‘suicide’ and immunostimulatory genes.  
Introduction of genes encoding immunostimulatory molecules and prodrug-converting 
enzymes have been used to enhance the cytolytic ability of oncolytic viruses and augment 
the antitumor immune response leading to increased tumor regression and survival. Initial 
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‘suicide’ gene therapy vectors focused on expressing HSV-1 tk to infer sensitivity to GCV. 
However, this method inhibited virus replication at early stages and therefore was not 
efficient. As a result, expression of therapeutic genes are generally placed under the control 
of a late viral promoter to allow for sufficient virus replication to occur before induction of 
cytolytic effects that would otherwise halt replication prematurely.  
Studies in immunocompetent animals have highlighted a bimodal mechanism of tumor 
clearance: tumor cell lysis as a result of oncolytic virus replication and induction of an 
antitumor immune response. Direct injection or use of oncolytic vectors expressing 
immunostimulatory cytokines has been used to induce inflammatory and tumor antigen-
specific responses. Several studies describe vectors expressing granulocyte-macrophage 
colony-stimulating factor (GM-CSF) as an immunostimulant. GM-CSF induces myeloid 
precursor cell activation, recruits DCs, and has been used in tumor cell vaccines resulting in 
increased therapeutic benefits (Toda et al., 2000; Nemunaitis, 2005; Eager et al., 2005). For 
example, treatment with OncoVEXGM-CSF (Table 1), a second generation HSV-1 vector, 
resulted in tumoristatic effects on injected and distal tumors in patients with cutaneous or 
subcutaneous breast, head and neck, gastrointestinal and malignant melanoma (Hu et al., 
2006). HSV-1 constructs NV1034 and NV1042 (Table 1) , expressing GM-CSF or IL-12 
respectively, prolonged survival and caused tumor regression in murine models of 
squamous cell carcinoma (Wong et al., 2001). NV1042 treatment resulted in an enhanced 
antitumor effect in comparison to NV1034 and a control vector NV1023, which does not 
express cytokines (Wong et al., 2001). Oncolytic virus treatment was accompanied by the 
induction of a strong inflammatory response, including accumulation of CD4+ and CD8+ T 
cells (Wong et al., 2001) and inhibition of tumor angiogenesis (Wong et al., 2004). Overall, 
57% of mice treated with NV1042 were refractory to tumor re-challenge, in comparison to 
14% of NV1034 and NV1023-treated animals (Wong et al., 2001). These results suggest the 
establishment of an antitumor memory immune response. The B7 family of membrane 
proteins, B7-1 (CD80) and B7–2 (CD86), are potent co-stimulatory molecules and interact 
with CD28 and CTLA-4 (CD152) on the T-cell surface. A HSV-1 vector expressing the B7-1-
immunoglobulin (B7-1-Ig) fusion transgene (dvB7Ig) (Table 1) has been studied in a murine 
model of neuroblastoma (Todo et al., 2001a). Intraneoplastic inoculation of dvB7Ig inhibited 
tumor growth and prolonged the survival of mice bearing intracerebral tumors. A 
significant CD4+ and CD8+ T-cell response was observed, with immunodepletion studies 
indicating that CD8+ T cells play a key role in the antitumor response. Cured animals were 
refractory to tumor re-challenge indicating establishment of an antitumor memory immune 
response.  
Prodrug-converting enzymes such as cytosine deaminase (CD) and cytochrome p450 
oxidase have been used to induce the expression of noxious compounds to enhance 
oncolytic cytotoxicity. Yeast CD converts the prodrug 5-fluorocytosine to 5-fluorouracil, 
which inhibits DNA synthesis. HSV1γCD (Table 1), in which ICP6 is inactivated by insertion 
of CD, has shown promise in murine models of liver metastases (Nakamura et al., 2001). 
Expression of CD prolonged survival and enhanced tumor regression without significantly 
affecting virus replication and oncolysis. Furthermore, similar results were obtained using 
rRp450 (Table 1) a HSV-1 mutant expressing the CYP2B1 transgene which codes for 
cytochrome p450 oxidase and converts cyclophosphoramide (CPA) into phosphoramide 
mustard. Despite the immunosuppressive activity of CPA, its expression enhanced the 
cytolytic effect of rRp450 against hepatocellular carcinoma both in vitro and in vivo without 
prematurely inhibiting HSV-1 replication (Pawlik et al., 2002). 
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3. Clinical trials 
The antitumor efficacy of oncolytic herpesviruses has been demonstrated in preclinical 
animal models. However, evaluation of tumor-selectivity, virus replication and spread must 
be evaluated in humans. Clinical trials have been completed, or are in progress, for NV1020, 
HSV1716, G207, OncoVEXGM-CSF and HF10 (Table 2). 
3.1 NV1020 clinical trials 
The liver is the most common site of colorectal metastases. It has been estimated that 60% of 
patients with metastatic colorectal cancer have liver-predominant disease which is the 
limiting factor determining patient survival (Kemeny et al., 1994; Rosen et al., 1995). 
Currently, chemotherapy is the first line of treatment prescribed to patients, but rarely 
produces significant antitumor results (Meyers et al., 2003). Second line therapies are thus 
pivotal in the treatment of colorectal liver metastases. 
In a phase I dose-escalating study twelve patients were divided equally into four cohorts 
receiving 3x106 plaque forming units (pfu), 1x107 pfu, 3x107 pfu or 1x108 pfu NV1020 via 
hepatic arterial infusion (Kemeny et al., 2006). NV1020 treatment was well tolerated; 
however, adverse events associated with virus administration occurred and included 
pyrexia, headache and rigors. Within the first forty-eight hours, minor elevations in liver 
enzymes occurred but were self-limiting without intervention and normalized shortly 
thereafter. Hepatic artery samples indicated viral clearance in all participants, including 
those receiving a dose of 1x108 pfu. With the exception of one patient, PCR analysis did not 
detect HSV DNA in saliva, urine, conjunctiva, vaginal, and serum samples. The HSV-
positive patient did not experience any HSV-specific adverse effects during the course of the 
study. Furthermore, levels of serum cytokines, including IL-1, IL-2, IFNγ, and TNFα, as well 
as cytotoxic T cell counts were measured one week following NV1020 treatment. Minor 
increases in serum IL-1, IL-2, IFNγ and TNFα occurred but with no apparent relationship to 
virus administration. Variations in cytotoxic T cell counts were minor and inconsistent 
among patients. Overall, at twenty-eight days post-treatment two patients exhibited 39% 
and 20% reductions in tumor size. Of the remaining patients, three showed tumor 
progression while seven achieved tumor stabilization. This study established that hepatic 
arterial infusion of NV1020 holds potential as a treatment for colorectal liver metastases. 
The phase I study by Kemeny et al. (2006) was used as the foundation for a multicentre 
phase I/II study evaluating the safety and antitumor effects of multiple doses of NV1020 in 
patients with colorectal liver metastases (Geevarghese et al., 2010). A total of thirteen and 
nineteen patients were enrolled in the phase I and II trials respectively. Each patient 
received four doses of NV1020 via hepatic arterial infusion followed by chemotherapy. The 
phase I cohort received doses of 3x106 pfu, 1x107 pfu, 3x107 pfu, and 1x108 pfu to determine 
the optimal dose for use in phase II trials. Adverse events associated with virus treatment 
were mild and did not involve altered liver function. PCR analysis failed to detect NV1020 
DNA in the serum, genital swabs, and saliva of patients. However, HSV-1 DNA was present 
in the samples of two patients but no HSV-related symptoms were observed. Moreover, 
serological levels of IL-6, TNFα and IFNγ transiently increased in a dose-dependent manor. 
Following NV1020 administration, 50% of patients exhibited stable disease and after 
subsequent chemotherapy 68% maintained this status. The one year survival was 47.2%, a 
significant increase compared to conventional outcomes. A phase III trial is currently 
underway for NV1020 treatment of colorectal liver metastases. 
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Virus Cancer Type Phase Participants Delivery Reference 
NV1020 
Colorectal liver 
metastases I 12 hepatic artery Kemeny et al., 2006 
Colorectal liver 
metastases I 13 hepatic artery
Geeverghese  
et al., 2010 
Colorectal liver 
metastases II 19 hepatic artery
Geeverghese  
et al., 2010 
HSV1716 
Recurrent glioma I 9 intratumoral Rampling et al., 2000 
High-grade 
glioma I 12 intratumoral
Papanastassiou  
et al., 2002 
Recurrent glioma I 12 intratumoral Harrow et al., 2004 
Malignant 
Melanoma I 5 intratumoral MacKie et al., 2001 
HNSCC I 20 intratumoral Mace et al., 2008 
G207 
Malignant 
glioma I 21 intratumoral Markert et al., 2000 
Malignant 
glioma Ib 6 intratumoral Markert et al., 2009 
Recurrent glioma I 9 intratumoral Karrasch et al., 2009 
OncoVEXGM-CSF 
Solid tumors I 30 intratumoral Hu et al., 2006 
HNSCC I/II 17 intratumoral Harrington  et al., 2010b 
Metastatic 






I 9 intratumoral Nakao et al., 2007 
pancreatic 
carcinoma I 6 intratumoral Nakao et al., 2011 
Table 2. Clinical Trials with Oncolytic Herpes Simplex Viruses (HNSCC; head and neck 
squamous cell carcinoma) 
3.2 HSV1716 clinical trials 
The use of HSV1716 in the treatment of patients with recurrent glioma and high grade 
glioma (HGG) has been evaluated in clinical trials. Current therapies for malignant 
glioma, including radiotherapy and chemotherapy, provide a median survival time of 
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only 1 year following diagnosis (Rampling et al., 1997; Rampling et al., 1998; Subach et al., 
1999). Patient survival following primary therapy is a staggering 5 months (Rajan et al., 
1994), warranting development of novel treatments which will prolong survival and 
improve patient outcomes. Preclinical data indicates the ability of HSV1716 to replicate in 
a wide variety of tumor types including those of central nervous system (CNS) origin 
(Brown et al., 1994; Randazzo et al., 1995). In murine models of malignant glioma 
HSV1716 induced significant tumor regression with minimal effect on normal CNS tissue 
(McKie et al., 1998).     
In a phase I dose escalation study nine patients with recurrent malignant glioma received an 
intratumoral injection of HSV1716 at doses ranging from 1x103-1x105 pfu (Rampling et al., 
2000). All patients had previously undergone radiotherapy and/or surgery and had since 
relapsed. Virus treatments were well tolerated with no adverse effects. In addition, PCR 
analysis failed to detect shed HSV1716 or HSV-1 DNA in patient buccal and serum samples. 
Furthermore, HSV-1 reactivation in the form of skin lesions did not occur. After 14 months, 
four patients remained alive with two in complete remission. This study demonstrated the 
feasibility and safety of HSV1716 for treatment of recurrent malignant glioma and 
constituted the framework for subsequent phase II clinical trials. 
An additional proof of principle study evaluated the toxicity and replication of HSV1716 
in patients with HGG (Papanastassiou et al., 2002). Twelve patients with HGG received an 
intratumoral injection of HSV1716 at 1x105 pfu. No adverse effects were observed 
following injection of the virus or throughout the duration of the study. At four to nine 
days post-injection, tumors were removed and assayed for the presence of virus. The 
tumors removed from two participants contained a higher concentration of virus than was 
injected and contained HSV-specific antigens. It should be noted that these patients were 
seronegative at the time of injection and subsequently seroconverted. Furthermore, virus 
replication was not detected in tumors of seropositive patients which could be the result 
of virus neutralization during the tumor resection process. However, PCR analysis 
detected HSV1716 DNA at the injection site of ten patients and at distal sites in four, 
including seropositive individuals. Together these data demonstrate that HSV1716 was 
able to selectively replicate in patient gliomas and spread to distal tumor sites despite the 
presence of pre-existing immunity in seropositive individuals. Further to the first study, 
this clinical trial added to the safety profile of HSV1716 for use in the treatment of 
malignant glioma. 
In the third clinical trial with HSV1716 for treatment of HGG, the virus was used to clear 
residual tumor cells after resection (Harrow et al., 2004). Following tumor resection, residual 
tumor cells remain within the resection cavity and ultimately divide to form a new tumor 
mass. A total of twelve patients were enrolled in the trial, six with recurrent disease and six 
newly diagnosed. Following tumor resection patients were injected with 1x105 pfu 
HSV17161 into adjacent brain tissue. In addition, eight to ten sites adjacent to the tumor bed 
were also injected. All patients received subsequent radiotherapy or chemotherapy. 
Magnetic resonance imaging (MRI) or computed tomography (CT) scans were taken pre- 
and postoperatively to monitor tumor regression and the structural anatomy of the 
surrounding brain tissue. Patients also underwent single photon emission computed 
tomography (SPECT) to identify HGG growth as indicated by areas of high cellular 
metabolic activity. At the time of tumor resection, patient tumor cells were collected for ex 
vivo HSV1716 replication analysis. Results indicate the ability of HSV1716 to replicate in 
HGG tumor cells. No significant adverse effects or toxicity associated with HSV1716 
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treatment was observed.  Overall, three patients were clinically stable up to twenty-two 
months post-treatment. Tumor regression was evident in the patient alive after twenty-two 
months as indicated by imaging analysis. The lack of viral-mediated toxicity post-HSV1716 
injection into normal brain tissue demonstrates the utility of this virus for use in 
combination therapy for patients with HGG.  
Preclinical studies indicate the ability of HSV1716 to selectively replicate in human 
melanoma cells in vitro and cause tumor regression in murine models of melanoma (MacKie 
et al., 2001). In a pilot study to ascertain the efficacy of HSV1716 treatment for melanoma, 
five HSV-1 seropositive patients with stage four melanoma received intratumoral injections 
of HSV1716 at 1x103 pfu (MacKie et al., 2001). Two patients received one injection, two 
received two injections and one received four injections. No adverse effects were observed 
and anti-HSV antibody titres did not significantly increase with treatment. Injected nodules 
were excised at fourteen (single injection) or twenty one (multiple injections) days post-
injection for assessment of pathology and virus replication. One patient showed flattening of 
tumor nodules twenty-one days post-injection while all participants had evidence of tumor 
necrosis. There was no indication of pathogenesis or necrosis in adjacent normal 
melanocytes. This study established the utility of HSV1716 as a treatment for melanoma, 
with replication and associated pathology restricted to tumor cells.  
Comparable to malignant glioma, the five year survival rates for patients with head and 
neck squamous cell carcinoma (HNSCC) ranges from 0-40% depending on localization of 
the tumor (Forastiere et al., 1998). Patient relapse rates and the high incidence of distant 
metastases makes HNSCC a formidable challenge requiring novel therapeutic options. A 
total of twenty patients with oral HNSCC received intratumoral injections of 1x105 pfu (five 
patients) or 5x105 pfu (fifteen patients) HSV1716 (Mace et al., 2008). Injections were well 
tolerated with no adverse effects associated with virus treatment. Of the patients enrolled in 
the study two were seronegative, but both seroconverted within a week of HSV1716 
injection. However, the seropositive cohort did not experience changes in anti-HSV 
antibody levels post-injection. Interestingly, PCR analysis detected HSV DNA in the blood 
of all patients receiving the lower dose of 1x105 pfu; however, no infectious virus was 
recovered from any tissue sample as determined by an infectious plaque assay. Tumor 
histology was negative for inflammation and necrosis at injection sites but infiltration of 
inflammatory lymphocytes was apparent.  Although significant tumor regression was not 
observed in this trial, results warrant a dose escalation study due to the established safety 
profile of HSV1716 for treatment of HNSCC.     
3.3 G207 Cclinical trials   
The HSV-1 mutant G207 has shown exceptional promise in clinical trials for the treatment of 
malignant glioma. Preclinical data shows that G207 is able to selectively replicate in tumor 
cells from a variety of histological origins including gliomas (Mineta et al., 1995). 
Furthermore, the non-pathogenic nature of G207 was confirmed through intracerebral 
injection of the virus into HSV-susceptible mice and simian primates (Hunter et al., 1999; 
Mineta et al., 1995). These data led to evaluation of G207 in a phase I dose escalation trial for 
the treatment of malignant glioma (Markert et al., 2000). Twenty one patients were enrolled 
in the study and received one of three intratumoral dosing regimens. Patients in the first 
cohort received doses ranging from 1x106 to 1x108 pfu, the second cohort received a single 
dose of 1x109 pfu, and the third cohort received a dose of 3x109 pfu at five distinct sites 
within the tumor mass. Three patients were included in each dose cohort and injection sites 
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were determined by contrast enhanced areas indicated on CT scans. All doses of G207 were 
well tolerated with no serious adverse effects associated with virus inoculation. Tumor 
biopsies were performed post-injection on six patients, and brains were obtained upon 
autopsy from five deceased patients. PCR analysis indicated the presence of G207 DNA in 
resected tumors obtained from patients at 56 and 157 days post-injection. However, viral 
shedding was absent from all patient saliva samples. Tumor regression was seen in eight 
patients ranging from four days to one month post-injection. Two patients have survived 
over four years and one patient died from causes unrelated to G207 treatment. The 
promising results borne from this trial are the cornerstones for design of a phase 1b trial 
involving G207 treatment of recurrent malignant glioma followed by tumor resection and 
tumor bed inoculation.  
Objectives of the phase 1b clinical trial were four fold (Markert et al., 2009). The safety of 
two intratumoral injections within a one week period was ascertained as well as the safety 
associated with direct injection of G207 into normal brain tissue. Furthermore, virus 
replication and the presence of anti-HSV immune effectors were measured in inoculated 
tumors. Six patients were enrolled in the study, each receiving two doses of G207 totalling 
1.5x109 pfu. Specifically, an initial intratumoral injection of 1.5x108 pfu was delivered via 
catheter followed by tumor resection two to five days later. Subsequent injections of G207 
were administered into brain tissue surrounding the resection cavity. Treatment was well 
tolerated with most adverse effects unrelated to G207 inoculation. PCR analysis did not 
detect HSV DNA in patient saliva, urine, conjunctiva and serum samples despite the 
presence of virus replication in resected tumor samples from three patients. Inflammation 
was not present at the inoculation site as determined through patient MRIs, and no 
patients developed viral encephalitis, even after two injections of G207. Tumor samples 
were obtained from one patient pre- and post-G207 treatment for immunohistochemical 
analysis. Prior to treatment only a small population of immune effectors, including 
lymphocytes and macrophages, were present in the tumor. However, two days post G207 
injection there was significant infiltration of mature T cells including cytotoxic T cells, 
monocytes, macrophages, microglia, and NK cells (Figure 3). The presence of B cells was 
also detected in the tumor sample but at much lower levels. All seronegative patients 
subsequently seroconverted following G207 treatment and half of seropositive 
participants experienced an increase in anti-HSV antibody titres. Due to the small sample 
size no conclusions regarding the efficacy of G207 treatment can be drawn. However, 
according to MRI analysis no participants achieved a complete or partial response, 
defined as a 50% decrease in contrast enhancing tumor volume following G207 
administration. Results from this study warrant the progression of G207 therapy for 
malignant glioma to phase II clinical trials. 
A combination therapy study for the treatment of recurrent malignant glioma demonstrated 
an additive effect of G207 and radiotherapy (Karrasch et al., 2009). In a phase I clinical trial, 
nine patients received intratumoral injections of 1x109 pfu G207 followed by focal 
radiotherapy (5 Gray) twenty four hours later. Combination therapy was well tolerated and 
dose-limiting toxicities were not reached. Patients achieving a partial response were re-
treated with G207 and radiotherapy one month following initial treatment due to tumor 
recurrence. The median survival times for patients suffering from relapsed gliomablastoma 
multiforme and anaplastic astrocytoma was 7.4 and 9.25 months, respectively. HSV DNA 
was detected within tumors indicating intratumoral G207 replication. Overall, G207 
combination therapy prolonged patient survival over traditional treatment modalities. 
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Fig. 3. Tumor-infiltrating lymphocytes and macrophages in patient tumor tissue pre- and 
post-G207 treatment. Immunohistochemical staining was performed on paraffin blocks of 
patient tumor samples pre- and post-G207 treatment using antibodies against CD3 
(infiltrating T cells), CD8 (cytotoxic and suppressor T cells), CD20 (B cells), and HAM56 
(monocyte/macrophage). 
3.4 OncoVEXGM-CSF clinical trials 
Generation of OncoVEXGM-CSF was prompted by the success of other HSV vectors as well as 
the need for increased antitumor immune activity during therapy.  
A phase I study involving thirty patients with breast, head and neck, gastrointestinal, and 
melanoma malignancies evaluated the safety and antitumor activity of OncoVEXGM-CSF 
(Hu et al., 2006). Participants were divided into two cohorts, thirteen received a single 
intratumoral injection at one of three dose levels (1x106 pfu, 1x107 pfu and 1x108 pfu), and 
the remaining seventeen were placed in a multi-dose group and received escalating doses 
of virus every one to three weeks. All doses were well tolerated with no adverse events 
associated with virus treatment occurring in either the single or multi-dose groups. 
However, seronegative participants experienced more pronounced injection site irritation 
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which eventually cleared without intervention. It was also observed that all seronegative 
individuals seroconverted within three to four weeks of their first injection of 
OncoVEXGM-CSF. Transient elevations in anti-HSV antibody titres occurred in seropositive 
patients but did not limit therapeutic efficacy. PCR analysis detected HSV DNA in the 
blood of two patients in the single dose cohort (eight hours and one week post-injection) 
and in eight patients in the multi-dose cohort (one and eight hours post-injection). Low 
levels of HSV DNA were detected in the urine of two patients in the single dose cohort 
(eight hours and one week post-injection), and no patients tested positive in the multi-
dose cohort. Viral DNA was not detected at any other time points during the study. 
Tumor biopsies indicated the infiltration of immune effectors following OncoVEXGM-CSF 
injection, including increases in T cell and macrophage populations. Areas of tumor 
necrosis were found to correspond to sites of virus injection, while normal tissue showed 
no evidence of necrosis. Stable disease was detected in three patients, two with melanoma 
and one with breast cancer. Furthermore, the injected tumors of several patients with 
metastatic melanoma regressed or were cleared but other metastatic lesions appeared at 
distal sites. No partial or complete responses were reached in this study but the safety and 
tumoristatic effects of OncoVEXGM-CSF treatment on injected and distal tumors was 
established. 
The phase I trial by Hu et al. (2006) established the safety and efficacy of OncoVEXGM-CSF for 
the treatment patients with metastatic melanoma, laying the ground work for a phase II 
clinical trial (Senzer et al., 2009). A total of fifty patients with stage IIIc (10) or stage IV (40) 
metastatic melanoma received an initial intratumoral injection of OncoVEXGM-CSF at 1x106 
pfu to seroconvert patients who were seronegative and to reduce adverse effects associated 
with virus injection, as primarily seen in seronegative patients. Three weeks later patients 
received another intratumoral injection at 1x108 pfu, which was repeated every two weeks 
thereafter. Tumors were injected based on size with a maximum of ten treated per visit. The 
adverse effects associated with OncoVEXGM-CSF administration were primarily mild in 
nature. However, ten patients experienced fatigue, dyspnea, and pain which was possibly 
disease related. Injection site swabs and urine were collected from patients and analyzed for 
the presence of HSV DNA by PCR. Analysis detected HSV DNA from the swab of one 
patient at very low levels, while no urine contained viral DNA. Local effects on OncoVEXGM-
CSF-injected tumors were apparent after as few as two treatments, but regression of distal 
tumors typically occurred twelve months after the first treatment. Overall, ten patients 
achieved complete response without additional surgery and thirteen did not have evidence 
of disease after further surgical tumor resection. Interestingly, HSV serostatus did not seem 
to play a role in response to OncoVEXGM-CSF therapy. The prolonged survival (>1 year) of 
patients enrolled in this study and the antitumor activity of OncoVEXGM-CSF prompted 
approval of a phase III study, which is currently underway.     
A study by Kaufman et al. (2010) evaluated local and distal immune responses in patients 
enrolled in the phase II Senzer et al. (2009) clinical trial. Peripheral blood and tumor samples 
were analyzed for the presence of myeloid-derived suppressive cells (MDSC), regulatory T 
cells (Treg, CD4+ FOXP3+) and suppressor T cells (Ts, CD8+ FOXP3+). Significant increases 
in the level of peripheral and tumor-associated antigen-specific T cells (MART-1) were 
observed following OncoVEXGM-CSF injection. Notable decreases in Treg and Ts cell 
populations occurred in injected tumors in comparison to non-injected distal tumors. This 
may be due to decreases in MDSCs which have been shown to negatively regulate activator 
T cell activity by diverting them to a regulatory phenotype. 
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Fig. 4. Patient 703 Response to OncoVEXGM-CSF Therapy. CT images of injections sites in the 
left shoulder, retroperitoneal lymph node, and lungs at baseline (left) and three months 
(right). Positron emission tomography (PET) image at baseline (left) and at eight months 
(right). Highlighted areas indicate lesions before and after OncoVEXGM-CSF injection.  
A combination therapy phase I/II trial for the treatment of stage III/IVA head and neck 
squamous cell carcinoma demonstrated an additive effect of OncoVEXGM-CSF and chemo 
radiotherapy (CRT) (Harrington et al., 2010b). Seventeen patients were enrolled in the study 
and received dose escalating OncoVEXGM-CSF (cohort one: four injections at 1x106 pfu; cohort 
two: 1x106 pfu followed by three injections at 1x107 pfu; cohort three: 1x106 pfu followed by 
three injection at 1x108 pfu) intratumoral injections on days one, twenty two, forty three and 
sixty four. Patients were treated with full-dose radical CRT comprised of radiotherapy (70 
Gray) in thirty five daily fractions over seven weeks with cisplatin administered on days 
one, twenty one and forty two at 100 mg/m2 body surface area. Treatment was well 
tolerated and dose-limiting toxicities were not identified in any cohorts. Viral shedding was 
detected at transient low levels in three patients. HSV DNA was detected at levels higher 
than the input dose in injected and adjacent uninjected tumors by immunohistochemistry 
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and PCR analysis. All seronegative patients seroconverted and increased antibody titres 
were measured in all patients in a dose-dependent manor. Overall, thirteen patients 
achieved partial or complete response including five whom achieved complete response 
following only two or three doses of OncoVEXGM-CSF. All patients achieved loco-regional 
control with 70.5% remaining alive and in complete remission at the time of publication. A 
phase III study is currently underway. 
3.5 HF10 clinical trials 
The HF10 oncolytic vector is a naturally mutated clonal derivative of patient strain HF 
which contains inactivating mutations in UL43, UL49.5, UL55, UL56 and LAT coding 
sequences (Takakuwa et al., 2003). Although the function of UL56 is unknown, UL43, UL49.5 
and UL55, encode membrane, envelope and tegument proteins, respectively. Preclinical data 
has shown that HF10 therapy causes significant tumor regression and prolongs survival in 
animal models of breast and colon carcinoma (Kimata et al., 2003; Teshigahara et al., 2004). 
Furthermore, cured mice were refractory to tumor re-challenge indicating that an antitumor 
immune response was established.  
A phase I trial to evaluate the safety and antitumor activity of HF10 was performed on six 
patients with recurrent breast carcinoma (Nakao et al., 2007). Patients were chosen with 
metastatic skin lesions to facilitate administration of the virus subcutaneously. Patients 
received 1x104 pfu, 1x105 pfu or 1x105 pfu for three days, 5x105 pfu or 5x105 pfu for three 
days. Tumor nodules were excised fourteen days post-injection for evaluation of virus 
pathology and replication. The same treatment regimen was adopted for three patients 
with non-resectable pancreatic carcinoma except HF10 was delivered via intratumoral 
catheter. HF10 therapy was well tolerated with no adverse events associated with virus 
administration in either the breast or pancreatic carcinoma participants. Analysis of 
excised tumor samples revealed significant decreases in tumor cell viability (30-100%) 
associated with virus replication. Tumor regression was evident in the skin nodule of one 
patient with recurrent breast carcinoma, but no other significant decreases in tumor 
volume were noted.  
An additional phase I clinical trial was performed on six patients with non-resectable 
pancreatic tumors caused by liver metastases and invasion of lymph nodes surrounding the 
aorta (Nakao et al., 2011). Intratumoral injection of HF10 (1x106 pfu) was performed at four 
sites during laparotomy or with the aid of CT imaging. An intratumoral catheter was 
inserted during surgery for subsequent delivery of three daily doses of HF10 for three days. 
No adverse effects associated with HF10 treatment were observed during the trial. PCR 
analysis failed to detect HSV DNA in blood samples and abdominal cavities of patients, but 
prolonged viral expression was evident in several patient tumors up to 318 days post-
injection. Moreover, analysis of resected tumor samples indicated significant infiltration of 
macrophages, CD4+ and CD8+ T cells into HF10-injected tumor tissue. Upon completion of 
this trial four patients achieved partial response while the remaining two maintained 
progressive disease status. Together, these studies demonstrate the efficacy of HF10 for use 
in oncolytic virotherapy for the treatment of patients with breast and pancreatic carcinoma.  
4. Challenges with oncolytic virotherapy 
The safety and antitumor efficacy of HSV-1 vectors in clinical trials has inspired the 
development of treatment platforms using engineered and natural oncolytic viruses, as well 
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and received dose escalating OncoVEXGM-CSF (cohort one: four injections at 1x106 pfu; cohort 
two: 1x106 pfu followed by three injections at 1x107 pfu; cohort three: 1x106 pfu followed by 
three injection at 1x108 pfu) intratumoral injections on days one, twenty two, forty three and 
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detected at transient low levels in three patients. HSV DNA was detected at levels higher 
than the input dose in injected and adjacent uninjected tumors by immunohistochemistry 
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and PCR analysis. All seronegative patients seroconverted and increased antibody titres 
were measured in all patients in a dose-dependent manor. Overall, thirteen patients 
achieved partial or complete response including five whom achieved complete response 
following only two or three doses of OncoVEXGM-CSF. All patients achieved loco-regional 
control with 70.5% remaining alive and in complete remission at the time of publication. A 
phase III study is currently underway. 
3.5 HF10 clinical trials 
The HF10 oncolytic vector is a naturally mutated clonal derivative of patient strain HF 
which contains inactivating mutations in UL43, UL49.5, UL55, UL56 and LAT coding 
sequences (Takakuwa et al., 2003). Although the function of UL56 is unknown, UL43, UL49.5 
and UL55, encode membrane, envelope and tegument proteins, respectively. Preclinical data 
has shown that HF10 therapy causes significant tumor regression and prolongs survival in 
animal models of breast and colon carcinoma (Kimata et al., 2003; Teshigahara et al., 2004). 
Furthermore, cured mice were refractory to tumor re-challenge indicating that an antitumor 
immune response was established.  
A phase I trial to evaluate the safety and antitumor activity of HF10 was performed on six 
patients with recurrent breast carcinoma (Nakao et al., 2007). Patients were chosen with 
metastatic skin lesions to facilitate administration of the virus subcutaneously. Patients 
received 1x104 pfu, 1x105 pfu or 1x105 pfu for three days, 5x105 pfu or 5x105 pfu for three 
days. Tumor nodules were excised fourteen days post-injection for evaluation of virus 
pathology and replication. The same treatment regimen was adopted for three patients 
with non-resectable pancreatic carcinoma except HF10 was delivered via intratumoral 
catheter. HF10 therapy was well tolerated with no adverse events associated with virus 
administration in either the breast or pancreatic carcinoma participants. Analysis of 
excised tumor samples revealed significant decreases in tumor cell viability (30-100%) 
associated with virus replication. Tumor regression was evident in the skin nodule of one 
patient with recurrent breast carcinoma, but no other significant decreases in tumor 
volume were noted.  
An additional phase I clinical trial was performed on six patients with non-resectable 
pancreatic tumors caused by liver metastases and invasion of lymph nodes surrounding the 
aorta (Nakao et al., 2011). Intratumoral injection of HF10 (1x106 pfu) was performed at four 
sites during laparotomy or with the aid of CT imaging. An intratumoral catheter was 
inserted during surgery for subsequent delivery of three daily doses of HF10 for three days. 
No adverse effects associated with HF10 treatment were observed during the trial. PCR 
analysis failed to detect HSV DNA in blood samples and abdominal cavities of patients, but 
prolonged viral expression was evident in several patient tumors up to 318 days post-
injection. Moreover, analysis of resected tumor samples indicated significant infiltration of 
macrophages, CD4+ and CD8+ T cells into HF10-injected tumor tissue. Upon completion of 
this trial four patients achieved partial response while the remaining two maintained 
progressive disease status. Together, these studies demonstrate the efficacy of HF10 for use 
in oncolytic virotherapy for the treatment of patients with breast and pancreatic carcinoma.  
4. Challenges with oncolytic virotherapy 
The safety and antitumor efficacy of HSV-1 vectors in clinical trials has inspired the 
development of treatment platforms using engineered and natural oncolytic viruses, as well 
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as combination therapy trials. Despite promising results in preclinical studies, in vitro assays 
do not always predict in vivo outcomes. These discrepancies can be attributed to the 
challenges of adapting therapy from cell culture to in vivo tumors which contain a plethora 
of hurdles to both virus replication and tumor clearance.  
4.1 The tumor microenvironment 
The heterogeneity of the tumor mass, including necrotic foci, normal stroma, the basal 
membrane and extracellular matrix (ECM), presents a formidable road block to virus 
penetration. Furthermore, viral infection often elicits host inflammatory responses resulting 
in increased recruitment of immune effectors. Overall, the effects of the tumor 
microenvironment may counteract the antitumor effects of oncolytic virotherapy.   
The ECM forms a complex molecular sieve which regulates cell signalling processes 
between tumor and normal stromal cells. Modifications to the ECM impact tumor biology 
and accessibility, and therefore the response to therapy. McKee et al. (2006) demonstrated 
that fibrillar collagen acts as a barrier to HSV-1 vector MGH2 spread within melanoma. 
Viral particles localized to collagen-free areas of the tumor with limited spread to collagen-
rich regions. Co-treatment of tumors with MGH2 and collagenase enhanced virus spread 
and tumor regression. In addition, viruses expressing enzymes such as matrix 
metalloproteinases (MMPs), which degrade ECM components, could be used. 
Chondroitinase ABC (Chase-ABC) is a bacterial enzyme which cleaves chondroitin sulphate 
glycosaminoglycans from proteoglycans. In comparison to the control (rHsvQ), the 
oncolytic HSV-1 vector expressing Chase-ABC (OV-Chase) enhanced viral spread, inhibited 
tumor growth, and prolonged survival of animals with subcutaneous and intracranial 
glioma xenografts (Dmitrieva et al., 2011). Furthermore, the ectopic expression of MMP-9 on 
murine malignant glioma xenografts has been shown to increase spread of the oncolytic 
HSV-1 vector JD0G through degradation of collagen type IV, a major component of the ECM 
and basal membrane.  
Angiogenesis is crucial to tumor growth as vasculature provides a network from which cells 
obtain oxygen, metabolites and dispose of waste. Disruption of the balance between pro- 
and anti-angiogenic factors is caused by changes in the tumor microenvironment such as 
hypoxia, acidosis, inflammation and gene mutations. Ultimately, an ‘angiogenic switch’ 
occurs which leads to increased synthesis of vasculature supporting rapid tumor growth. 
Necrotic, acidotic, and hypoxic areas result, in part, from abnormalities in tumor vasculature 
such as aberrations in the morphology of endothelial cells and mechanical stress on 
developing vessels from rapidly proliferating tumor cells. Infection of tumor cells with 
oncolytic viruses can have both pro- and anti-angiogenic effects. Infection of ovarian tumor 
endothelial cells with HSV1716 has been shown to disrupt tumor vasculature (Benencia et 
al., 2005). Conversely, infection of human glioma cells with G207 reduces expression of 
thrombospondin, resulting in increased vasculature (Aghi et al., 2007). This effect can be 
countered through the administration of thrombospondin-derived peptides. In models of 
glioblastoma, cases where oncolytic virus infection results in an anti-angiogenic response, 
adjacent virus-free areas have been shown to upregulate angiogenesis (Huszthy et al., 2010). 
Furthermore, increases in tumor angiogenesis can facilitate virus-induced inflammatory 
responses. The resultant changes in vascular perfusion can lead to hypoxia-mediated killing 
of uninfected tumor cells (Breitbach et al., 2007) and increased vascular leakage due to 
vascular shutdown and hyperpermeability, respectively (Kurozumi et al., 2007). The impact 
of vascularity on oncolytic virotherapy and vice versa has inspired combination therapy 
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trials using anti-angiogenic drugs such as Bevacizumab (Willett et al., 2004), Trichostatin A 
(Liu et al., 2008) and Cilengitide (Kurozumi et al., 2007). In addition, oncolytic vectors 
expressing anti-angiogenic genes have been engineered to modulate the activity of factors 
such as vascular epithelial growth factor (VEGF), MMPs, fibroblast growth factors (FGF), 
and interleukins. Rapid anti-angiogenesis mediated by oncolytic virus (RAMBO), a novel 
HSV-1 vector expressing vasculostatin, a brain-specific angiostatic peptide, has been used in 
the treatment of subcutaneous and intracranial gliomas. Compared to a control virus, 
intratumoral injection of RAMBO resulted in tumor regression and enhanced antitumor 
effects including decreased tumor vascularity, microvessel density, and angiogenesis 
(Hardcastle et al., 2010). 
4.2 Virus delivery 
The importance of diffuse inoculation has been illustrated in mathematical models of virus 
replication. Three methods of intratumoral inoculation including injection into the entire 
tumor, the tumor core and the tumor rim were analyzed for their ability to eradicate the entire 
tumor in the presence of necrosis and an innate immune response (Wein et al., 2003). Data 
from preclinical and clinical trials were used to design the model and identify parameter 
values. Even in the absence of an innate immune response, complete tumor regression requires 
widespread distribution of the virus achieved by multiple injections into the entire tumor. 
However, an antiviral innate immune response can prevent tumor eradication, warranting 
methods for immune evasion to ensure efficient virus spread. While intratumoral injection is 
feasible for easily accessible and solid tumors, systemic delivery options are necessary for the 
treatment of metastatic disease and non-accessible tumors. Virus inactivation by neutralizing 
antibodies, innate immune responses, complement-mediated opsonisation, and insufficient 
adsorption limit the efficacy of systemic delivery options. Delivery of oncolytic vectors within 
a collagen matrix or liposomes could be used to minimize premature inactivation by immune 
surveillance mechanisms. Alternatively, transient immunosuppression using antibody 
neutralizing compounds, inhibiting B cell maturation or antibody-receptor interactions may 
allow for efficient vector delivery. Administration of anti-CD20 antibodies, CPA, and 
plasmapheresis has been used to inhibit immunoglobulin production by B cells and counteract 
the neutralizing activity of antiviral antibodies (Ikeda et al., 2000; Vile et al., 2002). For instance, 
pretreatments of cobra venom factor (CVF) and CPA followed by intravascular injection of 
hrR3 leads to increased viral spread and prolonged survival in a rat model of malignant 
glioma (Ikeda et al., 2000). Although studies have indicated that pre-existing antibodies to 
HSV-1 do not limit antitumor efficacy of oncolytic virus treatment, seronegative patients have 
a higher incidence of adverse effects from virus inoculation (Chahlavi et al., 1999; Lambright et 
al., 2000; Hu et al., 2006). In a phase II study for the treatment of metastatic melanoma, 
seronegative participants received an initial intratumoral injection of OncoVEXGM-CSF to induce 
seroconvertion (Senzer et al., 2009). This pre-treatment reduced adverse effects associated with 
virus injection.  
Although increasing input dose is a tempting strategy to augment low infectivity from 
vector loss during systemic delivery, current manufacturing processes limit attainable HSV 
titres to 3x109 pfu/mL (Varghese & Rabkin, 2002). The use of a wild type virus, which does 
not require attenuation to achieve selective oncolysis, could facilitate manufacturing 
processes and yield higher titres. The use of replication-competent vectors is another 
method by which the input dose can be amplified. However, care should be taken to direct 
the tropism of such viruses to preclude unwanted replication within normal healthy tissue.  
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glioma xenografts (Dmitrieva et al., 2011). Furthermore, the ectopic expression of MMP-9 on 
murine malignant glioma xenografts has been shown to increase spread of the oncolytic 
HSV-1 vector JD0G through degradation of collagen type IV, a major component of the ECM 
and basal membrane.  
Angiogenesis is crucial to tumor growth as vasculature provides a network from which cells 
obtain oxygen, metabolites and dispose of waste. Disruption of the balance between pro- 
and anti-angiogenic factors is caused by changes in the tumor microenvironment such as 
hypoxia, acidosis, inflammation and gene mutations. Ultimately, an ‘angiogenic switch’ 
occurs which leads to increased synthesis of vasculature supporting rapid tumor growth. 
Necrotic, acidotic, and hypoxic areas result, in part, from abnormalities in tumor vasculature 
such as aberrations in the morphology of endothelial cells and mechanical stress on 
developing vessels from rapidly proliferating tumor cells. Infection of tumor cells with 
oncolytic viruses can have both pro- and anti-angiogenic effects. Infection of ovarian tumor 
endothelial cells with HSV1716 has been shown to disrupt tumor vasculature (Benencia et 
al., 2005). Conversely, infection of human glioma cells with G207 reduces expression of 
thrombospondin, resulting in increased vasculature (Aghi et al., 2007). This effect can be 
countered through the administration of thrombospondin-derived peptides. In models of 
glioblastoma, cases where oncolytic virus infection results in an anti-angiogenic response, 
adjacent virus-free areas have been shown to upregulate angiogenesis (Huszthy et al., 2010). 
Furthermore, increases in tumor angiogenesis can facilitate virus-induced inflammatory 
responses. The resultant changes in vascular perfusion can lead to hypoxia-mediated killing 
of uninfected tumor cells (Breitbach et al., 2007) and increased vascular leakage due to 
vascular shutdown and hyperpermeability, respectively (Kurozumi et al., 2007). The impact 
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trials using anti-angiogenic drugs such as Bevacizumab (Willett et al., 2004), Trichostatin A 
(Liu et al., 2008) and Cilengitide (Kurozumi et al., 2007). In addition, oncolytic vectors 
expressing anti-angiogenic genes have been engineered to modulate the activity of factors 
such as vascular epithelial growth factor (VEGF), MMPs, fibroblast growth factors (FGF), 
and interleukins. Rapid anti-angiogenesis mediated by oncolytic virus (RAMBO), a novel 
HSV-1 vector expressing vasculostatin, a brain-specific angiostatic peptide, has been used in 
the treatment of subcutaneous and intracranial gliomas. Compared to a control virus, 
intratumoral injection of RAMBO resulted in tumor regression and enhanced antitumor 
effects including decreased tumor vascularity, microvessel density, and angiogenesis 
(Hardcastle et al., 2010). 
4.2 Virus delivery 
The importance of diffuse inoculation has been illustrated in mathematical models of virus 
replication. Three methods of intratumoral inoculation including injection into the entire 
tumor, the tumor core and the tumor rim were analyzed for their ability to eradicate the entire 
tumor in the presence of necrosis and an innate immune response (Wein et al., 2003). Data 
from preclinical and clinical trials were used to design the model and identify parameter 
values. Even in the absence of an innate immune response, complete tumor regression requires 
widespread distribution of the virus achieved by multiple injections into the entire tumor. 
However, an antiviral innate immune response can prevent tumor eradication, warranting 
methods for immune evasion to ensure efficient virus spread. While intratumoral injection is 
feasible for easily accessible and solid tumors, systemic delivery options are necessary for the 
treatment of metastatic disease and non-accessible tumors. Virus inactivation by neutralizing 
antibodies, innate immune responses, complement-mediated opsonisation, and insufficient 
adsorption limit the efficacy of systemic delivery options. Delivery of oncolytic vectors within 
a collagen matrix or liposomes could be used to minimize premature inactivation by immune 
surveillance mechanisms. Alternatively, transient immunosuppression using antibody 
neutralizing compounds, inhibiting B cell maturation or antibody-receptor interactions may 
allow for efficient vector delivery. Administration of anti-CD20 antibodies, CPA, and 
plasmapheresis has been used to inhibit immunoglobulin production by B cells and counteract 
the neutralizing activity of antiviral antibodies (Ikeda et al., 2000; Vile et al., 2002). For instance, 
pretreatments of cobra venom factor (CVF) and CPA followed by intravascular injection of 
hrR3 leads to increased viral spread and prolonged survival in a rat model of malignant 
glioma (Ikeda et al., 2000). Although studies have indicated that pre-existing antibodies to 
HSV-1 do not limit antitumor efficacy of oncolytic virus treatment, seronegative patients have 
a higher incidence of adverse effects from virus inoculation (Chahlavi et al., 1999; Lambright et 
al., 2000; Hu et al., 2006). In a phase II study for the treatment of metastatic melanoma, 
seronegative participants received an initial intratumoral injection of OncoVEXGM-CSF to induce 
seroconvertion (Senzer et al., 2009). This pre-treatment reduced adverse effects associated with 
virus injection.  
Although increasing input dose is a tempting strategy to augment low infectivity from 
vector loss during systemic delivery, current manufacturing processes limit attainable HSV 
titres to 3x109 pfu/mL (Varghese & Rabkin, 2002). The use of a wild type virus, which does 
not require attenuation to achieve selective oncolysis, could facilitate manufacturing 
processes and yield higher titres. The use of replication-competent vectors is another 
method by which the input dose can be amplified. However, care should be taken to direct 
the tropism of such viruses to preclude unwanted replication within normal healthy tissue.  
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4.3 The immune response 
The infiltration of host immune cells into the tumor microenvironment is an important 
factor modulating the success of oncolytic virotherapy. Innate and adaptive immune 
responses can limit virus spread resulting in suboptimal tumor clearance and persistence of 
residual tumor cells. Treatment of metastatic glioma using oncolytic HSV-1 vectors results in 
an inflammatory response and increased vasodilation induced by expression of IFNγ and 
ISGs (Kurozumi et al., 2007). This prompts the infiltration of innate and adaptive immune 
cells causing a decrease in virus replication and spread. Controlling the entry of immune 
cells into the tumor microenvironment can be used to increase virus replication. Analysis of 
glioma tissue samples treated with hrR3 indicates acute depletion of virus particles due to 
infiltration of CD68+ and CD163+ monocytes, microglia and macrophages (Fulci et al., 
2006). Depletion of these cell populations in intracranial gliomas through systemic delivery 
of CPA decreased intratumoral infiltration resulting in increased hrR3 titres, viral 
persistence within the tumor and prolonged survival (Fulci et al., 2007). Alternatively, 
viruses which spread by intracellular methods evade virus-specific antibodies and the 
complement system. HSV-1 vectors expressing the fusogenic membrane glycoprotein (FMG) 
have shown that the formation of multinucleated syncytia can aid in viral spread and 
enhance the antitumor response (Galanis et al., 2001; Nakamori et al., 2003).  
In a seemingly contradictory paradigm, immunostimulatory vectors can augment the efficacy 
of oncolytic virotherapy by inducing an immune response against the virus as well as the 
tumor. It has been well established that induction of an antitumor immune response is vital to 
achieving complete and lasting tumor regression. The HSV-1 vector G47∆ contains a deletion 
in the ICP47 gene, which functions to block antigen presentation via MHC class I molecules. 
Accordingly, tumor cells infected with G47∆ show enhanced stimulation of tumor-associated T 
cells due to increased expression of MHC class I molecules compared to cells infected with 
G207 which expresses functional ICP47 (Todo et al., 2001b). In an immunocompetent model of 
neuroblastoma, G47∆ treatment enhanced tumor regression and prolonged survival compared 
to G207, which elicited tumor regression but did not significantly affect survival (Todo et al., 
2001b). Furthermore, a combination therapy trial involving co-administration of G47∆ with 
immature DCs resulted in significant reductions in tumor volume and increased survival 
attributed to substantial lymphocyte infiltration and robust antitumor immunity (Farrell et al., 
2008). The expression of peptides derived from the epitopes of tumor-associated antigens 
(TAAs) has been incorporated into replication-defective vectors to amplify cytotoxic T 
lymphocyte (CTL) responses (Rosenberg et al., 2004). However, the antitumor effects of these 
vectors are meagre due to immune tolerance which inhibits efficacy of the CTL response 
(Rosenberg et al., 2004; Frey et al., 2006). Replication-competent vectors expressing 
immunogenic model antigens circumvent tolerance and allow for sustained CTL responses 
against the bulk of the tumor due to virus spread. In a dual vaccination strategy Zhang et al. 
(2009) injected murine ovarian surface epithelial carcinomas (MOSECs) with vaccinia virus 
expressing ovalbumin (VV-OVA) followed by Semliki Forest Virus also expressing ovalbumin 
(SFV-OVA), or vice versa. Immune tolerance was not established and an enhanced OVA-
specific CTL response and antitumor effect was observed in comparison to treatment with the 
wild type viruses. This demonstrates the efficacy of the bimodal approach of oncolytic 
virotherapy, including viral oncolysis and tumor-specific immune responses. 
4.4 Safety 
Concerns regarding the use of oncolytic HSV vectors in cancer therapy focus on the risk of 
unwanted replication in normal healthy tissue. HSV-1 is able to infect a wide variety of cell 
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types due to the ubiquitous expression of its cellular receptor in multiple human tissues. 
This presents a danger for wide-spread replication, especially when patients receiving 
oncolytic virotherapy are most likely immunosuppressed and highly susceptible to viral 
infection. Therefore, mechanisms to ensure accurate viral targeting and methods to control 
unwanted replication are required. Use of tissue and tumor-specific promoters, or cellular 
receptor-mediated targeting can be used to direct tumor-specific infection. Furthermore, Tet-
off, Cre-recombinase, HSV-tk/gancyclovir regulation systems, and incorporation of suicide 
genes into oncolytic vectors provide a safeguard to restrict unwanted replication, should it 
occur. Safety evaluations in preclinical studies should include careful considerations of dose 
limiting toxicity, potential of reversion or acquisition of virulent phenotypes, altered 
tropism, and the effect of transgene expression on the host. Choosing an appropriate animal 
model is imperative to accurately evaluate vectors for clinical use.  
Results from clinical trials using oncolytic HSV-1 vectors are promising. Adverse effects are 
non-life threatening, including moderate to mild flu-like symptoms and injection site 
irritation demonstrating the safety profile of this treatment modality. In many cases 
complete responses were observed resulting in prolonged patient survival and therefore, 
initiation of subsequent clinical trials. Oncolytic vectors, especially HSV-1-based, are rookies 
in the field of cancer therapy. However, with careful coaching they have the potential to 
achieve all-star status.      
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1. Introduction 
Despite the development of various cancer treatments, including surgical treatment, 
radiation, and anti-cancer reagents, cancer cells are not completely eliminated from the body 
in many cases, which allows the tumors to recur. Disease recurrence is the most difficult 
problem in cancer treatment.  Much attention has been paid to cancer immunotherapy as a 
strategy to eliminate cancer cells from patients (1).  However, numerous failures of cancer 
immunotherapy have indicated the difficulty of achieving anti-cancer immunity (1, 2).  
Cancer tissues produce factors that attenuate anti-tumor immunity and eventually induce 
immunotolerance against cancers in tumor-bearing individuals (3, 4).  Therefore, to 
successfully eradicate cancer, first the tumor mass must be reduced as much as possible 
through surgery, radiation and chemotherapy; then, immunotherapy should be provided to 
increase the immune-activation signals and decrease the immune-suppression signals (5-7).  
Thus, multi-lateral strategies are needed in cancer treatment.   Gene therapy has been 
anticipated to be a new tool for cancer treatment (8).  Much attention has been also paid to 
immuno-gene therapy (9).  However, it is still very difficult to achieve long-term remissions 
in cancer patients (10).  Based on the concept of multi-lateral strategies, the control of 
multiple pathways of cancer growth is also necessary in gene therapy.  We have developed 
a hemagglutinating virus of Japan envelope (HVJ-E) vector by using inactivated Sendai 
virus as a pseudovirion for gene and drug delivery (11). This vector can deliver siRNA, 
DNA, proteins, and anti-cancer drugs to cells in vitro and in vivo (12). 
We previously reported that HVJ-E itself has a strong anti-tumor effect against mouse 
tumors, such as colon carcinoma and renal carcinoma, by the activation of cytotoxic T 
lymphocytes and natural killer cells and the suppression of regulatory T cells (13, 14). 
Recently, we also determined the direct tumor-killing activity of HVJ-E through the 
induction of type I interferon on hormone-resistant human prostate cancer cells and human 
glioblastoma cells (15, 16).  Thus, HVJ-E is a versatile gene and drug delivery vector with 
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1. Introduction 
Despite the development of various cancer treatments, including surgical treatment, 
radiation, and anti-cancer reagents, cancer cells are not completely eliminated from the body 
in many cases, which allows the tumors to recur. Disease recurrence is the most difficult 
problem in cancer treatment.  Much attention has been paid to cancer immunotherapy as a 
strategy to eliminate cancer cells from patients (1).  However, numerous failures of cancer 
immunotherapy have indicated the difficulty of achieving anti-cancer immunity (1, 2).  
Cancer tissues produce factors that attenuate anti-tumor immunity and eventually induce 
immunotolerance against cancers in tumor-bearing individuals (3, 4).  Therefore, to 
successfully eradicate cancer, first the tumor mass must be reduced as much as possible 
through surgery, radiation and chemotherapy; then, immunotherapy should be provided to 
increase the immune-activation signals and decrease the immune-suppression signals (5-7).  
Thus, multi-lateral strategies are needed in cancer treatment.   Gene therapy has been 
anticipated to be a new tool for cancer treatment (8).  Much attention has been also paid to 
immuno-gene therapy (9).  However, it is still very difficult to achieve long-term remissions 
in cancer patients (10).  Based on the concept of multi-lateral strategies, the control of 
multiple pathways of cancer growth is also necessary in gene therapy.  We have developed 
a hemagglutinating virus of Japan envelope (HVJ-E) vector by using inactivated Sendai 
virus as a pseudovirion for gene and drug delivery (11). This vector can deliver siRNA, 
DNA, proteins, and anti-cancer drugs to cells in vitro and in vivo (12). 
We previously reported that HVJ-E itself has a strong anti-tumor effect against mouse 
tumors, such as colon carcinoma and renal carcinoma, by the activation of cytotoxic T 
lymphocytes and natural killer cells and the suppression of regulatory T cells (13, 14). 
Recently, we also determined the direct tumor-killing activity of HVJ-E through the 
induction of type I interferon on hormone-resistant human prostate cancer cells and human 
glioblastoma cells (15, 16).  Thus, HVJ-E is a versatile gene and drug delivery vector with 
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intrinsic anti-cancer activities.  Therefore, it is expected that synergistic anti-tumor effects 
can be achieved by HVJ-E vector with incorporated therapeutic molecules. 
Melanoma is a one of the most aggressive tumors due to its strong ability to metastasize. In 
the United States, there were an estimated 62,480 new melanoma cases and 8,420 deaths 
caused by melanomas in 2008 (17). Although the 5-year survival rate of patients with 
localized melanoma at the early stage is greater than 90%, the survival rate drops to less 
than 20% once the melanoma has metastasized to distant sites (17).     
Many chemotherapeutic agents have been used alone or in combination to treat melanoma 
(18). However, these therapies are insufficient for the eradication of melanoma cells, and 
recurrences are often observed. A recent report indicates that B-RAF inhibitor is a promising 
treatment for malignant melanoma patients (19). However, after the initial response, 
melanoma recurrence frequently occurred in the inhibitor-treated patients due to the up-
regulation of other signaling molecules, such as RTK or N-RAS (20).  Thus, when some 
signaling pathways are inhibited, cancer cells become resistant to the drug by the up-
regulation of other pathways. Another report showed that the resistance to B-RAF inhibition 
in melanoma could be overcome by targeting both MEK and IGF-1receptor-mediated PI3 
kinase (21). However, even when these pathways are inhibited, the elimination of all cancer 
cells is unlikely.  Molecular-targeting drugs are very attractive because of their selectivity.  
However, this strategy may fall into a vicious cycle because cancers are heterogeneous and 
become adaptive to the drugs.  Thus, a novel strategy is needed for the treatment of 
melanoma.    
In the present study, we tested the possibility of HVJ-E with or without a therapeutic gene 
for the effective treatment of melanoma in a mouse model. We incorporated the IL12 gene 
into the HVJ-E vector (IL12/HVJ-E) and compared the tumor regression induced by 
IL12/HVJ-E and HVJ-E (without IL12 cDNA).  We also performed a series of six HVJ-E 
injections into both mouse and human melanomas in mouse models to compare the 
suppression of tumor growth and survival time with three injections of HVJ-E.  
2. Materials and methods 
Cell lines and animals: Mouse melanoma F10 cells were purchased from the American 
Tissue Culture Collection, and human melanoma Mewo cells were purchased from the 
Japanese Collection of Research Bioresources.  Mouse melanoma B16-BL6 cells expressing 
the luciferase gene were prepared by GenomIdea Inc. (Ikeda, Osaka, Japan).  Cancer cells 
were grown in DMEM supplemented with 10% fetal bovine serum and 5% penicillin-
streptomycin and maintained at 37°C in a humidified atmosphere with 5% CO2. Murine 
bone marrow-derived DCs were generated as previously described. More than 90% of these 
DCs were positive for CD11c. Five- to six-week-old male C.B-17/IcrCrj-SCID mice and 
C57BL/6 mice were purchased from Charles River Inc. (Yokohama, Japan) and maintained 
in a temperature-controlled, pathogen-free room.  All animals were handled according to 
the approved protocols and guidelines of the Animal Committee of Osaka University. 
HVJ-E preparation and siRNA transfection: HVJ (VR-105 parainfluenza 1 Sendai/52, Z 
strain) propagated in HEK293 cells was collected and inactivated by UV irradiation (99 
mJ/cm2) and β-propiolactone. The inactivated HVJ suspension (HVJ-E) was purified by 
GenomIdea Inc. by using four different columns.  The titer of HVJ-E was examined by 
neuraminidase activity (mNAU).  One mNAU corresponded to approximately 5 x 107 
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particles. Two hundred micrograms of plasmid DNA was mixed with 2000 mNAU HVJ-E in 
the presence of Tween 80 (final concentration, 0.05%).  
Cytokine measurements: Mouse dendritic cells or F10 melanoma cells were seeded at 5 x 
104 cells/well in 96-well plates.  The following day, HVJ-E (MOI: 102 - 104 ) was added, and 
the cells were cultured for another 24 hr.  After this, cytokines and chemokines were 
measured within the supernatant by ELISA performed with commercially available reagents 
(PBL Biomedical Laboratories, Piscataway, NJ, USA). 
TUNEL assay: Twenty-four hours after three injections of HVJ-E or PBS, tissue sections 
were prepared by using a microtome. The sections were washed twice with PBS and fixed 
with 4% paraformaldehyde for 15 min at 4°C.  The terminal deoxynucleotide transferase-
mediated dUTP nick-end labeling (TUNEL) assay was performed according to the protocol 
of an in situ Apoptosis Detection Kit (Takara Bio Inc.).  
Quantitative real-time RT-PCR: Isogen (Nippon Gene, Japan) was used to extract total 
RNA from tumors that had been resected and washed in PBS. A total of 2 μg of total RNA 
was reverse transcribed into cDNA and analyzed as in vitro. Probes and primer pairs 
specific for murine DX5, CD8, CD11c, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were purchased from Applied Biosystems. The concentration of target genes was 
determined by using the comparative CT method (threshold cycle number at the cross-point 
between amplification plot and threshold), and values were normalized to an internal 
GAPDH control. 
ELISPOT assay: Mice were sacrificed 7 days after the fifth IP injection. Splenocytes were 
harvested from the spleen and cultured as previously described (15). A total of 1×104 
lymphocytes were cultured with 0.2×104 mitomycin C-treated F10 cells at 37°C for 24 hr. The 
assay was performed by using a mouse IFN-gamma ELISPOT kit (R&D Systems). The 
number of spots was counted under a dissecting microscope (Leica, Cambridge, UK). 
Tumor growth in vivo: Viable melanoma cells were re-suspended in 100 μl of PBS and 
intradermally injected into the backs of the mice.  When each tumor had grown to 
approximately 4-6 mm in diameter, the mice were treated with intra-tumor injections of 
HVJ-E (in a total volume of 100 μl) or 100 μl of PBS.  Tumor size was measured in a blinded 
manner with slide calipers, and tumor volume was calculated with the following formula: 
tumor volume (mm3) = length × (width)2 / 2.  In a spontaneous lung metastasis model, B16-
BL6 cells (106 cells) were subcutaneously inoculated into a C57BL/6 mouse.  The mice were 
injected with HVJ-E (300, 1000 and 2000 mNAU) or PBS three times on days 4, 8 and 12.  On 
day 26, the mice were sacrificed.  Lungs were isolated and fixed with 10% formalin solution, 
and the size and number of metastatic foci were examined.   
Statistical analysis: In vitro results were analyzed with the Student’s non-paired t-test. 
Comparisons of in vivo results were made by using Kaplan-Meyer’s method or Dunnett’s 
test.  Differences with P values < 0.05 were considered statistically significant. 
3. Results 
HVJ envelope (HVJ-E) was constructed by inactivation of HVJ (hemagglutinating virus of 
Japan; Sendai virus) with ß-propiolactone (0.0075% - 0.001%) or UV irradiation (99 
mjoule/cm2), as described previously, and then purified by ion-exchange column 
chromatography and gel filtration.  The diameter of HVJ-E was 220 nm, and the zeta 
potential was approximately –5 mV.  Exogenous plasmid DNA was incorporated into 
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intrinsic anti-cancer activities.  Therefore, it is expected that synergistic anti-tumor effects 
can be achieved by HVJ-E vector with incorporated therapeutic molecules. 
Melanoma is a one of the most aggressive tumors due to its strong ability to metastasize. In 
the United States, there were an estimated 62,480 new melanoma cases and 8,420 deaths 
caused by melanomas in 2008 (17). Although the 5-year survival rate of patients with 
localized melanoma at the early stage is greater than 90%, the survival rate drops to less 
than 20% once the melanoma has metastasized to distant sites (17).     
Many chemotherapeutic agents have been used alone or in combination to treat melanoma 
(18). However, these therapies are insufficient for the eradication of melanoma cells, and 
recurrences are often observed. A recent report indicates that B-RAF inhibitor is a promising 
treatment for malignant melanoma patients (19). However, after the initial response, 
melanoma recurrence frequently occurred in the inhibitor-treated patients due to the up-
regulation of other signaling molecules, such as RTK or N-RAS (20).  Thus, when some 
signaling pathways are inhibited, cancer cells become resistant to the drug by the up-
regulation of other pathways. Another report showed that the resistance to B-RAF inhibition 
in melanoma could be overcome by targeting both MEK and IGF-1receptor-mediated PI3 
kinase (21). However, even when these pathways are inhibited, the elimination of all cancer 
cells is unlikely.  Molecular-targeting drugs are very attractive because of their selectivity.  
However, this strategy may fall into a vicious cycle because cancers are heterogeneous and 
become adaptive to the drugs.  Thus, a novel strategy is needed for the treatment of 
melanoma.    
In the present study, we tested the possibility of HVJ-E with or without a therapeutic gene 
for the effective treatment of melanoma in a mouse model. We incorporated the IL12 gene 
into the HVJ-E vector (IL12/HVJ-E) and compared the tumor regression induced by 
IL12/HVJ-E and HVJ-E (without IL12 cDNA).  We also performed a series of six HVJ-E 
injections into both mouse and human melanomas in mouse models to compare the 
suppression of tumor growth and survival time with three injections of HVJ-E.  
2. Materials and methods 
Cell lines and animals: Mouse melanoma F10 cells were purchased from the American 
Tissue Culture Collection, and human melanoma Mewo cells were purchased from the 
Japanese Collection of Research Bioresources.  Mouse melanoma B16-BL6 cells expressing 
the luciferase gene were prepared by GenomIdea Inc. (Ikeda, Osaka, Japan).  Cancer cells 
were grown in DMEM supplemented with 10% fetal bovine serum and 5% penicillin-
streptomycin and maintained at 37°C in a humidified atmosphere with 5% CO2. Murine 
bone marrow-derived DCs were generated as previously described. More than 90% of these 
DCs were positive for CD11c. Five- to six-week-old male C.B-17/IcrCrj-SCID mice and 
C57BL/6 mice were purchased from Charles River Inc. (Yokohama, Japan) and maintained 
in a temperature-controlled, pathogen-free room.  All animals were handled according to 
the approved protocols and guidelines of the Animal Committee of Osaka University. 
HVJ-E preparation and siRNA transfection: HVJ (VR-105 parainfluenza 1 Sendai/52, Z 
strain) propagated in HEK293 cells was collected and inactivated by UV irradiation (99 
mJ/cm2) and β-propiolactone. The inactivated HVJ suspension (HVJ-E) was purified by 
GenomIdea Inc. by using four different columns.  The titer of HVJ-E was examined by 
neuraminidase activity (mNAU).  One mNAU corresponded to approximately 5 x 107 
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particles. Two hundred micrograms of plasmid DNA was mixed with 2000 mNAU HVJ-E in 
the presence of Tween 80 (final concentration, 0.05%).  
Cytokine measurements: Mouse dendritic cells or F10 melanoma cells were seeded at 5 x 
104 cells/well in 96-well plates.  The following day, HVJ-E (MOI: 102 - 104 ) was added, and 
the cells were cultured for another 24 hr.  After this, cytokines and chemokines were 
measured within the supernatant by ELISA performed with commercially available reagents 
(PBL Biomedical Laboratories, Piscataway, NJ, USA). 
TUNEL assay: Twenty-four hours after three injections of HVJ-E or PBS, tissue sections 
were prepared by using a microtome. The sections were washed twice with PBS and fixed 
with 4% paraformaldehyde for 15 min at 4°C.  The terminal deoxynucleotide transferase-
mediated dUTP nick-end labeling (TUNEL) assay was performed according to the protocol 
of an in situ Apoptosis Detection Kit (Takara Bio Inc.).  
Quantitative real-time RT-PCR: Isogen (Nippon Gene, Japan) was used to extract total 
RNA from tumors that had been resected and washed in PBS. A total of 2 μg of total RNA 
was reverse transcribed into cDNA and analyzed as in vitro. Probes and primer pairs 
specific for murine DX5, CD8, CD11c, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were purchased from Applied Biosystems. The concentration of target genes was 
determined by using the comparative CT method (threshold cycle number at the cross-point 
between amplification plot and threshold), and values were normalized to an internal 
GAPDH control. 
ELISPOT assay: Mice were sacrificed 7 days after the fifth IP injection. Splenocytes were 
harvested from the spleen and cultured as previously described (15). A total of 1×104 
lymphocytes were cultured with 0.2×104 mitomycin C-treated F10 cells at 37°C for 24 hr. The 
assay was performed by using a mouse IFN-gamma ELISPOT kit (R&D Systems). The 
number of spots was counted under a dissecting microscope (Leica, Cambridge, UK). 
Tumor growth in vivo: Viable melanoma cells were re-suspended in 100 μl of PBS and 
intradermally injected into the backs of the mice.  When each tumor had grown to 
approximately 4-6 mm in diameter, the mice were treated with intra-tumor injections of 
HVJ-E (in a total volume of 100 μl) or 100 μl of PBS.  Tumor size was measured in a blinded 
manner with slide calipers, and tumor volume was calculated with the following formula: 
tumor volume (mm3) = length × (width)2 / 2.  In a spontaneous lung metastasis model, B16-
BL6 cells (106 cells) were subcutaneously inoculated into a C57BL/6 mouse.  The mice were 
injected with HVJ-E (300, 1000 and 2000 mNAU) or PBS three times on days 4, 8 and 12.  On 
day 26, the mice were sacrificed.  Lungs were isolated and fixed with 10% formalin solution, 
and the size and number of metastatic foci were examined.   
Statistical analysis: In vitro results were analyzed with the Student’s non-paired t-test. 
Comparisons of in vivo results were made by using Kaplan-Meyer’s method or Dunnett’s 
test.  Differences with P values < 0.05 were considered statistically significant. 
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Japan; Sendai virus) with ß-propiolactone (0.0075% - 0.001%) or UV irradiation (99 
mjoule/cm2), as described previously, and then purified by ion-exchange column 
chromatography and gel filtration.  The diameter of HVJ-E was 220 nm, and the zeta 
potential was approximately –5 mV.  Exogenous plasmid DNA was incorporated into 
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inactivated HVJ by treatment with mild detergent and centrifugation (10,000 g, 5-10 min).  
Various detergents, such as Triton X-100, NP-40, deoxycholate and Tween 80, were available 
for incorporating exogenous DNA into HVJ-E.  The exogenous DNA incorporation rate was 
approximately 15% – 20% and did not vary significantly among the different detergents.  
However, when detergent-treated HVJ-E was added to dendritic cells or melanoma cells, the 
cytokine production from those cells was varied.  IL-6, which plays a major role in the anti-
tumor immunity of HVJ-E, was produced from dendritic cells treatment with Tween 80-
treated HVJ-E as well as non-treated HVJ-E while it was dramatically suppressed by HVJ-E 
treated with other detergents (Fig. 1A).  Tween 80-treated HVJ-E maintained the production 
of interferon-α and RANTES from dendritic cells, but Triton X-100-treated HVJ-E lost this 
ability (Fig. 1B and C).   The optimum concentration of Tween 80 was 0.05%, which also 
enabled the incorporation of exogenous DNA into HVJ-E (data not shown).  Mouse 
melanoma B16-F10 cells produced a small amount of interferon-β in response to HVJ-E.  As 
shown in Fig. 1D, Tween 80-treated HVJ-E stimulated interferon-β secretion from melanoma 
cells in a dose-dependent manner.  However, the interferon-β production induced by Triton 
X-100-treated HVJ-E was greatly suppressed. Therefore, we used 0.05% Tween 80-treated 

























































































































Fig. 1. The effect of detergent on the production of cytokine and chemokine from dendritic 
cells and tumor cells treated with HVJ-E.  
IL-6 (A), IFN-α (B) and RANTES (C) in mouse dendritic cells were assessed by using ELISA 
kits 24 hours after HVJ-E treatment.  In (A), HVJ-E was treated with detergent (0.2% Triton 
X-100, 0.1% NP-40, 1.25 CHAPS or 0.05% Tween 80).  The concentration of each detergent 
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was required for incorporation of plasmid DNA into HVJ-E.  In (B) and (C), 0.1% Triton X-100 
(TX) and 0.01 – 0.4 % Tween 80 (TW) were used. 
To test the anti-tumor effects of Tween 80-treated HVJ-E, mouse melanoma B16-F10 cells 
were intradermally inoculated into C57BL/6 mice. When the diameter of the tumor was 
approximately 5 mm, various amounts of HVJ-E were injected into tumors in a series of 
three injections with 4 days between injections (Fig. 2). Tumor regression was induced by 
HVJ-E. After three injections of HVJ-E (1000 mNAU), a TUNEL assay was performed on 
tumor sections to detect apoptosis. As shown in Fig. 3, TUNEL-positive cells were 









0 6 9 12 14 16 19 22 26 29
PBS
HVJ-E











Normal tissue  
Fig. 3. Apoptotic cells in the tumor tissue by the injection of HVJ-E 
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was required for incorporation of plasmid DNA into HVJ-E.  In (B) and (C), 0.1% Triton X-100 
(TX) and 0.01 – 0.4 % Tween 80 (TW) were used. 
To test the anti-tumor effects of Tween 80-treated HVJ-E, mouse melanoma B16-F10 cells 
were intradermally inoculated into C57BL/6 mice. When the diameter of the tumor was 
approximately 5 mm, various amounts of HVJ-E were injected into tumors in a series of 
three injections with 4 days between injections (Fig. 2). Tumor regression was induced by 
HVJ-E. After three injections of HVJ-E (1000 mNAU), a TUNEL assay was performed on 
tumor sections to detect apoptosis. As shown in Fig. 3, TUNEL-positive cells were 
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C57BL/6 mice (each group; n=5) were challenged with 5×105 F10 cells by intradermal 
injection on the dorsal surface. After tumors reached 4~6 mm in diameter, 1000 mNAU HVJ-
E or PBS was injected into the tumors once every other day on days 6, 8 and 10. Tumor 
diameter was measured to calculate tumor volume.  Bars, SD. *P <0.05. 
Twenty-four hours after the third injection of HVJ-E (1000 mNAU) or PBS, tissue sections 
were prepared for a TUNEL assay.  Successive sections were stained with DAPI to confirm 
the position of nuclei.  The boundary between tumor and normal tissues was confirmed by 
H-E staining of successive sections and shown by a white dotted line. 
As we have previously reported the generation of multiple anti-tumor immunities by HVJ-E, 
the infiltration of immune cells into the tumor bed was analyzed by RT-PCR at 48 hours after 
the last of three injections of HVJ-E (1000 mNAU).  CD11c, CD8 and DX5 were highly 
expressed in melanoma tissues (Fig. 4A), indicating the infiltration of dendritic cells, CD8+ T 
cells and NK cells. Two weeks later, the cytotoxic T-cell response was evaluated by ELISPOT 
assay (Fig. 4B). A significant increase in interferon-γ spots was detected in spleen cells from 
mice injected with HVJ-E. 
The subcutaneous mouse melanoma (B16-BL6) cells spontaneously metastasized to the lung. 
When the subcutaneous tumor mass was treated with HVJ-E, the ratio of mice with more 
than one melanoma focus in the lungs significantly decreased (Table 1). In particular, the 
















































































(A) The transcripts for CD8, CD11c, and DX5 isolated from melanoma masses were analyzed by real-
time PCR.  Values were normalized to an internal GAPDH control.  The ratio of each transcript from 
HVJ-E-treated samples to that from PBS-injected samples is shown as the fold increase.  Bars, SD.  (B) 
ELISPOT assay of IFN-γ from lymphocytes collected from the spleen 7 days after the last injection of 
HVJ-E or PBS.  Control samples were prepared from lymphocytes collected from untreated tumor-
bearing mice.  Bars, SD. *P <0.05. 
Fig. 4. Infiltration of immune cells into tumor tissue by intratumoral injection of HVJ-E 
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Total >0.4 mmin length
>0.7 mm
in length
PBS                                10               100         80                    70
HVJ-E  300 mNAU 11                 82                            18∗ 9-
HVJ-E 1000 mNAU 8                 38∗ 13∗ 0-
HVJ-E 2000 mNAU 9                 44∗ 22∗ 0-
∗Statistical significance vs. PBS at p<0.05 by Steel’s test
- Impossible for statistical analysis  
Table 1. Ratio of mouse with more than one metastatic focus in lung 
To increase the anti-tumor effects of HVJ-E, mouse IL-12 cDNA (IL-12/HVJ-E) was 
incorporated into HVJ-E, and the resulting vector was injected into the intradermal tumor 
mass of B16-BL6 cells.  As shown in Fig. 5A, a series of three injections of IL-12/HVJ-E was 
more effective for melanoma regression than mock HVJ-E that contained vector plasmid 
without IL-12 cDNA.  The survival and body weight change of tumor-bearing mice were 
analyzed.  Fig 5B shows that 90% of mice injected with three times were alive on day 46, 
when all the mice injected with either mock HVJ or PBS had died.  There was no decrease in 
the body weight of mice treated with IL-12/HVJ-E.  No significant difference was observed 
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the position of nuclei.  The boundary between tumor and normal tissues was confirmed by 
H-E staining of successive sections and shown by a white dotted line. 
As we have previously reported the generation of multiple anti-tumor immunities by HVJ-E, 
the infiltration of immune cells into the tumor bed was analyzed by RT-PCR at 48 hours after 
the last of three injections of HVJ-E (1000 mNAU).  CD11c, CD8 and DX5 were highly 
expressed in melanoma tissues (Fig. 4A), indicating the infiltration of dendritic cells, CD8+ T 
cells and NK cells. Two weeks later, the cytotoxic T-cell response was evaluated by ELISPOT 
assay (Fig. 4B). A significant increase in interferon-γ spots was detected in spleen cells from 
mice injected with HVJ-E. 
The subcutaneous mouse melanoma (B16-BL6) cells spontaneously metastasized to the lung. 
When the subcutaneous tumor mass was treated with HVJ-E, the ratio of mice with more 
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(A) The transcripts for CD8, CD11c, and DX5 isolated from melanoma masses were analyzed by real-
time PCR.  Values were normalized to an internal GAPDH control.  The ratio of each transcript from 
HVJ-E-treated samples to that from PBS-injected samples is shown as the fold increase.  Bars, SD.  (B) 
ELISPOT assay of IFN-γ from lymphocytes collected from the spleen 7 days after the last injection of 
HVJ-E or PBS.  Control samples were prepared from lymphocytes collected from untreated tumor-
bearing mice.  Bars, SD. *P <0.05. 
Fig. 4. Infiltration of immune cells into tumor tissue by intratumoral injection of HVJ-E 
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To increase the anti-tumor effects of HVJ-E, mouse IL-12 cDNA (IL-12/HVJ-E) was 
incorporated into HVJ-E, and the resulting vector was injected into the intradermal tumor 
mass of B16-BL6 cells.  As shown in Fig. 5A, a series of three injections of IL-12/HVJ-E was 
more effective for melanoma regression than mock HVJ-E that contained vector plasmid 
without IL-12 cDNA.  The survival and body weight change of tumor-bearing mice were 
analyzed.  Fig 5B shows that 90% of mice injected with three times were alive on day 46, 
when all the mice injected with either mock HVJ or PBS had died.  There was no decrease in 
the body weight of mice treated with IL-12/HVJ-E.  No significant difference was observed 
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(A) C57BL/6 mice (each group; n=5) were challenged with 106 B16-BL6 cells by intradermal injection on 
the dorsal surface. After tumors reached 4~6 mm in diameter, HVJ-E (1000 mNAU), HVJ-E containing 
IL-12 cDNA or PBS were injected into the tumors on days 4, 8 and 12. Tumor diameter was measured to 
calculate tumor volume.  Bars, SD. *P <0.05. (B) The survival of mice injected with HVJ-E (1000 mNAU) 
containing IL-12 cDNA (IL12/HVJ-E) or HVJ-E containing vector plasmid without IL12 (mock HVJ-E) 
or PBS (each group; n=10) is shown. *P <0.05. (C) Body weight of mice treated with IL12/HVJ-E, mock 
HVJ-E or PBS is shown (each group; n=10). 
Fig. 5. Gene therapy of mouse melanoma by IL-12/HVJ-E 
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Three injections of HVJ-E without a therapeutic gene resulted in a significant regression of 
melanoma growth (Fig. 2), but the survival of tumor-bearing mice was not significantly 
prolonged as compared with the mice injected with PBS.  Then, we tested whether a series of 
six injections of HVJ-E without therapeutic genes could prolong mouse survival. We found 
that the series of six injections inhibited melanoma (B16-BL6) growth and significantly 
prolonged the survival (Fig. 6 A and B).  A similarly prolonged survival was also observed in 
B16-F10 melanoma model mice that received six HVJ-E injections (data not shown).  Based on 
these results, we attempted to treat human melanoma (Mewo) in immunodeficient SCID mice.  
Six injections of HVJ-E suppressed the growth of human melanoma in a dose-dependent 
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(A) A series of six injections of HVJ-E (1000 mNAU) or PBS was administered to mice with intradermal 
tumor B16-BL6 melanoma on days 4, 8, 12, 16, 20 and 24 (each group; n=5). Bars, SD. *P <0.05.  (B) The 
survival of mice injected with HVJ-E (1000 mNAU) or PBS (each group; n=10) is shown. *P <0.05.  

























(A) C57BL/6 mice (each group; n=5) were challenged with 106 B16-BL6 cells by intradermal injection on 
the dorsal surface. After tumors reached 4~6 mm in diameter, HVJ-E (1000 mNAU), HVJ-E containing 
IL-12 cDNA or PBS were injected into the tumors on days 4, 8 and 12. Tumor diameter was measured to 
calculate tumor volume.  Bars, SD. *P <0.05. (B) The survival of mice injected with HVJ-E (1000 mNAU) 
containing IL-12 cDNA (IL12/HVJ-E) or HVJ-E containing vector plasmid without IL12 (mock HVJ-E) 
or PBS (each group; n=10) is shown. *P <0.05. (C) Body weight of mice treated with IL12/HVJ-E, mock 
HVJ-E or PBS is shown (each group; n=10). 
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(A) A series of six injections of HVJ-E (1000 mNAU) or PBS was administered to mice with intradermal 
tumor B16-BL6 melanoma on days 4, 8, 12, 16, 20 and 24 (each group; n=5). Bars, SD. *P <0.05.  (B) The 
survival of mice injected with HVJ-E (1000 mNAU) or PBS (each group; n=10) is shown. *P <0.05.  
























(A) Human melanoma Mewo cells (106 cells) were inoculated intradermally into SCID mice.  Six 
injections of HVJ-E (200 mNAU, 1000 mNAU) or PBS were administered to the mice on days 7, 9, 11, 13, 
15 and 17 (each group; n=5). Bars, SD. *P <0.05. (B) The survival of mice injected with HVJ-E (1000 
mNAU) or PBS (each group; n=10) is shown. *P <0.05. 
Fig. 7. Human melanoma treatment by six-times injection of HVJ-E 
4. Discussion 
HVJ-E was originally developed as a vector for the delivery of drugs and genes (11, 12).  
Then, it was found that vector itself has anti-tumor activities (13-16).  For cancer treatment, a 
single modality of therapeutic strategy is not sufficient.  By using HVJ-E, multi-lateral cancer 
treatment can be achieved by incorporating therapeutic molecules into HVJ-E with intrinsic 
anti-tumor activities. Here, we demonstrate that the anti-tumor activities of HVJ-E are 
enhanced by the incorporation of IL-12 cDNA.  Our previous reports showed that HVJ-E 
induces the production of interferon-α, -β, IL-6 and CXCL10 in mouse dendritic cells  
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(13, 14). However, interferon-γ was not produced from dendritic cells treated with HVJ-E.  
Rather, interferon-γ was secreted from NK cells exposed to interferon-β produced from HVJ-
E-treated dendritic cells (14).  Since interferon-γ plays a key role in anti-tumor immunity 
(22), we selected IL-12, which induces interferon-γ in immune cells, for incorporation into 
HVJ-E.  Local injection of the IL-12 gene into melanoma by using the canarypox virus or 
naked plasmid DNA has already been clinically tested and shows promising results (23, 24). 
In the present study, the IL-12 gene was coupled with HVJ-E, which has intrinsic anti-tumor 
activities; therefore, synergistic anti-tumor effects were expected. Indeed, in mouse tumor 
models of melanoma, IL-12/HVJ-E enhanced tumor regression and prolonged mouse 
survival more effectively as compared to mock HVJ-E without IL-12 cDNA.  However, even 
when the therapeutic gene was not used, more frequent injections of HVJ-E increased the 
anti-tumor activities and prolonged the mouse survival.  This result might be due to the 
accumulation of the anti-tumor effects of HVJ-E.  A similar regression of human melanoma 
tumors in immunodeficient SCID mice was achieved by six injections of HVJ-E without 
therapeutic genes.  In SCID mice, which lack T-cell immunity, NK cells activated by HVJ-E 
play a role in tumor suppression, as previously reported (14).  Additionally, HVJ-E induces 
cancer cell killing in some human tumors, such as prostate cancer (15), glioblastoma (16), 
neuroblastoma and mammary carcinoma (YK; unpublished data).  We found that HVJ-E 
itself induced apoptosis in Mewo cells in a dose-dependent manner, although the efficiency 
was not as high as the efficiency in glioblastoma and prostate cancers.  This activity of HVJ-
E also achieved significant regression of human melanoma in SCID mice and prolonged 
mouse survival.  In SCID mice inoculated with Mewo cells, we compared the efficacy of 
HVJ-E to the efficacy of a clinically used anti-melanoma reagent, dacarbazine (DTIC).  Three 
intratumoral injections of HVJ-E were sufficient for overcoming the tumor suppression 
effect by six intraperitoneal injections of DTIC. 
The anti-tumor immunity induced by HVJ-E was shown to be caused by the production of 
cytokines and chemokines (14), which are produced in response to the recognition of viral 
RNA by RIG-I (25-27). HVJ-E contains viral RNA fragments (200 – 300 bases) that also have 
the potential to be recognized by RIG-I (28).  Therefore, it is likely that the production of 
chemokines and cytokines induced by HVJ-E depends on the amount of viral RNA 
fragments introduced into the cytoplasm by membrane fusion.  As shown in Figure 1, the 
production is dependent on the treatment of HVJ-E with detergent.  We recently found that 
depletion of cholesterol from HVJ by methyl-β-cyclodextrin attenuated the infectivity of the 
virus due to the irreversible dysfunction of fusion protein (29).  It is speculated that some 
detergents, such as Triton X-100 and NP-40, may damage fusion activity, while other 
detergents such as Tween 80 may maintain that activity.  The difference might be due to the 
amount of envelope lipids depleted by the detergent treatment.  Although the reason 
remains to be elucidated, Tween 80-treated HVJ-E is recommended for the treatment of 
cancer and infectious disease, and Triton X-100-treated HVJ-E is recommended for the 
treatment of other diseases, such as cardiovascular disease and inflammatory disease, which 
are exacerbated by cytokines and chemokines. 
It has been determined that the selective cancer-killing activity of HVJ-E is mediated 
through the RIG-I/MAVS signaling pathway, which is activated by viral RNA fragments of 
HVJ-E (YK; manuscript in preparation).  Therefore, Tween 80-treated HVJ-E can be 
equipped with both anti-tumor immunities and cancer-killing activities.   
Recently, we also demonstrated the augmentation of the anti-tumor activities of HVJ-E by 
incorporating siRNA against motor protein Eg5 in glioblastoma treatment (30).  The ability 
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Fig. 7. Human melanoma treatment by six-times injection of HVJ-E 
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of Eg5 siRNA to induce cell-cycle arrest compensated for HVJ-E in conducting apoptosis.  
Since the mechanism of apoptosis induced by Eg5 siRNA is different from that induced by 
HVJ-E, the combination of HVJ-E with Eg5 siRNA creates a synergistic anti-tumor effect.  
Thus, if a molecule to promote cancer progression after HVJ-E treatment is identified by 
comprehensive microarray analysis of transcripts in cancer cells, the combination of HVJ-E 
and siRNA against that molecule will be recommended as an effective cancer treatment. 
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1. Introduction 
Gene therapy may be described as the use of genes as medicines to treat disease, or, more 
precisely, as the delivery of nucleic acids by means of vectors to patients for some 
therapeutic purpose (Thanou, M. et al., 2007). The major goal of gene therapy is to introduce 
a functional gene into a target cell and restore protein production that is absent or deficient 
due to a genetic disorder (Neeltje, A. et al., 2003). This approach is a potentially powerful 
method for the treatment of diseases for which classical pharmacotherapy is unavailable or 
not easily applicable.  
Gene therapy is a therapeutic modality with enormous promise, which is also considered to 
have failed to deliver much of therapeutic significance in spite of all the apparent clinical 
interest. Clinical trial activity in gene therapy began in 1989, peaked in 1999, and is now 
currently declining (Thanou, M. et al., 2007). This decline was marked by some clinical trial 
problems, including a death from toxic liver shock during an adenovirus-based clinical trial 
in 1999 (Marshall, E., 2000), the anomalous appearance of a transgene in the gonads during 
adeno-associated virus-based preclinical trials in 2001 (Arruda, V. R. et al., 2001), signs of 
hypertension in lipofection clinical trials in 2005 (Pro-1) (MacLachlan, I. et al., 1999), and the 
development of leukemia in retrovirus-based clinical trials for ex vivo treatment of X-linked 
severe combined immunedeficiency (X-linked SCID) (Cavazzana-Calvo, M. et al., 2004; 
Gaspar, H. B., & Thrasher, A. J., 2005). 
Lessons from those frustrated results suggest that more basic research is required in gene 
therapy study, including mechanism of diseases and features of viral vectors. In order to 
modify a specific cell type or tissue, the therapeutic gene must be efficiently delivered to the 
cell, so that it will express at the appropriate level for a sufficient duration. Thus, identifying 
the ideal means of carriage for viral gene therapy is the key rate-limiting step in the 
development of most promising gene therapy strategies. In spite of long-term and extensive 
efforts to develop in vivo gene delivery systems, little achievements have been reported, 
especially as far as clinical applications are concerned. Apparently, the development of gene 
delivery systems will be one of the most critical issues for the success of in vivo gene 
therapy.  
Over the years, two broad approaches have been used to deliver therapeutic genes to cells, 
viral vectors and non-viral vectors. These two kinds of vectors are different as regard to 
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efficiency, ease of production and safety. Preclinical and current clinical trial data suggest 
that non-viral vector systems are much less affected by immunogenicity, toxicity, and 
oncogenicity. However, the lack of delivery efficacy and short-term expression in in vivo also 
pose their greatest drawback.  
By contrast, viral-based vectors are feasible for modification and long-term gene expression, 
meanwhile, they are characterized by their infectivity and satisfactory targeting, all of which 
make them even more attractive as gene delivery systems. Nowadays, many viral vectors 
have been developed and frequently used in the present gene therapy studies, such as 
Adenovirus, Adeno-associated virus, retroviruses, herpes simplex virus type 1 and vaccinia 
virus. The real success has been reported with a serotype 5 adenovirus vector delivering the 
p53 tumor suppressor gene (Gendicine, the World’s first commercial gene therapy product, 
licensed for use in China) (Pearson S. et al., 2004). Viral vectors have also been applied in the 
treatment of monogenic diseases. In 2000, the World’s first curative gene therapy trial was 
reported after bone marrow cells were isolated from patients with X-linked SCID 
(Cavazzana-Calvo, M. et al, 2000). In a word, gene therapy with viral vectors has been 
proven effective in a variety of model systems.  
However, studies have also shown that even if some common characteristics exist, an 
important variability is introduced by the administration route, the promoter and other key 
components of the construct (targeting modifications, etc) (Dani, S.U., 1999). The variability 
results in a variety of challenges, including circumvention of immune responses against viral 
vectors and difficulty in transferring the genes to a sufficient number of cells to change the 
phenotype, and in controlling the expression of the gene (Worgall, S. & Crystal, R.G., 2007). 
Thus, it is currently admitted that pharmacokinetic studies should be carried out prior to any 
clinical trial for a promising viral gene therapy. Additionally, preexisting knowledge about the 
viral vectors, including the viral vector titration standardization issues, specific formulation 
and purification process, also prompts for dedicated pharmacokinetic studies. 
Therefore, this chapter reviews the general strategies of the pharmacokinetic studies in viral 
gene therapy, provides an overview of the pharmacokinetic characteristics of viral vectors 
and the methods used in pharmacokinetic analysis of viral gene therapy, details the 
challenges and discusses the strategies being used to improve the analytical modality in 
viral gene therapy.  
2. Pharmacokinetic characteristics of viral vectors  
Viral vectors currently available for gene therapy can roughly be categorized into 
integrating and non-integrating vectors. Vectors based on adeno-associated virus and 
retroviruses (including lentivirus and foamy virus) are classified as integrating vectors as 
they have the ability to integrate their viral genome into the chromosomal DNA of the host 
cells, which will possibly achieve lifelong gene expression. Vectors based on adenovirus 
(Ad), modified vaccinia virus of Ankara (MVA) and herpes simplex virus type 1 (HSV-1) 
represent the non-integrating vectors (Pfeifer, A. & Verma, I.M., 2001). These vectors deliver 
their genomes into the nucleus of the target cells, where they remain episomal. The different 
behavior between these two kinds of viruses will frequently determine their difference in 
the availability at the target cells and also the undesirable sites following in vivo 
administration. 
Accordingly, principles of pharmacokinetic study are equally applicable to conventional 
small-molecule drugs and biotech drugs (Meibohm, B., 2006), including viral vectors. 
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However, viral vectors often exhibit unique pharmacokinetic properties that are different 
from others. 
As described previously, replication-deficient viral vectors remain in vivo for a temporal 
period due to rapidly elimination through degradation as well as by the clearance (Senoo, 
M., et al, 2000; Hackett, N.R., et al, 2000). Usually, the elimination of viral vectors within 
tissues or within the blood compartment results from the action of both endonucleases and 
exonucleases (Goncalves, MA. et al., 2002). Hence, viral nucleic acids must be extracted and 
detected as soon as possible when performing a pharmacokinetic study with PCR method in 
case of rapid degradation. However, the suitability or yield of nucleic acid from extraction 
procedures can vary depending on the nucleic acid and the biological material (Kok, T. et al., 
2000). Great differences were found on the recoveries of viral DNA between tissues and 
blood as shown in Table 1, most experiments produced recovery of greater than 50%, while 
some were relative low but stable. Interestingly, the lowest recovery was found in blood 
(Lovatt, A., 2002). Therefore, efficient extraction of target nucleic acid should be evaluated 
for the particular target and biological material to be used. 
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Table 1. Recovery of 10~100 copies of viral nucleic acid target per 100 microgram of animal 
tissue extracted with the Qiagen DNA mini kit (tissue and blood protocol)Additionally, it is 
very important to determine the optimal blood compartment for quantitative measurement 
of virus in peripheral blood specimens. Perlman, J. et al. compared the use of whole blood 
(WB), plasma, and peripheral blood mononuclear cells (PBMC) for the detection of 
adenovirus in peripheral blood specimens from a pediatric HSCT recipient population,  
and higher viral loads were in WB and plasma than in PBMC (Perlman, J. et al., 2007).  
In viral gene therapy, gene expression and duration is an important criterion and controlled 
by the choice of promoter, CpG content, topological form of DNA etc. Although viral 
vectors are structurally similar to the wild-type progenitor virus, they generally lack some 
or all of the viral genes, so that their ability to replicate is frequently impeded or obliterated 
(Worgall, S. & Crystal, R.G., 2007). Hence, the lack of sustained transgene expression may be 
another important characteristic of viral vectors, and must be taken into account when 
setting up treatment regiments and investigating their pharmacokinetics. What’s more, 
controlling the gene expression is a challenge that needs to be addressed.  
Ideally, each delivery problem should be assessed in the round from the site of 
administration to target cells of interest. And viral vectors probably present a much greater 
risk of oncogenicity, particularly retroviral vectors that mediate insertion into actively 
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efficiency, ease of production and safety. Preclinical and current clinical trial data suggest 
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expressing gene loci, thereby creating a high risk of oncogenesis (Pfeifer, A. & Verma, I.M., 
2001). This condition must be considered during pharmacokinetic studies.  
In short, gene therapy should be seen as a somatic medicine that seeks to treat disease at a 
more fundamental level than most other therapeutic modalities are capable of. In this field, 
viral vectors have been extremely attractive as delivery system. An understanding of the 
pharmacokinetic behavior of these vectors will be utmost important when designing an 
effective therapeutic regimen, also will provide a comprehensive review of viral vectors and 
stimulate novel approaches to improve their pharmacokinetics. 
3. Methods used in pharmacokinetic evaluation of viral vectors 
As for pharmacokinetic study of viral vectors in gene therapy, the appropriate methods are 
of vital importance. With the development of science and technology, there have been many 
advances in the field of pharmacokinetic study in viral gene therapy. Many approaches have 
been developed over the past decades, especially in the utilization of molecular strategies 
for the detection and quantification of viral vectors.  
3.1 Radioactive tracers 
Radioactive tracers are compounds containing one or more radioactive atoms that allow for 
easy detection and measurement. Tracers are frequently used to track the localization of a 
specific compound or to trace the path of a compound through a series of chemical 
reactions. A number of different radioactive forms of hydrogen, carbon, phosphorus, sulfur, 
and iodine are commonly used in biochemical assays, metabolism studies, and medical 
diagnostics (Rennie M., 1999).  
A radioactive tracer is identical in chemical composition to the compound of interest and is 
administered in minute amounts that do not perturb the experimental system. The tracer 
behaves in exactly the same way as an unlabeled molecule, but the tracer molecule 
continually gives off radiation that can be detected with a Geiger counter, scintillation 
counter or other type of radiation detection instrument. Zinn K.R. et al. labeled recombinant 
adenovirus serotype 5 knob with the gamma emitter 99mTc (Zinn, K.R. et al., 1998). Maarten 
ter Horst et al. also used 99mTc to track the distribution of adenoviral vector (Maarten ter 
Horst et al., 2006). Studies suggest that this technology is sensitive and the radiolabeling 
process had no effect on receptor binding. However, it is not available in clinic research 
because the tracers will give off radiation and labs specific for isotope detection are 
required, which limits its application in research.  
3.2 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR), developed in 1983 by Kary Mullis, is a scientific 
technique to amplify a single or a few copies of a piece of DNA across several orders of 
magnitude, generating thousands to millions of copies of a particular DNA sequence 
(Bartlett & Stirling, 2003). It is now a common and usually indispensable technique used in 
medical and biological research for a variety of applications, including DNA cloning for 
sequencing, DNA-based phylogeny, functional analysis of genes, identification of genetic 
fingerprints, and diagnosis of diseases (Saiki, RK. et al., 1988; Glorioso J.C. et al., 1995). A few 
years ago, the main approach was defining generic biodistribution properties of viral 
vectors by designing studies often relying on transgene expression and mostly nonvalidated 
PCR techniques.  
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This method has greatly advanced the development of viral gene therapy and progressively 
helped defining important features of these vectors. But it is just a semi-quantification 
technology with critical problems, including the number of replicates, the necessity of an 
internal control, the specificity and the carryover contamination during sample treatment. 
Besides, the limit of quantification is not as sensitive as expected. In our study, the detection 
limit of Ad DNA was 10,000 copies per microliter (Figure.1, data unpublished), which 
greatly hampers the utility of PCR technology in DNA detection when the concentration of 
DNA in the sample is less than the level mentioned above.  
 
             NTC        101           102          103            104              105            106             107         DL2000 
 
Fig. 1. Validation of the limit of detection of PCR.  
Concentrations of DNA in reactions range from 107~101 copies per microliter. 
3.3 Southern blotting 
Southern blot, developed by Edwin Southern at Edinburgh University in the 1975, allows 
investigators to determine the molecular weight of a restriction fragment, to measure 
relative amounts in different samples and to locate a particular DNA sequence within a 
complex mixture. In this method, DNA (genomic or other source) is digested with a 
restriction enzyme, separated by gel electrophoresis and transferred from the agarose gel 
onto a membrane. The membrane is then incubated with a probe, a single-strand DNA 
labeled either radioactively or enzymatically (e.g. alkaline phosphatase or horseradish 
peroxidase), which will form a double-strand DNA with its complementary DNA sequence. 
Finally, the location of the probe is detected by directly exposing the membrane to X-ray 
film or chemiluminescent methods. Southern blotting had ever played an important role in 
viral gene therapy. Henderson Y.C. et al developed a method for detecting adenovirus in 
serum and urine with Southern Blot. Ponnazhagan S. et al used it to evaluate Ad2 in 
nonpermissive human cells (Ponnazhagan S. et al., 1995). Cichon G et al. and Bernt KM et al. 
also applied it to investigate gene therapy with adenovirus vectors (Cichon G. et al., 1999; 
and Bernt K.M. et al., 2003). Those studies suggest its high sensitivity, reproducibility and 
specificity. However, this method requires a long time and careful manipulation to avoid 
contamination. 
3.4 Western blot 
Western blot, developed by W. Neal Burnette from the laboratory of George Stark at 
Stanford, is an effective and useful method to detect and characterize proteins in small 
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amounts. In this protocol, gel electrophoresis is used to separate proteins by length of the 
polypeptide (denaturing conditions) or by the 3-D structure of the protein (native/ non-
denaturing conditions). The proteins are then transferred to a membrane (typically 
nitrocellulose or PVDF), where they are probed using antibodies specific to the target 
protein. This technique is usually used to evaluate the distribution of vectors by detecting 
expression of target genes in tissues and demonstrates high specificity and sensitivity, 
therefore, has been widely used in viral gene therapy. Fanxia Shen et al. applied it to 
evaluate hypoxia-inducible vascular endothelial growth factor gene expression mediated by 
adeno-associated viral vector- in mice (Shen FX, et al., 2006).  
3.5 Immunohistochemistry 
Immunohistochemistry (IHC) refers to the process of detecting antigens (e.g., proteins) in 
cells of a tissue section by exploiting the principle of antibodies binding specifically to 
antigens in biological tissues (RAMOS-VARA J. A., 2005). ICH staining is widely used in the 
diagnosis of abnormal cells such as those found in cancerous tumors. Specific molecular 
markers are characteristic of particular cellular events such as proliferation or cell death 
(apoptosis). IHC is also widely used in basic research to understand the distribution and 
localization of biomarkers and differentially expressed proteins in different parts of a 
biological tissue. Visualising an antibody-antigen interaction can be accomplished in a 
number of ways. In the most common instance, an antibody is conjugated to an enzyme 
such as peroxidase that can catalyse a colour-producing reaction. Alternatively, the antibody 
can also be tagged to a fluorophore, such as fluorescein or rhodamine (Elias J.M., 2003). 
This method could provide precise information about the distribution of target proteins. 
However, there are several potential problems that will affect the outcome of the procedure. 
Although antibodies show preferential avidity for specific epitopes, endogenous biotin or 
reporter enzymes or primary/secondary antibody cross-reactivity are common causes of 
strong background staining that can mask the detection of the target antigen, while weak 
staining may be caused by poor enzyme activity or primary antibody potency. Furthermore, 
autofluorescence may be due to the nature of the tissue or the fixation method (Grizzle W.E. 
et al., 2001). 
3.6 Real-time quantitative polymerase chain reaction (Q-PCR) 
The idea to monitor the PCR reaction in the thermal cycler as it progresses was first realized 
by Higuchi and colleagues in 1992 (Higuchi R. et al., 1992). And the first commercial 
platform was the Applied Biosystems ABI Prism 7700 Sequence Detection System, followed 
by the Idaho Technology LightCycler (Wittwer C.T. et al., 1997). The principle of Q-PCR is 
based on monitoring of a fluorescent signal arising during the amplification process. In this 
technique two methods are used to obtain fluorescent signals from the PCR products (Fig. 
2). One method involves the use of DNA- specific intercalating dyes such as SYBR Green I 
and the other is to use fluorescent resonance energy transfer (FRET) such as TaqMan® 
probes (Didenko V.V., 2001). 
Q-PCR has revolutionised the detection and quantification of nucleic acid due to its 
improved rapidity, sensitivity, reproducibility, reduced risk of carry-over contamination, 
and ability to quantify viral nucleic acid directly from samples (Morris T. et al., 1996; Lovatt 
A. et al., 1999; Nitsche A. et al., 1999). As a result, real-time PCR assays, as an attractive tool 
for precise evaluation of nucleic acid, have received wider acceptance than conventional 
PCR assays in the field of gene therapy.  
 




Fig. 2. Two methods used to obtain fluorescent signals from the PCR products. 
(A) SYBR Green I; (B) TaqMan® probes. 
Quantification of viral vectors by a TaqMan real-time PCR assay has been previously 
reported. Our team employed TaqMan real-time PCR system to investigate the dynamics of 
Ad5-LFA-3/IgG1 by measuring its concentration in the blood of rhesus macaques and 
organs of rats (Xu XX et al., 2009).  Miyazawa N. et al. examined the kinetics of adenovirus 
genomic DNA delivery to the nucleus by measuring viral DNA with TaqMan-PCR 
(Miyazawa N. et al., 1999). Senoo M. et al. assessed the tissue distribution of recombinant 
adenovirus in mice and guinea pigs via TaqMan-PCR (Senoo M., et al, 2000). Hackett et al. 
also used TaqMan-PCR to track the time-dependent distribution of vectors in vivo (Hackett 
N.R. et al, 2000). These studies support the feasibility of utilizing Q-PCR to track viral 
vectors.  
3.7 In vivo imaging system (IVIS) 
In conventional experimental strategies, temporal information about biological processes is 
often obtained through repeated, time-stacked animal sacrifice. If fine temporal analysis is 
sought during the observation of key biological stages in normal development or disease, 
the number of animals required per experiment can be quite large (Christopher H.C. & 
Michael H.B., 2002). Noninvasive imaging methods enable gene expression assays to be 
conducted in living animals, and they comprise the emerging field of in vivo imaging in 
which a variety of imaging modalities are used for real-time visual monitoring and 
assessment of biological processes in living animals (Ntziachristos V., 2006). As shown in 
Fig.3, this technology greatly reduces the number of animals sacrificed per experiment 
because they allow the comprehensive assessment of each animal over the entire duration of 
the process (Contag P.R. et al., 1998; Rocchetta H.L. et al., 2001). 
Despite obvious progress in gene therapy, the recent failure of trials using adenoviral vectors 
reminds us that the use of viral vectors has risks that should be carefully assessed. What’s 
more, great the progress in viral vector production, and a better understanding of molecular 
aspects of vector delivery and targeting issues, has created the need for imaging techniques 
that could address the problems and opportunities inherent to gene therapy development.  
As noted previously, in vivo imaging could play a unique role in preclinical and clinical 
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Fig. 3. Comparison of conventional experimental strategies and Noninvasive imaging 
methods. (A) conventional experimental strategies; (B) Noninvasive imaging methods 
gene therapy research and answer the following fundamental questions asked by gene 
therapists: 
• How long would the vector reach its target after in vivo administration? 
• How many of the vectors are in the target? 
• When the expression would take place? 
• How long would the expression last? 
• Did gene transfer take place? 
There have been many recent advances in imaging research to provide answers to these 
questions mentioned above, and particularly in the utilization of such strategies for the 
distribution studies of viral vectors. The imaging technology alone, however, can only yield 
limited information, and pharmacokinetics parameters remain unclear. In this regard, more 
efforts are required to develop multi-modality imaging strategies allowing for co-
registration of high resolution anatomical data together with high sensitive molecular 
information. 
4. Challenges and prospects  
As noted previously, viral gene therapy research has evolved considerably since the first 
clinical trials of this technology. The range of therapeutic targets has also expanded from the 
treatment of monogenetic disorders to the prevention and treatment of acquired diseases, 
and so has the number and range of possible therapeutic nucleic acids. This therapeutic 
modality represents one of the most important developments to occur in medicine. On the 
other hand, certain technical problems arising from pharmacokinetic studies of viral gene 
therapy remain to be overcome.  
Design and development of ideal gene delivery vectors (Table. 2) are among the main 
challenges in the evolution of experimental gene therapy into a clinically acceptable 
mainstream therapy (Rubanyi, G.M., 2001). In spite of the relatively undemanding nature of 
the selected viral vectors in clinical trials, results from many early stage clinical trials have 
been frequently disappointing due to the inadequacy of the vectors. The main hurdle for 
successful viral gene therapy has been the host response to the gene therapy vector, the lack 
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of long-term gene expression, and problems related to the viral property of integration 
(Neeltje A. K. & Inder M. V. 2003), all of which represent the general aim of pharmacokinetic 
studies in viral gene therapies. Together, the choice of vector, the design of the expression 
cassette, and the coding sequence of the genes determine the pharmacokinetics of vectors. 
Additionally, innovations in vector design will require a better understanding of delivery 
problems, both at the level of intracellular trafficking of viral DNA to the nucleus and at the 
level of biological fluid stability and tissue penetration. Hence, much more basic research is 
needed to interpret the mechanism of viral gene therapy. 
 
Insert size capacity for one or more genes 
Targeting delivery to specific cell types or gene  expression limited to target cells 
Regulation controllable expression levels of transgenes 
Safety and stability safe for the patient and the environment- devoid  of the risk of insertional mutagenesis 
Immune response appropriate 
Titles high concentrations and stable final product 
Manufacture easy, reproducible, possible for scale-up and standardization 
Table 2. The ideal vector for gene transfer in gene therapy protocols (Dani, S.U., 1999). 
Over the past decades, the process and validation of bioanalytical methods have been well 
developed to generate pharmacokinetic data and provide ADME (absorption, distribution, 
metabolism, and elimination) information on biotech drugs. However, pharmacokinetic 
principles of viral gene therapy are far away from sufficiency in spite of long-term and 
extensive efforts, which requires more considerations when developing bioanalytical 
approaches in gene therapy with viral vectors, including validation and assay 
implementation. 
Despite recent advances in analytical techniques, further improvements in current analysis 
modalities are still at the center stage. As mentioned above, all of the technologies 
mentioned in the review have played important roles during the development of viral gene 
therapy and provided us important information. But only limited material can be obtained 
when these methods are used alone. 
Challenges including pharmacokinetic studies and analytical methods were shortly 
described above. It is evident that overcoming these barriers will contribute greatly to the 
development of viral gene therapy. 
In recent years, more attention has been paid on new viral vectors and modifying the 
existing ones to make them have less toxicity and immunity, besides, with ideal 
pharmacokinetic features. A number of strategies have evolved to enhance the targeting of 
gene transfer vectors by genetic or chemical modification on the surface of the vector. Gene 
expression directed by the transferred gene can be regulated by inducible promoters, tissue-
specific promoters, and trans-splicing. And many hybird or chinmeric vectors have 
emerged. Mizuguchi H. et al. developed adenovirus vectors containing chimeric type 5 and 
type 35 fiber proteins, which exhibit altered and expanded tropism and increase the size 
limit of foreign genes (Mizuguchi H. & Hayakawa T., 2002). Lars Mullera et al. developed 
hybrid vectors HSV–EBV (hepies-simplex-virus-epstein-barrvirus hybrid amplicons) to 
transfer genes into hepatocytes (Mullera L. et al., 2005). Goncalves MA et al. developed 
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AAV-Ad hybrid vectors, improving the transfer efficiency and expression duration 
(Goncalves M.A. et al., 2002). These approaches will, consequently, provide more vectors 
practicable in clinical gene therapies. 
Besides, on the basis of what mentioned above, no single modality is ideal for all possible 
applications and, thus, new protocols for pharmacokinetic studies have been developed in 
viral gene therapy. Wood M. et al. investigated the biodistribution of Ad vector following 
systemic administration with a PCR and luciferase assay (Mark Wood et al., 1999), which 
provided semi-quantitative and qualitative analyses of vector distribution. Pan D. et al. 
applied real-time PCR method and flow-cytometric analysis to measure the distribution of 
lentiviral Vector and expression of target gene in various organs (Dao Pan et al., 2002). And 
our team used TaqMan real-time PCR and in vivo imaging system to track the time-
dependent distribution of rAd5/35 in vivo post intramuscular injection. The vector was 
found to remain primarily at the injection site for about eight weeks, at which point it 
became undetectable (Fig. 4). This result was also shown by in vivo imaging of rAd5/35-luc 
in Balb/c mice (Fig. 5). What’s more, as shown in Fig. 6, the whole process of luciferase 
expression could be monitored in Balb/c mice post-injection with rAd5/35-luc. Quantitative 
and qualitative results could be attained through the utility of real-time PCR and IVIS 
technology in biodistribution study of viral gene therapy. In general, the combination of 
these two approaches provides a rapid, simple approach for a precise, visible result and will 
ultimately accelerate the progress of gene therapy studies.  
 
 
Fig. 4. Biodistribution of rAd5/35-HGEC in tissues of Balb/c mice post-injection with 
1.6×109vp 
 








Fig. 6. Duration of luciferase expression in Balb/c mice post-injection with rAd5/35-luc 
(2×1010vp)（n=5）. 
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The young field of viral gene therapy promises major medical progress toward the cure of  
a broad spectrum of human diseases, and has generated great hopes. To achieve this  
goal, scientists from many different disciplines should participate and pull together as a 
team. Geneticists must identify target genes while the task for the virologists is to develop 
efficient and safe vectors. Finally, clinicians carry out clinical trials with vectors optimized 
for the disease and the medical requirements of the patients (Pfeifer, A. & Verma, I.M., 
2001).  
On the whole, progress has been made in addressing many of these challenges over the past 
decades. Based on the continued focus on solving these issues, the knowledge gained from 
the successes and the setbacks will prove beneficial in viral gene therapy, and there is no 
doubt that prodigious work will result in innovative technology for pharmacokinetic 
studies.  
5. Conclusion 
Gene therapy with viral vectors has been proven very effective in a variety of model 
systems. And great progress has been made in pharmacokinetic studies of viral gene 
therapy. However, there are still many challenges, including the host response to the viral 
vectors, the lack of long-term gene expression, and the risks related to integration into the 
host genome. Thus, understanding of the pharmacokinetic behavior of viral vectors and 
developing ideal methods for pharmacokinetic studies will greatly accelerate the 
development of gene therapy. It’s believed that gene therapy has the power to become a 
dominant therapeutic modality in the future – but all in good time. 
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